PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BIANCHI, R; GIAMBANCO, I; DONATO, R				BIANCHI, R; GIAMBANCO, I; DONATO, R			S-100 PROTEIN, BUT NOT CALMODULIN, BINDS TO THE GLIAL FIBRILLARY ACIDIC PROTEIN AND INHIBITS ITS POLYMERIZATION IN A CA2+-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; BOVINE BRAIN; S100 PROTEIN; HEAD DOMAIN; CALCIUM; INVITRO; PHOSPHORYLATION; FILAMENTS; IDENTITY; SEQUENCE	S-100 protein, a Ca2+-binding protein of the EF-hand type, interacts with the glial fibrillary acidic protein (GFAP) in a Ca2+-dependent manner. The binding of S-100 protein to GFAP was investigated by fluorescence spectroscopy using acrylodan-S-100 protein and cross-linking experiments using the bifunctional cross-linker, disuccinimidyl suberate. The binding affinity was observed to be in the nanomolar range with a stoichiometry of 2 mol of GFAP/mol of S-100 protein (dimer). S-100 protein was found to inhibit the polymerization of GFAP in a dose- and Ca2+-dependent manner, with a half-maximal effect at an S-100 protein/GFAP molar ratio of 0.2 and maximal effect at a molar ratio of 0.5. Identical results were obtained irrespective of whether the unfractionated bovine brain S-100 protein mixture (S-100a plus S-100b), S-100a0, S-100a, or S-100b was used. S-100 protein was observed to be maximally effective as an inhibitor of GFAP polymerization at approximately 3 muM free Ca2+. Calmodulin neither bound to GFAP nor inhibited its polymerization. Altogether, the present results suggest that S-100 protein might be involved in the regulation of the state of assembly of glial filaments by binding to and sequestering unpolymerized GFAP.	UNIV PERUGIA,DEPT EXPTL MED & BIOCHEM SCI,ANAT SECT,CP 81 SUCC 3,I-06100 PERUGIA,ITALY	University of Perugia			Donato, Rosario/I-3943-2019	Giambanco, Ileana/0000-0003-0286-6302	Telethon [27] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		BACKHOVENS H, 1987, J NEUROCHEM, V49, P348, DOI 10.1111/j.1471-4159.1987.tb02872.x; BAUDIER J, 1983, BIOCHEMISTRY-US, V22, P3360, DOI 10.1021/bi00283a009; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BAUDIER J, 1988, BIOCHEMISTRY-US, V27, P2728, DOI 10.1021/bi00408a012; BIANCHI R, 1992, BIOCHIM BIOPHYS ACTA, V1160, P67, DOI 10.1016/0167-4838(92)90039-G; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; CALISSANO P, 1969, BIOCHEMISTRY-US, V8, P4318, DOI 10.1021/bi00839a015; DAHL D, 1983, HDB NEUROCHEMISTRY, V5, P127; DONATO R, 1988, CELL BIOL INT REP, V12, P565, DOI 10.1016/0309-1651(88)90044-6; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; DONATO R, 1989, J NEUROCHEM, V53, P566, DOI 10.1111/j.1471-4159.1989.tb07371.x; DONATO R, 1988, J BIOL CHEM, V263, P106; DONATO R, 1989, CELL CALCIUM, V10, P81, DOI 10.1016/0143-4160(89)90048-1; DONATO R, 1984, BIOCHEM BIOPH RES CO, V124, P850, DOI 10.1016/0006-291X(84)91035-0; DONATO R, 1986, J NEUROCHEM, V46, P1333, DOI 10.1111/j.1471-4159.1986.tb01743.x; FREEMAN MR, 1989, EXP CELL RES, V182, P370, DOI 10.1016/0014-4827(89)90242-5; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1985, FEBS LETT, V192, P79, DOI 10.1016/0014-5793(85)80047-8; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS CV, 1980, NEUROCHEM RES, V5, P1199, DOI 10.1007/BF00964899; LUCAS CV, 1980, NEUROCHEM RES, V5, P247, DOI 10.1007/BF00964613; MESSENS J, 1992, J NEUROCHEM, V58, P2071, DOI 10.1111/j.1471-4159.1992.tb10948.x; MINURA M, 1990, J NEUROCHEM, V55, P1180; NAKAMURA Y, 1991, GLIA, V4, P101, DOI 10.1002/glia.440040112; Pendergast F. G., 1983, J BIOL CHEM, V258, P7541; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PRITCHARD K, 1991, BIOCHEM J, V277, P819, DOI 10.1042/bj2770819; RAMBOTTI MG, 1990, J HISTOCHEM CYTOCHEM, V38, P1583, DOI 10.1177/38.11.2212618; RUEGER DC, 1979, J MOL BIOL, V135, P53, DOI 10.1016/0022-2836(79)90340-1; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; SHAW G, 1992, NEUROREPORT, V3, P461, DOI 10.1097/00001756-199206000-00001; SKRIPNIKOVA EV, 1989, FEBS LETT, V257, P380, DOI 10.1016/0014-5793(89)81577-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7038, DOI 10.1021/bi00418a055; YANG ZW, 1988, BIOCHEMISTRY-US, V27, P7045, DOI 10.1021/bi00418a056; ZOLESE G, 1993, BIOCHIM BIOPHYS ACTA, V1162, P47, DOI 10.1016/0167-4838(93)90126-C	43	114	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12669	12674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509402				2022-12-25	WOS:A1993LG65800066
J	GRILLEY, M; GRIFFITH, J; MODRICH, P				GRILLEY, M; GRIFFITH, J; MODRICH, P			BIDIRECTIONAL EXCISION IN METHYL-DIRECTED MISMATCH REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA; PURIFICATION; SEQUENCES; EXTRACTS; INVITRO	Using electron microscopy and indirect end-labeling methods, we have examined excision tracts produced by the Escherichia coli methyl-directed mismatch repair system on a closed circular G-T heteroduplex that contains a single d(GATC) site. Despite differing polarities of the unmodified strand in the two hemimethylated derivatives of the heteroduplex, that portion of the unmethylated strand spanning the shorter path between the d(GATC) site and mismatch is targeted for excision in both cases. Mismatch-provoked excision occurring on both hemimethylated DNAs requires DNA helicase II, but exonuclease requirements for the reaction depend on heteroduplex orientation. When the d(GATC) sequence on the unmodified strand resides 3' to the mismatch as viewed along the shorter path, excision requires exonuclease I. Excision occurring on the alternate hemimethylated heteroduplex depends on the 5' --> 3' hydrolytic activity of exonuclease VII. Coupled with the previous demonstration that repair initiates via the mismatch-provoked, MutHLS-dependent incision of the unmethylated strand at a d(GATC) sequence (Au, K. G., Welsh, K., and Modrich, P. (1992) J. Biol. Chem. 267, 12142-12148), these findings indicate an excision mechanism in which helicase II displacement renders the incised strand sensitive to the appropriate single-strand exonuclease. Our data imply that hydrolysis commences at the d(GATC) site, proceeds to a point beyond the mismatch, and terminates at a number of discrete sites within a 100-nucleotide region just beyond this site. The extent of excision is therefore controlled by one or more components of the repair system.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819, R01GM023719, R37GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819, GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1992, J BIOL CHEM, V267, P12142; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DL, 1993, J BIOL CHEM, V268, P11823; FANG WH, 1993, J BIOL CHEM, V268, P11838; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LAHUE RS, 1987, UCLA S MOL CELLULAR, V47, P125; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SU SS, 1989, GENOME, V31, P104, DOI 10.1139/g89-020; SU SS, 1988, J BIOL CHEM, V263, P6829; THOMAS DC, 1991, J BIOL CHEM, V266, P3744	20	129	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11830	11837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505311				2022-12-25	WOS:A1993LF28400057
J	ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E				ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E			P300, AND P300-ASSOCIATED PROTEINS, ARE COMPONENTS OF TATA-BINDING PROTEIN (TBP) COMPLEXES	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; HUMAN ADENOVIRUS TYPE-5; TFIID COMPLEX; DNA-SYNTHESIS; E1A GENE; PRODUCTS; DOMAINS; COACTIVATORS; ACTIVATION; ANTIBODIES	The transforming proteins encoded by the adenovirus E1A gene bind to a 300-kDa cellular product, p300, via the N-terminal E1A sequences. Residues important for p300 binding are required for the transformation function of E1A and for other E1A-mediated gene-regulating functions, including activation of cell cycle-regulated products and repression of tissue-specific enhancer activity. Recent evidence indicates that p300 is a DNA-binding protein with specific affinity for known enhancer motifs, suggesting that p300 may be a component of transcription factor complexes. The possibility that upstream element-binding factors might interact with basal transcription factors led us to investigate whether p300 interacts, directly or indirectly, with the TATA-binding protein (TBP). We report here that TBP-specific immunoprecipitations show a 300-kDa protein co-precipitating with TBP. This protein is lost from the precipitated material if the lysates are boiled in sodium dodecyl sulfate prior to immunoprecipitation, implying that its presence does not result from non-specific antibody cross-reactivity, but is dependent on specific association with TBP. The TBP-associated 300-kDa protein and p300 originally defined by EIA association show indistinguishable partial proteolytic digest patterns, indicating that these are identical or closely related species. Moreover, p300-specific complexes and TBP-specific complexes include at least two additional common polypeptide species, phosphoproteins of 64 and 59 kDa. These results suggest that p300 interacts with TBP, possibly through intermediate protein-protein associations. They thus provide additional biochemical evidence for postulated protein-protein interactions between upstream regulatory factors and the basal transcriptional machinery.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA055330, R01CA053592] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53592, CA-55330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	41	132	134	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502484				2022-12-25	WOS:A1993LE06400028
J	CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F				CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F			G1 EXPRESSION AND MULTISTAGE DYNAMICS OF CYCLIN-A IN HUMAN OSTEOSARCOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; P34CDC2 PROTEIN-KINASE; MATURATION-PROMOTING FACTOR; DNA-BINDING PROTEIN; CDC2 PROTEIN; TRANSCRIPTION FACTOR; HISTONE-H1 KINASE; RB PROTEIN; M-PHASE; PHOSPHORYLATION	Cyclin A was initially characterized as a 'mitotic cyclin', believed to function exclusively at the G2-to-M phase transition; however, recent studies have provided compelling evidence that cyclin A additionally functions earlier in the mammalian somatic cell cycle as a putative 'S-phase-promoting factor'. Moreover, numerous inconsistencies have arisen concerning the temporal induction, subcellular localization, subunit configuration, covalent modification and proteolytic destruction of cyclin A, as well as the physiological function of the cyclin A-associated protein kinase complexes. Utilizing precisely synchronized human MG-63 osteosarcoma cells, the present study demonstrates that cyclin A mRNA and protein are clearly expressed in late G1 prior to S-phase entry, as is cyclin A-associated kinase activity and concomitant phosphorylation of the Rb protein. A series of monospecific cyclin A antibodies were generated and utilized to confirm that multiple covalent modifications of cyclin A occur during the course of the cell cycle, and to characterize the subcellular dynamics in additional detail. Pharmacological blockade with mimosine was utilized to further delineate cyclin A expression and to distinguish the temporal induction from the mechanisms of enzyme activation. Subcellular fractionation and immunocytochemical staining localized nascent cyclin A to the cytoplasm, and revealed a distinct translocation to the nucleus during the G1-to-S phase transition. The results of these studies support a multistage model of cyclin A metabolism and enzyme activation.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA; CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULM, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH DENT, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, CTR CRANIOFACIAL MOLEC BIOL, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California			Zeichner-David, Margarita/A-6567-2008					BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cooper JA, 1990, CURR OPIN CELL BIOL, V2, P285, DOI 10.1016/0955-0674(90)90021-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; FOX MH, 1987, CYTOMETRY, V8, P315, DOI 10.1002/cyto.990080312; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LALANDE M, 1990, EXP CELL RES, V188, P117, DOI 10.1016/0014-4827(90)90285-I; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LU XP, 1992, J BIOL CHEM, V267, P2841; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Maniatis T., 1982, MOL CLONING; MARIA T, ONCOGENE, V43, P477; MARX J, 1991, SCIENCE, V252, P1490, DOI 10.1126/science.1828620; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA T, 1990, ONCOGENE, V5, P1259; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	77	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1649	1659						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502485				2022-12-25	WOS:A1993LE06400029
J	SCHWARTZ, D; GOLDFINGER, N; ROTTER, V				SCHWARTZ, D; GOLDFINGER, N; ROTTER, V			EXPRESSION OF P53 PROTEIN IN SPERMATOGENESIS IS CONFINED TO THE TETRAPLOID PACHYTENE PRIMARY SPERMATOCYTES	ONCOGENE			English	Article							WILD-TYPE P53; T-ANTIGEN; CELL-DEVELOPMENT; DNA-REPLICATION; SV40 ORIGIN; MUTANT; ONCOGENE; TRANSFORMATION; LOCALIZATION; INVITRO	The various steps of differentiation and maturation in spermatogenesis are well characterized and offer a convenient system to explore the possibility that p53 plays a role in cell differentiation in vivo. In situ hybridization experiments indicate that the p53 gene is expressed in tetraploid primary spermatocytes at the meiotic pachytene stage of the first round of spermatogenesis in young mice. An analysis of spermatogenic cells treated with anti-p53 antibodies reveals that the p53 protein is expressed in a discrete tetraploid cell population, with size and cellular structure parameters characteristic of mid-pachytene spermatocytes. The specific kinetics of p53 expression in the first round of spermatogenesis and its localization in adult testicular sections, coupled with the fact that the protein is expressed in the largest cells with lower DNA density, suggest that p53 expression is confined to the tetraploid primary spermatocytes of the meiotic pachytene phase. These observations identify p53 protein as a potential member of the meiosis control protein family.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; ALMON E, 1993, IN PRESS DEV BIOL; AUSTIN CR, 1982, GERM CELLS FERTILIZA; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN YM, 1991, ONCOGENE, V6, P1799; DILLER L, 1990, MOL CELL BIOL, V10, P5722; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOGEN B, 1986, MANIPULATING MOUSE E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANCA FC, 1986, BIOL REPROD, V34, P613, DOI 10.1095/biolreprod34.4.613; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; NEVEL BR, 1961, SCIENCE, V143, P832; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAHW P, 1992, P NATL ACAD SCI USA, V89, P4495; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STURZBECHER HW, 1988, ONCOGENE, V3, P405; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	49	140	146	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1487	1494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502474				2022-12-25	WOS:A1993LE06400011
J	BALDWIN, TO; ZIEGLER, MM; CHAFFOTTE, AF; GOLDBERG, ME				BALDWIN, TO; ZIEGLER, MM; CHAFFOTTE, AF; GOLDBERG, ME			CONTRIBUTION OF FOLDING STEPS INVOLVING THE INDIVIDUAL SUBUNITS OF BACTERIAL LUCIFERASE TO THE ASSEMBLY OF THE ACTIVE HETERODIMERIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; VIBRIO-HARVEYI; DENATURED SUBTILISIN; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; BETA-SUBUNIT; PRO-REGION; LUXB GENE; REQUIRE; INVIVO	Bacterial luciferase is an alphabeta heterodimer with a single active center in which the reaction of reduced FMN, O2, and an aliphatic aldehyde yields a photon of blue-green light. We have shown that refolding of the luciferase subunits from 5 M urea occurs via the intermediacy of several species, one of which is an inactive heterodimeric structure, resulting from the dimerization of alpha and beta, which isomerizes to the active alphabeta structure in a first-order reaction (Ziegler, M. M., Goldberg, M. E., Chaffotte, A. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10760-10765). We have also demonstrated the existence of an inactive heterodimeric species that is well populated at equilibrium in the presence of 1.6-2.8 M urea (Clark, A. C., Sinclair, J. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10773-10779). We have separated the alpha and beta subunits by ion exchange chromatography and investigated the effects on reformation of active luciferase of allowing the individual subunits to refold separately prior to mixing. These investigations show that the lag in formation of active luciferase is due to slow steps in folding of the individual subunits. The beta subunit appears to fold faster than the alpha subunit, but folding of the beta subunit also shows a distinct lag. When the alpha and beta subunits were allowed to refold from urea for periods of several hours or more prior to mixing, the yield of active heterodimeric luciferase was compromised, which is consistent with the finding that individual subunits produced in vivo fold into structures incompetent to interact with each other to form the active heterodimer (Waddle, J. J., Johnston, T. C., and Baldwin, T. O. (1987) Biochemistry 26, 4917-4921). It appeared that the rate with which the beta subunit assumed the heterodimerization-incompetent structure was faster than the rate with which the alpha subunit became heterodimerization-incompetent. These observations support a model for folding and assembly of the subunits of luciferase in which the two subunits fold into assembly-competent structures that associate to form the heterodimer. In a slow competing process, the subunits undergo a conformational rearrangement to form stable structures incompetent to form heterodimers. It appears that the association of the luciferase subunits might constitute an example of one polypeptide modifying the folding pathway of another, a model that is consistent with the suggestion that the formation of the heterodimeric structure of luciferase is a kinetic trap on the folding pathway of the individual subunits (Sugihara, J., and Baldwin, T. O. (1988) Biochemistry 27, 2872-2880).	TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,CTR MACROMOLEC DESIGN,COLL STN,TX 77843; INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Texas A&M University System; Texas A&M University College Station; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	BALDWIN, TO (corresponding author), TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843, USA.				FIC NIH HHS [1 FO6 TW016066-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P4303, DOI 10.1021/bi00132a022; CLARK AC, 1993, J BIOL CHEM, V268, P10773; COHN DH, 1985, J BIOL CHEM, V260, P6139; FRIEDLAND J, 1967, P NATL ACAD SCI USA, V58, P2336, DOI 10.1073/pnas.58.6.2336; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TU SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P342, DOI 10.1016/0003-9861(77)90120-5; TU SC, 1978, METHOD ENZYMOL, V57, P171; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WADDLE JJ, 1990, THESIS TEXAS AM U CO; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760	27	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10766	10772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496143				2022-12-25	WOS:A1993LD46600012
J	WICK, PF; SENTER, RA; PARSELS, LA; UHLER, MD; HOLZ, RW				WICK, PF; SENTER, RA; PARSELS, LA; UHLER, MD; HOLZ, RW			TRANSIENT TRANSFECTION STUDIES OF SECRETION IN BOVINE CHROMAFFIN CELLS AND PC12 CELLS - GENERATION OF KAINATE-SENSITIVE CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTOR CHANNELS; HUMAN GROWTH-HORMONE; CATECHOLAMINE SECRETION; ADRENAL-MEDULLA; PROTEIN-KINASE; MAMMALIAN-CELLS; CALCIUM; SUBUNIT; CA-2+; IDENTIFICATION	We have developed a transient transfection method to measure protein secretion from non-dividing, primary bovine chromaffin cells and from the continuous cell line, PC12. A plasmid coding human growth hormone (GH) was expressed in sufficient amounts in bovine chromaffin and PC12 cells to allow precise measurements of secretion from the small fraction (less than 1%) of transfected cells in a dish. GH was secreted in a similar proportion to endogenous catecholamine upon nicotinic stimulation, depolarization with elevated K+, and upon permeabilization with digitonin and subsequent stimulation with micromolar Ca2+. GH in homogenates from GH-transfected chromaffin cells cosedimented with catecholamine on discontinuous sucrose gradients. The data indicate that transiently expressed human GH in chromaffin and PC12 cells is localized predominantly in secretory vesicles in the regulated secretory pathway. With transient transfection there is a high probability of coexpression in the same cell of two plasmids which are cotransfected. Coexpression of a plasmid for GH and a plasmid for the non-N-methyl-D-aspartate glutamate receptor, GluR1, created chromaffin cells in which Ca2+-dependent GH secretion could be stimulated by the glutamatergic agonist kainate. The ability to coexpress a plasmid of interest with a plasmid for GH will allow the investigation of the role of other cloned proteins in the regulated secretory pathway in differentiated, non-dividing cells.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,M6222 MED SCI I,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,MENTAL HLTH RES INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27599] Funding Source: Medline; NIGMS NIH HHS [5T32GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS JC, 1983, J NEUROCHEM, V40, P468, DOI 10.1111/j.1471-4159.1983.tb11306.x; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; DUNN LA, 1983, J BIOL CHEM, V258, P4989; GORMAN CM, 1991, DNA PROTEIN ENG TECH, V2, P3; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HENNEBERRY RC, 1992, BIOESSAYS, V14, P465, DOI 10.1002/bies.950140707; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLZ RW, 1985, J NEUROCHEM, V45, P1548, DOI 10.1111/j.1471-4159.1985.tb07226.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KILPATRICK DL, 1981, J NEUROCHEM, V36, P1245, DOI 10.1111/j.1471-4159.1981.tb01724.x; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; MA WJ, 1992, J BIOL CHEM, V267, P22728; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; ROGERS SW, 1991, J NEUROSCI, V11, P2713; ROSS ME, 1990, J NEUROSCI, V10, P520; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCANGOS G, 1981, GENE, V14, P1, DOI 10.1016/0378-1119(81)90143-8; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; VALLAR L, 1987, J BIOL CHEM, V262, P5049; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101; WAGNER PD, 1990, J BIOL CHEM, V265, P10352; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WILSON SP, 1983, J BIOL CHEM, V258, P4994; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J	42	124	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10983	10989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496162				2022-12-25	WOS:A1993LD46600043
J	CZECH, MP; BUXTON, JM				CZECH, MP; BUXTON, JM			INSULIN ACTION ON THE INTERNALIZATION OF THE GLUT4 GLUCOSE TRANSPORTER IN ISOLATED RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE; TRANSLOCATION; CELLS; PROTEIN; FAMILY	A novel method was developed to measure relative amounts of the GLUT4 glucose transporter on the surface of intact fat cells and to monitor the action of insulin on cell surface glucose transporters as they internalize into intracellular membranes. The method takes advantage of two predicted trypsin cleavage sites in the major exofacial loop of this transporter protein. Treatment of cyanide-poisoned rat adipocytes with 1 mg/ml trypsin at 37-degrees-C for 30 min produced an immunoreactive GLUT4 protein species in subsequently isolated plasma membranes that migrated with higher mobility (apparent M(r) = 35,000) than native GLUT4 (apparent M(r)= 46,000) on SDS-polyacrylamide gel electrophoresis. This proteolyzed GLUT4 protein was absent in the intracellular low density microsomes. Insulin treatment of adipocytes for 20 min prior to sequential additions of cyanide and trypsin caused a 16-fold increase in the proteolytically cleaved GLUT4 species. Incubation of fresh fat cells with trypsin caused a rapid and progressive appearance of the proteolyzed GLUT4 species in the intracellular low density membranes as well as plasma membranes. After 5 min of trypsinization, 66% of the total cleaved GLUT4 in these cells had moved into the low density membranes. Insulin treatment markedly decreased the internalized cleaved GLUT4 to 20% of the total. These data indicate the following: 1) trypsinization of the GLUT4 transporter protein on intact fat cells is a convenient means to monitor the extent of transporter recruitment to the plasma membrane by insulin, as well as to estimate GLUT4 internalization rates; and 2) the action of insulin on glucose transporter redistribution to the cell surface is associated with a marked inhibition of the fraction of cell surface GLUT4 transporters internalized per unit time.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	CZECH, MP (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030898, R37DK030898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1988, J BIOL CHEM, V263, P13432; POKU J, 1992, DIABETES S1, V41, pA151; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	25	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9187	9190						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486618				2022-12-25	WOS:A1993LA68900009
J	PHAN, LD; PERENTESIS, JP; BODLEY, JW				PHAN, LD; PERENTESIS, JP; BODLEY, JW			SACCHAROMYCES-CEREVISIAE ELONGATION FACTOR-II - MUTAGENESIS OF THE HISTIDINE PRECURSOR OF DIPHTHAMIDE YIELDS A FUNCTIONAL PROTEIN THAT IS RESISTANT TO DIPHTHERIA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; FACTOR-II; ADP-RIBOSYLATION; HYDROLYSIS PRODUCTS; TRANSLOCATION; YEAST; MUTANTS; INVITRO; CELLS; SITE	Protein synthesis elongation factor 2 (EF-2) is the target of the ADP-ribosylating activity of diphtheria toxin which is responsible for cell killing. Diphthamide, an unique post-translationally modified histidine residue, is both required for and the site of this ADP-ribosylation. Although present in the EF-2 of all eukaryotes and archaebacteria, the function of diphthamide is unknown. Here we describe the site-specific mutagenesis of the histidine precursor of diphthamide, histidine 699, in yeast EF-2. Plasmid-borne EFT was randomly mutagenized at the histidine 699 codon, and the technique of plasmid shuffling was utilized to select strains that were maintained by the mutant EFT. These mutants were screened for diphtheria toxin resistance. Sequence analysis of the EFT in 49 toxin-resistant isolates showed that histidine 699 had been replaced by 1 of 4 amino acids: asparagine, glutamine, leucine, or methionine. All 11 of the possible codons corresponding to these 4 amino acids were found. The growth rates of cells sustained by the mutant forms of EF-2 were slightly slower than those of isogenic wild-type cells. We conclude that despite its strict conservation and universal post-translational modification, the histidine precursor of diphthamide is not essential to the function of yeast EF-2 in protein synthesis.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM,RM 4-225,MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Perentesis, John/0000-0002-4237-8226	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI00793] Funding Source: Medline; NIGMS NIH HHS [GM-26832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONUMA S, 1991, MUTAT RES, V250, P375, DOI 10.1016/0027-5107(91)90194-S; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BODLEY JW, 1984, ARCH BIOCHEM BIOPHYS, V230, P590, DOI 10.1016/0003-9861(84)90439-9; BODLEY JW, 1990, SCIENCE, V250, P832; BODLEY JW, 1990, ADP RIBOSYLATING TOX, P21; BROWN BA, 1979, FEBS LETT, V103, P253, DOI 10.1016/0014-5793(79)81339-3; CHEN JYC, 1985, MOL CELL BIOL, V5, P3357, DOI 10.1128/MCB.5.12.3357; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; DUNN B, 1990, CURRENT PROTOCOLS MO; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; EVANS DA, 1992, J AM CHEM SOC, V114, P1495, DOI 10.1021/ja00030a063; KESSEL M, 1980, NATURE, V287, P250, DOI 10.1038/287250a0; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; MOEHRING TJ, 1984, MOL CELL BIOL, V4, P642, DOI 10.1128/MCB.4.4.642; MOEHRING TJ, 1979, SOMAT CELL GENET, V5, P469, DOI 10.1007/BF01538881; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERENTESIS JP, 1988, P NATL ACAD SCI USA, V85, P8386, DOI 10.1073/pnas.85.22.8386; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; ROBINSON EA, 1974, J BIOL CHEM, V249, P5088; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TRECO DA, 1990, CURRENT PROTOCOLS MO; VANNESS BG, 1980, J BIOL CHEM, V255, P710; VANNESS BG, 1980, J BIOL CHEM, V255, P717	36	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8665	8668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473309				2022-12-25	WOS:A1993KX81100045
J	YANOFSKY, C; YEE, MC; HORN, V				YANOFSKY, C; YEE, MC; HORN, V			PARTIAL REVERTANTS OF TRYPTOPHAN SYNTHETASE-ALPHA CHAIN ACTIVE-SITE MUTANT ASP60-]ASN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BIENZYME COMPLEX; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MULTIENZYME COMPLEX; CATALYTIC RESIDUE; BETA-SUBUNIT; MECHANISM; PROTEINS; DNA	Residue Asp60 of the tryptophan synthetase alpha chain of Escherichia coli is thought to interact with the pyrrole NH of substrate indole-3-glycerol phosphate and facilitate its cleavage to indole and glyceraldehyde 3-phosphate. Two distinguishable partial revertants of DN60 tryptophan synthetase alpha mutant trpA34 were analyzed. The slower growing partial revertant, PR1, had the second-site change, YD102. The other partial revertant, PR2, lacked three consecutive base pairs, resulting in replacement of Ala59 and Asn60 of the DN60 mutant alpha polypeptide by Asp. Inspection of the three-dimensional structure of the enzyme-substrate analog complex (1) revealed that Tyr102 is in the vicinity of the pyrrole NH of the substrate. The PR1 alpha chain has a near normal K(m) for substrate, whereas the PR2 polypeptide has greatly reduced substrate affinity. The PR2 polypeptide is more active than the PR1 polypeptide in the alphabeta reaction in vitro and appears to be more active than the PR1 polypeptide in vivo. Attempts to obtain repeat occurrences of the PR2 deletion mutation were unsuccessful. A third type of trpA34 partial revertant, PR3, that grows very poorly in minimal medium, also has a Tyr102 replacement: YF102. These findings demonstrate that each of the second-site mutations affects a residue located in the vicinity of the active site residue altered by the primary mutation. Slightly leaky mutant trpA89, genetically altered near the site of the trpA34 mutation, was found to have a GS61 substitution.			YANOFSKY, C (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.							AHMED SA, 1991, J BIOL CHEM, V266, P21548; ALLEN MK, 1963, GENETICS, V48, P1065; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; BURNS DM, 1990, J BIOL CHEM, V265, P2060; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CRAWFORD IP, 1989, ANNU REV MICROBIOL, V43, P567, DOI 10.1146/annurev.mi.43.100189.003031; CRAWFORD IP, 1958, P NATL ACAD SCI USA, V44, P1161, DOI 10.1073/pnas.44.12.1161; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; HELINSKI DR, 1963, J BIOL CHEM, V238, P1043; HENNING U, 1963, J MOL BIOL, V6, P16, DOI 10.1016/S0022-2836(63)80077-7; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; IBEL K, 1985, EUR J BIOCHEM, V151, P505, DOI 10.1111/j.1432-1033.1985.tb09131.x; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LIM WK, 1991, J BIOL CHEM, V266, P20205; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; NAGATA S, 1989, J BIOL CHEM, V264, P6288; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; ROSS CM, 1988, J BACTERIOL, V170, P757, DOI 10.1128/jb.170.2.757-768.1988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; TWEEDY NB, 1990, BIOCHEMISTRY-US, V29, P1539, DOI 10.1021/bi00458a027; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; YANG XJ, 1992, J BIOL CHEM, V267, P7520; YANOFSKY C, 1961, COLD SPRING HARB SYM, V26, P11, DOI 10.1101/SQB.1961.026.01.006; YANOFSKY C, 1969, 12TH P INT C GEN, V3, P155; Yanofsky C., 1972, ENZYMES, VVII; YAP EPH, 1992, TRENDS GENET, V8, P49, DOI 10.1016/0168-9525(92)90339-6; YUTANI K, 1987, J BIOL CHEM, V262, P13429	52	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8213	8220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463331				2022-12-25	WOS:A1993KW97900091
J	KLEIN, ML; FULCO, AJ				KLEIN, ML; FULCO, AJ			CRITICAL RESIDUES INVOLVED IN FMN BINDING AND CATALYTIC ACTIVITY IN CYTOCHROME-P450(BM-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CYTOCHROME P-450 REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; BACILLUS-MEGATERIUM; ESCHERICHIA-COLI; FLAVODOXIN GENE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CODING NUCLEOTIDE; IDENTIFICATION	Cytochrome P450BM-3 from Bacillus megaterium is a soluble, catalytically self-sufficient fatty acid mono-oxygenase that, in structural organization and amino acid sequence, resembles the Class II (microsomal) P450 systems. Its single polypeptide chain contains both a P450 heme domain and an NADPH:P450 reductase domain, each of which bears significant homology with its microsomal counterparts. We report here the critical nature of three amino acids in the reductase domain of this enzyme with respect to FMN binding and catalytic activity. We used site-directed mutagenesis to change glycine 570 to bulkier amino acids; none of these mutant enzymes contained FMN after purification. We also made substitutions for tryptophan 574 and tyrosine 536, which by sequence analogy (Porter, T. D. (1991) Trends Biochem. Sci. 16, 154-158) were proposed to bind FMN through stacking of the aromatic rings with the isoalloxazine ring of the flavin. Mutants of tryptophan 574 which retained the aromatic side chain contained no less than 0.85 mol of FMN per mol of enzyme, while aspartate and glycine substitutions yielded enzymes which did not incorporate FMN. Substitution of tyrosine 536 with aspartate gave an enzyme which contained 0.44 mol of FMN per mol of enzyme but was inactive as a fatty acid hydroxylase and had only 2% of wild-type cytochrome c reductase activity, while the glycine mutant at this position bound no FMN. Furthermore, although all of the mutant enzymes contained 1 mol of FAD per mol of enzyme, the Y536D mutant and those entirely lacking FMN retained no more than 40% of wild-type ferricyanide reductase activity. By assaying these enzymes in the presence of added FMN, we were able to assess the relative importance of the residues in the wild-type sequence with respect to their contribution to FMN binding. In addition, the aromatic mutants of tryptophan 574, which were nearly as active in cytochrome c reduction as wild-type P450BM-3, were only 20% as active in myristate hydroxylation as the wild-type enzyme, suggesting that this amino acid plays an important role in the flow of electrons between the P450 heme and reductase domains.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07386] Funding Source: Medline; NIGMS NIH HHS [GM23913] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BODDUPALLI SS, 1992, P NATL ACAD SCI USA, V89, P5567, DOI 10.1073/pnas.89.12.5567; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRUMMOND MH, 1985, BIOCHEM J, V232, P891, DOI 10.1042/bj2320891; DUBOURDIEU M, 1977, J BIOL CHEM, V252, P1453; FULCO AJ, 1983, MOL CELL BIOCHEM, V53-4, P155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HANIU M, 1986, BIOCHEMISTRY-US, V25, P7906, DOI 10.1021/bi00372a018; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HELMS LR, 1990, BIOCHEM BIOPH RES CO, V168, P809, DOI 10.1016/0006-291X(90)92393-E; KATAGIRI M, 1986, J BIOCHEM-TOKYO, V100, P945, DOI 10.1093/oxfordjournals.jbchem.a121807; KLATT P, 1992, J BIOL CHEM, V267, P11374; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDENBACH DE, 1988, J BACTERIOL, V170, P258, DOI 10.1128/jb.170.1.258-265.1988; LEONHARDT KG, 1989, NUCLEIC ACIDS RES, V17, P4384, DOI 10.1093/nar/17.11.4384; LI HY, 1991, J BIOL CHEM, V266, P11909; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MIURA Y, 1974, J BIOL CHEM, V249, P1880; MURAKAMI H, 1986, DNA-J MOLEC CELL BIO, V5, P1, DOI 10.1089/dna.1986.5.1; NADLER SG, 1991, ARCH BIOCHEM BIOPHYS, V290, P277, DOI 10.1016/0003-9861(91)90542-Q; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1988, MOL CELL BIOCHEM, V79, P63, DOI 10.1007/BF00229399; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NARHI LO, 1984, THESIS U CALIFORNIA; NISIMOTO Y, 1992, EUR J BIOCHEM, V204, P1075, DOI 10.1111/j.1432-1033.1992.tb16731.x; OMURA T, 1964, J BIOL CHEM, V239, P2379; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; OSTER T, 1991, J BIOL CHEM, V266, P22718; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLENBERG KA, 1958, J BIOL CHEM, V231, P547; SHEN AL, 1989, J BIOL CHEM, V264, P7584; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TANAKA M, 1973, J BIOL CHEM, V248, P4354; TANAKA M, 1974, J BIOL CHEM, V249, P4393; TANAKA M, 1977, BIOCHEMISTRY-US, V16, P3525, DOI 10.1021/bi00635a005; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URENJAK J, 1987, J CHROMATOGR, V397, P123, DOI 10.1016/S0021-9673(01)84995-5; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WAKABAYASHI S, 1989, BIOCHEM J, V263, P981, DOI 10.1042/bj2630981; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; WEN LP, 1987, J BIOL CHEM, V262, P6676; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370	61	63	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7553	7561						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463285				2022-12-25	WOS:A1993KV14100105
J	MICHAEL, SI; HUANG, CH; ROMER, MU; WAGNER, E; HU, PC; CURIEL, DT				MICHAEL, SI; HUANG, CH; ROMER, MU; WAGNER, E; HU, PC; CURIEL, DT			BINDING-INCOMPETENT ADENOVIRUS FACILITATES MOLECULAR CONJUGATE-MEDIATED GENE-TRANSFER BY THE RECEPTOR-MEDIATED ENDOCYTOSIS PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA; CELLS; DELIVERY; EXPRESSION; POLYLYSINE; PROTEIN; AGENTS	Molecular conjugate vectors may be constructed that accomplish high efficiency gene transfer by the receptor-mediated endocytosis pathway. In order to mediate escape from lysosomal degradation, we have incorporated adenoviruses into the functional design of the conjugate. In doing so, however, we have introduced an additional ligand, which can bind to receptors on the cell surface, undermining the potential for cell specific targeting. To overcome this, we have treated the adenovirus with a monoclonal anti-fiber antibody, which renders the virus incapable of binding to its receptor. The result is a multi-functional molecular conjugate vector, which has preserved its binding specificity while at the same time being capable of preventing lysosomal degradation of endosome-internalized conjugate-DNA complexes. This finding indicates that adenoviral binding is not a prerequisite for adenoviral-mediated endosome disruption.	UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	MICHAEL, SI (corresponding author), UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.		Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934				COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; CURIEL DT, 1993, IN PRESS GENE THERAP; DAVIDSON D, 1987, J VIROL, V61, P1226, DOI 10.1128/JVI.61.4.1226-1239.1987; HU PC, 1982, SCIENCE, V216, P313, DOI 10.1126/science.6801766; HUCKETT B, 1990, BIOCHEM PHARMACOL, V40, P253, DOI 10.1016/0006-2952(90)90686-F; MICHAEL SI, 1993, 1993 KEYST S GEN TAR; Pastan I, 1986, VIRUS ATTACHMENT ENT, P141; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; ROSENKRANZ AA, 1992, EXP CELL RES, V199, P323, DOI 10.1016/0014-4827(92)90441-A; SETH P, 1984, MOL CELL BIOL, V4, P1528, DOI 10.1128/MCB.4.8.1528; WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WOHLFART C, 1985, VIRUS RES, V3, P77, DOI 10.1016/0168-1702(85)90043-7; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; ZATLOUKAL K, 1992, ANN NY ACAD SCI, V660, P136, DOI 10.1111/j.1749-6632.1992.tb21066.x	21	57	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6866	6869						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463214				2022-12-25	WOS:A1993KV14100012
J	PARKER, CM; PUJADES, C; BRENNER, MB; HEMLER, ME				PARKER, CM; PUJADES, C; BRENNER, MB; HEMLER, ME			ALPHA(4/180), A NOVEL FORM OF THE INTEGRIN ALPHA(4)-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; T-CELLS; BIOCHEMICAL-CHARACTERIZATION; FIBRONECTIN MOLECULES; CHEMICAL MODIFICATION; POLYACRYLAMIDE GELS; MELANOMA ADHESION; VLA PROTEINS; RECEPTOR	The integrin alpha4beta1 (VLA-4) is a versatile cell-cell and cell-extracellular matrix adhesion receptor. The alpha4 subunit can be expressed on the cell surface in two forms: an intact form (alpha4/150) and a cleaved form (alpha4/80, 70). Here we have characterized a third form of alpha4, called alpha3/180. Although alpha4/180 (M(r) 180, nonreduced) is different in size than alpha4/150 (M(r) 150, nonreduced), these two forms are clearly related, as they (i) shared the same amino- terminal sequence, (ii) were both recognized in Western blots by an anti-alpha4 COOH-terminal antiserum, (iii) migrated with the same apparent size and charge when reduced, and (iv) were both immunoprecipitated using anti-VLA-4 reagents. In pulse-chase experiments, precursors to both forms appeared simultaneously and matured at the same rate, indicating that one is most likely not the biosynthetic precursor of the other. Although reduction of alpha4/180 to yield alpha4/150 suggested the release of a cysteine-linked 30-kDa fragment, seven different biochemical techniques failed to identify such a fragment. Also, alpha4/180 was converted to alpha4/150 by incubation at pH 11, by treatment with EDTA at 56-degrees-C, or by heating in the presence of elevated SDS levels. Together our findings suggest that alpha4/180 and alpha4/150 represent different conformations of the same alpha4 polypeptide, with the former having anomalous slower migration in SDS-polyacrylamide gel electrophoresis. This unusual biochemical feature of alpha4 is not shared by other beta1-associated integrin alpha subunits and suggests that VLA-4 has unique structural properties.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	PARKER, CM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,SEELEY G MUDD BLDG,RM 504,BOSTON,MA 02115, USA.		Pujades, Cristina/F-7908-2014	Pujades, Cristina/0000-0001-6423-7451	NIAID NIH HHS [K11AI00903] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BRENNER MB, 1987, J IMMUNOL, V138, P1502; CLAYBERGER C, 1987, J IMMUNOL, V138, P1510; COMPANERO MR, 1990, J CELL BIOL, V110, P2157; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FISH WW, 1970, J BIOL CHEM, V245, P5166; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GEORGES E, 1987, EUR J BIOCHEM, V165, P281, DOI 10.1111/j.1432-1033.1987.tb11439.x; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1985, J BIOL CHEM, V260, P5246; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; ISLER P, 1988, EUR J IMMUNOL, V18, P1491, DOI 10.1002/eji.1830181004; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P109; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCINTYRE BW, 1989, J BIOL CHEM, V264, P13745; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUBIO M, 1992, EUR J IMMUNOL, V22, P1099, DOI 10.1002/eji.1830220434; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIXIDO J, 1992, J CLIN INVEST, V90, P358; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YEDNOCK YTA, 1992, NATURE, V356, P63; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	56	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7028	7035						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463236				2022-12-25	WOS:A1993KV14100035
J	RIETVELD, AG; KILLIAN, JA; DOWHAN, W; DEKRUIJFF, B				RIETVELD, AG; KILLIAN, JA; DOWHAN, W; DEKRUIJFF, B			POLYMORPHIC REGULATION OF MEMBRANE PHOSPHOLIPID-COMPOSITION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREEZE-FRACTURE TECHNIQUES; PHASE-BEHAVIOR; LIPID-COMPOSITION; P-31 NMR; ELECTRON-MICROSCOPY; MAGNETIC-RESONANCE; BILAYER STABILITY; PHOSPHATIDYLETHANOLAMINE; CARDIOLIPIN; GLYCOPHORIN	To investigate whether the phase preference of Escherichia coli membrane lipids is regulated by adjustment of the ratio of bilayer to non-bilayer lipids, the lipid biosynthetic mutant AD93 was used. This strain lacks the ability to synthesize phosphatidylethanolamine, a non-bilayer lipid which normally accounts for 70-80% of the phospholipids in the E. coli membrane. The lack of phosphatidylethanolamine is compensated by a large increase in the levels of phosphatidylglycerol and cardiolipin. This strain has an absolute requirement for high concentrations of divalent cations. Since divalent cations are known to induce H(II) phase formation in cardiolipin model systems, this suggests that cardiolipin in combination with divalent cations replaces phosphatidylethanolamine in the membrane and that it is the non-bilayer forming property of the latter which is important for membrane functioning. The growth of the mutant strain was found to be dependent on the type and concentration of divalent cations present in the growth medium. In media supplemented with MgCl2 and CaCl2, growth was maximal at concentrations of 30-50 mM. In the presence of SrCl2 a growth optimum was observed at 15 mM. The cells did not grow in the presence of BaCl2 oral high concentrations of SrCl2. Furthermore, this strain was found to adapt the lipid composition of the membrane in reaction to the type of cation present during growth. The phase behavior of dispersions of mutant and parental E. coli derived lipids was studied under a variety of conditions, using P-31 NMR. In the presence of the growth-promoting cations at concentrations where there is maximal growth, a bilayer to non-bilayer transition was observed in the lipid dispersions in a narrow temperature range, approximately 10-degrees-C above the growth temperature, whereas at concentrations where there is no growth, a bilayer structure was observed at all temperatures tested. This suggests a polymorphic regulation of membrane lipid composition in order to maintain a propensity toward type II structure formation in the membrane.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	University of Texas System	RIETVELD, AG (corresponding author), UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS.		Killian, J. Antoinette/I-3001-2016	Killian, J. Antoinette/0000-0001-8010-3816	NIGMS NIH HHS [GM 20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURNELL E, 1980, BIOCHIM BIOPHYS ACTA, V597, P492, DOI 10.1016/0005-2736(80)90222-9; CRONAN JE, 1972, BIOCHIM BIOPHYS ACTA, V265, P25, DOI 10.1016/0304-4157(72)90018-4; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V507, P207, DOI 10.1016/0005-2736(78)90417-0; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P11, DOI 10.1016/0005-2736(78)90107-4; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; FINE JB, 1982, J LIPID RES, V23, P660; GALLY HU, 1980, BIOCHEMISTRY-US, V19, P1638, DOI 10.1021/bi00549a018; GOLDFINE H, 1987, BIOCHEMISTRY-US, V26, P2814, DOI 10.1021/bi00384a024; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; IANZINI F, 1990, ARCH BIOCHEM BIOPHYS, V278, P1, DOI 10.1016/0003-9861(90)90223-L; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V469, P221, DOI 10.1016/0005-2736(77)90185-7; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; MENDELSOHN R, 1981, BIOCHEMISTRY-US, V20, P6699, DOI 10.1021/bi00526a027; NORRIS V, 1992, J THEOR BIOL, V154, P91, DOI 10.1016/S0022-5193(05)80190-0; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; SABELNIKOV AG, 1985, BIOCHEM BIOPH RES CO, V127, P464, DOI 10.1016/S0006-291X(85)80183-2; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; SIEGEL DP, 1986, CHEM PHYS LIPIDS, V42, P279, DOI 10.1016/0009-3084(86)90087-3; SIEGEL J, 1977, Q REV BIOPHYS, V10, P353; SMAAL EB, 1985, J LIPID RES, V26, P633; TILCOCK CPS, 1986, CHEM PHYS LIPIDS, V40, P47, DOI 10.1016/0009-3084(86)90061-7; VANDERSTEEN ATM, 1982, BIOCHIM BIOPHYS ACTA, V691, P13, DOI 10.1016/0005-2736(82)90208-5; VASILENKO I, 1982, BIOCHIM BIOPHYS ACTA, V684, P282, DOI 10.1016/0005-2736(82)90018-9; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002	32	128	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12427	12433						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509382				2022-12-25	WOS:A1993LG65800033
J	SCHNETKAMP, PPM; SZERENCSEI, RT				SCHNETKAMP, PPM; SZERENCSEI, RT			INTRACELLULAR CA2+ SEQUESTRATION AND RELEASE IN INTACT BOVINE RETINAL ROD OUTER SEGMENTS - ROLE IN INACTIVATION OF NA-CA+K EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; K EXCHANGE; PLASMA-MEMBRANE; CALCIUM; PHOTORECEPTORS; SODIUM; EXTRUSION; TRANSPORT; BINDING; GRADIENTS	Intracellular Ca2+ sequestration and Ca2+ release was analyzed in intact rod outer segments (ROS) purified from bovine retinas. Ca2+ influx in Ca2+-depleted and fully bleached ROS was mediated exclusively by the Na-Ca+K exchanger and was measured both as a rise in cytosolic free Ca2+ with fluo 3 and as a total transmembrane Ca2+ flux with Ca-45. Ca2+ fluxes across the ROS plasma membrane were not completely reversible, in small part due to inactivation of the Ca2+ extrusion mode of the Na-Ca+K exchanger but mostly due to sequestration of cytosolic Ca2+ into the intradiskal space. Ca2+ release from the intradiskal space into the cytosol could be induced by low concentrations of the Ca2+ ionophore A23187 which gave rise to increases in cytosolic free Ca2+ by several hundred nanomolar (low A23187 concentrations did not affect the Ca2+ permeability of the ROS plasma membrane). We have used intracellular Ca2+ release induced by A23187 to examine inactivation of the rapid Ca2+ efflux mode mediated by the plasma membrane Na-Ca+K exchanger. Inactivation of Na-Ca+K exchange appeared to be dependent on intradiskal Ca2+ as it was abolished by selective Ca2+ permeabilization of the disk membrane by A23187. We discuss possible physiological roles for Ca2+ sequestration and release from ROS disks.			SCHNETKAMP, PPM (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,AB,CANADA.							BAUER PJ, 1988, J PHYSIOL-LONDON, V401, P309, DOI 10.1113/jphysiol.1988.sp017164; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1991, J GEN PHYSIOL, V98, P479, DOI 10.1085/jgp.98.3.479; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; NICOL GD, 1987, J GEN PHYSIOL, V89, P297, DOI 10.1085/jgp.89.2.297; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1985, J MEMBRANE BIOL, V88, P249, DOI 10.1007/BF01871089; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P198; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1987, BIOCHEMISTRY-US, V26, P3249, DOI 10.1021/bi00386a002; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; SCHNETKAMP PPM, 1991, ANN NY ACAD SCI, V639, P10, DOI 10.1111/j.1749-6632.1991.tb17285.x; SCHNETKAMP PPM, 1990, J GEN PHYSIOL, V96, P517, DOI 10.1085/jgp.96.3.517; SCHNETKAMP PPM, 1987, J GEN PHYSIOL, V89, P481, DOI 10.1085/jgp.89.3.481; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0	26	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12449	12457						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509384				2022-12-25	WOS:A1993LG65800036
J	AVELDANO, MI; ROBINSON, BS; JOHNSON, DW; POULOS, A				AVELDANO, MI; ROBINSON, BS; JOHNSON, DW; POULOS, A			LONG AND VERY LONG-CHAIN POLYUNSATURATED FATTY-ACIDS OF THE N-6 SERIES IN RAT SEMINIFEROUS TUBULES - ACTIVE DESATURATION OF 24/4N-6 TO 24/5N-6 AND CONCOMITANT FORMATION OF ODD AND EVEN CHAIN TETRAENOIC AND PENTAENOIC FATTY-ACIDS UP TO C32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; METABOLISM; RETINA; SPERMATOZOA; SEPARATION; TESTES; LIVER	The formation of long and very long chain (VLC) n-6 polyunsaturated fatty acids (PUFA) in isolated rat seminiferous tubules was investigated by following the metabolism of three 1-C-14-labeled n-6 tetraenoic fatty acids (20:4, 24:4, and 32:4) and [U-C-14]acetate. In contrast to [C-14]32:4, which was poorly incorporated and altered, [C-14]20:4 and [C-14]24:4 were efficiently taken up by the tubules, esterified into lipids, elongated to VLCPUFA, and desaturated to pentaenoic fatty acids; the rate of [C-14]24:4 desaturation to [C-14]24:5 was notably high. The main products with [C-14]acetate as precursor were labeled saturates and VLCPUFA, most of the label in tetraenoic and pentaenoic acids appearing in 24:4 and 24:5, respectively. These two C24 polyenes, connected by a DELTA6 desaturation, may play a central role in n-6 PUFA metabolism, in their capacity as potential precursors of longer polyenes via elongation and of shorter ones, such as 22:5n-6, via retro-conversion. Triacylglycerols, rich in C22 and C24 polyenes, incorporated the greatest amounts of both [C-14] acetate-derived and exogenous C-14-PUFA, suggesting that this lipid class is involved in the traffic and metabolism of testicular PUFA. The detection of a series of unusual odd-chain tetraenoic and pentaenoic acids, also labeled with [U-C-14]acetate, suggests that a PUFA chain shortening mechanism occurs in testis involving alpha- in addition to beta-oxidation. We speculate that alpha-oxidation plays a role in the retroconversion of PUFA.	ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA		AVELDANO, MI (corresponding author), UNS,CONICET,INST BIOCHEM RES,CC 857,RA-8000 BAHIA BLANCA,ARGENTINA.							ALBERT DH, 1977, BIOCHIM BIOPHYS ACTA, V489, P390, DOI 10.1016/0005-2760(77)90159-X; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; AVELDANO MI, 1983, J LIPID RES, V24, P83; AVELDANO MI, 1992, BIOCHEM J, V283, P235, DOI 10.1042/bj2830235; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; AYALA S, 1973, J LIPID RES, V14, P296; BREMER J, 1984, FATTY ACID METABOLIS, P113; BRIDGES RB, 1970, J BIOL CHEM, V245, P46; BRIDGES RB, 1970, BIOCHIM BIOPHYS ACTA, V218, P29, DOI 10.1016/0005-2760(70)90089-5; CONIGLIO JG, 1977, FUNCTION BIOSYNTHESI, P575; CONIGLIO JG, 1977, LIPID METABOLISM MAM, V2, P83; EVANS OB, 1971, LIPIDS, V6, P706, DOI 10.1007/BF02531294; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROGAN WM, 1984, LIPIDS, V19, P341, DOI 10.1007/BF02534785; JOHNSON DW, 1990, CHEM PHYS LIPIDS, V56, P65, DOI 10.1016/0009-3084(90)90089-A; MORRISON WR, 1964, J LIPID RES, V5, P600; POTTER JER, 1981, J BIOL CHEM, V256, P7150; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; POULOS A, 1986, BIOCHEM J, V240, P891, DOI 10.1042/bj2400891; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROBINSON BS, 1990, BIOCHEM J, V267, P561, DOI 10.1042/bj2670561; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; ROSENTHAL MD, 1991, BIOCHIM BIOPHYS ACTA, V1083, P29, DOI 10.1016/0005-2760(91)90121-W; ROTSTEIN NP, 1988, BIOCHEM J, V249, P191, DOI 10.1042/bj2490191; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; SPRECHER H, 1975, BIOCHIM BIOPHYS ACTA, V388, P113, DOI 10.1016/0005-2760(75)90067-3; STREET JM, 1989, BIOCHEM J, V260, P647, DOI 10.1042/bj2600647; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361; VOSS A, 1991, J BIOL CHEM, V266, P19995; WORTHON AR, 1974, FED PROC, V33, P685	32	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11663	11669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505297				2022-12-25	WOS:A1993LF28400033
J	SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM				SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM			DNA-SEQUENCE ANALYSIS OF THE MAJOR BREAKPOINT CLUSTER REGION OF THE BCR GENE REARRANGED IN PHILADELPHIA-POSITIVE HUMAN LEUKEMIAS	ONCOGENE			English	Note							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; 1ST INTRON; ALU SEQUENCES; ABL GENES; TRANSLOCATION; CHROMOSOME; CONSENSUS; INSERTION; PATIENT	We sought sequence characteristics that might explain the apparent high recombination frequency of the 5-kb BgIII segment containing M-bcr exons 1, 2 and 3, and the intron to exon 4. An Alu sequence (subfamily Sx), in 5' --> 3' orientation, lay in the middle of a 3-kb region that contains the great majority of Philadelphia chromosome breakpoint sites. The breakpoint of only one out of five chronic myeloid leukemia patients, for whom the BCR breakpoint site had been sequenced, was located within this Alu. Other features of interest for recombination were a 51-bp AT-rich region close to the 3' end, six hypervariable minisatellite consensus octamers, GC[A/T]GG[A/T]GG, six lymphoid recombinase heptamer signal sequences, one nonamer and a 16-bp inverted repeat. Dot matrix comparisons of the 5-kb M-bcr sequence with a 3-kb m-bcr2 segment showed significant homology only in corresponding Alu sequences.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand; University of Otago			Morris, Christine/G-1690-2011; Sowerby, Stephen J/G-7601-2011; Kennedy, Martin A/A-4942-2008	Kennedy, Martin A/0000-0002-6445-8526				BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEN SJ, 1989, BLOOD, V73, P1312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FITZGERALD PH, 1991, CANCER GENET CYTOGEN, V55, P129, DOI 10.1016/0165-4608(91)90248-S; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HEISTERKAMP N, 1985, NATURE, V317, P559, DOI 10.1038/317559b0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLZMAN D, 1991, SCIENCE, V254, P1728, DOI 10.1126/science.1662411; HUEBNER K, 1989, CANCER RES, V49, P4071; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; MILLS KI, 1991, BLOOD, V78, P1155; MORRIS CM, 1991, BLOOD, V78, P1078; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0	32	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1679	1683						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502487				2022-12-25	WOS:A1993LE06400033
J	CHOWDHURY, NR; WU, CH; WU, GY; YERNENI, PC; BOMMINENI, VR; CHOWDHURY, JR				CHOWDHURY, NR; WU, CH; WU, GY; YERNENI, PC; BOMMINENI, VR; CHOWDHURY, JR			FATE OF DNA TARGETED TO THE LIVER BY ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ENDOCYTOSIS INVIVO - PROLONGED PERSISTENCE IN CYTOPLASMIC VESICLES AFTER PARTIAL-HEPATECTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DELIVERY; EXPRESSION	After intravenous injection, DNA complexed with asialoglycoprotein-polylysine conjugates is endocytosed by hepatocytes via asialoglycoprotein receptors and is expressed transiently. Long term persistence and expression occurs when partial hepatectomy is performed after gene delivery. To determine the intracellular location of the persisting DNA, we transferred a plasmid expressing bacterial chloramphenicol acetyltransferase into the liver of rats in vivo by asialoglycoprotein receptor-mediated endocytosis. The internalized DNA was measured by Southern blot. Twenty min after administration, 80-85% of the plasmid appeared in the liver, 80% of which was within hepatocytes (12,000-18,000 copies/hepatocyte). In sham-operated control rats, the transgene concentration decreased to 8-12 and 2-4% of the initial levels in 4 and 24 h, respectively, and became undetectable at 7 days. In rats subjected to 66% hepatectomy 20 min after DNA administration, 20, 9, and 7% of the plasmid in the residual liver persisted at 4 h, 24 h, and 7 days, respectively. Liver homogenates were fractionated by differential centrifugation and Percoll gradient centrifugation. In 66% hepatectomized rats, the plasmid persisted in an undegraded, transfection-competent form in plasma membrane/endosome-enriched fractions throughout the duration of the experiment (7 days), indicating that cytoplasmic vesicles are the main site of persistence of the endocytosed DNA.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,ULLMAN BLDG,RM 625,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV GASTROENTEROL & LIVER DIS,BRONX,NY 10461; UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL & HEPATOL,FARMINGTON,CT 06030	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK039137, R01DK042182] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 42182, R01-DK 39137, P30-DK 41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBER N, 1988, LIVER, V8, P80; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; DEBORA SL, 1988, CELL MOTIL CYTOSKEL, V10, P482; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATTON MWC, 1979, BIOCHEM J, V181, P633, DOI 10.1042/bj1810633; JANSEN PLM, 1977, J BIOL CHEM, V252, P2710; KOLBBACHOFEN V, 1984, BIOL CELL, V51, P219, DOI 10.1111/j.1768-322X.1984.tb00302.x; LEVVY GA, 1959, ADV CARBOHYD CHEM, V14, P381; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELGAR E, 1968, J BIOL CHEM, V243, P4409; PERTOFT H, 1979, J IMMUNOL METHODS, V27, P159; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; WAYNFORTH HB, 1980, EXPT SURGICAL TECHNI, P137; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P1314; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338	24	147	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11265	11271						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496181				2022-12-25	WOS:A1993LD46600080
J	COPELAND, WC; WANG, TSF				COPELAND, WC; WANG, TSF			MUTATIONAL ANALYSIS OF THE HUMAN DNA POLYMERASE-ALPHA - THE MOST CONSERVED REGION IN ALPHA-LIKE DNA-POLYMERASES IS INVOLVED IN METAL-SPECIFIC CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN KB-CELLS; ESCHERICHIA-COLI; ENZYMOLOGICAL CHARACTERIZATION; HOMOGENEOUS ENZYME; LARGE FRAGMENT; MECHANISM; BINDING; GENE; PURIFICATION	Five site-directed mutations were introduced at the most conserved amino acids in region I (YGDTDS) of the human DNA polymerase alpha catalytic subunit. Mutant proteins were expressed in the baculovirus system by an improved method and purified by a rapid one-step purification in high yield and high specific activity. The Asp1004 to Asn mutation produced a protein with no detectable polymerase activity while other mutations gave activities from 1 to 20% of the wild type polymerase activity. Steady state kinetic analysis of the active mutants indicates that none of the mutations caused a change in K(m(dNTP)) or K(D(DNA)), but all active mutants showed a decrease in k(cat). Thus, the effect of these conserved mutations is manifest in altered rates of catalysis. Two mutations, Asp1002 to Asn and Thr1003 to Ser, caused the enzyme to utilize Mn2+ more effectively in catalysis than Mg2+, suggesting that these amino acids are involved in metal binding. Rates of catalysis by the D1002N and T1003S mutants, as well as Y1000F mutant were improved 80-, 30-, and 70-fold, respectively, on homopolymer templates when Mn2+ replaced Mg2+ as the activator metal. The results from these mutational studies suggest that this highly conserved region binds the metal which is essential for catalysis. The Asp1002 may participate directly in chelating the metal. Results from the T1003S mutant suggest that the beta-methyl group of the threonine side chain might be locked in a hydrophobic pocket preventing free rotation around the C(alpha)-C(beta) bond, thus positioning the Thr1003 hydroxyl group to form a crucial bond with the metal ion. In addition, D1002N and T1003S displayed a 20-fold resistance to aphidicolin compared to the wild type polymerase alpha, and all of the active mutants displayed altered sensitivity to butylphenyl-dGTP. Models of the involvement of region I in catalysis and aphidicolin interaction are proposed. The mutational studies presented in this report will serve as a prototype for the functional role of region I in catalysis for all alpha-like DNA polymerases.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER; NCI NIH HHS [CA14835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHANG LMS, 1984, J BIOL CHEM, V259, P4679; CHIN DT, 1988, J BIOL CHEM, V263, P11718; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DORSKY DI, 1990, J VIROL, V64, P1394, DOI 10.1128/JVI.64.3.1394-1397.1990; ENGLUND PT, 1969, J BIOL CHEM, V244, P3045; FISHER PA, 1977, J BIOL CHEM, V252, P6528; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4560, DOI 10.1021/bi00519a008; FISHER PA, 1979, J BIOL CHEM, V254, P6128; FRY, 1986, ANIMAL CELL DNA POLY, P49; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; IRVING H, 1953, J CHEM SOC, V637, P3192; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; KHAN NN, 1991, NUCLEIC ACIDS RES, V19, P1627, DOI 10.1093/nar/19.7.1627; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA REPLICATION, P126; KORNBERG A, 1992, DNA REPLICATION, P135; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SEAL G, 1979, J BIOL CHEM, V254, P5229; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG TSF, 1977, BIOCHEMISTRY-US, V16, P4927, DOI 10.1021/bi00641a029; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; WRIGHT GE, 1990, PHARMACOL THERAPEUT, V47, P447, DOI 10.1016/0163-7258(90)90066-B	43	105	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11028	11040						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496164				2022-12-25	WOS:A1993LD46600049
J	NUOFFER, C; HORVATH, A; RIEZMAN, H				NUOFFER, C; HORVATH, A; RIEZMAN, H			ANALYSIS OF THE SEQUENCE REQUIREMENTS FOR GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORING OF SACCHAROMYCES-CEREVISIAE GAS1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOPHOSPHOLIPID MEMBRANE ANCHOR; CLEAVAGE ATTACHMENT SITE; TRYPANOSOMA-BRUCEI; THY-1 GLYCOPROTEIN; SIGNAL; BIOSYNTHESIS; MUTAGENESIS; PATHWAY	The Saccharomyces cerevisiae Gas1 protein is synthesized as a precursor with a hydrophobic extension at the carboxyl terminus which is removed and replaced with an inositol containing glycolipid that anchors the protein to the plasma membrane. We performed saturation mutagenesis on the anchor attachment site (Asn506) and showed that only a subset of amino acids with small side chains could act as substrates for peptide cleavage and glycolipid addition. After Asn, which is the most efficient anchor attachment site, Ser, Gly, Ala, Asp, and Cys function with decreasing effectiveness. Mutational analysis also revealed that the 2 adjacent amino acids to the carboxyl side of the anchor attachment site are important for efficient anchoring. These two amino acids should have relatively short side chains with the second position being more critical. Analysis of the region between the anchor attachment site and the carboxyl-terminal hydrophobic region indicated that this region may not simply perform a spacer function.	UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND	University of Basel			Horvath, Anton/I-3626-2014; Horvath, Anton/V-1097-2018	Horvath, Anton/0000-0003-0785-4204; Riezman, Howard/0000-0003-4680-9422				BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DULIC V, 1991, METHOD ENZYMOL, V194, P687; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MENON AK, 1990, J BIOL CHEM, V265, P9033; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SEKI T, 1985, NATURE, V313, P485, DOI 10.1038/313485a0; Sherman F., 1986, METHODS YEAST GENETI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	29	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10558	10563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486709				2022-12-25	WOS:A1993LB80000084
J	IWAMOTO, M; YAGAMI, K; VALLE, PL; OLSEN, BR; PETROPOULOS, CJ; EWERT, DL; PACIFICI, M				IWAMOTO, M; YAGAMI, K; VALLE, PL; OLSEN, BR; PETROPOULOS, CJ; EWERT, DL; PACIFICI, M			EXPRESSION AND ROLE OF C-MYC IN CHONDROCYTES UNDERGOING ENDOCHONDRAL OSSIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CHICK CHONDROCYTES; COLLAGEN GENE-EXPRESSION; FIBROBLAST GROWTH-FACTOR; X COLLAGEN; EMBRYONIC CHICK; MESSENGER-RNA; TERMINAL DIFFERENTIATION; EPIPHYSEAL CARTILAGE; MAMMALIAN-CELLS; DNA	To analyze the relationship between c-myc gene expression and chondrocyte proliferation and maturation during endochondral ossification, Day 18-19 chick embryo sterna were pulse-labeled with [H-3]thymidine, and serial sections were processed for autoradiography and in situ hybridization. Proliferating chondrocytes, located in four distinct areas of the developing sternum, all contained high levels of c-myc transcripts, whereas postmitotic chondrocytes (such as hypertrophic chondrocytes) contained undetectable amounts. These findings were confirmed by Northern blot analysis and by the observation that antisense c-myc oligomer treatment inhibited proliferation in cultured chondrocytes. Constitutive overexpression of c-myc by retroviral vectors in immature chondrocyte cultures (c-myc cultures) maintained the cells in a proliferative state and blocked their maturation into hypertrophic chondrocytes. The lack of maturation in the c-myc cultures was corroborated by analysis of type X collagen gene regulation. Control immature cultures contained strong repressor activity for the type X collagen gene promoter, as revealed by transfection assays; repressor activity was lost upon maturation and activation of type X collagen synthesis. In the c-myc cultures, however, repressor activity persisted. Thus, c-myc participates in the normal changes in proliferation accompanying chondrocyte maturation in vivo and in culture. The decreases in c-myc expression and cell proliferation appear to be required for completion of maturation.	HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; The Wistar Institute	IWAMOTO, M (corresponding author), UNIV PENN,SCH DENT,DEPT ANAT HISTOL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R01AR039705, R37AR036820, R01AR036819, R37AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 36819, AR 39705, AR 36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1991, EXP CELL RES, V193, P190, DOI 10.1016/0014-4827(91)90555-9; ALEMA S, 1985, MOL CELL BIOL, V5, P538, DOI 10.1128/MCB.5.3.538; ALI SY, 1976, FED PROC, V35, P135; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; CASTAGNOLA P, 1987, DEV BIOL, V123, P332, DOI 10.1016/0012-1606(87)90391-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EWERT DL, 1990, LAB INVEST, V62, P156; FISHER JA, 1988, NATURE, P853; GIARETTI W, 1988, CYTOMETRY, V9, P281, DOI 10.1002/cyto.990090403; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; GIONTI E, 1985, P NATL ACAD SCI USA, V82, P2756, DOI 10.1073/pnas.82.9.2756; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIRVONEN H, 1990, ONCOGENE, V5, P1787; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; HOWLETT CR, 1979, J ANAT, V128, P377; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; KATO Y, 1990, J BIOL CHEM, V265, P5903; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kember N.F., 1983, CARTILAGE, VI, P149; KOIKE T, 1990, J CLIN INVEST, V85, P626, DOI 10.1172/JCI114484; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LEBOY PS, 1988, J BIOL CHEM, V263, P8515; Lis J T, 1980, Methods Enzymol, V65, P347; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAYNE R, 1993, IN PRESS EXTRACELLUL; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; OSHIMA O, 1989, CALCIFIED TISSUE INT, V45, P182, DOI 10.1007/BF02556062; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; PACIFICI M, 1990, ANN NY ACAD SCI, V599, P45, DOI 10.1111/j.1749-6632.1990.tb42363.x; PACIFICI M, 1983, J CELL BIOL, V97, P1724, DOI 10.1083/jcb.97.6.1724; QUARTO R, 1992, DEV BIOL, V149, P168, DOI 10.1016/0012-1606(92)90273-J; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SMALE G, 1992, ANAL BIOCHEM, V203, P352, DOI 10.1016/0003-2697(92)90324-Z; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; VALLE PL, 1993, IN PRESS J CELL BIOL; VALLE PL, 1988, J BIOL CHEM, V263, P18378; VALLE PL, 1991, J CELL BIOL, V115, pA286; VINCENT F, 1991, EXP CELL RES, V192, P333, DOI 10.1016/0014-4827(91)90049-Z; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146	55	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9645	9652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486652				2022-12-25	WOS:A1993LA68900074
J	KANG, T; MARTINS, T; SADOWSKI, I				KANG, T; MARTINS, T; SADOWSKI, I			WILD-TYPE GAL4 BINDS COOPERATIVELY TO THE GAL1-10 UASG INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; REGULATORY PROTEIN; DNA-BINDING; YEAST; GENE; DERIVATIVES; MECHANISM; SITES	Transcription of the genes required for utilization of galactose in Saccharomyces cerevisiae is controlled primarily by the transcriptional activator protein GAL4. The upstream activating sequences for galactose (UAS(G)) of most GAL genes have multiple sites to which GAL4 can bind. In this report we compare the binding properties of wild type GAL4 and derivatives of GAL4 bearing the N-terminal DNA-binding domain to multiple DNA-binding sites in vitro. To produce wild type GAL4, we constructed a recombinant baculovirus for expression in insect cells. Recombinant wild type GAL4 was found to bind efficiently to an oligonucleotide containing a near-consensus 17-mer GAL4 DNA-binding site in electrophoretic mobility shift assays. Footprinting experiments revealed that wild type GAL4 binds cooperatively to the four GAL4 DNA-binding sites of the GAL1-10 UAS(G); however, in contrast an N-terminal fragment of GAL4 containing only the DNA-binding/dimerization domains binds to each of these sites with slightly different affinity. With increasing concentrations of GAL4(1-147), the four sites become filled in the following order: site II, site IV, site I, and site III. In experiments with wild type GAL4, these four sites become fully occupied at approximately the same concentration of protein. In footprints of wild type GAL4 on the UAS(G), enhancements and protections of DNase I-sensitive cleavages are detectable between sites III and IV, indicative of formation of a loop between these distantly spaced sites. Binding of wild type GAL4 to a strong near-consensus binding site assists binding to an adjacent mutant site in both electrophoretic mobility shift and footprinting assays. GAL4(1-147) and GAL4(1-147) fused to portions of GAL4's activating region II were incapable of cooperative DNA binding in our assays. We conclude from these observations that wild type GAL4 has a cooperative DNA-binding function that is distinct from the DNA binding and dimerization or transcriptional activation functions, and likely plays and important role in precise regulation of GAL gene transcription.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM,2146 HLTH SCI MALL,VANCOUVER V6T 1Z3,BC,CANADA; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	University of British Columbia; Harvard University								BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; FLICK JS, 1992, GENETICS, V130, P295; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1986, P NATL ACAD SCI USA, V83, P6553, DOI 10.1073/pnas.83.17.6553; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUDEN DM, 1988, P NATL ACAD SCI USA, V85, P4262, DOI 10.1073/pnas.85.12.4262; RUDEN DM, 1990, MOL CELL BIOL, V10, P1432, DOI 10.1128/MCB.10.4.1432; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; SHIMADA H, 1985, GENE, V39, P1; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991	31	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9629	9635						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486650				2022-12-25	WOS:A1993LA68900072
J	TANGIRALA, RK; MAHLBERG, FH; GLICK, JM; JEROME, WG; ROTHBLAT, GH				TANGIRALA, RK; MAHLBERG, FH; GLICK, JM; JEROME, WG; ROTHBLAT, GH			LYSOSOMAL ACCUMULATION OF UNESTERIFIED CHOLESTEROL IN MODEL MACROPHAGE FOAM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; LADEN AORTIC-CELLS; HAMSTER OVARY CELLS; FAT-FED RABBITS; ATHEROSCLEROTIC LESIONS; INTRACELLULAR-TRANSPORT; EARLY ATHEROGENESIS; LIPID-ACCUMULATION; ESTER ACCUMULATION; CULTURE MODEL	Lysosomal accumulation of unesterified (free) cholesterol, following the phagocytic incorporation of cholesteryl oleate lipid droplets, was quantitatively characterized in a murine J774 macrophage foam cell model. The induction of phagocytic incorporation by the macrophages, using an inverted culture technique, allowed the rapid delivery of large amounts of cholesteryl ester droplets to the lysosomes, leading to the subsequent generation of free cholesterol. The lysosomally generated free cholesterol was differentiated from the membrane cholesterol by a double radiolabeling procedure. Free cholesterol accumulation was quantitated in a population of low density lipid-filled lysosomes prepared by ultracentrifugal isolation of a floating lipid fraction from a homogenate of the cholesteryl ester-loaded cells. About 10% of the total N-acetyl-beta-glucosaminidase activity, a lysosomal marker, was recovered in the lipid fraction. Negligible amounts of alkaline phosphodiesterase-1, a plasma membrane marker, or membrane cholesterol were present in this fraction. Electron microscopic and cytochemical analysis of the isolated lipid fraction revealed the presence of lysosomes in the fraction with a diameter ranging from 1.5 to 4 mum. Continued hydrolysis of incorporated cholesteryl ester over a 24-h incubation resulted in approximately 30% of the generated free cholesterol in lipid-filled lysosomes. The accumulation of free cholesterol occurred whether or not the cholesterol esterifying enzyme, acyl-CoA: cholesterol acyltransferase, was inhibited. In addition, substantial amounts of free cholesterol accumulated even in the presence of efficient cholesterol acceptor particles, apolipoprotein high density lipoprotein-phosphatidylcholine complexes which stimulate cholesterol efflux. Also, increased accumulation of free cholesterol in the lipid fraction was observed when cholesteryl ester-loaded cells were treated with the compound U-18666A which blocks the movement of lysosomal cholesterol. The data demonstrate that the phagocytic incorporation and hydrolysis of cholesteryl ester lipid droplets by macrophage foam cells lead to a substantial accumulation of free cholesterol in the liPid-filled lysosomes. This process could result in a build-up of lysosomal free cholesterol in macrophage foam cells during the progression of atheroselerotic plaque.	MED COLL PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA; BOWMAN GRAY SCH MED, DEPT PATHOL, WINSTON SALEM, NC 27157 USA	Drexel University; Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL-22633, HL-07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, T32HL007443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FOWLER S, 1979, LAB INVEST, V41, P372; FOWLER S, 1978, INT C ATHEROSCLEROSI, P19; Gomori G., 1952, MICROSCOPIC HISTOCHE; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JEROME WG, 1985, AM J PATHOL, V119, P210; JEROME WG, 1991, EXP MOL PATHOL, V54, P144; JEROME WG, 1987, AM J PATHOL, V128, P253; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONES NL, 1991, AM J PATHOL, V139, P383; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOVANEN PT, 1991, ANN MED, V23, P551, DOI 10.3109/07853899109150517; LEWIS JC, 1988, EXP MOL PATHOL, V48, P103, DOI 10.1016/0014-4800(88)90049-4; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; MACKIE EJB, 1989, BIOCHIM BIOPHYS ACTA, V1006, P219, DOI 10.1016/0005-2760(89)90200-2; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1990, BIOCHIM BIOPHYS ACTA, V1045, P291, DOI 10.1016/0005-2760(90)90133-I; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MINOR LK, 1991, EXP MOL PATHOL, V54, P159, DOI 10.1016/0014-4800(91)90028-V; MINOR LK, 1989, J LIPID RES, V30, P189; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P24, DOI 10.1161/01.ATV.7.1.24; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; SHIO H, 1979, LAB INVEST, V41, P160; SHIO H, 1978, LAB INVEST, V39, P390; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VIJAYAGOPAL P, 1985, BIOCHIM BIOPHYS ACTA, V837, P251, DOI 10.1016/0005-2760(85)90048-7; WOLFBAUER G, 1986, P NATL ACAD SCI USA, V83, P7760, DOI 10.1073/pnas.83.20.7760	46	36	37	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9653	9660						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486653				2022-12-25	WOS:A1993LA68900075
J	SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB				SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB			DEFINING THE CRITICAL GENE-EXPRESSION CHANGES ASSOCIATED WITH EXPRESSION AND SUPPRESSION OF THE TUMORIGENIC AND METASTATIC PHENOTYPE IN HA-RAS-TRANSFORMED CLONED RAT EMBRYO FIBROBLAST CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GTPASE ACTIVATING PROTEIN; HUMAN COLORECTAL TUMORS; ADENOVIRUS TYPE-5; MESSENGER-RNA; DROSOPHILA GENE; HUMAN CANCER; E1A GENE; NM23; PROGRESSION	Carcinogenesis requires a complex series of genetic changes often involving multiple oncogenes and the inactivation of multiple tumor-suppressor genes. We presently examined the effect of the Krev-1 tumor-suppressor gene on the tumorigenic and metastatic potential of Ha-ras-transformed cloned rat embryo fibroblast (CREF) cells. Ha-ras-transformed CREF cells are morphologically transformed and anchorage independent, produce reduced levels of nm23-H1 (a putative metastasis-suppressor gene product) and TIMP-1 (tissue inhibitor of metalloproteinase 1) transcripts and mRNA compared with CREF cells; produce increased levels of cripto, 94-kDa gelatinase/type IV collagenase (94-kDa GEL), osteopontin (OPN) and transin/stromelysin transcripts and mRNA compared with CREF cells; and are tumorigenic and metastatic in both nude mice and syngeneic rats. Ha-ras-transformed CREF cells coexpressing the Krev-1 gene display a reversion in cellular phenotype and gene expression to that of untransformed CREF cells. However, Ha-ras/Krev-1-coexpressing CREF cells retain, albeit with extended latency periods, both tumorigenic and metastatic potential that is not related directly to the final level of Ha-ras or Krev-1 mRNA or the Ha-ras p21 transforming protein. Development of metastatic potential is, however, directly correlated with a reduction in nm23-H1 and TIMP-1 transcription and mRNA levels and an enhanced expression of cripto, 94-kDa GEL, osteopontin and transin. In contrast, expression of additional tumor-suppressor genes, such as the RB gene and p53, or genes associated with tumorigenesis in other model systems, such as major excreted glycoprotein (MEP), 72-kDa gelatinase/type IV collagenase (72-kDa GEL), fibronectin (FIB), tenascin and intracellular adhesion molecule 1 (ICAM-1) is not altered in a consistent manner during in vitro transformation suppression or escape from tumorigenic and metastatic suppression. These results indicate that Krev-1 suppression of the Ha-ras-transformed/oncogenic phenotype is associated with a distinct program of gene expression changes manifested by altered rates of transcription and steady-state mRNA levels of specific oncogenic-suppressing and oncogenic-inducing genes. These data support a model of Ha-ras-induced metastasis in CREF cells that involves a direct modulation in the expression/suppression of specific combinations of oncogenic-suppressor genes and metastasis-promoting genes that are regulated coordinately in the process of tumor progression.	COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,INST CANC RES,CTR COMPREHENS CANC,650 W 168TH ST,NEW YORK,NY 10032; UNIV KENTUCKY,MED CTR,DEPT MED MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,INST CANC RES,CTR COMPREHENS CANC,NEW YORK,NY 10032	Columbia University; University of Kentucky; Columbia University					NCI NIH HHS [CA33434, CA43208, CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R01CA033434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; Bar-Sagi D, 1992, Semin Cell Biol, V3, P93; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BOYLAN JF, 1992, MOL CARCINOGEN, P118; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KERBEL RS, 1988, CANCER SURV, V7, P597; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKKA R, 1991, J CANCER RES CLIN, V117, P333, DOI 10.1007/BF01630716; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUBOTA S, 1991, BIOCHEM BIOPH RES CO, V181, P1539, DOI 10.1016/0006-291X(91)92114-Y; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCORMICK F, 1992, PHILOS T ROY SOC B, V336, P43, DOI 10.1098/rstb.1992.0042; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NICHOLSON GL, 1988, CANCER METAST REV, V7, P143; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1991, CANCER CELL-MON REV, V3, P257; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	63	77	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1211	1219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479744				2022-12-25	WOS:A1993KY32800012
J	DOMIN, J; ROZENGURT, E				DOMIN, J; ROZENGURT, E			PLATELET-DERIVED GROWTH-FACTOR STIMULATES A BIPHASIC MOBILIZATION OF ARACHIDONIC-ACID IN SWISS 3T3 CELLS - THE ROLE OF PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; RECEPTOR-MEDIATED ACTIVATION; SIGNAL TRANSDUCTION; MESSENGER-RNA; PROSTAGLANDIN; RELEASE; CYCLOOXYGENASE; ACCUMULATION; METABOLITES; EXPRESSION	Stimulation of quiescent Swiss 3T3 cells with platelet-derived growth factor (PDGF) increased the initial rate of cytosolic phospholipase A2 activity by 95 +/- 6% over extracts from control cells. Cytosolic phospholipase A2 activity increased rapidly following PDGF treatment (near maximum stimulation by 2.5 min) and was dose-dependent (EC50 = 2 ng/ml). Epidermal growth factor, vasopressin, and phorbol 12,13-dibutyrate also increased cytosolic phospholipase A2 activity but did not produce a sustained mobilization of arachidonic acid in these cells. Detailed kinetic analysis of PDGF-induced arachidonic acid mobilization revealed a biphasic release of H-3 radioactivity into the extracellular medium. A first, rapid phase, occurred within 15 min which, like the activation of cytosolic phospholipase A2 activity, was independent of de novo RNA and protein synthesis. After 20 min of stimulation, a second phase became evident which accounts for the majority of arachidonic acid mobilized by PDGF. This second phase was abolished in the presence of either cycloheximide or actinomycin D. Both inhibitors blocked the release of arachidonic acid rather than inhibiting cyclooxygenase activity and consequently prostaglandin E2 production. These findings demonstrate a biphasic mobilization of arachidonic acid in Swiss 3T3 cells by PDGF. Cytosolic phospholipase A2 activity could contribute to the rapid first phase but not the second major phase, which is dependent upon de novo protein synthesis.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COCHRAN BH, 1985, ADV CANCER RES, V45, P183, DOI 10.1016/S0065-230X(08)60269-9; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOMIN J, 1992, J BIOL CHEM, V267, P15217; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HEINSOHN C, 1987, ARCH BIOCHEM BIOPHYS, V257, P251, DOI 10.1016/0003-9861(87)90564-9; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LIN AH, 1989, J BIOL CHEM, V264, P17379; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MEHMET H, 1991, BRIT MED BULL, V47, P76, DOI 10.1093/oxfordjournals.bmb.a072463; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, CANCER CELL-MON REV, V3, P397; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIER WT, 1982, J CELL PHYSIOL, V112, P171, DOI 10.1002/jcp.1041120204; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	44	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8927	8934						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473335				2022-12-25	WOS:A1993KX81100080
J	KVALNESKRICK, K; LABDON, JE; MA, XY; NIEVES, E; SCHRAMM, VL				KVALNESKRICK, K; LABDON, JE; MA, XY; NIEVES, E; SCHRAMM, VL			MUTAGENIC ANALYSIS OF AMP NUCLEOSIDASE FROM ESCHERICHIA-COLI - DELETION OF A REGION SIMILAR TO AMP DEAMINASE AND PEPTIDE CHARACTERIZATION BY MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ENZYME; GENE; HYDROLYSIS; ACID; DEGRADATION; PROTEIN; YEAST	AMP nucleosidase (EC 3.2.2.4) from Escherichia coli and AMP deaminase (EC 3.5.4.6) from bakers' yeast are proposed to regulate cellular AMP levels under allosteric control of the activator ATP and the inhibitor, PO4. Both enzymes contain catalytic sites which bind AMP and regulatory sites which bind ATP. The deduced amino acid sequences of the proteins revealed only one region of homology in which six of eight amino acids are identical. A similar sequence is found in glyceraldehyde-3-phosphate dehydrogenase, phoE, ras proteins, RNA polymerase, K+-ATPase, nucleolin, and other proteins expected to have nucleotide or phosphate binding properties. In the crystal structure of glyceraldehyde-3-phosphate dehydrogenase, this sequence is part of the NAD+-binding site. The function of these amino acids was explored with a deletion mutant of AMP nucleosidase. The protein was over-produced in a pTZ construct using the AMP nucleosidase promoter which resulted in approximately 30% of the total protein as the desired enzyme. The mutation was characterized by DNA sequence analysis and by direct analysis of the peptides using high performance liquid chromatography-mass spectrometry. Deletion of amino acids 128-135, corresponding to DGSELTLD, produced an enzyme with a 20-fold decrease in V(max) but with smaller changes in substrate saturation kinetics, activation by MgATP, inhibition by inorganic phosphate, and inhibition by the tight-binding inhibitor, formycin 5-phosphate. The deletion mutant of AMP nucleosidase exhibits hysteresis in establishing a steady-state rate of product formation which is most pronounced in the absence of MgATP. These results establish that the sequence DGSELTLD in E. coli AMP nucleosidase is not required for binding of AMP, MgATP, or inorganic phosphate. However, the mutant enzyme has a structural defect related to the polymerization state which delays the onset of catalysis and decreases the catalytic efficiency.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			kvalnes, kalla/F-9380-2013					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Battey, 1986, BASIC METHODS MOL BI; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHAPMAN AG, 1973, J BIOL CHEM, V248, P8309; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DEHAAN P, 1991, J GEN VIROL, V71, P2207; DEWOLF WE, 1979, J BIOL CHEM, V254, P868; FERRI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P36, DOI 10.1016/0167-4838(90)90119-Z; GIRANDA VL, 1989, J BIOL CHEM, V264, P15674; KVALNESKRICK K, 1986, BIOCHEMISTRY-US, V25, P6061, DOI 10.1021/bi00368a034; LEUNG HB, 1984, J BIOL CHEM, V259, P6972; LEUNG HB, 1989, BIOCHEMISTRY-US, V28, P8726, DOI 10.1021/bi00448a008; LEUNG HB, 1980, J BIOL CHEM, V255, P867; Maniatis T., 1982, MOL CLONING; MCCLEARY WR, 1990, P NATL ACAD SCI USA, V87, P5898, DOI 10.1073/pnas.87.15.5898; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MERKLER DJ, 1989, J BIOL CHEM, V264, P21422; MEYER SL, 1989, BIOCHEMISTRY-US, V28, P8734, DOI 10.1021/bi00448a009; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Schramm V L, 1978, Methods Enzymol, V51, P263; SCHRAMM VL, 1971, BIOCHEMISTRY-US, V10, P3411, DOI 10.1021/bi00794a015; SCHRAMM VL, 1974, J BIOL CHEM, V249, P1729; SCHRAMM VL, 1978, ARCH BIOCHEM BIOPHYS, V190, P263; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; VANDERLEY P, 1987, PHOSPHATE METABOLISM, P159; YAMAMOTO J, 1991, AGR BIOL CHEM TOKYO, V55, P1615, DOI 10.1080/00021369.1991.10870805; [No title captured]	32	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8717	8726						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473316				2022-12-25	WOS:A1993KX81100053
J	LU, ZC; NAGATA, S; MCPHIE, P; MILES, EW				LU, ZC; NAGATA, S; MCPHIE, P; MILES, EW			LYSINE-87 IN THE BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE THAT FORMS AN INTERNAL ALDIMINE WITH PYRIDOXAL-PHOSPHATE SERVES CRITICAL ROLES IN TRANSIMINATION, CATALYSIS, AND PRODUCT RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ULTRAVIOLET VISIBLE SPECTROSCOPY; COLI ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LYSYL RESIDUE; L-SERINE; CIRCULAR-DICHROISM; BRONSTED ANALYSIS; EXOGENOUS AMINES	This study provides valuable insights into the functions of the lysine residue that forms an internal aldimine with pyridoxal phosphate in the beta subunit of tryptophan synthase from Salmonella typhimurium. Our spectroscopic and kinetic studies demonstrate that a mutant alpha2beta2 complex having beta subunit lysine 87 replaced by threonine forms external aldimines with several amino acids including L-serine, beta-chloro-1-alanine, L-tryptophan, and D-tryptophan. Because the rates of aldimine formation are very slow, we conclude that one role of lysine 87 in the wild type enzyme is to facilitate formation of external aldimines by transimination. Lysine 87 is an essential catalytic residue because the mutant alpha2beta2 complex has no measurable activity in reactions catalyzed by the beta subunit and does not convert external aldimines to products. The mutant enzyme carries out two slow partial beta-elimination reactions: the conversion of beta-chloro-L-alanine and L-serine to enzyme-bound aminoacrylate. The reaction with L-serine is catalyzed by ammonia, which partially replaces the deleted epsilon-amino group. Lysine 87 is important for substrate and product release because L-serine, L-tryptophan, and aminoacrylate dissociate very slowly from the mutant alpha2beta2 complex. Our ability to prepare very stable derivatives of the mutant alpha2beta2 complex containing tightly bound aldimines with a substrate, a product, or a reaction intermediate provides valuable materials for ongoing x-ray crystallographic investigations and future kinetic analyses of the allosteric activation of the alpha subunit by beta subunit ligands.	NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A09, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; BRZOVLC P, 1991, INT UNION B, V199, P277; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CORDES EH, 1962, BIOCHEMISTRY-US, V1, P773, DOI 10.1021/bi00911a007; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DREWE WF, 1989, BIOCHIMIE, V71, P509, DOI 10.1016/0300-9084(89)90182-X; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; FLURI R, 1971, J BIOL CHEM, V246, P6620; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; GREGERMAN RI, 1956, J BIOL CHEM, V220, P765; HAYASHI H, 1990, BIOCHEM BIOPH RES CO, V167, P407, DOI 10.1016/0006-291X(90)92037-Z; HIGGINS W, 1980, J BIOL CHEM, V255, P512; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; INOUE Y, 1989, J BIOL CHEM, V264, P9673; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KIRSCH JF, 1990, UCLA SYM BI, V110, P105; KIRSCH JF, 1990, ANN NY ACAD SCI, V585, P48, DOI 10.1111/j.1749-6632.1990.tb28040.x; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KIRSCH JF, 1990, ENZYMES DEPENDENT PY, P161; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LONGENECKER JB, 1957, J BIOL CHEM, V225, P409; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1982, J BIOL CHEM, V257, P4203; MILES EW, 1975, BIOCHEM BIOPH RES CO, V66, P94, DOI 10.1016/S0006-291X(75)80299-3; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; ROBERTS WJ, 1988, J BIOL CHEM, V263, P7196; SCHLOSS JV, 1988, ACCOUNTS CHEM RES, V21, P348, DOI 10.1021/ar00153a005; SLEBE JC, 1976, J BIOL CHEM, V251, P5663; TATSUMOTO K, 1981, J AM CHEM SOC, V103, P6197, DOI 10.1021/ja00410a036; TATSUMOTO K, 1977, J AM CHEM SOC, V99, P6082, DOI 10.1021/ja00460a040; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; WADA H, 1962, J BIOL CHEM, V237, P127; YANOFSKY C, 1972, ENZYMES, V7, P1; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029; ZIAK M, 1990, EUR J BIOCHEM, V187, P329, DOI 10.1111/j.1432-1033.1990.tb15309.x	65	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8727	8734						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473317				2022-12-25	WOS:A1993KX81100054
J	GONZALEZMATEOS, F; GOMEZ, ME; GARCIASALGUERO, L; SANCHEZ, V; ARAGON, JJ				GONZALEZMATEOS, F; GOMEZ, ME; GARCIASALGUERO, L; SANCHEZ, V; ARAGON, JJ			INHIBITION OF GLYCOLYSIS BY AMINO-ACIDS IN ASCITES TUMOR-CELLS - SPECIFICITY AND MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE METABOLISM; ISOLATED RAT HEPATOCYTES; FRUCTOSE 2,6-BISPHOSPHATE; GLYCOGEN-SYNTHESIS; GLUTAMINE-METABOLISM; TRANSFORMED-CELLS; PHOSPHOFRUCTOKINASE; OXIDATION; PATHWAYS; LIVER	The effect of glutamine and asparagine on glucose metabolism has been studied in ascites tumor cells. Either of these amino acids decreased the glycolytic flux about 80%. Half-maximal effects were obtained with 0.14 mM glutamine and 0.087 mM asparagine. Among the 20 L-amino acids, only glutamate produced a similar effect. Glutamine and asparagine caused a 70% increase of hexose monophosphates and a large decrease of fructose-1,6-P2 and triose phosphates, evidencing a strong inhibition of the phosphofructokinase (EC 2.7.11) reaction. Analysis of the levels of various phosphofructokinase effectors revealed that fructose-2,6-P2 and AMP decreased 4-fold, phosphoenolpyruvate, citrate, and ATP increased 4-, 3-, and 1.8-fold, respectively, and that there was no change in ADP, P(i), and intracellular pH. Assay of phosphofructokinase at concentrations of substrates and effectors determined to be in the cells showed that the low activity of this enzyme could be accounted for by the change in the concentration of effectors, the major mechanism being the change in adenine nucleotides. The decrease in fructose-2,6-P2 contributed very little to the inhibition of phosphofructokinase activity. The effects of amino acids were prevented by amino-oxyacetate, suggesting that transamination was an obligatory step for these changes.	UNIV AUTONOMA MADRID, FAC MED, DEPT BIOQUIM, ARZOBISPO MORCILLO 4, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, INST INVEST BIOMED, CSIC, E-28029 MADRID, SPAIN	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)				Garcia Salguero, Encarnacion Leticia/0000-0002-5860-809X				ARAGON JJ, 1991, FASEB J, V5, P2945, DOI 10.1096/fasebj.5.14.1752361; ARDAWI MSM, 1983, BIOCHEM J, V212, P835, DOI 10.1042/bj2120835; BAQUET A, 1991, BIOCHEM J, V273, P57, DOI 10.1042/bj2730057; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P191; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V7, P3; BOERNER P, 1985, P NATL ACAD SCI USA, V82, P6750, DOI 10.1073/pnas.82.20.6750; BOSCA L, 1982, BIOCHEM BIOPH RES CO, V106, P486, DOI 10.1016/0006-291X(82)91136-6; BOSCA L, 1984, TRENDS BIOCHEM SCI, V9, P372, DOI 10.1016/0968-0004(84)90214-7; BOSCA L, 1985, CURR TOP CELL REGUL, V27, P411; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOME JD, 1967, BIOCHIM BIOPHYS ACTA, V138, P637, DOI 10.1016/0005-2787(67)90569-2; Capizzi R, 1981, ENZYMES DRUGS, P1; CARRASCOSA JM, 1984, CANCER RES, V44, P3831; CHAPMAN AG, 1976, CANCER RES, V36, P1144; COLES NW, 1962, BIOCHEM J, V83, P284, DOI 10.1042/bj0830284; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; FELIU JE, 1976, MOL CELL BIOCHEM, V13, P31, DOI 10.1007/BF01732393; FRANCOIS J, 1988, EUR J BIOCHEM, V171, P599, DOI 10.1111/j.1432-1033.1988.tb13830.x; GLASER G, 1980, BIOCHEM J, V192, P793, DOI 10.1042/bj1920793; GUMAA KA, 1969, BIOCHEM J, V115, P1009, DOI 10.1042/bj1151009; GUYNN RW, 1972, ANAL BIOCHEM, V45, P277, DOI 10.1016/0003-2697(72)90028-0; HUE L, 1984, BIOCHEM J, V224, P779, DOI 10.1042/bj2240779; JAWOREK D, 1985, METHOD ENZYMAT AN, V7, P365; KEDRYNA T, 1983, BIOCHIM BIOPHYS ACTA, V763, P64, DOI 10.1016/0167-4889(83)90026-5; KIEN CL, 1981, CANCER RES, V41, P2051; KOSOW DP, 1972, BIOCHEM BIOPH RES CO, V48, P376, DOI 10.1016/S0006-291X(72)80061-5; KOVACEVIC Z, 1991, BIOCHEM J, V273, P271, DOI 10.1042/bj2730271; KOVACEVIC Z, 1991, BIOCHEM J, V273, P277, DOI 10.1042/bj2730277; Krebs H., 1980, GLUTAMINE METABOLISM, P319; KREBS HA, 1960, BIOCHEM J, V75, P523, DOI 10.1042/bj0750523; LALOUX M, 1985, EUR J BIOCHEM, V148, P155, DOI 10.1111/j.1432-1033.1985.tb08819.x; LANKS KW, 1986, J CELL PHYSIOL, V126, P319, DOI 10.1002/jcp.1041260224; LAVIETES BB, 1974, P NATL ACAD SCI USA, V71, P3993, DOI 10.1073/pnas.71.10.3993; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; LAZO PA, 1981, EUR J BIOCHEM, V117, P19; MARQUEZ J, 1989, ARCH BIOCHEM BIOPHYS, V268, P667, DOI 10.1016/0003-9861(89)90335-4; MATSUNO T, 1987, INT J BIOCHEM, V19, P303, DOI 10.1016/0020-711X(87)90002-4; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; MOJENA M, 1985, BIOCHEM J, V232, P521, DOI 10.1042/bj2320521; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; Nakashima RA, 1990, INTEGRATION MITOCHON, P405; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429; Rottenberg H, 1979, Methods Enzymol, V55, P547; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; SOLING HD, 1973, EUR J BIOCHEM, V37, P233, DOI 10.1111/j.1432-1033.1973.tb02980.x; TEJWANI GA, 1978, TRENDS BIOCHEM SCI, V3, P31; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WEBER G, 1977, NEW ENGL J MED, V296, P541, DOI 10.1056/NEJM197703102961005; WEBER MJ, 1973, J BIOL CHEM, V248, P2978; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WU R, 1959, J BIOL CHEM, V234, P1029; YUSHOK WD, 1971, J BIOL CHEM, V246, P1607	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7809	7817						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463308				2022-12-25	WOS:A1993KW97900037
J	KAWASAKI, S; MIZUSHIMA, S; TOKUDA, H				KAWASAKI, S; MIZUSHIMA, S; TOKUDA, H			MEMBRANE-VESICLES CONTAINING OVERPRODUCED SECY AND SECE EXHIBIT HIGH TRANSLOCATION ATPASE ACTIVITY AND COUNTERMOVEMENT OF PROTONS IN A SECA-DEPENDENT AND PRESECRETORY PROTEIN-DEPENDENT MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR DISULFIDE BRIDGE; ESCHERICHIA-COLI; MOTIVE FORCE; INVITRO TRANSLOCATION; SECRETORY PROTEINS; SIGNAL PEPTIDE; RECONSTITUTION; ENERGIZATION; COMPONENTS; MACHINERY	Everted membrane vesicles were prepared from Escherichia coli cells containing either overproduced amounts (OP-membrane vesicles) or normal amounts (normal membrane vesicles) of SecY and SecE, both of which are essential components of the protein translocation apparatus. The rates of translocation of pro-OmpA were similar in the two types of membrane vesicles, whereas translocation ATPase activity, which requires SecA, a precursor protein (pro-OmpA), and membrane vesicles, was appreciably higher with OP-membrane vesicles than with normal membrane vesicles. Since ATP hydrolysis has been shown to take place at an earlier part of the translocation reaction, these results suggest that the overproduction of SecY and SecE enhanced the activity of the earlier process, but not the entire process, of the translocation reaction. The addition of pro-OmpA in the presence of SecA caused the partial collapse of DELTApH (inside acidic) generated on OP-membrane vesicles, suggesting that protons come out from the inside of the membrane vesicles in a pro-OmpA-dependent manner. The collapse of DELTApH caused by pro-OmpA required SecA, ATP, and SecY and was not detected when normal membrane vesicles were used. These results indicate that the early event of protein translocation, which requires the functioning of SecA, SecY, and SecE, causes the countermovement of protons.	UNIV TOKYO,INST APPL MICROBIOL,1-1-1 YAYOI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KATO M, 1992, J BIOL CHEM, V267, P413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OZAWA Y, 1987, J BACTERIOL, V169, P1331, DOI 10.1128/jb.169.3.1331-1334.1987; PANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHATZ PJ, 1989, GENE DEV, V3, P1035; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SUGIMURA K, 1988, BIOCHEM BIOPH RES CO, V153, P753, DOI 10.1016/S0006-291X(88)81159-8; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368	36	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8193	8198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463329				2022-12-25	WOS:A1993KW97900088
J	HONDA, S; MOROHASHI, K; NOMURA, M; TAKEYA, H; KITAJIMA, M; OMURA, T				HONDA, S; MOROHASHI, K; NOMURA, M; TAKEYA, H; KITAJIMA, M; OMURA, T			AD4BP REGULATING STEROIDOGENIC P-450 GENE IS A MEMBER OF STEROID-HORMONE RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC TRANSCRIPTION; DEPENDENT PROTEIN-KINASE; RETINOIC ACID RECEPTOR; AMP RESPONSE ELEMENT; SIDE-CHAIN CLEAVAGE; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; CYCLIC-AMP; P-450(11-BETA) GENE; MOLECULAR-CLONING	Bovine cytochrome P-450(11beta) gene (CYP11B) has six different cis-acting elements, Ad1, Ad2, Ad3, Ad4, Ad5, and Ad6, in the promoter region. The Ad4 site also exists in the promoter regions of other steroidogenic P-450 genes as well as in CYP11B1. An Ad4-binding protein (Ad4BP) which specifically binds to the Ad4 site was purified from bovine adrenal cortex nuclear extract, and its molecular mass was 53 kDa. A complementary DNA encoding Ad4BP was isolated from a bovine adrenal cortex cDNA library. The cDNA clone contained an open reading frame of 1383 base pairs encoding 461 amino acids, whose calculated molecular weight was 51,020. The predicted amino acid sequence of Ad4BP revealed that the protein has a zinc finger domain and a ligand binding/dimerization domain. Ad4BP is a novel member of the steroid hormone receptor superfamily. Comparison of the primary structures of the hormone receptor superfamily showed that Ad4BP was highly homologous to FTZ-F1, which regulates the fushi tarazu gene, and ELP, which is expressed in the murine embryonal carcinoma cells. Transfection of a Ad4BP expression plasmid into CV-1 cells activated the transcription of the CAT reporter gene carrying the Ad4 sequence in the promoter region.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, HIGASHI KU, FUKUOKA 812, JAPAN; FUJITSU LTD, MINATO KU, TOKYO 105, JAPAN	Kyushu University; Fujitsu Ltd								AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; BRENTANO ST, 1990, MOL ENDOCRINOL, V4, P1972, DOI 10.1210/mend-4-12-1972; CHUNG BC, 1989, BIOCHEM BIOPH RES CO, V160, P276, DOI 10.1016/0006-291X(89)91652-5; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DUFAU ML, 1971, BIOCHIM BIOPHYS ACTA, V252, P574, DOI 10.1016/0304-4165(71)90161-9; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUNKENSTEIN B, 1983, J BIOL CHEM, V258, P187; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOASCOGNE CL, 1987, SCIENCE, V237, P1212; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HASHIMOTO T, 1992, J BIOCHEM-TOKYO, V112, P573, DOI 10.1093/oxfordjournals.jbchem.a123941; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSEN R, 1989, GENE ANAL TECH, V6, P79, DOI 10.1016/0735-0651(89)90020-4; JOHN ME, 1985, J BIOL CHEM, V260, P5760; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KIRITA S, 1990, J BIOCHEM, V108, P1030, DOI 10.1093/oxfordjournals.jbchem.a123302; KOIKE G, 1990, J BIOL CHEM, V265, P14754; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAUBER ME, 1991, J BIOL CHEM, V266, P11170; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUND J, 1990, J BIOL CHEM, V265, P3304; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIZUKAMI Y, 1983, BIOCHEMISTRY-US, V22, P1223, DOI 10.1021/bi00274a036; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RICE DA, 1989, J BIOL CHEM, V264, P14011; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; Sambrook J, 1989, MOL CLONING LABORATO; SANDLER R, 1966, ENDOCRINOLOGY, V79, P647, DOI 10.1210/endo-79-3-647; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1979, MOL CELL ENDOCRINOL, V13, P213, DOI 10.1016/0303-7207(79)90082-0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WONG LH, 1989, NATURE, V340, P163; ZANGER UM, 1991, J BIOL CHEM, V266, P11417	86	356	361	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7494	7502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463279				2022-12-25	WOS:A1993KV14100096
J	MCKINNEY, TD; HOSFORD, MA				MCKINNEY, TD; HOSFORD, MA			ATP-STIMULATED TETRAETHYLAMMONIUM TRANSPORT BY RABBIT RENAL BRUSH-BORDER MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION-TRANSPORT; CARRIER-MEDIATED TRANSPORT; RESISTANCE GENE-PRODUCT; BASOLATERAL MEMBRANE; MULTIDRUG-RESISTANCE; BOVINE KIDNEY; CIMETIDINE TRANSPORT; DEPENDENT TRANSPORT; EXTRACELLULAR ATP; TUBULES INVITRO	These studies examined the ability of ATP to stimulate transport of the organic cation tetraethylammonium (TEA) into proximal tubular brush border membrane vesicles. ATP markedly enhanced TEA uptake for 1 h or more to values severalfold above those observed in the absence of ATP. The poorly hydrolyzable analogue of ATP, AMP-PNP (adenyl-5'-yl imidodiphosphate), reduced the effect of ATP but alone did not stimulate TEA uptake. GTP and ITP also stimulated TEA uptake, whereas other nucleotides did not. ATP-stimulated TEA uptake was saturable, temperature-dependent, and markedly reduced by the organic cations amiloride, quinidine, cimetidine, and verapamil, but only modestly reduced by the organic cations N'-methylnicotinamide and choline. Some inhibitors of other transport ATPases, including N-ethylmaleimide, N,N'-dicyclohexylcarbodiimide, and oligomycin, reduced the effect of ATP, whereas ouabain, vanadate, and azide did not. 4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid also reduced TEA uptake in the presence of ATP. Vinblastine, but not actinomycin D and colchicine (all inhibitors of P-glycoprotein-mediated transport), reduced TEA uptake. The reduction of TEA transport by amiloride and cimetidine was most consistent with competitive inhibition, whereas the inhibition produced by N-ethylmaleimide and vinblastine evidently was not. ATP also stimulated uptake of N'-methylnicotinamide but not that of vinblastine. These studies have identified a previously unrecognized process by which ATP hydrolysis may directly energize the reabsorption of organic cations from the renal tubule lumen.	INDIANA UNIV, MED CTR, DEPT MED, NEPHROL SECT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, MED CTR, VET AFFAIRS MED CTR, MED SERV, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ACARA M, 1979, AM J PHYSIOL, V236, pF112; Bashford C L, 1979, Methods Enzymol, V55, P569; BIBER J, 1983, PFLUG ARCH EUR J PHY, V398, P221, DOI 10.1007/BF00657155; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CUSACK NJ, 1990, ANN NY ACAD SCI, V603, P173; DONOWITZ M, 1987, AM J PHYSIOL, V252, pG723, DOI 10.1152/ajpgi.1987.252.6.G723; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FRIEDRICH F, 1989, AM J PHYSIOL, V256, pC1016, DOI 10.1152/ajpcell.1989.256.5.C1016; GARG LC, 1991, J AM SOC NEPHROL, V2, P949; GISCLON L, 1987, AM J PHYSIOL, V253, pF141, DOI 10.1152/ajprenal.1987.253.1.F141; GLUCK S, 1984, J CLIN INVEST, V73, P1704, DOI 10.1172/JCI111378; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRANTHAM JJ, 1980, AM J PHYSIOL, V239, pF97, DOI 10.1152/ajprenal.1980.239.2.F97; Grantham JJ, 1991, KIDNEY, P483; HASSE W, 1978, BIOCHEM J, V172, P57; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1990, BIOCHIM BIOPHYS ACTA, V1027, P116, DOI 10.1016/0005-2736(90)90074-X; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; HSYU PH, 1987, J BIOL CHEM, V262, P3964; INESI G, 1988, METHOD ENZYMOL, V157, P155; JOHNSON RG, 1982, MEMBRANES TRANSPORT, P237; JUNG JS, 1989, BIOCHEM J, V259, P377, DOI 10.1042/bj2590377; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLAASSEN CD, 1984, PHARMACOL REV, V36, P1; LAZARUK KDA, 1990, AM J PHYSIOL, V258, pF597, DOI 10.1152/ajprenal.1990.258.3.F597; LOWE A, 1988, METHOD ENZYMOL, V157, P611; MAEGAWA H, 1988, J BIOL CHEM, V263, P11150; MCKINNEY TD, 1981, AM J PHYSIOL, V241, pF69, DOI 10.1152/ajprenal.1981.241.1.F69; MCKINNEY TD, 1992, J AM SOC NEPHROL, V2, P1507; MCKINNEY TD, 1987, AM J PHYSIOL, V252, pF525, DOI 10.1152/ajprenal.1987.252.3.F525; MCKINNEY TD, 1988, J CELL PHYSIOL, V137, P513, DOI 10.1002/jcp.1041370317; MCKINNEY TD, 1982, AM J PHYSIOL, V242, pF672, DOI 10.1152/ajprenal.1982.242.6.F672; MCKINNEY TD, 1985, AM J PHYSIOL, V249, pF531; MCKINNEY TD, 1993, DISEASES KIDNEY, P261; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; MURER H, 1976, BIOCHEM J, V154, P597, DOI 10.1042/bj1540597; Pritchard J.B., 1992, KIDNEY PHYSL PATHOPH, P2921; RAFIZADEH C, 1987, J PHARMACOL EXP THER, V240, P308; SABOLIC I, 1986, AM J PHYSIOL, V250, pF817, DOI 10.1152/ajprenal.1986.250.5.F817; SABOLIC I, 1992, AM J PHYSIOL, V262, pF217, DOI 10.1152/ajprenal.1992.262.2.F217; Segel IH, 1976, BIOCH CALCULATIONS; SOKOL PP, 1990, AM J PHYSIOL, V258, pF1599; SOKOL PP, 1985, J PHARMACOL EXP THER, V233, P694; SOLEIMANI M, 1990, J CLIN INVEST, V86, P1076, DOI 10.1172/JCI114810; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TURRINI F, 1989, J MEMBRANE BIOL, V107, P1, DOI 10.1007/BF01871078; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WRIGHT EM, 1984, AM J PHYSIOL, V246, pF363, DOI 10.1152/ajprenal.1984.246.4.F363; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1992, J MEMBRANE BIOL, V126, P51; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903; WRIGHT SH, 1989, AM J PHYSIOL, V256, pF462, DOI 10.1152/ajprenal.1989.256.3.F462	61	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6886	6895						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463219				2022-12-25	WOS:A1993KV14100017
J	TSUKUBA, T; HORI, H; AZUMA, T; TAKAHASHI, T; TAGGART, RT; AKAMINE, A; EZAKI, M; NAKANISHI, H; SAKAI, H; YAMAMOTO, K				TSUKUBA, T; HORI, H; AZUMA, T; TAKAHASHI, T; TAGGART, RT; AKAMINE, A; EZAKI, M; NAKANISHI, H; SAKAI, H; YAMAMOTO, K			ISOLATION AND CHARACTERIZATION OF RECOMBINANT HUMAN CATHEPSIN-E EXPRESSED IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; SLOW-MOVING PROTEINASE; ACID PROTEINASE; ASPARTIC PROTEINASES; GASTRIC-MUCOSA; IMMUNOHISTOCHEMICAL LOCALIZATION; RAT SPLEEN; PURIFICATION; ENZYME	The cDNA sequence encoding precursor forms of human cathepsin E (CE), an intracellular aspartic proteinase, was expressed in Chinese hamster ovary cells using an SV40 promotor-driven expression vector. By immunoelectron microscopic studies using an anti-human CE antibody and by Percoll density gradient fractionation, the expressed CE was found to be in two different intracellular fractions; the cytosolic compartment and the vacuolar system. The CEs in both the cytosolic and the vacuolar fractions were highly purified by a simple method involving Percoll density gradient fractionation, chromatography on concanavalin A-Sepharose, Mono Q, and TSK-GelG2000SW, and termed s-CE and v-CE, respectively. The v-CE was further separated into a major (v-CE1) and a minor (v-CE2) form by Mono Q chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting revealed that the s-CE and v-CE1 consists of two polypeptides of 90 and 84 kDa, whereas v-CE2 is composed of 84- and 82-kDa polypeptides. The NH2-terminal amino acid sequence analyses showed that the 90- and 84-kDa proteins from both s-CE and v-CE started with Ser3 and Lys30 of the sequence of human gastric CE predicted from its cDNA sequence, respectively, and that the NH2 terminus of the 82-kDa protein of v-CE2 is the Ile37. Upon acid treatment at pH 3.5 and 37-degrees-C for 5 min, the 90- and 84-kDa forms are rapidly converted to the 82-kDa form, indicating that the 90-, 84- and 82-kDa proteins are the pro-CE, the intermediate form, and the mature CE, respectively. All the forms of CE are N-glycosylated with high-mannose-type oligosaccharides. The catalytic properties of s-CE and v-CE are comparable to those of natural human CE. These results suggest that the recombinant CE is initially synthesized on membrane-bound ribosomes as a N-glycosylated preproenzyme and that, after cleavage of the signal segment, the 90-kDa proenzyme is proteolytically processed to the intermediate (84 kDa) and mature (82 kDa) forms by the transport system.	KYUSHU UNIV,FAC DENT,DEPT PHARMACOL,FUKUOKA 812,JAPAN; TOSOH CO,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN; KYUSHU UNIV,FAC DENT,DEPT CONSERVAT DENT 1,FUKUOKA 812,JAPAN; KYOTO PREFECTURAL UNIV,DEPT PREVENT MED,KYOTO 602,JAPAN; NAGASAKI UNIV,SCH DENT,DEPT PHARMACOL,NAGASAKI 852,JAPAN; WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201	Kyushu University; Tosoh Corporation; Kyushu University; Kyoto Prefectural University; Nagasaki University; Wayne State University			Tsukuba, Takayuki/I-9542-2018	Tsukuba, Takayuki/0000-0003-3322-1339				ATHAUDA SBP, 1991, BIOCHEM BIOPH RES CO, V175, P152, DOI 10.1016/S0006-291X(05)81213-6; AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOWERS WE, 1972, J EXP MED, V136, P1394, DOI 10.1084/jem.136.6.1394; DUNN BM, 1987, BIOCHIM BIOPHYS ACTA, V913, P122, DOI 10.1016/0167-4838(87)90320-7; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FIOCCA R, 1990, HUM PATHOL, V21, P260, DOI 10.1016/0046-8177(90)90225-T; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; ICHIMARU E, 1990, J BIOCHEM-TOKYO, V108, P1009, DOI 10.1093/oxfordjournals.jbchem.a123299; JUPP RA, 1988, BIOCHEM J, V254, P895, DOI 10.1042/bj2540895; KAGEYAMA T, 1980, J BIOCHEM, V87, P725, DOI 10.1093/oxfordjournals.jbchem.a132801; KAGEYAMA T, 1989, J BIOCHEM-TOKYO, V105, P15, DOI 10.1093/oxfordjournals.jbchem.a122610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUTO N, 1988, J BIOCHEM-TOKYO, V103, P629, DOI 10.1093/oxfordjournals.jbchem.a122318; ROBINS E, 1968, J BIOL CHEM, V243, P4246; SAKAI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P412, DOI 10.1016/0003-9861(92)90705-2; SAKAI H, 1989, BIOCHIM BIOPHYS ACTA, V991, P367, DOI 10.1016/0304-4165(89)90130-X; SAKU T, 1991, J BIOCHEM-TOKYO, V110, P956, DOI 10.1093/oxfordjournals.jbchem.a123696; SAMLOFF IM, 1987, GASTROENTEROLOGY, V93, P77, DOI 10.1016/0016-5085(87)90317-9; SCHAHILL SJ, 1983, P NATL ACAD SCI USA, V80, P4654; TAKEDA M, 1986, J BIOCHEM-TOKYO, V100, P1269, DOI 10.1093/oxfordjournals.jbchem.a121833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRLAUB G, 1980, P NATL ACAD SCI USA, V77, P4216; YAMAMOTO K, 1978, EUR J BIOCHEM, V92, P499, DOI 10.1111/j.1432-1033.1978.tb12772.x; YAMAMOTO K, 1985, J BIOCHEM-TOKYO, V97, P821, DOI 10.1093/oxfordjournals.jbchem.a135122; YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167-4838(84)90024-4; YAMAMOTO K, 1984, JPN J PHARMACOL, V35, P253, DOI 10.1254/jjp.35.253; YAMAMOTO K, 1992, IN PRESS BIOL FUNCTI; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YONEZAWA S, 1988, ARCH BIOCHEM BIOPHYS, V267, P176, DOI 10.1016/0003-9861(88)90021-5; YONEZAWA S, 1990, BIOCHEM BIOPH RES CO, V166, P1032, DOI 10.1016/0006-291X(90)90914-9	33	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7276	7282						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463263				2022-12-25	WOS:A1993KV14100067
J	CERVERA, J; CONEJEROLARA, F; RUIZSANZ, J; GALISTEO, ML; MATEO, PL; LUSTY, CJ; RUBIO, V				CERVERA, J; CONEJEROLARA, F; RUIZSANZ, J; GALISTEO, ML; MATEO, PL; LUSTY, CJ; RUBIO, V			THE INFLUENCE OF EFFECTORS AND SUBUNIT INTERACTIONS ON ESCHERICHIA-COLI CARBAMOYL-PHOSPHATE SYNTHETASE STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL DOMAIN; ACETYL-L-GLUTAMATE; ATP BINDING-SITES; THERMAL-DENATURATION; MECHANISM; PROTEIN; LIVER; PROTEOLYSIS; INHIBITION; ACTIVATION	Differential scanning calorimetry of Escherichia coli carbamoyl-phosphate synthetase and its isolated large and small subunits reveals in each case an irreversible, kinetically controlled transition, at a temperature 14-degrees-C higher for the holoenzyme than for the subunits, indicating dramatic stabilization of the subunits in the heterodimer. The deletion of the COOH-terminal 171 (mutant CarB'2373) or 385 (mutant CarB2177) residues of the large subunit results in more asymmetric transitions at a temperature 7-degrees-C lower than for the wild type. The allosteric effectors IMP, UMP, and ornithine induce small reversible transitions at low temperature in the endotherm for the wild-type enzyme, but not for CarB'2373, as expected if the effectors bind in the 171-residue, COOH-terminal region. In contrast, two ligands that bind outside the deleted region, Ap5A (a ligand of both ATP sites) and glycine (an analog of glutamine) decrease and increase, respectively, the stability of the two mutants and of the wild type. The stabilization by glycine requires that the subunits are associated. The results support the implication of the 20-kDa COOH-terminal domain of the large subunit in the allosteric modulation by all the effectors and are consistent with the folding of the large subunit as a pseudohomodimer of its two homologous halves.	UNIV GRANADA, FAC CIENCIAS, DEPT QUIM FIS, GRANADA, SPAIN; PUBL HLTH RES INST CITY NEW YORK INC, DEPT MOLEC GENET, NEW YORK, NY 10016 USA	University of Granada	CERVERA, J (corresponding author), CSIC, CTR ASOCIADO, FDN VALENCIANA INVEST BIOMED, INST INVEST CITOL, AMADEO SABOYA, E-446010 VALENCIA, SPAIN.		Rubio, Vicente/K-7919-2014; Lara, Francisco Conejero/F-2962-2016	Rubio, Vicente/0000-0001-8124-1196; Lara, Francisco Conejero/0000-0002-8282-2168; Ruiz Sanz, Javier/0000-0002-4336-1274	NIGMS NIH HHS [GM25846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO E, 1992, J BIOL CHEM, V267, P4524; ANDERSON PM, 1970, BIOCHEMISTRY-US, V9, P171, DOI 10.1021/bi00803a022; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CONEJEROLARA F, 1991, EUR J BIOCHEM, V200, P663, DOI 10.1111/j.1432-1033.1991.tb16230.x; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUADALAJARA AM, 1987, THESIS U VALENCIA SP; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUZMANCASADO M, 1990, EUR J BIOCHEM, V188, P181, DOI 10.1111/j.1432-1033.1990.tb15386.x; HAN BD, 1990, J BACTERIOL, V172, P5089, DOI 10.1128/jb.172.9.5089-5096.1990; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KLIVANOV AM, 1987, PROTEIN ENG, P213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZMAYORGA O, 1987, BIOPHYS CHEM, V87, P87; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MATEO PL, 1984, THERMOCHEMISTRY ITS, P541; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PASCUALSALCEDO MD, 1979, THESIS U AUTONOMA MA; PIERARD A, 1978, J BACTERIOL, V134, P167; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1980, PURE APPL CHEM, V52, P479, DOI 10.1351/pac198052020479; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SANCHEZRUIZ JM, 1988, EUR J BIOCHEM, V176, P225, DOI 10.1111/j.1432-1033.1988.tb14272.x; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P6185, DOI 10.1021/bi00524a042	40	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12504	12511						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509390				2022-12-25	WOS:A1993LG65800043
J	PALMER, DJ; HELMS, JB; BECKERS, CJM; ORCI, L; ROTHMAN, JE				PALMER, DJ; HELMS, JB; BECKERS, CJM; ORCI, L; ROTHMAN, JE			BINDING OF COATOMER TO GOLGI MEMBRANES REQUIRES ADP-RIBOSYLATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; COATED VESICLES; CHOLERA-TOXIN; REGULATORY COMPONENT; PROTEIN COFACTOR; BREFELDIN-A; BETA-COP; TRANSPORT; PURIFICATION; COMPLEX	Coatomer, a complex of seven proteins, appears to be the precursor of the coat structure of non-clathrin-coated Golgi-derived vesicles. Another component of this vesicle coat is the cytosolic protein ADP-ribosylation factor (ARF). Like coatomer, ARF appears to reversibly associate with Golgi membranes. We now report that ARF is required for coatomer binding to Golgi membranes and that myristoylated, but not non-myristoylated, ARF is the required species. We utilize an antibody directed against the beta-subunit of coatomer (beta-COP) to follow coatomer binding. ARF and beta-COP bind stoichiometrically to Golgi membranes. ARF-dependent beta-COP binding requires a membrane-associated protein, is saturable, and is enhanced in the presence of stable GTP analogues like guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS). ARF and beta-COP bind sequentially to Golgi membranes, since beta-COP can be bound to reisolated membranes that had been previously incubated with ARF and GTPgammaS. We conclude that membrane-bound ARF confers to Golgi membranes all of the requirements for specific beta-COP binding.	SLOAN KETTERING INST CANC RES, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA; UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND	Memorial Sloan Kettering Cancer Center; University of Geneva								ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P182; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, IN PRESS J CELL BIOL; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, IN PRESS NATURE; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	38	296	298	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12083	12089						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505331				2022-12-25	WOS:A1993LF28400093
J	ROBERDS, SL; ERVASTI, JM; ANDERSON, RD; OHLENDIECK, K; KAHL, SD; ZOLOTO, D; CAMPBELL, KP				ROBERDS, SL; ERVASTI, JM; ANDERSON, RD; OHLENDIECK, K; KAHL, SD; ZOLOTO, D; CAMPBELL, KP			DISRUPTION OF THE DYSTROPHIN-GLYCOPROTEIN COMPLEX IN THE CARDIOMYOPATHIC HAMSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; CALCIUM CHANNELS; PROTEINS; HEART; BRAIN; ORGANIZATION; DEFICIENCY; MYOPATHY	Cardiomyopathies are a diverse group of primary cardiac diseases, most of which have a poorly understood etiology. One type of hereditary cardiomyopathy is caused by defects in the dystrophin gene in Duchenne and Becker muscular dystrophy patients. Our laboratory has identified a complex of dystrophin-associated proteins in skeletal and cardiac muscle which span the sarcolemma, linking the subsarcolemmal cytoskeleton to the extracellular matrix. The absence of dystrophin in Duchenne muscular dystrophy patients leads to the loss of dystrophin-associated proteins in both skeletal and cardiac muscle, suggesting that a primary loss of one or more dystrophin-associated proteins might lead to other forms of cardiomyopathy. Here we report the specific deficiency of the 50-kDa dystrophin-associated glycoprotein in cardiac and skeletal muscles of the BIO 14.6 strain of cardiomyopathic hamsters, which experience both autosomal recessive cardiomyopathy and myopathy. Other dystrophin-associated proteins are well preserved in myopathic hamster skeletal muscle, but the link between dystrophin and dystroglycan is disrupted. All dystrophin-associated proteins are decreased in abundance in the cardiomyopathic hamster heart, perhaps explaining why the cardiomyopathy is more severe than the myopathy. Thus, the disruption of the dystrophin-glycoprotein complex may play a role in skeletal and cardiac myocyte necrosis of the cardiomyopathic hamster.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 400 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Ervasti, James/AAZ-4786-2020; Roberds, Steven L/AAP-4985-2020	Roberds, Steven L/0000-0003-0676-272X; Kahl, Steven/0000-0001-7085-9556; Ohlendieck, Kay/0000-0002-6266-4510; Campbell, Kevin/0000-0003-2066-5889				ANAN R, 1992, AM HEART J, V123, P1088, DOI 10.1016/0002-8703(92)90732-B; BAJUSZ E, 1969, ANN NY ACAD SCI, V156, P105, DOI 10.1111/j.1749-6632.1969.tb16721.x; BAJUSZ E, 1969, AM HEART J, V77, P686, DOI 10.1016/0002-8703(69)90556-0; BAZAN E, 1991, J MOL CELL CARDIOL, V23, P111, DOI 10.1016/0022-2828(91)90098-7; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; FINKEL MS, 1987, LIFE SCI, V41, P153, DOI 10.1016/0024-3205(87)90488-7; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; Homburger F, 1979, Ann N Y Acad Sci, V317, P1, DOI 10.1111/j.1749-6632.1979.tb56503.x; HOWLETT SE, 1987, BIOCHEM PHARMACOL, V36, P2653, DOI 10.1016/0006-2952(87)90547-8; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, BIOCHEM BIOPH RES CO, V190, P589, DOI 10.1006/bbrc.1993.1089; Jasmin G, 1979, Ann N Y Acad Sci, V317, P46, DOI 10.1111/j.1749-6632.1979.tb56509.x; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KAWAGUCHI H, 1991, CIRC RES, V69, P1015, DOI 10.1161/01.RES.69.4.1015; KLIETSCH R, 1993, CIRC RES, V72, P349, DOI 10.1161/01.RES.72.2.349; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PALMUCCI L, 1992, J NEUROL SCI, V111, P218, DOI 10.1016/0022-510X(92)90073-T; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; SEN LY, 1990, CIRC RES, V67, P1182, DOI 10.1161/01.RES.67.5.1182; SHARP AH, 1989, J BIOL CHEM, V264, P2816; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330	38	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11496	11499						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505286				2022-12-25	WOS:A1993LF28400007
J	THOIDIS, G; KOTLIAR, N; PILCH, PF				THOIDIS, G; KOTLIAR, N; PILCH, PF			IMMUNOLOGICAL ANALYSIS OF GLUT4-ENRICHED VESICLES - IDENTIFICATION OF NOVEL PROTEINS REGULATED BY INSULIN AND DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; RECEPTOR-MEDIATED ENDOCYTOSIS; VESICULAR TRANSPORT; BINDING PROTEINS; PLASMA-MEMBRANE; RAT ADIPOCYTES; FUSION PROTEIN; MESSENGER-RNA; ADIPOSE-CELLS; TRANSLOCATION	In adipocytes and muscle, insulin stimulates the translocation of glucose transporter proteins from an intracellular vesicle pool to the plasma membrane. To study the molecular basis of this process, we used the anti-GLUT4 antibody 1F8 to isolate intracellular vesicles from rat adipocytes that are enriched in the muscle/fat glucose transporter isoform. These vesicles were then used as immunogens to generate monoclonal antibodies against their protein components. We isolated an antibody, 3F8, that recognizes three polypeptides, designated GTV3, migrating in the 36-40-kDa range as analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting. These proteins are enriched in GLUT4-containing vesicles, and the two smallest of the polypeptides recognized by 3F8 translocate to the cell surface in response to insulin. GTV3 proteins are also present in plasma membranes of fat cells and liver as well as in a wide number of tissues, red blood cells being the only exception. In adipocytes from streptozotocin-induced diabetic rats, GTV3 protein levels decrease dramatically and return to normal levels when animals are treated with insulin. The localization of GTV3 in glucose transporter-containing vesicles as well as their wide tissue distribution suggests that these proteins may be involved in vesicle mediated transport and regulated trafficking between membrane compartments.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Pilch, Paul/0000-0003-1997-0499	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07035] Funding Source: Medline; NIDDK NIH HHS [R01 DK30425-11] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAND SH, 1991, J BIOL CHEM, V266, P18949; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; Fleischer S, 1974, Methods Enzymol, V31, P3; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Galfre G, 1981, Methods Enzymol, V73, P3; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; RODBELL M, 1964, J BIOL CHEM, V239, P375; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	43	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11691	11696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505298				2022-12-25	WOS:A1993LF28400037
J	AHMED, S; LEE, J; KOZMA, R; BEST, A; MONFRIES, C; LIM, L				AHMED, S; LEE, J; KOZMA, R; BEST, A; MONFRIES, C; LIM, L			A NOVEL FUNCTIONAL TARGET FOR TUMOR-PROMOTING PHORBOL ESTERS AND LYSOPHOSPHATIDIC ACID - THE P21RAC-GTPASE ACTIVATING PROTEIN N-CHIMAERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C; BINDING; BRAIN; RECEPTOR; PRODUCT; ENCODES; DOMAIN; ZINC; GENE; BCR	Phorbol esters are potent tumor promoters widely used for investigating mechanisms of cell transformation with protein kinase C (PKC) generally considered as being their only protein target. Lysophosphatidic acid (LPA) can act as a mitogen, affecting cell shape and the actin cytoskeleton. There is no identified functional target for LPA. We have isolated a cDNA encoding a protein n-chimaerin that is a high affinity phorbol ester receptor and a p21rac-GTPase activating protein (rac-GAP). p21rac is a member of the ras superfamily of small molecular weight GTP-binding proteins, which stimulates actin microfilament formation in Swiss 3T3 cells and superoxide production by the neutrophil oxidase. We now show that the rac-GAP activity of n-chimaerin is stimulated by phosphatidylserine (PS) and phosphatidic acid (PA) and that phorbol esters can synergize with PS and PA. LPA, in contrast, was found to inhibit n-chimaerin. The phospholipid/phorbol ester modulation of the rac-GAP activity requires the PKC-like cysteine-rich domain of n-chimaerin. Thus, n-chimaerin is a novel functional target (distinct from PKC) for both phorbol esters and LPA. These data suggest that the physiological role of n-chimaerin is to link events initiating at the cell surface/membrane with p21rac effector pathways.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	AHMED, S (corresponding author), INST NEUROL,DEPT NEUROCHEM,1 WAKEFIELD ST,LONDON WC1N 1PJ,ENGLAND.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768				AHMED S, 1992, BIOCHEM J, V287, P995, DOI 10.1042/bj2870995; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ANDO S, 1992, J BIOL CHEM, V267, P25709; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; NAKANISHI N, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1992, CELL, V70, P411; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TIGYI G, 1992, J BIOL CHEM, V267, P21360; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND R, 1992, EMBO J, V7, P2495; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	34	173	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10709	10712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496137				2022-12-25	WOS:A1993LD46600003
J	LI, CW; MOORE, DS; ROSENBERG, RC				LI, CW; MOORE, DS; ROSENBERG, RC			CIRCULAR-DICHROISM STUDIES OF DIETHYL PYROCARBONATE-MODIFIED HISTIDINE IN HEN EGG-WHITE LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; CHEMICAL MODIFICATION; ETHOXYFORMIC ANHYDRIDE; RESIDUES; DIETHYLPYROCARBONATE; PROTEINS; SITE; INACTIVATION; BINDING; ENZYME	The single histidine residue (His- 15) in hen egg white lysozyme (EC 3.2.1.17) was chemically modified by diethyl pyrocarbonate (DEPC) to form exclusively the mono-N-carbethoxyimidazole adduct (second order rate constant of 252 +/- 16 M-1 min-1). Irreversible biscarbethoxylation of the His-15 imidazole ring by DEPC was observed when lysozyme was pretreated with 2-mercaptoethanol (2-ME), 2-ME plus 8 M urea, or 2-ME plus 1% (w/v) sodium dodecyl sulfate (SDS). Circular dichroism difference spectra were measured for the mono-N-carbethoxyimidazole derivatives of lysozyme, N(alpha)-acetyl-L-histidine, angiotensin-II, and O-carbethoxy-N(alpha)-acetyl-L-tyrosine. The circular dichroism difference spectrum for mono-N-carbethoxy lysozyme had one main band (DELTA[theta]244 nm = +17,000 degree.cm2.dmol-1) in the 240-260 nm region. Denaturing mono-N-carbethoxy lysozyme with 2-ME and 8 M urea (55-degrees-C) or 1% SDS (100-degrees-C) essentially abolished its circular dichroism difference spectrum in the 240-260 nm region without any decarbethoxylation. In this same region the circular dichroism difference spectra of DEPC-modified N(alpha)-acetyl-L-histidine and DEPC-modified angiotensin-II had two much weaker bands (DELTA[theta]233 nm = +1000 degree.cm2.dmol-1 and DELTA[theta]252 nm = -600 degree.cm2.dmol-1 for N(alpha)-acetyl-L-histidine). This study reports the first characterization of circular dichroism associated with mono-N-carbethoxyhistidine in an enzyme (lysozyme), a peptide (angiotensin-II), and a model compound (N(alpha)-acetyl-L-histidine).	HOWARD UNIV,DEPT CHEM,WASHINGTON,DC 20059	Howard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008016] Funding Source: NIH RePORTER; NIGMS NIH HHS [S06GM08016] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULWAJID AW, 1986, BIOCHEMISTRY-US, V25, P8167, DOI 10.1021/bi00373a007; ANDERSEN TT, 1979, J BIOL CHEM, V254, P995; BANYARD SH, 1974, LYSOZYME, P71; BATEMAN RC, 1987, BIOCHEMISTRY-US, V26, P4237, DOI 10.1021/bi00388a009; BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CARRILLO N, 1983, BIOCHEMISTRY-US, V22, P5889, DOI 10.1021/bi00294a031; CHENG KC, 1989, J BIOL CHEM, V264, P19666; DARON HH, 1982, BIOCHEMISTRY-US, V21, P737, DOI 10.1021/bi00533a024; DICKERSON RE, 1969, STRUCTURE ACTION PRO, P69; FAVOROVA OO, 1978, EUR J BIOCHEM, V86, P193, DOI 10.1111/j.1432-1033.1978.tb12299.x; GEORGE AL, 1979, BIOCHIM BIOPHYS ACTA, V569, P63, DOI 10.1016/0005-2744(79)90081-0; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GREENFIELD NJ, 1974, BIOCHEMISTRY-US, V13, P4494, DOI 10.1021/bi00719a004; HEGIY G, 1974, EUR J BIOCHEM, V44, P7; HERMANN J, 1971, EUR J BIOCHEM, V24, P12, DOI 10.1111/j.1432-1033.1971.tb19650.x; IGLESIAS AA, 1983, BIOCHIM BIOPHYS ACTA, V749, P9, DOI 10.1016/0167-4838(83)90144-9; JAWALI N, 1987, PHYTOCHEMISTRY, V26, P1859, DOI 10.1016/S0031-9422(00)81716-1; JOLLES J, 1983, FEBS LETT, V162, P120, DOI 10.1016/0014-5793(83)81061-8; KITA Y, 1982, J BIOCHEM-TOKYO, V92, P1499, DOI 10.1093/oxfordjournals.jbchem.a134074; KRAVCHENKO NA, 1964, BIOCHIM BIOPHYS ACTA, V92, P412, DOI 10.1016/0926-6569(64)90205-6; LAMBIRIS SK, 1981, BIOCHIM BIOPHYS ACTA, V660, P271, DOI 10.1016/0005-2744(81)90170-4; LOCQUET JP, 1968, BIOCHIM BIOPHYS ACTA, V167, P150, DOI 10.1016/0005-2744(68)90284-2; LOOSEMORE MJ, 1976, FEBS LETT, V72, P155, DOI 10.1016/0014-5793(76)80834-4; MATTICE WL, 1976, BIOCHEMISTRY-US, V15, P4264, DOI 10.1021/bi00664a020; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORRIS DL, 1972, EUR J BIOCHEM, V29, P515, DOI 10.1111/j.1432-1033.1972.tb02016.x; NAKANISHI Y, 1984, AGR BIOL CHEM TOKYO, V48, P2951, DOI 10.1080/00021369.1984.10866627; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSTERMANGOLKAR S, 1974, ACTA CHEM SCAND B, VB 28, P215, DOI 10.3891/acta.chem.scand.28b-0215; PELTON PD, 1992, J BIOL CHEM, V267, P5916; Phillips C, 1974, LYSOZYME, P9; PISZKIEWICZ D, 1968, BIOCHEMISTRY-US, V7, P3037, DOI 10.1021/bi00849a003; ROOSEMONT JL, 1978, ANAL BIOCHEM, V88, P314, DOI 10.1016/0003-2697(78)90424-4; SAMS CF, 1984, BIOCHIM BIOPHYS ACTA, P61; SCHMIDT PG, 1984, BIOCHEMISTRY-US, V23, P4261, DOI 10.1021/bi00313a038; TAKEDA K, 1989, J PROTEIN CHEM, V8, P487, DOI 10.1007/BF01026433; VINCENT JP, 1975, BIOCHEMISTRY-US, V14, P2521, DOI 10.1021/bi00682a035; WALLIS RB, 1973, BIOCHEM J, V133, P183, DOI 10.1042/bj1330183; WIEN RW, 1972, BIOCHEMISTRY-US, V11, P3707, DOI 10.1021/bi00770a008; WIJNANDS RA, 1982, BIOCHEMISTRY-US, V21, P6639, DOI 10.1021/bi00269a005; WILLIAMS AL, 1983, BIOPOLYMERS, V22, P755, DOI 10.1002/bip.360220214; YAMASAKI N, 1968, AGR BIOL CHEM TOKYO, V32, P55, DOI 10.1080/00021369.1968.10859011; ZHANG XH, 1992, BIOCHEMISTRY-US, V31, P2528, DOI 10.1021/bi00124a013	45	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11090	11096						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496171				2022-12-25	WOS:A1993LD46600057
J	BAUMANN, H; MORELLA, KK; CAMPOS, SP				BAUMANN, H; MORELLA, KK; CAMPOS, SP			INTERLEUKIN-6 SIGNAL COMMUNICATION TO THE ALPHA-1-ACID GLYCOPROTEIN GENE, BUT NOT JUNB GENE, IS IMPAIRED IN HTC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN GENES; GLUCOCORTICOID-RESPONSE ELEMENTS; HEPATOCYTE-STIMULATING FACTORS; RAT-LIVER; REGULATED EXPRESSION; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; CYTOKINE-RESPONSE; NUCLEAR FACTOR; C/EBP FAMILY	In the rat hepatoma (HTC) cell line, transcription of the alpha1-acid glycoprotein (AGP) gene is prominently stimulated by dexamethasone. Although interleukin (IL)-1 and IL-6 synergistically enhance expression of the AGP gene in liver, they have no detectable effect on this gene in HTC cells. Nevertheless, HTC cells have mRNA encoding the IL-6 receptor subunits and respond to IL-6 by increasing expression of the junB gene. The mRNA for the 80-kDa IL-6 receptors is increased severalfold following dexamethasone treatment. Even with elevated IL-6 receptor expression, no IL-6 regulation of the AGP gene is observed. The lack of response to IL-6 is also found with the transfected AGP gene sequence, suggesting the absence of specific trans-acting factors. Since IL-6 promotes only a minimal stimulation of the CCAAT/enhancer-binding protein beta, HTC cells lack the indirect IL-6 signaling pathway to acute phase plasma protein genes that has been found to be crucial in other hepatoma cell lines. Considering that a similar IL-6 regulation of the junB gene is manifested in HTC cells and normal liver, a separate IL-6 signal-transducing pathway controlling the AGP gene is assumed to be missing in HTC cells.	SUNY Buffalo, DEPT PEDIAT, BUFFALO, NY 14260 USA; CHILDRENS HOSP BUFFALO, DIV ENDOCRINOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	BAUMANN, H (corresponding author), ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, ELM & CARLTON ST, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1990, J BIOL CHEM, V265, P19420; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BAUMANN H, 1989, GENETICS BIOCH PHYSL, P99; BAUMANN H, 1993, IN PRESS ACUTE PHASE; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; KISHIMOTO T, 1992, CIBA F SYMP, V167, P5; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; NESBITT JE, 1992, MOL BIOL CELL, V3, P103, DOI 10.1091/mbc.3.1.103; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SEIFERT SC, 1979, J CELL PHYSIOL, V99, P333, DOI 10.1002/jcp.1040990308; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001	43	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10495	10500						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486702				2022-12-25	WOS:A1993LB80000075
J	WASLEY, LC; REHEMTULLA, A; BRISTOL, JA; KAUFMAN, RJ				WASLEY, LC; REHEMTULLA, A; BRISTOL, JA; KAUFMAN, RJ			PACE FURIN CAN PROCESS THE VITAMIN-K-DEPENDENT PRO-FACTOR-IX PRECURSOR WITHIN THE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; MOLECULAR-BASIS; EXPRESSION; PROPEPTIDE; MUTATION; ENZYME; INITIATION; PROALBUMIN; GLUTAMINE; SEQUENCES	Factor IX is synthesized as a precursor polypeptide which requires proteolytic cleavage of the propeptide for functional activity. Expression of factor IX at high levels in Chinese hamster ovary (CHO) cells results in the secretion of a mixture of profactor IX and mature factor IX. We have studied whether the processing of profactor IX may be mediated by the recently discovered subtilisin-like serine proteases PACE/furin and/or PACE4. Co-transfection of a PACE expression vector with a profactor IX expression vector resulted in the secretion of fully processed factor IX. In contrast, co-transfection of a PACE4 expression vector with a profactor IX expression vector did not increase processing of profactor IX to the mature form. A factor IX Arg-to-Thr mutation at the P1 position (residue 39) destroyed the ability for PACE to process profactor IX. Amino-terminal sequence analysis demonstrated that processing mediated by PACE occurred at the authentic site within profactor IX. The specificity of profactor IX processing by PACE was also evaluated by transfection of a vector encoding the serine protease inhibitor alpha1-antitrypsin. Expression of wild-type alpha1-antitrypsin, which does not inhibit PACE, did not influence processing of profactor IX mediated by co-expression of PACE. In contrast, the alpha1-antitrypsin Pittsburgh mutant, which inhibits PACE, inhibited profactor IX processing activity mediated by transfected PACE as well as the endogenous CHO cell propeptide processing enzyme. Pulse-chase labeling indicated that PACE processed profactor IX late within the secretory pathway, although a secreted soluble mutant PACE was also capable of processing profactor IX in the conditioned medium. The results implicate PACE as a candidate for the enzyme that processes profactor IX in vivo.	GENET INST,CAMBRIDGE,MA 02140; NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University					NHLBI NIH HHS [HL 42433] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1984, BIOCHIM BIOPHYS ACTA, V802, P24, DOI 10.1016/0304-4165(84)90029-1; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISTOL JA, 1991, BLOOD, V78, pA224; CHASIN LA, 1980, P NATL ACAD SCI USA, V77, P4216; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Davies Monique V., 1992, Current Opinion in Biotechnology, V3, P512, DOI 10.1016/0958-1669(92)90079-X; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FURIE B, 1990, BLOOD, V75, P1753; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; MCCLURE DB, 1992, J BIOL CHEM, V267, P19710; MISUMI Y, 1990, BIOCHEM BIOPH RES CO, V171, P236, DOI 10.1016/0006-291X(90)91382-3; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1992, BLOOD, V79, P2349; REHEMTULLA A, 1993, IN PRESS P NATL ACAD; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; STANTON C, 1992, BIOCHEM J, V284, P25, DOI 10.1042/bj2840025; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; SUGIMOTO M, 1989, BRIT J HAEMATOL, V72, P216, DOI 10.1111/j.1365-2141.1989.tb07685.x; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIDAUD D, 1992, J CLIN INVEST, V89, P1537, DOI 10.1172/JCI115746; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	39	109	145	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8458	8465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473289				2022-12-25	WOS:A1993KX81100016
J	WOOLFORD, CA; NOBLE, JA; GARMAN, JD; TAM, MF; INNIS, MA; JONES, EW				WOOLFORD, CA; NOBLE, JA; GARMAN, JD; TAM, MF; INNIS, MA; JONES, EW			PHENOTYPIC ANALYSIS OF PROTEINASE-A MUTANTS - IMPLICATIONS FOR AUTOACTIVATION AND THE MATURATION PATHWAY OF THE VACUOLAR HYDROLASES OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; PEP4 GENE; ALKALINE-PHOSPHATASE; INVIVO BIOSYNTHESIS; ONE-STEP; YEAST; INHIBITORS; ACTIVATION; DNA; AMINOPEPTIDASE	We have isolated a number of mutants deficient in activity of the vacuolar hydrolase proteinase A (PrA). The mutations were sequenced and although they all map in the PEP4 gene, which encodes the precursor to PrA, three distinguishable phenotypes have surfaced. The properties of the pep4-7 missense mutant suggested that the activation of the precursor to proteinase A is due to an autocatalytic cleavage. PrA active site mutations were constructed and resulted in accumulation of PrA antigen in the inactive precursor form. Although protease B (PrB), another vacuolar hydrolase, is not required for the production of active PrA, the active form of PrA that accumulates in a strain lacking PrB is larger than that found in a strain containing active PrB. We have purified this larger form of PrA and determined that it bears 7 additional amino acids at its NH2 terminus. It has become apparent from all the studies performed on the maturation pathway of the vacuolar hydrolases that there is a great deal of redundancy built into the system.	CHIRON CORP, EMERYVILLE, CA 94608 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Novartis; Academia Sinica - Taiwan	WOOLFORD, CA (corresponding author), CARNEGIE MELLON UNIV, DEPT BIOL SCI, 4400 5TH AVE, PITTSBURGH, PA 15213 USA.			Woolford, Carol/0000-0001-6261-3468	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018090, R37DK018090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029713] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18090] Funding Source: Medline; NIGMS NIH HHS [GM29713] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; AIBARA S, 1971, AGR BIOL CHEM TOKYO, V35, P658, DOI 10.1080/00021369.1971.10859972; ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BECK I, 1980, J BIOL CHEM, V255, P4821; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CABIB E, 1975, J BACTERIOL, V124, P1604, DOI 10.1128/JB.124.3.1604-1606.1975; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; Cryer D R, 1975, Methods Cell Biol, V12, P39; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DREYER T, 1989, CARLSBERG RES COMMUN, V54, P85, DOI 10.1007/BF02908301; DREYER T, 1986, CARLSBERG RES COMMUN, V51, P27, DOI 10.1007/BF02907993; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; HARRIS SD, 1987, CURR MICROBIOL, V15, P247, DOI 10.1007/BF01589375; HASILIK A, 1976, BIOCHEM BIOPH RES CO, V72, P1430, DOI 10.1016/S0006-291X(76)80173-8; HAWTHORNE DC, 1960, GENETICS, V45, P1085; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; HOLZER H, 1976, Tokai Journal of Experimental and Clinical Medicine, V1, P115; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; JONES EW, 1982, GENETICS, V102, P665; JONES EW, 1977, GENETICS, V85, P23; JONES EW, 1989, UCLA S CELLULAR PROT, P141; JONES EW, 1981, A BENZON S, V16, P182; KAGEYAMA T, 1987, EUR J BIOCHEM, V165, P483, DOI 10.1111/j.1432-1033.1987.tb11464.x; KAGEYAMA T, 1982, BIOCHEM BIOPH RES CO, V107, P1117, DOI 10.1016/0006-291X(82)90637-4; KANEKO Y, 1987, GENE, V58, P137; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNEY JF, 1974, BIOCHEM BIOPH RES CO, V60, P1378, DOI 10.1016/0006-291X(74)90350-7; Maniatis T., 1982, MOL CLONING; MATERN H, 1974, BIOCHEM BIOPH RES CO, V60, P1051, DOI 10.1016/0006-291X(74)90419-7; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MECHLER B, 1982, J BIOL CHEM, V257, P1203; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MOEHLE CM, 1989, J CELL BIOL, V108, P309, DOI 10.1083/jcb.108.2.309; NEBES VL, 1991, J BIOL CHEM, V266, P22851; RENDUELES MPS, 1981, FEBS LETT, V131, P296; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; RUPP S, 1991, FEBS LETT, V293, P62, DOI 10.1016/0014-5793(91)81153-Y; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STILES JI, 1983, METHOD ENZYMOL, V101, P290; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; TURK V, 1985, ASPARTIC PROTEINASES, P283; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; WILCHEK M, 1971, BIOCHEMISTRY-US, V10, P2828; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD CA, 1990, GENETICS, V125, P739; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUBENKO GS, 1979, P NATL ACAD SCI USA, V76, P2395, DOI 10.1073/pnas.76.5.2395; ZUBENKO GS, 1982, GENETICS, V102, P679; ZUBENKO GS, 1981, GENETICS, V97, P45; ZUBENKO GS, 1983, P NATL ACAD SCI-BIOL, V80, P510, DOI 10.1073/pnas.80.2.510	66	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8990	8998						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473342				2022-12-25	WOS:A1993KX81100088
J	AKIYAMA, Y; ITO, K				AKIYAMA, Y; ITO, K			FOLDING AND ASSEMBLY OF BACTERIAL ALKALINE-PHOSPHATASE INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; MEMBRANE-PROTEINS; DISULFIDE BOND; SECY	Alkaline phosphatase (PhoA), localized in the periplasmic space of Escherichia coli, is a homodimeric metalloprotein containing two intramolecular disulfide bonds. We attempted to clarify the folding-assembly pathways of this enzyme by allowing in vitro-synthesized PhoA polypeptide to fold into active enzyme and by examining the occurrence of similar pathways in vivo by pulse-chase experiments. PhoA (lacking the signal sequence) that was synthesized in a coupled transcription-translation system was effectively converted into active enzyme when incubated with either oxidized glutathione, periplasmic proteins, or purified DsbA protein in the presence of Zn2+. The first appreciable event in the activation of initially unfolded translation product (species I) was the disulfide bond formation, which was immediately followed by folding into a partially trypsin-resistant monomer (species II), and then by assembly into active dimer (species III). The species II PhoA molecules, but not the species III molecules, were found to be sensitized to trypsin in the presence of a reducing agent, dithiothreitol. Pulse-chase studies showed that PhoA acquires disulfide bonds immediately after the biosynthesis, whereas it acquires resistance to both dithiothreitol and certain endogenous protease over some 2 min at 15-degrees-C. These results indicate that PhoA undergoes a series of folding-assembly steps, some of which are of measurable speeds in vivo and mimicable in vitro.			AKIYAMA, Y (corresponding author), KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, KYOTO 60601, JAPAN.							AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; APPLEBURY ML, 1969, J BIOL CHEM, V244, P308; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Boyd D, 1987, PHOSPHATE METABOLISM, P89; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; FALK MC, 1982, BIOCHEMISTRY-US, V21, P1471, DOI 10.1021/bi00536a001; INOUYE H, 1977, J MOL BIOL, V110, P75, DOI 10.1016/S0022-2836(77)80099-5; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; NEU HC, 1965, J BIOL CHEM, V240, P3685; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; REYNOLDS JA, 1967, BIOCHEMISTRY-US, V6, P3552, DOI 10.1021/bi00863a029; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4293; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Wyckoff HW, 1987, PHOSPHATE METABOLISM, P118	28	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8146	8150						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463326				2022-12-25	WOS:A1993KW97900080
J	ORELLANA, SA; AMIEUX, PS; ZHAO, XY; MCKNIGHT, GS				ORELLANA, SA; AMIEUX, PS; ZHAO, XY; MCKNIGHT, GS			MUTATIONS IN THE CATALYTIC SUBUNIT OF THE CAMP-DEPENDENT PROTEIN-KINASE INTERFERE WITH HOLOENZYME FORMATION WITHOUT DISRUPTING INHIBITION BY PROTEIN-KINASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REGULATORY SUBUNIT; DOMAINS; FAMILY	Three amino acids were identified in the catalytic (C) subunit of the cyclic AMP-dependent protein kinase that are involved in interaction with regulatory (R) subunit, but not with the specific protein kinase inhibitor, PKI. In a functional assay for gene induction, a C expression vector with serine or arginine substituted for Leu-198 and the double mutant C, His-87 --> Gln/Trp-196 --> Arg (Orellana, S. A., and McKnight, G. S. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 4726-4730), retained activity in the presence of an excess of RI or RII. In contrast, cotransfection of a full-length PKI expression vector completely inhibited the activity of both mutant and wild type C subunits. These data suggest that although the substrate/pseudosubstrate sites of R and PKI interact with C at the catalytic site, there is an additional domain on the C subunit that is involved in holoenzyme formation with R subunit and is distinct from sites specifying high affinity PKI binding.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Amieux, Paul/AAG-4102-2021		NIGMS NIH HHS [GM-32875] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHENG HC, 1986, BIOCHEM J, V231, P655; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAY RN, 1989, J BIOL CHEM, V264, P431; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FLOCKHART DA, 1980, J BIOL CHEM, V255, P4435; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446	23	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6843	6846						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463209				2022-12-25	WOS:A1993KV14100006
J	POWELL, LD; SGROI, D; SJOBERG, ER; STAMENKOVIC, I; VARKI, A				POWELL, LD; SGROI, D; SJOBERG, ER; STAMENKOVIC, I; VARKI, A			NATURAL LIGANDS OF THE B-CELL ADHESION MOLECULE CD22-BETA CARRY N-LINKED OLIGOSACCHARIDES WITH ALPHA-2,6-LINKED SIALIC ACIDS THAT ARE REQUIRED FOR RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GLYCOPROTEIN OLIGOSACCHARIDES; ANTIGEN CD22; SIALYLTRANSFERASE; EXPRESSION; RECEPTOR; CHROMATOGRAPHY; GANGLIOSIDES; SPECTROSCOPY; SIALYLATION	CD22beta is a glycoprotein found on the surface of B cells during restricted stages of development. It is believed to play a role in cell-cell interactions and B cell activation. The accompanying paper (Sgroi, D., Varki, A., Braesch-Andersen, S., and Stamenkovic, I. (1993) J. Biol. Chem. 268, 7011-7018) shows that CD22beta recognizes multiple glycoproteins on the surfaces of T and B cells and that sialylation of these ligands is essential for binding. To identify the structure(s) of the sialylated oligosaccharide(s) recognized by CD22beta, [H-3]glucosamine-labeled glycoproteins were purified from Daudi cells by adsorption onto a CD22beta recombinant immunoglobulin (CD22betaRg) chimera attached to protein A-Sepharose (PAS), and the N-linked oligosaccharides were released by peptide N-glycosidase F. These released oligosaccharides failed to bind to CD22betaRg-PAS under the conditions used initially to adsorb the glycoproteins, but their elution from a column of CD22betaRg-PAS was significantly retarded. Populations of oligosaccharides with different affinities could be identified by their order of elution. Specific sialidases were used to determine the content of alpha-2,3- and alpha-2,6-linked sialic acid in these different populations and their contribution to binding. Multiantennary oligosaccharides with one alpha-2,6-linked residue bound marginally, and those with two or more bound more tightly. Alpha-2,3-linked sialic acid residues were without effect. Binding did not require divalent cations and was abrogated by mild periodate oxidation of the outer side chain of sialic acid. No marked differences in size or fucose content were found between the populations of high and low affinity oligosaccharides. However, the low affinity population could be partially converted into higher affinity by treatment with beta-galactoside alpha-2,6 sialyltransferase and CMP-sialic acid. Thus, CD22beta is a mammalian lectin that can recognize specific N-linked oligosaccharide structures containing alpha-2,6-linked sialic acids.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Sgroi, Dennis/AAV-2487-2021		NCI NIH HHS [R01CA55735] Funding Source: Medline; NIGMS NIH HHS [R01GM43257, R01GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043257, R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BOUE DR, 1988, BLOOD, V71, P1480; BOUE DR, 1988, J IMMUNOL, V140, P192; BREG J, 1989, EUR J BIOCHEM, V178, P727, DOI 10.1111/j.1432-1033.1989.tb14504.x; CAMPANA D, 1987, LEUKOCYTE TYPE, V3, P476; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DORKEN B, 1986, J IMMUNOL, V136, P4470; DORKEN B, 1987, LEUCOCYTE TYPING, V3, P474; DORKEN B, 1987, LEUKOCYTE TYPING, V3, P369; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FUKUDA M, 1989, METHOD ENZYMOL, V179, P17; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; GUY K, 1991, IMMUNOLOGY, V74, P206; HOUGH L, 1962, METHODS CARBOHYDRATE, V1, P21; KNIEP B, 1990, FEBS LETT, V261, P347, DOI 10.1016/0014-5793(90)80588-A; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2687, DOI 10.1021/bi00280a015; KUNDU SK, 1992, GLYCOCONJUGATES COMP, P203; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; OHANLON TP, 1992, GLYCOBIOLOGY, V2, P257, DOI 10.1093/glycob/2.3.257; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, LEUKOCYTE TYPING, V3, P364; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; POPPE L, 1992, J BIOMOL NMR, V2, P109, DOI 10.1007/BF01875524; ROUX L, 1988, J BIOL CHEM, V263, P8879; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCHUURMAN HJ, 1987, LEUKOCYTE TYPING, V3, P465; SGROI D, 1993, J BIOL CHEM, V268, P7011; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TONG PY, 1989, J BIOL CHEM, V264, P7962; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1983, J BIOL CHEM, V258, P2808; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	47	215	222	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7019	7027						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463235				2022-12-25	WOS:A1993KV14100034
J	SEROUSSI, E; LAVI, S				SEROUSSI, E; LAVI, S			REPLICATION PROTEIN A IS THE MAJOR SINGLE-STRANDED-DNA BINDING-PROTEIN DETECTED IN MAMMALIAN-CELL EXTRACTS BY GEL RETARDATION ASSAYS AND UV CROSS-LINKING OF LONG AND SHORT SINGLE-STRANDED-DNA MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; POLYMERASE-DELTA; MULTIPLE STAGES; SV40 DNA; INVITRO; IDENTIFICATION; ORIGIN; SUBUNIT; AMPLIFICATION; PURIFICATION	Band shift and UV cross-linking assays were used to analyze the major single-stranded DNA (ssDNA) binding activity in lysates of primate and rodent cells. The ssDNA binding activity behaved chromatographically similar to that of replication protein A (RP-A), a multisubunit protein containing three polypeptides of molecular mass 70, 34, and 14 kDa. A 70-kDa protein was found to harbor the ssDNA binding activity when UV cross-linked to long ssDNA or to oligonucleotide probes. Monoclonal antibodies against the 70- and the 34-kDa subunits produced super-gel-shift patterns, demonstrating that the reactive protein is indeed RP-A and that the retarded native binding complex included both subunits. RP-A displayed oligonucleotide-specific binding dependent on oligomer length. Increasing oligonucleotide length led to the formation of slow migrating complexes harboring multiple RP-A molecules, suggesting that an interval of about 20-30 bases is required for the binding of RP-A molecules. While similar binding activity was detected in cell extracts derived from proliferating and quiescent cells, a sharp decline in ssDNA binding activity was observed in the SV40-transformed Chinese hamster cell line 631 following UV irradiation. The nature of this decrease in activity and its possible effect on DNA replication is discussed.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								Alberts B., 1989, MOL BIOL CELL; BERKOFLINT Y, 1990, MOL CELL BIOL, V10, P75, DOI 10.1128/MCB.10.1.75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1991, J BIOL CHEM, V266, P3087; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRY M, 1988, NUCLEIC ACIDS RES, V16, P199, DOI 10.1093/nar/16.1.199; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOY CA, 1987, J BIOL CHEM, V262, P11927; KAISERMAN HB, 1989, BIOCHIM BIOPHYS ACTA, V1008, P23, DOI 10.1016/0167-4781(89)90165-6; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KLEINBERGER T, 1988, MOL CELL BIOL, V8, P1366, DOI 10.1128/MCB.8.3.1366; LAVI S, 1983, CELLULAR RESPONSES D, P659; LEE SH, 1991, J BIOL CHEM, V266, P594; LUCKEHUHLE C, 1989, MOL CELL BIOL, V9, P4812; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SALAH-UD-DIN S J B, 1990, Genes and Development, V4, P968; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	38	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7147	7154						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463251				2022-12-25	WOS:A1993KV14100052
J	SHAPIRO, AD; RIEDERER, MA; PFEFFER, SR				SHAPIRO, AD; RIEDERER, MA; PFEFFER, SR			BIOCHEMICAL-ANALYSIS OF RAB9, A RAS-LIKE GTPASE INVOLVED IN PROTEIN-TRANSPORT FROM LATE ENDOSOMES TO THE TRANS GOLGI NETWORK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING YPT1 PROTEIN; MUTATIONAL ANALYSIS; GUANINE-NUCLEOTIDE; MOLECULAR MECHANISM; VESICULAR TRANSPORT; KINETIC-ANALYSIS; YEAST SUGGESTS; P21; SECRETION; HYDROLYSIS	rab9 is a ras-like GTPase which has been implicated in the transport of mannose 6-phosphate receptors between late endosomes and the trans Golgi network. We have expressed recombinant rab9 in Escherichia coli, purified the protein to homogeneity, and initiated a biochemical analysis of this enzyme. rab9 hydrolyzed GTP with a rate constant of 0.0052 min-1 at 37-degrees-C. rab7, a highly homologous endosomal GTPase, hydrolyzed GTP with a rate constant of 0.0023 min-1 at 37-degrees-C. At this temperature, GDP and GTP each dissociated from rab9 with first-order rate constants of 0.017 min-1. GDP and GTP dissociated from rab7 at 37-degrees-C with first-order rate constants of 0.0054 and 0.0024 min-1, respectively. We modified the procedure of John et al. (John, J., Sohmen, R., Feuerstein, J., Linke, R., Wittinghofer, A., and Goody, R. (1990) Biochemistry 29, 6058-6065) for the preparation of nucleotide-free ras such that the procedure can now be applied to 1000-fold smaller quantities of protein. Using this method, we prepared microgram quantities of nucleotide-free rab9 in a form which is heat-stable, free of exogenous nucleotide-degrading enzymes and which can be stored at -80-degrees-C. At 37-degrees-C for GDP and GTP, the second-order rate constants for association with nucleotide-free rab9 were 1.7-10(6) M-1 s-1 and 1.2 . 10(5) M-1 s-1, respectively, and equilibrium binding constants were 170 pM and 2.4 nM, respectively.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			Riederer, Markus/B-5540-2008	Riederer, Markus/0000-0001-7081-1456	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037332, R37DK037332, R56DK037332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LOMBARDI D, 1993, IN PRESS EMBO J, V12; Maniatis T, 1989, DECONTAMINATION DILU; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; TOUCHOT N, 1989, FEBS LETT, V256, P79, DOI 10.1016/0014-5793(89)81722-3; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	49	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6925	6931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463223				2022-12-25	WOS:A1993KV14100022
J	MARCHOT, P; KHELIF, A; JI, YH; MANSUELLE, P; BOUGIS, PE				MARCHOT, P; KHELIF, A; JI, YH; MANSUELLE, P; BOUGIS, PE			BINDING OF I-125 FASCICULIN TO RAT-BRAIN ACETYLCHOLINESTERASE - THE COMPLEX STILL BINDS DIISOPROPYL FLUOROPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAJA-NIGRICOLLIS <H-3>ALPHA-TOXIN; DENDROASPIS-ANGUSTICEPS VENOM; TRITIATED ALPHA-NEUROTOXIN; TORPEDO ELECTRIC ORGANS; AMINO-ACID-SEQUENCE; SNAKE-VENOM; PERIPHERAL-SITE; MOLECULAR-FORMS; MEMBRANE FRAGMENTS; MAMBA VENOMS	Iodination of fasciculin 3 (FAS3) from Dendroaspis viridis venom provided us with a fully active specific probe of fasciculin binding sites on rat brain acetylcholinesterase (AChE). Binding and inhibition are concomitant, as association and inhibition rate constants k1 and k(i) are identical. The I-125-FAS3.AChE complex dissociates very slowly (t1/2 = 48 h) and is characterized by a dissociation constant, K(d), of 0.4 pM. All the specific binding of I-125-FAS3 to AChE is prevented by FAS3 as well as by the two other fasciculins, FAS1 and FAS2, from D. angusticeps venom (K(d) = 0.4, 14, and 25 pM, respectively). It is also prevented by propidium iodide, BW284C51, and d-tubocurarine, which bind to peripheral anionic sites of AChE, by Ca2+ and Mg2+, known to enhance AChE activity through an allosteric phenomenon and by acetylthiocholine concentrations which lead to excess substrate inhibition of the enzyme. Diisopropyl fluorophosphate and paraoxon, which inhibit AChE by phosphorylating the catalytic serine, have no effect on either the binding rate or the number of binding sites of I-125-FAS3. O-Ethyl-S2-diisopropylaminoethyl methylphosphonothionate, however, which binds irreversibly to the AChE catalytic site but reversibly to a peripheral site, induces a 130% increase in the binding rate of I-125-FAS3, without changing the total number of I-125-FAS3 binding sites. Our results demonstrate that fasciculins bind on a peripheral site of AChE, distinct from the catalytic site and, at least partly, common with the sites on which some cationic inhibitors and the substrate in excess bind. Since phosphorylation of the catalytic serine (esteratic subsite) by [1,3-H-3]diisopropyl fluorophosphate can still occur on the FAS3.AChE complex, the structural modification induced by fasciculins may affect the anionic subsite of AChE catalytic site.			MARCHOT, P (corresponding author), UNIV AIX MARSEILLE 2,FAC MED,SECT NORD,BIOCHIM LAB,CNRS,URA 1455,BD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.		MARCHOT, Pascale/AAC-4752-2022; BOUGIS, Pierre E/I-2111-2013	MARCHOT, Pascale/0000-0003-0630-0541; mansuelle, pascal/0000-0002-4504-6809				ALDRIDGE WN, 1969, BIOCHEM J, V115, P147, DOI 10.1042/bj1150147; ANDERSON AJ, 1985, NEUROSCI LETT, V54, P123, DOI 10.1016/S0304-3940(85)80066-5; Augustinsson K-B, 1963, HDB EXPERIMENTELLEN, V15, P89; AUSTIN L, 1953, BIOCHEM J, V54, P695, DOI 10.1042/bj0540695; BECHIS G, 1976, EUR J BIOCHEM, V68, P445, DOI 10.1111/j.1432-1033.1976.tb10832.x; BECHIS G, 1984, BIOCHEM BIOPH RES CO, V122, P1146, DOI 10.1016/0006-291X(84)91211-7; BERMAN HA, 1978, BIOCHEMISTRY-US, V17, P1704, DOI 10.1021/bi00602a019; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BISSO GM, 1991, NEUROCHEM RES, V16, P571, DOI 10.1007/BF00974876; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P5; BOUGIS P, 1983, MOL CELL BIOCHEM, V55, P49, DOI 10.1007/BF00229242; BOUGIS PE, 1986, BIOCHEMISTRY-US, V25, P7235, DOI 10.1021/bi00370a070; Cervenansky C., 1991, P303; CERVENANSKY C, 1991, Toxicon, V29, P1163; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; COHEN JA, 1963, HDB EXPERIMENTELLEN, V15, P299; DUCANCEL F, 1991, SNAKE TOXINS, P395; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EPSTEIN DJ, 1979, BIOCHEMISTRY-US, V18, P4749, DOI 10.1021/bi00588a040; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FISHBEIN JC, 1980, ANAL BIOCHEM, V108, P193, DOI 10.1016/0003-2697(80)90712-5; FRIBOULET A, 1986, NEUROCHEM INT, V9, P323, DOI 10.1016/0197-0186(86)90069-0; FRIBOULET A, 1990, BIOCHEMISTRY-US, V29, P914, DOI 10.1021/bi00456a010; GATINEAU E, 1990, BIOCHEMISTRY-US, V29, P6480, DOI 10.1021/bi00479a021; GRAY EG, 1962, J ANAT, V96, P79; Gros E., 1967, METHOD ENZYMOL, V11, P238; HARVEY AL, 1984, J TOXICOL-TOXIN REV, V3, P91, DOI 10.3109/15569548409097923; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; JOUBERT FJ, 1978, S AFR J CHEM, V31, P107; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; KOPEYAN C, 1975, EUR J BIOCHEM, V58, P117, DOI 10.1111/j.1432-1033.1975.tb02355.x; LEDU MH, 1989, J BIOL CHEM, V264, P21401; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LIN WW, 1987, ASIA PAC J PHARMACOL, V2, P79; LONG JP, 1963, CHOLINESTERASE ANTIC, V15, P374; MARCHOT P, 1988, EUR J BIOCHEM, V174, P537, DOI 10.1111/j.1432-1033.1988.tb14132.x; MARCHOT P, 1986, THESIS U AIX MARSEIL; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MOOSER G, 1974, BIOCHEMISTRY-US, V13, P2299, DOI 10.1021/bi00708a010; MURPHY SD, 1984, CELL MOL NEUROTOXICO, P165; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PATTISON S, 1978, P NATL ACAD SCI USA, V75, P3613, DOI 10.1073/pnas.75.8.3613; PUU G, 1990, BIOCHEM PHARMACOL, V40, P2209, DOI 10.1016/0006-2952(90)90713-U; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; ROBAIRE B, 1974, BIOCHEM PHARMACOL, V23, P2476, DOI 10.1016/0006-2952(74)90246-9; ROCHAT H, 1977, ANAL BIOCHEM, V82, P532, DOI 10.1016/0003-2697(77)90192-0; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SATO D, 1970, J BIOCHEM-TOKYO, V68, P867; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SINDHUPHAK R, 1988, J NEUROL SCI, V86, P195, DOI 10.1016/0022-510X(88)90098-6; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TOMLINSON G, 1980, MOL PHARMACOL, V18, P33; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; VILJOEN CC, 1973, J BIOL CHEM, V248, P4915; WEBER M, 1974, MOL PHARMACOL, V10, P15; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZORKO M, 1986, BIOCHEM PHARMACOL, V35, P2287, DOI 10.1016/0006-2952(86)90453-3	65	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12458	12467						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509385				2022-12-25	WOS:A1993LG65800037
J	ROSENBERG, IM; IYER, R; CHERAYIL, B; CHIODINO, C; PILLAI, S				ROSENBERG, IM; IYER, R; CHERAYIL, B; CHIODINO, C; PILLAI, S			STRUCTURE OF THE MURINE MAC-2 GENE - SPLICE VARIANTS ENCODE PROTEINS LACKING FUNCTIONAL SIGNAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTINS; INITIATION; ANTIGEN; CELLS; SEQUENCE; PATHWAY; IGE; EXPRESSION	The murine Mac-2 gene is composed of six exons dispersed over 10.5 kilobases. Sl nuclease mapping showed multiple transcription initiation sites, clustered within a 30-base pair region. Sequence analysis revealed that a consensus initiator sequence is located in this area which lacks a TATA motif. The untranslated first exon contains an alternative splice donor site, confirming the existence of two cDNA species with the potential to encode proteins differing at their NH2 termini. In vitro expression and translocation experiments demonstrate that both of the alternatively spliced variants of Mac-2 encode proteins which lack a functional signal peptide. Subcellular fractionation studies indicate that most of the Mac-2 protein is present in the cytosol. These results support the view that Mac-2 is exported from the cell by an unusual mechanism which does not depend on the presence of a signal peptide.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-27835] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027835] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HO MK, 1982, J IMMUNOL, V128, P1221; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; IRIMURA T, 1991, CANCER RES, V51, P387; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MACKMAN N, 1987, EMBO J, V6, P2835, DOI 10.1002/j.1460-2075.1987.tb02580.x; Maniatis T., 1982, MOL CLONING; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; ODA Y, 1991, GENE, V99, P279; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; RAZ A, 1987, INT J CANCER, V39, P353, DOI 10.1002/ijc.2910390314; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1989, CANCER RES, V49, P3489; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WOO HJ, 1990, J BIOL CHEM, V265, P7097	34	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12393	12400						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509379				2022-12-25	WOS:A1993LG65800029
J	WILLIAMS, AM; ENNS, CA				WILLIAMS, AM; ENNS, CA			A REGION OF THE C-TERMINAL PORTION OF THE HUMAN TRANSFERRIN RECEPTOR CONTAINS AN ASPARAGINE-LINKED GLYCOSYLATION SITE CRITICAL FOR RECEPTOR STRUCTURE AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SECRETION; PROTEIN; CELLS; IMMUNOGLOBULIN; BIOSYNTHESIS	The transferrin receptor is a cell surface protein and is responsible for the uptake of iron into many eukaryotic cells. In its mature form, the receptor possesses three asparagine-linked oligosaccharides. The effect of asparagine-linked glycosylation on the processing and cell surface localization of the human transferrin receptor is examined here by site-directed mutagenesis. Each of the extracellular consensus sequences (Asn-X-Ser/Thr) for asparagine-linked glycosylation was mutated individually and in all possible combinations. The constructs were transfected stably into NIH-3T3 cells and a Chinese hamster ovary cell line lacking endogenous transferrin receptors. Of the seven possible combinations of glycosylation sites, single mutations eliminating glycosylation at either Asn251 or Asn317 do not affect the processing and surface localization of the receptor. Eliminating both of these sites together has a small effect on the behavior of the receptor. However, mutation of the C-terminal glycosylation site (Asn727) has the most profound negative effect on the appearance of the receptor at the cell surface. The mutants lacking glycosylation at Asn727 appear to be retained in the endoplasmic reticulum as an increased association with binding immunoglobulin protein (BiP) is observed. Addition of a new glycosylation site in the C-terminal region of the unglycosylated mutated transferrin receptor restores the cell surface localization and the transferrin binding of the transferrin receptor, indicating that glycosylation in this region is critical for the correct transport of this receptor to the cell surface.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT L215,PORTLAND,OR 97201	Oregon Health & Science University					NIDDK NIH HHS [DK-40608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA J, 1990, J BIOL CHEM, V265, P13955; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENNS CA, 1982, P NATL ACAD SCI-BIOL, V79, P3241, DOI 10.1073/pnas.79.10.3241; ENNS CA, 1981, P NATL ACAD SCI-BIOL, V78, P4222, DOI 10.1073/pnas.78.7.4222; HOE MH, 1992, J BIOL CHEM, V267, P4916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Maniatis T., 1982, MOL CLONING; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; RUTLEDGE EA, 1991, J BIOL CHEM, V266, P21125; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; TROWBRIDGE IS, 1984, BIOCHEM PHARMACOL, V33, P925, DOI 10.1016/0006-2952(84)90447-7; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648	19	37	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12780	12786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509412				2022-12-25	WOS:A1993LG65800082
J	VANDERSPEK, JC; MINDELL, JA; FINKELSTEIN, A; MURPHY, JR				VANDERSPEK, JC; MINDELL, JA; FINKELSTEIN, A; MURPHY, JR			STRUCTURE-FUNCTION ANALYSIS OF THE TRANSMEMBRANE DOMAIN OF DAB389-INTERLEUKIN-2, AN INTERLEUKIN-2 RECEPTOR-TARGETED FUSION TOXIN - THE AMPHIPATHIC HELICAL REGION OF THE TRANSMEMBRANE DOMAIN IS ESSENTIAL FOR THE EFFICIENT DELIVERY OF THE CATALYTIC DOMAIN TO THE CYTOSOL OF TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; SECONDARY STRUCTURE; FRAGMENT-B; PROTEIN; BINDING; RESOLUTION; TOXICITY; DNA	Cassette and deletion mutagenesis were used to analyze the function of the amphipathic alpha-helices in the transmembrane domain of DAB389-interleukin-2 (IL-2), a fusion protein which is targeted to the interleukin-2 receptor. We demonstrate that the in-frame deletion of 60 amino acids, from Asn204 to Glu263 in DAB389-IL-2, results in complete loss of cytotoxic activity, whereas when the amphipathic regions from Asp208 to Ser220 and Ala244 to His258 are replaced with idealized amphipathic helices composed of repeating Glu, Lys, and Leu residues, the mutant fusion toxin has low but detectable activity. DAB389-IL-2 and both variants form channels in artificial phospholipid bilayers with conductances identical to those formed by diphtheria toxin. Both mutant fusion toxins bind to the high affinity IL-2 receptor with affinities similar to that of DAB389-IL-2. The fact that these mutants have markedly reduced or absent cytotoxic activity, but possess ''wild type'' catalytic activity, binding affinities, and channel conductances, suggests the existence of a step in the intoxication pathway, defective in the mutants, which occurs after DAB389-IL-2 binds to the IL-2 receptor. It is unknown whether this step occurs prior or subsequent to channel formation, but it is essential for the efficient delivery of the ADPL-ribosyltransferase from DAB389-IL-2 to the cytosol of target cells.	UNIV HOSP BOSTON,MED CTR,DEPT MED,BOSTON,MA 02118; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Boston Medical Center; Yeshiva University; Albert Einstein College of Medicine	VANDERSPEK, JC (corresponding author), UNIV HOSP BOSTON,MED CTR,EVANS DEPT CLIN RES,88 E NEWTON ST,BOSTON,MA 02118, USA.		Mindell, Joseph/P-4461-2017	Mindell, Joseph/0000-0002-6952-8247	NATIONAL CANCER INSTITUTE [U01CA048626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029210, T32GM007288, R37GM029210] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA-48626] Funding Source: Medline; NIGMS NIH HHS [GM 29210, T32 GM 07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BACHA P, 1992, EUR J IMMUNOL, V22, P1673, DOI 10.1002/eji.1830220702; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DEBOER H, 1986, MAXIMIZING GENE EXPR; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; ITTLESON TR, 1973, NATURE, V242, P330; JAKES KS, 1989, J BIOL CHEM, V265, P6984; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KANE JF, 1988, TRENDS BIOTECHNOL, V6, P95, DOI 10.1016/0167-7799(88)90065-0; KIYOKAWA T, 1991, PROTEIN ENG, V4, P463, DOI 10.1093/protein/4.4.463; LAMBOTTE P, 1980, J CELL BIOL, V87, P837, DOI 10.1083/jcb.87.3.837; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; Montal M, 1974, Methods Enzymol, V32, P545; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OKEEFE DO, 1992, P NATL ACAD SCI USA, V89, P6202, DOI 10.1073/pnas.89.13.6202; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILD HO, 1957, PHARMACOL REV, V9, P242; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; WONDERLIN WF, 1990, BIOPHYS J, V58, P289, DOI 10.1016/S0006-3495(90)82376-6	32	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12077	12082						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505330				2022-12-25	WOS:A1993LF28400092
J	HINKES, MT; GOLDBERGER, OA; NEUMANN, PE; KOKENYESI, R; BERNFIELD, M				HINKES, MT; GOLDBERGER, OA; NEUMANN, PE; KOKENYESI, R; BERNFIELD, M			ORGANIZATION AND PROMOTER ACTIVITY OF THE MOUSE SYNDECAN-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; NF-KAPPA-B; INTEGRAL MEMBRANE PROTEOGLYCAN; MESENCHYMAL INTERACTIONS; EXPRESSION; DIFFERENTIATION; RECEPTOR	Syndecan-1, the prototype of a family of heparan sulfate-containing integral membrane proteoglycans, associates extracellularly with a variety of matrix molecules and growth factors and intracellularly with the actin cytoskeleton. Expressed constitutively on epithelia in mature tissues and in a developmentally regulated manner on epithelial and induced mesenchymal cells during embryogenesis, syndecan-1 appears to be involved in controlling the shape and organization of cells and tissues. To better understand the function and regulation of syndecan- 1, we determined the structure of the mouse syndecan-1 gene (Synd-1). Synd-1 is approximately 19.5 kilobases in size and is organized into five exons that appear conserved in other family members. Exon 1 encodes the signal peptide; exon 2, the N-terminal glycosaminoglycan attachment region; exon 3, the bulk of the extracellular domain; exon 4, the protease-susceptible site; and exon 5, the transmembrane and cytoplasmic domains which are highly homologous between syndecan family members. Synd-1 has three transcriptional start sites, two polyadenylation sites, and is not alternatively spliced to produce its 2.6- and 3.4-kilobase mRNA species. Upstream sequences have promoter activity and contain TATA and CAAT boxes as well as a variety of other potential binding sites for transcription factors, including Sp1 (GC box), NF-kappaB, MyoD (E box), and Antennapedia. The structure of the promoter region suggests that control of Synd-1 expression is both constitutive and developmentally regulated. Because Synd-1 exons encode discrete functional domains of the syndecan-1 protein that are conserved throughout the syndecan family, all syndecan genes are likely derived from a common ancestor.	HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HINKES, MT (corresponding author), CHILDRENS HOSP MED CTR, JOINT PROGRAM NEONATOL, ENDERS BLDG, RM 950, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.			Neumann, Paul/0000-0002-8480-4799	NCI NIH HHS [CA28735] Funding Source: Medline; NIAMS NIH HHS [K11AR01816] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BACIU PC, 1992, MOL BIOL CELL, V3, pA64; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOUTIN EL, 1991, DEV BIOL, V148, P63, DOI 10.1016/0012-1606(91)90317-V; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DAVID G, 1979, P NATL ACAD SCI USA, V76, P786, DOI 10.1073/pnas.76.2.786; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HINKES M T, 1991, Journal of Cell Biology, V115, p125A; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1992, MOL BIOL CELL, V3, pA64; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LEPPA S, 1991, CELL REGUL, V2, P1; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OETTINGER HF, 1991, GENOMICS, V11, P334, DOI 10.1016/0888-7543(91)90140-A; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SAUNDERS S, 1989, Journal of Cell Biology, V109, p5A; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1991, DEV BIOL, V147, P322, DOI 10.1016/0012-1606(91)90290-J; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEAMAN C, 1992, MOL BIOL CELL, V3, pA64	79	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11440	11448						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496192				2022-12-25	WOS:A1993LD46600104
J	KEARNS, AE; VERTEL, BM; SCHWARTZ, NB				KEARNS, AE; VERTEL, BM; SCHWARTZ, NB			TOPOGRAPHY OF GLYCOSYLATION AND UDP-XYLOSE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; ROUGH ENDOPLASMIC-RETICULUM; SEMI-INTACT CELLS; RAT-LIVER GOLGI; CORE PROTEIN; SUBCELLULAR-LOCALIZATION; TRANSPORT; MEMBRANE; SECRETION; APPARATUS	In order to define the location and organization of the numerous reactions involved in polysaccharide assembly during synthesis of proteoglycans and glycoproteins, the topography of some of the glycosylation reactions in chondroitin sulfate synthesis was examined using a relatively new technique for generating permeable cells. Permeable chondrocytes were shown to directly take up nucleotide sugar precursors and incorporate them into chondroitin sulfate proteoglycan (CSPG), allowing specific labeling at each step in chondroitin sulfate synthesis. Subcellular fractionation following labeling with UDP-[C-14]xylose, UDP-[C-14]galactose, UDP-[C-14]glucuronic acid, or [S-35]PAPS localized the labeled CSPG to the compartment where each glycosylation reaction occurred. From these experiments it appears that xylose addition begins in the endoplasmic reticulum and continues in the Golgi apparatus where galactose, glucuronic acid, and sulfate are added. This conclusion was confirmed by direct visualization of xylose incorporation using electron microscopic autoradiography (Vertel, B. M., Walters, L. M., Flay, N., Kearns, A. E., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11105-11112). Further examination of xylose addition showed that permeable chondrocytes can utilize both exogenous UDP-xylose transported into the lumen and UDP-xylose generated from UDP-glucuronic acid within the lumen. The enzyme responsible for this reaction, UDP-glucuronate carboxy-lyase, co-localized with xylosyltransferase activity in subcellular fractions. Orientation toward the lumen in subcellular compartments was determined by trypsin sensitivity in the permeable chondrocytes. Therefore, we conclude that UDP-xylose can be produced in the lumen of the compartment where it is utilized in CSPG synthesis, obviating the need for a direct transport mechanism for this nucleotide sugar and providing close regulation of UDP-xylose and UDP-glucuronic acid levels.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV HLTH SCI CHICAGO MED SCH,DEPT CELL BIOL & ANAT,N CHICAGO,IL 60064	University of Chicago; University of Chicago; Chicago Medical School					NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARION WJ, 1976, J BIOL CHEM, V251, P4901; BAUER HC, 1985, BIOCHEM BIOPH RES CO, V128, P368, DOI 10.1016/0006-291X(85)91688-2; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW K, 1975, J BIOL CHEM, V250, P1434; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CAREY DJ, 1981, J BIOL CHEM, V256, P989; COATES SW, 1980, J BIOL CHEM, V255, P9225; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DELUCA G, 1976, CONNECT TISSUE RES, V4, P247; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GELLER DH, 1987, J BIOL CHEM, V262, P7374; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; HUTCHISON W, 1961, ANALYST, V86, P768, DOI 10.1039/an9618600768; JOHN KV, 1977, J BIOL CHEM, V252, P6707; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MAYOREK N, 1989, J BIOL CHEM, V264, P4450; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; MUNRO JR, 1975, ARCH BIOCHEM BIOPHYS, V169, P269, DOI 10.1016/0003-9861(75)90341-0; NG K, 1991, ANAL BIOCHEM, V198, P60, DOI 10.1016/0003-2697(91)90506-O; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PERSAT F, 1984, BIOCHIM BIOPHYS ACTA, V769, P377, DOI 10.1016/0005-2736(84)90320-1; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1976, J BIOL CHEM, V251, P3346; SCHWARTZ NB, 1979, J BIOL CHEM, V254, P2271; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SWANSON MA, 1974, METHOD ENZYMOL, V31, P92; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; YEO TK, 1989, BIOCHEM BIOPH RES CO, V160, P1421, DOI 10.1016/S0006-291X(89)80163-9	46	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11097	11104						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496172				2022-12-25	WOS:A1993LD46600058
J	HANAZAWA, S; TAKESHITA, A; AMANO, S; SEMBA, T; NIRAZUKA, T; KATOH, H; KITANO, S				HANAZAWA, S; TAKESHITA, A; AMANO, S; SEMBA, T; NIRAZUKA, T; KATOH, H; KITANO, S			TUMOR-NECROSIS-FACTOR-ALPHA INDUCES EXPRESSION OF MONOCYTE CHEMOATTRACTANT JE VIA FOS AND JUN GENES IN CLONAL OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMAL CELLS; BONE-RESORPTION; GROWTH-FACTOR; C-FOS; TRANSCRIPTIONAL REGULATION; ALKALINE-PHOSPHATASE; COLLAGEN-SYNTHESIS; HUMAN FIBROBLASTS; PROTEIN-1 MCP-1; CYTOKINES	The mechanism by which circulating monocytes are attracted to sites of bone remodeling is unknown. We now report that tumor necrosis factor-alpha (TNF-alpha), a potent osteotrophic cytokine, was stimulatory for expression of the monocyte chemoattractant JE gene in osteoblastic MC3T3-E1 cells. TNF-alpha stimulated this JE gene expression transcriptionally. The presence of JE gene product in conditioned medium of the cytokine-treated cells was evidenced by an immunoprecipitation assay with antiserum specific for JE/MCP-1. The stimulated JE gene expression was markedly inhibited by H-7, a potent inhibitor of protein kinase C. Phorbol 12-myristate 13-acetate induced the JE gene expression, and the cytokine-induced JE gene expression was down-regulated by the phorbol ester pretreatment. TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun, in the cells. Antisense oligonucleotides to these oncogenes significantly inhibited the cytokine-induced monocyte chemotactic activity. Furthermore, curcumin, a specific inhibitor of c-jun/AP-1, markedly inhibited JE gene expression and monocyte chemotactic activity induced by the cytokine. These results suggest that TNF-alpha may contribute to the regulation of remodeling and inflammation of bone tissues through the JE gene product.	APPL BIOSYST JAPAN INC, KOTO KU, TOKYO, JAPAN; NISSUI PHARMACEUT CO LTD, RES LAB, YUKI, IBARAKI, JAPAN	Thermo Fisher Scientific; Applied Biosystems	HANAZAWA, S (corresponding author), MEIKAI UNIV, SCH DENT, DEPT ORAL MICROBIOL, SAKADO, SAITAMA 35002, JAPAN.							ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; CALIGARISCAPPIO F, 1991, BLOOD, V77, P2688; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANAZAWA S, 1991, BIOCHEM BIOPH RES CO, V180, P1130, DOI 10.1016/S0006-291X(05)81184-2; HONG MH, 1991, ENDOCRINOLOGY, V129, P2774, DOI 10.1210/endo-129-5-2774; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; Maniatis T., 1982, MOL CLONING LABORATO, P86; MARK HT, 1990, NUCLEIC ACIDS RES, V18, P23; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; MUNDY GR, 1978, NATURE, V275, P132, DOI 10.1038/275132a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; OHMORI Y, 1988, BIOCHIM BIOPHYS ACTA, V970, P22, DOI 10.1016/0167-4889(88)90218-2; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATO K, 1987, BIOCHEM BIOPH RES CO, V145, P323, DOI 10.1016/0006-291X(87)91324-6; SMITH DD, 1987, ENDOCRINOLOGY, V120, P2494, DOI 10.1210/endo-120-6-2494; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STASHENKO P, 1987, J IMMUNOL, V138, P1464; THOMSON BM, 1987, J IMMUNOL, V138, P775; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	44	118	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9526	9532						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486642				2022-12-25	WOS:A1993LA68900059
J	HIRAIZUMI, S; SPOHR, U; SPIRO, RG				HIRAIZUMI, S; SPOHR, U; SPIRO, RG			CHARACTERIZATION OF ENDOMANNOSIDASE INHIBITORS AND EVALUATION OF THEIR EFFECT ON N-LINKED OLIGOSACCHARIDE PROCESSING DURING GLYCOPROTEIN-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOSIDASE; RAT-LIVER; ENDOPLASMIC-RETICULUM; SYNCYTIUM FORMATION; GLUCOSE REMOVAL; CELL-LINE; 1-DEOXYNOJIRIMYCIN; CASTANOSPERMINE; SECRETION; COMPLEX	Endo-alpha-D-mannosidase is a Golgi-located processing enzyme that achieves deglucosylation of N-linked carbohydrate units through its unique property of cleaving the oligosaccharide chain internally with the release of glucose-substituted mannose (Glc1-3Man). By chemically modifying the characteristic disaccharide product, Glcalpha1-->3Man, a number of potent inhibitors of the endomannosidase were obtained, foremost among which were Glcalpha1-->3(1-deoxy)mannojirimycin (Glcalpha1-->3DMJ) and Glcalpha1-->3(1,2-dideoxy)mannose (IC50 = 1.7 and 3.8 muM, respectively), which, while blocking the in vitro action of the enzyme, had negligible effect on other endoplasmic reticulum- and Golgi-processing glycosidases. Although preparation of a large number of Glcalpha1-->3DMJ derivatives did not yield a more effective endomannosidase inhibitor it provided valuable information relating to the structural requirements for the enzyme-substrate interaction. Glcalpha1-->3DMJ was found to be active not only on rat liver endomannosidase but also on the enzyme from a number of other sources including mouse lymphoma (BW5147.3), HepG2, baby hamster kidney, and Madin-Darby canine kidney cell lines. When tested in vivo in lymphoma and Madin-Darby canine kidney cells during a castanospermine-imposed glucosidase blockade, Glcalpha1-->3DMJ interrupted the endomannosidase processing pathway as evident from a concomitant inhibition of complex oligosaccharide formation and Glc3Man release; similarly the capacity of the glucosidase II-deficient mouse lymphoma cell line (PHA(R)2.7) to synthesize complex oligosaccharides was blocked by Glcalpha1-->3DMJ. Endomannosidase could not be detected in Chinese hamster ovary cells by in vitro assay and consistent with this these cells produced only glucosylated polymannose N-linked oligosaccharides during glucosidase blockade. It would appear that by acting in conjunction with a glucosidase inhibitor, Glcalpha1--> 3DMJ and related endomannosidase-blocking agents could have the potential of influencing the exit of glycoproteins from the endoplasmic reticulum and interfering with viral replication.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,ONE JOSLIN PL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; CHEM BIOMED LTD,EDMONTON T6G 2G2,AB,CANADA; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alberta					NIDDK NIH HHS [DK 17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DURONIO V, 1988, J BIOL CHEM, V263, P5436; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FRANC JL, 1986, EUR J BIOCHEM, V157, P225, DOI 10.1111/j.1432-1033.1986.tb09660.x; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GROSS V, 1983, J BIOL CHEM, V258, P2203; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HUGHES RC, 1987, BIOCHEM J, V247, P537, DOI 10.1042/bj2470537; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4056, DOI 10.1021/ja00847a032; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MATTER K, 1989, J BIOL CHEM, V264, P13131; MONTEFIORI DC, 1988, P NATL ACAD SCI USA, V85, P9248, DOI 10.1073/pnas.85.23.9248; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; REARICK JI, 1981, J BIOL CHEM, V256, P6255; REITMAN ML, 1982, J BIOL CHEM, V257, P357; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SCHWEDEN J, 1986, ARCH BIOCHEM BIOPHYS, V248, P335, DOI 10.1016/0003-9861(86)90429-7; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO RG, 1982, PHILOS T ROY SOC B, V300, P117, DOI 10.1098/rstb.1982.0160; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; STANNARD BS, 1988, J BIOL CHEM, V263, P8309; SUNKARA PS, 1989, LANCET, V1, P1206; TAN A, 1991, J BIOL CHEM, V266, P14504; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; VARKI A, 1983, J BIOL CHEM, V258, P2808; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120	47	60	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9927	9935						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486671				2022-12-25	WOS:A1993LA68900109
J	UTSUMI, T; LEVITAN, A; HUNG, MC; KLOSTERGAARD, J				UTSUMI, T; LEVITAN, A; HUNG, MC; KLOSTERGAARD, J			EFFECTS OF TRUNCATION OF HUMAN PRO-TUMOR NECROSIS FACTOR TRANSMEMBRANE DOMAIN ON CELLULAR TARGETING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; DETERMINANTS; ORIENTATION; MECHANISMS; RESIDUES; CELLS; FORM	Human tumor necrosis factor is initially synthesized as a transmembrane prohormone anchored by a hydrophobic region of the leader sequence. This hydrophobic domain has been previously localized to extend from Leu-46 to Ile-21 based on hydropathy calculations. To functionally determine the nature of this domain, we have generated a series of pro-TNF mutant cDNAs in which either half or both halves of this encoding domain is deleted. These cDNAs were analyzed both by the ability of their mRNAs to direct translation in a microsomal system and by cellular localization of their encoded TNFs following transfection of NIH/3T3 cells. We determined that the mutant protein with deletion of the periluminal region of the transmembrane domain (Thr-32 to Ile-21) was translocated into microsomes and localized on the inner surface of the microsomal membrane in a fashion identical to that of the parental TNF. In contrast, the mutants with deletion of either the pericytoplasmic aspect (Leu-46 to Gly-34) or of virtually the entire transmembrane domain were not localized in the microsomes. Transfection experiments indicated that only the cDNAs whose peptide products were translocated across microsomal membranes gave rise to transmembrane prohormones and matured TNFs. Thus, the functions of membrane targeting and orientation prior to proteolytic processing can be fulfilled by the sequence Leu-46 to Ala-33 of the transmembrane domain, but not by the sequence Ala-33 to Ile-21.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BELTZER JP, 1991, J BIOL CHEM, V266, P973; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CSEH K, 1989, J BIOL CHEM, V264, P16256; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KLOSTERGAARD J, 1992, TUMOR NECROSIS FACTOR : STRUCTURE-FUNCTION RELATIONSHIP AND CLINICAL APPLICATION, P101; KLOSTERGAARD J, 1987, CANCER RES, V47, P2014; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LUETTIG B, 1989, J IMMUNOL, V143, P4034; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; NIITSU Y, 1985, JPN J CANCER RES, V76, P1193; OKAMOTO T, 1992, CANCER RES, V52, P5278; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; SMITH MR, 1990, J IMMUNOL, V144, P162; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745	17	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9511	9516						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486641				2022-12-25	WOS:A1993LA68900056
J	WISNIEWSKI, E; KUNZ, WS; GELLERICH, FN				WISNIEWSKI, E; KUNZ, WS; GELLERICH, FN			PHOSPHATE AFFECTS THE DISTRIBUTION OF FLUX CONTROL AMONG THE ENZYMES OF OXIDATIVE-PHOSPHORYLATION IN RAT SKELETAL-MUSCLE MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA-MITOCHONDRIAL; LIVER-MITOCHONDRIA; HEART-MITOCHONDRIA; CONTROL COEFFICIENTS; RESPIRATORY CONTROL; ADP-RATIO; ATP; TRANSLOCATOR; STATE; POTENTIALS	The flux control coefficients of adenine nucleotide translocase, the phosphate transporter, and H+-ATPase were determined in rat skeletal muscle mitochondria using glutamate plus malate as substrates and soluble F1-ATPase as load enzyme. It was observed that the flux control coefficients of adenine nucleotide translocase, H+-ATPase, and the load enzyme F1-ATPase, at comparable rates of respiration, strongly depend on the phosphate concentration in the incubation medium. So, the flux control exerted by adenine nucleotide translocase, in the intermediate states of mitochondrial respiration (approximately 120 nmol of O2/min/mg) at 10 mM phosphate, was found to be about 0.37. At a phosphate concentration of 1 mM and comparable rates of respiration the flux control coefficient of the translocase decreased to about 0.20. Under these conditions, a sharp increase in the controlling influence of H+-ATPase from 0.10 to 0.74 was detected. Furthermore, at this flux rate, the sum of flux control coefficients of adenine nucleotide translocase, H+-ATPase, phosphate transporter, and the load enzyme F1-ATPase was noted to be very close to unity. This indicates that under the conditions of intermediate state respiration, all of the other reactions have a negligible controlling influence on oxidative phosphorylation in skeletal muscle mitochondria.	MED ACAD MAGDEBURG,INST BIOCHEM,LEIPZIGER STR 44,O-3090 MAGDEBURG,GERMANY				Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				CHANCE B, 1955, J BIOL CHEM, V217, P383; DAVIS EJ, 1975, J BIOL CHEM, V250, P2275; DAVIS EJ, 1984, ARCH BIOCHEM BIOPHYS, V233, P573, DOI 10.1016/0003-9861(84)90481-8; DOUSSIERE J, 1984, BIOCHIM BIOPHYS ACTA, V766, P492, DOI 10.1016/0005-2728(84)90265-2; DRAHOTA Z, 1977, BIOCHIM BIOPHYS ACTA, V460, P541, DOI 10.1016/0005-2728(77)90093-7; EBEL RE, 1975, J BIOL CHEM, V250, P191; FROM AHL, 1990, BIOCHEMISTRY-US, V29, P3731, DOI 10.1021/bi00467a020; GELLERICH FN, 1983, BIOCHIM BIOPHYS ACTA, V722, P381, DOI 10.1016/0005-2728(83)90086-5; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; GELLERICHH FN, 1987, BIOMED BIOCHIM ACTA, V89, P545; HALESTRAP AP, 1987, BIOCHEM J, V244, P159, DOI 10.1042/bj2440159; HASSINEN IE, 1986, BIOCHIM BIOPHYS ACTA, V853, P135, DOI 10.1016/0304-4173(86)90008-X; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; JACOBUS WE, 1982, J BIOL CHEM, V257, P2397; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KAMP G, 1987, BIOCHIM BIOPHYS ACTA, V929, P121, DOI 10.1016/0167-4889(87)90166-2; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KAWANO Y, 1988, J PHYSIOL-LONDON, V407, P243, DOI 10.1113/jphysiol.1988.sp017413; KHOLODENKO B, 1987, FEBS LETT, V223, P247, DOI 10.1016/0014-5793(87)80298-3; KUNZ W, 1988, FEBS LETT, V233, P17, DOI 10.1016/0014-5793(88)81347-4; KUNZ W, 1981, ARCH BIOCHEM BIOPHYS, V209, P219, DOI 10.1016/0003-9861(81)90274-5; KUNZ WS, 1991, ARCH BIOCHEM BIOPHYS, V284, P40, DOI 10.1016/0003-9861(91)90260-P; KUSTER U, 1976, BIOCHIM BIOPHYS ACTA, V440, P391, DOI 10.1016/0005-2728(76)90073-6; MORENOSANCHEZ R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P284, DOI 10.1016/S0005-2728(05)80318-4; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; OWEN CS, 1974, ARCH BIOCHEM BIOPHYS, V161, P581, DOI 10.1016/0003-9861(74)90341-5; REICHERT M, 1978, ACTA BIOL MED GER, V37, P1167; Sokolowski A, 1973, Z Med Labortech, V14, P247; WISNIEWSKI E, 1991, BIOL CHEM H-S, V372, P780	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9343	9346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486629				2022-12-25	WOS:A1993LA68900032
J	KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N				KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N			ABL ONCOGENES DIRECTLY STIMULATE 2 DISTINCT TARGET-CELLS IN BONE-MARROW FROM 5-FLUOROURACIL-TREATED MICE	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PRE-B-CELL; BCR-ABL; V-ABL; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODIES; PROGENITOR CELLS; GROWTH-FACTORS	Mice reconstituted with BCR/ABL-infected 5-fluorouracil-treated bone marrow are considered a model system for human chronic myelogenous leukemia, a malignancy that arises in hematopoietic stem cells. These animals develop multiple types of hematopoietic tumors, which could arise either from undifferentiated cells that mature during tumor development or from progenitors committed to different lineages. To examine the BCR/ABL-sensitive target celts present in the marrow of mice treated with 5-fluorouracil, we used a single-step in vitro assay. These experiments revealed that both the P210 and P185 BCR/ABL proteins and the related v-abl protein induce lymphoid and myeloid colonies, colony types that mimic two of the prominent types of tumors found in the reconstitution model. The lymphoid colonies were similar to lymphoid colonies found following infection of normal bone marrow with respect to differentiation state and tumorigenicity. The cells in the myeloid colonies were differentiated and non-tumorigenic. Fluorescence-activated cell sorting revealed that most of the lymphoid and myeloid colonies arose from distinct precursors and that the lymphoid colonies arose from B-lineage-committed cells. These data suggest that most of the lymphomas observed in the reconstitution model arise from committed progenitors that are distinct from those involved in the myeloid disease.	TUFTS UNIV, SCH MED, DEPT PATHOL, SC-313, 136 HARRISON AVE, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, DEPT MED, DIV HEMATOL & ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center; Tufts University					NCI NIH HHS [CA 33771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033771, R01CA033771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTERMAN LA, 1990, EUR J IMMUNOL, V20, P1597, DOI 10.1002/eji.1830200728; BOSWELL HS, 1984, J IMMUNOL, V133, P2940; BRUCE J, 1981, J IMMUNOL, V127, P2496; CHUNG SW, 1988, BLOOD, V71, P973; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO MK, 1982, J IMMUNOL, V128, P1221; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLER G, 1986, COLD SPRING HARB SYM, V51, P1053, DOI 10.1101/SQB.1986.051.01.122; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1991, VIRUSES AFFECT IMMUN, P143; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; MULLERSIEBURG CE, 1988, J EXP MED, V167, P1825, DOI 10.1084/jem.167.6.1825; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SHEVACH EM, 1989, IMMUNOL TODAY, V10, P195, DOI 10.1016/0167-5699(89)90324-1; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TIDMARSH GF, 1989, MOL CELL BIOL, V9, P2665, DOI 10.1128/MCB.9.6.2665; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WILLIAMS DE, 1985, J IMMUNOL, V135, P1004; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	52	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1249	1256						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479746				2022-12-25	WOS:A1993KY32800016
J	WALKER, MS; DEMOSS, JA				WALKER, MS; DEMOSS, JA			PHOSPHORYLATION AND DEPHOSPHORYLATION CATALYZED INVITRO BY PURIFIED COMPONENTS OF THE NITRATE SENSING SYSTEM, NARX AND NARL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI K-12; SIGNAL TRANSDUCTION; OMPC GENES; CONSTRUCTION; EXPRESSION; PROTEINS	The regulation of specific gene expression by nitrate in Escherichia coli is mediated by the NarX/NarQ-NarL system. Based on sequence homologies with a family of two-component regulatory systems in bacteria, NarL has been identified as a putative response regulator while NarX and NarQ were proposed to be alternative membrane-associated sensors that activate NarL in the presence of nitrate. To investigate the interaction of NarX and NarL in vitro, both proteins were purified from overproducing strains. Purified NarX was rapidly labeled when incubated with [gamma-P-32] ATP but not with [alpha-P-32]ATP in a reaction that required Mg2+ but was unaffected by nitrate. Incubation of the labeled NarX with purified NarL resulted in the transient phosphorylation of NarL. Both the phosphorylation and dephosphorylation of NarL required Mg2+, and neither reaction was affected by the presence of nitrate. NarL-phosphate, stabilized by the addition of EDTA, ran as a monomer on gel filtration. Dephosphorylation of the isolated NarL-phosphate required the addition of both Mg2+ and the NarX protein. The relative stabilities of the phosphorylated forms of the two proteins at different pH values were consistent with the proposal that, in analogy to other related two-component regulatory systems, NarX and NarL were phosphorylated on specific histidine and aspartate residues, respectively.			WALKER, MS (corresponding author), UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019511] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19511] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P8563; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CHIANG RC, 1992, MOL MICROBIOL, V6, P1913, DOI 10.1111/j.1365-2958.1992.tb01364.x; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; DONG XR, 1992, J BIOL CHEM, V267, P14122; EGAN SM, 1991, J BACTERIOL, V173, P4424, DOI 10.1128/JB.173.14.4424-4432.1991; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GUNSALUS RP, 1989, NUCLEIC ACIDS RES, V17, P1965, DOI 10.1093/nar/17.5.1965; LI J, 1992, J BACTERIOL, V174, P4935, DOI 10.1128/JB.174.15.4935-4942.1992; NOHNO T, 1989, NUCLEIC ACIDS RES, V17, P2947, DOI 10.1093/nar/17.8.2947; RABIN RS, 1992, P NATL ACAD SCI USA, V89, P8419, DOI 10.1073/pnas.89.18.8419; RONDEAU SS, 1984, J BACTERIOL, V159, P159, DOI 10.1128/JB.159.1.159-166.1984; RUSSELL DR, 1982, GENE, V20, P231, DOI 10.1016/0378-1119(82)90042-7; STEWART V, 1989, J BACTERIOL, V171, P2229, DOI 10.1128/jb.171.4.2229-2234.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0	17	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8391	8393						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473280				2022-12-25	WOS:A1993KX81100003
J	DEANCOS, JG; CORREAS, I; AVILA, J				DEANCOS, JG; CORREAS, I; AVILA, J			DIFFERENCES IN MICROTUBULE BINDING AND SELF-ASSOCIATION ABILITIES OF BOVINE BRAIN TAU-ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN KINASE-C; ALZHEIMERS-DISEASE; TUBULIN POLYMERIZATION; LIVING CELLS; PHOSPHORYLATION; EXPRESSION; CALMODULIN; PHOSPHOPROTEINS; IDENTIFICATION	We have fractionated tau isoforms by elution at increasing pH values using iron-chelated affinity chromatography, which discriminates between isoforms phosphorylated to different extents. Microtubule-associated tau elutes from the column at a pH gradient narrower than that of total brain tau. Neither under-phosphorylated nor highly phosphorylated isoforms are found in the microtubule-associated tau protein preparation. This indicates that phosphorylation at certain sites is needed for tau binding to microtubules, whereas phosphorylation at some other sites may prevent the association. The self-association ability of the different tau isoforms has also been analyzed. Tau isoforms containing three tubulin binding motifs form covalently bound dimers more efficiently than tau isoforms containing four motifs. This dimer-forming ability is notably diminished in the presence of a reducing agent, as determined by SDS-polyacrylamide gel electrophoresis, thus suggesting the involvement of cysteine residues. Additionally, tau forms larger aggregates, as detected by gel permeation chromatography, which are solubilized by SDS and cannot, therefore, be observed by SDS-polyacrylamide gel electrophoresis. These tau aggregates are observed even in the presence of reducing agents. These results support the idea that other regions in the tau molecule, besides the Cys-containing tubulin binding region, also contribute to tau self-association. Tau dimerization and aggregation may be prior steps to the formation of paired helical filaments.	UNIV AUTONOMA MADRID, CTR BIOL MOLEC, CANTO BLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid			Correas, Isabel/O-4061-2018; Avila, Jesus/I-2610-2015	Correas, Isabel/0000-0002-2286-186X; Avila, Jesus/0000-0002-6288-0571				ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DEGARCINI EM, 1988, FEBS LETT, V236, P150, DOI 10.1016/0014-5793(88)80304-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GONZALEZ PJ, 1992, NEUROSCIENCE, V50, P491, DOI 10.1016/0306-4522(92)90440-D; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HERNANDEZ MA, 1987, J NEUROCHEM, V48, P84, DOI 10.1111/j.1471-4159.1987.tb13130.x; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Kosik KS, 1990, CURR OPIN CELL BIOL, V2, P101, DOI 10.1016/S0955-0674(05)80038-9; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LICHTENBERGKRAAG B, 1990, J STRUCT BIOL, V105, P46, DOI 10.1016/1047-8477(90)90097-V; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NUNEZ J, 1986, DEV NEUROSCI-BASEL, V8, P125, DOI 10.1159/000112248; RUBEN GC, 1991, J BIOL CHEM, V266, P22019; SCHOENLE EJ, 1984, J BIOL CHEM, V259, P2112; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	48	80	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7976	7982						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463318				2022-12-25	WOS:A1993KW97900060
J	BLIER, PR; GRIFFITH, AJ; CRAFT, J; HARDIN, JA				BLIER, PR; GRIFFITH, AJ; CRAFT, J; HARDIN, JA			BINDING OF KU PROTEIN TO DNA - MEASUREMENT OF AFFINITY FOR ENDS AND DEMONSTRATION OF BINDING TO NICKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; AUTOANTIGEN-KU; STRAND BREAKS; AUTO-ANTIGEN; TRANSCRIPTION; REPLICATION; COMPLEX; PURIFICATION; SEQUENCE; CLONING	Ku, also known as nuclear Factor IV, is an abundant nuclear DNA-binding protein which requires free DNA ends for the initial interaction with double-stranded DNA (dsDNA) and can bind at multiple sites along dsDNA in an energy-independent manner. Its function in vivo is unknown, but it has been implicated in both DNA replication and repair and in transcriptional control. We have used an electrophoretic mobility shift assay to further define the DNA binding properties of the Ku protein. Titration of Ku to a fixed amount of any of several target linear dsDNA fragments produced ladders of shifted bands proportional to the length of DNA, confirming the multiple binding activity of Ku and demonstrating its sequence-independent nature. Using a short DNA fragment with one Ku binding site, the binding constant of Ku for dsDNA ends was calculated to be 2.4 x 10(9) M-1. Competitive inhibition experiments confirmed the requirement of a free DNA end for binding by Ku and demonstrated that Ku binds isolated nicks in dsDNA. Nick binding was also observed directly using radiolabeled singly nicked circular DNA. The relative affinities of Ku for specific nick sites and free DNA ends were approximately equal, and nick binding was sequence-independent. Finally, in a study of a possible role for Ku in protecting or repairing damaged DNA, Ku was shown to inhibit the ability of T4 DNA ligase to circularize linear dsDNA molecules, demonstrating that some Ku molecules remain at the DNA terminus rather than translocate. A similar inhibition was not observed at nicks. These experiments document a new DNA binding specificity for Ku and further suggest that the high affinity end and nick binding activity is biologically relevant to its functions in vivo.	YALE UNIV,SCH MED,DEPT INTERNAL MED,RHEUMATOL SECT,NEW HAVEN,CT 06510	Yale University								ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; CEGLAREK JA, 1989, ELECTROPHORESIS, V10, P360, DOI 10.1002/elps.1150100514; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GRIFFITH AJ, 1992, MOL BIOL REP, V16, P91, DOI 10.1007/BF00419754; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P3311; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; ISEKI S, 1986, EXP CELL RES, V167, P311, DOI 10.1016/0014-4827(86)90172-2; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Maniatis T., 1982, MOL CLONING; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5188; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; REEVES WH, 1987, J RHEUMATOL, V14, P97; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; STUIVER MH, 1991, FEBS LETT, V282, P189, DOI 10.1016/0014-5793(91)80474-H; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAKI T, 1990, EXP CELL RES, V190, P212, DOI 10.1016/0014-4827(90)90188-G; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407	42	276	277	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7594	7601						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463290				2022-12-25	WOS:A1993KV14100110
J	GUSE, AH; GREINER, E; EMMRICH, F; BRAND, K				GUSE, AH; GREINER, E; EMMRICH, F; BRAND, K			MASS CHANGES OF INOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE AND INOSITOL HEXAKISPHOSPHATE DURING CELL-CYCLE PROGRESSION IN RAT THYMOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAKISPHOSPHATE; STIMULATION; NEUTROPHILS; PHOSPHATES	Changes in the cellular mass and the cellular concentration of the highly phosphorylated inositol derivatives inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4, 5,6)P-5) and inositol hexakisphosphate (InsP6) were observed during a complete cell cycle of proliferating rat thymocytes. Inositol polyphosphates were determined by a recently developed anion-exchange HPLC/post-column complexometric dye system (Mayr, G. W. (1988) Biochem. J. 254, 585-591), and data were expressed as mass amounts per cell number or as absolute intracellular concentrations based on cell volume determinations by the cell analyzer system CASY 1. After a very early transient rise in both Ins(1,3, 4,5,6)P5 and InsP6 at the beginning of the cell cycle, a decrease of the intracellular concentration of both compounds occurred which then remained on a low level between 24 and 48 h. Between 48 and 72 h the cells divided resulting in a decrease of the cell volume by a factor of approximately 2. During this phase a pronounced increase of Ins(1,3,4,5,6)P5, and InsP6 was observed. These increases were already seen when the data were expressed as mass per cell number, but were even enhanced when expressed as absolute intracellular concentrations. In conclusion, we present as a novel finding long term changes in the intracellular concentrations of Ins(1,3,4,5,6)P5 and InsP6 in proliferating thymocytes. This may indicate a role for these compounds during cell cycle progression.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT BIOCHEM,W-8520 ERLANGEN,GERMANY	University of Erlangen Nuremberg	GUSE, AH (corresponding author), INST CLIN IMMUNOL,MAX PLANCK SOC,CLIN RES UNIT RHEUMATOL IMMUNOL,SCHWABACHANLAGE 10,W-8520 ERLANGEN,GERMANY.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRAND K, 1987, J BIOL CHEM, V262, P15232; BRAND K, 1988, EUR J BIOCHEM, V172, P695, DOI 10.1111/j.1432-1033.1988.tb13944.x; CULVENOR JG, 1976, BIOCHIM BIOPHYS ACTA, V437, P354, DOI 10.1016/0304-4165(76)90005-2; EGGLETON P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P309, DOI 10.1016/0167-4889(91)90091-B; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FLEISCHMAN LF, 1988, AM J PHYSIOL, V255, pC531, DOI 10.1152/ajpcell.1988.255.4.C531; FRENCH PJ, 1991, P ROY SOC B-BIOL SCI, V245, P193, DOI 10.1098/rspb.1991.0109; GUSE AH, 1992, J CHROMATOGR, V593, P157, DOI 10.1016/0021-9673(92)80281-X; GUSE AH, 1992, J IMMUNOL, V149, P2452; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HAWKINS PT, 1987, NATURE, V330, P656; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; NETZKER R, 1992, J BIOL CHEM, V267, P6421; PITTET D, 1989, J BIOL CHEM, V264, P18489; REGUNATHAN S, 1992, BIOCHEM PHARMACOL, V43, P1331, DOI 10.1016/0006-2952(92)90510-P; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; SCHOBITZ B, 1991, EUR J BIOCHEM, V199, P257, DOI 10.1111/j.1432-1033.1991.tb16118.x; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; VOGELMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7129	7133						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463248				2022-12-25	WOS:A1993KV14100049
J	IWAHANA, H; YAMAOKA, T; MIZUTANI, M; MIZUSAWA, N; II, S; YOSHIMOTO, K; ITAKURA, M				IWAHANA, H; YAMAOKA, T; MIZUTANI, M; MIZUSAWA, N; II, S; YOSHIMOTO, K; ITAKURA, M			MOLECULAR-CLONING OF RAT AMIDOPHOSPHORIBOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; ESCHERICHIA-COLI-PURF; IRON-SULFUR PROTEIN; NUCLEOTIDE-SEQUENCE; PURINE RIBONUCLEOTIDES; BACILLUS-SUBTILIS; ELECTROPHORESIS; GENE; BIOSYNTHESIS; SPECIFICITY	The cDNA of rat amidophosphoribosyltransferase (EC 2.4.2.14, ATase), which is the supposed regulatory allosteric enzyme of de novo purine nucleotide biosynthesis, has been cloned by polymerase chain reaction. The predicted open reading frame encodes a protein of 517 amino acids with a deduced molecular weight of 57,436 including a supposed 11-amino acid propeptide. The 16 amino acid residues next to the propeptide were identical to the N-terminal amino acid microsequence of a purified rat liver ATase, which is consistent with the cleavage of the propeptide from the proenzyme in rat liver. The derived amino acid sequence is the first sequence reported for a mammalian ATase and it exhibits 81, 41, 36, and 31% identity with the sequences of chicken, Bacillus subtilis, Escherichia coli, and Saccharomyces cerevisiae ATases, respectively. The molecular weight (M(r)) of 57,436 suggests a tetrameric structure of native ATase with a M(r) of 240,000-248,000. Southern blot analysis suggested that the ATase gene exists as a single copy in the rat genome. Northern blot analysis revealed that ATase is expressed at a high level in brain, heart, liver, and stomach. The ATase mRNA in brain, heart, and stomach was 3.5 kilobases (kb) and in liver the 3.5-kb band was observed as well as an additional band of 4.2 kb. Reverse transcription-polymerase chain reaction analysis showed that ATase is ubiquitously expressed in all tissues examined. Comparison with chicken ATase showed that 2 cysteine residues for an iron-sulfur cluster were conserved. Three conserved and two non-conserved consensus phosphorylation sites for cAMP-dependent protein kinase were found.	UNIV TOKUSHIMA,SCH MED,OTSUKA DEPT CLIN & MOLEC NUTR,TOKUSHIMA 770,JAPAN; UNIV TSUKUBA,INST CLIN MED,DIV ENDOCRINOL & METAB,TSUKUBA,IBARAKI 305,JAPAN	Tokushima University; University of Tsukuba								BECKER MA, 1987, J BIOL CHEM, V262, P14531; CAMPBELL WP, 1983, ANAL BIOCHEM, V129, P31, DOI 10.1016/0003-2697(83)90047-7; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; HOLMES EW, 1973, J BIOL CHEM, V248, P144; ITAKURA M, 1987, AM J PHYSIOL, V253, pE684, DOI 10.1152/ajpendo.1987.253.6.E684; ITAKURA M, 1986, METABOLISM, V35, P758, DOI 10.1016/0026-0495(86)90244-1; ITAKURA M, 1979, J BIOL CHEM, V254, P333; ITAKURA M, 1981, J CLIN INVEST, V67, P994, DOI 10.1172/JCI110150; ITAKURA M, 1988, BIOL RES S3, V9, P111; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MAKAROFF CA, 1986, J BIOL CHEM, V261, P1416; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MARGOLIS J, 1975, J CHROMATOGR, V106, P204, DOI 10.1016/S0021-9673(01)81066-9; MEI B, 1989, J BIOL CHEM, V264, P16613; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; PALELLA TD, 1989, METABOLIC BASIS INHE, P965; SAMPEI G, 1988, NUCLEIC ACIDS RES, V16, P8717, DOI 10.1093/nar/16.17.8717; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSO JY, 1982, J BIOL CHEM, V257, P3525; WONG JY, 1977, J BIOL CHEM, V252, P7424; ZHOU G, 1992, J BIOL CHEM, V267, P7936; ZHOU GC, 1990, J BIOL CHEM, V265, P21152	33	23	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7225	7237						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463258				2022-12-25	WOS:A1993KV14100061
J	STEINER, B; TRZECIAK, A; PFENNINGER, G; KOUNS, WC				STEINER, B; TRZECIAK, A; PFENNINGER, G; KOUNS, WC			PEPTIDES DERIVED FROM A SEQUENCE WITHIN BETA INTEGRIN BIND TO PLATELET ALPHA-IIB-BETA-3 (GPIIB-IIIA) AND INHIBIT LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE GLYCOPROTEIN-IIB; FIBRINOGEN BINDING; RECOGNITION SITE; CELL-ADHESION; GAMMA-CHAIN; RGD PEPTIDE; RECEPTOR; COMPLEX	Peptides derived from a sequence within the loop structure of human platelet glycoprotein (GP) IIIa (integrin beta3) were previously shown to inhibit fibrinogen binding to purified GPIIb-IIIa. In this study a series of peptides based on the GPIIIa sequence 211-221 (SVSRNRDAPEG) was synthesized. The most active peptide was determined to be RNRDA, and its inhibitory potency was 4-fold greater (IC50 = 4.8 muM) than that of SVSRNRDAPEG. These GPIIIa peptides also inhibited the binding of two monoclonal antibodies, pl-55 and PAC-1, which are directed against the activated conformer of GPIIb-IIIa. To determine whether these peptides bound directly to GPIIb-IIIa, an affinity matrix was prepared by coupling RNRDAPEGC to Sepharose. Fibrinogen or purified GPIIb-IIIa was applied to the affinity column. Only GPIIb-IIIa was retained on the column, and it could be specifically eluted by GPIIIa peptide or RGDV but not by an irrelevant peptide. Additionally, we observed that the binding of GPIIIa peptides to purified GPIIb-IIIa induced exposure of a neoepitope on GPIIb that was recognized by the monoclonal antibody pl-80. These data suggest that sequences within the loop structure of GPIIIa can interact with the ligand binding domain of GPIIb-IIIa. Thus, this GPIIIa domain may be involved in regulating the accessibility of ligands to GPIIb-IIIa following platelet activation.			STEINER, B (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,GRENZACHERSTR 124,CH-4002 BASEL,SWITZERLAND.							Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; CHARO IF, 1991, J BIOL CHEM, V266, P1415; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1988, J BIOL CHEM, V265, P3340; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GINSBERG MH, 1991, CHEM IMMUNOL, V50, P75; GOGSTAD G, 1983, BLOOD, V60, P663; GULINO D, 1992, J BIOL CHEM, V267, P1001; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1992, BLOOD, V80, P2539; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; NACHMAN RL, 1984, J BIOL CHEM, V259, P8584; SAMANEN J, 1991, J MED CHEM, V34, P3114, DOI 10.1021/jm00114a022; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; STEINER B, 1989, J BIOL CHEM, V264, P13102; STEINER B, 1992, CIRCULATION, V86, P683; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; YAMADA KM, 1985, J CELL BIOCHEM, V28, P99, DOI 10.1002/jcb.240280203	33	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6870	6873						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463215				2022-12-25	WOS:A1993KV14100013
J	DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS				DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS			INDUCTION OF THE METASTATIC PHENOTYPE BY TRANSFECTION OF A BENIGN RAT MAMMARY EPITHELIAL-CELL LINE WITH THE GENE FOR P9KA, A RAT CALCIUM-BINDING PROTEIN, BUT NOT WITH THE ONCOGENE EJ-RAS-1	ONCOGENE			English	Article							FIBROBLAST-LIKE CELLS; MESSENGER-RNA; GEL ELECTROPHORESIS; ELONGATED CELLS; CARCINOMA-CELLS; DNA; CLONING; GROWTH; S-100; TUMOR	The rat mammary epithelial cell tine, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Wistar-Furth rats. Transfection of this line with a drug resistance plasmid containing both the gene for resistance to Geneticin (neo) and the gene for p9Ka (pSV2neo-p9Ka), a rat calcium-binding protein, or with a similar plasmid containing neo and the oncogene EJ-ras-1 (pSV2neo-ras) yields drug-resistant transformants that express high levels of the p9Ka or EJ-ras-I mRNAs and proteins. These transfected cells all produce tumours when injected at subcutaneous sites with a shorter median latent period than the tumours produced by the parental untransfected Rama 37 cells in syngeneic hosts. Cells transfected with pSV2neo-p9Ka yield a higher incidence of tumours than untransfected Rama 37 cells, many of which metastasize to lungs and/or lymph nodes in syngeneic rats. However, cells transfected with pSV2neo-ras or pSV2neo plasmid alone yield tumours that fail to metastasize. Immunofluorescent studies suggest an association of p9Ka with the cytoskeleton, as depicted by F-actin staining with the reagent phalloidin. It is suggested that the transfection of copies of the gene for the rat calcium-binding protein p9Ka can enhance the tumorigenic potential and induce the metastatic phenotype in this rat mammary model, whereas transfection of control plasmid DNA or the oncogene EJ-ras-I fails to induce the metastatic phenotype, although EJ-ras-I transfectants, like those containing p9Ka, possess increased growth properties in vivo.	UNIV LIVERPOOL, DEPT BIOCHEM, CANCER & POLIO RES FUND LABS, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool			Davies, Michael/GWV-2527-2022; Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194; Davies, Michael Peter Alan/0000-0002-7609-4977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1991, NOVEL CALCIUM BINDIN, P105; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GAO J, 1987, PATHOL RES PRACT, V182, P48, DOI 10.1016/S0344-0338(87)80141-3; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1991, NOVEL CALCIUM BINDIN, P140; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; RUDLAND PS, 1987, CANCER METAST REV, V6, P55, DOI 10.1007/BF00047609; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TULCHINSKY E, 1992, IN PRESS ONCOGENE; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186	49	230	232	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					999	1008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455951				2022-12-25	WOS:A1993KT22000023
J	CAROFF, M; DEPRUN, C; KARIBIAN, D				CAROFF, M; DEPRUN, C; KARIBIAN, D			CF-252 PLASMA DESORPTION MASS-SPECTROMETRY APPLIED TO THE ANALYSIS OF UNDERIVATIZED ROUGH-TYPE ENDOTOXIN PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLETE STRUCTURAL DETERMINATION; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDES; PURIFICATION; POSITION; PROTEIN; ACID	Plasma desorption mass spectrometry has recently been used with success to characterize native, underivatized Re- to Rc-type endotoxins in terms of their constituent lipopolysaccharides. The spectra give masses for the major molecular species of lipopolysaccharide present from which their probable compositions could be inferred using the overall composition determined by chemical analyses. Moreover, the relative intensities of the signals are roughly proportional to the abundance of their corresponding molecular species. Native Rc-, Rb-, and Ra-type enterobacterial endotoxins with 5-10 core sugar units have been rendered amenable to plasma-desorption mass spectrometry analysis by improvement in their solubility and the use of cellobiose as an additive. The spectra of four Salmonella and Escherichia endotoxin preparations demonstrated heterogeneity in acylation and phosphorylation. Since these sources of heterogeneity are critical for many biological activities, the spectra underline the need to define the composition of each preparation of endotoxin used in structure-function studies.	UNIV PARIS 11,INST BIOCHIM,CNRS,URA 1116,EQUIPE ENDOTOXINS,BAT 432,F-91405 ORSAY,FRANCE; INST NATL PHYS NUCL & PHYS PARTICULES,CNRS,INST PHYS NUCL,EQUIPE INTERACT ION SURFACE & MAT,F-91406 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Caroff, Martine/N-4293-2019	CAROFF, Martine/0000-0002-7329-5247				BOLBACH G, 1988, NUCL INSTRUM METH B, V30, P74, DOI 10.1016/0168-583X(88)90082-1; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF MGL, 1990, APPL ENVIRON MICROB, V56, P1957, DOI 10.1128/AEM.56.6.1957-1959.1990; DELLANEGRA S, 1986, REV PHYS APPL, V21, P401, DOI 10.1051/rphysap:01986002106040100; Deprun C, 1989, Rapid Commun Mass Spectrom, V3, P171, DOI 10.1002/rcm.1290030602; GALANOS C, 1975, EUR J BIOCHEM, V54, P603, DOI 10.1111/j.1432-1033.1975.tb04172.x; GALANOS C, 1984, HDB ENDOTOXIN, V1, P46; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JONSSON GP, 1986, ANAL CHEM, V58, P1084, DOI 10.1021/ac00297a023; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; LEHMANN V, 1978, EUR J BIOCHEM, V86, P487, DOI 10.1111/j.1432-1033.1978.tb12332.x; MCFARLANE RD, 1976, SCIENCE, V191, P920; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RIETSCHEL ET, 1984, HDB ENDOTOXINS, V1, P187; ROWATT E, 1984, BIOCHEM J, V233, P23; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; WEISS J, 1986, INFECT IMMUN, V51, P594, DOI 10.1128/IAI.51.2.594-599.1986; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167	22	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12321	12324						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509370				2022-12-25	WOS:A1993LG65800018
J	GAUT, JR; HENDERSHOT, LM				GAUT, JR; HENDERSHOT, LM			THE IMMUNOGLOBULIN-BINDING PROTEIN INVITRO AUTOPHOSPHORYLATION SITE MAPS TO A THREONINE WITHIN THE ATP BINDING CLEFT BUT IS NOT A DETECTABLE SITE OF INVIVO PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; SODIUM DODECYL SULFATE; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; CHAIN; DNAK; EXPRESSION; BIP/GRP78; TRANSPORT	In vitro incubation of immunoprecipitated immunoglobulin-binding protein (BiP) complexes with calcium and [gamma-P-32]ATP resulted in the phosphorylation of BiP on a threonine residue. This autophosphorylation activity did not occur in the presence of magnesium but had the same pH optimum as reported for its magnesium-dependent ATPase activity. This suggested the possibility that both activities could occur through ATP hydrolysis at the same site. In support of this, mutation of either Thr-37 or Thr-229 to a glycine eliminated both autophosphorylation and ATPase activities, and mutation of either residue to a serine significantly reduced both activities. Glutamic acid 175 in HSC71 has been hypothesized to flank the divalent cation complexed with ATP. Mutation of the analogous glutamic acid, Glu-201, in BiP abolished ATPase activity but still supported some autophosphorylation. The in vitro phosphorylation site was mapped to Thr-229 by mutational analysis. This threonine has been hypothesized to interact with the gamma-phosphate of ATP through a polarized water molecule and would be in a position to act as a phosphate acceptor in the ATP hydrolysis reaction. These data imply that both ATPase and autophosphorylation result from ATP hydrolysis at the same site and that the cation associated with BiP determines which activity is observed. Comparison of partial protease digestion or cyanogen bromide cleavage products of in vitro and in vivo phosphorylated BiP demonstrated that Thr-229 is not a detectable site of phosphorylation in cells. Therefore, whatever functional role phosphorylation may have in vivo, it cannot be attributed to autophosphorylation of Thr-229.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE LN, MEMPHIS, TN 38103 USA; UNIV TENNESSEE, MED CTR, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BURR FA, 1983, METHOD ENZYMOL, V96, P716; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	26	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12691	12698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509403				2022-12-25	WOS:A1993LG65800069
J	PEJLER, G; KARLSTROM, A				PEJLER, G; KARLSTROM, A			THROMBIN IS INACTIVATED BY MAST-CELL SECRETORY GRANULE CHYMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED-TYPE HYPERSENSITIVITY; HEPARIN PROTEOGLYCAN; NEUTRAL PROTEASES; MOUSE; BINDING; PROTEINS; TRYPTASE; RAT; ANAPHYLATOXIN; MACROPHAGES	In a recent paper we demonstrated that cultures of murine adherent peritoneal cells expressed cell surface-associated serine protease activity that specifically inactivated thrombin by cleaving the enzyme into defined proteolytic fragments (Pejler, G., and Seljelid, R. (1992) J. Biol. Chem. 267, 3136-3142). In the present report, the purification and further characterization of the thrombin-inactivating serine protease is described. The serine protease is shown to be expressed by mast cells. Purification of the thrombin-inactivating serine protease by a combination of anion-exchange chromatography and Superdex 75 chromatography showed that the enzyme had an apparent molecular mass of 28 kDa. N-terminal sequence analysis of the purified protein demonstrated 100% identity of the thrombin-inactivating serine protease with the secretory granule chymases: murine mast cell protease 3 and murine mast cell protease 4. The serine protease showed chymotrypsin-like substrate specificity. The thrombin-inactivating activity was markedly enhanced by optimal concentrations of heparin.	KABI PHARMACIA, CTR BIOSCI, DEPT BIOCHEM, S-11287 STOCKHOLM, SWEDEN		PEJLER, G (corresponding author), BIOMED CTR, DEPT VET MED CHEM, POB 575, S-75123 UPPSALA, SWEDEN.							BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CLOHISY DR, 1990, J BIOL CHEM, V265, P7729; COLVIN RB, 1975, J IMMUNOL, V114, P377; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; DVORAK HF, 1979, J EXP MED, V150, P322, DOI 10.1084/jem.150.2.322; EKRE HPT, 1986, INT J IMMUNOPHARMACO, V8, P277, DOI 10.1016/0192-0561(86)90109-8; GECZY CL, 1982, J IMMUNOL, V128, P331; GECZY CL, 1983, LYMPHOKINES, V8, P201; GERVASONI JE, 1986, J IMMUNOL, V136, P285; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOLDSWORTH SR, 1979, CLIN EXP IMMUNOL, V37, P38; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSON DS, 1963, LANCET, V2, P175; OLSON ST, 1991, J BIOL CHEM, V266, P6342; PEJLER G, 1992, J BIOL CHEM, V267, P3136; RAZIN E, 1985, EXP CELL RES, V160, P380, DOI 10.1016/0014-4827(85)90184-3; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; STERK AR, 1982, J IMMUNOL, V128, P838; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; ZACHARSKI LR, 1992, CLIN IMMUNOL IMMUNOP, V63, P155, DOI 10.1016/0090-1229(92)90008-C; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	38	47	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11817	11822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505310				2022-12-25	WOS:A1993LF28400055
J	SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW				SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW			REGULATED EXPRESSION OF THE RETINOBLASTOMA GENE IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; MOUSE PGK-1 GENE; RETINOIC ACID; NEUROECTODERMAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; STEM-CELLS; PROTEIN; PRODUCT	The expression of the retinoblastoma susceptibility (RB) gene was investigated in P19 embryonal carcinoma cells and in these cells induced to differentiate with retinoic acid (RA) or with dimethyl sulfoxide (DMSO). In undifferentiated cells very low levels of RB mRNA and protein were present. DMSO-treated P19 cell cultures develop into mesodermal and endodermal cells and RB expression increased only slightly in these differentiating celts. RA-treated P19 cells develop into neuroectoderm and this differentiation was accompanied by a marked increase in RB expression with mRNA levels increasing 15 fold by 4-6 days following initiation of RA treatment. No such increase occurred in mutant cells that fail to respond to RA. The RB promoter did not appear to be directly activated by RA. Nevertheless, the increase in RB expression in RA-treated cells appeared to be due to enhanced initiation of transcription because cells transfected with a reporter gene driven by the RB promoter expressed the reporter gene with kinetics similar to that of the RB gene. Thus the activation of the RB gene appears to be achieved indirectly by RA-induced factor(s) in differentiating neuroectodermal cells. The post-mitotic neurons that developed in RA-treated cultured contained only the hypophosphorylated form of the RB protein. Recent studies (Clarke et aL, 1992; Jacks et al., 1992; Lee et al., 1992) have shown that mice lacking the RB gene have abnormalities in early brain development suggesting that the rapid rise in RB expression and the hypophosphorylation of the protein are essential for neuronal cell differentiation.	UNIV OTTAWA,DEPT CHEM,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Ottawa; University of Toronto				Slack, Ruth/0000-0002-1552-2835				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARLAND T, 1991, ONCOGENE, V6, P1367; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; Gill M., UNPUB; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLEN RJ, 1992, UNPUB; MURRAY EJ, 1991, MOL CELL BIOL, V1, P5534; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRATT MAC, 1992, UNPUB; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUSTGI AK, 1991, SYMPT QUANT BIOL, V56, P163; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; STAINES WA, 1992, UNPUB; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1988, ONCOGENE, V3, P553; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	54	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1585	1591						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502481				2022-12-25	WOS:A1993LE06400022
J	MORIYAMA, R; LOMBARDO, CR; WORKMAN, RF; LOW, PS				MORIYAMA, R; LOMBARDO, CR; WORKMAN, RF; LOW, PS			REGULATION OF LINKAGES BETWEEN THE ERYTHROCYTE-MEMBRANE AND ITS SKELETON BY 2,3-DIPHOSPHOGLYCERATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HEREDITARY SPHEROCYTOSIS; STRUCTURAL TRANSITIONS; MECHANICAL STABILITY; CYTOPLASMIC DOMAINS; MOLECULAR DEFECT; BINDING-SITE; 4.1 BINDING; SPECTRIN; ANKYRIN	In addition to reducing hemoglobin-O2 affinity, 2,3-diphosphoglycerate (DPG) is known to modulate the mechanical properties of the erythrocyte membrane. By fluorescence spectroscopy and differential scanning calorimetry, we demonstrate that DPG binds the cytoplasmic domain of erythrocyte membrane band 3 in two stages characterized by apparent K(D) values of approximately approximately 2 and 12 mM. DPG was also shown to perturb the stability of ankyrin, protein 4.1, and protein 4.2 in situ and to directly bind to protein 4.1. In studies of membrane-skeleton interactions, DPG was observed to inhibit the fast and slow phases of ankyrin binding to band 3 and to reduce both the number of ankyrin sites and affinity of ankyrin for each class of site. The inhibition was biphasic, similar to the band 3-DPG binding isotherm; however, at physiological DPG concentrations a reduction in only 15% of the ankyrin sites was observed. In contrast, inhibition of protein 4.1 binding to the membrane reached 65% at physiological DPG concentrations (approximately approximately 5.9 mM); at more elevated concentrations, blockade was nearly quantitative, affecting glycophorin and band 3 sites alike. Taken together with previous observations, these data suggest that DPG's effect on O2 delivery may extend beyond its well recognized impact on hemoglobin-O2 affinity.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRE P, 1981, J CLIN INVEST, V68, P1566, DOI 10.1172/JCI110411; ANDERSON RA, 1989, RED BLOOD CELL MEMBR, P187; APPELL KC, 1982, BIOCHEMISTRY-US, V21, P2151, DOI 10.1021/bi00538a026; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; BRANDTS JF, 1978, BIOCHIM BIOPHYS ACTA, V512, P566, DOI 10.1016/0005-2736(78)90166-9; BUNN HF, 1971, J BIOL CHEM, V246, P5273; CHAO TS, 1991, ARCH BIOCHEM BIOPHYS, V285, P221, DOI 10.1016/0003-9861(91)90352-J; CHASIS JA, 1988, J CELL BIOL, V107, P1351, DOI 10.1083/jcb.107.4.1351; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; DALEKE DL, 1989, J CELL BIOL, V108, P1375, DOI 10.1083/jcb.108.4.1375; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIO SR, 1982, BIOCHEMISTRY-US, V21, P3585, DOI 10.1021/bi00258a009; JINBU Y, 1982, BIOCHEM BIOPH RES CO, V104, P1087, DOI 10.1016/0006-291X(82)91361-4; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KANNAN R, 1991, BIOCHEM J, V278, P57, DOI 10.1042/bj2780057; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; LANGE Y, 1982, J CELL BIOL, V92, P714, DOI 10.1083/jcb.92.3.714; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOW PS, 1984, BLOOD, V259, P13070; LUX SE, 1979, NORMAL ABNORMAL RED, P463; LYSKO KA, 1981, BIOCHEMISTRY-US, V20, P5570, DOI 10.1021/bi00522a034; MENTZER WC, 1987, J CLIN INVEST, V79, P943, DOI 10.1172/JCI112905; MOHANDAS N, 1983, SEMIN HEMATOL, V20, P225; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MORROW JS, 1981, J CELL BIOL, V88, P463, DOI 10.1083/jcb.88.2.463; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PINDER JC, 1989, BIOCHEM J, V264, P423, DOI 10.1042/bj2640423; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; REID ME, 1989, RED CELL, P553; REINHART WH, 1988, AM J HEMATOL, V29, P195, DOI 10.1002/ajh.2830290404; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SCHINDLER M, 1980, P NATL ACAD SCI-BIOL, V77, P1457, DOI 10.1073/pnas.77.3.1457; SHEETZ MP, 1980, J BIOL CHEM, V255, P9955; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WAUGH RE, 1986, BLOOD, V68, P231; WOLFE LC, 1982, NEW ENGL J MED, V307, P1367, DOI 10.1056/NEJM198211253072203	46	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10990	10996						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496163				2022-12-25	WOS:A1993LD46600044
J	SCHTEINGART, CD; HAGEY, LR; SETCHELL, KDR; HOFMANN, AF				SCHTEINGART, CD; HAGEY, LR; SETCHELL, KDR; HOFMANN, AF			5-BETA-HYDROXYLATION BY THE LIVER - IDENTIFICATION OF 3,5,7-TRIHYDROXY NOR-BILE ACIDS AS NEW MAJOR BIOTRANSFORMATION PRODUCTS OF 3,7-DIHYDROXY NOR-BILE ACIDS IN RODENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY MASS SPECTROMETRY; SIDE-CHAIN; URSODEOXYCHOLIC ACID; BILIARY-SECRETION; HEPATIC TRANSPORT; RAT-LIVER; DERIVATIVES; CONJUGATION; CHOLESTASIS; METABOLISM	24-Norursodeoxycholic acid (nor-UDCA), when administered into the anesthetized biliary fistula hamster or injected into the perfusate of an isolated liver, was hydroxylated at C-5 to give 5beta-hydroxynorursodeoxycholic acid 2 (3alpha,5,7beta-trihydroxy-24-nor-5beta-cholan-23-oic acid), which was secreted into bile mainly as such. Similarly, 24-norchenodeoxycholic acid (nor-CDCA) was 5beta-hydroxylated to give 5beta-hydroxynorchenodeoxycholic acid 4 (3alpha,5,7alpha-trihydroxy-24-nor-5beta-cholan-23-oic acid), which was also secreted into bile without appreciable further biotransformation. The site of hydroxylation was assigned by C-13 and H-1 NMR and mass spectrometry. 5-Hydroxylation was a major biotransformation pathway at physiological bile acid loads. 5-Hydroxylation of UDCA also occurred in the perfused rat liver but to a lesser extent. 5-Hydroxylation of nor-UDCA was not observed in rabbit, dog, or man, indicating that its formation is species-specific. 5-Hydroxylation of nor-CDCA and nor-UDCA is the first reported example of hydroxylation of a tertiary carbon atom of bile acids. Nor-dihydroxy bile acids appear to be useful for the detection of minor hydroxylation pathways, because their prolonged hepatobiliary retention exposes them repeatedly to hydroxylases present in the hepatobiliary system.	CHILDRENS HOSP MED CTR, DEPT PEDIAT, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center	SCHTEINGART, CD (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, DIV GASTROENTEROL, BILE ACID RES SECT, LA JOLLA, CA 92093 USA.				NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [DK21506, DK32130] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021506, R01DK032130] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALME B, 1977, J LIPID RES, V18, P339; ARINGER L, 1981, BIOMED MASS SPECTROM, V8, P183, DOI 10.1002/bms.1200080502; BAUMGARTNER U, 1986, AM J PHYSIOL, V251, pG431, DOI 10.1152/ajpgi.1986.251.4.G431; BEIERBECK H, 1977, CAN J CHEM, V55, P2813, DOI 10.1139/v77-391; BREMMELGAARD A, 1980, J LIPID RES, V21, P1072; BROOKS CJW, 1973, BIOCHIM BIOPHYS ACTA, V296, P431, DOI 10.1016/0005-2760(73)90101-X; BULGER WH, 1973, BIOCHEM PHARMACOL, V22, P1745, DOI 10.1016/0006-2952(73)90388-2; BULL JR, 1977, S AFR J CHEM, V30, P105; CLAYTON LM, 1989, J PHARMACOL EXP THER, V248, P1130; COHEN BI, 1986, GASTROENTEROLOGY, V91, P189, DOI 10.1016/0016-5085(86)90457-9; COOKSON DJ, 1981, ORG MAGN RESONANCE, V16, P111, DOI 10.1002/mrc.1270160209; DEMARCO PV, 1968, J AM CHEM SOC, V90, P5480, DOI 10.1021/ja01022a027; DUMASWALA R, 1989, J LIPID RES, V30, P847; ELLIOTT WH, 1985, STEROLS BILE ACIDS, P303; HOFMANN AF, 1968, J LIPID RES, V9, P707; HOFMANN AF, 1978, JAMA-J AM MED ASSOC, V239, P1138, DOI 10.1001/jama.239.12.1138; HOFMANN AF, 1962, J LIPID RES, V3, P127; IIDA T, 1983, ORG MAGN RESONANCE, V21, P305, DOI 10.1002/omr.1270210504; KIRKPATRICK RB, 1988, HEPATOLOGY, V8, P353, DOI 10.1002/hep.1840080227; KOCOVSKY P, 1983, COLLECT CZECH CHEM C, V48, P3643, DOI 10.1135/cccc19833643; KOOPMAN BJ, 1987, BIOCHIM BIOPHYS ACTA, V917, P238, DOI 10.1016/0005-2760(87)90128-7; LAKE JR, 1988, GASTROENTEROLOGY, V95, P454, DOI 10.1016/0016-5085(88)90504-5; LAWSON AM, 1988, BILE ACIDS, V4, P1; LINDSTEDT S, 1957, ARK KEMI, V11, P137; MATOBA N, 1986, J LIPID RES, V27, P1154; MIHAILOVIC ML, 1981, HELV CHIM ACTA, V64, P1032, DOI 10.1002/hlca.19810640409; MUNOZ J, 1990, GASTROENTEROLOGY, V98, P613; NAKATOMI F, 1985, J PHARMACOBIO-DYNAM, V8, P557; OMAILLE ERL, 1984, AM J PHYSIOL, V246, pG67, DOI 10.1152/ajpgi.1984.246.1.G67; PALMER KR, 1987, AM J PHYSIOL, V252, pG219, DOI 10.1152/ajpgi.1987.252.2.G219; POPOVITZBIRO R, 1985, J AM CHEM SOC, V107, P4043, DOI 10.1021/ja00299a047; ROSSI SS, 1987, J LIPID RES, V28, P589; SCHNEIDER HJ, 1988, MAGN RESON CHEM, V26, P679, DOI 10.1002/mrc.1260260808; SCHTEINGART CD, 1988, J LIPID RES, V29, P1387; SETCHELL KDR, 1983, CLIN CHIM ACTA, V127, P1, DOI 10.1016/0009-8981(83)90070-0; SETCHELL KDR, 1988, CLIN BIOCH PRINCIPLE, V1, P54; SHOPPEE CW, 1957, J CHEM SOC, P3107, DOI 10.1039/jr9570003107; SJOVALL J, 1985, METHOD ENZYMOL, V111, P63, DOI 10.1016/S0076-6879(85)11006-2; STARY I, 1985, COLLECT CZECH CHEM C, V50, P1227, DOI 10.1135/cccc19851227; STELLAARD F, 1985, J LAB CLIN MED, V105, P504; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; TOHMA M, 1986, CHEM PHARM BULL, V34, P2890; TSERNG KY, 1977, J LIPID RES, V18, P400; VANANTWERP CL, 1977, J ORG CHEM, V42, P789, DOI 10.1021/jo00425a005; VANBERGEHENEGOUWEN GP, 1976, GUT, V17, P861, DOI 10.1136/gut.17.11.861; VESSEY DA, 1983, BIOCHEM J, V214, P923, DOI 10.1042/bj2140923; WATERHOUS DV, 1985, J LIPID RES, V26, P1068; YOON YB, 1986, GASTROENTEROLOGY, V90, P837, DOI 10.1016/0016-5085(86)90859-0; ZAKKO SF, 1987, GASTROENTEROLOGY, V92, P1792	49	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11239	11246						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496179				2022-12-25	WOS:A1993LD46600077
J	SEVLEVER, D; ROSENBERRY, TL				SEVLEVER, D; ROSENBERRY, TL			MANNOSAMINE INHIBITS THE SYNTHESIS OF PUTATIVE GLYCOINOSITOL PHOSPHOLIPID ANCHOR PRECURSORS IN MAMMALIAN-CELLS WITHOUT INCORPORATING INTO AN ACCUMULATED INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; TRYPANOSOMA-BRUCEI; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; STRUCTURAL CHARACTERIZATION; BIOSYNTHESIS; PROTEINS; MUTANTS; IDENTIFICATION	Mannosamine (ManN) has been reported to inhibit the formation of Manalpha-1,2Man linkages and to prevent the anchoring of membrane proteins by glycoinositol phospholipids (GPIs). In this paper, the effect of ManN on the synthesis of putative GPI anchor precursors in mammalian cells was studied. Three different cell lines were analyzed: HeLa cells and Thy-1 negative lymphoma mutants B and F that accumulate two-mannosyl GPI (Man2GPI) and three-mannosyl GPI (Man3GPI) species, respectively. ManN did not alter the incorporation of [H-3]Man into the Man2GPI in mutant B cells. However, when either HeLa cells or mutant F cells were labeled with [H-3]Man in the presence of ManN, [H-3]Man incorporation into Man3GPI species was blocked and the TLC profile of [H-3]Man-labeled glycolipids resembled that obtained with mutant B cells. Further characterization of the predominant labeled glycolipid that accumulated in ManN-treated HeLa cells by enzymatic and chromatographic criteria and permethylation analysis confirmed the structure as a Man2GPI indistinguishable from the Man2GPI that accumulates in mutant B cells. Based on previous reports that ManN inhibits Manalpha-1,2Man linkage formation and that in GPI-anchored proteins the third Man residue is attached by a Manalpha-1,2Man linkage, these results indicate that the third Man residue that distinguishes the putative Man2GPI precursor from the Man3GPI precursor also is attached by a Manalpha-1,2Man linkage. Furthermore, the observation that Man2GPI rather than a new GPI species containing ManN accumulated during ManN treatment revealed that the mechanism of ManN inhibition primarily involved inhibition of an alpha1,2-mannosyltransferase rather than incorporation of ManN into an aberrant GPI species.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DEEG MA, 1992, J BIOL CHEM, V267, P18581; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1991, J BIOL CHEM, V266, P8392; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOENER MC, 1990, EUR J BIOCHEM, V190, P593, DOI 10.1111/j.1432-1033.1990.tb15614.x; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HUANG KS, 1990, J BIOL CHEM, V265, P17738; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHWARZ RT, 1989, BIOCHEM SOC T, V17, P746, DOI 10.1042/bst0170746; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459	40	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10938	10945						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496158				2022-12-25	WOS:A1993LD46600037
J	BELISLE, JT; MCNEIL, MR; CHATTERJEE, D; INAMINE, JM; BRENNAN, PJ				BELISLE, JT; MCNEIL, MR; CHATTERJEE, D; INAMINE, JM; BRENNAN, PJ			EXPRESSION OF THE CORE LIPOPEPTIDE OF THE GLYCOPEPTIDOLIPID SURFACE-ANTIGENS IN ROUGH MUTANTS OF MYCOBACTERIUM-AVIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE HAPTEN; MASS-SPECTROMETRY; INTRACELLULARE; BIOSYNTHESIS; GLYCOLIPIDS; SMOOTH; INFECTION; VARIANTS; COMPLEX; ACIDS	Toward studying the genetics, biosynthesis, and roles in the pathogenesis of the dominant surface glycopeptidolipid antigens of Mycobacterium avium, rough colony variants of M. avium serovar 2 were picked, cultured in quantity, and their lipid composition examined. Two of the rough (Rg) variants, Rg-3 and Rg-4, were devoid of glycopeptidolipids or any more elemental structures and thus were similar to those described previously. Two others, Rg-0 and Rg-1, each contained two novel lipopeptides, devoid of any of the carbohydrate substituents that confer serotypic activity on the glycopeptidolipids. The application of gas chromatography, fast atom bombardment-mass spectrometry and H-1 NMR to lipopeptide I established the structure C32:2-beta-OH-fatty acyl-D-Phe-D-allo-Thr-D-Ala-L-alaninol. Lipopeptide II represented a minor variation of this structure: C32:1-beta-OH-fatty acyl-D-Phe-D-allo-Thr-D-Ala-L-alaninol. These newly discovered lipopeptides are identical to the fatty acyl-tripeptide-amino alcohol ''core'' component of the glycopeptidolipids of the M. avium complex, and thus the Rg-0 and Rg-1 variants represent a form of ''deep rough'' mutation in M. avium. Separately, we report that these rough variants of M. avium differ genetically from the smooth, virulent form by major deletions of portions of the genes responsible for glycopeptidolipid synthesis (Belisle, J. T., Klaczkiewicz, K., Brennan, P. J., Jacobs, W. R., Jr., and Inamine, J. M. (1993) J. Biol. Chem. 268, 10517-10523). The isolation of different sets of spontaneous mutants of M. avium differentially defective in the capacity to synthesize glycopeptidolipids provides the means to explore their biosynthesis and roles in opportunistic pathogenesis.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA	Colorado State University			Belisle, John T/B-8944-2017; McNeil, Michael/G-3325-2019	Belisle, John T/0000-0002-2539-2798; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, U01AI030189, R37AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357, AI 30189] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARROW WW, 1991, RES MICROBIOL, V142, P427, DOI 10.1016/0923-2508(91)90115-Q; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; BARROW WW, 1980, J BACTERIOL, V144, P814, DOI 10.1128/JB.144.2.814-822.1980; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; BELISLE JT, 1993, J BIOL CHEM, V268, P10517; BOZIC CM, 1988, J BIOL CHEM, V263, P14984; BRENNAN PJ, 1979, J BIOL CHEM, V254, P4205; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; BRENNAN PJ, 1984, MICROBIOLOGY 1984, P366; BROWNBACK PE, 1988, INFECT IMMUN, V56, P1044, DOI 10.1128/IAI.56.5.1044-1050.1988; CAMPHAUSEN RT, 1986, J BACTERIOL, V168, P660, DOI 10.1128/jb.168.2.660-667.1986; COHN ML, 1968, AM REV RESPIR DIS, V98, P295; DAVID HL, 1988, CURR MICROBIOL, V17, P61, DOI 10.1007/BF01568787; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREGNAN GB, 1962, J BACTERIOL, V83, P828, DOI 10.1128/JB.83.4.828-836.1962; Frehel C, 1989, Acta Leprol, V7 Suppl 1, P173; FREHEL C, 1986, ANN INST PASTEUR MIC, V137B, P239, DOI 10.1016/S0769-2609(86)80115-6; GHUYSEN JM, 1977, CELL SURF REV, V4, P463; Goren M. B., 1979, TUBERCULOSIS, P63; GULIG PA, 1983, INFECT IMMUN, V42, P728; HITCHCOCK PJ, 1986, J BACTERIOL, V166, P699, DOI 10.1128/jb.166.3.699-705.1986; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1337; HUASEK P, 1975, J CHROMATOGR, V113, P139; JARDINE I, 1989, ANAL CHEM, V61, P416, DOI 10.1021/ac00180a008; JOHNSON RS, 1987, BIOCHEMISTRY-US, V26, P1209, DOI 10.1021/bi00379a001; LAMBERT MA, 1983, J CLIN MICROBIOL, V18, P1370, DOI 10.1128/JCM.18.6.1370-1377.1983; LUDERITZ O, 1966, ANGEW CHEM INT EDIT, V5, P198, DOI 10.1002/anie.196601981; MACKENZIE SL, 1977, J CHROMATOGR, V132, P485, DOI 10.1016/S0021-9673(00)82912-X; MAKELA PH, 1984, CHEM ENDOTOXIN, V41, P59; MCNEIL M, 1987, J BIOL CHEM, V262, P2630; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MOEHRING JM, 1965, AM REV RESPIR DIS, V92, P704; MORRISON DC, 1983, REV INFECT DIS S4, V5, P733; PERLMAN D, 1971, ANNU REV BIOCHEM, V40, P449, DOI 10.1146/annurev.bi.40.070171.002313; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; RASTOGI N, 1989, ZBL BAKT-INT J MED M, V270, P345; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIVIERE M, 1991, J BIOL CHEM, V266, P9057; SCHAEFER WB, 1970, AM REV RESPIR DIS, V102, P499; SCHMIDT G, 1968, ZENTRALBL BAKTERIO A, V209, P483; TASSELL SK, 1992, INFECT IMMUN, V60, P706, DOI 10.1128/IAI.60.2.706-711.1992; TERELETSKY MJ, 1983, INFECT IMMUN, V41, P1312, DOI 10.1128/IAI.41.3.1312-1321.1983; TSUYUGUCHI I, 1988, CHEST, V94, P822, DOI 10.1378/chest.94.4.822; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; WATSON SR, 1980, IMMUNOLOGY, V39, P367; WRIGHT ER, 1991, 91ST GEN M AM SOC MI	48	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10510	10516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486703				2022-12-25	WOS:A1993LB80000077
J	HA, KS; EXTON, JH				HA, KS; EXTON, JH			DIFFERENTIAL TRANSLOCATION OF PROTEIN-KINASE-C ISOZYMES BY THROMBIN AND PLATELET-DERIVED GROWTH-FACTOR - A POSSIBLE FUNCTION FOR PHOSPHATIDYLCHOLINE-DERIVED DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-SPECIES ANALYSIS; ALPHA-THROMBIN; STIMULATED FIBROBLASTS; CULTURED FIBROBLASTS; DNA-SYNTHESIS; CA-2+ INFLUX; 1,2-DIACYLGLYCEROL; HYDROLYSIS; CELLS; ACCUMULATION	The translocation of protein kinase C (PKC) fro the cytosolic to the particulate fraction in IIC9 fibro blasts has been studied to define the functions of 1,2-diacylglycerol (DAG) derived from the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylcholine (PC). Alpha-thrombin caused a biphasic change in DAG, with two peaks at 15-60 s and 5-15 min, derived from PIP2 and PC, respectively, while platelet-derived growth factor (PDGF) induced a monophasic DAG increase from PC at 5-15 min. Alpha-thrombin also induced a rapid, but transient, increase of inositol 1,4,5-trisphosphate and cytosolic Ca2+, whereas PDGF did not. Three PKC isozymes, alpha, epsilon, and zeta, were identified by Western blotting in IIC9 cells and were mainly localized in the cytosol. A fraction of cytosolic PKC alpha was rapidly translocated by alpha-thrombin at 15 s, but its membrane association was lost within 1 min. PKC epsilon was also rapidly translocated; however, its membrane association was sustained for almost 60 min. PKC zeta was not translocated by alpha-thrombin or phorbol 12-myristate 13-acetate. PDGF translocated PKC epsilon at 5 min but had little effect at 15 s and did not translocate PKC alpha or zeta. Incubation with Bacillus cereus PC- or phosphatidylinositol-specific phospholipase C, which increased DAG but not phosphatidic acid, stimulated translocation of PKC epsilon, but not PKC alpha or zeta. Addition of chelators to inhibit the rise in intracellular Ca2+ largely blocked PKC alpha translocation induced by alpha-thrombin but had no effect on PKC epsilon translocation. Addition of ionomycin allowed alpha-thrombin to induce PKC alpha translocation at 5 min. PKC alpha translocation was mimicked by 1,2-dioctanoylglycerol plus ionomycin, but not by either alone. On the other hand, PKC epsilon was translocated by the DAG alone. These results support the conclusion that PIP2 hydrolysis activates both PKC alpha and epsilon at 15 s, whereas PC hydrolysis activates only PKC epsilon at 5 min. The differential activation at 5 min can be attributed to the failure of PC hydrolysis to increase Ca2+ and not to a difference in the molecular species of DAG derived from the phospholipids.	VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University				Ha, Kwon-Soo/0000-0002-4219-1787	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40919] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA Y, 1990, J BIOL CHEM, V265, P354; AUGERT G, 1989, J BIOL CHEM, V264, P21689; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BORNER C, 1992, J BIOL CHEM, V267, P12892; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; EXTON JH, 1990, J BIOL CHEM, V265, P1; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GRINDLING KK, 1986, J BIOL CHEM, V261, P5901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HO AK, 1988, J BIOL CHEM, V263, P9292; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEE C, 1991, J BIOL CHEM, V266, P22837; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PESSIN MS, 1991, CELL REGUL, V2, P383, DOI 10.1091/mbc.2.5.383; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; RABEN DM, 1990, J CELL BIOCHEM, V44, P117, DOI 10.1002/jcb.240440206; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WOLF M, 1985, J BIOL CHEM, V260, P5718; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	46	204	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10534	10539						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486706				2022-12-25	WOS:A1993LB80000080
J	IKEDA, M; OGATA, F; CURTIS, SW; LUBAHN, DB; FRENCH, FS; WILSON, EM; KORACH, KS				IKEDA, M; OGATA, F; CURTIS, SW; LUBAHN, DB; FRENCH, FS; WILSON, EM; KORACH, KS			CHARACTERIZATION OF THE DNA-BINDING DOMAIN OF THE MOUSE UTERINE ESTROGEN-RECEPTOR USING SITE-SPECIFIC POLYCLONAL ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; DEOXYRIBONUCLEIC-ACID; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; STEROID-RECEPTORS; COMPLEXES; FORM; SUPERFAMILY; ESTRADIOL	The DNA-binding domain of the mouse uterine estrogen receptor (ER) was characterized using site-specific polyclonal antibodies. The peptides used as antigens have sequences corresponding to amino acids 185-199 and 227-245, the two zinc finger regions of the DNA-binding domain of the human ER, and produced antisera designated A-1542 and A-1554, respectively. Mouse uterine nuclear ER and salt-activated 4 S cytosol receptor, as well as 8 S untransformed cytosol receptor, were observed to react with the antisera by Western blot and sucrose density gradient centrifugation analyses indicating that the DNA-binding domain of the 8 S cytosol receptor is not completely masked by heat shock protein 90 or other proteins. Only A-1554 detected a nuclear-specific doublet form of the ER on Western blot analysis. In a gel shift assay, neither antisera altered the pattern of the nuclear ER interaction with the vitellogenin A2 estrogen response element (VRE). In contrast, antiserum A-1554 partially shifted the 8 S cytosol receptor-VRE complex. This concurs with mutational analysis and x-ray crystallography studies with the human ER that have shown that the second finger is not in contact with the DNA. The results of the gel shift assay were confirmed by sucrose density gradient analysis using the same buffer conditions. The nuclear receptor-VRE complex did not react with either antisera, suggesting that when the dimeric nuclear receptor form binds the VRE, the specific receptor epitopes involved with the DNA binding may be blocked and unable to bind the antisera. The cytosol receptor-VRE complex reacted only partially with the second finger antisera A-1554, suggesting that on receptor monomers the second finger epitope is not completely blocked by DNA binding or dimer formation.	NIEHS,REPROD & DEV TOXICOL LAB,RECEPTOR BIOL SECT,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,SCH MED,REPROD BIOL LAB,CHAPEL HILL,NC 27514	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Korach, Kenneth/0000-0002-7765-418X	NICHD NIH HHS [HD16910, HD04466, P30-HD18968] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R37HD004466, R01HD016910, R01HD004466, R37HD016910] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; EDWARDS DP, 1991, STEROIDS, V56, P271, DOI 10.1016/0039-128X(91)90046-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOLDING TS, 1988, P NATL ACAD SCI USA, V85, P69, DOI 10.1073/pnas.85.1.69; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HORIGOME T, 1987, ENDOCRINOLOGY, V121, P2099; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; JENSEN EV, 1973, SCIENCE, V182, P126, DOI 10.1126/science.182.4108.126; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAISH A, 1989, ENDOCRINOLOGY, V125, P172, DOI 10.1210/endo-125-1-172; TRAISH AM, 1990, STEROIDS, V55, P551, DOI 10.1016/0039-128X(90)90051-C; TRAISH AM, 1990, STEROIDS, V55, P196, DOI 10.1016/0039-128X(90)90017-6; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; WILSON EM, 1988, MOL ENDOCRINOL, V2, P1018, DOI 10.1210/mend-2-11-1018	34	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10296	10302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486692				2022-12-25	WOS:A1993LB80000051
J	YAMADA, T; MATSUSHIMA, M; INAKA, K; OHKUBO, T; UYEDA, A; MAEDA, T; TITANI, K; SEKIGUCHI, K; KIKUCHI, M				YAMADA, T; MATSUSHIMA, M; INAKA, K; OHKUBO, T; UYEDA, A; MAEDA, T; TITANI, K; SEKIGUCHI, K; KIKUCHI, M			STRUCTURAL AND FUNCTIONAL ANALYSES OF THE ARG-GLY-ASP SEQUENCE INTRODUCED INTO HUMAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SACCHAROMYCES-CEREVISIAE; CELL-ADHESION; PROTEIN; FIBRONECTIN; SECRETION; CHAIN; SITE; INTEGRINS; DOMAIN	To determine the functional conformation of the Arg-Gly-Asp (RGD) sequence, we have constructed mutant proteins by inserting 4-12 amino acid residues from the RGD region of human fibronectin between Val74 and Asn75 of human lysozyme. RGDS-, GRGDSP-, TGRGDSPA-, VTGRGDSPAS-, and AVTGRGDS-PASS- introduced mutant lysozymes were expressed in yeast, purified, and designated as RGD4, -6, -8, -10, and -12, respectively. Using baby hamster kidney cells, RGD8, RGD10, and RGD12 were shown to possess high cell adhesion activity nearly equal to 10% of human vitronectin activity. RGD4 and RGD6 exhibited somewhat lower cell adhesion activity. The activities of these mutant proteins were inhibited by the addition of either GRGDSP peptide or polyclonal antibody against vitronectin receptor, as was the case for the vitronectin activity. The results suggest that the cell adhesion signals are transduced to cells through the interaction with the vitronectin receptor. The three-dimensional structures of RGD4 and RGD8 were determined at 1.8-angstrom resolution by x-ray crystallography. A model of the inserted region in RGD4 could be built in the electron density map, but the positions of the preceding residues, Ala73-Val74, were uncertain. The inserted region in RGD8 did not demonstrate continuous electron densities. The results suggest that these RGD sequence-containing regions are highly flexible and that such flexibility could allow the conformation of the RGD regions to be induced to fit into the binding pocket of the integrin receptor.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS,TOYOAKE,AICHI 47011,JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,IZUMI,OSAKA 59002,JAPAN	Fujita Health University	KIKUCHI, M (corresponding author), PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN.							ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; HEMLER ME, 1991, RECEPTORS EXTRACELLU, P255; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INAKA K, 1991, J BIOL CHEM, V266, P12599; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAEDA T, 1989, J BIOL CHEM, V264, P15165; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OHKUBO T, 1991, J BIOCHEM-TOKYO, V110, P1022, DOI 10.1093/oxfordjournals.jbchem.a123672; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	24	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10588	10592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486712				2022-12-25	WOS:A1993LB80000088
J	CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC				CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC			STABILIZED P53 FACILITATES ANEUPLOID CLONAL DIVERGENCE IN COLORECTAL-CANCER	ONCOGENE			English	Note							MUTATIONS; TUMORS; TUMORIGENESIS; EXPRESSION; ADENOMAS; MODEL	Mutations in the p53 tumour suppressor gene are amongst the most frequent genetic abnormalities acquired in tumours. Recent studies in vitro suggest that mutant p53 destabilises the genome and facilitates development of aneuploidy. Here, in a study of 83 colorectal carcinomas, we demonstrate that alterations in p53 (detected by immunocytochemical stabilisation) precede and apparently facilitate divergence of aneuploid sub-clones. Aneuploidy in these tumours (but not those with normal p53) is predominantly in the subtetraploid range, suggesting that endoreduplication is important in its origin. This association with a specific phase of carcinoma progression is not shared by other commonly acquired genetic abnormalities in these tumours. These observations highlight the critical role of p53 in the regulation of abnormal chromosome replication and afford an explanation for the association between p53 abnormalities, aneuploidy and biological aggression in cancer.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; GEN INFIRM,DEPT HISTOPATHOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Edinburgh; Leeds General Infirmary				Purdie, Colin/0000-0002-1258-4010				AHSTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BODNER SM, 1992, ONCOGENE, V7, P743; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDLANDER ML, 1984, J CLIN PATHOL, V37, P961, DOI 10.1136/jcp.37.9.961; FRITSCHE M, 1993, ONCOGENE, V8, P307; GIARETTI W, 1991, CANCER, V67, P1921, DOI 10.1002/1097-0142(19910401)67:7<1921::AID-CNCR2820670717>3.0.CO;2-X; HIDDEMANN W, 1986, CANCER, V58, P258, DOI 10.1002/1097-0142(19860715)58:2<258::AID-CNCR2820580210>3.0.CO;2-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS LR, 1987, J CLIN PATHOL, V40, P26, DOI 10.1136/jcp.40.1.26; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1986, BRIT J CANCER, V53, P477, DOI 10.1038/bjc.1986.75; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VANDENINGH HF, 1985, CANCER RES, V45, P3392; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	137	137	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1397	1401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479757				2022-12-25	WOS:A1993KY32800035
J	CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC				CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC			DELETION MAPPING IN COLORECTAL-CANCER OF A PUTATIVE TUMOR SUPPRESSOR GENE IN 8P22-P21.3	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; POLYMORPHISM; CARCINOMAS; CHROMOSOME-17; LOCUS; PCR	Although previous studies of acquired loss of heterozygosity (LOH) in colorectal tumours have suggested that a tumour suppressor gene may lie within the short arm of chromosome 8, its precise localisation remains to be determined. To obtain a more accurate positional map 120 colorectal cancers were examined with eight chromosome 8 polymorphic markers comprising both restriction fragment length polymorphisms and microsatellite polymorphisms based on (CA)n repeats. 91 cases were informative and LOH was detected in 47 (51%). The markers most commonly sited within the lost region mapped to the lipoprotein lipase gene (LPL) at chromosome 8p22. From study of tumours showing break-points within 8p, a common region of deletion was established extending centromerically from LPL to the ankyrin 1 gene (ANK1) which is mapped to 8p21.1-11.2. This overlaps with common deleted regions observed in other studies of colorectal tumours (8p23.1-p21.3) and bladder tumours (8p21-q11.2). Taken together, the results in colorectal cancer delineate a region in 8p22-p21.3 where the putative tumour suppressor gene must lie. The chromosome 8p deletions appear to be independent of those involving 5q and 17p in the same tumours. No relationship was found between the presence of 8p deletion and site or stage of the tumour, or the sex or age of the patient at diagnosis.	MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND	University of Edinburgh	CUNNINGHAM, C (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				ARMOUR JAL, 1991, NUCLEIC ACIDS RES, V19, P6344; ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRUIN T, 1991, NUCLEIC ACIDS RES, V19, P6346, DOI 10.1093/nar/19.22.6346-a; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P437; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; HEIGHWAY J, 1992, NUCLEIC ACIDS RES, V20, P1160, DOI 10.1093/nar/20.5.1160; HEINZMANN C, 1987, NUCLEIC ACIDS RES, V15, P6763, DOI 10.1093/nar/15.16.6763; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KNOWLES MA, 1993, IN PRESS ONCOGENE; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCDANIEL T, 1991, NUCLEIC ACIDS RES, V19, P4796, DOI 10.1093/nar/19.17.4796-a; MIKI Y, 1991, JPN J CANCER RES, V82, P1003, DOI 10.1111/j.1349-7006.1991.tb01935.x; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1991, CYTOGENET CELL GENET, V58, P1	32	90	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479756				2022-12-25	WOS:A1993KY32800034
J	RAJ, NBK; PITHA, PM				RAJ, NBK; PITHA, PM			65-KDA PROTEIN BINDS TO DESTABILIZING SEQUENCES IN THE IFN-BETA MESSENGER-RNA CODING AND 3' UTR	FASEB JOURNAL			English	Article						IFN-BETA MESSENGER RNA; INSTABILITY DOMAINS; RNA BINDING PROTEINS	INTERFERON GENE-EXPRESSION; AU-RICH SEQUENCES; UNTRANSLATED REGION; DEGRADATION; TURNOVER; CELLS; IDENTIFICATION; DECAY; LYMPHOKINE; INDUCTION	The transient expression of human interferon (IFN-beta) gene in response to viral induction is regulated both at the transcriptional and posttranscriptional levels. The decrease in levels of IFN-beta mRNA, which requires protein synthesis, is due to transcriptional repression as well as a rapid turnover of beta mRNA. Previous studies have shown the presence of two destabilizing sequences, one in the 3' untranslated region (UTR) and the other in the coding region. We have shown in this study that the coding region destabilizing element resides in the 3' end of the coding region (+538 to +637) and that the degradation does not require the translation of IFN-beta mRNA through its coding region. In addition, we have identified three domains of 19, 20, and 29 nucleotides long that specifically bind a 65-kilodalton (kDa) cytoplasmic protein. One of the binding sites is in the 3' end of the coding region and the other two in the 3' UTR. All these regions are AU-rich and show considerable homology to each other. Interestingly, the levels of the 65-kDa protein was increased after poly rI.rC induction. We suggest that this 65-kDa protein is a component of the IFN-beta mRNA destabilizing complex or plays a role in the degradation of IFN-beta mRNA.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21231 USA	Johns Hopkins University	RAJ, NBK (corresponding author), JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21231 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19737] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; BONNIEU A, 1990, ONCOGENE, V5, P1585; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P4415, DOI 10.1073/pnas.74.10.4415; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND D W, 1989, New Biologist, V1, P121; Demaeyer E., 1988, INTERFERONS OTHER RE; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; MOSCA JD, 1992, J VIROL, V66, P3811, DOI 10.1128/JVI.66.6.3811-3822.1992; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PEPPEL K, 1991, J BIOL CHEM, V266, P6663; PITHA PM, 1983, A BENZON S GENE EXPR, V19, P477; RAJ NBK, 1985, J INTERFERON RES, V5, P493, DOI 10.1089/jir.1985.5.493; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; RAJ NBK, 1988, J INTERFERON RES, V8, P179, DOI 10.1089/jir.1988.8.179; REEVES R, 1990, PROG NUCLEIC ACID RE, V38, P241; SEHGAL PB, 1979, VIROLOGY, V92, P240, DOI 10.1016/0042-6822(79)90230-7; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SORENSON CM, 1991, NUCLEIC ACIDS RES, V19, P4459, DOI 10.1093/nar/19.16.4459; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	47	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1993	7	8					702	710		10.1096/fasebj.7.8.8500695	http://dx.doi.org/10.1096/fasebj.7.8.8500695			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500695				2022-12-25	WOS:A1993LE29000013
J	KAR, L; LAI, CS; WOLFF, CE; NETTESHEIM, D; SHERMAN, S; JOHNSON, ME				KAR, L; LAI, CS; WOLFF, CE; NETTESHEIM, D; SHERMAN, S; JOHNSON, ME			H-1 NMR-BASED DETERMINATION OF THE 3-DIMENSIONAL STRUCTURE OF THE HUMAN PLASMA FIBRONECTIN FRAGMENT CONTAINING INTER-CHAIN DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PROTEIN CONFORMATIONS; SPECTROSCOPY DATA; SEMINAL PLASMA; H-1-NMR	Human plasma fibronectin is a plasma glycoprotein that plays an important role in many biological processes. It consists of two identical 230-250-kDa subunits that are joined by two disulfide bonds near their carboxyl termini. Each subunit contains various binding domains composed of three types of homologous repeats. Recent work has determined the three-dimensional structures of various repeat fragments, but little is known about the three-dimensional structure of the carboxyl-terminal region. A recent NMR study of a plasmin-digested carboxyl-terminal inter-chain disulfide-linked heptapeptide dimer has proposed that the two subunits are arranged in an antiparallel fashion (An et al. (1992) Biochemistry 31, 9927-9933). We have now determined the three-dimensional structure for a substantial portion of a trypsin-digested inter-chain disulfide-linked 52-residue (6 kDa) fragment of the carboxyl-terminal of human plasma fibronectin (which includes the above-mentioned heptapeptide dimer) using two-dimensional NMR methods and a new strategy for NMR-based protein structure determination. The NMR data requires that the two chains in the dimer be linked in a symmetric, antiparallel arrangement. The resulting monomer conformation consists of two twisted or coiled segments, Thr3-Asn6 and Ile9-Phe12, connected by the Cys7-Pro8 residues in extended conformations, with the two monomer chains cross-linked at residues Cys7 and Cys11. The conformation of the heptapeptide dimer region differs substantially from the conformations proposed by An et al.	UNIV ILLINOIS,CTR PHARMACEUT BIOTECHNOL,POB 6998,CHICAGO,IL 60680; UNIV ILLINOIS,DEPT MEDICINAL CHEM & PHARMACOGNOSY,CHICAGO,IL 60680; MED COLL WISCONSIN,DEPT RADIOL,BIOPHYS SECT,MILWAUKEE,WI 53226; UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53201	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Milwaukee			Johnson, Michael E/F-5141-2013	Johnson, Michael E/0000-0002-8246-4081	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035719] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01008] Funding Source: Medline; NHLBI NIH HHS [HL45977] Funding Source: Medline; NIGMS NIH HHS [GM-35719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1987, ADV ENZYMOL RAMB, V59, P1; AN SSA, 1992, BIOCHEMISTRY-US, V31, P9927, DOI 10.1021/bi00156a010; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CONSTANTINE KL, 1992, BIOCHEM J, V283, P247, DOI 10.1042/bj2830247; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GARCIAPARDO A, 1984, BIOCHEM BIOPH RES CO, V120, P1015, DOI 10.1016/S0006-291X(84)80208-9; Hoffmann-Ostenhof O., 1974, PURE APPL CHEM, V40, P291; HOLLAND SK, 1987, EMBO J, V6, P1875, DOI 10.1002/j.1460-2075.1987.tb02446.x; HORMANN H, 1982, KLIN WOCHENSCHR, V60, P1265, DOI 10.1007/BF01727483; Hynes RO, 1990, FIBRONECTINS; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LARIVE CK, 1992, J AM CHEM SOC, V114, P7331, DOI 10.1021/ja00045a001; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Mosher DF, 1989, FIBRONECTIN; NERDAL W, 1988, J MOL BIOL, V201, P717, DOI 10.1016/0022-2836(88)90469-X; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; SHERMAN SA, 1987, J BIOMOL STRUCT DYN, V4, P869, DOI 10.1080/07391102.1987.10507684; SHERMAN SA, 1988, J BIOMOL STRUCT DYN, V5, P785, DOI 10.1080/07391102.1988.10506427; SHERMAN SA, 1991, PROTEINS : STRUCTURE, DYNAMICS AND DESIGN, P62; SHERMAN SA, 1993, PROG BIOPHYS MOL BIO, V59, P285, DOI 10.1016/0079-6107(93)90003-3; SHERMAN SA, 1992, J MAGN RESON, V966, P457; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VUENTO M, 1980, H-S Z PHYSIOL CHEM, V361, P1453; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; WUTHRICH K, 1989, SCIENCE, V243, P45, DOI 10.1126/science.2911719; Wuthrich K, 1976, NMR BIOL RES PEPTIDE	34	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8580	8589						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473304				2022-12-25	WOS:A1993KX81100034
J	VYSOTCHIN, A; MEDVED, LV; INGHAM, KC				VYSOTCHIN, A; MEDVED, LV; INGHAM, KC			DOMAIN-STRUCTURE AND DOMAIN-DOMAIN INTERACTIONS IN HUMAN COAGULATION FACTOR-IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GAMMA-CARBOXYGLUTAMIC ACID; TISSUE PLASMINOGEN-ACTIVATOR; BOVINE FACTOR-IX; BLOOD-COAGULATION; PROTHROMBIN FRAGMENT-1; CALCIUM-BINDING; FACTOR-X; CHRISTMAS FACTOR; CA2+ BINDING	Coagulation factor IX has the modular composition Gla-(EGF)2-SP, where Gla, EGF, and SP represent the gamma-carboxy-Glu-rich, epidermal growth factor-like, and serine protease modules, respectively. The protein melts in two distinct temperature regions. The SP module melts at lower temperature between 42 and 55-degrees-C, depending on the pH, with irreversible loss of esterolytic activity. The endotherm corresponding to this transition is readily described by a two-state transition indicating the melting of a single cooperative unit. A thrombin-generated 12-kDa fragment representing the COOH-terminal half of the SP module and a 45-kDa fragment containing the NH2-terminal half of the SP module and the rest of the molecule can be separated by exclusion chromatography in 3 M urea and recombined in its absence. Both fragments retain a compact structure as evidenced by melting transitions near 60-degrees-C at neutral pH. This indicates that the SP module contains two independently folded domains that strongly interact with each other and seem to merge into one cooperative unit in the intact protein. At low pH at high temperature a second peak appears which is also observed in a 19-kDa fragment containing the EGF modules. Thermodynamic analysis of this second peak showed that the two EGF modules are independently folded and provided evidence for a weak interaction between them. Fluorescence and CD measurements indicated that the secondary structure of the isolated 6-kDa Gla fragment is substantially increased in the presence of Ca2+. The Ca2+-loaded Gla fragment undergoes a sigmoidal unfolding transition as revealed by fluorescence and CD measurements. This same transition in a 25-kDa Gla-(EGF)2 fragment was stabilized by more than 10-degrees-C, indicating a strong interaction between the Ca2+-loaded Gla and EGF domains. Thus, factor IX consists of five independently folded interacting domains.	AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, J BIOL CHEM, V267, P8571; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BARON M, 1992, PROTEIN SCI, V1, P81; BILTONEN RL, 1978, CRC CR REV BIOCH MOL, V5, P85, DOI 10.3109/07388557809148191; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1987, FEBS LETT, V224, P97, DOI 10.1016/0014-5793(87)80429-5; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KISIEL W, 1985, BLOOD, V66, P1302; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; MEDVED LV, 1983, FEBS LETT, V160, P291, DOI 10.1016/0014-5793(83)80985-5; MEDVED LV, 1989, BIOCHEMISTRY-US, V28, P5408, DOI 10.1021/bi00439a014; MENACHE D, 1984, BLOOD, V64, P1220; MITCHELL GA, 1978, THROMB RES, V13, P47, DOI 10.1016/0049-3848(78)90108-1; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; PACE CN, 1988, J BIOL CHEM, V263, P11820; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; THARAKAN J, 1990, VOX SANG, V58, P21, DOI 10.1111/j.1423-0410.1990.tb02050.x; THOMPSON AR, 1986, BLOOD, V67, P565; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; TSALKOVA TN, 1980, BIOCHIM BIOPHYS ACTA, V624, P196, DOI 10.1016/0005-2795(80)90238-X; ULLNER M, 1992, BIOCHEMISTRY-US, V31, P5974, DOI 10.1021/bi00141a004	50	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8436	8446						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473287				2022-12-25	WOS:A1993KX81100014
J	YE, SQ; REARDON, CA; GETZ, GS				YE, SQ; REARDON, CA; GETZ, GS			INHIBITION OF APOLIPOPROTEIN-E DEGRADATION IN A POST-GOLGI COMPARTMENT BY A CYSTEINE PROTEASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN GRANULOSA-CELLS; LOW-DENSITY LIPOPROTEIN; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; CHOLESTEROL TRANSPORT; ENDOPLASMIC-RETICULUM; NEUTRAL PROTEASE; E GENE; CALCIUM; LIVER; EXPRESSION	In our prior studies on lipoprotein stimulation of apolipoprotein E (apoE) secretion in HepG2 cells, it became clear that a proportion of the newly synthesized apoE was degraded intracellularly (Ye, S. Q., Olson, L. M., Reardon, C. A., and Getz, G. S. (1992) J. Biol. Chem. 267, 21961-21966). The present study was designed to determine the nature of the proteases and the intracellular sites involved in newly synthesized apoE degradation. The effect of seven protease inhibitors on total apoE levels was examined. Only N-acetyl-leucyl-leucyl-norleucinal (ALLN), a cysteine protease inhibitor, significantly blocked apoE degradation in HepG2 cells. The amount of total apoE from cells chased with ALLN for 4 h was increased by 1.58 +/- 0.05-fold relative to the controls (n = 11, p < 0.01). ALLN extended the half-life of apoE from 2.61 h to 4.38 h (p < 0.01). This effect occurs in a post-Golgi compartment since in the presence of brefeldin A, ALLN had no effect on intracellular apoE levels. Chloroquine and NH4Cl significantly reduced apoE degradation; however, ALLN plus either of these reagents appear to have an additive effect. The amount of apoE in cells chased in Ca2+-free medium was significantly higher than that in cells chased in Ca2+-containing medium (1.70 +/- 0.07-fold, n = 6, p < 0.01). ALLN plus Ca2+-free medium had no additive effect. ALLN had no significant influence on the degradation of albumin but had a similar effect on transfected apoE in Chinese hamster ovary cells. Overall, these data suggest that apoE may be degraded in a post-Golgi compartment of HepG2 and Chinese hamster ovary cells by lysosomal enzymes and cytosolic Ca2+-dependent cysteine proteases. ALLN inhibits the latter.	UNIV CHICAGO,DEPT PATHOL,MC 6079,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NHLBI NIH HHS [HL 15062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMITAY R, 1992, J BIOL CHEM, V267, P20694; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DORY L, 1991, J LIPID RES, V32, P783; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ERIKSON SK, 1986, J LIPID RES, V27, P875; GRAIG WY, 1988, J BIOL CHEM, V263, P13880; HAY R, 1979, J LIPID RES, V20, P334; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUI DY, 1981, J BIOL CHEM, V256, P5646; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INOUE S, 1991, J BIOL CHEM, V266, P13311; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1989, J LIPID RES, V30, P1055; MENJU M, 1989, J BIOCHEM-TOKYO, V106, P505, DOI 10.1093/oxfordjournals.jbchem.a122882; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NISHIURA I, 1978, J BIOCHEM-TOKYO, V84, P1657, DOI 10.1093/oxfordjournals.jbchem.a132296; ODA K, 1992, J BIOL CHEM, V267, P17465; ORCI L, 1991, CELL, V64, P1183; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; Sambrook J, 1989, MOL CLONING LABORATO; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHORE VG, 1973, BIOCHEMISTRY-US, V12, P502, DOI 10.1021/bi00727a022; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WYNE KL, 1989, J BIOL CHEM, V264, P981; YE SQ, 1992, J BIOL CHEM, V267, P21961	43	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8497	8502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473293				2022-12-25	WOS:A1993KX81100021
J	KASTURI, R; VASULKA, C; JOHNSON, JD				KASTURI, R; VASULKA, C; JOHNSON, JD			CA2+, CALDESMON, AND MYOSIN LIGHT CHAIN KINASE EXCHANGE WITH CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW FLUORESCENCE; WHEAT-GERM CALMODULIN; AMINO-ACID-SEQUENCE; SMOOTH-MUSCLE; MOLECULAR-WEIGHT; PROTEIN-KINASE; BINDING; CALCIUM; PHOSPHORYLATION; PURIFICATION	Wheat calmodulin (CaM) was labeled at Cys-27 with the sulfhydryl-specific fluorescent probe 2-(4'-maleimidoanilino)-naphthalene-6-sulfonic acid (MIANS), to form MIANS.CaM. In the presence of Ca2+, MIANS.CaM undergoes a large fluorescence increase when it binds myosin light chain kinase (MLCK) and caldesmon (CaD), but little fluorescence change when it binds CaM antagonists or Ca2+. MLCK associates with MIANS.CaM at a rate of 2.8 x 10(7) M-1 s-1 and dissociates at 0.031 s-1 (K(d) = 1.1 nM). Protein kinase A phosphorylation of MLCK (P-MLCK) produces a 3.5-fold decrease in its association rate with CaM and a 6-fold increase in its dissociation rate (K(d) = 23 nM). CaD associates with MIANS.CaM with a rate of 5.3 x 10(8) M-1 s-1 and dissociates at 57 s-1 (K(d) = 10(8) nM). EGTA disrupts the CaM.MLCK, CaM.P-MLCK, and the CaM.CaD complexes at rates of 3.5 s-1, 6.5 s-1, and 13.5 s-1, respectively. MLCK, therefore, dissociates from CaM more quickly by Ca2+ removal while the lower affinity CaD is dissociated more quickly by competition from higher affinity CaM target proteins than by Ca2+ removal. MLCK binding to CaM slowed Ca2+ dissociation from CaM's C-terminal Ca2+-binding sites from 30 s-1 to 6 s-1 while CaD had little effect on Ca2+ dissociation from these sites. During a Ca2+ transient, CaM could exchange with MLCK and CaD rapidly enough for these proteins to be directly involved in the contraction/relaxation cycle of smooth muscle.	OHIO STATE UNIV, MED CTR,DEPT MED BIOCHEM,333 HAMILTON HALL, 1645 NEIL AVE, COLUMBUS, OH 43210 USA	Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1982, CALMODULIN INTRACELL, P199; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CONTI MA, 1981, J BIOL CHEM, V256, P3178; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1986, MED RES REV, V6, P341, DOI 10.1002/med.2610060304; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Klee CB, 1985, CONTROL MANIPULATION, P131; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MALENCIK DA, 1989, BIOCHEMISTRY-US, V28, P8227, DOI 10.1021/bi00446a039; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MANN DM, 1989, J BIOL CHEM, V264, P2373; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; OLWIN BB, 1984, J BIOL CHEM, V259, P949; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; SOBUE K, 1988, J CELL BIOCHEM, V37, P317, DOI 10.1002/jcb.240370306; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SPARROW MP, 1981, FEBS LETT, V125, P141, DOI 10.1016/0014-5793(81)80704-1; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; STULL JT, 1986, ENZYMES, P113; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; TSURUTA H, 1990, BIOPHYS CHEM, V35, P75, DOI 10.1016/0301-4622(90)80062-C; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; YACKO MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P7, DOI 10.1016/0005-2736(91)90405-W; YAGI K, 1989, CALCIUM PROTEIN SIGN, P147; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; ZOT HG, 1990, J BIOL CHEM, V265, P14796	50	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7958	7964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463316				2022-12-25	WOS:A1993KW97900058
J	SHA, RS; KANE, CD; XU, ZH; BANASZAK, LJ; BERNLOHR, DA				SHA, RS; KANE, CD; XU, ZH; BANASZAK, LJ; BERNLOHR, DA			MODULATION OF LIGAND-BINDING AFFINITY OF THE ADIPOCYTE LIPID-BINDING PROTEIN BY SELECTIVE MUTATION - ANALYSIS INVITRO AND INSITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; ESCHERICHIA-COLI; MESSENGER-RNAS; RAT-HEART; PURIFICATION; CLONING; LIVER; EXPRESSION; MYELIN; CDNA	The crystal structure of the adipocyte lipid-binding protein (ALBP) with coordinated fatty acid shows the hydrophobic ligand bound within a water-filled central cavity with its carboxyl group engaged in a hydrogen bonding network involving, at least in part, the functional groups of residues R126 and Y128. We produced mutant forms of ALBP which altered these amino acids, expressed these in Escherichia coli as glutathione S-transferase (GST) fusion proteins, and examined their ligand-binding properties using the fluorescent fatty acids cis-parinaric acid (c-PA) and 12-(9-anthroyloxy)-oleate (12-AO). The wild-type and all mutated forms of GST-ALBP displayed similar binding affinities for 12-AO, with K(d,app) values ranging from 0.5 to 2.4 muM. The binding affinity of ALBP forms R126Q and Y128W for c-PA were reduced about 30-50-fold in comparison to GST-ALBP, while that for the double mutation R126L+Y128F was below the limits of detection. To determine if the hydrogen bonding system functioned in situ, Chinese hamster ovary (CHO) cell transfectants expressing wild-type ALBP demonstrated a moderate (1.5-2-fold) increase in the total rate of [H-3]oleate uptake and trafficking into the esterified lipid pools over that of untransfected cells, while the rate of [H-3]oleate uptake of the transfected CHOs expressing the R126L+Y128F mutation was identical to that of the control CHOs. In summary, these results suggest that the primary factor contributing to binding affinity of ALBP for fatty acids such as c-PA or oleic acid both in vitro and in situ is the hydrogen bonding network involving at least R126, Y128, and the lipid carboxyl group. However, a ligand with sufficiently large hydrophobic character such as 12-AO can bind in the absence of a functional carboxylate hydrogen bonding network, presumably due to stabilizing entropic interactions with other cavity atoms.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,1479 GORTNER AVE,ST PAUL,MN 55108; UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108; UNIV MINNESOTA,INST HUMAN GENET,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Kane, Christopher/C-8256-2019	Kane, Christopher/0000-0002-0469-1668	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BAXA CA, 1989, BIOCHEMISTRY-US, V28, P8683, DOI 10.1021/bi00448a003; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; BERNLOHR DA, 1984, P NATL ACAD SCI USA, V84, P1844; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; CHINANDER LL, 1989, J BIOL CHEM, V264, P19564; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KWOH TJ, 1988, NUCLEIC ACIDS RES, V16, P11489, DOI 10.1093/nar/16.24.11489; LOWE JB, 1985, J BIOL CHEM, V260, P3413; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MATARESE V, 1988, J BIOL CHEM, V263, P14544; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SAID B, 1984, J BIOL CHEM, V259, P1155; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UYEMURA K, 1984, NEUROCHEM RES, V9, P1509, DOI 10.1007/BF00964676; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1993, J BIOL CHEM, V268, P7874; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	29	84	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7885	7892						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463312				2022-12-25	WOS:A1993KW97900047
J	FRATTALI, AL; PESSIN, JE				FRATTALI, AL; PESSIN, JE			RELATIONSHIP BETWEEN ALPHA-SUBUNIT LIGAND OCCUPANCY AND BETA-SUBUNIT AUTOPHOSPHORYLATION IN INSULIN INSULIN-LIKE GROWTH FACTOR-I HYBRID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; BINDING-SITE; DEPENDENT COVALENT; STRUCTURAL BASIS; HEPATOMA-CELLS; PHOSPHORYLATION; SPECIFICITY; COMPLEX	Insulin receptor beta subunit autophosphorylation occurs in an intramolecular trans-reaction in which one beta subunit phosphorylates the adjacent beta subunit within an alpha2beta2 holoreceptor complex (Frattali, A. L., Treadway, J. L., and Pessin, J. E. (1992) J. Biol. Chem. 267, 19521-19528). To determine the spatial relationship between alpha subunit occupancy and beta subunit autophosphorylation, the vaccinia virus/bacteriophage T7 transient expression system was used to generate insulin/insulin-like growth factor (IGF)-1 hybrid receptors. The extent of hybrid receptor formation was proportional to the molar ratio of the insulin and IGF-1 receptor expression plasmids used for transfection of cultured fibroblasts. Insulin/IGF-1 hybrid receptors displayed high affinity binding for insulin and IGF-1 similar to that observed for homotypic insulin and IGF-1 receptors, respectively. As expected, insulin poorly competed for I-125-IGF-1 binding to the insulin/IGF-1 hybrid receptors compared with IGF-1. IGF-1, however, competed more efficiently than insulin for I-125-insulin binding, indicating interactions between the a subunit binding sites. Furthermore, insulin or IGF-1 stimulated the autophosphorylation of both beta subunits within wild type insulin/IGF-1 hybrid receptors. Ligand-stimulated autophosphorylation of two different mutant/wild type insulin/IGF-1 hybrid receptors also resulted in the labeling of each beta subunit independent of which alpha subunit was occupied with ligand. These data demonstrate that insulin/IGF-1 hybrid receptors bind both ligands with high affinity and that occupancy of either alpha subunit results in a series of intramolecular trans-autophosphorylation reactions between beta subunits.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK33823, DK25295, DK01822] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001822, R01DK033823, P30DK025295, R37DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; FELTZ SM, 1988, BIOCHEMISTRY-US, V27, P3234, DOI 10.1021/bi00409a017; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GAROFALO RS, 1992, J BIOL CHEM, V267, P11470; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OLSON TS, 1988, J BIOL CHEM, V263, P7342; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TREADWAY JL, 1991, P NATL ACAD SCI USA, V88, P214, DOI 10.1073/pnas.88.1.214; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	44	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7393	7400						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463272				2022-12-25	WOS:A1993KV14100081
J	MARINO, LR				MARINO, LR			CHARACTERIZATION OF THE MOUSE CARBONIC ANHYDRASE-II GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; TRANSCRIPTION FACTOR; ACTIVATION PROPERTIES; EXPRESSION; ELEMENTS; SEQUENCE; PROTEIN; CELLS; AP-2	This work characterizes a 250-base pair (bp) fragment of the mouse carbonic anhydrase II (CAII) gene as an efficient but not cell-specific promoter. This fragment contains multiple consensus cis regulatory regions that interact in a complex fashion to regulate transcriptional activity from the promoter. Truncated fragments of the 250-bp promoter retain transcriptional activity. The 90-bp 5' ''GC''-rich portion of the promoter can direct transcription independently from the consensus TATA box and also contains a silencer that diminishes transcription from the 3' 160-bp portion of the CAII promoter as well as from the SV40 promoter. There are two nonconsensus dual functioning Ap2-like elements on the promoter that are essential for core promoter activity and cAMP-mediated increases in transcription of the gene. A nuclear protein of approximately 65 kDa binds to these elements and is present in nuclear extracts of nonstimulated and forskolin-stimulated NIH-3T3 cells. I conclude that these non-consensus Ap2-like elements and their cognitive binding protein play a major role in the expression of the CAII gene.	UNIV MICHIGAN,MED CTR,CTR PEPTIDE HORMONE,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025983, K08HD000760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD25983, H08 HD00760] Funding Source: Medline; NIDDK NIH HHS [2P30 DK34933] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BOYER TG, 1990, J BIOL CHEM, V265, P20524; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; CAMPBELL VW, 1989, AM J PHYSIOL, V256, pG631, DOI 10.1152/ajpgi.1989.256.3.G631; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; EDWARDS Y, 1990, BIOCHEM SOC T, V18, P171, DOI 10.1042/bst0180171; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO LH, 1987, MOL CELL BIOL, V7, P4589, DOI 10.1128/MCB.7.12.4589; TAMURA T, 1991, FEBS LETT, V282, P87, DOI 10.1016/0014-5793(91)80450-H; VENTA PJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P195, DOI 10.1016/0167-4781(85)90006-5; VENTA PJ, 1985, J BIOL CHEM, V260, P2130; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	23	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7081	7089						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463242				2022-12-25	WOS:A1993KV14100042
J	MCLAUGHLIN, S; DIXON, JE				MCLAUGHLIN, S; DIXON, JE			ALTERNATIVE SPLICING GIVES RISE TO A NUCLEAR-PROTEIN TYROSINE PHOSPHATASE IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXPRESSION; CLONING; LOCALIZATION; SEQUENCE; HOMOLOGY; FAMILY; GENE	A novel Drosophila protein tyrosine phosphatase gene (dPTP61F) undergoes alternative splicing to encode two non-receptor-like proteins of 61,000 daltons. This splice selection occurs at the 3' end of the message, altering the carboxyl termini of the encoded proteins. These carboxyl-terminal sequences govern the targeting of each protein tyrosine phosphatase either to a cytoplasmic membrane or to the nucleus. The catalytic activity of the two protein products is indistinguishable, suggesting that substrate specificity is modulated by the protein's subcellular location.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; WALTHER CANC INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Walther Cancer Institute					PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DAVID M, 1993, J BIOL CHEM, V268, P6593; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FISHER EH, 1991, SCIENCE, V253, P401; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG YL, 1993, J BIOL CHEM, V268, P5899; WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	24	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6839	6842						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463208				2022-12-25	WOS:A1993KV14100005
J	TAN, XH; STOVER, DR; WALSH, KA				TAN, XH; STOVER, DR; WALSH, KA			DEMONSTRATION OF PROTEIN TYROSINE PHOSPHATASE-ACTIVITY IN THE 2ND OF 2 HOMOLOGOUS DOMAINS OF CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILY	It has been reported that alteration or deletion of critical residues within one of the two homologous protein tyrosine phosphatase (PTPase)-like domains of CD45 completely abolishes all activity, suggesting that only the more N-terminal domain is catalytically active. However, we now demonstrate, by two independent techniques, that the second (C-terminal) domain is also a viable phosphatase. Limited proteolysis by endoproteinase Lys-C or trypsin increased the phosphatase activity toward reduced, carboxymethylated, and maleylated lysozyme approximately 8-fold. A 50-kDa fragment, isolated by ion exchange chromatography, was found to be responsible for this activity. N-terminal sequencing revealed that this fragment includes less than half of the first phosphatase domain and most, if not all, of the second. In a second experiment, 109 residues, including the presumed catalytic region, were removed from domain I by site-directed mutagenesis. Expression of this construct in a mammalian cell line resulted in increased PTPase activity over non-transfected control cells. Isolation of the recombinant CD45 by immunoprecipitation and immunoaffinity chromatography revealed that it had phosphatase activity. Both of these experimental approaches demonstrate that the second conserved PTPase domain of CD45 is a functioning PTPase, but that external regulation may be required to express its activity in the context of the native molecule.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM15731, GM07270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HUNTER T, 1986, ENZYMES, V17, P191; ITOH M, 1992, J BIOL CHEM, V267, P12356; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNKEL TA, 1988, NUCLEIC ACIDS MOL BI, V2, P124; MULVIHILL E, 1988, Patent No. 39944; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WHITE MF, 1986, ENZYMES, V17, P247	24	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6835	6838						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463207				2022-12-25	WOS:A1993KV14100004
J	VANHILLE, B; RICHENER, H; EVANS, DB; GREEN, JR; BILBE, G				VANHILLE, B; RICHENER, H; EVANS, DB; GREEN, JR; BILBE, G			IDENTIFICATION OF 2 SUBUNIT A ISOFORMS OF THE VACUOLAR H+-ATPASE IN HUMAN OSTEOCLASTOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE KIDNEY; PROTON PUMP; HOMOLOGY; CHAIN; RNA	Subunit A is thought to be the main component of the catalytic site of the vacuolar-type H+-ATPase. Screening of a cDNA library made from human osteoclastoma tumor tissue revealed the presence of two isoforms of subunit A. HO68 is a cDNA of 3.1 kilobase pairs, corresponding to a mRNA of approximately 3.4 kilobases in osteoclastoma only, encoding a protein of 615 amino acids with a predicted molecular mass of 68177 Da. A second subtype, VA68, corresponding to a mRNA of approximately 4.8 kilobases was present in all tissues analyzed, and codes for a predicted protein of 617 residues and theoretical molecular mass of 68264 Da. These clones share homology with previously published subunit A sequences, and this, together with the tissue distribution of the mRNA, suggests there are ubiquitous (VA68-type) and tissue-specific (HO68-type) isoforms. HO68 shows the closest sequence homology (95% at the amino acid level) to subunit A of a proton-secreting vacuolar-type H+-ATPase located in the apical membrane of midgut goblet cells of tobacco hornworm larva (Manduca sexta). We propose that HO68 could correspond to an isoform of subunit A specific for a vacuolar-type H+-ATPase located in the osteoclast plasma membrane.			VANHILLE, B (corresponding author), CIBA GEIGY AG,DEPT MOLEC BIOL,DIV PHARMACEUT,RES DEPT,BIOTECHNOL,K681-403,CH-4002 BASEL,SWITZERLAND.							ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V253, P553; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403; CHAMBERS TJ, 1978, J PATHOL, V2, P126; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLUCK S, 1992, AM J MED SCI, V303, P134, DOI 10.1097/00000441-199202000-00016; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; MARUSHACK MM, 1992, AM J PHYSIOL, V263, pF171, DOI 10.1152/ajprenal.1992.263.1.F171; Moore M. J., 1993, RNA WORLD; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; PAN YX, 1991, FEBS LETT, V293, P89, DOI 10.1016/0014-5793(91)81158-5; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIH CK, 1988, MOL CELL BIOL, V263, P13994; STARKE T, 1991, Z NATURFORSCH C, V46, P613; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; ZWICKL M, 1990, J IMMUNOL METHODS, V130, P49, DOI 10.1016/0022-1759(90)90298-A	32	53	56	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7075	7080						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463241				2022-12-25	WOS:A1993KV14100041
J	WELLINGTON, SR; SPIEGELMAN, GB				WELLINGTON, SR; SPIEGELMAN, GB			THE KINETICS OF FORMATION OF COMPLEXES BETWEEN ESCHERICHIA-COLI RNA-POLYMERASE AND THE RRNB P1 AND P2 PROMOTERS OF BACILLUS-SUBTILIS - EFFECTS OF GUANOSINE TETRAPHOSPHATE ON SELECT STEPS OF TRANSCRIPTION INITIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; RATE-DEPENDENT REGULATION; NUCLEIC-ACID INTERACTIONS; LAMBDA-PRM PROMOTER; RIBOSOMAL-RNA; BACTERIOPHAGE-T7 DNA; GEL-ELECTROPHORESIS; STRINGENT CONTROL; HOLOENZYME; MECHANISM	The kinetics of formation and dissociation of heparin-resistant transcription initiation complexes between Escherichia coli RNA polymerase and the rrnB P1 and P2 promoters from Bacillus subtilis were investigated using a gel retardation assay. The results suggest that the formation of polymerase-promoter complexes proceeds by a three-step reaction mechanism. The bimolecular collision between free RNA polymerase and the promoter creates a heparin-sensitive complex, which then isomerizes to an initial, and then a subsequent, heparin-resistant complex. We propose that a sequential mechanism best describes the bimolecular collision and that the forward rate constants predominate in the overall rate of heparin-resistant complex formation. At 35-degrees-C, the association of polymerase with P1 and P2 was very rapid (k(a) = 1.5 - 2.1 x 10(8) M-1 s-1; k(f) greater-than-or-equal-to 0.56 s-1). Direct information on the formation of the closed and intermediate transcription complexes and indirect information on the formation of open complexes suggest that guanosine tetraphosphate did not differentially affect any step between growth rate-regulated and non-growth rate-regulated rRNA promoters by more than 2-fold.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,6174 UNIV BLVD,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia								ATKINSON T, 1984, OLIGONUCLEOTIDE SYNT, P70; BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P1697, DOI 10.1093/nar/12.3.1697; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUJARD H, 1987, RNA POLYM REGULATION, P95; Burgess R.R., 1987, RNA POLYM REGULATION, P3; CARPOUSIS AJ, 1982, J MOL BIOL, V157, P619, DOI 10.1016/0022-2836(82)90502-2; Castellan GW., 1983, PHYS CHEM, P221; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; DENEER HG, 1987, J BACTERIOL, V169, P995, DOI 10.1128/jb.169.3.995-1002.1987; DICKSON RR, 1989, J BACTERIOL, V171, P4862, DOI 10.1128/jb.171.9.4862-4870.1989; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GAAL T, 1989, J BACTERIOL, V171, P4852, DOI 10.1128/jb.171.9.4852-4861.1989; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; Ishihama A, 1986, Adv Biophys, V21, P163, DOI 10.1016/0065-227X(86)90021-3; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; LANGERT W, 1991, J BIOL CHEM, V266, P21608; LIERMOS, 1991, J MOL BIOL, V220, P555; LINDAHL L, 1986, ANNU REV GENET, V20, P297; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; LITTLE R, 1983, J BACTERIOL, V155, P1162, DOI 10.1128/JB.155.3.1162-1170.1983; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; MANGEL WF, 1974, J BIOL CHEM, V249, P2995; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCDANIEL DH, 1956, J PHYS CHEM-US, V60, P966, DOI 10.1021/j150541a035; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROSENBERG S, 1982, J MOL BIOL, V155, P31, DOI 10.1016/0022-2836(82)90490-9; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; Sambrook J, 1989, MOL CLONING LABORATO; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SHIH MC, 1983, P NATL ACAD SCI-BIOL, V80, P496, DOI 10.1073/pnas.80.2.496; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SINGER PT, 1988, J BIOL CHEM, V263, P4208; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STEWART GC, 1983, NUCLEIC ACIDS RES, V11, P6289, DOI 10.1093/nar/11.18.6289; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; WELLINGTON SR, 1991, BIOCHEM BIOPH RES CO, V179, P1107, DOI 10.1016/0006-291X(91)91934-5; WELLINGTON SR, 1991, THESIS U BRIT COLUMB	70	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7205	7214						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463256				2022-12-25	WOS:A1993KV14100059
J	EMANUEL, SL; PESTKA, S				EMANUEL, SL; PESTKA, S			HUMAN INTERFERON-ALPHA-A, INTERFERON-ALPHA-2, AND INTERFERON-ALPHA-2(ARG) GENES IN GENOMIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; HUMAN-LEUKOCYTE; NEUTRALIZING ANTIBODIES; CLINICAL-SIGNIFICANCE; MYELOGENOUS LEUKEMIA; AMPLIFICATION; FIBROBLAST; FREQUENCY; SEQUENCE	The frequency in human genomic DNA of three human interferon (IFN) alpha genes which differ from each other by a single base substitution was examined in 11 normal individuals. The polymerase chain reaction (PCR) was used to amplify the coding sequence for the Hu-IFN-alpha2, Hu-IFN-alphaA, and Hu-IFN-alpha2(Arg) sequences from genomic DNA. The PCR products were then cloned and individual clones were sequenced. PCR products were also analyzed by restriction endonuclease analysis for the IFN-alpha2 and IFN-alphaA genes by use of a HinfI site which is eliminated by the substitution of an A for a G in IFN-alphaA. The IFN-alphaA gene which was cloned from the myeloblastoid cell line KG-1 was not observed in any of the 201 clones sequenced from normal individuals or in the Namalwa cell line. It was detected in KG-1 cell genomic DNA where it represented 49% of the clones sequenced. Similarly the IFN-alpha2(Arg) gene was not detected in normal individuals or in the KG-1 cell line but only in the lymphoblastoid cell line from which it was cloned. In Namalwa cells the IFN-alpha2(Arg) sequence represented 35% of the clones sequenced while the IFN-alpha2 sequence comprised 59%. Therefore, both the IFN-alpha2 and IFN-alpha2(Arg) sequences represent alleles of the IFN-alpha2 gene.			EMANUEL, SL (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007403] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLF GR, 1991, BIOCHEM J, V276, P511, DOI 10.1042/bj2760511; ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CAVALIERI RL, 1977, P NATL ACAD SCI USA, V74, P3287, DOI 10.1073/pnas.74.8.3287; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW F, 1981, NUCLEIC ACIDS RES, V9, P2807, DOI 10.1093/nar/9.12.2807; COLAMONICI O, 1991, Journal of Interferon Research, V11, pS54; Desai M., 1992, Journal of Interferon Research, V12, pS138; DIAZ M O, 1991, Journal of Interferon Research, V11, pS85; DWORKINRASTL E, 1982, J INTERFERON RES, V2, P575, DOI 10.1089/jir.1982.2.575; FAMILLETTI PC, 1981, ANTIMICROB AGENTS CH, V20, P5, DOI 10.1128/AAC.20.1.5; FOON KA, 1986, AM J MED, V80, P351, DOI 10.1016/0002-9343(86)90705-9; FREUND M, 1989, BRIT J HAEMATOL, V72, P350, DOI 10.1111/j.1365-2141.1989.tb07715.x; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; GOEDDEL DV, 1989, Patent No. 4801685; GOEDDEL DV, 1982, Patent No. 811050673; GRANDER D, 1992, BLOOD, V79, P2076; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAVELL EA, 1975, P NATL ACAD SCI USA, V72, P2185, DOI 10.1073/pnas.72.6.2185; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; HOSOI H, 1992, 1992 P INT SOC STUD, P113; HOTTA K, 1988, J INTERFERON RES, V8, P51, DOI 10.1089/jir.1988.8.51; HOTTA K, 1986, METHOD ENZYMOL, V119, P481; HUBER C, 1985, ONCOLOGY-BASEL, V42, P7, DOI 10.1159/000226076; ITRI LM, 1987, CANCER, V59, P668, DOI 10.1002/1097-0142(19870201)59:3+<668::AID-CNCR2820591317>3.0.CO;2-J; JOHNSON BA, 1990, BIOTECHNIQUES, V8, P424; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LANGER JA, 1984, J INVEST DERMATOL, V83, P128; LAWN RM, 1981, P NATL ACAD SCI-BIOL, V78, P5435, DOI 10.1073/pnas.78.9.5435; MAEDA S, 1980, P NATL ACAD SCI-BIOL, V77, P7010, DOI 10.1073/pnas.77.12.7010; MAEDA S, 1981, P NATL ACAD SCI-BIOL, V78, P4648; Maniatis T., 1982, MOL CLONING; McCandliss R, 1981, Methods Enzymol, V79, P51; Moormeier J A, 1989, Leuk Lymphoma, V1, P43, DOI 10.3109/10428198909042457; NADKARNI JS, 1969, CANCER, V23, P64, DOI 10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M; OWERBACH D, 1981, P NATL ACAD SCI-BIOL, V78, P3123, DOI 10.1073/pnas.78.5.3123; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; Pestka S, 1981, Methods Enzymol, V78, P3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; PESTKA S, 1986, METHOD ENZYMOL, V119, P14; QUESADA JR, 1985, J CLIN ONCOL, V3, P1522, DOI 10.1200/JCO.1985.3.11.1522; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEIS RG, 1988, NEW ENGL J MED, V318, P1409, DOI 10.1056/NEJM198806023182201; STREULI M, 1980, SCIENCE, V209, P1343, DOI 10.1126/science.6158094; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRENT JM, 1982, P NATL ACAD SCI-BIOL, V79, P7809, DOI 10.1073/pnas.79.24.7809; VONWUSSOW P, 1987, J INTERFERON RES, V7, P680; ZOON KC, 1992, J BIOL CHEM, V267, P15210	53	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12565	12569						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509397				2022-12-25	WOS:A1993LG65800052
J	FALCONE, DJ; MCCAFFREY, TA; HAIMOVITZFRIEDMAN, A; VERGILIO, JA; NICHOLSON, AC				FALCONE, DJ; MCCAFFREY, TA; HAIMOVITZFRIEDMAN, A; VERGILIO, JA; NICHOLSON, AC			MACROPHAGE AND FOAM CELL RELEASE OF MATRIX-BOUND GROWTH-FACTORS - ROLE OF PLASMINOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; LOW-DENSITY LIPOPROTEINS; CAPILLARY ENDOTHELIAL-CELLS; HUMAN MONOCYTE-MACROPHAGES; FACTOR-LIKE PROTEIN; FACTOR-BETA; UROKINASE-TYPE; ATHEROSCLEROTIC LESIONS; BASEMENT-MEMBRANES	We have determined whether macrophage derived-foam cells, a prominent component of the atherosclerotic lesion, express more urokinase-type plasminogen activator (uPA) and whether their ability to generate plasmin stimulates the.release of matrix-bound growth factors. Steady state levels of uPA mRNA and both membrane and intracellular uPA activities were significantly increased in foam cells. When cultured on cell-derived matrices containing bound I-125-basic fibroblast growth factor (bFGF), both macrophage and foam cells released intact I-125-bFGF into their media. The release of I-125-bFGF by either cell was significantly enhanced in the presence of plasminogen. However, foam cells, which expressed more membrane uPA, released more I-125-bFGF than control cells. The release of matrix-bound bFGF was independent of heparanase activity, since neither macrophage nor foam cells degraded (SO4)-S-35-labeled heparan sulfate proteoglycans. In addition, media derived from foam cells cultured on cell-derived matrices in the presence of plasminogen had increased levels of transforming growth factor (TGF) beta activity as compared to cells grown in the absence of plasminogen. In contrast, plasminogen had no effect on TGF-beta activity recovered in the media of foam cells grown on plastic. Moreover, when macrophage were cultured on matrices containing bound I-125-TGF-beta, the release of labeled TGF-beta was increased in the presence of plasminogen. This is the first demonstration that foam cells can release two important growth regulators, bFGF and TGF-beta, from the extracellular matrix, and provides a mechanism by which macrophage and foam cells can stimulate atherosclerotic lesion development.	CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT RADIAT ONCOL, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	FALCONE, DJ (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT PATHOL C440, NEW YORK, NY 10021 USA.				NHLBI NIH HHS [HL-46403, HL-35724, HL-40819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035724, P01HL046403, R01HL040819] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; CHAPMAN HA, 1985, BIOCHEM J, V230, P109, DOI 10.1042/bj2300109; CHEIFETZ S, 1989, J BIOL CHEM, V264, P12025; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FALCONE DJ, 1984, J CELL BIOL, V99, P1266, DOI 10.1083/jcb.99.4.1266; FALCONE DJ, 1989, J CELL PHYSIOL, V140, P219, DOI 10.1002/jcp.1041400205; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOX PL, 1986, P NATL ACAD SCI USA, V83, P4774, DOI 10.1073/pnas.83.13.4774; FOX PL, 1987, J BIOL CHEM, V262, P6046; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GOLSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOWN AM, 1986, AM J PATHOL, V125, P191; HAIMOVITZFRIEDMAN A, 1991, BLOOD, V78, P789, DOI 10.1182/blood.V78.3.789.bloodjournal783789; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KELLEY JL, 1988, AM J PATHOL, V131, P539; KIRCHHEIMER JC, 1988, J IMMUNOL, V141, P4229; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MORTON K, 1989, CURR EYE RES, V8, P975, DOI 10.3109/02713688908997390; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAKSELA O, 1985, J CELL PHYSIOL, V122, P125, DOI 10.1002/jcp.1041220119; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SHECHTER I, 1981, J LIPID RES, V22, P63; SILVERSTEIN RL, 1988, J CLIN INVEST, V82, P1948, DOI 10.1172/JCI113814; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	79	119	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11951	11958						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505319				2022-12-25	WOS:A1993LF28400074
J	LI, ZP; BURKE, EP; FRANK, JS; BENNETT, V; PHILIPSON, KD				LI, ZP; BURKE, EP; FRANK, JS; BENNETT, V; PHILIPSON, KD			THE CARDIAC NA+-CA2+ EXCHANGER BINDS TO THE CYTOSKELETAL PROTEIN ANKYRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELLS; SPECTRIN; CHANNELS; CALCIUM; BRAIN	Na+-Ca2+ exchange is the major pathway of Ca2+ efflux during excitation-contraction coupling in cardiac muscle. The Na+-Ca2+ exchanger is present in cardiac transverse tubules with an apparent high density (Frank, J. S., Mottino, G., Reid, D., Molday, R. S., and Philipson, K. D. (1992) J. Cell Biol. 117, 337-345). The mechanism for this localization is unknown but may involve interactions with the cytoskeleton. In the present study, we examined the interaction of the Na+-Ca2+ exchanger with the cytoskeletal protein ankyrin. On immunoblots of isolated canine cardiac sarcolemma, an antibody raised against purified rabbit red blood cell-ankyrin (RBC-ankyrin) recognized a 220-kDa protein, which is the same size as RBC-ankyrin. Alkaline extraction of sarcolemma removed this protein. The Na+-Ca2+ exchange protein, purified from recombinant baculovirus-infected insect cells, bound I-125-labeled-RBC-ankyrin with a K(D) of 42 +/- 3 nm. I-125-RBC-ankyrin was co-precipitated by antibodies to the Na+-Ca2+ exchanger after preincubation with solubilized cardiac sarcolemma. Myocardial ankyrin could be localized to both surface and T-tubular sarcolemma by immunofluorescence techniques. These results demonstrate that the cardiac Na+-Ca2+ exchanger binds ankyrin with high affinity. This interaction may be important for localizing the Na+-Ca2+ exchanger to specific domains of the sarcolemma.	UNIV CALIF LOS ANGELES, SCH MED,CARDIOVASC RES LABS,MACDONALD BLDG,RM 3645, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90024 USA; DUKE UNIV, HOWARD HUGHES INST, DURHAM, NC 27710 USA; DUKE UNIV, DEPT BIOCHEM, DURHAM, NC 27710 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University; Howard Hughes Medical Institute; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028791, R01HL027821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029808, R37DK029808] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27821, HL28791] Funding Source: Medline; NIDDK NIH HHS [DK29808] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bennett V, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P647; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; KIEVAL RS, 1992, AM J PHYSIOL, V263, pC545, DOI 10.1152/ajpcell.1992.263.2.C545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LANGER GA, 1992, AM J PHYSIOL, V262, pC1149, DOI 10.1152/ajpcell.1992.262.5.C1149; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LI ZP, 1992, J BIOL CHEM, V267, P7828; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; PHILIPSON KD, 1990, CALCIUM HEART, P85; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307	23	109	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11489	11491						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505285				2022-12-25	WOS:A1993LF28400005
J	SIROIS, J; LEVY, LO; SIMMONS, DL; RICHARDS, JS				SIROIS, J; LEVY, LO; SIMMONS, DL; RICHARDS, JS			CHARACTERIZATION AND HORMONAL-REGULATION OF THE PROMOTER OF THE RAT PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 GENE IN GRANULOSA-CELLS - IDENTIFICATION OF FUNCTIONAL AND PROTEIN-BINDING REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; LUTEINIZING-HORMONE; COMPLEMENTARY-DNA; OVARIAN FOLLICLES; MAMMALIAN-CELLS; RECEPTOR GENE; G/H SYNTHASE; TRANSCRIPTION; CYCLOOXYGENASE; PURIFICATION	Prostaglandin endoperoxide synthase isoform 2 (PGS-2) mRNA and protein are transiently induced by gonadotropins in granulosa cells of preovulatory follicles prior to ovulation. To better understand the hormonal regulation of the rat PGS-2 (rPGS-2) gene in these cells, genomic clones containing rPGS-2 as well as up to 6 kilobases of 5'-flanking DNA were isolated by screening a rat liver genomic library with a labeled 5'-fragment of the mouse PGS-2 cDNA. Primer extension analysis using ovarian follicular mRNA identified the presence of a single rPGS-2 transcription initiation site located 144 nucleotides upstream of the ATG translation initiation codon. To test for promoter activity within the 5'-flanking region of the rPGS-2 gene, a genomic fragment, -2698/32 (1 = cap site), as well as a series of 5'-deletion mutants, were fused upstream of the chloramphenicol acetyltransferase (CAT) reporter gene and transfected into primary cultures of granulosa cells. Forskolin (7.5 muM), follicle-stimulating hormone (500 ng/ml) and luteinizing hormone (500 ng/ml) induced CAT activity following transfection with the -2698/32PGS.CAT, whereas gonadotropin-releasing hormone (10(-6) M) and interleukin-1beta (30 ng/ml) had no effect. Deletion mutants delineated the region spanning from -192 to -54 of the transcription start site to be essential for both basal and forskolin-regulated expression of the reporter gene. The same DNA fragment (-192/-54) exhibited specific binding to granulosa cell nuclear extract proteins as analyzed by electrophoretic mobility shift assays. Additional specific bands were observed in extracts prepared from granulosa cells exposed to an ovulatory dose of gonadotropin. Collectively, these results provide the first structural and functional evidence that the transcriptional regulation of the rat PGS-2 gene by gonadotropins and forskolin in granulosa cells involves 5'-flanking DNA sequences, specifically a region between -192 and -54 of the transcription initiation site.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602	Baylor College of Medicine; Brigham Young University					NCI NIH HHS [CA-55585] Funding Source: Medline; NICHD NIH HHS [HD-16229] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA055585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; KNOLL BJ, 1983, NUCLEIC ACIDS RES, V11, P6733, DOI 10.1093/nar/11.19.6733; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LEE SH, 1992, J BIOL CHEM, V267, P25934; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OONK RB, 1990, J BIOL CHEM, V265, P22392; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDS JS, 1993, OVARY; Sambrook J, 1989, MOL CLONING LABORATO; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1992, Biology of Reproduction, V46, P178; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE W, 1991, P NATL ACAD SCI USA, P67; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	53	182	184	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12199	12206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505340				2022-12-25	WOS:A1993LF28400108
J	RAY, P; BERMAN, JD; MIDDLETON, W; BRENDLE, J				RAY, P; BERMAN, JD; MIDDLETON, W; BRENDLE, J			BOTULINUM TOXIN INHIBITS ARACHIDONIC-ACID RELEASE ASSOCIATED WITH ACETYLCHOLINE-RELEASE FROM PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADRENAL CHROMAFFIN CELLS; CATECHOLAMINE SECRETION; DIGLYCERIDE LIPASE; BINDING-PROTEIN; RAT; ACTIVATION; MECHANISM; PLATELET; PHOSPHOLIPASE-A2	The molecular mechanisms of depolarization-induced calcium-dependent acetylcholine (ACh) release and its inhibition by botulinum neurotoxin type A (BoTx) are not clear. We studied these mechanisms in an in vitro cholinergic neuronal pheochromocytoma PC12 cell line model. Cultured monolayer PC12 cells were differentiated by treatment with 50 ng/ml nerve growth factor (NGF) for 4 days to enhance cellular ACh synthesis and release. Stimulation of these cells with high K+ (80 mM) in the perfusion medium caused a marked increase (three to four times) in [H-3]ACh release in a Ca2+-dependent manner. K+-stimulated [H-3]ACh release was totally inhibited by pretreatment of cells with BoTx (2 nM) for 2 h. High K+ also stimulated the release of arachidonic acid ([H-3]AA) from the cell membrane, which was inhibited by BoTx (2 nM). Addition of phospholipase A2 (PLA2) inhibitors (quinacrine, 4-bromophenacyl bromide, manoalide) to the perfusion medium inhibited K+-stimulated [H-3]ACh and [H-3]AA release in a dose-dependent manner. Inclusion of exogenous AA, the PLA2 activator melittin, or PLA2 itself prevented the effect of BoTx. These results demonstrate that in NGF-differentiated PC12 cells, AA release is associated with ACh release, BoTx inhibits both processes, and increased AA can protect against BoTx.	WALTER REED ARMY INST RES, DEPT BIOL, DIV EXPTL THERAPEUT, WASHINGTON, DC 20067 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								ABOUSAMRA AB, 1986, ENDOCRINOLOGY, V119, P1427, DOI 10.1210/endo-119-4-1427; ASHTON AC, 1988, J NEUROCHEM, V50, P1808, DOI 10.1111/j.1471-4159.1988.tb02482.x; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; BOURDEAU A, 1992, ENDOCRINOLOGY, V130, P1339, DOI 10.1210/en.130.3.1339; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOI OH, 1992, J PHARMACOL EXP THER, V260, P369; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; CRUETZ CE, 1981, J CELL BIOL, V91, P247; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DOLLY JO, 1988, E H S BIOT, P79; DUNIEC Z, 1983, BIOCHEM PHARMACOL, V32, P2283, DOI 10.1016/0006-2952(83)90239-3; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; FRYE RA, 1984, J NEUROCHEM, V43, P146, DOI 10.1111/j.1471-4159.1984.tb06690.x; FRYE RA, 1983, MOL PHARMACOL, V23, P547; GAN RW, 1984, PROSTAGLANDINS LEUKO, P593; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUNDERSEN CB, 1980, PROG NEUROBIOL, V14, P99, DOI 10.1016/0301-0082(80)90019-2; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; HOFFMAN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237; JOPE RS, 1985, MOL PHARMACOL, V29, P45; JUNIER MP, 1990, LIFE SCI, V47, P1829, DOI 10.1016/0024-3205(90)90285-Y; KADIRI C, 1990, MOL PHARMACOL, V38, P418; KANTERMAN RY, 1990, J NEUROCHEM, V54, P1225, DOI 10.1111/j.1471-4159.1990.tb01952.x; KAO I, 1976, SCIENCE, V193, P1256, DOI 10.1126/science.785600; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER AMS, 1988, J PHARMACOL EXP THER, V244, P871; MCGEE R, 1978, P NATL ACAD SCI USA, V75, P1314, DOI 10.1073/pnas.75.3.1314; METZ SA, 1989, BIOCHEM PHARMACOL, V38, P1849, DOI 10.1016/0006-2952(89)90421-8; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MOSKOWITZ N, 1982, SCIENCE, V216, P305, DOI 10.1126/science.6278597; NEGISHI M, 1990, BIOCHEM BIOPH RES CO, V169, P773, DOI 10.1016/0006-291X(90)90398-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POOLE AR, 1970, NATURE, V227, P810, DOI 10.1038/227810a0; Ray P., 1992, Society for Neuroscience Abstracts, V18, P790; RAY P, 1992, PHARMACOLOGIST, V34, P187; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SHAFER TJ, 1991, NEUROTOXICOLOGY, V12, P473; SHEN TY, 1977, ADV DRUG RES, V56, P665; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SLACK BE, 1992, BRAIN RES, V585, P169, DOI 10.1016/0006-8993(92)91203-Q; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; WOLF BA, 1986, J BIOL CHEM, V261, P3501	51	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11057	11064						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496167				2022-12-25	WOS:A1993LD46600052
J	SETO, Y; GUENGERICH, FP				SETO, Y; GUENGERICH, FP			PARTITIONING BETWEEN N-DEALKYLATION AND N-OXYGENATION IN THE OXIDATION OF N,N-DIALKYLARYLAMINES CATALYZED BY CYTOCHROME-P450-2B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; FLAVIN-CONTAINING MONOOXYGENASE; MECHANISM-BASED INACTIVATION; HYDROGEN-PEROXIDE FORMATION; ENZYMATIC S-OXYGENATION; RAT-LIVER; ELECTROCHEMICAL GENERATION; PURIFIED CYTOCHROME-P-450; RECONSTITUTED SYSTEM; CATION RADICALS	Aminium radicals have been proposed as intermediates in amine N-dealkylations and N-oxygenations catalyzed by cytochrome P450 (P450) and some other enzymes. P450s can form some N-oxides and hydroxylamines but these are not favored whenever N-dealkylation is possible. However, if a paradigm involving 1-electron oxidation is valid, then some finite level of partitioning of aminium radicals between N-oxygenation and N-dealkylation might be expected in all cases. Methods were developed for the selective and sensitive measurement of N,N-dialkylaniline N-oxides using high performance liquid chromatography, radiochromatography, and TiCl3 reduction. These N-oxides were relatively stable in the presence of P4 50 2B1. In the presence of NADPH and NADPH-P450 reductase some reduction to N,N-dialkylamines occurred, along with N-dealkylation (to monoalkylanilines); there was also slow N-dealkylation in the absence of NADPH, which is interpreted in terms of homolytic scission of the N-O bond; N,N-dialkylanilines were not formed nor did the N-oxides support other oxygenation reactions. P450 2B1 (with its reductase and NADPH) formed N-oxides at low rates from several N,N-dialkylaniline derivatives, including N,N-dimethylaniline, N,N-diethylaniline, N-ethyl-N-methylaniline, 4-methyl-N,N-dimethylaniline, 4-cyano-N,N-dimethylaniline, N-phenylpyrrolidine, and N,N-dimethyl-2-aminofluorene. The ratio of N-dealkylation:N-oxygenation varied from 1020 to 6 in this series. These results are consistent with the view that aminium radicals are a branch point in N-oxygenation and N-dealkylation reactions catalyzed by metalloproteins, although some alternate explanations cannot be ruled out. While N-dealkylation is the dominant process in all of the P450-catalyzed amine oxidations, there should be a finite partition ratio between these reactions depending upon the particular enzyme and substrate. The N-oxygenation reaction is probably more complex than a direct radical recombination event and is postulated to involve one or more intermediates.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, CTR MOLEC TOXICOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44353] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; BABA T, 1987, XENOBIOTICA, V17, P1029, DOI 10.3109/00498258709044201; BONDON A, 1989, J BIOL CHEM, V264, P1988; BOWRY VW, 1991, J AM CHEM SOC, V113, P5699, DOI 10.1021/ja00015a025; BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; BURKA LT, 1985, J AM CHEM SOC, V107, P2549, DOI 10.1021/ja00294a057; BURSTYN JN, 1991, CHEM RES TOXICOL, V4, P70, DOI 10.1021/tx00019a009; CASHMAN JR, 1989, MOL PHARMACOL, V36, P497; CRAIG JC, 1961, J AM CHEM SOC, V83, P1871, DOI 10.1021/ja01469a023; CRAIG JC, 1970, J ORG CHEM, V35, P1721, DOI 10.1021/jo00830a121; DAMANI LA, 1978, J CHROMATOGR, V155, P337, DOI 10.1016/S0021-9673(00)87994-7; DEMONTELLANO PRO, 1987, J AM CHEM SOC, V109, P3415; DINNOCENZO JP, 1989, J AM CHEM SOC, V111, P8646, DOI 10.1021/ja00205a014; FERRIS JP, 1968, J ORG CHEM, V33, P3493, DOI 10.1021/jo01273a028; FREDERICK CB, 1982, CANCER RES, V42, P2671; FUJIMORI K, 1986, TETRAHEDRON LETT, V27, P1617, DOI 10.1016/S0040-4039(00)84329-4; GORROD J W, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P195; GROVES JT, 1986, INORG CHEM, V25, P123, DOI 10.1021/ic00222a003; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8168; GUENGERICH FP, 1984, J MED CHEM, V27, P1101, DOI 10.1021/jm00375a002; GUENGERICH FP, 1984, J AM CHEM SOC, V106, P6446, DOI 10.1021/ja00333a071; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; GUENGERICH FP, 1989, J BIOL CHEM, V264, P17198; GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287; GUENGERICH FP, 1977, MOL PHARMACOL, V13, P993; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; Guengerich FP, 1989, PRINCIPLES METHODS T, P777; HAMMONS GJ, 1985, CANCER RES, V45, P3578; HAYASHI Y, 1979, J BIOL CHEM, V254, P9101; HEIMBROOK DC, 1984, J AM CHEM SOC, V106, P1514, DOI 10.1021/ja00317a072; HLAVICA P, 1979, BIOCHEM J, V182, P109, DOI 10.1042/bj1820109; IWASAKI K, 1977, BIOCHEM BIOPH RES CO, V77, P1143, DOI 10.1016/S0006-291X(77)80098-3; KUREBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V270, P320, DOI 10.1016/0003-9861(89)90034-9; LABEQUE R, 1989, J AM CHEM SOC, V111, P6621, DOI 10.1021/ja00199a022; Lashmet Johnson P R, 1986, J Biochem Toxicol, V1, P15; LEE WA, 1985, P NATL ACAD SCI USA, V82, P4301, DOI 10.1073/pnas.82.13.4301; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MACDONALD TL, 1982, J AM CHEM SOC, V104, P2050, DOI 10.1021/ja00371a056; MANSUY D, 1989, EUR J BIOCHEM, V184, P267, DOI 10.1111/j.1432-1033.1989.tb15017.x; MASUI M, 1971, J CHEM SOC B, P1593, DOI 10.1039/j29710001593; MIWA GT, 1983, J BIOL CHEM, V258, P4445; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NEE MW, 1982, J AM CHEM SOC, V104, P6123, DOI 10.1021/ja00386a052; NELSEN SF, 1986, J AM CHEM SOC, V108, P4879, DOI 10.1021/ja00276a028; NORDBLOM GD, 1977, ARCH BIOCHEM BIOPHYS, V180, P343, DOI 10.1016/0003-9861(77)90047-9; OAE S, 1963, TETRAHEDRON, V19, P1783, DOI 10.1016/S0040-4020(01)99252-X; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTOVIC D, 1987, J AM CHEM SOC, V109, P3444, DOI 10.1021/ja00245a041; PALMER G, 1992, J BIOL CHEM, V267, P665; PANDEY RN, 1989, BIOCHEM PHARMACOL, V38, P2181, DOI 10.1016/0006-2952(89)90074-9; PLE P, 1989, J BIOL CHEM, V264, P13983; PROUGH RA, 1984, CANCER RES, V44, P543; SHANNON P, 1981, J AM CHEM SOC, V103, P4580, DOI 10.1021/ja00405a049; SHONO T, 1984, TETRAHEDRON, V40, P811, DOI 10.1016/S0040-4020(01)91472-3; SMITH PJ, 1969, J ORG CHEM, V34, P1821, DOI 10.1021/jo01258a063; SUGIURA M, 1976, MOL PHARMACOL, V12, P322; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TRABER W, 1958, HELV CHIM ACTA, V41, P2066, DOI 10.1002/hlca.19580410715; WALSH CT, 1979, ENZYMATIC REACTION M; WATANABE Y, 1982, TETRAHEDRON LETT, V23, P533, DOI 10.1016/S0040-4039(00)86881-1; WATANABE Y, 1982, B CHEM SOC JPN, V55, P188, DOI 10.1246/bcsj.55.188; WATANABE Y, 1980, TETRAHEDRON LETT, V21, P3685, DOI 10.1016/S0040-4039(00)78745-4; WATANABE Y, 1981, B CHEM SOC JPN, V54, P1163, DOI 10.1246/bcsj.54.1163; WEINBERG NL, 1966, J ORG CHEM, V31, P4058, DOI 10.1021/jo01350a041; WILLIAMS DE, 1989, DRUG METAB DISPOS, V17, P387; WITTIG G, 1955, LIEBIGS ANN CHEM, V594, P1; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YASUKOUCHI K, 1979, B CHEM SOC JPN, V52, P3208, DOI 10.1246/bcsj.52.3208; ZIEGLER DM, 1991, DRUG METAB DISPOS, V19, P847; ZIEGLER DM, 1964, BIOCHEM BIOPH RES CO, V15, P188, DOI 10.1016/0006-291X(64)90322-5	75	68	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9986	9997						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486725				2022-12-25	WOS:A1993LB80000011
J	CHEN, WJ; MOOMAW, JF; OVERTON, L; KOST, TA; CASEY, PJ				CHEN, WJ; MOOMAW, JF; OVERTON, L; KOST, TA; CASEY, PJ			HIGH-LEVEL EXPRESSION OF MAMMALIAN PROTEIN FARNESYLTRANSFERASE IN A BACULOVIRUS SYSTEM - THE PURIFIED PROTEIN CONTAINS ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; PEPTIDE-BINDING; ALPHA-SUBUNIT; A-FACTOR; YEAST; FARNESYL; CLONING; GENE	The mammalian enzyme protein farnesyltransferase is a heterodimeric protein that catalyzes the addition of a farnesyl isoprenoid to a cysteine in ras proteins. Since oncogenic forms of ras proteins require the farnesyl group for transforming activity, the structure and mechanism of this enzyme are important to define. However, such studies have been difficult to approach because of the low abundance of the enzyme in mammalian tissues and hence the problems of obtaining large quantities of the protein. We report here the coexpression of the two subunits of protein farnesyltransferase by Sf9 cells infected with a recombinant baculovirus containing the coding sequences of both polypeptides. This results in the production of milligram quantities of enzyme which can be readily purified by conventional chromatographic methods. The individual subunits of the enzyme can also be expressed in the Sf9 cells, but the ability to reconstitute active enzyme from extracts containing individual subunits is quite low. In contrast, the enzyme produced by coexpression of the two subunits is fully active and retains the properties of the mammalian form, including the specificity for the COOH-terminal amino acid of substrate proteins and the ability to bind short peptides encompassing the prenylation site of a ras protein. Furthermore, through atomic absorption analysis of the purified protein, we have confirmed the previous tentative assignment of protein farnesyltransferase as a zinc metalloenzyme by demonstrating that it contains an essentially stoichiometric amount of zinc. The ability to produce and purify milligram quantities of protein farnesyltransferase readily will allow detailed mechanistic and structural studies on this enzyme.	DUKE UNIV,MED CTR,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; GLAXO INC,RES INST,DEPT MOLEC BIOL,RES TRIANGLE PK,NC 27709	Duke University; Duke University; GlaxoSmithKline				Casey, Patrick/0000-0002-7366-9309				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIGGINS JA, 1992, FASEB J, V6, P97; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P29; VALLEE BL, 1983, ZINC ENZYMES, P25	29	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9675	9680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486655				2022-12-25	WOS:A1993LA68900078
J	HUANG, KM; SNIDER, MD				HUANG, KM; SNIDER, MD			GLYCOPROTEIN RECYCLING TO THE GALACTOSYLTRANSFERASE COMPARTMENT OF THE GOLGI-COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; HAMSTER OVARY CELLS; BREFELDIN-A CAUSES; INTRACELLULAR MOVEMENT; TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEINS; MDCK CELLS; NETWORK; ENDOSOMES	The recycling of plasma membrane glycoproteins to the Golgi complex is well established, but it is not clear which Golgi subcompartments receive this traffic. To date, recycling into the trans-Golgi compartment that contains sialyltransferase and the early Golgi region that contains alpha-mannosidase I has been demonstrated. However, transport into other Golgi compartments has not been reported. In this study we tested the return of cell surface glycoproteins to the Golgi galactosyltransferase compartment using the ldlD mutant of Chinese hamster ovary cells. The cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor recycled through this Golgi region with a half-time of 4 h and was transported to the sialyltransferase compartment as well. Because galactosyltransferase and sialyltransferases are probably located in different trans-Golgi regions in Chinese hamster ovary cells, these results suggest that the two compartments each receive recycling traffic or that recycling glycoproteins enter one region and are then transported to the other. The extent of cell surface protein recycling through the galactosyltransferase compartment was also studied. At least 10 different glycoproteins were transported from the cell surface to this Golgi region. Moreover, our results suggest that recycling glycoproteins make up 12-25% of the flux of cell surface glycoproteins through the Golgi galactosyltransferase compartment; the balance is comprised of newly made glycoproteins.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,10900 EUCLID AVE,CLEVELAND,OH 44106	Case Western Reserve University					NIDDK NIH HHS [DK07319] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BRANDLI AW, 1989, EMBO J, V8, P3207, DOI 10.1002/j.1460-2075.1989.tb08479.x; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; FISHMAN JB, 1987, CELL, V48, P157, DOI 10.1016/0092-8674(87)90366-7; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; JIN M, 1989, J BIOL CHEM, V264, P7675; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; OMARY MB, 1981, J BIOL CHEM, V256, P2888; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; ROBBINS AR, 1981, J BIOL CHEM, V256, P623; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; ROTH J, 1982, J CELL BIOL, V92, P223; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SNIDER MD, 1991, INTRACELLULAR TRAFFI, P361; WARD JH, 1982, J BIOL CHEM, V257, P317; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	41	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9302	9310						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486626				2022-12-25	WOS:A1993LA68900026
J	TIESMAN, J; HART, CE				TIESMAN, J; HART, CE			IDENTIFICATION OF A SOLUBLE RECEPTOR FOR PLATELET-DERIVED GROWTH-FACTOR IN CELL-CONDITIONED MEDIUM AND HUMAN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; FACTOR PDGF; CARCINOMA-CELLS; TRUNCATED FORM; HUMAN-URINE; EXPRESSION; PROTEIN; DOMAIN; PURIFICATION	We have discovered a soluble form of the platelet-derived growth factor (PDGF) alpha receptor, designated sPDGF-Ralpha, that is produced by and secreted into the conditioned medium of the human osteosarcoma cell line, MG-63. Additionally, sPDGF-Ralpha activity has been detected in normal human blood plasma and serum. We have achieved partial purification of this protein by column chromatography using three different affinity matrices: anti-PDGF-Ralpha monoclonal antibody (mAb) 292.15-Sepharose, PDGF-BB-Sepharose, and wheat germ agglutinin-agarose. All three matrices have been shown to purify a 90-kDa protein that is recognized by mAbs specific for the PDGF-Ralpha extracellular domain. sPDGF-Ralpha is capable of binding PDGF ligand in solution and can compete with cell-associated PDGF receptors for ligand binding. We provide three pieces of data suggesting that the sPDGF-Ralpha is generated by proteolytic clipping of the full-length PDGF-Ralpha protein. First, the conditioned medium of an expression cell line transfected with a cDNA construct designed to produce only full-length PDGFRalpha exhibits sPDGF-Ralpha activity. Second, a truncated intracellular fragment of the PDGF-Ralpha, presumably representing the intracellular counterpart of the clipped sPDGF-Ralpha, can be immunoprecipitated from the MG-63 osteosarcoma cell extracts using antiserum raised against an intracellular portion of PDGF-Ralpha. Finally, we have been unable to detect alternative splicing in the PDGF-Ralpha transcript using reverse transcription-polymerase chain reaction.			TIESMAN, J (corresponding author), ZYMOGENET INC,SEATTLE,WA 98105, USA.							BEGUIN Y, 1988, P NATL ACAD SCI USA, V85, P637, DOI 10.1073/pnas.85.2.637; BIGLER J, 1992, MOL CELL BIOL, V12, P2406, DOI 10.1128/MCB.12.5.2406; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DUAN DSR, 1991, J BIOL CHEM, V266, P413; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; DUMMER R, 1992, J INVEST DERMATOL, V98, P50, DOI 10.1111/1523-1747.ep12494223; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAUDEWITZ P, 1988, J INVEST DERMATOL, V91, P386; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHERR CJ, 1988, J CELL BIOCHEM, V38, P179, DOI 10.1002/jcb.240380305; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TENDIJKE P, 1989, BIO-TECHNOL, V7, P793, DOI 10.1038/nbt0889-793; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; TIESMAN J, 1989, Cytotechnology, V2, P333, DOI 10.1007/BF00364997; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	48	44	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9621	9628						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486649				2022-12-25	WOS:A1993LA68900071
J	KOSFELD, MD; FRAZIER, WA				KOSFELD, MD; FRAZIER, WA			IDENTIFICATION OF A NEW CELL-ADHESION MOTIF IN 2 HOMOLOGOUS PEPTIDES FROM THE COOH-TERMINAL CELL BINDING DOMAIN OF HUMAN THROMBOSPONDIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SQUAMOUS CARCINOMA; III CONNECTING SEGMENT; TENASCIN; ATTACHMENT; FIBRONECTIN; SEQUENCE; ANGIOGENESIS; MIGRATION; MOTILITY; TISSUE	Thrombospondin-1 (TS1) contains at least four domains that support cell attachment. The COOH-terminal cell binding domain (CBD) was first identified with a monoclonal antibody against TS1 that blocked secretion-dependent platelet aggregation. Subsequently, this domain of TS1 has been found to bind a number of normal and transformed cells. We have localized attachment sites for human melanoma cells (G361) within the CBD to two noncontiguous 30-residue peptides designated C4 and C7 (Kosfeld, M. D., and Frazier, W. A. (1991) J. Biol. Chem. 267,16230-16236). Here we report studies to define the active sequences within C4 and C7. An octapeptide, RFYVVMWK (4N1-1), from C4 and a pentapeptide, IRVVM (7N3-1), from C7 were found to support attachment of G361 melanomas, K562 erythroleukemia cells, HT1080 fibrosarcomas, C32 amelanotic melanomas, and endothelial cells. These peptides also inhibit the adhesion of cells to the recombinant CBD of TS1. The hexapeptide RFYVVM (4N1-2) also inhibits cell attachment. The inhibitory effect of combinations of C4- and C7-derived peptides is synergistic. The sequences 4N1-1 and 7N3-1 of TS1 share homology with two cell adhesive peptides from laminin (LM), LMF9 and LMPA22-2, respectively. These TS1 and LM peptides are interchangeable in inhibiting the adhesion of G361 cells to LM or TS1, suggesting a possible sharing of receptors by LM and TS1. K562 cells, however, bound only to TS1, and this binding was inhibited preferentially by the TS1 CBD peptides, indicating a receptor specific for TS1 which does not recognize LM. The active TS1 peptides are highly conserved among five species and four isoforms of TS1. Homologs of the TS1 peptides are found in tenascin, a matrix protein that shares several properties with TS1 and in factor VIII, alpha2-macroglobulin, and von Willebrand factor.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FRAZIER WA, 1991, CURR OPIN CELL BIOL, V3, P793; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEUNG LLK, 1984, J CLIN INVEST, V74, P1964; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAUGI GJ, 1987, J INVEST DERMATOL, V89, P551, DOI 10.1111/1523-1747.ep12461198; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SKUBITZ APN, 1990, CANCER RES, V50, P7612; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; ULLRICH A, 1990, EMBO J, V10, P2849; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; VAS HL, 1992, J BIOL CHEM, V267, P12192; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	42	64	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8808	8814						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473325				2022-12-25	WOS:A1993KX81100065
J	MATSUKAWA, N; NONAKA, Y; HIGAKI, J; NAGANO, M; MIKAMI, H; OGIHARA, T; OKAMOTO, M				MATSUKAWA, N; NONAKA, Y; HIGAKI, J; NAGANO, M; MIKAMI, H; OGIHARA, T; OKAMOTO, M			DAHLS SALT-RESISTANT NORMOTENSIVE RAT HAS MUTATIONS IN CYTOCHROME-P450(11-BETA), BUT THE SALT-SENSITIVE HYPERTENSIVE RAT DOES NOT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSTERONE SYNTHASE; MOLECULAR-CLONING; ADRENAL-CORTEX; CYTOCHROME-P-45011-BETA; FORMS; INHERITANCE; SEQUENCE	Molecular cloning of cytochrome P450(11beta) cDNAs from the adrenal glands of Dahl's salt-sensitive hypertensive (DS) and salt-resistant normotensive (DR) rats was performed using a combined technique of the first strand cDNA synthesis by reverse transcriptase followed by polymerase chain reaction. The cDNA sequence of P450(11beta)-DS was identical to that of wild type P450(11beta). In contrast, the clone obtained from the DR rat contained six nucleotide substitutions causing five amino acid alterations (Arg-127 --> Cys, Val-351 --> Ala, Val-381 --> Leu, Ile-384 --> Leu, and Val-443 --> Met). When the two cDNAs were expressed in COS-7 cells and steroid conversion rates of the transformed cells were determined, a ratio of 18-hydroxylation to 11beta-hydroxylation of 11-deoxycorticosterone by P450(11beta)-DS-expressed cells was 0.58, whereas that by P450(11beta)-DR-expressed cells was 0.23. Plasma levels of 18-hydroxy-11-deoxycorticosterone and corticosterone (the 11beta-hydroxylation product of 11-deoxycorticosterone) in DS and DR rats well reflected the steroidogenic activities of the two P450s. These results suggest that the characteristic plasma steroid level of the DR rat is caused by the mutations in P450(11beta) gene and may act to maintain the normotensive blood pressure in this rat strain during sodium loading.	OSAKA UNIV,SCH MED,DEPT MOLEC PHYSIOL CHEM,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GERIATR,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL LK, 1962, NATURE, V194, P480, DOI 10.1038/194480b0; DEN K, 1978, ENDOCRINOL JAPON, V25, P171; GOTOH O, 1992, J BIOL CHEM, V267, P83; IWAI J, 1969, J EXP MED, V129, P663, DOI 10.1084/jem.129.4.663; KNUDSEN KD, 1970, J EXP MED, V132, P976, DOI 10.1084/jem.132.5.976; LAUBER M, 1989, ARCH BIOCHEM BIOPHYS, V274, P109, DOI 10.1016/0003-9861(89)90421-9; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; NONAKA Y, 1991, EUR J BIOCHEM, V202, P897, DOI 10.1111/j.1432-1033.1991.tb16449.x; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OHTA M, 1988, J STEROID BIOCHEM, V29, P699; OZOLS J, 1981, J BIOL CHEM, V256, P1405; RAPP JP, 1982, HYPERTENSION, V4, P753, DOI 10.1161/01.HYP.4.6.753; RAPP JP, 1972, ENDOCRINOLOGY, V90, P1435, DOI 10.1210/endo-90-6-1435; RAPP JP, 1972, NATURE, V237, P338, DOI 10.1038/237338a0; RAPP JP, 1976, BIOCHEMISTRY-US, V15, P1235, DOI 10.1021/bi00651a010; SUGANO S, 1985, J STEROID BIOCHEM, V23, P1013; WADA A, 1992, J BIOL CHEM, V267, P22877; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1	20	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9117	9121						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473350				2022-12-25	WOS:A1993KX81100104
J	STRUBE, KH; KROGER, B; BIALOJAN, S; OTTE, M; DODT, J				STRUBE, KH; KROGER, B; BIALOJAN, S; OTTE, M; DODT, J			ISOLATION, SEQUENCE-ANALYSIS, AND CLONING OF HAEMADIN - AN ANTICOAGULANT PEPTIDE FROM THE INDIAN LEECH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XA; ALPHA-THROMBIN; HIRUDIN; INHIBITOR; BINDING; KINETICS; COMPLEX	A slow, tight-binding inhibitor of thrombin with an apparent molecular mass of about 5 kDa has been isolated from Haemadipsa sylvestris, an Indian leech of the family of Haemadipsidae. The inhibitory activity, called haemadin, is thrombin specific since it does not inhibit other proteases like trypsin, chymotrypsin, factor Xa, or plasmin. NH2-terminal amino acid sequence analysis (residues 1-45) does not reveal any homology to known serine protease inhibitors, including the thrombin-specific inhibitor hirudin. The haemadin cDNA cloned by polymerase chain reaction techniques codes for a polypeptide of 57 amino acid residues preceded by 20 residues of a signal peptide sequence. A synthetic gene coding for the mature haemadin was expressed in Escherichia coli. Recombinant haemadin displays a similar inhibition constant and specific activity as its natural counterpart. Although there is no obvious sequence identity between haemadin and hirudin, both proteins seem to share common mechanisms for thrombin inhibition.	BASF AG,DEPT BIOTECHNOL,W-6700 LUDWIGSHAFEN,GERMANY; TH DARMSTADT,INST BIOCHEM,W-6100 DARMSTADT,GERMANY	BASF; Technical University of Darmstadt								BETZ A, 1992, BIOCHEMISTRY-US, V31, P4557, DOI 10.1021/bi00134a004; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CONDRA C, 1989, THROMB HAEMOSTASIS, V61, P437; DODT J, 1985, BIOL CHEM H-S, V366, P379, DOI 10.1515/bchm3.1985.366.1.379; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DODT J, 1990, J BIOL CHEM, V265, P713; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; FINK E, 1989, SEMIN THROMB HEMOST, V15, P283, DOI 10.1055/s-2007-1002720; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; JACOBS JW, 1990, THROMB HAEMOSTASIS, V64, P235; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KOHLER S, 1989, DECHEMA BIO, V3, P405; LAZAR JB, 1991, J BIOL CHEM, V266, P685; Maniatis T, 1989, DECONTAMINATION DILU; Mann K G, 1976, Methods Enzymol, V45, P123; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NASKI MC, 1990, J BIOL CHEM, V265, P13484; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Sawyer R. T, 1986, LEECH BIOL BEHAVIOUR, VII; SAWYER RT, 1991, BIO-TECHNOL, V9, P513, DOI 10.1038/nbt0691-513; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHARF M, 1989, FEBS LETT, V255, P105, DOI 10.1016/0014-5793(89)81070-1; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STEINER V, 1992, BIOCHEMISTRY-US, V31, P2294, DOI 10.1021/bi00123a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Tripier D, 1988, Folia Haematol Int Mag Klin Morphol Blutforsch, V115, P30; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Williams J W, 1979, Methods Enzymol, V63, P437	40	77	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8590	8595						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473305				2022-12-25	WOS:A1993KX81100035
J	THWAITES, DT; BROWN, CDA; HIRST, BH; SIMMONS, NL				THWAITES, DT; BROWN, CDA; HIRST, BH; SIMMONS, NL			TRANSEPITHELIAL GLYCYLSARCOSINE TRANSPORT IN INTESTINAL CACO-2 CELLS MEDIATED BY EXPRESSION OF H+-COUPLED CARRIERS AT BOTH APICAL AND BASAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLYCYL-L-PROLINE; DIPEPTIDE TRANSPORT; LINE; VESICLES; RABBIT; GRADIENT; JEJUNUM; COLON; MODEL	Glycylsarcosine (Gly-Sar) transport in human intestinal epithelial (Caco-2) cells has been investigated. Gly-Sar transport, from apical to basal surfaces (J(a-b)), and intracellular accumulation are greatest when the apical medium is acidified (apical pH 6.0, basal pH 7.4). Both transport and accumulation are susceptible to saturation and competition. Similarly, Gly-Sar transport, from basal to apical surfaces (J(b-a)), is increased with acidification of the basal medium (basal pH 6.0, apical pH 7.4). Apical addition of 20 mM Gly-Sar (pH 6.0) to Caco-2 cell monolayers loaded with the pH indicator BCECF (2',7'-bis(2-carboxyethyl)-5-(6)-carboxyfluorescein) caused a marked cytosolic acidification. Basolateral application of 20 mM Gly-Sar (pH 6.0) also caused a fall in intracellular pH. These observations are consistent with the expression of H+-coupled dipeptide transporters at both membrane faces of the human intestinal epithelial Caco-2 cell line. We also provide direct evidence for dipeptide-stimulated H+-influx, across both apical and basolateral membranes, in this intact epithelial cell system.			THWAITES, DT (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,GASTROINTESTINAL DRUG DELIVERY RES CTR,DEPT PHYSIOL SCI,NEWCASTLE TYNE NE2 4HH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADDISON JM, 1972, CLIN SCI, V43, P907, DOI 10.1042/cs0430907; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BOYD CAR, 1982, J PHYSIOL-LONDON, V324, P411, DOI 10.1113/jphysiol.1982.sp014121; DANTZIG AH, 1990, BIOCHIM BIOPHYS ACTA, V1027, P211, DOI 10.1016/0005-2736(90)90309-C; DYER J, 1990, BIOCHEM J, V269, P565, DOI 10.1042/bj2690565; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; HARRIS DS, 1992, P NATL ACAD SCI USA, V89, P7556, DOI 10.1073/pnas.89.16.7556; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P97, DOI 10.1016/0304-4165(90)90179-Z; HIDALGO IJ, 1990, BIOCHIM BIOPHYS ACTA, V1028, P25, DOI 10.1016/0005-2736(90)90261-L; INUI K, 1992, J PHARMACOL EXP THER, V261, P195; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; LUCAS ML, 1978, GUT, V19, P735, DOI 10.1136/gut.19.8.735; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; SIMMONS NL, 1990, METHOD ENZYMOL, V191, P426; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2230; VERRI T, 1992, BIOCHIM BIOPHYS ACTA, V1110, P123, DOI 10.1016/0005-2736(92)90303-4	19	143	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7640	7642						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463293				2022-12-25	WOS:A1993KW97900011
J	GU, HH; XU, J; GALLAGHER, M; DEAN, GE				GU, HH; XU, J; GALLAGHER, M; DEAN, GE			PEPTIDE SPLICING IN THE VACUOLAR ATPASE SUBUNIT-A FROM CANDIDA-TROPICALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; H+-ATPASE; YEAST; MEMBRANES; ACIDIFICATION; HOMOLOGY; PROTEIN; GENES	Subunit A of the vacuolar proton pump appears to be responsible for the ATP hydrolysis which is coupled to the pumping of protons into a variety of intracellular acid compartments, including the fungal vacuole. We report here the cloning and sequence determination of the gene encoding subunit A from Candida tropicalis. Southern blot hybridization analysis indicates that there is a single gene which encodes this protein. The gene contains a single intron at the extreme 5'-end of the coding region. The gene is predicted to encode a polypeptide of 1088 residues with a calculated molecular mass of 119,019 daltons, yet the mature polypeptide appears to be approximately 67 kDa, indicating that this protein probably undergoes the same sort of processing that is evidenced in the homologous protein from Saccharomyces cerevisiae in which an approximately 50-kDa polypeptide (the spacer) is spliced out of the mature protein. The Candida gene, with and without this middle portion, has been expressed in S. cerevisiae and found to restore a Saccharomyces subunit A deletion mutant (tfp1-DELTA8) to apparently wild-type growth at pH 7.6, and normal vacuolar acidification. The peptide sequence of the two predicted mature ends is very similar to the sequences of the analogous proteins from Daucus carota, S. cerevisiae, and Neurospora crassa (60.5, 87.4, and 72.9% identity, respectively), but the middle portion bears only very limited homology with the Saccharomyces protein sequence. Processing of the gene product occurs in S. cerevisiae, Escherichia coli, and in rabbit reticulocyte-mediated in vitro translation, indicating that the excision is probably autocatalytic. The limited sequence identity seen between the Saccharomyces and Candida spacer domains may considerably narrow the functionally important regions responsible for the excision event.	UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039555] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI28392] Funding Source: Medline; NIGMS NIH HHS [R01-GM39555] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANRAKU Y, 1989, J BIOENERG BIOMEMBR, V21, P589, DOI 10.1007/BF00808115; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHEN C, 1987, BIOCHEM BIOPH RES CO, V143, P1311; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; PAN YX, 1991, FEBS LETT, V293, P89, DOI 10.1016/0014-5793(91)81158-5; PERCY JM, 1986, BIOCHEM J, V239, P77, DOI 10.1042/bj2390077; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RUDNICK G, 1986, ANNU REV PHYSIOL, V48, P403; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; STONE DK, 1989, J BIOENERG BIOMEMBR, V21, P605, DOI 10.1007/BF00808116; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WIECZOREK H, 1989, J BIOL CHEM, V264, P11143; XIE XS, 1986, J BIOL CHEM, V261, P2492; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	34	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7372	7381						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463270				2022-12-25	WOS:A1993KV14100079
J	TANOKURA, M; YAMADA, K				TANOKURA, M; YAMADA, K			A CALORIMETRIC STUDY OF CA2+ BINDING BY WHEAT-GERM CALMODULIN - REGULATORY STEPS DRIVEN BY ENTROPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLFROG SKELETAL-MUSCLE; 2 MAJOR ISOTYPES; CALCIUM-BINDING; TROPONIN-C; HEAT-CAPACITY; THERMODYNAMIC ANALYSIS; PARVALBUMIN; PROTEINS; IONS	A hypothesis has been proposed for Ca2+-binding proteins that a regulatory Ca2+ binding step is endothermic and is driven solely by entropy in the absence of Mg2+ (Imaizumi, M., Tanokura, M., and Yamada, K. (1987) J. Biol. Chem. 262, 7963-7966). To confirm this idea, microcalorimetric titrations of wheat germ calmodulin, with Ca2+ in the presence and absence of Mg2+ and with Mg2+ in the absence of Ca2+, have been carried out at 25-degrees-C and at pH 7.0. The results indicate that the four binding sites in each molecule are thermodynamically equivalent to one another for both Ca2+ and Mg2+ binding and that the reaction is endothermic for Ca2+ binding in the absence of Mg2+. As compared with bovine brain calmodulin on Ca2+ binding in the absence of Mg2+, Ca2+ binding in both proteins is driven solely by a large favorable entropy change despite unfavorable enthalpy change. Therefore, the above idea seems plausible.	OITA MED UNIV,DEPT PHYSIOL,OITA 87955,JAPAN	Oita University				Tanokura, Masaru/0000-0001-5072-2480				BERES L, 1971, BIOCHEMISTRY-US, V10, P2120; EBASHI S, 1988, HDB EXPT PHARM, V83, P31; GERDAY C, 1988, CALCIUM CALCIUM BIND, P23; Heizmann CW, 1988, CALCIUM CALCIUM BIND, P93; IMAIZUMI M, 1987, J BIOL CHEM, V262, P7963; IMAIZUMI M, 1990, J BIOCHEM-TOKYO, V107, P127, DOI 10.1093/oxfordjournals.jbchem.a122995; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KOMETANI K, 1983, BIOCHEM BIOPH RES CO, V114, P162, DOI 10.1016/0006-291X(83)91608-X; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESCHLER HJ, 1980, EUR J BIOCHEM, V111, P73; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; POTTER JD, 1977, J BIOL CHEM, V252, P2452; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; SMITH SJ, 1985, J MUSCLE RES CELL M, V6, P757, DOI 10.1007/BF00712240; TANOKURA M, 1985, FEBS LETT, V185, P165, DOI 10.1016/0014-5793(85)80763-8; TANOKURA M, 1986, J BIOL CHEM, V261, P749; TANOKURA M, 1983, J BIOCHEM-TOKYO, V94, P607, DOI 10.1093/oxfordjournals.jbchem.a134393; TANOKURA M, 1987, BIOCHEMISTRY-US, V26, P7668, DOI 10.1021/bi00398a020; TANOKURA M, 1986, FEBS LETT, V209, P77, DOI 10.1016/0014-5793(86)81087-0; TANOKURA M, 1984, J BIOCHEM-TOKYO, V95, P643, DOI 10.1093/oxfordjournals.jbchem.a134653; TANOKURA M, 1985, J BIOL CHEM, V3260, P8680; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; YAMADA K, 1982, J BIOCHEM-TOKYO, V92, P1505, DOI 10.1093/oxfordjournals.jbchem.a134075; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YOSHIDA M, 1983, J BIOCHEM-TOKYO, V94, P1925, DOI 10.1093/oxfordjournals.jbchem.a134546	28	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7090	7092						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463243				2022-12-25	WOS:A1993KV14100043
J	RAY, SD; KAMENDULIS, LM; GURULE, MW; YORKIN, RD; CORCORAN, GB				RAY, SD; KAMENDULIS, LM; GURULE, MW; YORKIN, RD; CORCORAN, GB			CA2+ ANTAGONISTS INHIBIT DNA FRAGMENTATION AND TOXIC CELL-DEATH INDUCED BY ACETAMINOPHEN	FASEB JOURNAL			English	Article						ACETAMINOPHEN; APOPTOSIS; CA2+ ANTAGONISTS; DNA FRAGMENTATION; NECROSIS (TOXIC CELL DEATH)	CHANNEL BLOCKING-AGENTS; INDUCED LIVER NECROSIS; CALCIUM CHANNELS; RAT HEPATOCYTES; CA-2+ INFLOW; INDUCED CYTOTOXICITY; N-ACETYLCYSTEINE; CYTOSOLIC CA-2+; PLASMA-MEMBRANE; MICE	Ca2+ accumulates in the nucleus and DNA undergoes enzymatic cleavage into internucleosome-length fragments before acetaminophen and dimethylnitrosamine produce hepatic necrosis in vivo and toxic cell death in vitro. However, Ca2+-endonuclease fragmentation of DNA is characteristic of apoptosis, a type of cell death considered biochemically and functionally distinct from toxic cell death. The present studies investigate DNA fragmentation as a critical event in toxic cell death by testing whether die Ca2+-calmodulin antagonist chlorpromazine and the Ca2+ channel blocker verapamil prevent acetaminophen-induced hepatic necrosis by inhibiting Ca2+ deregulation and DNA damage. Acetaminophen overdose in mice produced accumulation of Ca2+ in the nucleus (358% of control) and fragmentation of DNA (250% of control) by 6 h, with peak release of ALT occurring at 12-24 h (38,000 U/1). Pretreatment with chlorpromazine prevented increases in nuclear Ca2+ and DNA fragmentation and nearly abolished biochemical evidence of toxic cell death. Verapamil pretreatment also decreased Ca2+ accumulation and DNA damage while attenuating liver injury. The Ca2+ antagonists did not protect against toxic cell death through hypothermia because neither produced the delay in toxicity that is customarily associated with hypothermia. Nor did chlorpromazine or verapamil protect through inhibiting acetaminophen bioactivation. Chlorpromazine failed to diminish glutathione depletion in whole liver and isolated nuclei. Verapamil (250 muM) also failed to alter glutathione depletion in whole liver and had no effect on acetaminophen-glutathione adduct formation by mouse liver microsomes and by cultured mouse hepatocytes. Collectively, these results support the hypothesis that Ca2+-induced DNA fragmentation plays a significant role in cell necrosis produced by acetaminophen and may contribute to toxic cell death caused by other alkylating hepatotoxins.	UNIV NEW MEXICO, COLL PHARM, TOXICOL PROGRAM, ALBUQUERQUE, NM 87131 USA	University of New Mexico			Ray, Sidhartha/AAE-9879-2021	Corcoran, George/0000-0002-4816-8836				BAGINSKI ES, 1973, CLIN CHIM ACTA, V46, P49, DOI 10.1016/0009-8981(73)90101-0; BEALES D, 1985, BIOCHEM PHARMACOL, V34, P19, DOI 10.1016/0006-2952(85)90094-2; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BLAZKA ME, 1991, TOXICOL APPL PHARM, V110, P355, DOI 10.1016/S0041-008X(05)80018-3; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BURCHAM PC, 1988, TOXICOL LETT, V44, P91, DOI 10.1016/0378-4274(88)90134-8; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; CHIEN KR, 1979, AM J PATHOL, V97, P505; CORCORAN GB, 1992, TOXICOL APPL PHARM, V113, P167, DOI 10.1016/0041-008X(92)90112-6; CORCORAN GB, 1988, TOXICOLOGY, V50, P157, DOI 10.1016/0300-483X(88)90088-1; CORCORAN GB, 1987, RES COMMUN CHEM PATH, V58, P291; CORCORAN GB, 1985, J PHARMACOL EXP THER, V232, P857; CORCORAN GB, 1980, MOL PHARMACOL, V18, P536; CORCORAN GB, 1991, TOXICOLOGIST, V11, P102; CROFTS JN, 1990, BIOCHEM J, V269, P579, DOI 10.1042/bj2690579; DEFERREYRA EC, 1985, RES COMMUN CHEM PATH, V47, P289; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; FAWTHROP DJ, 1991, ARCH TOXICOL, V65, P437, DOI 10.1007/BF01977355; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; GALIZZI JP, 1986, P NATL ACAD SCI USA, V83, P7513, DOI 10.1073/pnas.83.19.7513; GOULD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P5122, DOI 10.1073/pnas.80.16.5122; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HALLIWELL G, 1964, BRIT J PHARM CHEMOTH, V23, P330, DOI 10.1111/j.1476-5381.1964.tb01590.x; HAMANN SR, 1983, PHARMACOLOGY, V27, P1, DOI 10.1159/000137823; HARTMANN F, 1983, DRUG METAB DISPOS, V11, P244; Heilmann C, 1990, Prog Liver Dis, V9, P261; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; HIKADA H, 1981, P NATL ACAD SCI USA, V78, P4354; HUGHES BP, 1989, BIOCHIM BIOPHYS ACTA, V1013, P197, DOI 10.1016/0167-4889(89)90135-3; ITOH S, 1988, RES COMMUN CHEM PATH, V60, P133; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JOHNSON JD, 1983, J PHARMACOL EXP THER, V226, P330; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KOBUSCH AB, 1990, RES COMMUN CHEM PATH, V68, P143; KRAUSFRIEDMANN N, 1990, CELL CALCIUM, V11, P625, DOI 10.1016/0143-4160(90)90017-O; LAMB RG, 1984, TOXICOL APPL PHARM, V75, P510, DOI 10.1016/0041-008X(84)90187-X; LANDON EJ, 1986, BIOCHEM PHARMACOL, V35, P697, DOI 10.1016/0006-2952(86)90369-2; LAUTERBURG BH, 1987, HEPATOLOGY, V7, P1179, DOI 10.1002/hep.1840070602; LOH SN, 1990, RADIAT RES, V121, P98, DOI 10.2307/3577570; LONG RM, 1988, J BIOCHEM TOXICOL, V3, P353, DOI 10.1002/jbt.2570030412; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZI A, 1980, TOXICOL APPL PHARM, V52, P82, DOI 10.1016/0041-008X(80)90250-1; MASINI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P19, DOI 10.1016/0005-2728(86)90051-4; mclean a. e. m., 1965, INT REV EXP PATHOL, V4, P127; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MOORE M, 1985, J BIOL CHEM, V260, P3035; NAKAE D, 1990, AM J PATHOL, V136, P787; NELSON SD, 1990, ANNU REV PHARMACOL, V30, P169; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; OGATA N, 1990, J PHARMACOL EXP THER, V252, P1142; PECK RC, 1981, AGENTS ACTIONS, V11, P421, DOI 10.1007/BF01982481; PROZIALECK WC, 1982, J PHARMACOL EXP THER, V222, P509; PUMFORD NR, 1989, J PHARMACOL EXP THER, V248, P190; RAY SD, 1990, TOXICOL APPL PHARM, V106, P346, DOI 10.1016/0041-008X(90)90254-R; RAY SD, 1992, J PHARMACOL EXP THER, V263, P387; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; REES KR, 1961, NATURE, V190, P821, DOI 10.1038/190821a0; RENTON KW, 1985, BIOCHEM PHARMACOL, V34, P2549, DOI 10.1016/0006-2952(85)90541-6; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR BCR, 1967, ANAL BIOCHEM, V20, P155, DOI 10.1016/0003-2697(67)90273-4; SAVILLE JG, 1988, BIOCHEM PHARMACOL, V37, P2467, DOI 10.1016/0006-2952(88)90375-9; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; SEEMAN P, 1980, PHARMACOL REV, V32, P229; SHEN W, 1991, TOXICOL APPL PHARM, V111, P242, DOI 10.1016/0041-008X(91)90028-D; THIBAULT N, 1991, J BIOCHEM TOXICOL, V6, P237, DOI 10.1002/jbt.2570060310; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TIRMENSTEIN MA, 1989, J BIOL CHEM, V264, P9814; TSOKOSKUHN JO, 1989, BIOCHEM PHARMACOL, V38, P3061, DOI 10.1016/0006-2952(89)90016-6; TSOKOSKUHN JO, 1988, BIOCHEM PHARMACOL, V37, P2125, DOI 10.1016/0006-2952(88)90570-9; WALKER RM, 1981, TOXICOL APPL PHARM, V59, P500, DOI 10.1016/0041-008X(81)90303-3; WEI S, 1992, TOXICOL APPL PHARM, V112, P32, DOI 10.1016/0041-008X(92)90276-X; WROBLEWSKI F, 1956, P SOC EXP BIOL MED, V91, P569; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAGUCHI M, 1991, MOL CELL ENDOCRINOL, V75, P65; YAMAMOTO H, 1990, PHARMACOL TOXICOL, V67, P115, DOI 10.1111/j.1600-0773.1990.tb00795.x; Zar J. H., 2009, BIOSTATISTICAL ANAL	82	195	205	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					453	463		10.1096/fasebj.7.5.8462787	http://dx.doi.org/10.1096/fasebj.7.5.8462787			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462787				2022-12-25	WOS:A1993KV35100010
J	GEORGE, A; SABSAY, B; SIMONIAN, PAL; VEIS, A				GEORGE, A; SABSAY, B; SIMONIAN, PAL; VEIS, A			CHARACTERIZATION OF A NOVEL DENTIN MATRIX ACIDIC PHOSPHOPROTEIN - IMPLICATIONS FOR INDUCTION OF BIOMINERALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT INCISOR DENTIN; MOLECULAR-WEIGHT; PHOSPHOPHORYN; CASEIN; DETERMINANTS; CLONING; LIVER	Acidic phosphorylated proteins have been shown t be prominent constituents of the extracellular matrix of bone and dentin. The acidic phosphoproteins of bon contain more glutamic acid than aspartic acid and a lower serine content than either. On the other hand, the major dentin acidic phosphoproteins, phosphophoryns, have been defined as aspartic acid- and serine-rich proteins, with a lesser content of glutamic acid. Both sets of phosphoproteins have been implicated as key participants in regulating mineralization, but it has been difficult to unify their mechanisms of action. We have now identified, by cDNA cloning, a new serine-rich acidic protein of the dentin matrix, AG1, with a composition intermediate between the bone acidic proteins and dentin phosphophoryns. AG1 has numerous acidic consensus sites for phosphorylation by both casein kinases I and II. Immunochemical and organ culture biosynthetic studies show that AG1 is present in phosphorylated form at low levels in the dentin matrix. If fully phosphorylated, AG1 would bear a net charge of -175/molecule of 473 residues. AG1 contains single RGD integrin binding and N-glycosylation sequences. The overall picture that emerges is that of a matrix-associated acidic phosphoprotein, with a potentially high calcium ion binding capacity, present at levels compatible with a regulatory role in dentin mineralization.	NORTHWESTERN UNIV,DIV ORAL BIOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				GEORGE, ANNE/0000-0002-9008-7642	NIAMS NIH HHS [AR-13921] Funding Source: Medline; NIDCR NIH HHS [DE-01374] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR013921, R37AR013921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARNES WM, 1983, METHOD ENZYMOL, V101, P98; Butler W T, 1991, J Biol Buccale, V19, P83; CARMICHAEL DJ, 1971, CALC TISS RES, V7, P331, DOI 10.1007/BF02062622; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIMUZIO MT, 1985, CALCIFIED TISSUE INT, V37, P242, DOI 10.1007/BF02554870; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; Lowenstam H. A., BIOMINERALIZATION; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEGGIO F, 1989, EUR J BIOCHEM, V186, P459, DOI 10.1111/j.1432-1033.1989.tb15229.x; MEIR UT, 1992, CELL, V70, P127; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; ROACH PJ, 1991, J BIOL CHEM, V266, P3724; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHLUETER RJ, 1964, BIOCHEMISTRY-US, V3, P1657, DOI 10.1021/bi00899a010; STETLERSTEVENSON WG, 1987, CALCIFIED TISSUE INT, V40, P97, DOI 10.1007/BF02555712; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; TABOR S, 1989, J BIOL CHEM, V264, P6447; Veis A., 1989, P189; VEIS A, 1983, BIOMINERALIZATION BI, P191; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTON GM, 1985, J BIOL CHEM, V260, P4745; WU CB, 1992, J BIOL CHEM, V267, P16588	30	353	379	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12624	12630						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509401				2022-12-25	WOS:A1993LG65800060
J	LIU, JN; GUREWICH, V				LIU, JN; GUREWICH, V			SUBSTRATE-INHIBITION OF FIBRIN-DEPENDENT PLASMINOGEN ACTIVATION BY TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ONE-CHAIN; KINETICS; CLEAVAGE; BINDING	Tissue plasminogen activator (t-PA) is a poor activator of plasminogen, but its catalytic efficiency is greatly enhanced in the presence of fibrin or certain fibrin derivatives. These two very different rates of plasminogen activation provide a basis for the phenomenon of substrate inhibition, which was the subject of the present study. The reaction mixture contained Glu-plasminogen (0-4.0 muM), +/-D-dimer (0.06-1.0 muM), t-PA (0.05-50.0 nM), and S2251 (1.5 mM). Inhibition of the reaction at higher plasminogen concentrations was seen at lower concentrations of t-PA (< 1.0 nM) and D-dimer (<0.5 muM). The maximum rate of plasminogen activation occurred at 0.2 muM Glu-plasminogen but then decreased progressively above this concentration. At a physiological concentration of plasminogen (2.0 muM), activation was about half that at 0.2 muM. This phenomenon was shown not to be related to Glu-plasminogen aggregation or to a non-competitive inhibiting contaminant. Instead, the non-linear Lineweaver-Burk curve in the presence of D-dimer was consistent with substrate inhibition. Increasing the concentration of D-dimer (1.0 muM) and/or t-PA (50 nM) overcame the inhibition and reestablished linearity in the Lineweaver-Burk plots. However, at the higher concentrations of t-PA, the catalytic efficiency was reduced by 50-120-fold, suggesting that t-PA may be less efficient at pharmacological than at physiological concentrations. In conclusion, substrate inhibition in t-PA-induced plasminogen activation is reported for the first time. This phenomenon was confined to low concentrations of t-PA and D-dimer in the presence of physiological concentrations of plasminogen. The observation suggests that small fibrin clots (hemostatic plugs) may be more resistant to tPA-induced lysis than an occlusive thrombus.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; FISCHER BE, 1990, BIOCHIM BIOPHYS ACTA, V952, P245; HASAN AAK, 1992, BLOOD, V79, P2313; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER KJ, 1973, CHEM KINETICS ENZYME, P89; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; NIEUWENHUIZEN W, 1988, EUR J BIOCHEM, V174, P163, DOI 10.1111/j.1432-1033.1988.tb14077.x; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RANBY M, 1983, PROGR FIBRINOLYSIS, V6, P182; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SEGEL I, 1975, ENZYME KINETICS, P149; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; URDEN G, 1984, SCAND J CLIN LAB INV, V44, P495, DOI 10.3109/00365518409083602; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VARADI A, 1984, BIOCHEMISTRY-US, V23, P2108, DOI 10.1021/bi00304a036; ZAMARRON C, 1984, J BIOL CHEM, V259, P2080	19	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12257	12259						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509362				2022-12-25	WOS:A1993LG65800008
J	YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S				YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S			ADP-RIBOSYLATION OF THE RHOA GENE-PRODUCT BY BOTULINUM C3 EXOENZYME CAUSES SWISS 3T3 CELLS TO ACCUMULATE IN THE G(1) PHASE OF THE CELL-CYCLE	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; IMMOBILIZED PH GRADIENTS; CLOSTRIDIUM-BOTULINUM; RIBOSYLTRANSFERASE; GROWTH; SEQUENCE; IDENTIFICATION; PURIFICATION; FIBROBLASTS; EXPRESSION	Using botulinum C3 exoenzyme, which specifically ADP-ribosylates the rho gene products (rho proteins), we examined the role of these proteins in cell cycle progression in Swiss 3T3 cells. Incubation of cell lysates with C3 exoenzyme revealed a single [P-32]ADP-ribosylated protein with an M(r) of 23K. This protein was identified as rhoA protein by isoelectric focusing and peptide mapping. When C3 exoenzyme was added to the culture, it ADP-ribosylated the substrate protein in the celts and reduced their growth rate and saturation density. The reduction was dependent on the amount of C3 exoenzyme and on the extent of ADP-ribosylation of the rho protein in the cells. Flow cytometric analysis of logarithmically growing cells showed that the enzyme treatment concentration-dependently accumulated the cells in the G1 phase of the cell cycle. When G1-enriched cells were treated with C3 exoenzyme and cell cycle progression initiated by the addition of serum was monitored, inhibition of G1-S transition was clearly observed. These results suggest that the rhoA gene product plays a critical role in G1-S progression in cultured Swiss 3T3 cells and that the ADP-ribosylation abolishes this activity and causes the cells to accumulate in G1 phase.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,FIS,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 606,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 591,JAPAN	Kyoto University; Kyoto University; Kyoto Prefectural University of Medicine; Osaka Metropolitan University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; ALTLAND K, 1985, ELECTROPHORESIS, V6, P314, DOI 10.1002/elps.1150060704; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; ONEILL C, 1990, J CELL SCI, V95, P577; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIMPILAINEN MA, 1985, ELECTROPHORESIS, V6, P419, DOI 10.1002/elps.1150060903; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TOMINAGA T, 1993, IN PRESS J CELL BIOL; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	40	173	175	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1449	1455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502473				2022-12-25	WOS:A1993LE06400007
J	BUDEL, LM; HOOGERBRUGGE, H; POUWELS, K; VANBUITENEN, C; DELWEL, R; LOWENBERG, B; TOUW, IP				BUDEL, LM; HOOGERBRUGGE, H; POUWELS, K; VANBUITENEN, C; DELWEL, R; LOWENBERG, B; TOUW, IP			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTORS ALTER THEIR BINDING CHARACTERISTICS DURING MYELOID MATURATION THROUGH UP-REGULATION OF THE AFFINITY CONVERTING BETA-SUBUNIT (KH97)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-3 RECEPTORS; ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; GROWTH-FACTOR RECEPTORS; FACTOR GM-CSF; EXPRESSION CLONING; MOLECULAR-CLONING; BLAST CELLS; HUMAN IL-3; RADIOACTIVITIES	Acute myeloid leukemia blasts express dual affinity (high and low) granulocyte-macrophage colony-stimulating factor (GM-CSF) binding, and the high affinity GM-CSF binding is counteracted by excess interteukin-3 (IL-3). Neutrophils express a single class of GM-CSF-R with intermediate affinity that lack IL-3 cross-reactivity. Here we demonstrate the differentiation associated changes of GM-CSF binding characteristics in three models representative of different stages of myeloid maturation. We find that high affinity GM-CSF binding is converted into intermediate affinity binding, which still cross-reacts with IL-3, beyond the stage of promyelocytes. During terminal maturation towards neutrophils, IL-3 cross-reactivity is gradually lost. We sought to determine the mechanism underlying the affinity conversion of the GM-CSF-R. Northern and reverse transcriptase-polymerase chain reaction analysis of GM-CSF-Ralpha and -beta(c) (KH97) transcripts did not provide indications for the involvement of GM-CSF-R splice variants in the formation of the intermediate affinity GM-CSFR complex. In COS-cell transfectants with increasing amounts of beta(c) in the presence of a fixed number of GM-CSF-Ralpha chains, the high affinity GM-CSF binding converted into intermediate affinity GM-CSF binding. These results are discussed in view of the concept that increasing expression of beta(c) subunits may cause alternative oligomerization of the GM-CSF-Ralpha and -beta(c) subunits resulting in the formation of intermediate rather than high affinity GM-CSFRalpha.beta(c) complexes.	DR DANIEL DENHOED CANC CTR,PB 5201,3008 AE ROTTERDAM,NETHERLANDS; ERASMUS UNIV,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOT FJ, 1989, EXP HEMATOL, V17, P292; BOT FJ, 1988, BLOOD, V71, P1609; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUDEL LM, 1989, BLOOD, V74, P2668; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARLING DC, 1989, LEUKEMIA RES, V13, P407, DOI 10.1016/0145-2126(89)90081-7; DELWEL R, 1988, BLOOD, V72, P1944; ELLIOTT MJ, 1989, BLOOD, V74, P2349; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; MUROHASHI I, 1989, LEUKEMIA RES, V13, P599, DOI 10.1016/0145-2126(89)90127-6; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OKUDA K, 1992, BLOOD, V79, P2880; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; ONETTOPOTHIER N, 1990, LEUKEMIA, V4, P329; PARK LS, 1989, J BIOL CHEM, V264, P5420; Sambrook J, 1989, MOL CLONING LABORATO; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SIEFF CA, 1987, J CLIN INVEST, V79, P1549, DOI 10.1172/JCI112988; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAMURA S, 1990, BLOOD, V76, P501; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; 1985, ANN INTERN MED, V103, P620; 1976, BRIT J HAEMATOL, V33, P451	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10154	10159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486685				2022-12-25	WOS:A1993LB80000034
J	CRAWFORD, JA; MUTCHLER, KJ; SULLIVAN, BE; LANIGAN, TM; CLARK, MS; RUSSO, AF				CRAWFORD, JA; MUTCHLER, KJ; SULLIVAN, BE; LANIGAN, TM; CLARK, MS; RUSSO, AF			NEURAL EXPRESSION OF A NOVEL ALTERNATIVELY SPLICED AND POLYADENYLATED GS-ALPHA TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; NERVE GROWTH-FACTOR; MESSENGER-RNA; G-PROTEINS; ADENYLYL CYCLASE; RAT-BRAIN; DIFFERENTIAL EXPRESSION; REGULATORY PROTEINS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	We have isolated an alternative transcript of the rat Gsalpha signal transduction protein gene, referred to as GsalphaN1. GsalphaN1 was isolated by differential hybridization screening of genes induced upon dexamethasone treatment of the neuronal-like CA77 rat thyroid C-cell line. The 1-kilobase GsalphaN1 transcript is generated by alternative splicing and polyadenylation of a novel terminal exon. This exon lies 800 base pairs downstream of exon 3 in the Gsalpha gene. Dexamethasone differentially induced GsalphaN1 severalfold relative to Gsalpha mRNA in the CA77 cells, similar to the bias seen with alternative processing of the calcitonin/calcitonin gene-related peptide transcript. In addition to the differential regulation by dexamethasone, the expression pattern of GsalphaN1 in rat tissues differed markedly from Gsalpha. GsalphaN1 mRNA was much more abundant in the brain, with intermediate levels in skeletal muscle and very low levels in other tissues. This was in contrast to the more ubiquitously expressed Gsalpha mRNA. Within the brain, GsalphaN1 was particularly abundant in discrete regions of the brainstem and hypothalamus that modulate autonomic functions. Examination of rat embryos demonstrated that Gsalpha is expressed in both brain and nonneural tissue at least 1 day before GsalphaN1 mRNA could be detected in the embryonic brain. Based on the regulated expression of the GsalphaN1 transcript and previous studies on Galpha proteins, the predicted GsalphaN1 protein may potentially modulate several heterotrimeric G protein functions in the nervous system.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa				Russo, Andrew/0000-0002-8156-5649	NIDCR NIH HHS [DEOP170] Funding Source: Medline; NIGMS NIH HHS [GM07337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI IU, 1992, NUCLEIC ACIDS RES, V20, P4263, DOI 10.1093/nar/20.16.4263; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; ANDERSON DJ, 1989, TRENDS GENET, V5, P174, DOI 10.1016/0168-9525(89)90072-3; ARONIN N, 1992, J NEUROSCI, V12, P3435; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRANN MR, 1987, FEBS LETT, V222, P191, DOI 10.1016/0014-5793(87)80218-1; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COOPER DMF, 1990, BRAIN RES, V523, P143, DOI 10.1016/0006-8993(90)91648-Z; DENKER BM, 1992, J BIOL CHEM, V267, P6272; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANNEMAN JG, 1991, J NEUROCHEM, V57, P1019, DOI 10.1111/j.1471-4159.1991.tb08252.x; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; Le Douarin N.M., 1982, NEURAL CREST; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Mutchler K J, 1992, PCR Methods Appl, V1, P195; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NISHIYAMA I, 1992, EXP CELL RES, V198, P214, DOI 10.1016/0014-4827(92)90373-G; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; RIUS RA, 1991, FEBS LETT, V288, P51, DOI 10.1016/0014-5793(91)81001-O; RODAN SB, 1986, ENDOCRINOLOGY, V118, P2510, DOI 10.1210/endo-118-6-2510; RUSSO AF, 1988, NEURON, V1, P311, DOI 10.1016/0896-6273(88)90079-7; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3906, DOI 10.1073/pnas.86.10.3906; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SWAROOP A, 1991, NUCLEIC ACIDS RES, V19, P4725, DOI 10.1093/nar/19.17.4725; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG HY, 1991, ENDOCRINOLOGY, V129, P133, DOI 10.1210/endo-129-1-133; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	54	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9879	9885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486667				2022-12-25	WOS:A1993LA68900103
J	KAIKAUS, RM; CHAN, WK; LYSENKO, N; RAY, R; DEMONTELLANO, PRO; BASS, NM				KAIKAUS, RM; CHAN, WK; LYSENKO, N; RAY, R; DEMONTELLANO, PRO; BASS, NM			INDUCTION OF PEROXISOMAL FATTY-ACID BETA-OXIDATION AND LIVER FATTY ACID-BINDING PROTEIN BY PEROXISOME PROLIFERATORS - MEDIATION VIA THE CYTOCHROME P-450IVA1 OMEGA-HYDROXYLASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; RAT-LIVER; DICARBOXYLIC-ACIDS; TREATED RATS; HEPATOCYTES; CLOFIBRATE; MITOCHONDRIAL; INACTIVATION; CULTURE; SYSTEM	Both the enzymes of peroxisomal fatty acid beta-oxidation and the liver fatty acid-binding protein (L-FABP) are induced in the liver by peroxisome proliferators, such as clofibrate (CF), as well as high fat diets. One proposed mechanism for this induction is that it represents an adaptive response to altered intracellular fatty acid fluxes, mediated by dicarboxylic fatty acids formed via the cytochrome P-450IVA1 omega-oxidation pathway. The studies presented in this paper were designed to investigate the role of the products of P-450IVA1 omega-oxidation in the regulation of peroxisomal beta-oxidation and L-FABP. In primary hepatocyte cultures exposed to CF, the increase in P-450IVA1 activity preceded the induction of peroxisomal beta-oxidation and L-FABP. The CF-mediated increases in peroxisomal beta-oxidation and L-FABP, but not P-450IVA1, could be significantly inhibited pretranslationally by concurrent exposure of cultured hepatocytes to inactivators of cytochromes P-450, such as 1-aminobenzotriazole and 10-undecynoic acid. Hexadecanedioic acid, a 16-carbon dicarboxylic fatty acid, that is poorly metabolized in hepatocytes, induced peroxisomal beta-oxidation and L-FABP, but not P-450IVA1, via a pretranslational mechanism that was not inhibited by 1-aminobenzotriazole. Long-chain monocarboxylic acids were without such inducing effect. In further studies, non-beta-oxidizable dicarboxylic acid analogs were found to display greater potency as inducers of peroxisomal beta-oxidation when compared to hexadecanedioic acid. The inducing effects of the dicarboxylic acid analogs were also independent of the P-450 omega-oxidation pathway. The results of these studies suggest that the regulation of peroxisomal beta-oxidation enzymes and L-FABP is mediated, to a significant extent, by poorly metabolized long-chain dicarboxylic acids formed via the P-450IVA1 pathway.	UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0538,HSW 1120,3RD & PARNASSUS AVES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013328, R01DK032926, R01DK013328, K08DK002056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13328-21, DK-02056, DK-32926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1980, BIOCHIM BIOPHYS ACTA, V617, P156, DOI 10.1016/0005-2760(80)90233-7; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BASS NM, 1985, J BIOL CHEM, V260, P9603; BASS NM, 1993, IN PRESS MOL CELL BI; BELL DR, 1991, BIOCHEM J, V280, P249, DOI 10.1042/bj2800249; BELL DR, 1991, BIOCHEM J, V275, P247, DOI 10.1042/bj2750247; BERGE RK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P345, DOI 10.1016/0005-2760(89)90083-0; BISSELL D M, 1975, P119; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1034, P53, DOI 10.1016/0304-4165(90)90152-M; BRONFMAN M, 1986, BIOCHEM J, V239, P781, DOI 10.1042/bj2390781; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CAMPBELL CD, 1969, J CHEM SOC C, P742, DOI 10.1039/j39690000742; CHAN WK, 1992, DISS ABS INT B, V53, pB292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMONTELLANO PRO, 1981, ARCH BIOCHEM BIOPHYS, V210, P717, DOI 10.1016/0003-9861(81)90239-3; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; DEMONTELLANO PRO, 1984, TETRAHEDRON, V40, P511; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EACHO PI, 1988, BIOCHEM BIOPH RES CO, V157, P1148, DOI 10.1016/S0006-291X(88)80993-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HERTZ R, 1985, BIOCHIM BIOPHYS ACTA, V836, P192, DOI 10.1016/0005-2760(85)90066-9; HERTZ R, 1988, BIOCHEM PHARMACOL, V37, P3571, DOI 10.1016/0006-2952(88)90387-5; ICHIHARA K, 1979, J BIOCHEM-TOKYO, V86, P139; ICHIHARA K, 1971, BIOCHIM BIOPHYS ACTA, V239, P178; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KAWASHIMA Y, 1982, J PHARMACOBIO-DYNAM, V5, P771; KONDRUP J, 1985, BIOCHIM BIOPHYS ACTA, V835, P147, DOI 10.1016/0005-2760(85)90041-4; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AYH, 1968, J BIOL CHEM, V243, P1331; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MEISNER H, 1975, BIOCHEM BIOPH RES CO, V66, P1134, DOI 10.1016/0006-291X(75)90476-3; METCALFE LD, 1961, ANAL CHEM, V33, P363, DOI 10.1021/ac60171a016; MICO BA, 1988, BIOCHEM PHARMACOL, V37, P2515, DOI 10.1016/0006-2952(88)90240-7; MILTON MN, 1990, BIOCHEM PHARMACOL, V40, P2727, DOI 10.1016/0006-2952(90)90594-B; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V666, P394, DOI 10.1016/0005-2760(81)90298-8; MUAKKASSAHKELLY SF, 1987, EXP CELL RES, V171, P37, DOI 10.1016/0014-4827(87)90249-7; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; REICH NO, 1986, BIOCHEM PHARMACOL, V35, P1227, DOI 10.1016/0006-2952(86)90264-9; REUBSAET FAG, 1990, FEBS LETT, V267, P229, DOI 10.1016/0014-5793(90)80931-8; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1203, DOI 10.1016/0006-2952(88)90771-X; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; TABOR S, 1988, CURRENT PROTOCOLS MO, V1; TANAKA K, 1972, J BIOL CHEM, V247, P7465; TONSGARD JH, 1988, J CLIN INVEST, V82, P1567, DOI 10.1172/JCI113767; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x	65	96	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9593	9603						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486647				2022-12-25	WOS:A1993LA68900068
J	RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y				RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y			WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF	ONCOGENE			English	Article							RNA POLYMERASE-II; HIGH-LEVEL EXPRESSION; LARGE T-ANTIGEN; C-MYC-GENE; P53 PROTEIN; ACCURATE TRANSCRIPTION; NUCLEAR-LOCALIZATION; DNA-REPLICATION; TFIID COMPLEX; PROMOTER	It has previously been shown that excess wild type (wt) p53 can repress the transcriptional activity of a variety of promoters in intact cells. To determine whether this transcriptional repression represented a direct effect of p53, wt and mutant p53 were prepared from E. coli-produced p53 and from insect cells infected with a recombinant baculovirus. When added into an in vitro transcription system, wt p53, but not mutant p53 reduced markedly transcription from the c-myc promoter, as well as from an array of other promoters, with the exception of an MHC class I gene promoter. The presence of wt p53 seemed to affect specifically the formation of the transcription preinitiation complex because preformed initiation complexes were completely refractory to wt p53, as was also the process of transcript elongation. Wild-type but not mutant p53 interfered with the stable binding of TBP and TFIIA to the TATA motif, although both wt and mutant p53 could associate in vitro with purified TBP. We propose that upon binding to TBP, wt but not mutant p53 specifically blocks the ability of TBP to engage in interactions required for efficient transcriptional initiation. This may account, at least in part, for the ability of excess wt p53 to inhibit cell proliferation and to interfere with neoplastic processes.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIRE A, 1984, J BIOL CHEM, V259, P2509; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAHN SR, 1985, NATURE, V314, P366; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V34, P752; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OROURKE RW, 1990, ONCOGENE, V5, P1829; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Seiberg M, 1987, Virus Genes, V1, P97; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Summers MD, 1987, TEXAS AGR EXPT STATI; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAWEL L, 1992, IN PRESS PROG NUCLEI	87	193	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1183	1193						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479742				2022-12-25	WOS:A1993KY32800009
J	HAMILTON, BJ; NAGY, E; MALTER, JS; ARRICK, BA; RIGBY, WFC				HAMILTON, BJ; NAGY, E; MALTER, JS; ARRICK, BA; RIGBY, WFC			ASSOCIATION OF HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-A1 AND C-PROTEINS WITH REITERATED AUUUA SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA STABILITY; BINDING PROTEINS; NUCLEOTIDE-SEQUENCE; GENE-REGULATION; RICH SEQUENCES; HNRNP PROTEINS; GM-CSF; CELLS; PARTICLES	Post-transcriptional regulatory mechanisms have been shown to play a major role in gene expression in eukaryotic cells. The presence of a reiterated pentamer (AUUUA) in the 3'-untranslated region (UTR) of mRNAs encoding lymphokines, cytokines, transcription factors, and proto-oncogenes has been shown to be associated with rapid turnover and translation attenuation. Cytoplasmic proteins (70, 50, 43, 36, and 25 kDa) capable of specifically binding to RNAs containing these AU-rich sequences were identified in human peripheral blood T lymphocytes. Levels of the 36-kDa protein were markedly increased following transcriptional, but not translational inhibition, a feature recently reported for hnRNP A1, a protein of comparable mass. Antibodies directed against heterogeneous nuclear ribonucleoproteins (hnRNPs) Al and C immunoprecipitated 36- and 43-kDa proteins that had bound the AUUUA-rich region contained in the 3'-UTR of granulocyte-macrophage colony-stimulating factor mRNA. Recombinant hnRNP A1 was shown to preferentially bind to RNAs containing AUUUA sequences in a specific manner, and displayed comparable patterns to the 36-kDa AU-specific binding proteins following partial proteolysis. These data identify for the first time hnRNP A1 and C as cytoplasmic proteins in human lymphocytes that are capable of specifically associating with reiterated AUUUA sequences present in the 3'-UTR of labile mRNAs. As such, they may play a role as trans-acting factors in the modulation of cytoplasmic mRNA turnover and translation, in addition to their previously characterized roles as pre-mRNA binding proteins involved in nuclear mRNA processing.	DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MED, HANOVER, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MICROBIOL, HANOVER, NH 03756 USA; WHITE RIVER JUNCT VET ADM MED CTR, WHITE RIVER JCT, VT 05001 USA; UNIV WISCONSIN, DEPT PATHOL LAB MED, MADISON, WI 53792 USA	Dartmouth College; Dartmouth College; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI2434, K04 AI00910] Funding Source: Medline; NIDDK NIH HHS [R01 DK 45213] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BICKEL M, 1990, J IMMUNOL, V145, P840; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, MOL BIOL REP, V14, P83, DOI 10.1007/BF00360425; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NAKAGAWA TY, 1986, P NATL ACAD SCI USA, V83, P2007, DOI 10.1073/pnas.83.7.2007; PANDOLFO M, 1985, NUCLEIC ACIDS RES, V13, P6577, DOI 10.1093/nar/13.18.6577; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; ROSS J, 1988, MOL BIOL MED, V5, P1; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	44	202	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8881	8887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473331				2022-12-25	WOS:A1993KX81100074
J	LU, KP; OSMANI, SA; MEANS, AR				LU, KP; OSMANI, SA; MEANS, AR			PROPERTIES AND REGULATION OF THE CELL CYCLE-SPECIFIC NIMA PROTEIN-KINASE OF ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ACTIVATION; MITOSIS; CALMODULIN; SERINE; YEAST; DEPHOSPHORYLATION; SEQUENCE; CLONING; ENTRY	NIMA is the protein product of the nimA gene of the filamentous fungus Aspergillus nidulans, required for progression of cells from G2 into mitosis. The protein kinase activity of NIMA, assayed by phosphorylation of beta-casein, varies during the nuclear division cycle, reaching a maximum in late G2 and M. To investigate the biochemical properties of this cell cycle-regulated protein kinase, we have expressed nimA cDNA that encodes full-length NIMA in Escherichia coli as a fusion product with glutathione S-transferase. Purified NIMA phosphorylated beta-casein, with a K(m) of 38 muM and V(max) of 156 nmol/min/mg. NIMA also demonstrated a K(m) of 69 muM for ATP. Both recombinant and cellular NIMA kinases behaved as oligomers on gel filtration chromatography, and their kinase activities were strongly inhibited by various salts. By using both protein and peptide substrates, NIMA demonstrated a serine/threonine-specific protein kinase activity. Cellular NIMA exists as a phosphoprotein, and bacterially expressed NIMA was also phosphorylated on multiple serine/threonine residues. Some of these phosphorylations appeared essential for NIMA activity as the enzyme could be dephosphorylated and inactivated in vitro by protein serine/threonine phosphatases. Use of a kinase-negative mutant of NIMA revealed that the NIMA enzyme undergoes autophosphorylation when expressed at high concentrations in bacteria. Taken together, these data suggest that cellular mechanisms may exist to regulate the phosphorylation state and activity of the NIMA protein kinase during the nuclear division cycle in A. nidulans.	DUKE UNIV, MED CTR, DEPT PHARMACOL, POB 3813, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Duke University; Duke University; Baylor College of Medicine			Osmani, Stephen A./AAS-3904-2021		NIGMS NIH HHS [GM42564] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BARTELT DC, 1988, P NATL ACAD SCI USA, V85, P3279, DOI 10.1073/pnas.85.10.3279; BARTON AB, 1992, GENE, V117, P137, DOI 10.1016/0378-1119(92)90502-G; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8025; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOOVER D, 1991, J BIOL CHEM, V266, P14018; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; KORNSTEIN LB, 1992, GENE, V113, P75, DOI 10.1016/0378-1119(92)90671-B; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KU KP, 1991, J CELL BIOL, V115, pA426; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; MATSUDA S, 1992, EMBO J, V11, P937; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONO T, 1989, J BIOL CHEM, V264, P2081; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHWEITZER B, 1992, MOL GEN GENET, V234, P164, DOI 10.1007/BF00272358; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBIESZEK A, 1991, J MOL BIOL, V220, P947, DOI 10.1016/0022-2836(91)90365-D; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	45	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8769	8776						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473320				2022-12-25	WOS:A1993KX81100059
J	GEHM, BD; KUO, WL; PERLMAN, RK; ROSNER, MR				GEHM, BD; KUO, WL; PERLMAN, RK; ROSNER, MR			MUTATIONS IN A ZINC-BINDING DOMAIN OF HUMAN INSULIN-DEGRADING ENZYME ELIMINATE CATALYTIC ACTIVITY BUT NOT INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; METALLOENDOPROTEASE INHIBITORS; DEGRADATION PRODUCTS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; PROTEASE-III; FACTOR-ALPHA; DIFFERENTIATION; THERMOLYSIN; EXPRESSION	Insulin-degrading enzyme is a nonlysosomal metalloprotease that initiates degradation of internalized insulin in some cells. We previously identified a potential catalytic site containing an inversion of the Zn2+-binding domain of the thermolysin family (Kuo, W.-L., Gehm, B. D., and Rosner, M. R. (1991) Mol. Endocrinol. 4, 1580-1591). The role of this site in catalysis was examined by mutating one of the presumptive Zn2+-coordinating histidines (His108) in human insulin-degrading enzyme to leucine or glutamine, which were predicted to reduce or eliminate Zn2+ binding without substantially altering secondary structure. cDNAs for the mutant and wild-type enzymes were incorporated into an expression vector and transfected into COS cells. Expression of the transfected genes was confirmed by Northern and Western blots. In contrast to the wild-type gene, which increased insulin degradation by cell extracts and intact cells several-fold, the mutated genes had no effect on insulin degradation, indicating a loss of catalytic activity. However, the mutants' ability to bind substrate was unimpaired, as affinity labeling with I-125-insulin was increased compared to the wild type. These results suggest that an intact Zn2+-binding domain in human insulin-degrading enzyme is required for catalytic activity and can affect, but is not required for, substrate binding.	UNIV CHICAGO, BEN MAY INST,DEPT PHARMACOL & PHYSIOL SCI, 5841 S MARYLAND,BOX 424, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago								AFFHOLTER JA, 1990, MOL ENDOCRINOL, V4, P1125, DOI 10.1210/mend-4-8-1125; AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AFFHOLTER JA, 1990, BIOCHEMISTRY-US, V29, P7727, DOI 10.1021/bi00485a022; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BIGNER SH, 1990, CANCER RES, V50, P8017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; DUCKWORTH WC, 1990, INSULIN HDB EXPT PHA, V92, P143; EBRAHIM A, 1991, BIOCHEM BIOPH RES CO, V181, P1398, DOI 10.1016/0006-291X(91)92094-Z; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLDEN HM, 1988, J BIOL CHEM, V263, P3256; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KAYALAR C, 1990, J CELL BIOCHEM, V44, P137, DOI 10.1002/jcb.240440303; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; KUO WL, 1991, MOL ENDOCRINOL, V5, P1467, DOI 10.1210/mend-5-10-1467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 1992, J BIOL CHEM, V267, P2414; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P41, DOI 10.1038/newbio238041a0; OGAWA W, 1992, J BIOL CHEM, V267, P1310; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; Sambrook J, 1989, MOL CLONING LABORATO; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220	35	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7943	7948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463315				2022-12-25	WOS:A1993KW97900056
J	GARDNER, HW; HAMBERG, M				GARDNER, HW; HAMBERG, M			OXYGENATION OF (3Z)-NONENAL TO (2E)-4-HYDROXY-2-NONENAL IN THE BROAD BEAN (VICIA-FABA L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; LIPOXYGENASE PATHWAY; STERIC ANALYSIS; GLYCINE-MAX; HYDROPEROXIDES; EPOXIDATION; CHEMISTRY; ALDEHYDES; LIPIDS	Incubation of (3Z)-nonenal (NON) with the 269,000-g particle fraction of seed homogenate of the broad bean (Vicia faba L.) afforded (2E)-4-hydroxy-2-nonenal (HNE) as the principal product. One pathway of HNE formation consisted of initial oxygenation of NON into (2E)-4-hydroperoxy-2-nonenal (HPNE) by a novel (3Z)-alkenal oxygenase activity, followed by conversion of HPNE into HNE by a previously recognized hydroperoxide-dependent epoxygenase. The hydroperoxide intermediate was detected in coincubations of NON and oleic acid, in which experiments the HPNE generated from NON supported epoxygenase-catalyzed epoxidation of oleic acid into 9,10-epoxystearic acid. Furthermore, by using an enzyme preparation in which the epoxygenase had been inactivated by pretreatment with hydrogen peroxide it was possible to isolate and characterize racemic (4R,4S) HPNE following incubation of NON. Although the (3Z)-alkenal oxygenase resembled a lipoxygenase in its action, it was not inhibited by the lipoxygenase inhibitors, 5,8,11,14-eicosatetraynoic acid and nordihydroguaiaretic acid. In a second pathway, HNE was produced by rearrangement of 3,4-epoxynonenal, which was in turn formed from NON by a reaction catalyzed by hydroperoxide-dependent epoxygenase. Support for this pathway came from experiments in which O-18-labeled HNE was isolated following coincubation of NON and 13-O-18-labeled linoleic acid 13-hydroperoxide. The existence of 3,4-epoxynonenal as a transient intermediate in HNE biosynthesis was further demonstrated by the isolation of 3,4-epoxynonenol (61% (4R)-configuration) as a trapping product in short time incubations interrupted by addition of sodium borohydride. The two pathways established for biosynthesis of HNE involved the hydroperoxide-reducing and the olefin-epoxidizing activities of hydroperoxide-dependent epoxygenase. In the absence of extraneous olefins and hydroperoxides the two pathways would be tightly coupled and follow the stoichiometry: 2NON + 1O2 --> 2HNE. It was also shown that the V. faba particle fraction catalyzed oxygenation of (3Z)-hexenal into (2E)-4-hydroxy-2-hexenal.	KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	GARDNER, HW (corresponding author), USDA ARS,NATL CTR AGR UTILIZAT RES,1815 N UNIV ST,PEORIA,IL 61604, USA.							BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; BLEE E, 1990, J BIOL CHEM, V265, P12887; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FAHLSTADIUS P, 1989, CHEM PHYS LIPIDS, V51, P15, DOI 10.1016/0009-3084(89)90061-3; GARDNER HW, 1992, LIPIDS, V27, P686, DOI 10.1007/BF02536025; GARDNER HW, 1991, PLANT PHYSIOL, V97, P1059, DOI 10.1104/pp.97.3.1059; GARDNER HW, 1984, LIPIDS, V19, P294, DOI 10.1007/BF02534458; GARDNER HW, 1990, J AGR FOOD CHEM, V38, P1316, DOI 10.1021/jf00096a005; GARDNER HW, 1979, J AGR FOOD CHEM, V27, P220, DOI 10.1021/jf60222a034; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GRECHKIN AN, 1991, EUR J BIOCHEM, V199, P451, DOI 10.1111/j.1432-1033.1991.tb16143.x; Grosch W., 1987, AUTOXIDATION UNSATUR, P95; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMBERG M, 1992, PLANT PHYSIOL, V99, P987, DOI 10.1104/pp.99.3.987; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; KUHN H, 1991, BIOCHEMISTRY-US, V30, P10269; PAUL VJ, 1980, TETRAHEDRON LETT, V21, P3327, DOI 10.1016/S0040-4039(00)78680-1; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; RATCLIFF.R, 1970, J ORG CHEM, V35, P4000, DOI 10.1021/jo00836a108; SEGALL HJ, 1985, SCIENCE, V229, P472, DOI 10.1126/science.4012327; VANKUIJK FJGM, 1990, METHOD ENZYMOL, V186, P399	23	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6971	6977						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463229				2022-12-25	WOS:A1993KV14100028
J	TSUJI, Y; KWAK, E; SAIKA, T; TORTI, SV; TORTI, FM				TSUJI, Y; KWAK, E; SAIKA, T; TORTI, SV; TORTI, FM			PREFERENTIAL REPRESSION OF THE H-SUBUNIT OF FERRITIN BY ADENOVIRUS E1A IN NIH-3T3 MOUSE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MALIGNANT LYMPHOID-CELLS; MESSENGER-RNA; HEAVY-CHAIN; TRANSCRIPTIONAL REGULATION; TRANSFERRIN RECEPTOR; UNTRANSLATED REGION; TISSUE ISOFERRITINS; FUNCTIONAL DOMAINS; MOLECULAR-CLONING	Ferritin is the major intracellular iron-storage protein in eucaryotic cells and plays a prominent role in maintaining intracellular iron homeostasis. We observed that transfection of NIH-3T3 mouse fibroblasts with the adenovirus E1A oncogene specifically repressed the mRNA for one of the subunits of ferritin, ferritin H. This occurred in the absence of any effect of E1A on the mRNA for the L subunit of ferritin. The repression of ferritin H was not a general feature of oncogene expression since transfection of NIH-3T3 cells with H-ras did not affect ferritin composition. Deletion of the conserved regions of E1A responsible for immortalization and transcriptional repression impaired the ability of E1A to repress ferritin H. Immunoprecipitation of ferritin in E1A transfectants demonstrated that the decrease in the ferritin H/L ratio observed at the mRNA level was also exhibited at the protein level. The E1A-dependent inhibition of ferritin H was also observed in a chimeric gene containing the ferritin H promoter ligated to the chloramphenicol acetyltransferase reporter gene, but was not observed in control genes in which chloramphenicol acetyltransferase activity was dependent on promoters derived from SV40 or the interleukin-3 gene. This suggests that E1A may repress ferritin H at the transcriptional level. These results demonstrate that the adenovirus E1A oncogene specifically modulates ferritin H expression. They also suggest that alterations in cellular iron metabolism may be among the diverse array of cellular responses induced by E1A.	VET ADM MED CTR,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NIDDK NIH HHS [DK42412] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412, R01DK042412] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1976, CANCER RES, V36, P1735; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BEVILACQUA MA, 1988, ITAL J BIOCHEM, V37, P1; BOMFORD A, 1981, J BIOL CHEM, V256, P948; BOYD D, 1985, J BIOL CHEM, V260, P1755; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CAIRO G, 1986, BIOCHEM BIOPH RES CO, V139, P652, DOI 10.1016/S0006-291X(86)80040-7; CHAZENBALK GD, 1990, MOL ENDOCRINOL, V4, P1117, DOI 10.1210/mend-4-8-1117; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COX F, 1988, J BIOL CHEM, V263, P7060; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIAU G, 1991, J BIOL CHEM, V266, P18819; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER MC, 1982, ENZYME, V27, P189, DOI 10.1159/000459048; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNRO HN, 1990, J CELL BIOCHEM, V44, P107, DOI 10.1002/jcb.240440205; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NIITSU Y, 1984, JPN J CANCER RES, V75, P699; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; Sambrook J, 1989, MOL CLONING LABORATO; SARCIONE EJ, 1977, INT J CANCER, V20, P339, DOI 10.1002/ijc.2910200304; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; VAUGHN CB, 1980, CANCER INVEST, V5, P7; VEZZONI P, 1986, BRIT J HAEMATOL, V62, P105, DOI 10.1111/j.1365-2141.1986.tb02905.x; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; WHITE K, 1988, J BIOL CHEM, V263, P8938; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WORWOOD M, 1980, BIOCHEM MEDICA, V2, P204; Wrigglesworth J.M, 1980, IRON BIOCH MED, P29; YOKOMORI N, 1991, ENDOCRINOLOGY, V128, P1474, DOI 10.1210/endo-128-3-1474; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	65	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7270	7275						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463262				2022-12-25	WOS:A1993KV14100066
J	CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H				CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H			EXPRESSION OF AML1 ETO FUSION TRANSCRIPTS AND DETECTION OF MINIMAL RESIDUAL DISEASE IN T(8 21)-POSITIVE ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; TRANSLOCATION BREAKPOINT; T(15-17) TRANSLOCATION; RAR-ALPHA; GENE; AMPLIFICATION; CLASSIFICATION; T(14-18)	The t(8;21) translocation breakpoint, which is observed in acute myeloid leukemia (AML), has recently been cloned and a fusion transcript identified. We have now designed primer sets capable of amplifying the breakpoint junction of the fusion transcript by the reverse transcription-polymerase chain reaction (RT-PCR). Primer set 821U/821D1 amplified a 200-bp DNA fragment, and primer set 821U/821D2 amplified a 1.2-kb DNA fragment in all t(8;21)-positive AML tested. Sequence analysis of the amplified DNA fragments demonstrated that all fusion transcripts were fused at exactly the same site, indicating that this translocation breakpoint occurs within a single intron of the AML1 and ETO genes. Forty-five cycles of RT-PCR were used to detect residual t(8;21)-positive leukemia cells in three patients who had been in complete remission for 1, 3 and 5 years. Minimal residual disease was found in all three samples. Northern blot analysis demonstrated that two fusion transcripts of 7 and 10 kb were expressed in the t(8;21)-positive AML and that the ETO gene is not normally expressed in the hematopoietic system. Expression of a normal 5.5-kb ETO mRNA was found in the lung. From these results we concluded that expression of the ETO gene in t(8;21)-positive AML was activated as a result of the translocation.	UNIV COLORADO,CTR HLTH SCI & CANC,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver	CHANG, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,HOUSTON,TX 77030, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NICHD NIH HHS [P01HD017449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1992, BLOOD, V79, P554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DELFAU MH, 1990, LEUKEMIA, V4, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOBROVIC A, 1988, BLOOD, V72, P3063; ERICKSON P, 1992, BLOOD, V80, P1825; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LANGE W, 1989, BLOOD, V73, P1735; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PIGNON JM, 1990, LEUKEMIA, V4, P83; SHIMIZU K, 1991, GENE CHROMOSOME CANC, V3, P163, DOI 10.1002/gcc.2870030302	24	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					983	988						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455949				2022-12-25	WOS:A1993KT22000021
J	LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D				LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D			CHARACTERIZATION OF A FUNCTIONAL PROMOTER FOR THE HUMAN THYROID-HORMONE RECEPTOR ALPHA (C-ERBA-1) GENE	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; REGULATED EXPRESSION; NUCLEAR RECEPTORS; RESPONSE ELEMENT; OPPOSITE STRAND; BINDING-SITE; MINUTE VIRUS; BETA-GENE; RAT-CELLS	The thyroid hormone receptor alpha (THRA or c-erbA-1) gene belongs to a family of genes that encode nuclear receptors for various hydrophobic ligands such as steroids, retinoic acid and thyroid hormones. We have previously described the genomic organization of the human THRA gene, which comprises 10 exons distributed along 27 kbp of genomic DNA. We describe here a promoter that initiates THRA transcription. This promoter contains no obvious TATA-like element but is very GC rich and harbors numerous Spl sites. It also contains several sites similar to previously described cis-acting sequences including hormone-responsive elements (HREs). When transfected into cultured HeLa cells, it drives the expression of a CAT reporter gene. The activity of this human THRA promoter is enhanced by the synthetic glucocorticoid dexamethasone but seems unaffected by thyroid hormones.			LAUDET, V (corresponding author), INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.							AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; BAKER BS, 1990, EMBO J, V9, P879, DOI 10.1002/j.1460-2075.1990.tb08185.x; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DENAYER P, 1987, EUR J CLIN INVEST, V17, P106, DOI 10.1111/j.1365-2362.1987.tb02388.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOZIER C, 1991, ONCOGENE, V6, P1307; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GALTON VA, 1990, ENDOCRINOLOGY, V127, P2997, DOI 10.1210/endo-127-6-2997; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HABER DA, 1992, NEW BIOL, V4, P97; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1990, MOL BIOL CARD SYST, V3, P111; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEE JT, 1991, PANCREAS, V6, P96, DOI 10.1097/00006676-199101000-00013; LUADET V, 1992, CURR BIOL, V2, P93; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANITATIS T, 1989, MOL CLONING LABORATO; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE D D, 1990, New Biologist, V2, P100; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; NIKI K, 1981, P JPN ACAD B-PHYS, V57, P271, DOI 10.2183/pjab.57.271; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1987, NUCLEIC ACIDS RES, V15, P9613, DOI 10.1093/nar/15.22.9613; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAMUELS HH, 1977, J BIOL CHEM, V252, P6052; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; VANHILLE B, 1989, VIROLOGY, V171, P89, DOI 10.1016/0042-6822(89)90514-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	70	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					975	982						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455948				2022-12-25	WOS:A1993KT22000020
J	SOSA, MA; SCHMIDT, B; VONFIGURA, K; HILLEREHFELD, A				SOSA, MA; SCHMIDT, B; VONFIGURA, K; HILLEREHFELD, A			INVITRO BINDING OF PLASMA MEMBRANE-COATED VESICLE ADAPTERS TO THE CYTOPLASMIC DOMAIN OF LYSOSOMAL ACID-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; PROTEIN COMPLEX; AMINO-ACIDS; CLATHRIN; INTERNALIZATION; IDENTIFICATION; PURIFICATION; SIGNAL; TAIL; ENDOCYTOSIS	Sorting of the newly synthesized membrane-bound precursor of lysosomal acid phosphatase (LAP) involves internalization from the plasma membrane via clathrin-coated pits. Using an in vitro system, we present direct evidence for high affinity interaction of the cytoplasmic domain of LAP with the amino-terminal trunk portion of plasma membrane-coated vesicle adaptors. Coated vesicle adaptors of the trans-Golgi network displayed poor binding to LAP, but high affinity binding to the cytoplasmic tail of the 46-kDa mannose 6-phosphate receptor, which is included in clathrin-coated pits of the trans-Golgi network. Binding of plasma membrane adaptors to the tail peptide of LAP required an internalization signal that contains either tyrosine or phenylalanine.			SOSA, MA (corresponding author), UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY.							AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GEUZE H, 1991, HEPATIC ENDOCYTOSIS, P28; GIESELMANN V, 1984, H-S Z PHYSIOL CHEM, V365, P651, DOI 10.1515/bchm2.1984.365.1.651; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; HILLE A, 1992, EUR J CELL BIOL, V59, P106; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KLUMPERMAN J, 1993, IN PRESS J CELL BIOL; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; NADIMPALLI SK, 1991, FEBS LETT, V280, P61, DOI 10.1016/0014-5793(91)80204-G; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; PRILL V, 1993, IN PRESS EMBO J; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x	39	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12537	12543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509395				2022-12-25	WOS:A1993LG65800048
J	MEINS, M; JENO, P; MULLER, D; RICHTER, WJ; ROSENBUSCH, JP; ERNI, B				MEINS, M; JENO, P; MULLER, D; RICHTER, WJ; ROSENBUSCH, JP; ERNI, B			CYSTEINE PHOSPHORYLATION OF THE GLUCOSE TRANSPORTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID SEQUENCE; PROTEIN-KINASE; MANNITOL TRANSPORT; BACILLUS-SUBTILIS; CARRIER PROTEIN; PHOSPHOENOLPYRUVATE; PERMEASE; RESIDUE	The glucose transporter (IIBC(Glc)/IIA(Glc) complex) of the bacterial phosphotransferase system couples vectorial translocation to phosphorylation of the transported sugar. The IIA(Glc) subunit transfers the phosphoryl group from the phosphoryl carrier protein P-HPr to the IIBC(Glc) subunit. IIBC(Glc) translocates and phosphorylates glucose. The site of IIBC(Glc) phosphorylation is cysteine 421 as shown by mass spectrometric and biochemical analyses of phosphorylated peptides. Site-directed mutagenesis of Cys421 (C421S) afforded a stable but completely inactive protein (Nuoffer, C., Zanolari, B., and Erni, B. (1988) J. Biol. Chem. 263, 6647-6655). Cys421 is located in the C-terminal cytoplasmic domain of the IIBC(Glc) subunit in a sequence context (LDACITRL) which is well conserved in other transporters of the bacterial phosphotransferase system. Phosphocysteine has been shown previously to be the catalytic intermediate of the mannitol transporter (Pas, H. H., Meyer, G. H., Kruizinga, W. H., Tamminga, K. S., van Weeghel, R. P., and Robillard, G. T. (1991) J. Biol. Chem. 266, 6690-6692).	UNIV BASEL,BIOCTR,DEPT BIOCHEM,CH-4056 BASEL,SWITZERLAND; CIBA GEIGY AG,DEPT PHYS,CH-4002 BASEL,SWITZERLAND	University of Basel; Novartis	MEINS, M (corresponding author), UNIV BASEL,BIOCTR,DEPT MICROBIOL,CH-4056 BASEL,SWITZERLAND.							AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; ALPERT CA, 1990, J BIOL CHEM, V265, P22561; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BIEMANN K, 1987, MASS SPECTROM REV, V6, P1, DOI 10.1002/mas.1280060102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHR A, 1993, J BIOL CHEM, V268, P11599; BURK RR, 1983, METHOD ENZYMOL, V91, P247; Cantor C.R., 1980, BIOPHYS CHEM; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DEREUSE H, 1986, J BACTERIOL, V177, P3827; DEUTSCHER J, 1982, BIOCHEMISTRY-US, V21, P4867, DOI 10.1021/bi00263a006; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1986, J BACTERIOL, V166, P829, DOI 10.1128/jb.166.3.829-836.1986; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1986, J BIOL CHEM, V261, P6398; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; ERNI B, 1989, J BIOL CHEM, V264, P18733; FAIRBROTHER WJ, 1992, BIOCHEMISTRY-US, V31, P4413, DOI 10.1021/bi00133a005; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GIBSON BW, 1990, METHOD ENZYMOL, V193, P480, DOI 10.1016/0076-6879(90)93434-M; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KREIL G, 1964, BIOCHEM BIOPH RES CO, V16, P551, DOI 10.1016/0006-291X(64)90191-3; KURODA Y, 1983, BIOCHEM BIOPH RES CO, V112, P884, DOI 10.1016/0006-291X(83)91700-X; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; POST RL, 1973, J BIOL CHEM, V248, P6993; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WIELAND T, 1956, CHEM BER-RECL, V89, P2476, DOI 10.1002/cber.19560891046; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	51	66	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11604	11609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505292				2022-12-25	WOS:A1993LF28400026
J	NA, SQ; PERLIN, DS; SETOYOUNG, D; WANG, GF; HABER, JE				NA, SQ; PERLIN, DS; SETOYOUNG, D; WANG, GF; HABER, JE			CHARACTERIZATION OF YEAST PLASMA-MEMBRANE H+-ATPASE MUTANT PMA1-A135V AND ITS REVERTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; SITE-DIRECTED MUTAGENESIS; RESISTANT PMA1 MUTANTS; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; COMPLEMENTARY-DNA; MISMATCH REPAIR; IDENTIFICATION; OUABAIN; CELLS	An A135V substitution in the first transmembrane segment of the yeast plasma membrane H+-ATPase (PMA1) confers cellular resistance to hygromycin B, exhibits growth sensitivity to low external pH, and results in a defective enzyme that hydrolyzes ATP at 33% of wild type level. The importance of the A135 residue was probed genetically by analysis involving both site-directed mutagenesis and randomly generated second-site intragenic suppressor mutations. No other amino acid at position 135 gave either the wild type phenotype or the normal enzyme activity of A135. Substitutions with the bulkier amino acid residues A135L, A135I, and A135F produced more severe cellular phenotypes than the original A135V mutation. The substitution of the smaller side chain residue Gly was also a mutant, although not as severe as the A135V mutant. The introduction of a bulky Trp or a polar Ser residue produced dominant lethality, while charged amino acids produced recessive lethality. Reduced rates of proton transport measured by acidification of the medium by whole cells correlate closely with the severity of cellular phenotype. Some of the mutant enzymes exhibit an apparent instability in vitro. Thus, the localized structure around A135 is highly constrained. The cellular sensitivity to low external pH of the A135V mutant was used to select intragenic revertants. Most full revertants (low pH(R), Hyg(S)) restored A135, but second-site mutations in putative transmembrane segments 2 (V146I and V157F) and 4 (L327V) were also observed. Two partial revertants (low pH(R), Hyg(R)) have secondary mutations at S660C or a double change at F611L-S660F in the putative ATP binding domain. These results provide additional evidence for functional coupling between the cytoplasmic domain catalyzing ATP hydrolysis and transmembrane helices 1 and 2.	BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039739, R01GM038225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39739, GM38225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P79, DOI 10.1016/0167-4838(86)90192-5; CALVIN NM, 1988, J BACTERIOL, V170, P2796, DOI 10.1128/jb.170.6.2796-2801.1988; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HASSELBACH W, 1981, MEMBRANE TRANSPORT, P183; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIRLEY TL, 1991, J BIOL CHEM, V266, P19953; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PERIYASAMY SM, 1983, COMP BIOCHEM PHYS B, V76, P449, DOI 10.1016/0305-0491(83)90274-2; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO US, 1991, J BIOL CHEM, V266, P14740; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; Sherman F., 1983, METHODS YEAST GENETI; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11792	11797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505307				2022-12-25	WOS:A1993LF28400051
J	PALMER, M; JURSCH, R; WELLER, U; VALEVA, A; HILGERT, K; KEHOE, M; BHAKDI, S				PALMER, M; JURSCH, R; WELLER, U; VALEVA, A; HILGERT, K; KEHOE, M; BHAKDI, S			STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - PRODUCTION OF FUNCTIONALLY INTACT, SITE-SPECIFICALLY MODIFIABLE PROTEIN BY INTRODUCTION OF CYSTEINE AT POSITION-69, POSITION-130, AND POSITION-186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; DAMAGE; CELLS	Staphylococcal alpha-toxin, the prototype of an oligomerizing, pore-forming cytotoxin, is sensitive to biochemical modifications and cannot be labeled with biotin or fluorescein under preservation of its biological activity. In this study, we have used site-directed mutagenesis to introduce cysteine residues at positions 69, 130, and 186. Each mutant was fully and rapidly reactive with several sulfhydryl-specific reagents, indicating superficial location. Coupling of SH-groups with fluorescein-maleimide or biotin-maleimide was tolerated without loss of hemolytic activity at position 130, and the formed hexamers were visible on target cells by fluorescence microscopy and could be detected on electroblots by reaction with streptavidin-peroxidase. At the two other positions, modification caused significant loss of activity. However, the labeled proteins still bound to red cells, as shown by fluorescence microscopy and electroblotting. Intrinsically labeled alpha-toxin represents a novel tool to study the interaction of this pore-former with target membranes.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MICROBIOL,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	PALMER, M (corresponding author), UNIV MAINZ,INST MED MICROBIOL,AUGUSTUSPL,W-6500 MAINZ,GERMANY.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERNHEIMER AW, 1974, BIOCHIM BIOPHYS ACTA, V344, P27, DOI 10.1016/0304-4157(74)90007-0; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; FAIRWEATHER N, 1983, INFECT IMMUN, V41, P1112, DOI 10.1128/IAI.41.3.1112-1117.1983; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; KEHOE M, 1983, INFECT IMMUN, V41, P1111; MCCARTNEY C, 1978, BACTERIAL TOXINS CEL, P89; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	12	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11959	11962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505320				2022-12-25	WOS:A1993LF28400075
J	SHIBUTANI, S; GROLLMAN, AP				SHIBUTANI, S; GROLLMAN, AP			ON THE MECHANISM OF FRAMESHIFT (DELETION) MUTAGENESIS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE INSERTION FIDELITY; DNA-SYNTHESIS; ESCHERICHIA-COLI; MUTATIONAL SPECIFICITY; TRANSIENT MISALIGNMENT; DEOXYRIBONUCLEIC-ACID; BASE SUBSTITUTION; OLIGODEOXYNUCLEOTIDES; CARCINOGEN; ADDUCTS	An experimental system has been developed to quantify frameshift deletions and base substitutions formed during DNA synthesis in vitro. Oligodeoxynucleotides, modified site-specifically with acetylaminofluorene or other adducts and lesions, were used as templates in primer extension reactions catalyzed by the Klenow fragment of Escherichia coli DNA polymerase I. The influence of DNA sequence context on frameshift mutagenesis was determined by modifying systematically the bases flanking the lesion. Frequencies of nucleotide insertion opposite the lesion and chain extension from the 3'-primer terminus were established by steady state kinetic analysis. The ability of a damaged nucleotide to generate one-base and two-base frameshift deletions was determined primarily by two parameters: the nature of the base inserted opposite the adduct with respect to the sequence context in which the lesion is embedded and the overall rate of translesional DNA synthesis. Frameshift deletions generated during DNA synthesis were greatly enhanced in the absence of proofreading exonuclease. Misinsertion of bases opposite the lesion precedes misalignment of the template-primer. Extending on earlier studies (Kunkel, T. A. (1990) Biochemistry 29, 8003-8011), a model has been proposed and used in various sequence contexts to predict the propensity of aminofluorene adducts, exocyclic DNA adducts, 8-oxopurines, and synthetic abasic sites to generate frameshift deletions in vitro.			SHIBUTANI, S (corresponding author), SUNY,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.			Shibutani, Shinya/0000-0003-4190-9512	NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NCI NIH HHS [CA17395] Funding Source: Medline; NIEHS NIH HHS [ES04068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BROYDE S, 1983, BIOPOLYMERS, V22, P2423, DOI 10.1002/bip.360221109; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DEBOER JG, 1988, GENETICS, V118, P181; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EVANS FE, 1980, CARCINOGENESIS, V1, P955, DOI 10.1093/carcin/1.11.955; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; FRESCO JR, 1960, P NATL ACAD SCI USA, V46, P311, DOI 10.1073/pnas.46.3.311; FUCHS R, 1972, BIOCHEMISTRY-US, V11, P2659, DOI 10.1021/bi00764a017; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GROLLMAN A P, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P682; GRUNBERG.D, 1970, P NATL ACAD SCI USA, V66, P488, DOI 10.1073/pnas.66.2.488; GUPTA PK, 1989, J BIOL CHEM, V264, P20120; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON F, 1992, J AM CHEM SOC, V114, P4923, DOI 10.1021/ja00038a079; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; MORIYA M, 1988, P NATL ACAD SCI USA, V85, P1586, DOI 10.1073/pnas.85.5.1586; OHANDLEY SF, 1992, 7TH P CONV BIOM STER, V1, P137; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RIPLEY LS, 1986, J MOL BIOL, V191, P601, DOI 10.1016/0022-2836(86)90448-1; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016	49	136	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11703	11710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505300				2022-12-25	WOS:A1993LF28400039
J	MARQUES, G; ANTON, LC; BARRIO, E; SANCHEZ, A; RUIZ, S; GAVILANES, F; VIVANCO, F				MARQUES, G; ANTON, LC; BARRIO, E; SANCHEZ, A; RUIZ, S; GAVILANES, F; VIVANCO, F			ARGININE RESIDUES OF THE GLOBULAR REGIONS OF HUMAN C1Q INVOLVED IN THE INTERACTION WITH IMMUNOGLOBULIN-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; ANION-BINDING-SITES; HUMAN-COMPLEMENT; 1ST COMPONENT; HUMAN-CLQ; SUBCOMPONENT C1Q; B-CHAIN; GLUTAMATE-DEHYDROGENASE; ELECTRON-MICROSCOPY; A-CHAIN	The immunoglobulin G binding site in the globular regions of human complement subcomponent C1q has been investigated by chemical modification of histidine residues with diethylpyrocarbonate and arginine residues with phenylglyoxal and cyclohexane-1,2-dione (CHD). Only the modification of arginine residues with CHD fulfills the requirements of a specific modification without unwanted side reactions. Specific modification of arginine residues with CHD results in loss of immune complex recognition without affecting the binding of C1r2s2 to form C1. The gross structure of C1q is not changed by CHD treatment, and immune complex binding is restored to 82% of the control upon NH2OH treatment. Enzymic digestion and isolation of the modified peptides indicate that the modification by CHD of 4 to 5 arginine residues (A162, B114, B129, C156, and possibly B163) per C1q globular ''head'' abolishes the ability of C1q to interact with immune complexes. These residues define two areas (and possible binding sites for IgG) on the globular region of C1q: B114-B129 (site 1) and A162-(B163)-C156 (site 2). Sequence comparison and solvent exposure predictive studies favor site 2 as the immunoglobulin G binding site on the globular regions of Clq, although the participation of site 1 cannot be ruled out.	FDN JIMENEZ DIAZ,DEPT INMUNOL,AVE REYES CATOLICOS 2,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,DEPT BIOQUIM & BIOL MOLEC 1,E-28040 MADRID,SPAIN	Complutense University of Madrid			Gavilanes, Francisco/K-9903-2014; Vivanco, Fernando/Q-6866-2016; Antón, Luis C/C-4740-2013	Gavilanes, Francisco/0000-0003-1047-2362; Antón, Luis C/0000-0001-9665-011X				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; ALCOLEA JM, 1986, MOL IMMUNOL, V23, P39, DOI 10.1016/0161-5890(86)90169-0; ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; AUSTEN BM, 1976, J BIOL CHEM, V251, P5835; BACHMAYER H, 1968, J BIOL CHEM, V243, P1022; BAUMANN MA, 1990, J BIOL CHEM, V265, P18414; BLUMENTHAL KM, 1975, J BIOL CHEM, V250, P3644; BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; Bornstein P, 1977, Methods Enzymol, V47, P132; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; CANOVADAVIS E, 1992, BIOCHEM J, V285, P207, DOI 10.1042/bj2850207; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CHEUNG ST, 1979, BIOCHEM BIOPH RES CO, V90, P940, DOI 10.1016/0006-291X(79)91918-1; COMIS A, 1985, BIOCHIM BIOPHYS ACTA, V842, P45, DOI 10.1016/0304-4165(85)90291-0; DUNCAN AR, 1988, NATURE, V332, P778; EASTERBROOKSMITH SB, 1983, BIOSCIENCE REP, V3, P135, DOI 10.1007/BF01121944; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; HEUSSER CH, 1975, IMMUNOCHEMISTRY, V12, P213, DOI 10.1016/0019-2791(75)90234-7; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; Kabat EA, 1991, SEQUENCES PROTEINS I; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; LIBERTI PA, 1981, J IMMUNOL METHODS, V40, P243, DOI 10.1016/0022-1759(81)90071-5; LIN TY, 1978, IMMUNOCHEMISTRY, V15, P107; LIU WH, 1968, BIOCHEMISTRY-US, V7, P2886, DOI 10.1021/bi00848a027; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; MENENDEZARIAS L, 1990, COMPUT APPL BIOSCI, V6, P101; Miles E W, 1977, Methods Enzymol, V47, P431; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PATTHY L, 1980, EUR J BIOCHEM, V105, P387, DOI 10.1111/j.1432-1033.1980.tb04512.x; PATTHY L, 1975, J BIOL CHEM, V250, P565; PAUL SM, 1978, J BIOL CHEM, V253, P5658; PERKINS SJ, 1985, BIOCHEM J, V288, P13; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1989, FEBS LETT, V258, P89, DOI 10.1016/0014-5793(89)81622-9; PLAPP BV, 1967, J BIOL CHEM, V242, P265; Prevelige P., 1989, PREDICTION PROTEIN S, P391; REID KBM, 1990, IMMUNOL TODAY, V11, P387, DOI 10.1016/0167-5699(90)90150-8; REID KBM, 1981, METHOD ENZYMOL, V80, P16; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Richardson JS., 1989, PREDICT PROTEIN STRU; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; SCHIFFERLI JA, 1987, CLIN EXP IMMUNOL, V69, P188; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V16, P5175; SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; SLEDGE CR, 1973, J IMMUNOL, V111, P661; Smith E L, 1977, Methods Enzymol, V47, P156; STRANG CJ, 1982, P NATL ACAD SCI USA, V77, P7014; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TENNER AJ, 1981, J IMMUNOL, V127, P648; TITANI K, 1975, BIOCHEMISTRY-US, V14, P1358, DOI 10.1021/bi00678a003; TSCHOPP J, 1980, EUR J IMMUNOL, V10, P529, DOI 10.1002/eji.1830100709; ULLAH AHJ, 1991, BIOCHEM BIOPH RES CO, V178, P45, DOI 10.1016/0006-291X(91)91777-A; VIVANCOMARTINEZ F, 1980, MOL IMMUNOL, V17, P327, DOI 10.1016/0161-5890(80)90053-X; WERBER MM, 1975, EUR J BIOCHEM, V53, P207, DOI 10.1111/j.1432-1033.1975.tb04059.x; WINES BD, 1990, MOL IMMUNOL, V27, P321; YONEMASU K, 1981, BIOCHEM J, V193, P621, DOI 10.1042/bj1930621; ZICCARDI RJ, 1985, MOL IMMUNOL, V22, P489, DOI 10.1016/0161-5890(85)90133-6	71	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10393	10402						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486696				2022-12-25	WOS:A1993LB80000063
J	POULTER, L; BARRATT, D; SCOTT, CW; CAPUTO, CB				POULTER, L; BARRATT, D; SCOTT, CW; CAPUTO, CB			LOCATIONS AND IMMUNOREACTIVITIES OF PHOSPHORYLATION SITES ON BOVINE AND PORCINE TAU PROTEINS AND A PHF-TAU FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-DISEASE; NEUROFIBRILLARY TANGLES; ABNORMAL PHOSPHORYLATION; MICROTUBULE; KINASE; IDENTIFICATION; PURIFICATION; UBIQUITIN; ISOFORMS	Tau protein is a phosphorylated neuronal microtubule-associated protein. Tau protein is also present in the major pathological lesions of Alzheimer's disease in an insoluble hyperphosphorylated state as paired helical filaments (PHFs). We have investigated the phosphorylation state of control taus and a fragment of PHF-tau. Tau samples were digested with protease, separated by reversed-phase high-performance liquid chromatography, and analyzed by mass spectrometry and Edman microsequencing. The serine homologous with S404 of human tau441 was phosphorylated on bovine and porcine tau and up to two phosphates were present on a peptide of amino acids 182-240 of bovine tau (193-251 of human tau441). The serine within the KSPV motif was not phosphorylated on bovine or porcine tau. PHF-tau fragments, isolated from pronase-treated PHFs encompassed a 93-amino acid region within the microtubule binding domain. Enzymatic digestion and mass spectrometric analysis showed no phosphate was present and a second carboxyl terminus was identified at E380. Antibodies T3P and SMI34, which recognize PHF-tau and peptides phosphorylated at the sequence KSPV, both reacted with bovine and porcine tau even though the KSPV sequence was not phosphorylated. These data indicate that the 93-amino acid sequence of F5.5 tau from PHFs is not phosphorylated, and the serine equivalent to S404 of human tau is phosphorylated in bovine and porcine tau. Antibodies T3P and SMI34 react with phosphorylated epitopes that are not unique to PHF-tau and that are not necessarily at the KSPV site.	ICI AMER INC,ICI PHARMACEUT GRP,DEPT PHARMACOL,WILMINGTON,DE 19897		POULTER, L (corresponding author), ICI PHARMACEUT PLC,DEPT BIOTECHNOL,ALDERLEY PK,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND.							BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CAPUTO CB, 1992, NEUROBIOL AGING, V13, P267, DOI 10.1016/0197-4580(92)90039-Z; CAPUTO CB, 1992, BRAIN RES, V597, P227, DOI 10.1016/0006-8993(92)91478-W; CAPUTO CB, 1989, NEUROBIOL AGING, V10, P451, DOI 10.1016/0197-4580(89)90096-1; COLE GM, 1987, NEUROSCI LETT, V79, P207, DOI 10.1016/0304-3940(87)90698-7; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HARRINGTON CR, 1991, P NATL ACAD SCI USA, V88, P5842, DOI 10.1073/pnas.88.13.5842; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1990, J CELL BIOL, V111; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MUKAETOVALADINSKA EB, 1992, DEMENTIA, V3, P61, DOI 10.1159/000106996; MURPHY DB, 1982, METHOD CELL BIOL, V24, P31; SCHLESINGER DH, 1975, NATURE, V255, P423, DOI 10.1038/255423a0; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	43	22	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9636	9644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486651				2022-12-25	WOS:A1993LA68900073
J	EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP				EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP			CONSTITUTIONAL MUTATION IN EXON-8 OF THE P53 GENE IN A PATIENT WITH MULTIPLE PRIMARY TUMORS - MOLECULAR AND IMMUNOHISTOCHEMICAL FINDINGS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CANCER FAMILY SYNDROME; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA; SUPPRESSOR; CARCINOMAS; ONCOGENE; SARCOMAS; TUMORS	We report a constitutional mutation of codon 273 in exon 8 of the p53 gene. The affected individual has developed multiple independent benign and malignant tumours (tricholemmoma of the scalp, multiple trichoepitheliomata of the face, osteosarcoma of the ovary, bilateral breast cancer, maligant fibrous histiocytoma of the thigh and endometrial adenocarcinoma) and belongs to a family with some, but not all, features of the Li-Fraumeni syndrome. The mutation, found in both blood lymphocyte and tumour specimens, is a cytosine to thymine transition at codon 273, resulting in an amino acid change from arginine to cysteine. The mother and sister of the index case both died of tumours at an early age. We have demonstrated that formalin-preserved material from these tumours contains the same C-->T mutation at codon 273, indicating that this mutation has probably been transmitted through the germline. All tumours from the index case, both benign and malignant, showed immunohistochemical positivity with four antibodies to the p53 protein. Positive staining was also seen in scattered nuclei of morphologically normal epidermal keratinocytes and pilosebaceous cells, but not in lymphocytes or other morphologically normal cells from the index case. However, a similar staining pattern in apparently normal tissue was also observed in 13/48 sections from other individuals with various skin conditions (melanocytic naevi, psoriasis and normal skin adjacent to malignant melanoma and fibrous histiocytomas), suggesting that this pattern of p53 staining may not be unique to individuals with constitutional p53 mutations.	ROYAL MARSDEN HOSP, DEPT HISTOPATHOL, SUTTON SM2 5PT, SURREY, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, DEPT TUMOUR BIOL, CS-10103 PRAGUE, CZECHOSLOVAKIA; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; ROYAL MARSDEN HOSP, DEPT GYNAECOL ONCOL, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust; Institute of Hematology Prague; University of Dundee; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	EELES, RA (corresponding author), ROYAL MARSDEN HOSP, CRC, ACAD UNIT RADIOTHERAPY & ONCOL, DOWNS RD, SUTTON SM2 5PT, SURREY, ENGLAND.		Bartek, Jiri/G-5870-2014; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Eeles, Rosalind/0000-0002-3698-6241				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; CASEY G, 1991, ONCOGENE, V6, P1791; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PROSSER J, 1990, ONCOGENE, V5, P1573; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, CANCER RES, V49, P6324; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VARLEY JM, 1991, ONCOGENE, V6, P413; VOJETSEK B, 1992, IN PRESS J IMMUNOL M	33	74	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479749				2022-12-25	WOS:A1993KY32800019
J	FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD				FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD			A NOVEL GERMLINE P53 SPLICING MUTATION IN A PEDIATRIC-PATIENT WITH A 2ND MALIGNANT NEOPLASM	ONCOGENE			English	Article							CELLULAR PROTEIN P53; BREAST-CANCER; GENE; TUMOR; RETINOBLASTOMA; IDENTIFICATION; ANTIBODIES; EXPRESSION; COMPLEX	A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.	USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV TEXAS,SW MED CTR,SIMMONS COMPREHENS CANC RES CTR,DALLAS,TX 75235; NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	United States Department of Defense; United States Navy; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FELIX, CA (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV ONCOL,34TH ST & CIVIC CTR BLVD,ROOM 9093,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				ADDISON C, 1990, ONCOGENE, V5, P423; BODNER SM, 1992, ONCOGENE, V7, P743; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LI FP, 1991, CANCER EPIDEM BIOMAR, V1, P91; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MEADOWS AT, 1988, B CANCER, V75, P125; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WINTER SF, 1993, IN PRESS CANCER RES; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	44	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1203	1210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479743				2022-12-25	WOS:A1993KY32800011
J	MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK				MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK			AMINO-ACID SUBSTITUTIONS MODULATE THE EFFECT OF JUN ON TRANSFORMATION, TRANSCRIPTIONAL ACTIVATION AND DNA-REPLICATION	ONCOGENE			English	Article							C-JUN; V-JUN; BINDING PROTEINS; MAMMALIAN-CELLS; LEUCINE ZIPPER; FOS; ONCOGENE; AP-1; INVITRO; ENCODES	The retroviral oncogene v-jun and its cellular counterpart code for proteins that function as major components of the transcription factor complex AP-1. Jun proteins bind to the AP-1 consensus sequence as homodimers or heterodimers with members of the Fos protein family. This report compares the ability of viral and cellular Jun proteins (v-Jun and c-Jun) to activate transcription and to stimulate DNA synthesis. The effect of amino acid substitutions on cellular transformation is also described. In F9 cells c-Jun is a more effective transactivator than v-Jun, which carries two amino acid substitutions in the carboxy-terminal region that together down-regulate transactivation. The delta deletion, present in the amino-terminal region of v-Jun, does not affect transactivation in F9 cells; however, it does modulate the stimulation of DNA synthesis. When delta is deleted, the amino acid substitutions are without consequence on DNA synthesis. In the presence of delta the amino acid substitutions down-regulate DNA synthesis. Deletion of the Jun transactivation domain, which is required for cellular transformation, abolishes both transactivation and stimulation of DNA synthesis. We conclude that transformation, transactivation and stimulation of DNA synthesis all depend on the presence of the transactivation domain. The three functions are, however, not tightly correlated, and further work is needed to define the role of the biochemical activities of Jun in oncogenesis.	USC,SCH MED,DEPT MICROBIOL,2011 ZONAL AVE,HMR 401,LOS ANGELES,CA 90033; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; Kyoto University			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL R, 1990, NEW BIOL, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OLIVIERO S, 1992, IN PRESS GENES DEV; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WONG WY, 1992, IN PRESS ONCOGENE; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	36	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1135	1140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479738				2022-12-25	WOS:A1993KY32800004
J	BURNETTE, B; YU, G; FELSTED, RL				BURNETTE, B; YU, G; FELSTED, RL			PHOSPHORYLATION OF HIV-1 GAG PROTEINS BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; RECOMBINANT VACCINIA VIRUS; LONG TERMINAL REPEAT; SUBSTRATE-SPECIFICITY; T-CELLS; PLASMA-MEMBRANE; GENE-PRODUCTS; HTLV-III/LAV; FACTOR-ALPHA	We have demonstrated that the 17-kDa N-terminal matrix protein (p17gag) of HIV-1 Pr55gag is a substrate for protein kinase C (PKC). Phosphorylation of p17gag and Pr55gag was studied in vivo by infecting COS-7 cells with a recombinant vaccinia virus containing the HIV-1 gag-pol gene. Basal gag protein phosphorylation was inhibited up to 75% with the PKC inhibitor, H-7, and stimulated 3-4-fold with phorbol 12-myristate 13-acetate. In experiments using MCF-7 cell lines, p17gag and Pr55gag were dramatically phosphorylated only in clones with high PKC activity. Bacterially expressed and purified non-myristoylated and N-myristoylated p17gag were efficiently phosphorylated in a Ca2+ and phosphatidylserine-dependent manner by purified PKC. The N-myristoylated p17gag exhibited an apparent K(m) = 4 muM for PKC phosphorylation. Both in vitro and in vivo phosphorylated p17gag yielded identical V8 protease digestion phosphopeptide maps, indicating identical PKC phosphorylation sites. Phosphoamino acid analysis of the in vitro phosphorylated p17gag revealed only phosphoserine. These data are consistent with the identification of a highly conserved consensus PKC phosphorylation site motif in the HIV-1 gag protein at Ser111 and suggests that PKC phosphorylation plays an important role in gag protein function.	NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AQUINO A, 1990, BIOCHEM BIOPH RES CO, V166, P723, DOI 10.1016/0006-291X(90)90869-O; BATIST G, 1986, J BIOL CHEM, V261, P5544; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BURNETTE B, 1992, J PROTEIN EXP PURIF, V3, P395; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FOLKS T, 1986, J IMMUNOL, V136, P4049; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOWDA SD, 1989, J VIROL, V63, P1451, DOI 10.1128/JVI.63.3.1451-1454.1989; GOWDA SD, 1989, J BIOL CHEM, V264, P8459; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; GUY B, 1990, J ACQ IMMUN DEF SYND, V3, P797; HAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V164, P339, DOI 10.1016/0006-291X(89)91723-3; HAMAMOTO Y, 1990, CANCER RES, V50, P5287; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INAGAKI M, 1984, J BIOL CHEM, V259, P4321; JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KROGSTAD P, 1991, GENETIC STRUCTURE RE, P473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAURENCE J, 1990, BLOOD, V75, P696; LAURENT AG, 1990, J GEN VIROL, V71, P2273, DOI 10.1099/0022-1317-71-10-2273; LEIS J, 1989, EUR J BIOCHEM, V179, P415, DOI 10.1111/j.1432-1033.1989.tb14569.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAHONEY CW, 1990, J BIOL CHEM, V265, P5424; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MOHAGHEGHPOUR N, 1991, J BIOL CHEM, V266, P7233; MYERS G, 1990, HUMAN RETROVIRUSES A; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OVERTON HA, 1989, VIROLOGY, V170, P107, DOI 10.1016/0042-6822(89)90357-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STANLEY SK, 1989, AIDS RES HUM RETROV, V5, P375, DOI 10.1089/aid.1989.5.375; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; WISE BC, 1982, J BIOL CHEM, V257, P8489; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	60	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8698	8703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473314				2022-12-25	WOS:A1993KX81100050
J	DARNAY, BG; RODWELL, VW				DARNAY, BG; RODWELL, VW			HIS(865) IS THE CATALYTICALLY IMPORTANT HISTIDYL RESIDUE OF SYRIAN-HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CHEMICAL MODIFICATION; ARABIDOPSIS-THALIANA; ACTIVE-SITE; PHOSPHORYLATION; ENZYME; CDNA; EXPRESSION	Involvement in catalysis of a histidyl residue of Syrian hamster 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase was suggested by the ability of diethyl pyrocarbonate to abolish catalytic activity, accompanying spectral changes, and reactivation by hydroxylamine. The 7 histidines present in the catalytic domain of the hamster enzyme were changed to glutamine (His474, His487, His634, His751, His860, and His865), lysine (His865), or tyrosine (His868). Overexpression in Escherichia coli yielded six soluble mutant proteins, one insoluble protein (H634Q), and one which was degraded in vivo (H487Q). Following purification to homogeneity, mutant enzymes H474Q, H751Q, H860Q, and H868Y had essentially wild-type catalytic activity, while mutant enzymes H865K and H865Q had less than 0.6% wild-type activity. The low activity of mutant enzymes H865K and H865Q is unlikely to reflect altered structural integrity since both chromatographed on affinity supports like wild-type enzyme and had K(m) values for (S)-HMG-CoA (31 and 16 muM) and for NADPH (60 and 24 muM) close to those for wild-type enzyme (31 and 52 muM for (S)-HMG-CoA and NADPH, respectively). His865 of hamster HMG-CoA reductase, the histidine of the consensus Leu-Val-Xaa-Ser-His-Met-Xaa-Xaa-Asn-Arg-Ser motif and the only histidine conserved among the catalytic domains of all HMG-CoA reductases, thus appears to be a general acid/base functional in catalysis.			DARNAY, BG (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; CLARKE PR, 1991, EMBO J, V9, P2439; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DRABIKOWSKA AK, 1990, BIOCHEM J, V270, P319, DOI 10.1042/bj2700319; DUGAN RE, 1986, BIOCHEM BIOPH RES CO, V141, P278, DOI 10.1016/S0006-291X(86)80365-5; ENDO A, 1992, J LIPID RES, V33, P1569; FERRER A, 1990, FEBS LETT, V266, P67, DOI 10.1016/0014-5793(90)81508-L; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GIBSON DM, 1987, ENZYMES ENZYME CONTR, V18, P179; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KEITH ML, 1983, J PROTEIN CHEM, V2, P209, DOI 10.1007/BF01025355; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KIM YS, 1988, BIOCHIM BIOPHYS ACTA, V956, P103, DOI 10.1016/0167-4838(88)90255-5; LAM WL, 1992, J BIOL CHEM, V267, P5829; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; STERMER BA, 1991, PHYSIOL MOL PLANT P, V39, P135, DOI 10.1016/0885-5765(91)90024-C; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSOU C, 1962, SCI SINICA, V11, P1535; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; 1991, PROTOCOLS APPLICATIO, P110; 1983, OLIGONUCLEOTIDE DIRE, P1	44	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8429	8435						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473286				2022-12-25	WOS:A1993KX81100013
J	NISHIMURA, H; PALLARDO, FV; SEIDNER, GA; VANNUCCI, S; SIMPSON, IA; BIRNBAUM, MJ				NISHIMURA, H; PALLARDO, FV; SEIDNER, GA; VANNUCCI, S; SIMPSON, IA; BIRNBAUM, MJ			KINETICS OF GLUT1 AND GLUT4 GLUCOSE TRANSPORTERS EXPRESSED IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE CELL; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; HEXOSE-TRANSPORT; INSULIN; TRANSLOCATION; PROTEIN; PARAMETERS; GENE; 3-O-METHYLGLUCOSE	The predominant mechanism by which insulin activates glucose transport in muscle and adipose tissue is by affecting the redistribution of the facilitated hexose carriers, GLUT1 and GLUT4, from an intracellular site to the plasma membrane. A quantitative analysis of this process has been hampered by the lack of reliable determinations for kinetic constants catalyzed by each of these isoforms. In order to obtain such information, each transporter was expressed in Xenopus oocytes by the injection of mRNA encoding rat GLUT1 or GLUT4. Equilibrium exchange 3-O-methylglucose uptake was measured and the data fitted to a two-compartment model, yielding K(m) = 26.2 mM and V(max) = 3.5 nmol/min/cell for GLUT1 and K(m) = 4.3 mM and V(max) = 0.7 nmol/min/cell for GLUT4. Measurement of the abundance of cell surface transporters was accomplished by two independent protocols: photolabeling with the impermeant hexose analog 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine and subcellular fractionation of oocytes. Data obtained by either technique revealed that the ratio of plasma membrane GLUT1 to GLUT4 was about 4; this paralleled the relative maximal velocities for hexose transport, indicating that the turnover numbers for the two isoforms were the same. Moreover, measurement of the concentration of exofacially disposed transporters with 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine allowed calculation of the turnover number to be about 20,000 min-1. These data indicate that, at low substrate concentrations, the catalytic efficiency of GLUT4 is significantly greater than GLUT1. Extrapolation to mammalian systems suggests that GLUT4 is responsible for virtually all of the hexose uptake in insulin-responsive targets, particularly in the presence of hormone.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 25 SHATTUCK ST, BOSTON, MA 02115 USA; NIDDKD, DIABET BRANCH, EXPTL DIABET METAB & NUTR SECT, BETHESDA, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Pallardo, Federico V./T-1156-2017	Pallardo, Federico V./0000-0003-3715-1980; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1990, BIOCHEM J, V269, P597, DOI 10.1042/bj2690597; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; COLMAN A, 1984, EXPRESSION EXOGENOUS, P49; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KELLER K, 1989, J BIOL CHEM, V264, P18884; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PALFREYMAN RW, 1992, BIOCHEM J, V284, P275, DOI 10.1042/bj2840275; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR LP, 1981, BIOCHIM BIOPHYS ACTA, V642, P325, DOI 10.1016/0005-2736(81)90449-1; TOYODA N, 1987, J BIOL CHEM, V262, P2737; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P6937, DOI 10.1021/bi00443a024	37	114	116	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8514	8520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473295				2022-12-25	WOS:A1993KX81100024
J	YAMADA, T; AGUI, T; SUZUKI, Y; SATO, M; MATSUMOTO, K				YAMADA, T; AGUI, T; SUZUKI, Y; SATO, M; MATSUMOTO, K			INHIBITION OF THE COPPER INCORPORATION INTO CERULOPLASMIN LEADS TO THE DEFICIENCY IN SERUM CERULOPLASMIN ACTIVITY IN LONG-EVANS CINNAMON MUTANT RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRINDLED MOUSE MODEL; GENE-EXPRESSION; WILSONS-DISEASE; MENKES DISEASE; ESTERASE-D; METABOLISM; HEPATOCYTES; TRANSPORT; PROTEINS; BINDING	Although ceruloplasmin is known to be a copper-transporting protein, little is known about the biochemical mechanisms of copper incorporation into ceruloplasmin during the biosynthesis. We have examined various levels of ceruloplasmin biosynthesis in the Long-Evans Cinnamon (LEC) rat, which possesses a mutation causing the deficiency in serum ceruloplasmin activity associated with excess hepatic copper accumulation. Southern and Northern blot analyses revealed that the gene and mRNA encoding ceruloplasmin resided normally in LEC rat liver. Western blot analysis showed a normal level of ceruloplasmin in LEC rat serum. Following metabolic labeling of hepatocytes with Cu-64, no radioactive copper was detected in the ceruloplasmin fraction in LEC rat hepatocytes using Sephadex G-75 column chromatography, indicating that copper incorporation into ceruloplasmin is deficient in the LEC rat. Furthermore, LEC rat hepatocytes incubated with Cu-64 also showed a reduction in the efficiency of copper transport from cytosolic to noncytosolic fractions and a reduced copper efflux from the hepatocytes, indicating that LEC rat hepatocytes possess an abnormality in copper metabolism. These results suggest that an abnormality of the copper delivery mechanism causes an inhibition of copper incorporation into the ceruloplasmin molecule in the liver, leading to the deficiency in serum ceruloplasmin activity in the LEC rat. In addition, this abnormality also seems to cause an inhibition of biliary copper excretion. The blocking of these two copper exclusion pathways is thought to lead to excess hepatic copper accumulation in the LEC rat. Thus, the LEC rat should be a good model for studying the biochemical process responsible for copper delivery.	UNIV TOKUSHIMA,SCH MED,INST ANIM EXPERIMENTAT,KURAMOTO 3,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT HYG,TOKUSHIMA 770,JAPAN; AKITA UNIV,SCH MED,DEPT ANAT,AKITA 010,JAPAN	Tokushima University; Tokushima University; Akita University								BONNETAMIR B, 1986, GENET EPIDEMIOL, V3, P201, DOI 10.1002/gepi.1370030307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DANKS DM, 1991, EUR J PEDIATR, V150, P142, DOI 10.1007/BF01963553; DARWISH HM, 1983, J BIOL CHEM, V258, P3621; DEDOVE C, 1966, ANN REV PHYSL, V28, P435; EPSTEIN O, 1981, LANCET, V1, P303; Ettinger MJ, 1984, COPPER PROTEIN COPPE, V3, P175; EVANS GW, 1970, AM J PHYSIOL, V218, P298, DOI 10.1152/ajplegacy.1970.218.1.298; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FLEMING RE, 1992, J BIOL CHEM, V267, P479; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDEN E, 1986, CLIN PHYSIOL BIOCH, V4, P11; FRYDMAN M, 1985, P NATL ACAD SCI USA, V82, P1819, DOI 10.1073/pnas.82.6.1819; GITLIN D, 1960, NATURE, V185, P693, DOI 10.1038/185693a0; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; GOLDSTEIN IM, 1979, J BIOL CHEM, V254, P4040; GREGORIA.G, 1967, CAN J BIOCHEM CELL B, V45, P1841, DOI 10.1139/o67-217; GUTTERIDGE JMC, 1981, CRC CR REV CL LAB SC, V14, P257, DOI 10.3109/10408368109105866; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2350; KOSCHINSKY ML, 1986, P NATL ACAD SCI USA, V83, P5086, DOI 10.1073/pnas.83.14.5086; LI Y, 1991, J CLIN INVEST, V87, P1858, DOI 10.1172/JCI115208; MATSUMOTO K, 1987, TRANSPLANT P, V19, P3207; OBRIEN SJ, 1987, GENETIC MAPS, P564; ORENA SJ, 1986, BIOCHEM BIOPH RES CO, V139, P822, DOI 10.1016/S0006-291X(86)80064-X; PALIDA FA, 1990, BIOCHEM J, V268, P359, DOI 10.1042/bj2680359; PALIDA FA, 1991, J BIOL CHEM, V266, P4586; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SASAKI M, 1985, RAT NEWS LETT, V14, P4; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHMITT RC, 1983, AM J PHYSIOL, V244, pG183, DOI 10.1152/ajpgi.1983.244.2.G183; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; STERNLIEB I, 1961, J CLIN INVEST, V40, P1834, DOI 10.1172/JCI104407; STERNLIEB I, 1979, GASTROENTEROLOGY, V77, P138; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER FJ, 1990, J BIOL CHEM, V265, P1834; WINGE DR, 1984, SEMIN LIVER DIS, V4, P239, DOI 10.1055/s-2008-1041774; YAMADA T, 1992, BIOCHEM INT, V27, P243; YAMADA T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P188, DOI 10.1016/0167-4781(92)90075-B; [No title captured]	43	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8965	8971						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473340				2022-12-25	WOS:A1993KX81100085
J	VENABLE, ME; OLSON, SC; NIETO, ML; WYKLE, RL				VENABLE, ME; OLSON, SC; NIETO, ML; WYKLE, RL			ENZYMATIC STUDIES OF LYSO-PLATELET-ACTIVATING-FACTOR ACYLATION IN HUMAN NEUTROPHILS AND CHANGES UPON STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLTRANSFERASE-CATALYZED CLEAVAGE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RABBIT ALVEOLAR MACROPHAGES; ARACHIDONIC-ACID; INDEPENDENT TRANSACYLASE; EICOSAPENTAENOIC ACID; FACTOR PAF; PHOSPHOLIPIDS; PHOSPHATIDYLCHOLINE; PHOSPHOGLYCERIDES	Resting human neutrophils acylate 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (1-O-alkyl-2-lyso-GPC; lyso-PAF) specifically with arachidonate (AA); upon stimulation, however, the specificity is lost and other fatty acid residues are added. The major goals of this study were to compare the various acylation reactions present in the cells and to determine the cause of the specificity loss upon stimulation. The CoA-independent transacylase was active in neutrophil homogenates and was found to be both highly specific for AA and stereospecific, requiring 1-O-alkyl-2-lyso-GPC for activity. Homogenates also contained acyl-CoA:1-radyl-2-lyso-sn-glycero-3-phosphocholine acyltransferase activity, which transferred acyl chains from oleoyl-, linoleoyl-, or linolenoyl-CoA to both 1-alkyl and 1-acyl acceptors, but preferred the 1-acyl acceptor when arachidonoyl-CoA was used. The CoA-dependent and -independent activities co-sedimented on a discontinuous Percoll gradient in a single band containing plasma membrane and possibly other membranes. CoA alone promoted nonspecific acylation in the homogenates. The AA-specific acylation was attenuated up to 80% in sonicates of ionophore-stimulated cells, whereas the CoA-dependent acyltransferase remained unchanged. Potential phospholipid AA donors for the transacylase were substantially depleted in the stimulated cells but could not account for the large decrease in acylation. An accumulation of 1-O-alk-1'-enyl-2-lyso-sn-glycero-3-phosphoethanolamine (alkenyl-2-lyso-GPE), which acts as a competing substrate, appeared to be the major cause of the reduced AA-specific acylation of lyso-PAF observed in the stimulated preparations. Removal of the alkenyl-2-lyso-GPE restored the activity, whereas the addition of alkenyl-2-lyso-GPE (2 muM) to resting membrane preparations resulted in a marked decrease in transacylation of lyso-PAF.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center			Nieto, Maria L/G-7492-2015	Nieto, Maria L/0000-0001-6842-799X; Venable, Mark/0000-0003-1708-9163	NHLBI NIH HHS [HL-26818] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; BIANTON DF, 1971, J EXP MED, V134, P907; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; BLANK ML, 1984, J CHROMATOGR, V298, P474; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P473; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; CHABOT MC, 1987, BIOCHIM BIOPHYS ACTA, V922, P214, DOI 10.1016/0005-2760(87)90157-3; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CHILTON FH, 1987, BIOCHIM BIOPHYS ACTA, V917, P48, DOI 10.1016/0005-2760(87)90282-7; CHILTON FH, 1983, J BIOL CHEM, V258, P7268; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COLARD O, 1984, BIOCHIM BIOPHYS ACTA, V793, P42, DOI 10.1016/0005-2760(84)90051-1; COLARD O, 1984, BIOCHEM J, V222, P657, DOI 10.1042/bj2220657; COLEMAN R, 1977, J BIOL CHEM, V252, P3050; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; ERBLAND JF, 1965, BIOCHIM BIOPHYS ACTA, V106, P128, DOI 10.1016/0005-2760(65)90101-3; FLESCH I, 1984, EUR J BIOCHEM, V139, P431, DOI 10.1111/j.1432-1033.1984.tb08023.x; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; IRVINE RF, 1979, BIOCHEM BIOPH RES CO, V91, P1399, DOI 10.1016/0006-291X(79)91222-1; JESAITIS AJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P556, DOI 10.1016/0304-4165(82)90246-X; KRAMER RM, 1984, J BIOL CHEM, V259, P2403; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; MACDONALD JIS, 1989, J BIOL CHEM, V264, P17718; MACDONALD JIS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P151, DOI 10.1016/0005-2760(89)90263-4; MAHADEVAPPA VG, 1986, BIOCHEM BIOPH RES CO, V134, P1327, DOI 10.1016/0006-291X(86)90395-5; MALONE B, 1985, J BIOL CHEM, V260, P1531; MATTSON FH, 1962, J LIPID RES, V3, P281; MCKEAN ML, 1986, FEBS LETT, V195, P38, DOI 10.1016/0014-5793(86)80125-9; MUELLER HW, 1984, J LIPID RES, V25, P383; NAKAGAWA Y, 1985, BIOCHIM BIOPHYS ACTA, V833, P323; NIETO M, 1990, J CELL BIOL, V111, P257; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OKITA JR, 1982, J BIOL CHEM, V257, P4029; PATEL KM, 1979, LIPIDS, V14, P596, DOI 10.1007/BF02533539; PATTON GM, 1982, J LIPID RES, V23, P190; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; ROBINSON BS, 1989, BIOCHEM J, V264, P125, DOI 10.1042/bj2640125; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROCK CO, 1975, J BIOL CHEM, V250, P6564; ROOS D, 1979, BLOOD, V53, P851; ROSENTHAL MD, 1987, PROG LIPID RES, V26, P87, DOI 10.1016/0163-7827(87)90009-9; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047; STOFFEL W, 1975, METHODS ENZYMOLOGY B, V35, P533; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V127, P384, DOI 10.1016/S0006-291X(85)80171-6; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; TOU JS, 1987, LIPIDS, V22, P333, DOI 10.1007/BF02534002; TOU JS, 1989, LIPIDS, V24, P812, DOI 10.1007/BF02544589; TOU JS, 1984, LIPIDS, V19, P573, DOI 10.1007/BF02534713; TROTTER J, 1982, J BIOL CHEM, V257, P1816; TROTTER J, 1981, FEBS LETT, V128, P237, DOI 10.1016/0014-5793(81)80089-0; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VANHEUSDEN GPH, 1980, J BIOL CHEM, V255, P9312; VOETMAN AA, 1981, J CLIN INVEST, V67, P1541, DOI 10.1172/JCI110185; WAKU K, 1977, J BIOCHEM-TOKYO, V82, P1779, DOI 10.1093/oxfordjournals.jbchem.a131876; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; WYKLE RL, 1981, BIOCHEM BIOPH RES CO, V100, P1651, DOI 10.1016/0006-291X(81)90708-7; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1986, ADV INFLAMMAT RES, V11, P71; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	70	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7965	7975						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463317				2022-12-25	WOS:A1993KW97900059
J	BYRON, KL; TAYLOR, CW				BYRON, KL; TAYLOR, CW			SPONTANEOUS CA2+ SPIKING IN A VASCULAR SMOOTH-MUSCLE CELL-LINE IS INDEPENDENT OF THE RELEASE OF INTRACELLULAR CA2+ STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM STORE; SARCOPLASMIC-RETICULUM; CA-2+ STORES; PORTAL-VEIN; RYANODINE; RABBIT; CAFFEINE; A7R5; RAT; PHARMACOLOGY	Monolayers of fura-2-loaded A7r5 cells, a cell line derived from rat embryonic aorta, generated spontaneous Ca2+ spikes that were synchronized within the cell population. These Ca2+ spikes were abolished by removal of extracellular Ca2+ or addition of nimodipine (50 nM), and their frequency was increased by depolarization with high K+ or by treatment with BAYK 8644 (1 muM), indicating that Ca2+ entry through L-type Ca2+ channels is required for Ca2+ spiking. Several lines of evidence indicate that mobilization of intracellular Ca2+ stores is not necessary for this Ca2+ spiking. 1) Ryanodine (0.1-50 muM) neither stimulated Ca2+ mobilization nor affected Ca2+ spiking; 2) the complex effects of caffeine were mimicked by theophylline, 8-bromo-cyclic adenosine 3':5'-monophosphate (8-bromo-cAMP), and forskolin, suggesting that the caffeine effects may be mediated by cAMP and not by ryanodine receptors; 3) prolonged incubation with thapsigargin (50 nM), which depletes intracellular Ca2+ stores, did not affect the frequency of Ca2+ spiking; 4) Ba2+ or Sr2+ could substitute for Ca2+ in the spike-generating mechanism even when intracellular stores were depleted of Ca2+. Under conditions where the sarcoplasmic reticulum (SR) contained Ca2+, Ba2+ spikes did not cause Ca2+ mobilization. The mechanisms involved in generating spontaneous Ca2+ spiking in A7r5 cells are therefore likely to reside in the sarcolemma and to operate independently of SR Ca2+ uptake and release.			BYRON, KL (corresponding author), UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND.		; Taylor, Colin/G-2447-2010	Byron, Kenneth/0000-0002-3875-9667; Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BYRON KL, 1989, J BIOL CHEM, V264, P18234; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GIANNATTASIO B, 1991, J GEN PHYSIOL, V98, P987, DOI 10.1085/jgp.98.5.987; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HISAYAMA T, 1988, PFLUG ARCH EUR J PHY, V412, P376, DOI 10.1007/BF01907555; HWANG KS, 1987, PFLUG ARCH EUR J PHY, V408, P343, DOI 10.1007/BF00581127; ITO K, 1986, CIRC RES, V58, P730, DOI 10.1161/01.RES.58.5.730; KANMURA Y, 1988, PFLUG ARCH EUR J PHY, V413, P153, DOI 10.1007/BF00582525; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KOMORI S, 1989, BRIT J PHARMACOL, V97, P973, DOI 10.1111/j.1476-5381.1989.tb12039.x; KWAN CY, 1990, J BIOL CHEM, V265, P678; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LEIJTEN PAA, 1984, J PHYSIOL-LONDON, V357, P327, DOI 10.1113/jphysiol.1984.sp015502; LIU CM, 1978, J BIOL CHEM, V253, P5892; LONGMORE J, 1990, POTASSIUM CHANNELS S, P259; MARTIN C, 1989, BRIT J PHARMACOL, V98, P493, DOI 10.1111/j.1476-5381.1989.tb12622.x; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MOORE LK, 1991, AM J PHYSIOL, V260, pC975, DOI 10.1152/ajpcell.1991.260.5.C975; NOACK T, 1990, PFLUG ARCH EUR J PHY, V416, P467, DOI 10.1007/BF00370756; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PIZARRO G, 1988, CALCIUM CHANNEL STRU, P138; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RALL TW, 1985, GOODMAN GILMANS PHAR, P589; SAIDA K, 1982, J GEN PHYSIOL, V80, P191, DOI 10.1085/jgp.80.2.191; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Somlyo AP, 1970, PHARMACOL REV, V22, P249; SOMLYO AP, 1987, NATURE, V329, P719; SOMLYO AV, 1971, SCIENCE, V174, P955, DOI 10.1126/science.174.4012.955; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; VANRENTERGHEM C, 1988, P NATL ACAD SCI USA, V85, P9365; WANG Q, 1992, J PHYSIOL-LONDON, V451, P525, DOI 10.1113/jphysiol.1992.sp019177; WEISSBERG PL, 1989, AM J PHYSIOL, V256, pC951, DOI 10.1152/ajpcell.1989.256.5.C951	39	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6945	6952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463226				2022-12-25	WOS:A1993KV14100025
J	PUTKEY, JA; DOTSON, DG; MOUAWAD, P				PUTKEY, JA; DOTSON, DG; MOUAWAD, P			FORMATION OF INTERMOLECULAR AND INTRAMOLECULAR DISULFIDE BONDS CAN ACTIVATE CARDIAC TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-BINDING SITES; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITION; CALMODULIN; CONTRACTION; TRIGGER; CALMIDAZOLIUM; MYOFIBRILS; EXCHANGE	Troponin C regulates contraction in striated muscle by alternating between the Ca2+-bound and apo conformations. We report here that spontaneous formation of an intramolecular disulfide bond between Cys-35 and Cys-84, or dimerization via an intermolecular disulfide bond between Cys-84 in cardiac troponin C, renders the protein Ca2+-independent when assayed in fast skeletal muscle myofibrils but to a much lesser extent in cardiac myofibrils. Formation of the intramolecular disulfide bond appears to expose hydrophobic surfaces, as indicated by an increase in fluorescence from hydrophobic fluorescent dyes, but does not alter the affinity of Ca2+-binding site II. These disulfide bonds constrain the protein into a conformation that either resembles or can substitute for the Ca2+-bound form of cardiac troponin C in fast skeletal muscle myofibrils.			PUTKEY, JA (corresponding author), UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, POB 20708, 6431 FANNIN ST, HOUSTON, TX 77225 USA.				NIAMS NIH HHS [AR-39210] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUCHS F, 1989, J BIOL CHEM, V264, P20344; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INGRAHAM RH, 1988, BIOCHEMISTRY-US, V27, P5891, DOI 10.1021/bi00416a011; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUREBAYASHI N, 1988, J PHYSIOL-LONDON, V403, P407, DOI 10.1113/jphysiol.1988.sp017256; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; PUTKEY JA, 1992, FASEB J, V6, pA281; REID DG, 1990, J BIOL CHEM, V265, P9744; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; TSUDA S, 1988, BIOCHEMISTRY-US, V27, P4120, DOI 10.1021/bi00411a032; ZOT HG, 1982, J BIOL CHEM, V257, P7678	27	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6827	6830						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463206				2022-12-25	WOS:A1993KV14100002
J	KAWABATA, S; NAKAGAWA, K; MUTA, T; IWANAGA, S; DAVIE, EW				KAWABATA, S; NAKAGAWA, K; MUTA, T; IWANAGA, S; DAVIE, EW			RABBIT LIVER MICROSOMAL ENDOPEPTIDASE WITH SUBSTRATE-SPECIFICITY FOR PROCESSING PROPROTEINS IS STRUCTURALLY RELATED TO RAT TESTES METALLOENDOPEPTIDASE-24.15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC ENZYMES; PROTEIN; GENE; PROHORMONE; MUTATION; SEQUENCE; HORMONE; PROTEOLYSIS; PROPEPTIDE; ENKEPHALIN	The detergent extract of rabbit liver microsomes contains an endopeptidase (MEP) with substrate specificity for peptides containing Arg residues at the P1 and P4 positions in the cleavage site (Kawabata, S., and Davie, E. W. (1992) J. Biol. Chem. 267, 10331-10336). These sequences occur in many proproteins such as the vitamin K-dependent proproteins and pro-hormones. A cDNA coding for MEP has been obtained from three overlapping clones isolated from two rabbit liver lambdagt10 cDNA libraries. The longest open reading frame of the 3507-base pair cDNA codes for a protein of 704 amino acids, of which 406 residues were confirmed by amino acid sequence analysis. MEP contains a putative active site of -His-Glu-X-X-His-, which is typical of mammalian zinc metallopeptidases. Based on a hydropathy plot, MEP is a hydrophilic protein with no transmembrane domain and no NH2-terminal signal sequence. Amino acid sequence analysis identified Asn at the three potential N-glycosylation sites in the enzyme, indicating that MEP contains no N-linked sugar. MEP is homologous with rat testes metalloendopeptidase 24.15 (60% identity), rat mitochondrial intermediate peptidase (24% identity), Escherichia coli dipeptidyl carboxypeptidase (25% identity), and the open reading frame YCL57w present in yeast chromosome III (35% identity).	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; KYUSHU UNIV 33,FAC SCI,DEPT PATHOL,FUKUOKA 812,JAPAN	University of Washington; University of Washington Seattle; Kyushu University	KAWABATA, S (corresponding author), KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN.							ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; BARRETT AJ, 1989, BIOCHEM J, V261, P1047, DOI 10.1042/bj2611047; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MOLINEAUX CJ, 1988, J NEUROCHEM, V51, P624, DOI 10.1111/j.1471-4159.1988.tb01084.x; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984	36	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12498	12503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509389				2022-12-25	WOS:A1993LG65800042
J	ZHANG, L; CASTELLINO, FJ				ZHANG, L; CASTELLINO, FJ			THE CONTRIBUTIONS OF INDIVIDUAL GAMMA-CARBOXYGLUTAMIC ACID RESIDUES IN THE CALCIUM-DEPENDENT BINDING OF RECOMBINANT HUMAN PROTEIN-C TO ACIDIC PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; CLOTTING FACTOR-X; CONFORMATION-SPECIFIC ANTIBODIES; FACTOR-IX; FACTOR-VA; BLOOD-COAGULATION; PROTHROMBIN FRAGMENT-1; METAL-BINDING; ACTIVATION; DOMAIN	The dependence on the integrity of the human protein C (PC) gamma-carboxyglutamic acid (Gla) domain on its Ca2+-dependent binding properties to acidic phospholipid (PL) vesicles has been examined by analysis of these interactions with recombinant(r)-PC Gla domain muteins. The concentration of Ca2+ that results in 50% saturation (C50-Ca) of PL with wild-type (wt) r-PC was not altered by more than 2-fold for the following r-variants of PC, viz. [Gla6 --> Asp]r-PC, [Gla14 --> Asp]r-PC, [Gla19 --> Asp]r-PC, [Gla25 --> Asp]r-PC, [Gl29 --> Asp] r-PC, and [Gln32 --> Gla]r-PC. The Cro-Ca was substantially higher than that of wtr-PC for [Gla7 --> Asp]r-PC (8.2 mM), [Arg15 --> Leu]r-PC (4.5 mM), [Gla16 --> Asp] r-PC (> 10 mM), [Gla20 --> Asp]r-PC (>10 mM), and [Gla26 --> Asp]r-PC (> 10 mM), indicating that the Ca2+-induced conformations of these latter variants interacted poorly with these acidic PL vesicles. Titration of the PL vesicles with wtr-PC at a constant concentration of 20 mM Ca2+ leads to calculation of a concentration of PC that results in 50% saturation of the PL (C50-PC) of 0.38 muM. Essentially this same value was determined for the r-mutants, [Gla7 --> Asp] r-PC and [Gln32 --> Gla]r-PC. An approximate 2-fold lower C50-PC was obtained for [Gla14 --> Asp]r-PC (0.14 muM), [Gla25 --> Asp]r-PC (0.16 muM), and [Gla29 --> Asp]r-PC (0.15 muM). Somewhat higher C50-PC values were found for [Gla6 --> Asp]r-PC (1.2 muM), [Arg15 --> Leu]r-PC (1.2 muM), [Gla16 --> Asp]r-PC (1.2 muM), [Gla19 --> Asp]r-PC (1.8 muM), [Gla20 --> Asp]r-PC (1.1 muM), and [Gla26 --> Asp]r-PC (1.6 muM). The results of this investigation, in conjunction with other structural and functional studies with these mutants, and the x-ray crystallographic structure of the prothrombin Gla domain-Ca2+ complex, show that Gla16 and Gla26 are the most indispensable Gla residues for maintenance of the functional Ca2+-dependent structure of the Gla domain of PC, whereas Gla14 is the least critical Gla residue in this regard. Of the non-Gla residues investigated, Arg15 is of great importance for maintenance of a functional Ca2+-dependent structure of PC, and insertion of a Gla residue at position 32, a situation that exists in the cases of some other proteins of this type, does not significantly alter these characteristics of r-PC.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1978, J BIOL CHEM, V253, P6774; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BAJAJ SP, 1977, J BIOL CHEM, V252, P4758; BAJAJ SP, 1976, J BIOL CHEM, V251, P6294; BEALS JM, 1989, ARCH BIOCHEM BIOPHYS, V268, P485, DOI 10.1016/0003-9861(89)90316-0; BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE BC, 1976, J BIOL CHEM, V251, P3235; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; ISRAELS SJ, 1987, J PEDIATR-US, V111, P562, DOI 10.1016/S0022-3476(87)80122-1; KEYT B, 1982, J BIOL CHEM, V257, P8687; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MANN KG, 1990, BLOOD, V76, P1; MANNUCCI PM, 1982, LANCET, V2, P463; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; SAKATA Y, 1986, BLOOD, V68, P1218; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STRICKLAND DK, 1980, ARCH BIOCHEM BIOPHYS, V199, P61, DOI 10.1016/0003-9861(80)90256-8; SUGO T, 1984, J BIOL CHEM, V259, P5705; SUGO T, 1985, J BIOL CHEM, V260, P453; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WAKABAYASHI K, 1986, J BIOL CHEM, V261, P1097; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	54	42	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12040	12045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505327				2022-12-25	WOS:A1993LF28400087
J	ZANOTTI, G; BERNI, R; MONACO, HL				ZANOTTI, G; BERNI, R; MONACO, HL			CRYSTAL-STRUCTURE OF LIGANDED AND UNLIGANDED FORMS OF BOVINE PLASMA RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY DATA; AMINO-ACID-SEQUENCE; VITAMIN-A TRANSPORT; MACROMOLECULAR STRUCTURES; MOLECULAR-DYNAMICS; REFINEMENT; CRYSTALLIZATION; TRANSTHYRETIN	The three-dimensional structures of bovine plasma retinol-binding protein (bRBP) complexed with retinol (space group P2(1)2(1)2(1), a = 46.08, b = 49.12, c = 76. 10 angstrom) and of the unliganded protein prepared in vitro by extracting retinol with ethyl ether (space group P2(1)2(1)2(1), a = 46.55, b = 48.97, c = 76.87 angstrom) have been solved at 1.9 and 1.7 angstrom resolution, respectively. The final crystallographic R factors are 0.190 for holobRBP and 0.196 for the unliganded bRBP. The model for the bovine holoprotein is quite similar to that of the human protein, with which it exhibits 92% sequence similarity. The root mean square deviation between the alpha-carbons in the two proteins is 0.31 angstrom. The retinol binding site is almost completely preserved. The loops that surround the opening of the beta-barrel are also particularly conserved, in contrast with the presence of several substitutions in parts of the RBP molecule opposite the opening of the calyx that binds retinol. Despite the fact that unliganded bovine RBP was prepared and crystallized using procedures completely different from those used to obtain the unliganded human RBP, the conformational differences between unliganded and liganded forms of bRBP are almost identical to those found previously between the same forms of human RBP. They mainly involve a few residues in the region extending from amino acid residues 32 to 37. Therefore, similar differences are very likely to exist between holoRBP and the physiologically occurring apoprotein. A not yet identified electron density, different in shape and orientation from retinol, also occupies the central cavity of the beta-barrel in the unliganded bRBP, as found for unliganded human RBP. The functional consequences of the conformational change induced by the removal of retinol on the interaction between RBP and transthyretin, coupled with the conservation of the entrance loops of the beta-barrel in mammalian RBPs, are consistent with their participation in molecular interactions.	CNR,BIOPOLYMER RES CTR,I-35100 PADUA,ITALY; UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; UNIV PAVIA,CTR INTERUNIV STUDIO MACROMOLEC INFORMAZ,I-27100 PAVIA,ITALY; UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Parma; University of Pavia; University of Pavia	ZANOTTI, G (corresponding author), UNIV PADUA,DEPT ORGAN CHEM,VIA MARZOLO 1,I-35131 PADUA,ITALY.			Monaco, Hugo L./0000-0002-2067-0365; Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501				AQVIST J, 1986, J MOL BIOL, V192, P593, DOI 10.1016/0022-2836(86)90279-2; AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BAVIK CO, 1991, J BIOL CHEM, V266, P14985; BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O; BERNI R, 1992, EUR J BIOCHEM, V204, P99, DOI 10.1111/j.1432-1033.1992.tb16610.x; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BERNI R, 1993, RETINOIDS PROGR RES, P91; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; CRAWFORD JL, 1977, THESIS HARVARD U CAM; FEX G, 1979, EUR J BIOCHEM, V94, P307, DOI 10.1111/j.1432-1033.1979.tb12896.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELLER J, 1975, J BIOL CHEM, V250, P6549; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HORWITZ J, 1974, J BIOL CHEM, V249, P7181; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KONNERT JH, 1976, ACTA CRYSTALLOGR A, V32, P614, DOI 10.1107/S0567739476001289; MOKADY S, 1974, BIOCHIM BIOPHYS ACTA, V336, P361, DOI 10.1016/0005-2795(74)90415-2; MONACO HL, 1984, J MOL BIOL, V178, P477, DOI 10.1016/0022-2836(84)90153-0; MUTO Y, 1972, J BIOL CHEM, V247, P2533; NEWCOMER ME, 1984, J BIOL CHEM, V259, P5230; Nyborg J., 1977, ROTATION METHOD CRYS, P139; OTTONELLO S, 1983, J MOL BIOL, V163, P679, DOI 10.1016/0022-2836(83)90118-3; PFLUGRATH JW, 1984, METHODS APPLICATIONS, P407; POOLE AR, 1975, J CELL SCI, V19, P379; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1974, EUR J BIOCHEM, V44, P1, DOI 10.1111/j.1432-1033.1974.tb03451.x; RAZ A, 1970, J BIOL CHEM, V245, P1903; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHIDOJI Y, 1977, J LIPID RES, V18, P679; SIM GA, 1959, ACTA CRYSTALLOGR, V12, P813, DOI 10.1107/S0365110X59002316; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x; ZANOTTI G, 1993, IN PRESS J MOL BIOL; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	45	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10728	10738						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496140				2022-12-25	WOS:A1993LD46600007
J	KUHM, AE; KNACKMUSS, HJ; STOLZ, A				KUHM, AE; KNACKMUSS, HJ; STOLZ, A			PURIFICATION AND PROPERTIES OF 2'-HYDROXYBENZALPYRUVATE ALDOLASE FROM A BACTERIUM THAT DEGRADES NAPHTHALENESULFONATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-PUTIDA; 2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOIC ACID; 2-KETO-3-DEOXY-6-PHOSPHOGLUCONATE ALDOLASE; 2-KETO-4-HYDROXYGLUTARATE ALDOLASE; CHEMICAL EVIDENCE; CLASS I; DEGRADATION; 2,3-DIHYDROXYBIPHENYL	2'-Hydroxybenzalpyruvate aldolase catalyzes the cleavage of 2'-hydroxybenzalpyruvate to salicylaldehyde and pyruvate. This reaction is part of the degradative pathways for naphthalene and naphthalenesulfonates by bacteria. 2'-Hydroxybenzalpyruvate aldolase has been purified to homogeneity from a bacterium that degrades naphthalenesulfonates (strain BN6). The enzyme has a molecular weight of about 120,000 and is composed of identical subunits with a molecular weight of about 38,500. Thus the enzyme appears to exist as a trimeric oligomer. The NH2-terminal amino acid sequence did not show significant homology to other published amino acid sequences. Extensive loss of enzyme activity occurred when the enzyme was incubated with 2'-hydroxybenzalpyruvate in the presence of sodium borhydride. This suggested the intermediate formation of a stable Schiff base between enzyme and substrate. 2'-Hydroxybenzalpyruvate aldolase was inhibited by p-chloromercuribenzoate and by the reaction product salicylaldehyde. The enzyme converted 2'-hydroxybenzalpyruvate, 2',4'- and 2',6'-dihydroxybenzalpyruvate.	UNIV STUTTGART,INST MIKROBIOL,AZENBERGSTR 18,W-7000 STUTTGART 1,GERMANY	University of Stuttgart								BARNSLEY EA, 1976, BIOCHEM BIOPH RES CO, V72, P1116, DOI 10.1016/S0006-291X(76)80247-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILON C, 1981, APPL ENVIRON MICROB, V42, P44, DOI 10.1128/AEM.42.1.44-55.1981; BRILON C, 1981, APPL ENVIRON MICROB, V42, P39, DOI 10.1128/AEM.42.1.39-43.1981; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; DAVIES JI, 1964, BIOCHEM J, V91, P251, DOI 10.1042/bj0910251; FRENCH CJ, 1976, PHYTOCHEMISTRY, V15, P564, DOI 10.1016/S0031-9422(00)88979-7; FRIEDMANN E, 1931, HELV CHIM ACTA, V14, P783; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; HARRIS CE, 1969, BIOCHEMISTRY-US, V8, P2442, DOI 10.1021/bi00834a029; HAUG W, 1991, APPL ENVIRON MICROB, V57, P3144, DOI 10.1128/AEM.57.11.3144-3149.1991; HILTON MD, 1990, APPL ENVIRON MICROB, V56, P623, DOI 10.1128/AEM.56.3.623-627.1990; HOFFEE PA, 1968, ARCH BIOCHEM BIOPHYS, V126, P795, DOI 10.1016/0003-9861(68)90473-6; JEFFREY AM, 1975, BIOCHEMISTRY-US, V14, P575, DOI 10.1021/bi00674a018; KIMBARA K, 1989, J BACTERIOL, V171, P2740, DOI 10.1128/jb.171.5.2740-2747.1989; Kuhm A E, 1991, Biodegradation, V2, P115, DOI 10.1007/BF00114601; KUHM AE, 1991, J BACTERIOL, V173, P3795, DOI 10.1128/JB.173.12.3795-3802.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1975, ARCH BIOCHEM BIOPHYS, V166, P358, DOI 10.1016/0003-9861(75)90398-7; LEBHERZ HG, 1973, J BIOL CHEM, V248, P1650; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LONDON J, 1974, J BIOL CHEM, V249, P7977; MALEK AA, 1988, ARCH BIOCHEM BIOPHYS, V266, P10, DOI 10.1016/0003-9861(88)90232-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NORTEMANN B, 1986, APPL ENVIRON MICROB, V52, P1195; OHE T, 1990, AGR BIOL CHEM TOKYO, V54, P669, DOI 10.1080/00021369.1990.10870006; OHE T, 1986, AGR BIOL CHEM TOKYO, V50, P1419, DOI 10.1080/00021369.1986.10867607; OHE T, 1988, AGR BIOL CHEM TOKYO, V52, P2409, DOI 10.1080/00021369.1988.10869059; OMORI T, 1988, APPL MICROBIOL BIOT, V29, P497, DOI 10.1007/BF00269075; OMORI T, 1986, AGR BIOL CHEM TOKYO, V50, P931, DOI 10.1080/00021369.1986.10867489; PATEL TR, 1974, J BACTERIOL, V119, P879, DOI 10.1128/JB.119.3.879-888.1974; ROBERTSON DC, 1971, J BIOL CHEM, V246, P2075; RUTTER WJ, 1964, FED PROC, V23, P1248; SARIASLANI FS, 1974, BIOCHEM J, V140, P31, DOI 10.1042/bj1400031; STOLZ A, 1992, BIOCHEM J, V282, P675, DOI 10.1042/bj2820675; SUZUKI N, 1980, J BIOL CHEM, V255, P3427; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; TOMS A, 1970, BIOCHEMISTRY-US, V9, P337, DOI 10.1021/bi00804a021; VALENTINHANSEN P, 1982, EUR J BIOCHEM, V125, P561, DOI 10.1111/j.1432-1033.1982.tb06719.x; VANDLEN RL, 1973, J BIOL CHEM, V248, P2251; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; VLAHOS CJ, 1988, J BIOL CHEM, V263, P11683; WANG JK, 1981, J BIOL CHEM, V256, P1793; WITTICH RM, 1988, APPL ENVIRON MICROB, V54, P1842, DOI 10.1128/AEM.54.7.1842-1847.1988; WOOD WA, 1977, TRENDS BIOCHEM SCI, P223; YEN KM, 1988, CRIT REV MICROBIOL, V15, P247, DOI 10.3109/10408418809104459; ZURRER D, 1987, APPL ENVIRON MICROB, V53, P1459	47	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9484	9489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486638				2022-12-25	WOS:A1993LA68900052
J	MYERS, M; FORGAC, M				MYERS, M; FORGAC, M			THE COATED VESICLE VACUOLAR (H+)-ATPASE ASSOCIATES WITH AND IS PHOSPHORYLATED BY THE 50-KDA POLYPEPTIDE OF THE CLATHRIN ASSEMBLY PROTEIN AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE; PROTON PUMP; TRANSLOCATING ATPASE; SUBUNIT COMPOSITION; H+-ATPASE; PURIFICATION; TRIPHOSPHATASE; RECONSTITUTION; TOPOGRAPHY; SEQUENCE	We have previously noted a 50-kDa polypeptide (p50) co-purifying with preparations of the bovine brain clathrin-coated vesicle vacuolar (H+)-ATPase (V-ATPase) (Zhang, J., Myers, M., and Forgac, M. (1992) J. Biol. Chem. 267,9773-9778). We show that p50 is also immunoprecipitated with the V-ATPase, further suggesting its specific association with the proton pump. To determine the identity of this 50-kDa polypeptide and the stoichiometry of its association with the V-ATPase, we performed N-terminal amino acid sequencing and quantitative amino acid analysis of the gel-purified protein. These results revealed the unknown polypeptide to be the 50-kDa subunit of the clathrin assembly protein AP-2 (AP50); we estimate the stoichiometry of association is one AP50 per V-ATPase complex. AP50 is an N-ethylmaleimide (NEM)-inhibitable autokinase and incubation of purified V-ATPase with [gamma-P-32]ATP resulted in the NEM-sensitive phosphorylation of AP50 and the B subunit of the V-ATPase. The same phosphorylation pattern is seen if the labeling reaction is done with intact clathrin-coated vesicles and the V-ATPase subsequently immunoprecipitated from the solubilized vesicles. This represents the first report of phosphorylation of one of the V-ATPase subunits. The functional significance of this phosphorylation for regulation or targeting of the V-ATPase in vivo remains to be determined.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07542] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; APPS DK, 1989, BIOCHEM J, V263, P81, DOI 10.1042/bj2630081; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; BECK KA, 1991, J BIOL CHEM, V266, P4442; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; KANE PM, 1989, J BIOL CHEM, V264, P19236; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J BIOL CHEM, V262, P3864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI SP, 1988, J BIOL CHEM, V263, P16731; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MYERS M, 1993, NEWS PHYSIOL SCI, V8, P24; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OAKEY BR, 1980, ANAL BIOCHEM, V105, P361; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PAULOIN A, 1982, NATURE, V298, P574, DOI 10.1038/298574a0; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; PUOLPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; THURIEAU C, 1988, DNA-J MOLEC CELL BIO, V7, P663, DOI 10.1089/dna.1988.7.663; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590	34	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9184	9186						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486617				2022-12-25	WOS:A1993LA68900008
J	LEE, DH; MITTAG, M; SCZEKAN, S; MORSE, D; HASTINGS, JW				LEE, DH; MITTAG, M; SCZEKAN, S; MORSE, D; HASTINGS, JW			MOLECULAR-CLONING AND GENOMIC ORGANIZATION OF A GENE FOR LUCIFERIN-BINDING PROTEIN FROM THE DINOFLAGELLATE GONYAULAX-POLYEDRA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL CONTROL; MESSENGER-RNA; SEQUENCES; BIOLUMINESCENCE; COHNII; CLOCK; DNA	The circadian expressed luciferin-binding protein (LBP) gene from the marine bioluminescent alga Gonyaulax polyedra represents the first dinoflagellate gene that has been cloned and sequenced at both cDNA and genomic levels. Starting with a fragment from the 3'-end of the LBP cDNA that was found by immuno-screening of a cDNA library, genomic clones were obtained by the inverse polymerase chain reaction technique. Full-length cDNA clones were selected by screening a cDNA library by plaque hybridizations and by polymerase chain reaction amplifications. The LBP sequence has a 2004-nucleotide open reading frame coding for a protein of 668 amino acids (approximately 75 kDa). The reading frame and identity of the clone were confirmed by the sequence of an octapeptide obtained from a purified fragment of CNBr-treated LBP. A variant LBP cDNA was found to differ in sequence by approximately 11% at the DNA level. The untranslated regions of the mRNA are 111 nucleotides (5'-untranslated region) and 158 nucleotides (3'-untranslated region) long, respectively. The LBP gene contains no introns and exhibits certain features not typical for a eukaryotic gene. Its promoter does not include the typical TATA box within approximately 50 nucleotides upstream of the transcription start site, and the usual poly(A+) signal (AAUAAA) is not present on the end of the LBP mRNA. The copy number of the gene is very high (approximately 1000 copies/cell). However, the universal genetic code and conserved positions relevant for the translational apparatus are maintained.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM-19536] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; DUNLAP JC, 1981, J BIOL CHEM, V256, P509; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Eckert K A, 1991, PCR Methods Appl, V1, P17; Edmunds LN, 1988, CELLULAR MOL BASES B; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HAAPALA OK, 1974, HEREDITAS, V76, P83; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HIMES M, 1975, P NATL ACAD SCI USA, V72, P4546, DOI 10.1073/pnas.72.11.4546; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOFFMAN K, 1981, HDB BEHAVIORAL NEURO, V2, P449; HOLMHANSEN O, 1969, SCIENCE, V163, P87, DOI 10.1126/science.163.3862.87; JOHNSON CH, 1986, AM SCI, V74, P29; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEWIN B, 1990, GENES, V4, P545; LUMSDEN PJ, 1991, ANNU REV PLANT PHYS, V42, P351, DOI 10.1146/annurev.pp.42.060191.002031; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYFIELD SP, 1989, PLANT MOL BIOL, V12, P683, DOI 10.1007/BF00044159; MORSE D, 1989, P NATL ACAD SCI USA, V86, P172, DOI 10.1073/pnas.86.1.172; MORSE D, 1989, J BIOL CHEM, V264, P11822; MORSE DS, 1990, TRENDS BIOCHEM SCI, V15, P262, DOI 10.1016/0968-0004(90)90050-L; NAKAMURA H, 1989, J AM CHEM SOC, V111, P7607, DOI 10.1021/ja00201a050; RAE PMM, 1976, SCIENCE, V194, P1062, DOI 10.1126/science.988637; RIZZO PJ, 1991, J PROTOZOOL, V38, P246, DOI 10.1111/j.1550-7408.1991.tb04437.x; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; SALAROVIRA M, 1991, CHROMOSOMA, V100, P510, DOI 10.1007/BF00352201; Sambrook J, 1989, MOL CLONING LABORATO; SILFLOW CD, 1985, MOL CELL BIOL, V5, P2389, DOI 10.1128/MCB.5.9.2389; SLIGHTOM JL, 1908, PLANT MOL BIOL A, V6, P1; Spector D.L., 1984, P107; STEELE RE, 1982, THESIS YALE U; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES; TAYLOR FJR, 1980, BIOSYSTEMS, V13, P65, DOI 10.1016/0303-2647(80)90006-4; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	35	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8842	8850						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473328				2022-12-25	WOS:A1993KX81100069
J	OLEYKOWSKI, CA; MAYERNIK, JA; LIM, SE; GROOPMAN, JD; GROSSMAN, L; WOGAN, GN; YEUNG, AT				OLEYKOWSKI, CA; MAYERNIK, JA; LIM, SE; GROOPMAN, JD; GROSSMAN, L; WOGAN, GN; YEUNG, AT			REPAIR OF AFLATOXIN-B1 DNA ADDUCTS BY THE UVRABC ENDONUCLEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; RAT-LIVER; BIFUNCTIONAL INTERCALATOR; ACTIVATED AFLATOXIN-B1; EXCISION NUCLEASE; GLYCOSYLASE; INCISION; GUANINE; CELLS; BINDING	The repair by UvrABC endonuclease of two major adducts formed by aflatoxin B1 in DNA was found to be similar. Aflatoxin epoxide was used to generate the aflatoxin B1.N7-guanine adduct which can convert to aflatoxin B1-formamidopyrimidine adduct. The reaction of the aflatoxin B1 epoxide with DNA follows pseudo-first order kinetics. The DNA sequence-specific relative reactivity of the epoxide is the same as previously observed for afltoxin B1 activated by liver microsomes, therefore strongly reinforcing the notion that aflatoxin B1 reacts with DNA through the epoxide intermediate. For the majority of lesion sites, a high affinity protein-DNA complex was formed from the UvrA and the UvrB proteins with similar efficiency to both adducts, and to pyrimidine dimers, and then nicks the DNA when UvrC was added. The two incisions are at the eighth phosphodiester moiety 5' and the sixth phosphodiester moiety 3' of a modified guanine nucleotide. Both incisions appeared to be concerted. For some sites, the DNA sequence can alter the relative incision efficiency up to 15-fold. However, the majority of these AFB1 lesion structures in most DNA sequences are similar with respect to recognition by this nucleotide excision repair enzyme. Therefore the observation that the aflatoxin B1.N7-guanine lesion is removed rapidly, while the aflatoxin B1-formamidopyrimidine lesion persists in the mammalian cell may have other mechanistic explanations.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD	Fox Chase Cancer Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University			/X-4205-2019	/0000-0003-4690-2133	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000597] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NIEHS NIH HHS [P01ES00597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; BAERTSCHI SW, 1989, CHEM RES TOXICOL, V2, P114, DOI 10.1021/tx00008a008; BAERTSCHI SW, 1988, J AM CHEM SOC, V110, P7929, DOI 10.1021/ja00231a083; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BUSBY WF, 1984, CHEM CARCINOGENS, P945; Bushby WF, 1979, FOOD BORNE INFECTION, P519; CAMPBELL TC, 1976, TOXICOL APPL PHARM, V35, P199, DOI 10.1016/0041-008X(76)90282-9; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CROY RG, 1981, CANCER RES, V41, P197; CROY RG, 1978, P NATL ACAD SCI USA, V75, P1745, DOI 10.1073/pnas.75.4.1745; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P4120, DOI 10.1073/pnas.75.9.4120; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; GOPALAKRISHNAN S, 1989, BIOCHEMISTRY-US, V28, P726, DOI 10.1021/bi00428a047; GROOPMAN JD, 1981, CARCINOGENESIS, V2, P1371, DOI 10.1093/carcin/2.12.1371; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HERTZOG PJ, 1982, CARCINOGENESIS, V3, P723, DOI 10.1093/carcin/3.6.723; HOWARDFLANDERS P, 1966, GENETICS, V53, P1119; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; JONES BK, 1990, J BIOL CHEM, V265, P3489; LAMBERT B, 1989, P NATL ACAD SCI USA, V86, P6557, DOI 10.1073/pnas.86.17.6557; LAMBERT B, 1988, NUCLEIC ACIDS RES, V16, P1063, DOI 10.1093/nar/16.3.1063; LEADON SA, 1983, NUCLEIC ACIDS RES, V11, P5675, DOI 10.1093/nar/11.16.5675; LIN JK, 1977, CANCER RES, V37, P4430; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MARGISON GP, 1981, P NATL ACAD SCI-BIOL, V78, P861, DOI 10.1073/pnas.78.2.861; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MUNN MM, 1991, J BIOL CHEM, V266, P24748; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OTSUJI N, 1972, J BACTERIOL, V109, P475, DOI 10.1128/JB.109.2.475-483.1972; PU WT, 1989, J BIOL CHEM, V264, P20697; Rogers S G, 1980, Methods Enzymol, V65, P201; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SANCAR A, 1985, J MOL BIOL, V184, P725, DOI 10.1016/0022-2836(85)90316-X; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SARASIN A, 1977, MUTAT RES, V42, P205, DOI 10.1016/S0027-5107(77)80024-9; SARASIN AR, 1977, CANCER RES, V37, P1786; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; SWENSON DH, 1977, CANCER RES, V37, P172; TANG MS, 1989, J BIOL CHEM, V264, P14455; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1987, NUCLEIC ACIDS RES, V15, P4957, DOI 10.1093/nar/15.12.4957; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	60	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7990	8002						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463319				2022-12-25	WOS:A1993KW97900062
J	SALHANY, JM; SCHOPFER, LM				SALHANY, JM; SCHOPFER, LM			PYRIDOXAL 5'-PHOSPHATE BINDS SPECIFICALLY TO SOLUBLE CD4 PROTEIN, THE HIV-1 RECEPTOR - IMPLICATIONS FOR AIDS THERAPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 approximately 30 muM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (approximately 10(6)/cell), and to the very small K(d) for DIDS binding to band 3 (approximately 30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (K(d) = 45 muM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.	UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	SALHANY, JM (corresponding author), VET ADM MED CTR,RES SERV,4101 WOOLWORTH AVE,OMAHA,NE 68105, USA.							BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030; CARDIN AD, 1991, J BIOL CHEM, V266, P13355; CHURCHIC.JE, 1965, BIOCHIM BIOPHYS ACTA, V102, P280, DOI 10.1016/0926-6585(65)90220-7; DEMPSEY WB, 1962, J BIOL CHEM, V237, P1113; EISINGER J, 1982, P NATL ACAD SCI USA, P408; FISCHER EH, 1963, 1962 P S CHEM BIOL A, P543; FONDA ML, 1991, ARCH BIOCHEM BIOPHYS, V288, P79, DOI 10.1016/0003-9861(91)90167-H; GEHRMANN G, 1965, BRIT J HAEMATOL, V11, P86, DOI 10.1111/j.1365-2141.1965.tb00087.x; HUGHES RC, 1962, P NATL ACAD SCI USA, V48, P1615, DOI 10.1073/pnas.48.9.1615; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; KENT AB, 1958, J BIOL CHEM, V232, P549; LUI A, 1985, J LAB CLIN MED, V106, P491; MATSUO Y, 1957, J AM CHEM SOC, V79, P2011, DOI 10.1021/ja01565a068; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SALHANY JM, 1987, J BIOL CHEM, V262, P15965; SALHANY JM, 1990, ERYTHROCYTE BAND 3 P; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719	17	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7643	7645						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463294				2022-12-25	WOS:A1993KW97900012
J	KESSLER, E; SAFRIN, M; OLSON, JC; OHMAN, DE				KESSLER, E; SAFRIN, M; OLSON, JC; OHMAN, DE			SECRETED LASA OF PSEUDOMONAS-AERUGINOSA IS A STAPHYLOLYTIC PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; CYSTIC-FIBROSIS; ELASTASE; GENE; VIRULENCE; PROTEINS; CLONING; INACTIVATION; PURIFICATION; EXPRESSION	Full expression of the elastolytic phenotype of Pseudomonas aeruginosa depends on LasA, an extracellular protease with restricted specificity whose mode of action on elastin and biological role is not understood. LasA exhibits amino acid sequence homology to some bacteriolytic proteases and shares several physicochemical properties with the staphylolytic protease of P. aeruginosa. This led us to examine whether the two proteases are the same. Production of LasA and staphylolytic protease by prototrophic and lasA mutant strains of P. aeruginosa was investigated. The two prototrophic strains examined, PAO1 and FRD2, exhibited extracellular staphylolytic activity and secreted LasA. LasA mutants, PAO-E64 lasA1 (Ts), FRD2128 DELTAlasA, and FRD244 lasA::mTn10, did not exhibit staphylolytic activity. A low level of the LasA protein was detected in the culture filtrate of the temperature-sensitive lasA mutant PAO-E64, but none was detectable in those of the deletion and insertion mutants, FRD2128, and FRD244, respectively. The staphylolytic protease was purified from the culture filtrate of P. aeruginosa strain FRD2 by DEAE-cellulose chromatography. The purified enzyme hydrolyzed pentaglycine into the respective di- and tripeptides and reacted specifically with antibodies against a synthetic peptide identical in sequence to positions 77-98 in LasA. The amino-terminal sequence of the first 15 amino acid residues of the staphylolytic protease was found to be identical with that of the secreted LasA. These results clearly indicate that LasA is a staphylolytic protease. In addition to lysing staphylococci, it may enhance elastolysis by cleaving Gly-Gly bonds, which are abundant in elastin.	UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425; VET ADM MED CTR,MEMPHIS,TN 38104	University of Tennessee System; University of Tennessee Health Science Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	KESSLER, E (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,SHEBA MED CTR,IL-52621 TEL HASHOMER,ISRAEL.				NIAID NIH HHS [AI-26187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACKWOOD LL, 1983, INFECT IMMUN, V39, P198, DOI 10.1128/IAI.39.1.198-201.1983; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRITO N, 1989, RES MICROBIOL, V140, P125, DOI 10.1016/0923-2508(89)90046-6; COLES NW, 1969, BIOCHEM J, V111, P7, DOI 10.1042/bj1110007; DAMAGLOU AP, 1976, ATLAS PROTEIN SEQ S2, V5, P98; DARZINS A, 1990, NUCLEIC ACIDS RES, V18, P1644; DORING G, 1981, ZBL BAKT-INT J MED M, V249, P89, DOI 10.1016/S0174-3031(81)80045-5; EPSTEIN DM, 1988, J BIOL CHEM, V263, P16586; FAZIO MJ, 1988, LAB INVEST, V58, P270; GOLDBERG JB, 1987, J BACTERIOL, V169, P4532, DOI 10.1128/jb.169.10.4532-4539.1987; GOLDBERG JB, 1987, J BACTERIOL, V169, P1349, DOI 10.1128/jb.169.3.1349-1351.1987; HAMADAOUI A, 1987, AM REV RESPIR DIS, V135, P860; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HECK LW, 1986, INFECT IMMUN, V54, P149, DOI 10.1128/IAI.54.1.149-153.1986; HECK LW, 1986, J IMMUNOL, V6, P2253; Homma J. Y., 1985, BACTERIAL ENZYMES VI, P41; JURASEK L, 1965, CAN J BIOCHEM CELL B, V43, P1955, DOI 10.1139/o65-218; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; KESSLER E, 1992, FEBS LETT, V299, P291, DOI 10.1016/0014-5793(92)80134-3; KESSLER E, 1982, INFECT IMMUN, V38, P716, DOI 10.1128/IAI.38.2.716-723.1982; LACHE M, 1969, J BACTERIOL, V100, P254, DOI 10.1128/JB.100.1.254-259.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SL, 1990, J BACTERIOL, V172, P6506, DOI 10.1128/jb.172.11.6506-6511.1990; LIU PV, 1974, J INFECT DIS, V130, pS94, DOI 10.1093/infdis/130.Supplement.S94; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHEWS LW, 1984, PEDIATR CLIN N AM, V31, P133; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; MORIHARA K, 1979, INFECT IMMUN, V24, P188, DOI 10.1128/IAI.24.1.188-193.1979; NICAS TI, 1985, CAN J MICROBIOL, V31, P387, DOI 10.1139/m85-074; OHMAN DE, 1982, INFECT IMMUN, V37, P662, DOI 10.1128/IAI.37.2.662-669.1982; OHMAN DE, 1980, J BACTERIOL, V142, P836, DOI 10.1128/JB.142.3.836-842.1980; OLSON JC, 1992, J BACTERIOL, V174, P4140, DOI 10.1128/jb.174.12.4140-4147.1992; PERESTELO F R, 1985, Microbios Letters, V30, P85; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; PETERS JE, 1992, MOL MICROBIOL, V6, P1155, DOI 10.1111/j.1365-2958.1992.tb01554.x; RAJU K, 1987, J BIOL CHEM, V262, P5755; SCHAD PA, 1988, J BACTERIOL, V170, P2784, DOI 10.1128/jb.170.6.2784-2789.1988; SCHAD PA, 1987, J BACTERIOL, V169, P2691, DOI 10.1128/jb.169.6.2691-2696.1987; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; STROMINGER JL, 1967, SCIENCE, V7156, P213; SZEWCZYK B, 1985, ANAL BIOCHEM, V150, P403, DOI 10.1016/0003-2697(85)90528-7; TODER DS, 1991, MOL MICROBIOL, V5, P2003, DOI 10.1111/j.1365-2958.1991.tb00822.x; WOLZ C, 1991, MOL MICROBIOL, V5, P2125, DOI 10.1111/j.1365-2958.1991.tb02142.x; WOODS DE, 1982, INFECT IMMUN, V36, P1223, DOI 10.1128/IAI.36.3.1223-1228.1982; WRETLIND B, 1977, J GEN MICROBIOL, V103, P329, DOI 10.1099/00221287-103-2-329	45	218	226	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7503	7508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463280				2022-12-25	WOS:A1993KV14100097
J	KIMURA, M; AVIV, A; REEVES, JP				KIMURA, M; AVIV, A; REEVES, JP			K+-DEPENDENT NA+/CA2+ EXCHANGE IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; PLASMA-MEMBRANE VESICLES; NA+-CA-2+ EXCHANGE; CA-2+ HOMEOSTASIS; SODIUM; CALCIUM; INDICATORS; EXTRUSION; GRADIENTS; NA+	Ca2+ influx via Na-/Ca2+ exchange was examined using fura-2 fluorescence techniques in human platelets loaded internally with Na+ by pretreatment with ouabain. In 140 mM LiCl, Ca2+ influx via the exchanger was completely dependent upon the presence of extracellular K+ (K(m) almost-equal-to 1 mM). In 140 mM N-methyl-D-glucamine (NMDG), Ca2+ influx was stimulated by K+ but was not absolutely dependent upon it; the inclusion of 20 mM NaCl in the NMDG medium restored the K+ dependence of Ca2+ influx. Stimulation of Ca2+ influx by K+ was confirmed by Ca-45(2+) flux studies. Rb-86+ fluxes were measured to determine if Ca2+ and Rb-86+ were co-transported by the exchanger. The presence of extracellular Ca2+ stimulated Rb-86+ influx in ouabain-treated platelets in 160 mM LiCl or NMDG. The Rb+/Ca2+ influx ratio was 0.42 +/- 0.04 (n = 3) at [Rb+] = 0.2 mM and 0.89 at [Rb+] = 1.3 mM. Neither K+-dependent Ca2+ influx nor Ca2+-dependent Rb+ influx was observed in 160 mM NaCl or in platelets that had not been pretreated with ouabain, indicating that these fluxes resulted from Na+/Ca2+ exchange activity. Na+-dependent Ca2+ efflux was also shown to be dependent upon the presence of internal K+. These properties are similar to those of the Na+/Ca2+-K+ exchanger found in retinal rods, as distinct from the more widely distributed cardiac-type exchanger.	UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, HYPERTENS RES CTR, NEWARK, NJ 07103 USA; ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT GENE REGULAT, NUTLEY, NJ 07110 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Roche Holding					NHLBI NIH HHS [HL42856, HL34807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042856, R01HL034807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASS LF, 1984, J BIOL CHEM, V259, P2571; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; DAHAN D, 1991, J BIOL CHEM, V266, P2067; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYNES DH, 1991, ANN NY ACAD SCI, V639, P593; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KIMURA M, 1992, J CLIN INVEST, V89, P1121, DOI 10.1172/JCI115692; KIMURA M, 1993, IN PRESS PFLUG ARCH; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; MINTA A, 1989, J BIOL CHEM, V264, P19449; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REEVES JP, 1988, METHOD ENZYMOL, V157, P505; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; RENGASAMY A, 1987, THROMB HAEMOSTASIS, V57, P337; SCHAEFFER J, 1989, CELL CALCIUM, V10, P101, DOI 10.1016/0143-4160(89)90050-X; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22983; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153	21	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6874	6877						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463216				2022-12-25	WOS:A1993KV14100014
J	MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H				MANENTI, S; SOROKINE, O; VANDORSSELAER, A; TANIGUCHI, H			ISOLATION OF THE NON-MYRISTOYLATED FORM OF A MAJOR SUBSTRATE OF PROTEIN-KINASE-C (MARCKS) FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROMINENT CELLULAR SUBSTRATE; MOLECULAR-CLONING; RAT-BRAIN; PHOSPHORYLATION; CALMODULIN; 80-KDA; EXPRESSION; BINDING; CHICKEN	A substrate protein of protein kinase C with an apparent molecular mass of 70 kDa has been purified from bovine brain. This protein shares several properties with a major substrate of protein kinase C (myristoylated alanine-rich C kinase substrate; MARCKS). It is heat-stable and copurifies with MARCKS during various steps (ammonium sulfate precipitation and gel filtration). However, its elution from a calmodulin affinity column is different from that of MARCKS. It can be eluted by high ionic strength in the presence of calcium, whereas MARCKS can be eluted only in the absence of calcium. Its earlier elution from a reversed phase column suggests that p70 is less hydrophobic than MARCKS. The electrospray mass spectrum revealed an actual mass of 31,550 +/- 6.5 Da, very far from the apparent molecular mass in SDS-polyacrylamide gel electrophoresis (70,000 Da). This mass is about 200 Da smaller than that of MARCKS determined by mass spectrometry analysis (Manenti, S., Sorokine, O., Van Dorsselaer, A., and Taniguchi, H. (1992) J. Biol. Chem. 267, 22310-22315), close to the value expected for the change due to N-terminal myristoylation (210 Da). N-terminal amino acid sequencing showed that the N terminus is not blocked, and the sequence found for the 10 first amino acids is identical to that deduced from the cDNA sequence of bovine MARCKS. These data clearly establish that this protein is a non-myristoylated form of MARCKS and that the absence of the myristoyl moiety at the N terminus lowers the affinity to calmodulin. The purification performed both from the membrane and the cytoplasmic fractions of bovine brain indicated that this non-myristoylated form represents 20-30% of the MARCKS protein in the cytoplasmic fraction, and less than 5% in the membrane one.	CNRS,URA 31,CHIM ORGA SUBST NAT LAB,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MANENTI, S (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; AMESS B, 1992, FEBS LETT, V297, P285; CARR SA, 1991, ANAL CHEM, V63, P2802, DOI 10.1021/ac00024a003; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; JACOBSON BC, 1992, J CELL PHYSIOL, V152, P166, DOI 10.1002/jcp.1041520121; JAMES G, 1989, J BIOL CHEM, V264, P20928; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; PATEL J, 1987, J BIOL CHEM, V262, P16686; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445	28	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6878	6881						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463217				2022-12-25	WOS:A1993KV14100015
J	WARMERDAM, PAM; NABBEN, NMJM; VANDEGRAAF, SAR; VANDEWINKEL, JGJ; CAPEL, PJA				WARMERDAM, PAM; NABBEN, NMJM; VANDEGRAAF, SAR; VANDEWINKEL, JGJ; CAPEL, PJA			THE HUMAN LOW AFFINITY IMMUNOGLOBULIN-G FC RECEPTOR-IIC GENE IS A RESULT OF AN UNEQUAL CROSSOVER EVENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IGG; ORGANIZATION; EXPRESSION; CD32; ENDOCYTOSIS; COMPLEXES; DOMAINS; CHAIN	We have isolated and characterized three genes coding for hFcgammaRIIA, IIB, and IIC. Each gene spans almost-equal-to 15-19 kilobases of DNA and consists of eight exons. Two exons encode the 5'-untranslated region and signal peptides, two exons code for homologous Ig-like extracellular domains, a single exon encodes the transmembrane spanning region, and three exons encode the cytoplasmic domains and 3'-untranslated regions. Analysis of gene structures support the concept that the hFcgammaRIIA and hFcgammaRIIB genes originated via gene duplication and divergence processes. The hFcgammaRIIC gene, however, showed a remarkable homology at its 5' end with the hFcgammaRIIB gene, whereas its 3' region was highly homologous with the hFcgammaRIIA gene, suggesting that the hFcgammaRIIC gene results from an unequal crossover event between the hFcgammaRIIA and IIB genes. This hypothesis was supported by nucleotide sequence analyses of the putative break-point region. The proposed site of recombination was located approximately 300 nucleotides downstream from the sixth (C1) exon. These data provide a unique model for the evolutionary generation of a receptor family with multiple biological functions.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3511 GV UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; ENGELHARDT W, 1991, EUR J IMMUNOL, V21, P2227, DOI 10.1002/eji.1830210934; ERNST LK, 1992, J BIOL CHEM, V267, P15692; FRISCHAUF AM, 1983, J MOL BIOL, V85, P426; HONING S, 1991, EUR J CELL BIOL, V55, P48; KULCZYCKI A, 1990, P NATL ACAD SCI USA, V87, P2856, DOI 10.1073/pnas.87.7.2856; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Sambrook J, 1989, MOL CLONING LABORATO; SAMMARTINO L, 1988, IMMUNOGENETICS, V28, P380, DOI 10.1007/BF00364238; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TEPLER I, 1989, J BIOL CHEM, V264, P5912; TUIJNMAN WB, 1992, BLOOD, V79, P1651; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WARMERDAM PAM, 1993, IN PRESS INT IMMUNOL; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	23	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7346	7349						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463268				2022-12-25	WOS:A1993KV14100075
J	TANAKA, M; JINGAMI, H; OTANI, H; CHO, M; UEDA, Y; ARAI, H; NAGANO, Y; DOI, T; YOKODE, M; KITA, T				TANAKA, M; JINGAMI, H; OTANI, H; CHO, M; UEDA, Y; ARAI, H; NAGANO, Y; DOI, T; YOKODE, M; KITA, T			REGULATION OF APOLIPOPROTEIN-B PRODUCTION AND SECRETION IN RESPONSE TO THE CHANGE OF INTRACELLULAR CHOLESTERYL ESTER CONTENTS IN RABBIT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; RAT HEPATOCYTES; WHHL RABBITS; HEPG2 CELLS; INSULIN; ACID; MACROPHAGES; TURNOVER; RECEPTOR	In the present study, we investigated the mechanisms that regulate apolipoprotein B-100 (apoB) secretion in response to the change of intracellular cholesteryl ester contents by adding low density lipoprotein (LDL) and an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (pravastatin) in rabbit hepatocyte culture system. LDL caused a significant dose-dependent increase in apoB secretion. On the other hand, the addition of pravastatin decreased apoB secretion significantly. LDL caused a dose-dependent increase in cellular cholesteryl ester, while cellular cholesteryl ester was decreased by pravastatin significantly. Therefore, these results indicate that the change of apoB secretion was in parallel with the change of cellular cholesteryl ester contents. Cellular contents of free cholesterol, triglyceride, and phospholipid did not change. To investigate intracellular degradation of apoB prior to secretion, pulse-chase experiments were performed. It was shown that the addition of pravastatin accelerated intracellular degradation of apoB, while LDL slowed the apoB intracellular degradation rate. We also investigated whether the change of cellular cholesteryl ester could affect the apoB mRNA level. Northern blot analysis and solution hybridization RNase protection assay demonstrated that neither LDL nor pravastatin caused a significant change in cellular apoB mRNA level. We conclude that intracellular cholesteryl ester contents play a critical role in apoB secretion, and the intracellular apoB degradation rate could be the main mechanism that regulates apoB secretion in response to the change of intracellular cholesteryl ester level.	KYOTO UNIV,FAC MED,DEPT INTERNAL MED,DIV 2,KYOTO 606,JAPAN	Kyoto University	TANAKA, M (corresponding author), KYOTO UNIV,FAC MED,DEPT GERIATR MED,54 SHOGOIN KAWAHARA HO,SAKYO KU,KYOTO 606,JAPAN.							ARAD Y, 1990, J LIPID RES, V31, P567; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16398; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; GINSBERG HN, 1987, J CLIN INVEST, V80, P1692, DOI 10.1172/JCI113259; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW A, 1990, J LIPID RES, V31, P1109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; OBRIEN K, 1991, ARTERIOSCLER THROMB, V11, P751, DOI 10.1161/01.ATV.11.3.751; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1990, J BIOL CHEM, V265, P11880; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377; 1985, JAMA-J AM MED ASSOC, V253, P2080	31	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12713	12718						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509406				2022-12-25	WOS:A1993LG65800072
J	WOLFE, BL; RICH, CB; GOUD, HD; TERPSTRA, AJ; BASHIR, M; ROSENBLOOM, J; SONENSHEIN, GE; FOSTER, JA				WOLFE, BL; RICH, CB; GOUD, HD; TERPSTRA, AJ; BASHIR, M; ROSENBLOOM, J; SONENSHEIN, GE; FOSTER, JA			INSULIN-LIKE GROWTH FACTOR-I REGULATES TRANSCRIPTION OF THE ELASTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; 5'-FLANKING REGION; MESSENGER-RNA; FUNCTIONAL PROMOTER; RIBONUCLEIC-ACID; SOMATOMEDIN-C; CIS-ELEMENTS; FACTOR-BETA; EXPRESSION; DNA	Neonatal rat aortic smooth muscle cell cultures were used to investigate the mechanisms by which insulin-like growth factor-I (IGF-I) up-regulates aortic elastogenesis. The addition of IGF-I (50 ng/ml) to quiescent smooth muscle cell cultures resulted in a 5-fold increase in the steady-state levels of tropoelastin mRNA beginning between 2 and 4 h and reaching maximal levels at 8 h. Addition of cycloheximide blocked the effect of IGF-I. Nuclear run-on transcription analyses of nuclei isolated from IGF-I-treated cells showed increased synthesis of new tropoelastin transcripts indicating that transcriptional activation is a major component of IGF-I up-regulation. Transient transfections with deletion constructs containing different portions of the elastin 5'-upstream region localized the IGF-I-responsive area to sequences between -195 and -136 base pairs and further showed that this region contains a negative element. Gel retardation assays using nuclear proteins extracted from control and IGF-I-treated cells demonstrated that IGF-I treatment results in the loss of binding complexes. Footprint analyses of specific binding complexes affected by IGF-I show the deprotection of two closely positioned sequences spanning positions -165 to -137 base pairs. These results suggest that IGF-I up-regulation of elastogenesis involves the abrogation of a negative element functionality.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030061, P01HL046902, R01HL046100] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46902, HL 30061, HL 46100] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BARONE LM, 1988, BIOCHEMISTRY-US, V27, P3175, DOI 10.1021/bi00409a008; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMMONS DR, 1989, BRIT MED BULL, V45, P465, DOI 10.1093/oxfordjournals.bmb.a072335; DAVIDSON JM, 1986, BIOL EXTRACELLULAR M, V1, P177; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1990, AM J PHYSIOL, V259, pL13, DOI 10.1152/ajplung.1990.259.2.L13; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; FOSTER JA, 1990, J GERONTOL, V13, P113; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; LU L, 1989, MOL CELL BIOL, V9, P3411; NARGIS N, 1990, P NATL ACAD SCI USA, V87, P5223; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; RICH CB, 1992, AM J PHYSIOL, V263, pL276, DOI 10.1152/ajplung.1992.263.2.L276; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; VELDHUIS JD, 1986, J BIOL CHEM, V261, P2499; VOGEL A, 1978, P NATL ACAD SCI USA, V75, P2810, DOI 10.1073/pnas.75.6.2810; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; ZUMSTEIN P, 1987, J BIOL CHEM, V262, P11252	43	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12418	12426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509381				2022-12-25	WOS:A1993LG65800032
J	LINDSTEDT, R; APODACA, G; BARONDES, SH; MOSTOV, KE; LEFFLER, H				LINDSTEDT, R; APODACA, G; BARONDES, SH; MOSTOV, KE; LEFFLER, H			APICAL SECRETION OF A CYTOSOLIC PROTEIN BY MADIN-DARBY CANINE KIDNEY-CELLS - EVIDENCE FOR POLARIZED RELEASE OF AN ENDOGENOUS LECTIN BY A NONCLASSICAL SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING PROTEIN; CULTURED-CELLS; BREFELDIN-A; VERTEBRATE LECTINS; EPITHELIAL-CELL; TISSUE-SECTIONS; SIGNAL SEQUENCE; MAC-2 ANTIGEN; MDCK CELLS; TRANSPORT	In the classical secretory pathway proteins containing a signal peptide are translocated from the cytoplasm of the cell into the lumen of the endoplasmic reticulum (ER). From the ER they are transported to the Golgi apparatus and finally to the plasma membrane (PM) where they are released into the extracellular compartment. However, some proteins are synthesized without a signal peptide and maintain a predominantly cytosolic distribution until they are released from the cell. As a marker for this nonclassical secretory pathway we have chosen L-29, a soluble lectin of M(r) about 29,000, that has affinity for lactose and other beta-galactoside containing glycoconjugates. We were interested in determining if cultured epithelial cells secrete L-29 and if they do so in a polarized fashion. Madin-Darby canine kidney (MDCK)-II cells were found to express large quantities of L-29 (about 1% of the detergent soluble protein). The lectin was diffusely distributed in the cytosol, with little or none in vesicular compartments. The polarity of L-29 secretion, when analyzed in pulse-chase experiments, was selectively into the apical compartment of filter-grown MDCK cells. This secretion was not inhibited by brefeldin A or monensin, drugs that are known to inhibit protein transport through the ER-Golgi-PM pathway. Secretion of L-29 was augmented 3-5-fold by the calcium ionophore A23187 and by increasing the temperature to 42-degrees-C, whereas lowering the temperature to 20-degrees-C or addition of nocodazole prevented secretion. These results demonstrate the polarized secretion of a cytosolic protein by a nonclassical secretory pathway.	UNIV CALIF SAN FRANCISCO, LANGLEY PORTER NEUROPSYCHIAT INST, BOX F-0984, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019; Apodaca, Gerard/HCJ-0048-2022	Leffler, Hakon/0000-0003-4482-8945; mostov, keith/0000-0002-8123-6247	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI25144] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALONSO FV, 1981, J CELL BIOL, V89, P700, DOI 10.1083/jcb.89.3.700; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BENNETT MK, 1989, METHOD CELL BIOL, V31, P103; BEYER EC, 1982, J CELL BIOL, V92, P28, DOI 10.1083/jcb.92.1.28; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRASSART D, 1992, EUR J BIOCHEM, V203, P393, DOI 10.1111/j.1432-1033.1992.tb16563.x; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; CAMERON AA, 1991, NEUROSCI LETT, V131, P249, DOI 10.1016/0304-3940(91)90625-4; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GITT MA, 1992, J BIOL CHEM, V267, P10601; HARRISON FL, 1991, J CELL SCI, V100, P9; HO MK, 1982, J IMMUNOL, V128, P1221; HORIO M, 1989, J BIOL CHEM, V264, P14880; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; LEE EC, 1991, ARCH SURG-CHICAGO, V126, P1498; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINDSTEDT R, 1991, J CELL BIOL, V11, pA399; LOW SH, 1991, J BIOL CHEM, V266, P17729; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PINTO M, 1983, BIOL CELL, V47, P323; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHNEIDER H, 1991, J EXP MED, V174, P1601, DOI 10.1084/jem.174.6.1601; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WOO HJ, 1990, J BIOL CHEM, V265, P7097	56	171	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11750	11757						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505302				2022-12-25	WOS:A1993LF28400045
J	BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF				BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF			P59(FYN) IN RAT-BRAIN IS LOCALIZED IN DEVELOPING AXONAL TRACTS AND SUBPOPULATIONS OF ADULT NEURONS AND GLIA	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NERVE GROWTH CONE; SRC GENE-PRODUCT; CEREBRAL-CORTEX; MOUSE; RECEPTOR; PROTOONCOGENE; PP60C-SRC; FAMILY	Expression of the c-fyn proto-oncogene was analysed in the developing and adult rat brain by subcellular fractionation and immunocytochemistry using polyclonal antibodies specific for its protein product (p59fyn). Immunoperoxidase staining revealed widespread localization of p59fyn in developing axonal tracts throughout the fetal (E18) rat brain. fyn immunoreactivity was not observed in most axon-rich regions of the adult brain, but continued to be expressed at elevated levels in the adult olfactory and vomeronasal systems. At other sites in the adult rat brain, fyn immunoreactivity was restricted to cell bodies of neuronal subpopulations, especially those in brain stem and hypothalamic nuclei, and to subpopulations of glial cells along axonal tracts in the medulla, optic nerve and white matter of the spinal cord. In the peripheral nervous system, fyn staining was also prominent in Schwann cells. Subcellular fractionation of fetal and adult rat brain confirmed the immunocytochemical localization, demonstrating an enrichment of p59fyn in membranes from a fetal brain fraction containing nerve growth cones, and lower levels in adult brain where there was only a small enrichment in synaptosomal membranes. The developmental regulation of p59fyn suggests that the fyn tyrosine kinase may serve separate cellular roles in axonal growth and specialized functions of mature neurons and glia.	UNIV N CAROLINA, SCH MED, DEPT CELL BIOL & ANAT, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NEI NIH HHS [EY06336] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; BISCARDI JS, 1993, IN PRESS EXP EYE RES; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GRAZIADEI PPC, 1978, NEURONAL PLASTICITY; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGNELZI MA, 1992, J COMP NEUROL, V315, P171, DOI 10.1002/cne.903150205; IGNELZI MA, 1992, SOC NEUR ABSTR, V4614, P1095; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LIUZZI FJ, 1987, BRAIN RES, V403, P385, DOI 10.1016/0006-8993(87)90081-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; POMEROY SL, 1990, J NEUROSCI, V10, P1952; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMKOWITZ P, 1989, J NEUROSCI, V9, P1004; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; UNGER JW, 1991, NEUROSCIENCE, V42, P853, DOI 10.1016/0306-4522(91)90049-T; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WOODHAMS PL, 1981, ANAT EMBRYOL, V163, P331, DOI 10.1007/BF00315709; ZHAO YH, 1991, ONCOGENE, V6, P1725	38	84	85	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1429	1436						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502471				2022-12-25	WOS:A1993LE06400005
J	KANE, SE				KANE, SE			MOUSE PROCATHEPSIN-L LACKING A FUNCTIONAL GLYCOSYLATION SITE IS PROPERLY FOLDED, STABLE, AND SECRETED BY NIH-3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; MULTIDRUG RESISTANCE GENE; MAJOR EXCRETED PROTEIN; LYSOSOMAL-ENZYMES; DEPENDENT SECRETION; CATHEPSIN-D; CARBOXYPEPTIDASE-Y; MURINE FIBROBLASTS; HEPG2 CELLS; BIOSYNTHESIS	The role of glycosylation in the synthesis, transport, and localization of procathepsin L has been analyzed. Procathepsin L is the precursor form of a lysosomal cysteine protease which is synthesized in large amounts by malignantly transformed cells and cells treated with growth factors or tumor promoters. As for other lysosomal hydrolases, procathepsin L is predominantly secreted when it is overexpressed, despite the presence of the lysosomal sorting marker mannose 6-phosphate. To study the role of glycosylation in procathepsin L trafficking, we constructed a cDNA in which the codon for Asn-204 was mutated to encode Gln. When this mutated cDNA was transfected into NIH 3T3 cells, a completely nonglycosylated form of procathepsin L was expressed. The protein appeared to be folded properly, as judged by its ability to be proteolytically processed to a lower molecular weight form during incubation at pH 4. Nonglycosylated protein was stable, both as unprocessed proenzyme and after processing at pH 4, and it was predominantly secreted instead of being delivered to lysosomes. Nonglycosylated and endogenous glycosylated procathepsin L were secreted by NIH 3T3 cells with identical kinetics. These studies therefore confirm that Asn-204 is the normal functional carbohydrate acceptor in procathepsin L and that carbohydrate in wild-type procathepsin L serves predominantly as a lysosomal targeting signal, with little or no role in protein folding or stability. Furthermore, there does not appear to be a major mannose 6-phosphate-independent route of lysosomal localization in NIH 3T3 cells. In experiments with a second mutant, the glycosylation signal at Asn-251, which normally is not utilized, was capable of serving as a carbohydrate acceptor, suggesting that there is normally a structural impediment to glycosylation at Asn-251 in procathepsin L.			KANE, SE (corresponding author), CITY HOPE NATL MED CTR,DIV SURG,DEPT CELL & TUMOR BIOL,1500 E DUARTE RD,DUARTE,CA 91010, USA.							BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; GOTTESMAN MM, 1981, BIOCHEMISTRY-US, V20, P1659, DOI 10.1021/bi00509a039; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1980, J BIOL CHEM, V255, P4946; ISODORO C, 1991, BIOCHEM J, V273, P363; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kane S E, 1990, Semin Cancer Biol, V1, P127; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KANE SE, 1989, GENE, V84, P439, DOI 10.1016/0378-1119(89)90518-0; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rochefort H, 1990, Semin Cancer Biol, V1, P153; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11456	11462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496193				2022-12-25	WOS:A1993LD46600106
J	REDWOOD, CS; MARSTON, SB				REDWOOD, CS; MARSTON, SB			BINDING AND REGULATORY PROPERTIES OF EXPRESSED FUNCTIONAL DOMAINS OF CHICKEN GIZZARD SMOOTH-MUSCLE CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-FILAMENTS; ATPASE ACTIVITY; CALMODULIN-BINDING; HEAVY-MEROMYOSIN; ESCHERICHIA-COLI; NONMUSCLE CALDESMON; MOLECULAR-WEIGHT; CA-2+ REGULATION; SKELETAL-MUSCLE; P34CDC2 KINASE	We expressed the following fragments of chicken gizzard caldesmon in the pMW172/BL21(DE3) system at 0.4-2.2 mg of pure protein/liter of culture: full-length smooth muscle caldesmon (CDh) (amino acids 1-756), nonmuscle caldesmon (CDl), amino acids 1-128 (N128), 1-578 (N578), 230-419, 606-756 (606C), and 658-756 (658C). CDh bound tropomyosin with a K(d) of 1.5 muM; N578, 230-419, and 606C bound with affinities at least 2-5-fold lower; N128 bound weakly; and 658C did not bind. Only N128 and N578 bound to smooth muscle myosin, both about 10-fold weaker than CDh and CDl. Only 606C and 658C bound to actin-tropomyosin with affinities CDh = 606C > 658C. The binding to actin-tropomyosin was biphasic, whereas the binding to actin was monophasic, corresponding to the weak binding component found in the presence of tropomyosin. Calmodulin bound only to the C-terminal fragments with the same affinity as CDh. CDh, 606C, and 658C inhibited actin-tropomyosin-activated myosin ATPase, with maximal inhibition correlated with 1 caldesmon bound/14 actins, and inhibition was reversed by Ca2+-calmodulin. Thus, the actomyosin ATPase regulatory function, calmodulin binding, and most actin binding is located within the C-terminal 99 amino acids, whereas tropomyosin binding is distributed throughout the rest of the molecule.	NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND	Imperial College London				Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1989, J MUSCLE RES CELL M, V10, P95, DOI 10.1007/BF01739964; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHEN GFT, 1990, NUCLEIC ACIDS RES, V18, P1465, DOI 10.1093/nar/18.6.1465; CROSBIE R, 1991, J BIOL CHEM, V266, P20001; CROSBIE RH, 1992, BIOCHEM BIOPH RES CO, V184, P239, DOI 10.1016/0006-291X(92)91184-R; CZURYLO EA, 1993, IN PRESS BIOCH J; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FUJII T, 1987, J BIOL CHEM, V262, P2757; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRACEFFA P, 1990, J MUSCLE RES CELL M, V11, P440; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUBER PAJ, 1993, IN RPESS J MUSCLE RE, V14; HUMPHREY MB, 1992, GENE, V112, P197, DOI 10.1016/0378-1119(92)90376-Z; IKEBE M, 1988, J BIOL CHEM, V263, P3055; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P210, DOI 10.1016/0006-291X(89)91642-2; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MARSTON SB, 1985, ADV PROTEIN PHOSPHAT, V2, P171; MARSTON SB, 1993, IN PRESS J BIOL CHEM; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; NOVY RE, 1991, J BIOL CHEM, V266, P16917; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; REDWOOD CS, 1993, BIOPHYS J, V64, pA30; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TOROK K, 1990, J MUSCLE RES CELL M, V11, P443; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; VIBERT P, 1992, J CELL BIOL, V115, pA376; Walsh M P, 1989, Adv Exp Med Biol, V255, P337; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; YAMAKITA V, 1992, J BIOL CHEM, V267, P12022; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIRO S, 1991, BIOESSAYS, V13, P563, DOI 10.1002/bies.950131103; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	69	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10969	10976						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496161				2022-12-25	WOS:A1993LD46600041
J	KORETZKY, GA; KOHMETSCHER, M; ROSS, S				KORETZKY, GA; KOHMETSCHER, M; ROSS, S			CD45-ASSOCIATED KINASE-ACTIVITY REQUIRES LCK BUT NOT T-CELL RECEPTOR EXPRESSION IN THE JURKAT T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; LEUKOCYTE-COMMON ANTIGEN; SIGNAL TRANSDUCTION; PHOSPHATASE CD45; PHOSPHORYLATION; P56LCK; ACTIVATION; CD8; STIMULATION; ASSOCIATION	The earliest biochemical event known to be associated with T cell receptor (TCR) engagement is the activation of a protein tyrosine kinase thought to be a member of the src family. Expression of CD45, the major receptor tyrosine phosphatase present on T cells, is required for efficient coupling between the TCR and its signaling machinery. One model to explain the role of CD45 in regulating TCR signaling is that the phosphatase dephosphorylates the regulatory C-terminal tyrosine of lck. In the present report we confirm the finding of a trimolecular complex containing CD45, lck, and a 34-kDa protein (p34) in the Jurkat T cell line. Additionally, we extend this work with the observation that specific in vitro kinase activity associated with CD45 requires the expression of lck in Jurkat-derived clones as does the in vivo phosphorylation of p34. The association between CD45 and lck is shown not to require the expression of or activation of the TCR. Finally, we demonstrate that even in the absence of lck p34 associates with CD45, implying a direct association between this molecule and the phosphatase. These data suggest strongly that lck is the relevant protein tyrosine kinase found in CD45 immunoprecipitates in the Jurkat T cell line and that there is an additional association between CD45 and p34 which does not require the presence of the protein tyrosine kinase.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	KORETZKY, GA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,540 EMRB,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021		NATIONAL CANCER INSTITUTE [R01CA056050, R29CA056843] Funding Source: NIH RePORTER; NCI NIH HHS [1R29 CA56843-02, 1 R01 CA56050-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL G M, 1991, Arthritis and Rheumatism, V34, pS79; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	38	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8958	8964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473339				2022-12-25	WOS:A1993KX81100084
J	PIGNOLO, RJ; CRISTOFALO, VJ; ROTENBERG, MO				PIGNOLO, RJ; CRISTOFALO, VJ; ROTENBERG, MO			SENESCENT WI-38 CELLS FAIL TO EXPRESS EPC-1, A GENE INDUCED IN YOUNG CELLS UPON ENTRY INTO THE G(0) STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; PROTEASE INHIBITORY ACTIVITY; REPLICATIVE LIFE-SPAN; DNA-SYNTHESIS; CELLULAR SENESCENCE; ALZHEIMERS-DISEASE; GROWTH ARREST; NEURITE OUTGROWTH; RIBONUCLEIC-ACID; MEMBRANE-PROTEIN	Recently we reported the isolation of cDNAs for a number of genes that are differentially expressed between nonproliferating early (young) and late (senescent) population doubling level (PDL) WI-38 human, fetal lung-derived, fibroblast-like cells. We now demonstrate that one of these isolates, EPC-1 (early PDL cDNA-1), derives from an approximately 1.4-kilobase mRNA species that is expressed at a greater-than-or-equal-to 100-fold higher level in serum-starved, confluent, young versus similarly treated senescent WI-38 cells. Complete nucleotide sequence analysis of this cDNA confirms its identity with that of a cDNA encoding a secreted, retinal pigmented epithelium differentiation factor as well as similarity of the encoded protein with a number of mammalian serine protease inhibitors. We show that EPC-1 expression is associated with Go growth arrest in WI-38 cells. The mRNA readily accumulates in density-arrested and/or serum-starved young cells but not in log phase, low density young cells. In contrast, EPC-1 transcript abundance and expression of the encoded, secreted protein are both negligible in senescent WI-38 cells under all culture conditions tested. These findings support the hypothesis that senescent WI-38 cells exhibit a state of growth arrest fundamentally distinct from that of quiescent (G0) young cells.	MED COLL PENN,CTR GERONTOL RES,3300 HENRY AVE,PHILADELPHIA,PA 19129; MED COLL PENN,DEPT PHYSIOL & BIOCHEM,PHILADELPHIA,PA 19129	Drexel University; Drexel University					NIA NIH HHS [AG00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642; BADERGA R, 1985, BIOL CEL REPRODUCTIO, P23; BAKER JB, 1986, RECEPTORS, V3, P153; BIERMAN EL, 1978, IN VITRO CELL DEV B, V14, P951; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P2487; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BURMER GC, 1984, J CELL PHYSIOL, V118, P97, DOI 10.1002/jcp.1041180116; BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; BURMER GC, 1982, J CELL BIOL, V94, P187, DOI 10.1083/jcb.94.1.187; CARRELL RW, 1988, NATURE, V331, P478, DOI 10.1038/331478a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISTOFALO V J, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V27, P65; CRISTOFALO VJ, 1976, GERONTOLOGY, V22, P9, DOI 10.1159/000212122; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; Cristofalo VJ, 1980, J TISSUE CULTURE MET, V6, P117; CRISTOFALO VJ, 1982, ADV CELL CULT, V2, P1; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOGGETT DL, 1992, MECH AGEING DEV, V65, P239, DOI 10.1016/0047-6374(92)90039-G; DRESCHERLINCOLN CK, 1984, EXP CELL RES, V153, P208, DOI 10.1016/0014-4827(84)90462-2; DRESCHERLINCOLN CK, 1983, EXP CELL RES, V144, P455, DOI 10.1016/0014-4827(83)90424-X; GERHARD GS, 1991, EXP CELL RES, V193, P87, DOI 10.1016/0014-4827(91)90541-2; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GLOOR S, 1986, CELL, V47, P687; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GORMAN SD, 1986, EXP CELL RES, V167, P87, DOI 10.1016/0014-4827(86)90206-5; GROVE GL, 1977, J CELL PHYSIOL, V90, P415, DOI 10.1002/jcp.1040900305; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOJ A, 1985, ACUTE PHASE RESPONSE; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MACIEIRA.A, 1966, EXP CELL RES, V42, P673, DOI 10.1016/0014-4827(66)90280-1; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARTIN GM, 1970, LAB INVEST, V23, P86; MUELLER SN, 1980, SCIENCE, V207, P889, DOI 10.1126/science.7355268; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OLASHAW NE, 1983, EXP CELL RES, V149, P547, DOI 10.1016/0014-4827(83)90365-8; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PEREIRASMITH OM, 1985, EXP CELL RES, V160, P297, DOI 10.1016/0014-4827(85)90177-6; PHILLIPS PD, 1983, J CELL PHYSIOL, V114, P311, DOI 10.1002/jcp.1041140309; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PONTEN J, 1963, J CELL COMPAR PHYSL, V61, P145, DOI 10.1002/jcp.1030610206; PONTEN J, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V27, P53; RABINOVITCH PS, 1980, EXP CELL RES, V130, P101, DOI 10.1016/0014-4827(80)90046-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STEIN GH, 1986, EXP CELL RES, V162, P255, DOI 10.1016/0014-4827(86)90443-X; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SUMI Y, 1986, J BIOCHEM, V100, P1399, DOI 10.1093/oxfordjournals.jbchem.a121846; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TASSIN J, 1979, EXP CELL RES, V123, P388, DOI 10.1016/0014-4827(79)90483-X; TICE RR, 1979, J EXP MED, V149, P1029, DOI 10.1084/jem.149.5.1029; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; TOMBRANTINK J, 1991, EXP EYE RES, V50, P411; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284; WANG E, 1991, J CELL PHYSIOL, V147, P514, DOI 10.1002/jcp.1041470318; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	78	111	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8949	8957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473338				2022-12-25	WOS:A1993KX81100083
J	LEVIN, MS				LEVIN, MS			CELLULAR RETINOL-BINDING PROTEINS ARE DETERMINANTS OF RETINOL UPTAKE AND METABOLISM IN STABLY TRANSFECTED CACO-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; TISSUE-SPECIFIC EXPRESSION; ACYLTRANSFERASE ACTIVITY; VITAMIN-A; ESCHERICHIA-COLI; DEVELOPMENTAL REGULATION; ACYL-COA; ACID; ESTERIFICATION; LECITHIN	The mammalian small intestine contains two related cellular retinol-binding proteins, CRBP and CRBP II, which are thought to have distinct functions. The human intestinal cell line, Caco-2, was used as a model system for testing the hypothesis that intracellular levels of these proteins directly modulate the absorption and subsequent metabolism of retinol in enterocytes. Immunoblot and Northern blot hybridization demonstrated that Caco-2 cells express CRBP II and cellular retinoic acid-binding protein I in increasing amounts as the cells become more differentiated but do not express detectable quantities of CRBP. Stably transfected cloned Caco-2 cell lines that over-express CRBP II or coexpress CRBP and CRBP II and a control cell line that contains the expression vector without an insert were established. Retinol uptake and retinyl ester synthesis were increased up to 2-fold by coexpression of CRBP or over-expression of CRBP II. No significant differences were detected in the pattern of retinyl esters synthesized from exogenous [H-3]retinol. This suggests that the fatty acid pools utilized for retinol esterification were the same despite differences in the CRBP and CRBP II phenotype of the cell lines. There were no differences between apical and basolateral [H-3]retinol uptake or metabolism for filter grown transfected or wild type cell monolayers. Thus, neither CRBP II nor CRBP appear to preferentially interact with luminal- or plasma-derived retinol. Notably, in a cell line which over-expressed CRBP, endogenous CRBP II was reduced by 5-10-fold compared with the wild type and control cell lines. These studies indicate that CRBP and CRBP II levels are determinants of intracellular retinol accumulation and esterification, and they suggest that CRBP-bound retinol or a metabolite can regulate the expression of CRBP II in the mammalian intestine.			LEVIN, MS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8124,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK43029] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043029] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chytil F., 1984, RETINOIDS, V2, P90; CROW JA, 1985, P NATL ACAD SCI USA, V82, P4707, DOI 10.1073/pnas.82.14.4707; ELLER MS, 1992, EXP CELL RES, V199, P328; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; GOODMAN DS, 1984, RETINOIDS, V2, P1; HELGERUD P, 1983, J CLIN INVEST, V71, P747, DOI 10.1172/JCI110822; HELGERUD P, 1982, J LIPID RES, V23, P609; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS GM, 1990, METHOD ENZYMOL, V189, P70; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVIN MS, 1990, METHOD ENZYMOL, V189, P506; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1987, J BIOL CHEM, V262, P13773; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; NOY N, 1990, BIOCHEMISTRY-US, V29, P3888, DOI 10.1021/bi00468a014; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1987, J LIPID RES, V28, P739; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; QUICK TC, 1989, J LIPID RES, V30, P1049; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RAJAN N, 1991, J LIPID RES, V32, P1195; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANHEIM T, 1992, J LIPID RES, V33, P1281; Sambrook J, 1989, MOL CLONING LABORATO; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	50	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8267	8276						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463337				2022-12-25	WOS:A1993KW97900099
J	QUINN, J; LI, HH; SINGER, J; MORIMOTO, B; METS, L; KINDLE, K; MERCHANT, S				QUINN, J; LI, HH; SINGER, J; MORIMOTO, B; METS, L; KINDLE, K; MERCHANT, S			THE PLASTOCYANIN-DEFICIENT PHENOTYPE OF CHLAMYDOMONAS-REINHARDTII AC-208 RESULTS FROM A FRAME-SHIFT MUTATION IN THE NUCLEAR GENE ENCODING PREAPOPLASTOCYANIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ACCUMULATION; ELECTRON-TRANSFER; ISOLATED-CHLOROPLASTS; TRANSGENIC TOBACCO; NONSENSE MUTATIONS; NITRATE REDUCTASE; PEA PLASTOCYANIN; PHOTOSYSTEM-I; EXPRESSION; PROTEINS	Ac-208 is a plastocyanin-deficient mutant of Chlamydomonas reinhardtii that contains only 2-3% of the wild-type level of plastocyanin-encoding mRNA and no detectable plastocyanin. Sequence analysis of the ac-208 plastocyanin-encoding gene reveals a single nucleotide insertion in the first exon compared with the wild-type gene; this alters the reading frame and results in a premature nonsense codon. We have introduced the genomic sequence encoding plastocyanin from a wild-type strain into ac-208 by cotransformation with a selectable marker encoding nitrate reductase. Of 22 nit+ transformants characterized, nine contained additional plastocyanin-encoding sequences (compared with untransformed cells) and each of these nine transformants was found to accumulate the protein. Transformants that do not contain newly introduced plastocyanin sequences retain the plastocyanin-deficient phenotype. The introduced plastocyanin-encoding sequences are stable during mitotic growth in liquid culture over a period of several months, as is expression from the introduced sequences. We suggest that the decreased steady state level of plastocyanin-encoding messages is a consequence of the frame-shift mutation in the structural gene. The ability to complement ac-208 with plastocyanin-encoding sequences will allow the introduction and analysis of in vitro mutagenized plastocyanin sequences in vivo in transgenic C. reinhardtii cells.	UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; CORNELL UNIV, CTR PLANT SCI, ITHACA, NY 14853 USA	University of California System; University of California Los Angeles; University of Chicago; Cornell University					NIGMS NIH HHS [GM-00594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1991, J BIOL CHEM, V266, P5884; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; BERGMAN C, 1977, BIOCHEM BIOPH RES CO, V77, P1052, DOI 10.1016/S0006-291X(77)80084-3; BLANKENSHIP JE, 1992, MOL CELL BIOL, V12, P5268, DOI 10.1128/MCB.12.11.5268; BOULTER D, 1977, INT REV BIOCHEM, V13, P3; CHANG TK, 1991, P NATL ACAD SCI USA, V88, P1325, DOI 10.1073/pnas.88.4.1325; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLDSCHMIDTCLERMONT M, 1986, PLANT MOL BIOL, V6, P13, DOI 10.1007/BF00021302; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GORMAN DS, 1966, PLANT PHYSIOL, V41, P1648, DOI 10.1104/pp.41.10.1648; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; GUSS GM, 1983, J MOL BIOL, V169, P512; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HILL KL, 1991, J BIOL CHEM, V266, P15060; HOWE G, 1992, PLANT PHYSIOL BIOCH, V30, P299; IMBAULT P, 1988, GENE, V73, P397, DOI 10.1016/0378-1119(88)90504-5; JOFUKU KD, 1989, PLANT CELL, V1, P427, DOI 10.1105/tpc.1.4.427; KANO A, 1991, J MOL BIOL, V221, P387, DOI 10.1016/0022-2836(91)80061-X; KARLSSON BG, 1991, PROTEIN ENG, V4, P343, DOI 10.1093/protein/4.3.343; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KINNIBURGH AJ, 1982, NUCLEIC ACIDS RES, V10, P5421, DOI 10.1093/nar/10.18.5421; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAST DI, 1989, PLANT MOL BIOL, V12, P655, DOI 10.1007/BF00044156; LAST DI, 1990, PLANT MOL BIOL, V14, P229, DOI 10.1007/BF00018563; LI HH, 1992, J BIOL CHEM, V267, P9368; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1987, PROGR PHOTOSYNTHESIS, V4, P10663; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; NIELSEN PS, 1987, FEBS LETT, V225, P159, DOI 10.1016/0014-5793(87)81149-3; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; OBA T, 1991, P NATL ACAD SCI USA, V88, P921, DOI 10.1073/pnas.88.3.921; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SYKES AG, 1985, CHEM SOC REV, V14, P283, DOI 10.1039/cs9851400283; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VOELKER TA, 1990, PLANT CELL, V2, P255, DOI 10.1105/tpc.2.3.255; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; ZIMMER WE, 1988, J BIOL CHEM, V263, P19370	56	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7832	7841						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463310				2022-12-25	WOS:A1993KW97900040
J	COAN, C; AMARAL, JA; VERJOVSKIALMEIDA, S				COAN, C; AMARAL, JA; VERJOVSKIALMEIDA, S			ELIMINATION OF THE HYDROXYL-GROUPS IN THE RIBOSE RING OF ATP REDUCES ITS ABILITY TO PHOSPHORYLATE THE SARCOPLASMIC-RETICULUM CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; CALCIUM ADENOSINE-TRIPHOSPHATASE; LIMITING CONFORMATIONAL CHANGE; CATALYTIC SITE; HIGH-AFFINITY; CA-2+-ATPASE; 5'-TRIPHOSPHATE; DISSOCIATION; ORIENTATION; SUBSTRATE	2'-Deoxyadenosine 5'-triphosphate, 3'-deoxyadenosine 5'-triphosphate, and 3'-amino-3'-deoxyadenosine 5'-triphosphate were substituted for ATP in the Ca2+ pumping cycle of the sarcoplasmic reticulum Ca2+-ATPase. The rate of phosphorylation of the enzyme decreased by more than an order of magnitude when either of the hydroxyl groups was eliminated from the ribose ring. This resulted in low rates of hydrolysis and low levels of phosphoenzyme intermediate. In addition, the K(m(1)) of hydrolysis and the K1/2 of phosphorylation of the derivatives modified in the 3' position were decreased by a factor of 5-10. Otherwise, the 3'-amino-3'-deoxyadenosine 5'-triphosphate was utilized in a manner equivalent to ATP. Because the observed rates of phosphoenzyme formation with the deoxynucleotides were lowered to the extent that they would be rate-limiting in the enzyme cycle, and the level of phosphoenzyme intermediate remained low when the enzyme was back-inhibited by high Ca2+ concentrations, it was concluded that the majority of the enzyme remained in a preliminary conformation, in which the phosphorylation reaction could not proceed although substrate and Ca2+ were bound. It was then proposed that, following Ca2+-induced changes in conformation, the hydroxyl groups are able to form hydrogen bonds with pertinent segments of the phosphorylation domain, helping to stabilize an enzyme-substrate complex, one function of which may be to provide the proper stereochemistry for phosphate transfer.	UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, BR-21944 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro	COAN, C (corresponding author), UNIV PACIFIC, DEPT PHYSIOL, SAN FRANCISCO, CA 94115 USA.		Verjovski-Almeida, Sergio/E-4082-2012	Verjovski-Almeida, Sergio/0000-0002-6356-2401	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038073] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05301] Funding Source: Medline; NIGMS NIH HHS [GM38073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KW, 1983, J BIOL CHEM, V258, P4276; Bevington PR, 1969, DATA REDUCTION ERROR; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CARVALHOALVES PC, 1985, J BIOL CHEM, V260, P4282; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1978, J BIOL CHEM, V253, P1179; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; COAN C, 1983, BIOCHEMISTRY-US, V22, P5826, DOI 10.1021/bi00294a022; COAN CR, 1977, J BIOL CHEM, V252, P3044; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FERNANDEZBELDA F, 1986, BIOCHEMISTRY-US, V24, P8083; FERREIRA ST, 1988, J BIOL CHEM, V263, P9973; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; Guillory R J, 1977, Methods Enzymol, V46, P259; HANEL AM, 1990, BIOCHEMISTRY-US, V29, P5210, DOI 10.1021/bi00473a030; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MURPHY AJ, 1976, BIOCHEMISTRY-US, V15, P4492, DOI 10.1021/bi00665a025; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; OLIVEIRA CRG, 1988, BIOCHEMISTRY-US, V27, P5923, DOI 10.1021/bi00416a015; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICKART CM, 1982, J BIOL CHEM, V257, P5319; SCOTT TL, 1985, J BIOL CHEM, V260, P4421; SOUZA DOG, 1976, J BIOL CHEM, V251, P6355; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TERUEL JA, 1987, J BIOL CHEM, V262, P13055; THORLEYL.DA, 1973, EUR J BIOCHEM, V40, P403, DOI 10.1111/j.1432-1033.1973.tb03209.x; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; WATANABE T, 1982, J BIOL CHEM, V257, P1510	40	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6917	6924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463222				2022-12-25	WOS:A1993KV14100021
J	DISCHER, D; PARRA, M; CONBOY, JG; MOHANDAS, N				DISCHER, D; PARRA, M; CONBOY, JG; MOHANDAS, N			MECHANOCHEMISTRY OF THE ALTERNATIVELY SPLICED SPECTRIN-ACTIN BINDING DOMAIN IN MEMBRANE SKELETAL PROTEIN-4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE; HEREDITARY ELLIPTOCYTOSIS; MECHANICAL-PROPERTIES; BETA-SPECTRIN; BAND 4.1; PHOSPHORYLATION; STABILITY; MODULATION; SITE; PURIFICATION	Protein 4.1's interaction with the erythroid skeletal proteins spectrin and actin and its essential role in regulating membrane strength are both attributable to expression of an alternatively spliced 63-nucleotide exon. The corresponding 21-amino acid (21-aa) cassette is within the previously identified spectrin-actin binding domain (10 kDa molecular mass) of erythroid protein 4.1. This cassette is absent, however, in several isoforms that are generated by tissue- and development-specific RNA splicing. Four isoforms of the 10-kDa domain were constructed for comparative assessment of functions particularly relevant to red cells. In vitro translated isoforms containing the 21-aa cassette, denoted 10k21 and 10k19,21, were able to bind spectrin, stabilize spectrin-actin complexes, and associate with red cell membrane. Isoforms replacing or lacking the 21-aa cassette, 10k19 and 10k0, did not function in these assays. A bacterially expressed fusion protein with glutathione-S-transferase, designated GST-10k21, congealed-spectrin-actin into a network in vitro as found with purified protein 4.1. Additionally, incorporation of GST-10k21 into mechanically weak, 4.1-deficient membranes increased mechanical strength of these membranes to normal. GST-10k19 did not function in these assays. These results show that the 21-aa sequence in protein 4.1 is critical to mechanical integrity of the red cell membrane. These results also allow the role of protein 4.1 in membrane mechanics to be interpreted primarily in terms of its spectrinactin binding function. Alternatively expressed sequences within the 10-kDa domain of nonerythroid protein 4.1 are suggested to have different, yet to be defined functions.	LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY UNIV CALIF SAN FRANCISCO,JOINT GRAD GRP BIOENGN,SAN FRANCISCO,CA 94143	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				discher, dennis/0000-0001-6163-2229	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BENZ FJ, 1991, BLOOD S1, V78, pA365; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6151; CHAO TS, 1991, BIOCHEMISTRY-US, V30, P10529, DOI 10.1021/bi00107a023; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; CHASIS JA, 1992, IN PRESS J CLIN INVE; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; COHEN CM, 1982, ULTRAMICROSCOPY, V8, P185, DOI 10.1016/0304-3991(82)90287-X; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CONBOY JG, 1991, BLOOD, V78, P2438, DOI 10.1182/blood.V78.9.2438.bloodjournal7892438; CORREAS I, 1988, BIOCHEM J, V255, P217; CORREAS I, 1986, J BIOL CHEM, V261, P3310; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; DISCHER D, 1991, BLOOD S, V78, pA83; DISCHER DE, 1992, MOL BIOL CELL S, V3, pA268; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; EVANS EA, 1980, MECHANICS THERMODYNA; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; INABA M, 1992, BLOOD, V79, P3355; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; LIEBER MR, 1982, J BIOL CHEM, V257, P1651; LING E, 1988, J BIOL CHEM, V263, P2209; MAYS KT, 1992, BLOOD S1, V80, P273; MCGUIRE M, 1988, BLOOD, V72, P287; MOHANDAS N, 1993, IN PRESS SEMIN HEMAT; OHANIAN V, 1984, BIOCHEMISTRY-US, V23, P4416, DOI 10.1021/bi00314a027; PASTERNACK GR, 1989, P NATL ACAD SCI USA, V86, P9712, DOI 10.1073/pnas.86.24.9712; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PODGORSKI A, 1988, BIOCHEMISTRY-US, V27, P609, DOI 10.1021/bi00402a017; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1989, RED CELL, P553; SCHANUS E, 1985, J BIOL CHEM, V260, P3724; SEIDEL HM, 1992, SCIENCE, V257, P1489, DOI 10.1126/science.1523407; SHOHET SS, 1988, RED CELL MEMBRANES; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; SUTERA SP, 1989, BIORHEOLOGY, V26, P177; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TANG TK, 1988, P NATL ACAD SCI USA, V85, P3713, DOI 10.1073/pnas.85.11.3713; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TYLER JM, 1980, J BIOL CHEM, V255, P7034; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; WAUGH RE, 1983, CELL MOTIL CYTOSKEL, V3, P609, DOI 10.1002/cm.970030526; WEAVER FE, 1990, BIOPHYS J, V58, P1427, DOI 10.1016/S0006-3495(90)82488-7; WOLFE LC, 1980, J CELL BIOL, V87, pA203; YOUNG M, 1967, P NATL ACAD SCI USA, V58, P2393, DOI 10.1073/pnas.58.6.2393	57	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7186	7195						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463254				2022-12-25	WOS:A1993KV14100057
J	GAYLE, RB; SLEATH, PR; SRINIVASON, S; BIRKS, CW; WEERAWARNA, KS; CERRETTI, DP; KOZLOSKY, CJ; NELSON, N; VANDENBOS, T; BECKMANN, MP				GAYLE, RB; SLEATH, PR; SRINIVASON, S; BIRKS, CW; WEERAWARNA, KS; CERRETTI, DP; KOZLOSKY, CJ; NELSON, N; VANDENBOS, T; BECKMANN, MP			IMPORTANCE OF THE AMINO TERMINUS OF THE INTERLEUKIN-8 RECEPTOR IN LIGAND INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; GROWTH-STIMULATORY ACTIVITY; MOLECULAR CHARACTERIZATION; PROTEINS; BINDING; CLONING; IDENTIFICATION; PURIFICATION; EXPRESSION; MECHANISM	Interleukin-8 (IL-8) and growth regulatory gene/melanoma growth stimulatory activity (GRO/MGSA) are small polypeptide molecules involved in the chemotactic response of certain cell types. Two receptors have been described which interact with IL-8, designated type 1 and type 2. IL-8 binds with high affinity to both receptors, whereas GRO/MGSA and neutrophil-activating peptide-2 demonstrate a high degree of binding only to the type 2 receptor. The two forms of IL-8 receptor are members of the rhodopsin seven-helix membrane-spanning superfamily, and share a high degree of overall homology, although the amino termini are very divergent. By using conserved restriction enzyme sites, a series of chimeric IL-8 receptor molecules were constructed between the type 1 and type 2 receptors and transfected into human 293 kidney epithelial cells. These chimeric molecules altered regions of the receptor presented to the ligand. The ability of the chimeric receptors to bind IL-8 was determined, as well as the ability of IL-8 and GRO/MGSA to inhibit radiolabeled IL-8 binding. The amino terminus of the IL-8 receptors was found to be important for differential binding of GRO/MGSA and IL-8. In addition, a series of peptides was also constructed to further investigate which residues of IL-8 receptor interact with IL-8. These peptides also identified the amino-terminal sequence of the IL-8 receptors as being important in interacting with IL-8.			GAYLE, RB (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; BUCK F, 1991, BIOCHEM BIOPH RES CO, V178, P1421, DOI 10.1016/0006-291X(91)91052-E; CERRETTI DP, 1992, IN PRESS MOLIMMUNOL; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWER SK, 1984, J IMMUNOL, V132, P751; GROB PM, 1990, J BIOL CHEM, V265, P8311; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1992, J IMMUNOL, V148, P1261; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; SAGER R, 1992, IN PRESS STRUCTURAL; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	28	147	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7283	7289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463264				2022-12-25	WOS:A1993KV14100068
J	PUOTI, A; CONZELMANN, A				PUOTI, A; CONZELMANN, A			CHARACTERIZATION OF ABNORMAL FREE GLYCOPHOSPHATIDYLINOSITOLS ACCUMULATING IN MUTANT LYMPHOMA-CELLS OF CLASS-B, CLASS-E, CLASS-F, AND CLASS-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEINS; N-ACETYLGLUCOSAMINYL-PLASMANYLINOSITOL; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; GLYCOLIPID PRECURSORS	Several mutant lymphoma lines are unable to add glycophosphatidylinositol membrane anchors to proteins. Some of them accumulate abnormal glycolipids which can be labeled by tritiated myo-inositol, mannose, or ethanolamine and which are not present in the corresponding parental cell lines. The [H-3]myo-inositol-labeled abnormal lipids were isolated and characterized using hydrofluoric acid dephosphorylation, nitrous acid deamination, acetolysis, and exoglycosidase treatments alone or in combination. This partial characterization suggests that the class F mutant EL-4-f contains 3 abnormal glycolipids containing 3, 2, or 1 mannose residues, the headgroups of which are Manalpha1,2Manalpha1,6(X-->) Manalpha-GlcN-acylinositol, Manalpha1,6(X-->)Manalpha-GlcN-inositol, and (X-->)Manalpha-GlcN-acylinositol where X represents a charged, hydrofluoric acid-sensitive substituent. A fourth, minor abnormal lipid with a Manalpha1,6(X-->)Manalpha-GlcN-inositol headgroup but a different lipid moiety is also found. The substituent X is likely to consist of phosphoethanolamine since hydrofluoric acid releases [H-3]ethanolamine from the [H-3]ethanolamine-labeled version of these lipids. Pulse-chase experiments indicate that the abnormal glycophosphatidylinositols of class F mutants are very long-lived. The class B mutant S1A(-b) has previously been shown to contain an abnormal Manalpha1,6(phosphoethanolamine-->)Manalpha-GlcN-acylinositol-P-lipid intermediate. Here we show that S1A-b also accumulates a more polar but less abundant lipid which has the identical headgroup structure but lacks the acyl group on the inositol residue. The class E mutant BW5147-e accumulates a hydrophobic glycolipid with the headgroup structure GlcN-acylinositol. All the abnormal glycolipids except those of EL-4-f are heterogeneous with regard to their lipid moiety since base-resistant as well as base-sensitive lipids are present. This suggests that the base-resistant alkylglycerols typical of mammalian anchors can get integrated into anchors at early stages of glycophosphatidylinositol formation.	INST BIOCHIM,RUE MUSEE 5,CH-1700 FRIBOURG,SWITZERLAND; UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV FRIBOURG,CH-1700 FRIBOURG,SWITZERLAND	University of Lausanne; University of Fribourg			Puoti, Alessandro/E-5700-2012	Puoti, Alessandro/0000-0002-1396-7662				CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; DEGASPERI R, 1990, SCIENCE, V250, P988, DOI 10.1126/science.1978413; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FATEMI SH, 1988, J BIOL CHEM, V236, P1288; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LI E, 1978, J BIOL CHEM, V253, P7762; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MAHONEY JF, 1992, BLOOD, V79, P1400; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSSE WF, 1990, ANNU REV MED, V41, P431; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHUBERT J, 1990, BLOOD, V76, P1181; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; TROWBRIDGE IS, 1978, CELL, V14, P21, DOI 10.1016/0092-8674(78)90297-0; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WALTER EI, 1990, J IMMUNOL, V144, P1030; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	43	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7215	7224						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463257				2022-12-25	WOS:A1993KV14100060
J	SENIOR, AE; WILKEMOUNTS, S; ALSHAWI, MK				SENIOR, AE; WILKEMOUNTS, S; ALSHAWI, MK			LYSINE-155 IN BETA-SUBUNIT IS A CATALYTIC RESIDUE OF ESCHERICHIA-COLI F(1) ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; NUCLEOTIDE-BINDING DOMAIN; ADENOSINE-TRIPHOSPHATASE; DIRECTED MUTAGENESIS; ELEMENTARY STEPS; MUTANT STRAINS; RATE CONSTANTS; F1-ATPASE; SITE; HYDROLYSIS	The ''homology A'' (''glycine-rich'' or ''P-loop'') consensus sequence occurs in the catalytic sites of F1F0 ATP synthase enzymes. The conserved lysine of this motif is beta-subunit Lys-155 in Escherichia coli F1. The role of this lysine in binding and catalysis at the high affinity ATP binding site was studied with the mutants betaK155Q and betaK155E by measuring the rates of ATP binding/release, ATP hydrolysis/synthesis, and P(i) release as a function of pH varied from 5.5 to 9.5. In wild type, protonated betaLys-155 appears to contribute significantly to high affinity binding of ATP, probably through hydrogen bonding to the gamma-phosphate. ATP hydrolysis and synthesis were impaired strongly in the mutants, and the reaction equilibrium constant, which was pH-independent in wild type, was highly pH-dependent in betaK155Q and betaK155E. Studies of steady-state ATPase turnover showed that positive catalytic cooperativity was virtually absent and the pH-dependent component of positive catalytic cooperativity was abolished or reversed in the mutants. The data demonstrate that residue betaK155 is a critical catalytic residue in F1 ATPase.			SENIOR, AE (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNCAN TM, 1992, J BIOENERG BIOMEMBR, V24, P453, DOI 10.1007/BF00762362; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HISABORI T, 1992, J BIOL CHEM, V267, P4551; IDA K, 1991, J BIOL CHEM, V266, P5424; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1988, J BIOL CHEM, V263, P6020; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOUNT RG, 1975, ADV ENZYMOL RAMB, V43, P1; [No title captured]	44	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6989	6994						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463232				2022-12-25	WOS:A1993KV14100031
J	YU, JJ; VERMAAS, WFJ				YU, JJ; VERMAAS, WFJ			SYNTHESIS AND TURNOVER OF PHOTOSYSTEM-II REACTION CENTER POLYPEPTIDES IN CYANOBACTERIAL-D2 MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; SCENEDESMUS-OBLIQUUS; D2 PROTEIN; COMPLEX; D1; PHOTOINHIBITION; DEGRADATION; STABILITY; INVIVO	Several mutations in psbD (coding for the photosystem II reaction protein D2) lead to a loss of the entire photosystem II complex from the thylakoid membrane. For two site-directed D2 mutants, E69V (Glu-69 mutated to Val) and ET-9 (introducing a premature stop codon in psbD), and two psbD deletion mutants, the synthesis and degradation of photosystem II reaction center components were analyzed. In E69V, no D2 or psbC-encoded CP43 was detected upon 5-min pulse labeling or Western blotting, whereas a psbDI/C transcript was present. Either D2 and CP43 are very unstable in this mutant, or the mutation causes an inhibition of translation of the psbDC operon. In E69V, the predominant lifetime of D1 is several minutes, but a small fraction of D1 remains stable in the thylakoid for several hours. In E69V, also a 43-kDa band is detected by D1 antisera. We attribute this band to a D1 cross-linking product possibly involved in D1 degradation. We identified a D1 precursor in E69V and psbDI/C/DII-, two mutants with particularly short D1 lifetimes. A unique feature of the E69V mutant is that destabilization of the photosystem II complex is triggered by a single-site mutation leading to extremely rapid turnover or lack of synthesis of D2.	ARIZONA STATE UNIV,CTR STUDY EARLY EVENTS PHOTOSYNTHESIS,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe	YU, JJ (corresponding author), ARIZONA STATE UNIV,DEPT BOT,TEMPE,AZ 85287, USA.							ARNTZEN CJ, 1986, ENCY PLANT PHYSL, V19, P457; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; BRYANT DA, 1986, PHOTOSYNTHETIC PICOP, P423; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; DINER BA, 1988, J BIOL CHEM, V263, P8972; EGGERS M, 1992, REGULATION CHLOROPLA, P559; EICHACKER L, 1992, EUR J BIOCHEM, V205, P17, DOI 10.1111/j.1432-1033.1992.tb16747.x; ELICH TD, 1992, J BIOL CHEM, V267, P3523; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; GOLOUBINOFF P, 1988, PLANT MOL BIOL, V11, P441, DOI 10.1007/BF00039025; KUHN M, 1988, Z NATURFORSCH C, V43, P413; LERS A, 1992, J BIOL CHEM, V267, P17494; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MISRA AN, 1991, BIOCHIM BIOPHYS ACTA, V1059, P239, DOI 10.1016/S0005-2728(05)80209-9; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NIXON PJ, 1992, PLANT PROTEIN ENG, P93; OHAD I, 1990, J BIOL CHEM, V265, P1972; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SEIBERT M, 1989, BIOCHIM BIOPHYS ACTA, V974, P185, DOI 10.1016/S0005-2728(89)80371-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMAAS W, 1990, BIOCHEMISTRY-US, V29, P5325, DOI 10.1021/bi00474a017; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; VERMAAS WFJ, 1987, PLANT MOL BIOL, V8, P317, DOI 10.1007/BF00021311; VERMAAS WFJ, 1991, CELL CULTURE SOMAT B, V7, P25; YU JJ, 1990, PLANT CELL, V2, P315	28	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7407	7413						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463274				2022-12-25	WOS:A1993KV14100083
J	KIM, RY; WISTOW, GJ				KIM, RY; WISTOW, GJ			EXPRESSION OF THE DUCK ALPHA-ENOLASE/TAU-CRYSTALLIN GENE IN TRANSGENIC MICE	FASEB JOURNAL			English	Article						LENS; CRYSTALLIN; ENOLASE; EVOLUTION	LENS CRYSTALLINS; TAU-CRYSTALLIN; PROTEIN SUPERFAMILY; STRUCTURAL PROTEIN; GAMMA-CRYSTALLIN; TURTLE LENS; RECRUITMENT; EVOLUTION; ENZYME; PURIFICATION	In many vertebrates, metabolic enzymes have been directly recruited to an additional structural role as crystallins in the eye lens. In some species the glycolytic enzyme alpha-enolase. (AlphaENO) attains high concentrations in the lens, as tau-crystallin (tauCRY). A line of transgenic mice was constructed containing the entire duck alphaENO/tauCRY gene with 5'- and 3-flanking regions and all introns. Full-sized duck alphaENO mRNA was expressed in the transgenic mice with the same pattern as the endogenous mouse alphaENO isozyme. Although there was no evidence for tissue preference, the concentration of enolase increased markedly in transgenic lens as well as in other tissues. In spite of this, transgenic lenses were transparent and the animals were normal in appearance. The increase in enolase levels in the transgenic lens mimics the stepped increase that might occur in the early stages of enzyme crystallin recruitment. These results demonstrate that lens transparency is sufficiently robust to be refractory to some increase in metabolic enzyme concentration without the need for compensatory adaptation.	NEI,MOLEC & DEV BIOL LAB,MOLEC STRUCT & FUNCT SECT,BLDG 6,RM 222,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								Battey, 1986, BASIC METHODS MOL BI; BERMAN ER, 1991, PERSPECTIVES VISION; Bloemendal H., 1981, MOL CELLULAR BIOL EY; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; FARNSWORTH PN, 1990, CURR EYE RES, V9, P819, DOI 10.3109/02713689008999554; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harding JJ, 1984, EYE B, V1b, P207; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KAGHAD M, 1990, NUCLEIC ACIDS RES, V18, P3638, DOI 10.1093/nar/18.12.3638; KIM RY, 1991, GENE, V103, P193, DOI 10.1016/0378-1119(91)90273-E; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; RUDNER G, 1990, CURR EYE RES, V9, P139, DOI 10.3109/02713689008995200; STAPEL SO, 1983, FEBS LETT, V162, P305, DOI 10.1016/0014-5793(83)80777-7; TANAKA M, 1985, J BIOCHEM-TOKYO, V98, P1527, DOI 10.1093/oxfordjournals.jbchem.a135421; TODHUNTER JA, 1979, METHOD ENZYMOL, V63, P388; WARWAR RE, 1992, INVEST OPHTH VIS SCI, V33, P794; WESTHEAD EW, 1967, METHOD ENZYMOL, V9, P670; WILLIAMS LA, 1985, EXP EYE RES, V40, P741, DOI 10.1016/0014-4835(85)90143-5; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1985, NATURE, V315, P771, DOI 10.1038/315771a0; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wold F., 1971, ENZYMES, P499; ZIESKE JD, 1991, DEV BIOL, V151, P18; ZOMZELYNEURATH CE, 1983, HDB NEUROCHEMISTRY, V4, P403	35	8	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1993	7	5					464	469		10.1096/fasebj.7.5.8462788	http://dx.doi.org/10.1096/fasebj.7.5.8462788			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462788				2022-12-25	WOS:A1993KV35100011
J	OHKI, S; IWAMOTO, U; AIMOTO, S; YAZAWA, M; HIKICHI, K				OHKI, S; IWAMOTO, U; AIMOTO, S; YAZAWA, M; HIKICHI, K			MG2+ INHIBITS FORMATION OF 4CA2+-CALMODULIN-ENZYME COMPLEX AT LOWER CA2+ CONCENTRATION - H-1 AND CD-113 NMR-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; NUCLEAR MAGNETIC-RESONANCE; CALMODULIN-BINDING DOMAIN; RABBIT SKELETAL-MUSCLE; 2 GLOBULAR DOMAINS; CONFORMATIONAL CHANGE; CALCIUM-BINDING; MASTOPARAN BINDING; TRYPTIC FRAGMENTS; PROTEOLYTIC FRAGMENTS	Our previous H-1 NMR studies indicated that when mastoparan (MP) is added to Ca2+-half-saturated calmodulin (2Ca2+-CaM) in the absence of Mg2+, ions, Ca2+ ions transfer from the C-terminal-half domain of CaM not interacting with MP to the N-terminal-half domain of CaM interacting with MP at lower MP concentrations (Ohki, S., Yazawa, M., Yagi, K., and Hikichi, K. (1991b) J. Biochem. (Tokyo) 110, 737-742). As a consequence, the active form of 4Ca2+-CaM.MP complex is formed. In the present study, we studied the effect of Mg2+ ions on Ca2+ transfer. In the presence of Mg2+ ions, such Ca2+ transfer does not occur. The effects of Mg2+ ions are also studied by observing Cd-113 NMR in the presence of M13, the 26-residue peptide of the CaM-binding region of myosin light chain kinase. The Cd-113 NMR results show that Mg2+ ions prevent to form the active complex. Mg2+ plays an important role as an inactivating factor to CaM.	HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC SCI,DEPT CHEM,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Hokkaido University; Hokkaido University; Osaka University								AULABAUGH A, 1984, BIOCHEM BIOPH RES CO, V118, P225, DOI 10.1016/0006-291X(84)91090-8; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; Cohen P, 1988, CALMODULIN; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; DABROWSKA R, 1977, BIOCHEM BIOPH RES CO, V78, P1263, DOI 10.1016/0006-291X(77)91429-2; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; FORSEN S, 1980, FEBS LETT, V117, P189, DOI 10.1016/0014-5793(80)80942-2; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUNG CY, 1981, P NATL ACAD SCI USA, V78, P871; HURWITZ MY, 1988, FEBS LETT, V238, P82, DOI 10.1016/0014-5793(88)80230-8; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2573, DOI 10.1021/bi00279a039; IKURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1233, DOI 10.1016/0006-291X(89)91374-0; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KLEVIT RE, 1984, EUR J BIOCHEM, V139, P109, DOI 10.1111/j.1432-1033.1984.tb07983.x; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; MUCHMORE DC, 1986, BIOCHEM BIOPH RES CO, V137, P1069, DOI 10.1016/0006-291X(86)90334-7; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; OGAWA Y, 1986, J BIOCHEM-TOKYO, V99, P73, DOI 10.1093/oxfordjournals.jbchem.a135481; OHKI S, 1991, J BIOCHEM-TOKYO, V109, P234; OHKI S, 1991, J BIOCHEM-TOKYO, V110, P737, DOI 10.1093/oxfordjournals.jbchem.a123650; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V25, P4011; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; SUTOO D, 1985, JPN J PHARMACOL, V40, P169; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; TSAI MD, 1987, BIOCHEMISTRY-US, V26, P3635, DOI 10.1021/bi00386a057; TSUDA S, 1990, BIOCHEMISTRY-US, V29, P4951, DOI 10.1021/bi00472a027; YAGI K, 1989, BIOFORMATICS, P27; YAZAWA M, 1984, J BIOCHEM-TOKYO, V95, P443, DOI 10.1093/oxfordjournals.jbchem.a134625; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YOSHINO H, 1989, J BIOL CHEM, V264, P19706	48	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12388	12392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509378				2022-12-25	WOS:A1993LG65800028
J	BERNAL, D; QUINONES, S; SAUS, J				BERNAL, D; QUINONES, S; SAUS, J			THE HUMAN MESSENGER-RNA ENCODING THE GOODPASTURE ANTIGEN IS ALTERNATIVELY SPLICED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; SYNDROME TYPE-VII; IV COLLAGEN; ALPHA-3(IV) CHAIN; SEQUENCE-ANALYSIS; GLOBULAR DOMAIN; TRIPLE HELIX; GENE; LOCALIZATION; PROCOLLAGEN	The noncollagenous (NC1) domain of the human collagen alpha3(IV)-chain is the primary target of autoantibodies produced in Goodpasture syndrome and, therefore, has been designated as the Goodpasture antigen. In this report, we show that Goodpasture antigen mRNA undergoes processing to at least two alternatively spliced forms in a variety of human tissues, resulting in the exclusion of sequence encoded by either one or two exons. Interestingly, no alternatively spliced forms were observed in bovine or rat tissues. The derived amino acid sequences of the two variant mRNA forms are identical and significantly shorter than that arising from the complete Goodpasture antigen mRNA. They lack the carboxyl-terminal region contributing to the formation of the Goodpasture epitope and all but one of the cysteines found in the complete form. These sequence characteristics suggest that, if translated, the variant Goodpasture antigen is likely to be defective in triple helix formation and no longer reactive with Goodpasture autoantibodies. Although each tissue expressing Goodpasture antigen displayed a specific mRNA pattern, the complete form was always the most abundant and was present at levels apparently unrelated to whether or not the organ of origin is a potential target in Goodpasture syndrome. Furthermore, the antigen sequence was identical in the kidneys of normal and Goodpasture-affected individuals, and no major differences in the expression of the complete and spliced forms were observed.	INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA,FDN VALENCIANA INVEST BIOMED,C AMADEO SABOYA 4,E-46010 VALENCIA,SPAIN; UNIV VALENCIA,FAC FARM,DEPT BIOQUIM & BIOL MOLEC,E-46100 VALENCIA,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	University of Valencia; Rutgers State University New Brunswick; Rutgers State University Medical Center			Bernal, Dolores/K-7769-2014	Bernal, Dolores/0000-0003-4627-8393; Saus, Juan/0000-0003-2082-1597	NIDDK NIH HHS [DK-42514] Funding Source: Medline; NIEHS NIH HHS [ESO 5022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042514] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; HUDSON BG, 1989, LAB INVEST, V61, P259; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRISON KE, 1991, AM J HUM GENET, V49, P545; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; QUINONES S, 1992, J BIOL CHEM, V267, P19780; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WEIL D, 1989, J BIOL CHEM, V264, P16804; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564	35	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12090	12094						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505332				2022-12-25	WOS:A1993LF28400094
J	CORDLE, SR; DONALD, R; READ, MA; HAWIGER, J				CORDLE, SR; DONALD, R; READ, MA; HAWIGER, J			LIPOPOLYSACCHARIDE INDUCES PHOSPHORYLATION OF MAD3 AND ACTIVATION OF C-REL AND RELATED NF-KAPPA-B PROTEINS IN HUMAN MONOCYTIC THP-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; HUMAN-BLOOD MONOCYTES; NECROSIS-FACTOR-ALPHA; FACTOR MESSENGER-RNA; DNA-BINDING; TRANSCRIPTION FACTOR; P65 SUBUNIT; T-CELLS; MONONUCLEAR PHAGOCYTES	Many effects of lipopolysaccharide (LPS) on gene expression, including that of human immunodeficiency virus (HIV), in monocytic cells are mediated by activation of kappaB DNA-binding proteins. However, the specific members of the NF-kappaB/Rel transcription factor family involved in the LPS response, and the mechanisms through which LPS-generated signals are transduced remain unclear. Here we show that LPS induces nuclear expression of c-Rel/p50 heterodimers as well as p50/p65 (NF-kappaB) kappaB DNA-binding complexes in human monocytic THP-1 cells. Nuclear localization of these proteins occurred concomitantly with a rapid decrease in their cytosolic levels and was independent of phorbol ester-sensitive protein kinase C. Within 24 h following LPS stimulation there was a striking increase in the levels of c-Rel, p105, and p50 in the cytosol. The increased levels of these proteins correlated with increases in the amounts of their mRNAs during LPS activation of THP-1 cells. LPS activation of THP-1 cells resulted in phosphorylation of MAD3 (an IkappaB-like protein), a rapid increase in MAD3 mRNA, and an increase in MAD3 protein by 2 h. Thus, LPS activation of human monocytic cells results in nuclear expression of c-Rel/p50 and p50/p65 (NF-kappaB) and induces phosphorylation of MAD3.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Vanderbilt University					NHLBI NIH HHS [R37 HL30647] Funding Source: Medline; PHS HHS [T32-07186] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1986, CURRENT PROTOCOLS MO; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BAUER J, 1988, BLOOD, V72, P1134; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOULET I, 1992, ONCOGENE, V7, P703; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROWNELL E, 1988, ONCOGENE, V3, P93; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DROUET C, 1991, J IMMUNOL, V147, P1694; ERNST TJ, 1989, J BIOL CHEM, V264, P5700; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INTRONA M, 1986, J IMMUNOL, V137, P2711; IP YT, 1991, CELL, V64, P439; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1992, ONCOGENE, V7, P567; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LEE JH, 1991, ONCOGENE, V6, P665; LINK E, 1992, J BIOL CHEM, V267, P239; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOUCHARDT C, 1992, J VIROL, V66, P244; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHWARTZ BS, 1991, J BIOL CHEM, V267, P7089; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	85	233	236	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11803	11810						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505309				2022-12-25	WOS:A1993LF28400053
J	ROSCIGNO, RF; WEINER, M; GARCIABLANCO, MA				ROSCIGNO, RF; WEINER, M; GARCIABLANCO, MA			A MUTATIONAL ANALYSIS OF THE POLYPYRIMIDINE TRACT OF INTRONS - EFFECTS OF SEQUENCE DIFFERENCES IN PYRIMIDINE TRACTS ON SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; MAMMALIAN INTRONS; SEX-LETHAL; U1 SNRNA; U2 SNRNP; SITE; PROTEIN; INVITRO; COMPLEX	The polypyrimidine (py) tract of introns is required for efficient spliceosome assembly and splicing of pre-mRNAs. A detailed mutational analysis of the py tract of an adenovirus 2 intron was carried out. Utilizing a ''precursor in pieces'' vector system, it was possible to synthesize py tract mutant pre-mRNAs that were otherwise identical. The mutant pre-mRNAs were analyzed for in vitro splicing, for formation of splicing complexes, and for binding to proteins in the HeLa nuclear extract. Chimeric pre-mRNAs that contained the yeast branch point consensus sequence (UAC-UAAC) and altered py tracts were also analyzed. Mutational analysis showed the following. First, any mutation in the py tract that affected splicing did so by interferring with complex A formation in spliceosome assembly. Second, introduction of purines into the py tract is detrimental only if the length of the tract is shortened and if there is a reduction in the number of consecutive uracil residues. Third, uracil and cytosine do not have equivalent functions in the py tract. Our results with chimeric pre-mRNAs also show that a strong py tract can partially replace a weak branch point sequence and a strong branch point sequence can partially replace a weak py tract. Finally, the one surprising finding obtained when examining protein binding was that a mutant pre-mRNA did not bind to heterogeneous nuclear ribonucleoprotein C proteins and yet spliced close to wild type level.	DUKE UNIV, MED CTR, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University			Weiner, Michael/M-5185-2013	Weiner, Michael/0000-0002-0877-4583				AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; BRODY J, 1985, SCIENCE, V228, P1344; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1985, CELL, V43, P131, DOI 10.1016/0092-8674(85)90018-2; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEMAKER HJ, 1974, J MOL BIOL, V84, P503, DOI 10.1016/0022-2836(74)90112-0; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1988, JAMA-J AM MED ASSOC, V260, P3035, DOI 10.1001/jama.260.20.3035; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	54	139	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11222	11229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496178				2022-12-25	WOS:A1993LD46600075
J	SAGAMI, H; KURISAKI, A; OGURA, K				SAGAMI, H; KURISAKI, A; OGURA, K			FORMATION OF DOLICHOL FROM DEHYDRODOLICHOL IS CATALYZED BY NADPH-DEPENDENT REDUCTASE LOCALIZED IN MICROSOMES OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE SYNTHASE; BIOSYNTHESIS; PYROPHOSPHATES; PHOSPHATASE	The alpha-saturation reaction involved in the biosynthesis of dolichol has been investigated with rat liver preparations. Under improved in vitro conditions with 10,000 x g supernatant of rat liver homogenates in the presence of NADPH at pH 8.0, dolichol was synthesized from isopentenyl diphosphate and Z,E,E-geranylgeranyl diphosphate. Neither dolichyl diphosphate nor dolichyl phosphate was detected. The chain length distribution of the dolicohol was the same as that of dehydrodolichyl products. In an assay system containing dehydrodolichol, dehydrodolichyl phosphate, or dehydrodolichyl diphosphate as a substrate, dehydrodolichol was predominantly converted into dolichol. The enzyme that catalyzes the conversion of dehydrodolichol to dolichol was localized in microsomes. The reductase activity was stimulated 9-fold by the addition of a 100,000 x g soluble fraction. The reductase had an opimal pH at 8.0. These results indicate that dolichol is formed from dehydrodolichol in rat liver microsomes. The formation of dolichol from dehydrodolichol was also catalyzed by 10,000 x g supernatant of rat or pig testis homogenates.			SAGAMI, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN.							ALLEN CM, 1978, BIOCHEMISTRY-US, V17, P5020, DOI 10.1021/bi00616a025; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; EKSTROM TJ, 1987, J BIOL CHEM, V262, P4090; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; ROSENWALD AG, 1990, J LIPID RES, V31, P523; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; SAGAMI H, 1992, J LIPID RES, V33, P1857; SCHER MG, 1984, J BIOL CHEM, V259, P4580; STOLL J, 1988, J BIOL CHEM, V263, P10774; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35	15	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10109	10113						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486680				2022-12-25	WOS:A1993LB80000027
J	SARABIA, VE; CASEY, JR; REITHMEIER, RAF				SARABIA, VE; CASEY, JR; REITHMEIER, RAF			MOLECULAR CHARACTERIZATION OF THE BAND-3 PROTEIN FROM SOUTHEAST-ASIAN OVALOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN-ERYTHROCYTE-MEMBRANE; ANION-TRANSPORT PROTEIN; PAPUA-NEW-GUINEA; MELANESIAN OVALOCYTES; CARBOHYDRATE MOIETY; MALARIA PARASITES; INVASION; RESISTANT; DELETION	Southeast Asian ovalocytosis (SAO) is a hereditary form of elliptocytosis resulting in rigid, oval-shaped erythrocytes resistant to invasion by malaria parasites. The molecular defect is due to deletion of codons 400-408, encoding a 9-amino-acid sequence located at the boundary between the cytosol and the first transmembrane segment in Band 3, the erythrocyte anion transport protein. We have carried out an extensive characterization of Band 3 isolated from SAO erythrocytes which contain about 50% mutant Band 3. A slightly higher proportion of Band 3 in SAO erythrocytes was left associated with the cytoskeleton after extraction of ghost membranes with non-ionic detergents. Size exclusion high performance liquid chromatography analysis showed that SAO Band 3 contained a higher proportion of tetramers relative to dimers (50% tetramer) than normal Band 3 (33% tetramer). The circular dichroism spectrum of Band 3 from SAO erythrocytes was very similar to the spectrum for normal Band 3. Enzymatic deglycosylation and tomato lectin binding showed that SAO Band 3 lacked the polylactosaminyl oligosaccharide found on normal Band 3. SAO Band 3 was unable to bind the anion transport inhibitor 4-benzamido-4'-aminostilbene-2,2'-disulfonate, suggesting a dramatic alteration in the inhibitor binding site. In conclusion, deletion of 9 amino acids from Band 3 on the cytosolic side of the membrane affects the properties (glycosylation and inhibitor binding) of Band 3 on the opposite side of the membrane without dramatic changes in the secondary and quaternary structure of the protein.	UNIV TORONTO, DEPT MED,MRC,MEMBRANE BIOL GRP,RM 7307, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				BANNISTER LH, 1990, BLOOD CELLS, V16, P257; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1992, J BIOL CHEM, V267, P11940; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HADLEY T, 1983, J CLIN INVEST, V71, P780, DOI 10.1172/JCI110827; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KIDSON C, 1981, P NATL ACAD SCI-BIOL, V78, P5829, DOI 10.1073/pnas.78.9.5829; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MOHANDAS N, 1992, J CLIN INVEST, V89, P686, DOI 10.1172/JCI115636; MOHANDAS N, 1984, BLOOD, V63, P1385; MORIYAMA R, 1992, J BIOL CHEM, V267, P25792; MUELLER TJ, 1977, J BIOL CHEM, V252, P6573; PALATNIK M, 1990, HUM GENET, V86, P126, DOI 10.1007/BF00197692; SAUL A, 1984, J CELL BIOL, V98, P1348, DOI 10.1083/jcb.98.4.1348; SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TANNER MJA, 1991, BLOOD, V78, P2785; TILLEY L, 1991, J MEMBRANE BIOL, V121, P59, DOI 10.1007/BF01870651; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANNOUKAKOS D, 1991, BLOOD, V78, P1117	32	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10676	10680						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486716				2022-12-25	WOS:A1993LB80000099
J	TANIGUCHI, H; MANENTI, S				TANIGUCHI, H; MANENTI, S			INTERACTION OF MYRISTOYLATED ALANINE-RICH PROTEIN-KINASE-C SUBSTRATE (MARCKS) WITH MEMBRANE PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; BACTERIAL LIPOPOLYSACCHARIDE; CELLULAR SUBSTRATE; PHORBOL ESTERS; GROWTH-FACTORS; PHOSPHORYLATION; 80-KDA; BRAIN; ACTIVATION; CALMODULIN	A major in vivo substrate of Ca2+-phospholipid-dependent protein kinase (MARCKS) shows phosphorylation-dependent translocation between the cytoplasmic and the membrane fractions. The mechanism of the translocation was studied with purified MARCKS and various membranes. MARCKS was found to bind to pure phospholipid membranes as well as to the synaptic vesicle membranes. Although the interaction of MARCKS with the latter was phosphorylation-dependent, phosphorylation by protein kinase C showed no significant effect on the binding to the phosphatidylcholine liposomes. However, when phosphatidylserine was included in the membranes, the association became phosphorylation-dependent. A synthetic phosphorylation domain peptide showed a similar phosphorylation-dependent interaction with the negatively charged liposomes. Phosphatidylserine but not phosphatidylcholine inhibited phosphorylation of MARCKS by protein kinase C. MARCKS seems to bind to the biomembranes through two binding sites: the N-terminal myristoyl moiety and the basic phosphorylation domain of amphiphilic nature. Phosphorylation of this domain lowers its affinity to phosphatidylserine and makes the whole molecule strongly negatively charged, which causes its dissociation from the membranes.			TANIGUCHI, H (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BURN P, 1988, TRENDS BIOCHEM SCI, V13, P79, DOI 10.1016/0968-0004(88)90043-6; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMES G, 1989, J BIOL CHEM, V264, P20928; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KISH PE, 1989, METHOD ENZYMOL, V174, P10; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MIZUTANI A, 1992, BIOCHEM BIOPH RES CO, V182, P1395, DOI 10.1016/0006-291X(92)91888-W; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	29	147	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9960	9963						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486722				2022-12-25	WOS:A1993LB80000007
J	HANSBROUGH, JR; FINE, SM; GORDON, JI				HANSBROUGH, JR; FINE, SM; GORDON, JI			A TRANSGENIC MOUSE MODEL FOR STUDYING THE LINEAGE RELATIONSHIPS AND DIFFERENTIATION PROGRAM OF TYPE-II PNEUMOCYTES AT VARIOUS STAGES OF LUNG DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROENDOCRINE CELL-POPULATIONS; FETAL-RAT LUNG; EPITHELIAL-CELL; SUBEPITHELIAL FIBROBLASTS; DEVELOPING INTESTINE; GENE-EXPRESSION; MAMMALIAN-CELLS; FLOW-CYTOMETRY; MESSENGER-RNA; STEM-CELLS	A pedigree of transgenic mice has been characterized that contains a H2-K(b)/LacZ fusion gene that exhibits integration site-dependent expression from the earliest stages of lung development through adulthood. Histochemical and immunocytochemical studies indicate that the LacZ reporter appears throughout the pulmonary endoderm by embryonic day 11 (E11). A proximal-to-distal wave of extinction of transgene expression occurs during E13-14 that parallels the wave of cytodifferentiation of the pulmonary endoderm. By E16, the LacZ reporter is restricted to the distal portion of epithelial tubules and by birth to scattered cells located in alveoli. Crude epithelial cell suspensions were prepared from lungs harvested from E16 and 14 day postnatal transgenic mice, labeled with the fluorescent LacZ substrate fluorescein di-(beta-galactopyranoside), and the LacZ expressing population isolated by fluorescence-activated cell sorting. Electron microscopic, immunocytochemical and histochemical studies of this purified cell population establish that type II pneumocytes are the only cell lineage that support H2K(b)/LacZ expression in the mature postnatal lung. Fluorescence-activated cell sorting of E16 lung suspensions yielded a homogeneous population of cells that produced surfactant protein A, that could be maintained in cell culture, and that are likely precursors of adult type II pneumocytes. Together these studies indicate that (i) expression of the transgene in this pedigree of mice provides a marker for describing early differentiation of the pulmonary epithelium; (ii) the transgene may be useful as an enhancer trap to isolate cis-acting sequences that regulate gene transcription within this lineage; (iii) the LacZ reporter expression can be used to purify specific embryonic pulmonary epithelial cell populations; and (iv) primary cultures of these embryonic populations represent a potentially useful model system for analyzing the cellular components and signaling pathways necessary to support and complete passage through the type II pneumocyte differentiation program.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	HANSBROUGH, JR (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,BOX 8052,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESCIO T, 1962, J EXP ZOOL, V150, P83, DOI 10.1002/jez.1401500202; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; BALLARD PL, 1986, BIOCHIM BIOPHYS ACTA, V883, P335, DOI 10.1016/0304-4165(86)90326-0; BATENBURG JJ, 1988, BIOCHIM BIOPHYS ACTA, V960, P441, DOI 10.1016/0005-2760(88)90053-7; BAUSCH JN, 1977, BIOCHEMISTRY-US, V16, P5790, DOI 10.1021/bi00645a023; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; DOBBS LG, 1985, BIOCHIM BIOPHYS ACTA, V846, P155, DOI 10.1016/0167-4889(85)90121-1; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; EVANS MJ, 1989, LUNG CELL BIOL, V41, P1; Gilbert Scott F., 1988, DEV BIOL; GLASSER SW, 1992, AM REV RESPIR DIS, V145, P225; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAFFEN K, 1983, DIFFERENTIATION, V23, P226; Have-Opbroek A. T., 1986, ANAT EMBRYOL, V174, P49; HAVEOPBROEK AAW, 1988, ANAT REC, V221, P846; HAVEOPHBROEK AAW, 1981, AM J ANAT, V162, P201; HOGAN B, 1986, MANIPULATING MOUSE E; Jones KH, 1987, J HISTOCHEM CYTOCHEM, V35, P123, DOI 10.1177/35.1.2432112; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; KIKKAWA Y, 1974, LAB INVEST, V30, P76; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LEARY JF, 1982, AM REV RESPIR DIS, V125, P326; MARSH MN, 1974, GASTROENTEROLOGY, V67, P636; MARSH MN, 1974, GASTROENTEROLOGY, V67, P622; MASKENS AP, 1979, GUT, V20, P775, DOI 10.1136/gut.20.9.775; MASON RJ, 1977, PULMONARY MACROPHAGE, P280; MASSEY TE, 1987, CAN J PHYSIOL PHARM, V65, P2368, DOI 10.1139/y87-375; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; OOMEN LCJM, 1990, AM J RESP CELL MOL, V3, P325, DOI 10.1165/ajrcmb/3.4.325; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1992, AM J PHYSIOL, V263, pG186, DOI 10.1152/ajpgi.1992.263.2.G186; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROTH KA, 1992, AM J PHYSIOL, V263, P174; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELLHASE DE, 1989, PEDIATR RES, V26, P167, DOI 10.1203/00006450-198909000-00001; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SEVANIAN A, 1981, BIOCHIM BIOPHYS ACTA, V664, P498, DOI 10.1016/0005-2760(81)90128-4; SHANNON JM, 1989, AM REV RESPIR DIS, V139, P255; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SIMONASSMANN P, 1990, J CELL BIOL, V110, P849, DOI 10.1083/jcb.110.3.849; SIMONASSMANN P, 1988, DEVELOPMENT, V102, P339; SLAVKIN HC, 1989, DIFFERENTIATION, V41, P223, DOI 10.1111/j.1432-0436.1989.tb00751.x; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; Ten Have-Opbroek A.A., 1991, EXP LUNG RES, V17, P111, DOI DOI 10.3109/01902149109064406; Theiler K., 1972, HOUSE MOUSE; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; WHITSETT JA, 1985, BIOCHIM BIOPHYS ACTA, V828, P162, DOI 10.1016/0167-4838(85)90053-6; WILLIAMS MC, 1990, AM J RESP CELL MOL, V2, P533, DOI 10.1165/ajrcmb/2.6.533; WILSON JS, 1986, CYTOMETRY, V7, P157, DOI 10.1002/cyto.990070206; WOODCOCKMITCHELL J, 1990, AM J RESP CELL MOL, V2, P503, DOI 10.1165/ajrcmb/2.6.503	61	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9762	9770						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486660				2022-12-25	WOS:A1993LA68900089
J	COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S				COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S			TRANSFECTED WILD-TYPE AND MUTANT MAX REGULATE CELL-GROWTH AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; ERYTHROID-DIFFERENTIATION; EXPRESSION; COMMITMENT; GENE; PROTEIN; G0/G1	Max protein forms specific DNA-binding dimeric complexes with itself and with proteins of the c-myc gene family. A large volume of data has accumulated on the role of the c-myc proto-oncogene in cell proliferation, differentiation and tumorigenesis. To elucidate the role of max in regulating c-myc functions and the effect of both proteins on cell proliferation and differentiation, we transfected murine erythroleukemia (MEL) cells with a full-length wild-type (wt) human max gene and a mutant containing a double point mutation in the basic region (bm), which abolishes specific DNA binding. All clones expressing wt-max grow slowly, and the process of inducer-mediated differentiation is delayed. Furthermore, cells transfected with the mutated max exhibit growth retardation, accumulation in the G0/G1 phase of the cell cycle and spontaneous differentiation. Our findings are consistent with a model in which a large excess of wt-Max in the cells enhances the formation of Max-Max growth-suppressor complexes, while elevated bm-Max deprives the cell of growth-promoting Myc-Max heterodimers in a dominant-negative manner, presumably by inactivating endogenous Myc and Max.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; NCI,MED ONCOL BRANCH,BETHESDA,MD 20889	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS LG, 1986, METHODS MOL BIOL; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUBE SK, 1974, DIFFERENTIATION CONT, P99; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GELLER R, 1978, J CELL PHYSIOL, V95, P213, DOI 10.1002/jcp.1040950211; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAHN S M, 1990, Technique (Philadelphia), V2, P27; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	37	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1263	1268						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479748				2022-12-25	WOS:A1993KY32800018
J	FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP				FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP			THE EZRIN-LIKE FAMILY OF TYROSINE KINASE SUBSTRATES - RECEPTOR-SPECIFIC PATTERN OF TYROSINE PHOSPHORYLATION AND RELATIONSHIP TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; CDNA CLONING; MONOCLONAL-ANTIBODIES; MEMBRANE SKELETON; CELLULAR PROTEINS	A method for the isolation of tyrosine kinases substrates was developed. The method takes advantage of immunoaffinity purification of an entire set of proteins phosphorylated by tyrosine kinases, followed by generation of antisera against the purified protein pool and immunological screening of bacterial expression libraries with these antisera. By applying this methodology to the study of the phosphorylation events triggered by activation of the epidermal growth factor receptors, we have isolated several cDNAs encoding novel putative tyrosine kinase substrates. One of these cDNAs encodes radixin, a protein belonging to the band 4.1 family of proteins and highly related to ezrin and moesin. We demonstrated that, despite a high degree of relatedness, these three proteins exhibit a distinct receptor-specific pattern of phosphorylation, raising the possibility that they might mediate receptor-specific cellular changes. In addition the generation of antibodies specific for either radixin, ezrin or moesin allowed us to show that a previously described tumor transplantation antigen is indeed ezrin, thus implicating this protein in the determination of the biological phenotype of certain tumors.	NCI, MOLEC & CELLULAR BIOL LAB, BLDG 37, ROOM 1D23, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sakaguchi, Kazuyasu/0000-0002-8434-4171				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; CORREAS I, 1986, J BIOL CHEM, V261, P3362; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DUBOIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P7669, DOI 10.1073/pnas.79.24.7669; DUBOIS GC, 1980, CANCER RES, V40, P4204; EGERTON M, 1992, J IMMUNOL, V149, P1847; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMBROOK J, 1989, MOL BIOL LABORATORY; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH SJ, 1986, MOL IMMUNOL, V23, P545, DOI 10.1016/0161-5890(86)90118-5; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	67	96	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1335	1345						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479753				2022-12-25	WOS:A1993KY32800027
J	PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC				PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC			TUMORIGENIC ACTIVITY OF RHO GENES FROM APLYSIA-CALIFORNICA	ONCOGENE			English	Article							GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE; PARTIAL-PURIFICATION; ESCHERICHIA-COLI; BRAIN CYTOSOL; RAS; PRODUCT; SUBSTRATE; FAMILY; SEQUENCE	rho genes have been found in both lower and higher eucaryotes. They code for proteins of 21 kDa, highly conserved in evolution, which belong to the superfamily of ras GTPases. Among the members of this superfamily there are proteins with a regulatory function, such as ras, and proteins involved in vesicular trafficking, such as the family of rab proteins. We have investigated the putative role of rho proteins from Aplysia californica as transforming GTPases utilizing the wild-type and a Val-14 mutant, equivalent to the oncogenic Val-12 mutation of ras genes found in animal and human tumors. Overexpression of either rho gene was sufficient to confer anchorage- and serum-independent growth. Moreover, when introduced into nude mice, selected clones generated from either gene were able to induce tumors, although those carrying the mutated version were more efficient. Pathological analysis indicated that generated tumors corresponded to well-differentiated fibrosarcomas with distinct and intersecting bundles and spindle cells. By contrast, ras-induced tumors were poorly differentiated fibrosarcomas. Thus, our results indicate that under appropriate conditions rho genes function as oncogenes and may have a role in the regulation of proliferation in fibroblast cells.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,MADRID 6,SPAIN; CLIN PUERTA HIERRO,DEPT PATOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Espinosas, Maribel/H-8083-2012; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/N-9064-2015	Ramon y Cajal, Santiago/0000-0002-3867-1390; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Perez-Ballestero, Rafael/0000-0001-8251-2875				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIECKMANN D, 1991, NATURE, V351, P400; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIGESKUNI K, 1989, MOL BRAIN RES, V6, P167; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; TOKI C, 1989, BIOCHEM BIOPH RES CO, V164, P333, DOI 10.1016/0006-291X(89)91722-1; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	37	126	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1285	1292						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479750				2022-12-25	WOS:A1993KY32800021
J	GUIMBAL, C; KILIMANN, MW				GUIMBAL, C; KILIMANN, MW			A NA+-DEPENDENT CREATINE TRANSPORTER IN RABBIT BRAIN, MUSCLE, HEART, AND KIDNEY - CDNA CLONING AND FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SEROTONIN TRANSPORTER; RAT-BRAIN; DOPAMINE TRANSPORTER; CULTURED-CELLS; RNA; ANTIDEPRESSANTS; KINASE; DNA	A cDNA has been cloned from rabbit brain that is a new member of the emerging family of Na+-dependent plasma membrane transporters for several neurotransmitters and structurally related compounds. Functional expression of this cDNA in COS-7 cells identifies its product as a Na+- and Cl--dependent creatine transporter with a K(m) of approximately 35 muM. Its creatine transporter activity is efficiently antagonized by 3-guanidinopropionate, a well characterized alternative substrate of creatine transport in several tissues, and by 4-guanidinobutyrate. More distant structural analogues of creatine are much less efficient or inactive as antagonists, indicating a high substrate specificity of the transporter. Northern blot hybridization detects the expression of its mRNA in most tissues tested, most prominently in kidney, heart, and muscle, but not in liver and intestine. A full-length cDNA clone was also isolated from a muscle cDNA library and found to contain the same coding sequence. Substrate affinity and specificity of the cloned transporter are very similar to the endogenous creatine transporter of the COS-7 cells and to the creatine transport activities of several cell types described in the literature. Moreover, its mRNA is most abundant in the tissues known to possess high creatine uptake capacity.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,UNIV STR 150,W-4630 BOCHUM 1,GERMANY	Ruhr University Bochum								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERLET HH, 1976, BIOCHIM BIOPHYS ACTA, V437, P166, DOI 10.1016/0304-4165(76)90358-5; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; FITCH CD, 1968, J BIOL CHEM, V243, P2024; FITCH CD, 1966, J BIOL CHEM, V241, P3611; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARMANN B, 1990, FEBS LETT, V273, P248, DOI 10.1016/0014-5793(90)81096-7; HARMANN B, 1991, J BIOL CHEM, V266, P15631; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KU CP, 1980, BIOCHIM BIOPHYS ACTA, V600, P212, DOI 10.1016/0005-2736(80)90426-5; KURAHASHI M, 1977, AM J PHYSIOL, V233, pE91, DOI 10.1152/ajpendo.1977.233.2.E91; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOIKE JD, 1986, AM J PHYSIOL, V251, pC128, DOI 10.1152/ajpcell.1986.251.1.C128; LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MAYSER W, 1992, FEBS LETT, V305, P31, DOI 10.1016/0014-5793(92)80649-2; MOLLER A, 1989, J NEUROCHEM, V52, P544, DOI 10.1111/j.1471-4159.1989.tb09154.x; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SYLLMRAPOPORT I, 1981, ACTA BIOL MED GER, V40, P653; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	36	226	234	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8418	8421						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473283				2022-12-25	WOS:A1993KX81100010
J	SAKAMOTO, A; YANAGISAWA, M; SAWAMURA, T; ENOKI, T; OHTANI, T; SAKURAI, T; NAKAO, K; TOYOOKA, T; MASAKI, T				SAKAMOTO, A; YANAGISAWA, M; SAWAMURA, T; ENOKI, T; OHTANI, T; SAKURAI, T; NAKAO, K; TOYOOKA, T; MASAKI, T			DISTINCT SUBDOMAINS OF HUMAN ENDOTHELIN RECEPTORS DETERMINE THEIR SELECTIVITY TO ENDOTHELIN(A)-SELECTIVE ANTAGONIST AND ENDOTHELIN(B)-SELECTIVE AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA; EXPRESSION; CLONING; EFFICIENT; FAMILY	The endothelin (ET) family of peptides acts via two subtypes of G-protein-coupled heptahelical receptors termed ET(A) and ET(B), which have distinct rank orders of affinity to endothelin receptor agonists and antagonists. To delineate which portions of the receptor molecules determine ligand selectivity, we have constructed a series of chimeras between human ET(A) and ET(B) receptors and characterized the chimeric receptors expressed in heterologous cell lines by competitive radioligand binding analysis and by measuring agonist-induced transients of intracellular Ca2+. We demonstrate that the binding determinant for the ET(B)-selective agonists ET-3, BQ3020, and IRL1620 resides within the region spanning the putative transmembrane helices IV-VI and the adjacent loop regions. In contrast, the transmembrane helices I, II, III, and VII plus the intervening loop regions specify the selectivity for BQ123, an ET(A)-selective antagonist. BQ123 exhibited no detectable agonistic activity in all wild-type and chimeric receptors tested. A chimeric receptor that has the transmembrane helices IV-VI (and adjacent loops) from the ET(B) receptor inserted into the remaining regions from the ET(A) receptor binds both the ET(A)- and ET(B)-selective ligands with high affinities. Moreover, BQ123 competitively inhibits the binding of the amino-terminally truncated ET(B) agonists, I-125-BQ3020 and I-125-IRL1620, to this chimeric receptor, suggesting that BQ123 is a mimic of the carboxyl-terminal linear portion of endothelins. These findings indicate that there are at least two separable ligand interaction subdomains within the endothelin receptors.	KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT INTERNAL MED 2, KYOTO 606, JAPAN; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	Kyoto University; Kyoto University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo			Sawamura, Tatsuya/E-7103-2010					ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; ANDERSEN NH, 1992, BIOCHEMISTRY-US, V31, P1280, DOI 10.1021/bi00120a003; ATKINSON RA, 1992, FEBS LETT, V296, P1, DOI 10.1016/0014-5793(92)80390-3; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DOHERTY AM, 1992, J MED CHEM, V35, P1493, DOI 10.1021/jm00087a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FUKURODA T, 1992, LIFE SCI, V50, pPL107, DOI 10.1016/0024-3205(92)90353-Q; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; IHARA M, 1992, LIFE SCI, V51, pPL47, DOI 10.1016/0024-3205(92)90418-O; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1992, J MED CHEM, V35, P2139, DOI 10.1021/jm00089a028; JACKSON T, 1991, PHARMACOL THERAPEUT, V50, P425, DOI 10.1016/0163-7258(91)90052-N; KRYSTEK SR, 1992, FEBS LETT, V299, P255, DOI 10.1016/0014-5793(92)80127-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; NAKAMICHI K, 1992, BIOCHEM BIOPH RES CO, V182, P144, DOI 10.1016/S0006-291X(05)80123-8; REILY MD, 1992, FEBS LETT, V300, P136, DOI 10.1016/0014-5793(92)80181-F; SAIDA K, 1991, J CARDIOVASC PHARM, V17, pS55, DOI 10.1097/00005344-199100177-00015; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEMORI AE, 1992, ANNU REV PHARMACOL, V32, P239, DOI 10.1146/annurev.pa.32.040192.001323; URADE Y, 1992, FEBS LETT, V311, P12, DOI 10.1016/0014-5793(92)81355-P; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WATAKABE T, 1992, BIOCHEM BIOPH RES CO, V185, P867, DOI 10.1016/0006-291X(92)91707-W; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	32	175	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8547	8553						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473300				2022-12-25	WOS:A1993KX81100029
J	STOVER, T; KOHLER, E; FAGIN, U; WENDE, W; WOLFES, H; PINGOUD, A				STOVER, T; KOHLER, E; FAGIN, U; WENDE, W; WOLFES, H; PINGOUD, A			DETERMINATION OF THE DNA BEND ANGLE INDUCED BY THE RESTRICTION ENDONUCLEASE ECORV IN THE PRESENCE OF MG2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLITE ACTIVATOR PROTEIN; GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; B-DNA; RECOGNITION; RESOLUTION; SEQUENCE; COMPLEX; CONFORMATION; REFINEMENT	We have used the method of Zinkel and Crothers (Zinkel, S. S., and Crothers, D. M. (1990) Biopolymers 29, 29-38) to determine the degree of bending induced by the binding of the restriction endonuclease EcoRV to its recognition sequence (-GATATC-). A set of four calibration DNA fragments was constructed that contained zero, two, four, or six phased A-tracts in their centers and an EcoRV site at the 5'-end to account for the electrophoretic influence of the bound protein. The mobilities of these calibration molecules complexed with EcoRV were compared to that of a test DNA containing a central EcoRV site also complexed with EcoRV. The EcoRV-induced bend angle was found to be 44-degrees +/- 4-degrees. These experiments were performed with a catalytically inactive EcoRV mutant that still binds DNA specifically in the presence of Mg2+. In the absence of Mg2+, which is necessary for specific binding, there is no difference in the mobilities of the fragments with a peripheral or a central EcoRV site complexed with EcoRV, indicating that nonspecific binding on average does not lead to measurable DNA bending.			STOVER, T (corresponding author), HANNOVER MED SCH,ZENTRUM BIOCHEM,KONSTANTY GUTSCHOW STR 8,W-3000 HANNOVER 61,GERMANY.		Wende, Wolfgang/F-6127-2014; Köhler, Eleonore/D-2915-2012	Köhler, Eleonore/0000-0003-1977-9977; Wende, Wolfgang/0000-0001-6577-9535				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DIEKMANN S, 1988, J MOL BIOL, V202, P823, DOI 10.1016/0022-2836(88)90561-X; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; FREDERICK CA, 1988, J BIOL CHEM, V263, P17872; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; THOMAS GA, 1989, BIOCHEMISTRY-US, V28, P2001, DOI 10.1021/bi00431a007; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WENDE W, 1991, BIOL CHEM H-S, V372, P777; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8645	8650						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473307				2022-12-25	WOS:A1993KX81100042
J	WEITZMAN, JB; PASQUALINI, R; TAKADA, Y; HEMLER, ME				WEITZMAN, JB; PASQUALINI, R; TAKADA, Y; HEMLER, ME			THE FUNCTION AND DISTINCTIVE REGULATION OF THE INTEGRIN VLA-3 IN CELL-ADHESION, SPREADING, AND HOMOTYPIC CELL-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; MEMBRANE GLYCOPROTEIN; T-CELLS; ONCOGENIC TRANSFORMATION; FIBRONECTIN RECEPTOR; COLLAGEN RECEPTOR; DIVALENT-CATIONS; LAMININ RECEPTOR; BINDING-SITE; ALPHA-3-BETA-1	To assess directly the functional role of the integrin VLA-3 (alpha3beta1), we transfected human alpha3 cDNA into erythroleukemia (K562) cells and rhabdomyosarcoma (RD) cells. The resulting transfectants (KA3 and RA3) expressed alpha3beta1 on the cell surface as confirmed using a panel of nine anti-alpha3 monoclonal antibodies. Neither of the transfected cells exhibited increased adhesion to the extracellular matrix proteins fibronectin, laminin, and collagen. However, the KA3 transfectants did bind strongly to the extracellular matrix deposited by epidermal and carcinoma cell lines, allowing the cells to attach and spread. Binding to this cell-deposited ligand, probably containing epiligrin/kalinin, was specific to VLA-3 and could be inhibited by anti-alpha3 antibodies and by EDTA, but not by RGD peptides. In marked contrast to other integrins (VLA-2 and VLA-4), VLA-3 showed high constitutive activity in K562 cells, but was minimally active in RD cells. Also contrasting with other beta1 integrins, VLA-3 was minimally stimulated by the anti-beta1 monoclonal antibody TS/216 under normal conditions. VLA-3-mediated adhesive function was well supported by either Mg2+ or Mn2+, but was almost completely abolished by the presence of 1 mM Ca2+. Surprisingly, this negative Ca2+ effect was completely overcome by the addition of the stimulatory anti-beta1 monoclonal antibody TS2/16. Together, these results point to markedly distinct regulation for VLA-3 function compared to other beta1 integrins. Also, all anti-VLA-3 antibodies were able to induce temperature-dependent homotypic cell aggregation of KA3 cells, but not K562 cells. However, this aggregation did not appear to be directly mediated by VLA-3 since it was not inhibited by EDTA. In addition, no enhancement of heterotypic cell-cell adhesion was observed in alpha3-transfected cells.	Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	WEITZMAN, JB (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.			Weitzman, Jonathan/0000-0001-8445-0102; takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903, R01GM047157, R01GM046526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157, GM38903, GM46526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHOY MY, 1990, J PATHOL, V160, P35, DOI 10.1002/path.1711600109; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MORHENN VB, 1985, J CLIN INVEST, V76, P1978, DOI 10.1172/JCI112197; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; RETTIG WJ, 1989, ANNU REV IMMUNOL, V7, P481, DOI 10.1146/annurev.iy.07.040189.002405; ROUSELLE P, 1992, J CELL BIOL, V114, P567; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STAQUET MJ, 1990, EXP CELL RES, V187, P277, DOI 10.1016/0014-4827(90)90092-O; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WATT F M, 1992, Current Biology, V2, P106, DOI 10.1016/0960-9822(92)90236-4; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	62	158	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8651	8657						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473308				2022-12-25	WOS:A1993KX81100043
J	MURGIA, M; HANAU, S; PIZZO, P; RIPPA, M; DIVIRGILIO, F				MURGIA, M; HANAU, S; PIZZO, P; RIPPA, M; DIVIRGILIO, F			OXIDIZED ATP - AN IRREVERSIBLE INHIBITOR OF THE MACROPHAGE PURINERGIC-P2Z RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PLASMA-MEMBRANE; CELLS; NUCLEOTIDES; MECHANISMS; FLUXES; PC12	The effects of oxidized ATP (oATP) on responses triggered by extracellular adenosine 5'-triphosphate (ATP(e)) were investigated in the mouse macrophage-like cell line J774. ATP(e) induced in this cell line two kinds of responses mediated by two different P2 purinergic receptors: 1) an early permeabilization of the plasma membrane to extracellular hydrophilic markers of M(r) up to 900 mediated by P2Z receptors; and 2) a fast mobilization of Ca2+ from intracellular stores mediated by P2Y receptors. Low oATP concentrations (100 muM) completely blocked the first response without affecting the second. ATP(e)-dependent cell swelling, vacuolization, and lysis were also inhibited. Antagonism developed slowly, as an incubation at 37-degrees-C for at least 2 h in the presence of oATP was needed and was irreversible, thus suggesting that the inhibitory action was due to covalent modification of the receptor. The rate of hydrolysis of exogenous ATP was slightly decreased by oATP, indicating a minor blocking effect of this compound on plasma membrane ecto-ATPases in the concentration range tested. These observations suggest that oATP may be a potentially very useful tool for isolation and characterization of the P2Z purinergic receptor.	UNIV FERRARA, INST GEN PATHOL, VIA BORSARI 46, I-44100 FERRARA, ITALY; UNIV FERRARA, INST BIOCHEM, I-44100 FERRARA, ITALY; UNIV PADUA, NATL RES COUNCIL, STUDY PHYSIOL MITOCHONDRIA UNIT, I-35100 PADUA, ITALY; UNIV PADUA, DEPT EXPTL BIOMED, I-35100 PADUA, ITALY	University of Ferrara; University of Ferrara; University of Padua; University of Padua			Hanau, Stefania/AAG-7534-2021; Pizzo, Paola/T-4874-2018; DI VIRGILIO, Francesco/O-4634-2019; Di Virgilio, Francesco/J-3754-2018	Hanau, Stefania/0000-0002-2817-9941; Pizzo, Paola/0000-0001-6077-3265; DI VIRGILIO, Francesco/0000-0003-3566-1362; Di Virgilio, Francesco/0000-0003-3566-1362	Telethon [187] Funding Source: Medline	Telethon(Fondazione Telethon)		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P118; BURNSTOCK G, 1964, INT J NEUROPHARMACOL, V3, P163, DOI 10.1016/0028-3908(64)90003-6; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COLMAN RF, 1990, ENZYMES, V19, P283; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DIVIRGILIO F, 1993, IN PRESS PROTOCOLS C; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; FEDAN JS, 1990, ANN NY ACAD SCI, V603, P182; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; MURGIA M, 1992, BIOCHEM J, V288, P897, DOI 10.1042/bj2880897; MURGIA M, 1992, ATLA-ALTERN LAB ANIM, V20, P66; NAKAZAWA K, 1990, BRIT J PHARMACOL, V101, P224, DOI 10.1111/j.1476-5381.1990.tb12117.x; OCONNOR SE, 1992, LIFE SCI, V50, P1657, DOI 10.1016/0024-3205(92)90420-T; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE PH, 1978, EUR J BIOCHEM, V88, P543, DOI 10.1111/j.1432-1033.1978.tb12480.x; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x	28	325	326	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8199	8203						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463330				2022-12-25	WOS:A1993KW97900089
J	RAVANELLO, MP; FRANKE, CA; HRUBY, DE				RAVANELLO, MP; FRANKE, CA; HRUBY, DE			AN NH2-TERMINAL PEPTIDE FROM THE VACCINIA VIRUS L1R PROTEIN DIRECTS THE MYRISTYLATION AND VIRION ENVELOPE LOCALIZATION OF A HETEROLOGOUS FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; CELL-FREE SYSTEM; MYRISTIC ACID; PLASMA-MEMBRANE; MORPHOLOGICAL TRANSFORMATION; N-MYRISTOYLTRANSFERASE; RNA-POLYMERASE; ALPHA-SUBUNIT; MYRISTOYLATION; EXPRESSION	The vaccinia virus L1R gene product is a late protein destined for insertion into the envelope of intracellular virus particles. Because this protein is co-translationally modified by the addition of myristic acid to the penultimate NH2-terminal glycine residue, it was of interest to identify the modification signal within the L1R protein and to assess the relevance of myristylation to protein localization. To this end, a family of chimeric reporter genes containing 0-13 codons from the NH2 terminus of the L1R open reading frame fused in-frame to the bacterial chloramphenicol acetyltransferase gene was constructed. The encoded proteins were tested as myristylation substrates in cell-free extracts and infected cells. The results obtained in vitro and in vivo were similar and suggested that although the NH2-terminal 5 amino acids of the L1R protein were the minimum signal required to observe modification by myristate, 12 amino acids were required to obtain wild type levels of myristylation with a modulating role played by the intervening amino acid residues. Furthermore, subcellular fractionation of infected cells expressing the fusion proteins indicated that the NH2 terminus of the L1R protein was capable of targeting the fusion proteins to membrane-containing fractions only if myristylated. In particular, the myristylated fusion protein containing the first 12 amino acids of the L1R protein abutted to the chloramphenicol acetyltransferase protein was found associated with the envelope of intracellular vaccinia virus particles.	OREGON STATE UNIV, CTR GENE RES & BIOTECHNOL, DEPT MICROBIOL, CORVALLIS, OR 97331 USA	Oregon State University					NIAID NIH HHS [AI-20563] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ERLICH HA, 1989, PCR TECHNOLOGY, P61; ESSANI K, 1982, VIROLOGY, V118, P279, DOI 10.1016/0042-6822(82)90347-6; FRANKE CA, 1990, J VIROL, V64, P5988, DOI 10.1128/JVI.64.12.5988-5996.1990; FRANKE CA, 1989, J VIROL, V63, P4285, DOI 10.1128/JVI.63.10.4285-4291.1989; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HRUBY DE, 1979, J VIROL, V29, P705, DOI 10.1128/JVI.29.2.705-715.1979; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERSING DH, 1987, J VIROL, V61, P1672, DOI 10.1128/JVI.61.5.1672-1677.1987; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STREULI CH, 1987, NATURE, V326, P619, DOI 10.1038/326619a0; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; VANSLYKE JK, 1991, VIROLOGY, V183, P467, DOI 10.1016/0042-6822(91)90976-I; WEIR JP, 1985, J VIROL, V56, P534, DOI 10.1128/JVI.56.2.534-540.1985; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008	49	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7585	7593						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463289				2022-12-25	WOS:A1993KV14100109
J	TURINA, P; AGGELER, R; LEE, RSF; SENIOR, AE; CAPALDI, RA				TURINA, P; AGGELER, R; LEE, RSF; SENIOR, AE; CAPALDI, RA			THE CYSTEINE INTRODUCED INTO THE ALPHA-SUBUNIT OF THE ESCHERICHIA-COLI F(1)-ATPASE BY THE MUTATION ALPHA-R376C IS NEAR THE ALPHA-BETA-SUBUNIT INTERFACE AND CLOSE TO A NONCATALYTIC NUCLEOTIDE BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTON-ATPASE; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; UNCA MUTANTS; F1 ATPASE; F1-ATPASE; SYNTHASE; ADENINE; FLUORESCENCE; CATALYSIS; RESIDUES	Mutation of the alpha subunit of the Escherichia coli F1-ATPase to convert Arg-376 to a Cys (alphaR376C) lowers multisite ATPase activity 400-1,000-fold while affecting unisite catalysis only around 6-fold, suggesting that the mutation is in a region important for transmission of conformational changes between catalytic sites (Soga, S., Noumi, T., Takeyama, M., Maeda, M., and Futai, M. (1989) Arch. Biochem. Biophys. 268, 643-648; this study). To learn more of the structural features of the segment of the alpha subunit around Arg-376, mutant enzyme with a Cys at this position was modified with several maleimides. N-[C-14]Ethylmaleimide reacted rapidly with this Cys in one of the three alpha subunits/F1 (2,500 M-1 s-1); more slowly with a second alpha subunit (390 M-1 s-1); and the same Cys in the third copy of the alpha subunit was completely unreactive to the reagent, indicating asymmetry of alpha subunits in the ECF1 complex. The photoactivatable cross-linker N-(4-azido-2,3,5,6-tetrafluorobenzyl)-3-maleimidopropionamide, when reacted via its maleimide to alphaCys-376 of the mutant, covalently linked alpha to beta subunits upon photolysis, indicating that Cys-376 of alpha is close to an interface between the alpha and beta subunits. The EDTA-induced exchangeable noncatalytic site could be filled by TNP-ATP in both wild type and alphaR376C mutant ECF1. Occupancy of this site in the alphaR376C mutant altered the rate of reaction of the second-fastest reacting Cys-376 from 390 M-1 s-1 to below 130 M-1 s-1, suggesting that the two sites are on the same alpha subunit. TNP-ATP in the EDTA-induced exchangeable noncatalytic site was quenched by reacting Cys-376 with 4-maleimido-(2,2,6,6-tetramethylpiperidine-N(oxyl), indicating that the region around Cys-376, which is involved in transmission of conformational changes between alpha and beta, and noncatalytic sites are maximally 10-12 angstrom from each other.	UNIV OREGON,DEPT BIOL,EUGENE,OR 97403; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV ROCHESTER,CTR MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Oregon; University of Oregon; University of Rochester			Turina, Paola/P-9342-2015; Turina, Paola/GYJ-0656-2022	Turina, Paola/0000-0001-9174-511X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24526] Funding Source: Medline; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; FORSTER T, 1959, DISCUSS FARADAY SOC, V27, P1; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GREEN JA, 1973, J CHEM PHYS, V58, P2690, DOI 10.1063/1.1679569; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARRIS DA, 1978, BIOCHIM BIOPHYS ACTA, V504, P364, DOI 10.1016/0005-2728(78)90060-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; LONDON E, 1981, BIOCHEMISTRY-US, V20, P1932, DOI 10.1021/bi00510a032; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; PRESS WH, 1986, NUMERICAL RECIPES AR, P550; RAO R, 1988, J BIOL CHEM, V263, P15957; SCHNEIDER F, 1969, Z. Physiol. Chem., V350, P1521; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; WISE JG, 1981, J BIOL CHEM, V256, P383	37	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6978	6984						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463230				2022-12-25	WOS:A1993KV14100029
J	YANG, B; HOE, MH; BLACK, P; HUNT, RC				YANG, B; HOE, MH; BLACK, P; HUNT, RC			ROLE OF OLIGOSACCHARIDES IN THE PROCESSING AND FUNCTION OF HUMAN TRANSFERRIN RECEPTORS - EFFECT OF THE LOSS OF THE 3 N-GLYCOSYL OLIGOSACCHARIDES INDIVIDUALLY OR TOGETHER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BINDING-ACTIVITY; SIGNAL SEQUENCE; PRE-GOLGI; PROTEIN; CELLS; DEGRADATION; PHOSPHORYLATION; ACQUISITION; CONTAINS	When the coding sequence for human transferrin receptors was expressed in a Chinese hamster ovary cell line lacking endogenous transferrin receptors, 86-kDa molecules containing three N-glycosidically linked oligosaccharides were synthesized. These rapidly dimerized to form 172-kDa molecules which increased in size to 190 kDa. After site-directed mutagenesis of all three N-glycosylation sites, 80-kDa receptors were synthesized and only a few dimers were formed. 84-kDa monomers were synthesized in the absence of the oligosaccharide attached to Asn727 or Asn317. Dimerization and maturation through the Golgi body of the Asn727 mutant receptors were much slower than the wild type whereas the Asn317 mutant receptors behaved more similarly to the wild type. Lack of the oligosaccharide at Asn251 gave rise to 73-kDa monomers because of proteolytic processing (Hoe, M. H., and Hunt, R. C. (1992) J. Biol. Chem. 267, 4916-4923), but a second mutation at a potential cleavage site allowed the formation of 84-kDa receptors. These also dimerized at a similar rate to wild type receptors. The three-site mutant receptors were degraded in the endoplasmic reticulum but all three 84-kDa single site mutant receptor species migrated to the cell surface. However, receptors lacking the oligosaccharide at Asn727 bound and internalized little transferrin as a result of reduced affinity.	UNIV S CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia								AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; DAVIS RJ, 1984, J BIOL CHEM, V261, P9034; DO SI, 1990, J BIOL CHEM, V265, P114; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; Hanover JA, 1985, ENDOCYTOSIS, P131; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUNT RC, 1984, J BIOL CHEM, V259, P9944; HUNT RC, 1989, J BIOL CHEM, V264, P9643; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JING SQ, 1990, J BIOL CHEM, V265, P11555; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OMARY MB, 1981, J BIOL CHEM, V256, P2888; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x; [No title captured]	29	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7435	7441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463276				2022-12-25	WOS:A1993KV14100087
J	ALZANI, R; CORTI, A; GRAZIOLI, L; COZZI, E; GHEZZI, P; MARCUCCI, F				ALZANI, R; CORTI, A; GRAZIOLI, L; COZZI, E; GHEZZI, P; MARCUCCI, F			SURAMIN INDUCES DEOLIGOMERIZATION OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; RECEPTOR; BINDING; TRIMER; FORM	Suramin inhibits the biological activity of human tumor necrosis factor alpha (TNF) through a direct action on the ligand rather than on its receptors (Grazioli, L., Alzani, R., Ciomei, M., Mariani, M., Restivo, A., Cozzi, E., and Marcucci, F. (1992) Int. J. Immunopharmacol. 14, 637-642). In order to clarify the mechanism whereby suramin leads to inhibition of TNF, we investigated the possibility that suramin might modify the quaternary structure of TNF which is biologically active as a trimer. For this purpose we used a new assay (double streptavidin sandwich assay) designed for the rapid detection of oligomer-monomer conversion of proteins. Taking advantage of this assay we observed, upon incubation with suramin, dissociation of TNF. Suramin-induced dissociation of TNF was confirmed by gel filtration chromatography. Under conditions of partial dissociation, two molecular species were separated. One of higher molecular weight, corresponding to trimeric TNF, was biologically active, whereas the other, corresponding to monomeric TNF, was inactive. These results are at variance with others recently reported, where suramin has been shown to induce microaggregation of several polypeptides (Middaugh, C. R., Mach, H., Burke, C. J., Volkin, D. B., Dabora, J. M., Tsai, P. K., Bruner, M. W., Ryan, J. A., and Marfia, K. E. (1992) Biochemistry 31, 9016-9024). This suggests that suramin inhibits the bioactivity of different protein molecules through opposite effects on their quaternary structure. The present results are, to our knowledge, the first demonstration of a drug inhibiting a target molecule through dissociation of its quaternary structure.	TECNOGEN SCPA,MOLEC IMMUNOL & BIOCHEM UNIT,I-20131 MILAN,ITALY; MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	ALZANI, R (corresponding author), FARMITALIA CARLO ERBA SPA,DEPT IMMUNOL,VIA GIOVANNI XXIII 23,I-20014 NERVIANO,ITALY.		Corti, Angelo/F-7046-2012	Corti, Angelo/0000-0002-0893-6191; marcucci, fabrizio/0000-0002-2977-294X; Subba, Rajkrishna/0000-0003-0051-0062; Ghezzi, Pietro/0000-0003-0911-8358				ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P1322, DOI 10.1021/bi00379a018; ECK MJ, 1988, J BIOL CHEM, V263, P12816; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FECK MJ, 1989, J BIOL CHEM, V264, P17595; GRAZIOLI L, 1992, INT J IMMUNOPHARMACO, V14, P637, DOI 10.1016/0192-0561(92)90125-5; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KUNITANI MG, 1988, J CHROMATOGR, V443, P205, DOI 10.1016/S0021-9673(00)94794-0; LAM KS, 1988, J BIOL RESP MODIF, V7, P267; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LEWITBENTLEY A, 1988, J MOL BIOL, V199, P389, DOI 10.1016/0022-2836(88)90323-3; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; MILLS GB, 1990, CANCER RES, V50, P3036; SEMENZATO G, 1990, BRIT J CANCER, V61, P354, DOI 10.1038/bjc.1990.78; SMITH RA, 1987, J BIOL CHEM, V262, P6951; WINGFIELD P, 1987, FEBS LETT, V211, P179, DOI 10.1016/0014-5793(87)81432-1	21	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12526	12529						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509393				2022-12-25	WOS:A1993LG65800046
J	KRUEGER, KM; BARBIERI, JT				KRUEGER, KM; BARBIERI, JT			MOLECULAR CHARACTERIZATION OF THE INVITRO ACTIVATION OF PERTUSSIS TOXIN BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; ADENINE-NUCLEOTIDES; NAD GLYCOHYDROLASE; A-SUBUNIT; PROTEIN; RIBOSYLTRANSFERASE; S1-SUBUNIT; TRANSDUCIN; BINDING; CYCLASE	Pertussis toxin (PT)-catalyzed ADP-ribosylation of transducin (G(t)) is stimulated by ATP. In the absence of ATP, PT exhibited an approximately 20-fold lower linear velocity than the recombinant S1 subunit (rS1) in catalyzing the ADP-ribosylation of G(t). In the presence of 0.1 mM ATP, the linear velocities of rS1 and PT were essentially identical. ATP increased the k(cat) of PT-catalyzed ADP-ribosylation of G(t) without altering the K(mapp) for either G(t) or NAD. Further, in the presence of ATP, PT exhibited similar kinetic constants under conditions of variable G(t) and variable NAD as rS1 in catalyzing the ADP-ribosylation of G(t). The S1 subunit of PT was cleaved by chymotrypsin to a single immunoreactive peptide in the absence of ATP, while three immunoreactive peptides were generated in the presence of ATP. The S1 subunit of PT was not cleaved by trypsin in the absence of ATP, at the concentrations of trypsin used, while two immunoreactive peptides were produced in the presence of ATP. The immunoreactive peptides produced either by chymotrypsin or trypsin cleavage of the S1 subunit of PT in the presence of ATP were indistinguishable from those produced by cleavage of rS1 with the same protease. Chymotryptic and tryptic cleavage of rS1 was not altered by ATP. When PT was incubated with ATP prior to Bio-Gel P-100 gel filtration, approximately 8% of the S1 subunit dissociated from the B oligomer, as determined by ADP-ribosyltransferase assays of the column eluant. This increased to 20% when ATP was included in the column buffer. The presence of dithiothreitol and NAD in addition to ATP did not affect the amount of dissociated S1 subunit. Our data further indicated that activation of PT by ATP was a reversible process. Together, these data showed that ATP quantitatively converted the S1 subunit of PT to a form which was kinetically and conformationally identical with rS1, while only a fraction of the S1 subunit was dissociated from the B oligomer. These results indicate that both S1 subunit which is bound to the B oligomer as well as dissociated S1 subunit are capable of catalyzing the ADP-ribosylation of G(t).	MED COLL WISCONSIN,DEPT MICROBIOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIAID NIH HHS [AI-30162, AI-01087] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162, K04AI001087] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBIERI JT, 1990, INFECT IMMUN, V58, P999, DOI 10.1128/IAI.58.4.999-1003.1990; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS DL, 1987, J BIOL CHEM, V262, P17677; BURNS DL, 1986, J BIOL CHEM, V261, P4324; BURNS DL, 1989, J BIOL CHEM, V264, P564; CORTINA G, 1991, J BIOL CHEM, V266, P3022; CORTINA G, 1991, J BIOL CHEM, V266, P23810; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; HAUSMAN SZ, 1990, BIOCHEMISTRY-US, V29, P6128, DOI 10.1021/bi00478a003; HAUSMAN SZ, 1992, J BIOL CHEM, V267, P13735; KASLOW HR, 1987, BIOCHEMISTRY-US, V26, P123, DOI 10.1021/bi00375a018; KATADA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P290, DOI 10.1016/0003-9861(83)90212-6; KRUEGER KM, 1991, J BIOL CHEM, V266, P8122; LIM LK, 1985, J BIOL CHEM, V260, P2585; MATTERA R, 1986, J BIOL CHEM, V261, P1173; MONTECUCCO C, 1986, FEBS LETT, V194, P301, DOI 10.1016/0014-5793(86)80105-3; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; Peppler M S, 1985, Dev Biol Stand, V61, P75; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; UI M, 1990, ADP RIBOSYLATING TOX, P45; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WEST RE, 1985, J BIOL CHEM, V260, P4428	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12570	12578						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509398				2022-12-25	WOS:A1993LG65800053
J	ODA, T; WU, HC				ODA, T; WU, HC			CERULENIN INHIBITS THE CYTOTOXICITY OF RICIN, MODECCIN, PSEUDOMONAS TOXIN, AND DIPHTHERIA-TOXIN IN BREFELDIN A-RESISTANT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; NUCLEOTIDES MODULATE; ANTIBIOTIC CERULENIN; STRUCTURAL PROTEINS; INTERNALIZED RICIN; SECRETORY PROTEINS; RAT HEPATOCYTES	We have found that cerulenin, an antibiotic that inhibits de novo fatty acid and cholesterol biosynthesis and fatty acylation of proteins, strongly inhibited the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in a brefeldin A (BFA)-resistant mutant of Vero cells (BER-40). The protective effect of cerulenin against ricin was also observed in two other BFA-resistant cell lines, Madin-Darby canine kidney, and PtK1 cells. In contrast to BER-40 cells, no significant effect of cerulenin was observed in Vero cells. Cerulenin did not affect the binding of ricin to the cell-surface receptors, but reduced significantly the internalization of ricin in BER-40 cells; no effect of cerulenin on the binding or internalization of ricin was observed in Vero, PtK1, and Madin-Darby canine kidney cells. Endocytic uptake of fluid-phase markers such as horseradish peroxidase and lucifer yellow was inhibited by cerulenin in BER-40 cells, but the endocytosis of transferrin via the coated pit/coated vesicle pathway was slightly increased. Cerulenin inhibited the degradation and excretion of ricin in BER-40 cells, and this effect of cerulenin was not observed in Vero cells. Furthermore, cerulenin inhibited the bulk protein secretion in a dose-dependent manner, with BER-40 cells being more susceptible than Vero cells. These results suggest that in addition to its effect on endocytosis, cerulenin interferes with the intracellular trafficking or processing of toxin molecules, and the vesicle transport system in BER-40 cells appears to be cerulenin-sensitive. Since addition of fatty acids and cholesterol did not reverse the effects of cerulenin, the protective effect of cerulenin against protein toxins is not due to an inhibition of de novo fatty acids and cholesterol biosynthesis.	UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA					NIGMS NIH HHS [GM28810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARISON BH, 1974, J ANTIBIOT, V27, P28, DOI 10.7164/antibiotics.27.28; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN C, 1992, EXP CELL RES, V203, P321, DOI 10.1016/0014-4827(92)90005-S; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLDFINE H, 1978, BIOCHIM BIOPHYS ACTA, V512, P229, DOI 10.1016/0005-2736(78)90249-3; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JACQUES NA, 1983, J GEN MICROBIOL, V129, P3293; KARIN M, 1981, J BIOL CHEM, V256, P3245; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOW SH, 1991, J BIOL CHEM, V266, P17729; MADSHUS IH, 1991, J BIOL CHEM, V266, P17446; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OHNO T, 1974, BIOCHEM BIOPH RES CO, V57, P1119, DOI 10.1016/0006-291X(74)90812-2; Olsnes S, 1988, Cancer Treat Res, V37, P39; OLSNES S, 1987, MEMBRANE MEDIATED CY, P83; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHLESINGER MJ, 1982, J BIOL CHEM, V257, P9887; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P21297; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; WILEMAN T, 1985, BIOCHEM J, V232, P1; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y; YOULE RJ, 1987, J BIOL CHEM, V262, P4676; ZEUZEM S, 1991, FEBS LETT, V288, P143, DOI 10.1016/0014-5793(91)81021-Y	60	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12596	12602						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509400				2022-12-25	WOS:A1993LG65800056
J	IIJIMA, R; KURATA, S; NATORI, S				IIJIMA, R; KURATA, S; NATORI, S			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF AN ANTIFUNGAL PROTEIN FROM THE HEMOLYMPH OF SARCOPHAGA-PEREGRINA (FLESH FLY) LARVAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH POLYPEPTIDES; CELL-FREE IMMUNITY; ANTIBACTERIAL PROTEINS; MOLECULAR-CLONING; SARCOTOXIN-II; GENE-CLUSTER; BARLEY	An antifungal protein (AFP) was purified from the hemolymph of third instar larvae of Sarcophaga peregrina. This protein repressed the growth of Candida albicans in Sabouraud medium in the presence of nitrofurazone. However, in distilled water or saline, AFP alone killed C. albicans. Significant synergism was detected between AFP and sarcotoxin IA, an antibacterial protein of Sarcophaga. The lethal effect of AFP on C. albicans was greatly enhanced by the presence of a small amount of sarcotoxin IA. AFP was shown to bind to C. albicans and cause leakage of a substance(s) with absorbance at 260 nm from the cells. Analysis of its cDNA showed that AFP is a novel histidine-rich protein consisting of 67 amino acid residues.	UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ANDO K, 1987, BIOCHEMISTRY-US, V26, P226, DOI 10.1021/bi00375a030; ANDO K, 1988, BIOCHEMISTRY-US, V27, P1715, DOI 10.1021/bi00405a050; BABA K, 1987, J BIOCHEM-TOKYO, V102, P69, DOI 10.1093/oxfordjournals.jbchem.a122042; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Chadwick J.S., 1975, P241; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; ISHIKAWA M, 1992, BIOCHEM J, V287, P573, DOI 10.1042/bj2870573; KANAI A, 1989, FEBS LETT, V258, P199, DOI 10.1016/0014-5793(89)81652-7; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKAY BJ, 1984, INFECT IMMUN, V44, P688, DOI 10.1128/IAI.44.3.688-694.1984; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; Natori S., 1987, Molecular entomology. Proceedings of a Monsanto-UCLA Symposium held in Steamboat Springs, Colorado, April 6-13, 1986., P369; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; OKADA M, 1985, J BIOL CHEM, V260, P7174; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; POSTLETHWAIT JH, 1988, J INSECT PHYSIOL, V34, P91, DOI 10.1016/0022-1910(88)90159-X; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771, DOI 10.1099/00221287-136-9-1771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELESTED ME, 1985, INFECT IMMUN, V49, P202; WITHCOMB RF, 1974, PHYSL INSECTA, V5, P447	34	112	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12055	12061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505329				2022-12-25	WOS:A1993LF28400089
J	TREMETHICK, DJ; DREW, HR				TREMETHICK, DJ; DREW, HR			HIGH-MOBILITY GROUP PROTEIN-14 AND PROTEIN-17 CAN SPACE NUCLEOSOMES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-PROTEINS; CHROMATIN STRUCTURE; XENOPUS-LAEVIS; SEQUENCE; HISTONES; DNA	Recently we partially purified from Xenopus laevis ovaries a novel, ATP-dependent, spacing activity that can convert a DNA template consisting of irregularly spaced nucleosomes into a chromatin structure made up of regularly spaced nucleosomes with a repeat length of 160-165 base pairs. In a second independent step, the longer spacing of higher eukaryotic chromatin can be generated by the addition of histone H1. The partially purified spacing fraction contains several proteins that display chromatographic properties and mobilities on polyacrylamide gels similar to high mobility group (HMG) proteins. For that reason, different HMG proteins were tested for their ability to generate chromatin structures with regularly spaced nucleosomes. In this report, using two different nucleosome assembly systems, we show that the addition of phosphorylated HMGs 14 and 17 to the histone octamer results in the formation of chromatin with a repeat length of 160-165 base pairs. The results are similar to those obtained from studies of chromatin structure in simple cells, such as fungi and yeast, and in active genes.	CSIRO,DIV BIOMOLEC ENGN,MOLEC BIOL LAB,N RYDE,NSW 2113,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; COLLIS C, 1989, NUCLEIC ACIDS RES, V7, P9447; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1993, IN PRESS J MOL BIOL, V240; ESPEL E, 1987, BIOCHIM BIOPHYS ACTA, V909, P190, DOI 10.1016/0167-4781(87)90077-7; GODDE JS, 1992, J MOL BIOL, V226, P1009, DOI 10.1016/0022-2836(92)91049-U; GORDON JS, 1980, BIOCHEMISTRY-US, V19, P4395, DOI 10.1021/bi00560a003; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; RAMAKRISHNAN S, 1982, J BIOL CHEM, V257, P11448; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHICK VV, 1985, J MOL BIOL, V185, P329, DOI 10.1016/0022-2836(85)90407-3; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; VILLEPONTEAU B, 1992, BIOCHEMISTRY-US, V31, P1554, DOI 10.1021/bi00120a037	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11389	11393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496189				2022-12-25	WOS:A1993LD46600097
J	AMATRUDA, TT; GERARD, NP; GERARD, C; SIMON, MI				AMATRUDA, TT; GERARD, NP; GERARD, C; SIMON, MI			SPECIFIC INTERACTIONS OF CHEMOATTRACTANT FACTOR RECEPTORS WITH G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; NUCLEOTIDE REGULATORY PROTEIN; PLATELET-ACTIVATING FACTOR; PERTUSSIS TOXIN; HL-60 CELLS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; C5A RECEPTOR; INOSITOL TRISPHOSPHATE; HUMAN-NEUTROPHILS	Stimulation of leukocytes with chemoattractant ligands activates phospholipid turnover and calcium release, ultimately leading to chemotaxis, degranulation, and the inflammatory response. The leukocyte response to these ligands is transduced by the interaction of transmembrane receptors with GTP-binding regulatory proteins (G-proteins). To examine the mechanisms of signal transduction by these receptors, we transfected cDNA clones encoding the receptors for the active cleavage product of the fifth component of complement (C5a) and platelet-activating factor (PAF) into COS-7 cells, then measured the production of inositol phosphates (IP) in response to stimulation with these chemoattractant ligands. Cells transfected with the C5a receptor showed no increase in IP production when stimulated with ligand (5-120 nm). However, in cells co-transfected with these receptors and with the cDNA for Galpha16, a G-protein alpha subunit that is specific to cells of hematopoietic lineage, addition of ligand caused up to a 5-fold increase in IP production. This interaction was specific, as co-transfection of receptors with the G-proteins Galpha(q), or Galpha11 did not allow ligand-dependent increase in IP production. In contrast, ligand-dependent activation of IP production was seen in COS cells transfected solely with the PAF receptor. These results indicate that the C5a receptor utilizes signaling pathways distinct from the PAF receptor and suggest that a pertussis toxin-resistant G-protein, Galpha16, may play a role in the leukocyte response to inflammatory ligands.	CALTECH,DIV BIOL,PASADENA,CA 91125; CHILDRENS HOSP MED CTR,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,INA SUE PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,THORNDIKE LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	California Institute of Technology; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School					NHLBI NIH HHS [HL36162] Funding Source: Medline; NIGMS NIH HHS [GM34236] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COWEN DS, 1990, J BIOL CHEM, V265, P16181; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; GERARD C, 1993, IN PRESS ANN REV IMM; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GUTOWSKI S, 1991, J BIOL CHEM, V266, P11409; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HWANG SB, 1988, J BIOL CHEM, V263, P3225; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MURPHY PM, 1990, J IMMUNOL, V145, P2227; OMANN GM, 1991, J IMMUNOL, V146, P1303; OMANN GM, 1987, J IMMUNOL, V138, P2626; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SHIRATO M, 1988, FEBS LETT, V234, P231, DOI 10.1016/0014-5793(88)81341-3; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH CD, 1985, J BIOL CHEM, V260, P5875; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SNYDERMAN R, 1984, J CELL BIOL, V98, P444, DOI 10.1083/jcb.98.2.444; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VERGHESE MW, 1986, J IMMUNOL, V137, P271; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1992, J BIOL CHEM, V267, P1811	46	200	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10139	10144						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486684				2022-12-25	WOS:A1993LB80000032
J	MATSUMOTO, K; NAGATA, K; UI, M; HANAOKA, F				MATSUMOTO, K; NAGATA, K; UI, M; HANAOKA, F			TEMPLATE ACTIVATING FACTOR-I, A NOVEL HOST FACTOR REQUIRED TO STIMULATE THE ADENOVIRUS CORE DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PROTEINS; INFECTED-CELLS; TERMINAL PROTEIN; TYPE-4 DNA; INVITRO; TRANSCRIPTION; PURIFICATION; CHROMATIN; BINDING; INITIATION	The adenovirus (Ad) genome in virion exists in the form of the Ad core, which is a complex of Ad DNA and viral basic proteins. The Ad core supported only initiation and limited elongation in DNA replication in a cell-free system which was developed for DNA replication of naked Ad DNA. We found that addition of a cytoplasmic fraction from uninfected HeLa cells on the top of the system stimulated Ad core DNA replication, although it had no effect on DNA replication of naked Ad DNA. The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation. SDS-polyacrylamide gel electrophoresis of the purified fraction revealed the presence of proteins with molecular masses of 41 and 39 kDa. TAF-I stimulated both initiation and elongation in Ad core DNA replication. Judging from its behavior in purification steps, TAF-I could be acidic. These findings suggest that TAF-I stimulates Ad core DNA replication by interacting with viral basic core proteins.	INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOMOLEC ENGN,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	RIKEN; Tokyo Institute of Technology; University of Tokyo			Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GODING CR, 1983, EMBO J, V2, P339, DOI 10.1002/j.1460-2075.1983.tb01428.x; HARRIS MPG, 1988, J MOL BIOL, V201, P57, DOI 10.1016/0022-2836(88)90438-X; HAY RT, 1985, J MOL BIOL, V186, P129, DOI 10.1016/0022-2836(85)90263-3; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; KAPLAN LM, 1979, P NATL ACAD SCI USA, V76, P5534, DOI 10.1073/pnas.76.11.5534; KOIKEDA S, 1990, BIOCHIM BIOPHYS ACTA, V1048, P85, DOI 10.1016/0167-4781(90)90026-X; KORN R, 1986, VIROLOGY, V150, P342, DOI 10.1016/0042-6822(86)90299-0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEEGWATER PAJ, 1988, BIOCHIM BIOPHYS ACTA, V951, P403, DOI 10.1016/0167-4781(88)90113-3; LEITH IR, 1989, J GEN VIROL, V70, P3235, DOI 10.1099/0022-1317-70-12-3235; MATSUMOTO K, 1991, FEBS LETT, V280, P53, DOI 10.1016/0014-5793(91)80202-E; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANISHI Y, 1986, BIOCHEM BIOPH RES CO, V136, P86, DOI 10.1016/0006-291X(86)90880-6; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRAGE L, 1970, VIROLOGY, V42, P341, DOI 10.1016/0042-6822(70)90278-3; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; RUSSELL WC, 1971, J GEN VIROL, V11, P35, DOI 10.1099/0022-1317-11-1-35; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TEMPERLEY SM, 1991, NUCLEIC ACIDS RES, V19, P3243, DOI 10.1093/nar/19.12.3243; WEBER J, 1984, VIROLOGY, V136, P321, DOI 10.1016/0042-6822(84)90168-5; WONG ML, 1990, J VIROL, V64, P691, DOI 10.1128/JVI.64.2.691-699.1990	36	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10582	10587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486711				2022-12-25	WOS:A1993LB80000087
J	GIBSON, KR; VANEK, PG; KALOSS, WD; COLLIER, GB; CONNAUGHTON, JF; ANGELICHIO, M; LIVI, GP; FLEMING, PJ				GIBSON, KR; VANEK, PG; KALOSS, WD; COLLIER, GB; CONNAUGHTON, JF; ANGELICHIO, M; LIVI, GP; FLEMING, PJ			EXPRESSION OF DOPAMINE-BETA-HYDROXYLASE IN DROSOPHILA SCHNEIDER 2 CELLS - EVIDENCE FOR A MECHANISM OF MEMBRANE-BINDING OTHER THAN UNCLEAVED SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; CHROMAFFIN GRANULES; INSECT CELLS; MAMMALIAN-CELLS; MESSENGER-RNA; BOUND FORMS; SEQUENCE; VECTOR; CDNA; IMMUNOFLUORESCENCE	To characterize the mechanism of membrane attachment of dopamine beta-hydroxylase, an expression system producing the processed form of this enzyme has been developed. We have replaced the endogenous signal peptide of bovine dopamine beta-hydroxylase with a heterologous signal peptide which is efficiently recognized and cleaved in Drosophila Schneider 2 cells. A cDNA encoding this chimeric recombinant bovine enzyme has been stably transfected into Schneider 2 cells. The inducible expression of active dopamine beta-hydroxylase in these cells has been verified by Western blotting and enzyme activity assays. N-terminal sequence analysis of purified recombinant enzyme demonstrates complete removal of the signal peptide. Subcellular analysis shows that the recombinant enzyme exists as both a soluble and a membrane-bound form in these cells. These data demonstrate that the endogenous signal peptide is not required for the formation of the membranous dopamine beta-hydroxylase and further that the enzyme can be bound to membranes via a mechanism other than uncleaved signal sequence.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701; ONCOR INC,GAITHERSBURG,MD 20877; SMITHKLINE BEECHAM,KING OF PRUSSIA,PA 19406	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); GlaxoSmithKline			Fleming, Karen/E-7892-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27695] Funding Source: Medline; NIMH NIH HHS [MH10223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BELPAIRE F, 1968, BIOCHEM PHARMACOL, V17, P411, DOI 10.1016/0006-2952(68)90251-7; BERG DT, 1991, BIOCHEM BIOPH RES CO, V179, P1289, DOI 10.1016/0006-291X(91)91713-M; BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; BLAKEBOROUGH P, 1981, BIOCHIM BIOPHYS ACTA, V669, P33, DOI 10.1016/0005-2795(81)90220-8; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CORCORAN JJ, 1990, AM J PHYSIOL, V251, P161; CRAINE JE, 1973, J BIOL CHEM, V248, P7838; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DEPOTTER WP, 1980, TISSUE CELL, V12, P227, DOI 10.1016/0040-8166(80)90001-4; DUONG LT, 1985, J BIOL CHEM, V260, P2393; FALLON AM, 1985, TRENDS BIOTECHNOL, V3, P217, DOI 10.1016/0167-7799(85)90008-3; FENG ZH, 1992, J BIOL CHEM, V267, P21808; FRIEDMAN S, 1965, J BIOL CHEM, V240, P4763; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; HAMOS J, 1987, FASEB J, V1, P143, DOI 10.1096/fasebj.1.2.3609611; HARTMAN BK, 1973, J HISTOCHEM CYTOCHEM, V21, P312, DOI 10.1177/21.4.312; HEGNER M, 1992, J BIOL CHEM, V267, P16928; JOH TH, 1986, ANN NY ACAD SCI, V493, P343; KALVAKOLANU DVR, 1991, BIOTECHNIQUES, V10, P176; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LENGYEL J, 1975, METHOD CELL BIOL, P195; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; LJONES T, 1976, EUR J BIOCHEM, V61, P525, DOI 10.1111/j.1432-1033.1976.tb10047.x; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; NAGATSU T, 1972, CLIN CHEM, V18, P980; OKA M., 1967, LIFE SCI, V6, P461, DOI 10.1016/0024-3205(67)90048-3; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; OYARCE AM, 1991, THESIS GEORGETOWN U; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PATZAK A, 1984, J CELL BIOL, V98, P1817, DOI 10.1083/jcb.98.5.1817; PHILLIPS JH, 1983, J CELL BIOL, V97, P1906, DOI 10.1083/jcb.97.6.1906; POTTER LT, 1963, J PHARMACOL EXP THER, V142, P291; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; Schneider I, 1972, J EMBRYOL EXP MORPH, V27, P363; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; STEWART LC, 1988, J BIOL CHEM, V263, P12183; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; TAYLOR CS, 1989, J BIOL CHEM, V264, P15242; TAYLOR CS, THESIS GEORGETOWN U; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIFARO JM, 1969, MOL PHARMACOL, V5, P382; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; VIVEROS OH, 1968, LIFE SCI PT 1 PHYSI, V7, P609, DOI 10.1016/0024-3205(68)90186-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLACE EF, 1973, P NATL ACAD SCI USA, V70, P2253, DOI 10.1073/pnas.70.8.2253; WEINSHILBOUM R, 1971, CIRC RES, V28, P307, DOI 10.1161/01.RES.28.3.307; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303; Winkler H, 1982, SECRETORY GRANULE, P3; WU HJ, 1988, J NEUROCHEM, V55, P97	61	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9490	9495						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486639				2022-12-25	WOS:A1993LA68900053
J	YEH, JI; BIEMANN, HP; PANDIT, J; KOSHLAND, DE; KIM, SH				YEH, JI; BIEMANN, HP; PANDIT, J; KOSHLAND, DE; KIM, SH			THE 3-DIMENSIONAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF A WILD-TYPE BACTERIAL CHEMOTAXIS RECEPTOR - STRUCTURAL COMPARISON TO THE CROSS-LINKED MUTANT FORMS AND CONFORMATIONAL-CHANGES UPON LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE RECEPTOR; SENSORY RECEPTOR; CRYSTALLIZATION	The three-dimensional structures of the ligand-binding domain of the wild-type Salmonella typhimurium aspartate receptor have been determined in the absence (apo) and presence of bound aspartate (complex) and compared to a cross-linked mutant containing a cysteine at position 36 which does not change signaling behavior of the intact receptor. The structures of the wild-type forms were determined in order to assess the effects of cross-linking on the structure and its influence on conformational changes upon ligand binding. As in the case of the cross-linked mutant receptor, the non-cross-linked ligand-binding domain is dimeric and is composed of 4-alpha-helical bundle monomer subunits related by a crystallographic 2-fold axis in the unbound form and by a non-crystallographic axis in the aspartate-bound form. A comparative study between the non-cross-linked and cross-linked structures has led to the following observations: 1) The long N-terminal helices of the individual subunits in the cross-linked structures are bent toward each other to accommodate the disulfide bond. 2) The rest of the subunit conformation is very similar to that of the wild-type. 3) The intersubunit angle of the cross-linked apo structure is larger by about 13 degrees when compared to the wild-type apo structure. 4) The nature and magnitude of the aspartate-induced conformational changes in the non-crosslinked wild-type structures are very similar to those of the cross-linked structures.	LAWRENCE BERKELEY LAB,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; LAWRENCE BERKELEY LAB,DIV STRUCT BIOL,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	YEH, JI (corresponding author), LAWRENCE BERKELEY LAB,DEPT CHEM,BERKELEY,CA 94720, USA.			Pandit, Jayvardhan/0000-0001-6128-7779	NIAID NIH HHS [AI 30725] Funding Source: Medline; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [T32 GM08295-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; BRUNGER A, 1992, XPLOR 3 0 SYSTEM CRY; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; HUBER R, 1985, MOL REPLACEMENT, P58; JANCARIK J, 1991, J MOL BIOL, V221, P31, DOI 10.1016/0022-2836(91)80198-4; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MILLIGAN DL, 1991, THESIS U CALIFORNIA; WANG EA, 1980, P NATL ACAD SCI-BIOL, V77, P7157, DOI 10.1073/pnas.77.12.7157	13	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9787	9792						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486661				2022-12-25	WOS:A1993LA68900092
J	YU, C; BASSLER, BL; ROSEMAN, S				YU, C; BASSLER, BL; ROSEMAN, S			CHEMOTAXIS OF THE MARINE BACTERIUM VIBRIO-FURNISSII TO SUGARS - A POTENTIAL MECHANISM FOR INITIATING THE CHITIN CATABOLIC CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSE PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; TRANSPORT	Immense quantities of chitin are catabolized by marine bacteria, and this process involves at least three signal transduction systems in Vibrio furnissii. One system, chemotaxis to chitin oligosaccharides, is probably used to colonize chitin particles. But how do the first few cells find this highly insoluble polysaccharide? The following hypothesis is proposed to answer this question: the bacteria respond to soluble chemoattractants in exudates from injured organisms. Virtually all chitin-producing organisms also contain glucose and/or trehalose, often at high concentrations such as trehalose in insect hemolymph. Chemotaxis of V. furnissii was therefore studied with a variety of sugars. Fructose, ribose, and glycerol are catabolites but not attractants. The cells exhibit weak constitutive taxis to Glc and GlcNAc. After induction, they show a weak response to galactose but are strongly attracted to the following substrates of the phosphoenolpyruvate:glycose phosphotransferase system (PTS): GlcNAc, trehalose, glucose, sucrose, mannose, and mannitol. There is a rough qualitative but no quantitative correlation between the rate of phosphorylation and the chemotactic response to PTS sugars. Trehalose is especially noteworthy because it is phosphorylated at a very rapid rate by uninduced cells but is not an attractant until the cells are induced. We suggest that unidentified inducible factors link the PTS to chemotaxis.	JOHNS HOPKINS UNIV HOSP,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins Medicine	YU, C (corresponding author), JOHNS HOPKINS UNIV HOSP,MCCOLLUM PRATT INST,BALTIMORE,MD 21218, USA.			Bassler, Bonnie/0000-0002-0043-746X	NIGMS NIH HHS [5T32 GM07321, GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J BACTERIOL, V115, P824, DOI 10.1128/JB.115.3.824-847.1973; ALTMAN PL, 1971, BLOOD OTHER BODY FLU, P287; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOOS W, 1990, J BACTERIOL, V172, P3450, DOI 10.1128/jb.172.6.3450-3461.1990; Colwell R. R., 1984, VIBRIOS ENV, P367; FLORKIN M, 1970, CHEM ZOOL, P147; GACHELIN G, 1969, BIOCHEM BIOPH RES CO, V34, P382, DOI 10.1016/0006-291X(69)90392-1; GRUBL G, 1990, J BACTERIOL, V172, P5871; Jeuniaux C, 1971, COMPREHENSIVE BIOC C, V26, P595; Johnstone J., 1908, CONDITIONS LIFE SEA; KUBOTA Y, 1982, FEMS MICROBIOL LETT, V13, P5; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; POULICEK M, 1989, CHITIN CHITOSAN, P151; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; STANK J, 1965, OLIGOSACCHARIDES, P154; TRACEY M. V., 1957, REVS PURE AND APPL CHEM, V7, P1; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WOD WA, 1988, METHODS EZYMOL, V161, P403; YU C, 1991, J BIOL CHEM, V266, P24260; ZOBELL CE, 1937, J BACTERIOL, V35, P275	23	41	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9405	9409						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486635				2022-12-25	WOS:A1993LA68900041
J	HUANG, SM; MULVIHILL, ER; FARRELL, DH; CHUNG, DW; DAVIE, EW				HUANG, SM; MULVIHILL, ER; FARRELL, DH; CHUNG, DW; DAVIE, EW			BIOSYNTHESIS OF HUMAN FIBRINOGEN - SUBUNIT INTERACTIONS AND POTENTIAL INTERMEDIATES IN THE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; RECOMBINANT HUMAN FIBRINOGEN; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; ALPHA-CHAIN; BREFELDIN-A; BETA-CHAIN; PROTEINS; BINDING; CONVERSION	Stable transfected baby hamster kidney (BHK) cells expressing human alpha, beta, and gamma fibrinogen chains together, in various combinations of any two, or individually, were established. Several types of subunit interactions were observed in the intracellular extracts of the transfected BHK cell lines as well as in Hep G2 cells. These included: 1) formation of alphagamma dimers linked by a disulfide bond(s), 2) formation of betagamma dimers linked by a disulfide bond(s), 3) formation of alphabetagamma half-molecules linked by disulfide bonds, and 4) formation of mature fibrinogen, which was also secreted into the cell culture medium. Analysis of the chain composition confirmed the stoichiometry of the alphagamma, betagamma, and alphabetagamma complexes. These data are consistent with the proposal that the alphagamma and betagamma dimers as well as the alphabetagamma half-molecules are intermediates in the assembly and biosynthesis of fibrinogen. In contrast, disulfide-linked alphabeta complexes were not found in transfected BHK cells or in Hep G2 cells, suggesting that the formation of disulfide bonds between these two chains most likely occurs when alphabetagamma half-molecules are formed from alphagamma and/or betagamma complexes and when alphabetagamma half-molecules dimerize to generate the mature molecule. Dimers, trimers, and larger oligomers of each individual chain linked by disulfide bonds were also identified when each chain was expressed in the absence of the other two chains. Preferential formation of alphagamma and betagamma complexes, rather than oligomers of individual chains, suggested that the oligomers were less likely to be intermediates in the assembly of fibrinogen. A model for fibrinogen assembly is presented based on these results.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; ZYMOGENET INC, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle; Zymogenet Inc.			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; DAVIDSON JM, 1977, EUR J BIOCHEM, V81, P349, DOI 10.1111/j.1432-1033.1977.tb11958.x; Doolittle R F, 1973, Adv Protein Chem, V27, P1, DOI 10.1016/S0065-3233(08)60446-5; Doolittle R.F., 1975, PLASMA PROTEINS STRU, VII, P110; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FARRELL DH, 1992, J CELL BIOCH F, V16, P173; FARRELL DH, 1989, BLOOD, V74, P55; FORMAN WB, 1964, JAMA-J AM MED ASSOC, V187, P128; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HENSCHEN A, 1978, HOPPESEYLERS Z PHYSL, V359, P1751; HUANG S, 1992, BLOOD, V80, P263; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTSPEICH F, 1977, HOPPESEYLERS Z PHYSL, V358, P3787; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MULVILHILL E, 1988, Patent No. 339944; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1991, CELL, V64, P1183; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROY SN, 1991, J BIOL CHEM, V266, P4758; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, FIBRINOGEN FIBRIN FO, V4, P665	43	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8919	8926						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473334				2022-12-25	WOS:A1993KX81100079
J	KRAEMER, R; POMERANTZ, KB; JOSEPHSILVERSTEIN, J; HAJJAR, DP				KRAEMER, R; POMERANTZ, KB; JOSEPHSILVERSTEIN, J; HAJJAR, DP			INDUCTION OF BASIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA AND PROTEIN-SYNTHESIS IN SMOOTH-MUSCLE CELLS BY CHOLESTERYL ESTER ENRICHMENT AND 25-HYDROXYCHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; HEPARIN; MACROPHAGES; INHIBITION; RELEASE; LDL; ATHEROSCLEROSIS	Basic fibroblast growth factor (bFGF) is a potent smooth muscle cell mitogen. Smooth muscle cell and macrophage-derived foam cells, resulting from cholesteryl ester accretion, are hallmark characteristics of atherosclerosis. We wanted to determine if bFGF synthesis is altered during cholesteryl ester accumulation in smooth muscle cells. Cholesteryl ester enrichment causes a 3-fold increase in bFGF in cellular lysates and a 3-fold increase in steady state mRNA levels for bFGF, as compared with control cells. Conditioned media from cholesteryl ester-enriched smooth muscle cells contains 6 times more mitogenic activity than conditioned media from control cells; this activity is neutralized by an antibody directed against bFGF but not by an antibody directed against platelet-derived growth factor. These results suggest that cholesteryl ester enrichment also enhances bFGF release. Since oxysterols have been implicated in the pathogenesis of atherosclerosis, we determined if oxysterols could affect bFGF production and release. 25-Hydroxycholesterol also increases the release of bFGF-like mitogens from smooth muscle cells, as well as increasing mRNA transcript levels for bFGF. Cholesteryl ester enrichment and 25-hydroxycholesterol did not promote bFGF release secondary to cell injury. In conclusion, these data define a basic mechanism for smooth muscle cell hyperplasia during atherogenesis involving the generation of bFGF by smooth muscle cell-derived foam cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; ST JOHNS UNIV,DEPT BIOL SCI,JAMAICA,NY 11439	Cornell University; Cornell University; Saint John's University	KRAEMER, R (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,1300 YORK AVE,NEW YORK,NY 10021, USA.			Pomerantz, Kenneth/0000-0001-9443-5301	NHLBI NIH HHS [P01-HL-46403, T32 HL-07423, R01 HL-39701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423, R01HL039701, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ANDRADEGORDON P, 1990, P NATL ACAD SCI USA, V87, P1865, DOI 10.1073/pnas.87.5.1865; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BROOKS RA, 1991, BIOCHEM J, V276, P113, DOI 10.1042/bj2760113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FLORKIEWICZ R, 1989, P NATL ACAD SCI USA, V86, P3971; FOX PL, 1986, P NATL ACAD SCI USA, V83, P4774, DOI 10.1073/pnas.83.13.4774; FOX PL, 1987, J BIOL CHEM, V262, P6046; GOSPODAROWICZ D, 1988, EUR J CELL BIOL, V46, P144; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAJJAR DP, 1987, J BIOL CHEM, V262, P6976; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; INABA T, 1992, J BIOL CHEM, V267, P5693; JOSEPHSILVERSTEIN J, 1988, J IMMUNOL METHODS, V110, P183, DOI 10.1016/0022-1759(88)90102-0; KATSUDA S, 1992, AM J PATHOL, V140, P907; KAUL D, 1987, ATHEROSCLEROSIS, V64, P211, DOI 10.1016/0021-9150(87)90248-6; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KUSUHARA H, 1992, LIPIDS, V27, P478, DOI 10.1007/BF02536393; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARNETT LJ, 1979, ANAL BIOCHEM, V99, P458, DOI 10.1016/S0003-2697(79)80033-0; MAZZONE T, 1991, J LIPID RES, V32, P507; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; OLSON NE, 1992, AM J PATHOL, V140, P1017; PIE JE, 1992, LIPIDS, V27, P270, DOI 10.1007/BF02536474; PITAS RE, 1990, J BIOL CHEM, V265, P12722; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; POMERANTZ KB, 1990, BIOCHEMISTRY-US, V29, P1892, DOI 10.1021/bi00459a033; POMERANTZ KB, 1989, J LIPID RES, V30, P1219; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; TAKAGI K, 1989, J BIOL CHEM, V264, P12353; VLODAVSKY I, 1987, J CELL PHYSIOL, V131, P402, DOI 10.1002/jcp.1041310312; WINKLES JA, 1992, CANCER RES, V52, P1040; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; ZHANG HF, 1990, J LIPID RES, V31, P1361	47	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8040	8045						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463321				2022-12-25	WOS:A1993KW97900067
J	HOWELL, ML; ROSEMAN, NA; SLABAUGH, MB; MATHEWS, CK				HOWELL, ML; ROSEMAN, NA; SLABAUGH, MB; MATHEWS, CK			VACCINIA VIRUS RIBONUCLEOTIDE REDUCTASE - CORRELATION BETWEEN DEOXYRIBONUCLEOTIDE SUPPLY-AND-DEMAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; DNA-SYNTHESIS; KINASE GENE; CELL-CYCLE; HYDROXYUREA; EXPRESSION; SUBUNIT; LOCALIZATION; BACTERIOPHAGE-T4; FRAGMENT	Ribonucleotide reductase has been suggested as a rate-limiting enzyme in DNA synthesis, partly because activities of the enzyme in cell-free preparations are low relative to rates needed to sustain DNA replication at observed rates. Vaccinia virus, with a large duplex DNA genome, encodes both subunits of a specific ribonucleoside diphosphate reductase. In this report, we describe quantitative analysis of ribonucleotide reductase protein levels and DNA accumulation in vaccinia virus-infected cell extracts, to correlate the supply of deoxyribonucleotides with the demand for these precursors in viral DNA synthesis. To do this, we generated polyclonal antisera to TrpE fusion proteins constructed from the carboxyl termini of both subunits of viral ribonucleotide reductase. We used S1 nuclease and immunoprecipitation analysis to determine the transcriptional and translational kinetics of vaccinia virus ribonucleotide reductase expression. Enzyme activity and ribonucleotide reductase protein stability were also assayed during the time course of viral infection. Enzyme-linked immunoassays were used to quantitate protein levels, and filter hybridizations were used to measure the accumulation of viral DNA. We show that ribonucleotide reductase activity in vaccinia virus-infected cells is severalfold higher than needed to provide deoxyribonucleotides at rates commensurate with DNA synthesis. Thus, while the enzyme is important as catalyst for the first committed reaction in DNA replication, it is not rate-limiting for this process.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, AGR LIFE SCI 2011, CORVALLIS, OR 97331 USA	Oregon State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM037508, R01GM037508] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24295] Funding Source: Medline; NIGMS NIH HHS [GM07774, GM37508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKOOSH MR, 1990, TECHNIQUES FISH IMMU, P15; BERGLUND O, 1975, J BIOL CHEM, V250, P7450; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; CAIRNS J, 1960, VIROLOGY, V11, P603, DOI 10.1016/0042-6822(60)90103-3; CHILD SJ, 1990, VIROLOGY, V174, P625, DOI 10.1016/0042-6822(90)90119-C; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; DAVIS RE, 1993, P NATL ACAD SCI USA, V90, P745, DOI 10.1073/pnas.90.2.745; DAVISON AJ, 1989, J MOL BIOL, V210, P771, DOI 10.1016/0022-2836(89)90108-3; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; EARL PL, 1988, CURRENT PROTOCOLS MO; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ENGSTROM Y, 1982, ORG CHEM BIOCH, V5, P343; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HRUBY DE, 1981, J VIROL, V40, P456, DOI 10.1128/JVI.40.2.456-464.1981; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; HURTA RAR, 1991, J BIOL CHEM, V266, P24097; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; JOKLIK WK, 1964, J MOL BIOL, V10, P452, DOI 10.1016/S0022-2836(64)80066-8; JUNGWIRT.C, 1968, J VIROL, V2, P401, DOI 10.1128/JVI.2.5.401-408.1968; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KIT S, 1962, VIROLOGY, V18, P286, DOI 10.1016/0042-6822(62)90015-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS M, 1986, ARCH BIOCHEM BIOPHYS, V244, P430, DOI 10.1016/0003-9861(86)90610-7; MANN GJ, 1988, CANCER RES, V48, P5151; MARTIN R, 1990, BIOTECHNIQUES, V9, P762; MINER JN, 1989, VIROLOGY, V170, P227, DOI 10.1016/0042-6822(89)90370-X; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; OKI T, 1971, J GEN VIROL, V13, P401, DOI 10.1099/0022-1317-13-3-401; PARKHURST JR, 1973, P NATL ACAD SCI USA, V70, P3200, DOI 10.1073/pnas.70.11.3200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RIKSSON S, 1984, J BIOL CHEM, V259, P11695; ROSEMAN NA, 1987, J VIROL, V61, P1398, DOI 10.1128/JVI.61.5.1398-1406.1987; ROSEMAN NA, 1990, VIROLOGY, V178, P410, DOI 10.1016/0042-6822(90)90338-R; SCHMITT JFC, 1988, J VIROL, V62, P1889, DOI 10.1128/JVI.62.6.1889-1897.1988; SLABAUGH M, 1988, J VIROL, V62, P519, DOI 10.1128/JVI.62.2.519-527.1988; SLABAUGH MB, 1986, J VIROL, V60, P506, DOI 10.1128/JVI.60.2.506-514.1986; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P7581, DOI 10.1093/nar/17.19.7581; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TENGELSON LA, 1988, VIROLOGY, V164, P7426; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1985, J BIOL CHEM, V260, P2737; TRAKTMAN P, 1984, J VIROL, V49, P125, DOI 10.1128/JVI.49.1.125-131.1984; WEINRICH SL, 1985, J VIROL, V55, P450, DOI 10.1128/JVI.55.2.450-457.1985	53	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7155	7162						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463252				2022-12-25	WOS:A1993KV14100053
J	MARUTA, S; HENRY, GD; SYKES, BD; IKEBE, M				MARUTA, S; HENRY, GD; SYKES, BD; IKEBE, M			FORMATION OF THE STABLE MYOSIN-ADP-ALUMINUM FLUORIDE AND MYOSIN-ADP-BERYLLIUM FLUORIDE COMPLEXES AND THEIR ANALYSIS USING F-19 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; GAMMA-PHOSPHATE; STRUCTURAL ANALOGS; BINDING-SITE; HEAVY-CHAIN; ACTIVE-SITE; F-ACTIN; INHIBITION; VANADATE; ATPASE	The effects of aluminum fluoride and beryllium fluoride on smooth muscle myosin and its subfragments were studied. Mg2+-ATPase activity was inhibited in the presence of aluminum fluoride (beryllium fluoride). [H-3]ADP bound to heavy meromyosin (HMM) in the presence of aluminum fluoride (beryllium fluoride) and was not dissociated after 3 days of dialysis demonstrating that [H-3]ADP was trapped in HMM. These results suggest the formation of a stable HMM-ADP-fluoroaluminate (fluoroberyllate) complex. The intrinsic tryptophane fluorescence intensity was increased in the presence of ADP and aluminum fluoride (beryllium fluoride). Acto-S1 was dissociated upon the formation of S1-ADP-fluoroberyllate and actin destabilized S1-ADP-fluoroberyllate complex, while S1-ADP-fluoroaluminate failed to bind to actin. Furthermore, when S1 formed the complex with actin, nucleotide trapping did not occur in the presence of fluoroaluminate. These results indicated that the myosin-ADP-fluoroberyllate complex resembles a weak binding state while myosin-ADP-fluoroaluminate complex is a distinct conformation although the binding to actin was also weak. The structure of the ternary complex was investigated using F-19 NMR. The F-19 NMR spectrum of the S1-ADP-fluoroaluminate complex showed a peak at -66.7 ppm which is due to the binding of fluoroaluminate to S1. The peak was not observed when 5'-adenylylimidodiphosphate was substituted for ADP suggesting that aluminum fluoride plays a role as a phosphate analogue. The stoichiometry of the bound fluoride was determined to be 3.8 mol/mol S1 suggesting that the bound species is AlF4-.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA	Case Western Reserve University; University of Alberta					NIAMS NIH HHS [AR41653, R01-AR38888] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038888, R01AR041653] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI DR, 1992, BIOCHEMISTRY-US, V31, P8043, DOI 10.1021/bi00149a039; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CARLIER MF, 1989, BIOCHEMISTRY-US, V28, P1783, DOI 10.1021/bi00430a054; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DUPUIS A, 1989, FEBS LETT, V255, P47, DOI 10.1016/0014-5793(89)81058-0; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; GARABEDIAN TE, 1990, J BIOL CHEM, V265, P22547; GOLDSTEIN G, 1964, ANAL CHEM, V36, P243, DOI 10.1021/ac60207a074; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HIGASHIHARA M, 1990, FEBS LETT, V263, P224; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HOGBEN MG, 1970, CAN J CHEMISTRY, V48, P2960, DOI 10.1139/v70-500; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JACKSON GE, 1988, INORG CHIM A-BIOINOR, V151, P273, DOI 10.1016/S0020-1693(00)90812-0; KERWIN B, 1992, BIOPHYS J, V61, P143; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MACDONALD TL, 1988, TRENDS BIOCHEM SCI, V13, P15, DOI 10.1016/0968-0004(88)90012-6; MAHMOOD R, 1984, J BIOL CHEM, V259, P2956; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MARUTA S, 1991, BIOPHYS J, V59, P436; MISSIAEN L, 1988, BIOCHEM J, V253, P827, DOI 10.1042/bj2530827; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PHAN B, 1992, BIOCHEMISTRY-US, V31, P4787, DOI 10.1021/bi00135a007; ROBINSON JD, 1986, J BIOENERG BIOMEMBR, V18, P521, DOI 10.1007/BF00743148; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Youngburg GE, 1930, J LAB CLIN MED, V16, P158	40	87	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7093	7100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463244				2022-12-25	WOS:A1993KV14100044
J	LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG				LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG			REQUIREMENT OF AN ETS-BINDING ELEMENT FOR TRANSCRIPTION OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; RECEPTOR ALPHA-GENE; HUMAN LYMPHOCYTES-T; LYMPHOMA CELL-LINE; NUCLEAR FACTOR-I; C-FOS; EXPRESSION; ACTIVATION; SEQUENCE; ENHANCER	The requirement for cis-acting DNA sequences for transcriptional activity of the human lck type I promoter was investigated in two human cell lines that express type I transcripts, the leukemic T-cell line, Jurkat, and the colon carcinoma line, SW620. Transient transfection assays in Jurkat and SW620 cells revealed negative and positive cis-acting regulatory elements in the lck type I promoter between -570 and -480 and between -128 and -63 respectively. For the latter, a triple point mutation of a sequence, GCAGGAAGT, from -99 and -91, resulted in complete loss of lck type I promoter activity in both Jurkat and SW620 cells. In vitro binding assays indicated that this sequence, denoted the ETS-binding element or EBE, can interact with the lymphoid-specific transcription factor ETS-1. Thus, a protein(s) in the ETS family appears to be required for transcription of the lck type I promoter in T cells and may be important for the activation of the lck gene in human colon carcinoma.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; INST CURIE,BIOL SECT,CNRS,UNITE 1443,F-91405 ORSAY,FRANCE; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GORMAN C, 1985, DNA CLONING, V2, P152; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GUNTHER CV, 1990, GENE DEV, V4, P67; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOGA Y, 1989, J IMMUNOL, V142, P4493; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEUNG S, 1992, THESIS U TORONTO; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SACCHI N, 1988, LEUKEMIA, V2, P12; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	56	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455950				2022-12-25	WOS:A1993KT22000022
J	BHASKER, CR; BURGIEL, G; NEUPERT, B; EMERYGOODMAN, A; KUHN, LC; MAY, BK				BHASKER, CR; BURGIEL, G; NEUPERT, B; EMERYGOODMAN, A; KUHN, LC; MAY, BK			THE PUTATIVE IRON-RESPONSIVE ELEMENT IN THE HUMAN ERYTHROID 5-AMINOLEVULINATE SYNTHASE MESSENGER-RNA MEDIATES TRANSLATIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; UNTRANSLATED REGION; AFFINITY PURIFICATION; REGULATORY REGION; RABBIT LIVER; FERRITIN; SEQUENCE; IDENTIFICATION; REPRESSION; EXPRESSION	The 52-nucleotide 5'-untranslated region of the human erythroid 5-aminolevulinate synthase mRNA contains a 28-nucleotide iron-responsive element-like stem-loop motif. We fused the 5'-untranslated region upstream to the coding sequence of the human growth hormone cDNA. A chimeric construct containing a mutated variant of the presumptive iron-responsive element was similarly synthesized. Translation of the wild type chimeric transcript was markedly repressed (approximately 95%) in rabbit reticulocyte lysates as opposed to the mutant. Both transcripts translated with comparable efficiency in wheat germ extracts. Purified placental iron regulatory factor selectively and markedly inhibited translation of the wild type chimeric transcript (>90%) when tested in wheat germ extracts. By contrast, translations of either the mutant chimeric transcript or other control mRNA species were unaffected. The proximal position of the iron-responsive element relative to the cap site was shown to be important for translational control, in vitro. Our studies suggest that interaction of the iron regulatory factor with the iron-responsive element sterically hinders formation of the preinitiation complex, resulting in translational repression. Thus inactivation of the repressor protein by critical levels of iron or heme would trigger translation of this mRNA in erythroid cells. Consequently, protoporphyrin and heme synthesis would be subtly coordinated with iron supply.	SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	BHASKER, CR (corresponding author), UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5001,AUSTRALIA.							AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BAWDEN MJ, 1987, NUCLEIC ACIDS RES, V15, P8563, DOI 10.1093/nar/15.20.8563; BOTTOMLEY SS, 1988, SEMIN HEMATOL, V25, P282; BROWN PH, 1989, J BIOL CHEM, V264, P13383; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAY BK, 1990, MOL BIOL MED, V7, P405; MOSKAITIS JE, 1990, NUCLEIC ACIDS RES, V18, P2184, DOI 10.1093/nar/18.8.2184; MULLER JP, 1991, DNA CELL BIOL, V10, P571, DOI 10.1089/dna.1991.10.571; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WANG YH, 1990, NUCLEIC ACIDS RES, V18, P4463, DOI 10.1093/nar/18.15.4463; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	91	92	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12699	12705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509404				2022-12-25	WOS:A1993LG65800070
J	CARROLL, MA; BALAZY, M; MARGIOTTA, P; FALCK, JR; MCGIFF, JC				CARROLL, MA; BALAZY, M; MARGIOTTA, P; FALCK, JR; MCGIFF, JC			RENAL VASODILATOR ACTIVITY OF 5,6-EPOXYEICOSATRIENOIC ACID DEPENDS UPON CONVERSION BY CYCLOOXYGENASE AND RELEASE OF PROSTAGLANDINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAM SEMINAL-VESICLES; ARACHIDONIC-ACID; METABOLITES; CELLS; MECHANISM	The 5,6-epoxyeicosatrienoic acid (5,6-EET), a renal vasodilator metabolite of arachidonic acid via cytochrome P450 (P450) requires cyclooxygenase for expression of its vasoactivity as the responses are inhibited by indomethacin and other aspirin-like drugs. We now report on the metabolism of 5,6-EET by rabbit kidneys in order to characterize those metabolites that may account for its vasoactivity. The 5,6-EET was injected close-arterially into the rabbit isolated Krebs-Henseleit perfused kidney, preconstricted with phenylephrine, and the effluent collected throughout the response period. Basal collections, following injection of 100 mul of vehicle, were made at 20-min intervals before each 5,6-EET injection. Prior to acidic extraction, deuterated 6-keto-prostaglandin (PG) F1alpha and PGE2 were added as internal standards. The extracts were separated by TLC and prostaglandins were derivatized for gas chromatography-mass spectrometry analysis using a negative ion chemical ionization mode. Injection of 0.5, 1, 5, 10, and 20 mug of 5,6-EET (n = 4) resulted in dose-related decreases in perfusion pressure of 6 +/- 2, 12 +/- 4, 21 +/- 4, 26 +/- 4, and 27 +/- 7 mm g, respectively. Basal perfusates contained 6-keto-PGF1alpha and PGE2, levels of which were increased by 2-fold or more by 5,6-EET. Perfusates, collected during 5,6-EET administration, also contained 5-hydroxy-PGI1 and 5,6-epoxy-PGE1, cyclooxygenase metabolites of 5,6-EET. This is the first report of the recovery and identification of these 5,6-EET metabolites from an intact organ. Since the responses to 5,6-EET are endothelial-dependent, we also studied the profile of eicosanoids formed following incubation of 5,6-EET with cultured bovine pulmonary endothelial cells. Endothelial cells metabolized 5,6-EET to products with a similar radioactive profile on reverse-phase high pressure liquid chromatography compared to kidney perfusates. We compared the vasodilator activity of 5,6-epoxy-PGE1 and 5-hydroxy-PGI1, chemically synthesized by us from PGE2 and PGF2alpha, respectively, with PGE2 and PGI2 in the rabbit kidney. The 5,6-epoxy-PGE1 was equipotent to PGE2 as a vasodilator. The ED50 values for 5,6-EET, 5,6-epoxy-PGE1, and PGE2 were 4.69, 0.43, and 0.42 nmol, respectively. Although PGI2 was a potent vasodilator (ED50, 0.24 nmol), 5-hydroxy-PGI1 was devoid of activity. Thus, the cyclooxygenase-dependent vasoactivity of 5,6-EET in the rabbit kidney has two components: release of vasodilator prostaglandins, PGE2 and PGI2, and metabolism of 5,6-EET to a prostaglandin analog, 5,6-epoxy-PGE1.	UNIV TEXAS, HLTH SCI CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas	CARROLL, MA (corresponding author), NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA.			Falck, John/0000-0002-9219-7845; Balazy, Ph.D., Michael/0000-0003-0218-8820	NHLBI NIH HHS [HL25394, HL34300] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, R37HL025394, P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAZY M, 1991, J BIOL CHEM, V266, P23561; BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; CAPDEVILA JH, 1992, 8TH INT C PROST REL, P5; CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; CARROLL MA, 1990, CIRC RES, V67, P1082, DOI 10.1161/01.RES.67.5.1082; COREY EJ, 1979, J AM CHEM SOC, V101, P1586, DOI 10.1021/ja00500a035; DOUGLAS JG, 1990, KIDNEY INT, V38, pS43; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; FULTON D, 1993, IN PRESS J AM SOC MA; KARARA A, 1991, J BIOL CHEM, V266, P7561; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; MURRAY RW, 1985, J ORG CHEM, V50, P2847, DOI 10.1021/jo00216a007; OLIW EH, 1984, J BIOL CHEM, V259, P2716; OLIW EH, 1984, FEBS LETT, V172, P279, DOI 10.1016/0014-5793(84)81141-2; OLIW EH, 1984, BIOCHIM BIOPHYS ACTA, V793, P408, DOI 10.1016/0005-2760(84)90256-X; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; Terragno N A, 1978, Clin Sci Mol Med Suppl, V4, p199s; VENTON D, 1990, METHOD ENZYMOL, V187, P245; WONG PYK, 1982, J PHARMACOL EXP THER, V223, P757; ZHANG JY, 1992, BIOCHEM BIOPH RES CO, V183, P138, DOI 10.1016/0006-291X(92)91619-2; ZUSMAN RM, 1977, J BIOL CHEM, V252, P2069	25	105	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12260	12266						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509363				2022-12-25	WOS:A1993LG65800009
J	HOCHMAN, Y; CARMELI, S; CARMELI, C				HOCHMAN, Y; CARMELI, S; CARMELI, C			VANADATE, A TRANSITION-STATE INHIBITOR OF CHLOROPLAST CF(1)-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; HEART MITOCHONDRIAL ATPASE; NUCLEOTIDE-BINDING-SITES; ADENOSINE-TRIPHOSPHATASE; H+-ATPASE; MECHANISM; HYDROLYSIS; CATALYSIS; SYNTHASE; ADP	The activity of CF1-ATPase was inhibited by vanadate in an allosteric manner with respect to CaATP as substrate. The cooperative interaction was enhanced by preincubation of the enzyme in the presence of ADP and Ca2+ ions and of free divalent metal ions during assay of the activity. The strongest cooperative interaction with a Hill coefficient of 5.3 +/- 0.1 was found when the reaction was stopped after 30 s, before steady state was reached. Under these conditions, the concentration of an exchangeable ADP, tightly bound to one of the active sites on the enzyme, was shown to be the highest. A K(i) of 12.4 +/- 1.2 muM for vanadate inhibition was determined under these conditions. Direct measurements with the aid of V-51 NMR indicated that vanadate binds to CF1 in the presence of Ca2+ and ADP in a positive cooperative manner with a Hill coefficient of 2.3 +/- 0.2 and an average K(d) of 0.3 +/- 0.04 nM. It was suggested that a formation of pentacovalent vanadyl-ADP at the active site caused the inhibition. Vanadyl-ADP was suggested to be a strong inhibitor, being an analogue of a pentacovalent phosphoryl-ADP, which is proposed to be the transition state intermediate of CF1.	TEL AVIV UNIV,DEPT CHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University	HOCHMAN, Y (corresponding author), TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL.		Carmeli, shmuel/N-1273-2018	Carmeli, shmuel/0000-0002-9641-9943				ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; ANTON GE, 1983, BIOCH BIPHYS ACTA, V723, P358; BINDER A, 1978, J BIOL CHEM, V253, P3094; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BOWMAN BJ, 1978, BIOCHIM BIOPHYS ACTA, V512, P13, DOI 10.1016/0005-2736(78)90214-6; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; BRUIST MF, 1982, BIOCHEMISTRY-US, V21, P3370, DOI 10.1021/bi00257a019; CARMELI C, 1981, BIOCHEMISTRY-US, V20, P3940, DOI 10.1021/bi00516a042; CARMELI C, 1992, FEBS LETT, V299, P227, DOI 10.1016/0014-5793(92)80120-6; CARMELI C, 1972, BIOCHIM BIOPHYS ACTA, V267, P86, DOI 10.1016/0005-2728(72)90140-5; CARMELI C, 1986, J BIOL CHEM, V261, P1669; CARMELI C, 1989, PHYSIOL PLANTARUM, V76, P858; CRANS DC, 1990, J AM CHEM SOC, V112, P427, DOI 10.1021/ja00157a063; DEMASTER EG, 1973, BIOCHEMISTRY-US, V12, P3616, DOI 10.1021/bi00743a007; FARRON F, 1970, BIOCHEMISTRY-US, V9, P3829, DOI 10.1021/bi00821a024; FELDMAN RI, 1982, J BIOL CHEM, V257, P1676; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1020, P187, DOI 10.1016/0005-2728(90)90050-E; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Gresser MJ, 1990, VANADIUM BIOL SYSTEM, P63; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HILLER R, 1985, J BIOL CHEM, V260, P1614; LECKBAND D, 1978, BIOCHEMISTRY-US, V26, P2306; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; MCCARTY RE, 1982, PHOTOSYNTHESIS ENERG, V1, P647; MORONEY JV, 1983, FEBS LETT, V158, P58, DOI 10.1016/0014-5793(83)80676-0; NELSON N, 1972, J BIOL CHEM, V247, P6506; SCHREIER AA, 1974, J MOL BIOL, V86, P601, DOI 10.1016/0022-2836(74)90183-1; SMITH LT, 1983, J BIOL CHEM, V258, P887; STROOP SD, 1985, BIOCHEMISTRY-US, V24, P2304, DOI 10.1021/bi00330a027; WALAAS E, 1958, ACTA CHEM SCAND, V12, P528, DOI 10.3891/acta.chem.scand.12-0528; WEBB MR, 1980, J BIOL CHEM, V255, P1637; ZHIXONG X, 1987, BIOCHEMISTRY-US, V26, P3749; ZHOU JM, 1992, BIOCHEMISTRY-US, V31, P3166, DOI 10.1021/bi00127a017	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12373	12379						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509376				2022-12-25	WOS:A1993LG65800026
J	PALMER, M; WELLER, U; MESSNER, M; BHAKDI, S				PALMER, M; WELLER, U; MESSNER, M; BHAKDI, S			ALTERED PORE-FORMING PROPERTIES OF PROTEOLYTICALLY NICKED STAPHYLOCOCCAL ALPHA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PORES; MEMBRANE DAMAGE; AUREUS; MECHANISM; FRAGMENT; BINDING; CELLS	Staphylococcal alpha-toxin is a single-chain polypeptide with a molecular weight of 34,000 that hexamerizes in lipid bilayers to form pores of 1-1.5 nm effective diameter in membranes. We demonstrate that limited proteolysis of purified alpha-toxin with proteinase K generates a hemolytically active product that yields one major protein band of 17-18 kDa in SDS-polyacrylamide gel electrophoresis. The 17-18-kDa protein band harbors two major fragments of similar size representing the N- and C-terminal halves, which remain associated with each other in non-denaturing buffers but dissociate in 6 M urea. Dissociation in urea leads to loss of hemolytic activity. In contrast, unnicked alpha-toxin is not inactivated by urea. Nicked, hemolytically active alpha-toxin forms hexamers on erythrocyte membranes and on lymphocytes and monocytes. However, the nicked toxin can only lyse erythrocytes and fails to permeabilize nucleated cells. Osmotic protection experiments indicate that the size of pores generated by the nicked toxin is considerably smaller (0.6-0.9 nm effective diameter) than that generated by native toxin. The collective results do not support a previous proposal that different functions of alpha-toxin are contained in separate domains of the molecule.	UNIV MAINZ,INST MED MICROBIOL,AUGUSTUSPL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz								BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BLOMQVIST L, 1987, FEBS LETT, V211, P127, DOI 10.1016/0014-5793(87)81422-9; BLOMQVIST L, 1986, ACTA PATH MICRO IM B, V94, P277; BLOMQVIST L, 1987, INFECT IMMUN, V55, P1906, DOI 10.1128/IAI.55.8.1906-1913.1987; BLOMQVIST L, 1988, MICROB PATHOGENESIS, V4, P223, DOI 10.1016/0882-4010(88)90072-1; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; PALMER M, 1993, J BIOL CHEM, V268, P11959; THELESTAM M, 1975, INFECT IMMUN, V12, P225, DOI 10.1128/IAI.12.2.225-232.1975; THELESTAM M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P245, DOI 10.1016/0005-2736(91)90399-S; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017	18	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11963	11967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505321				2022-12-25	WOS:A1993LF28400076
J	SHIPLEY, JM; GRUBB, JH; SLY, WS				SHIPLEY, JM; GRUBB, JH; SLY, WS			THE ROLE OF GLYCOSYLATION AND PHOSPHORYLATION IN THE EXPRESSION OF ACTIVE HUMAN BETA-GLUCURONIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYL PHOSPHODIESTERASE; LYSOSOMAL-ENZYME; DEFICIENCY MUCOPOLYSACCHARIDOSIS; PARTIAL-PURIFICATION; PROTEIN; LIVER; BIOSYNTHESIS; RECOGNITION; CELLS; N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE	Phosphorylation of mannose residues on N-linked oligosaccharide side chains of lysosomal enzymes targets them to lysosomes. We used site-directed mutagenesis to observe the effect of eliminating selective glycosylation sites from human beta-glucuronidase on enzyme sorting. Expression studies allowed us to determine which of four potential sites were glycosylated, preferentially phosphorylated, and required for catalytic activity. All four sites of the human enzyme were glycosylated, whereas in the mouse and rat enzymes, only three of four sites are used. Sites 2 and 3 were preferentially phosphorylated. Elimination of sites 2 and 3 in combination markedly decreased sorting to lysosomes and increased enzyme secretion. Each of the four glycosylation sites could be eliminated individually without drastic reduction in catalytic activity. Activity was progressively lost as combinations of two, three, and four sites were eliminated. Wild-type enzyme produced in the presence of tunicamycin was also inactive, indicating that glycosylation is required for realization of enzyme activity. However, active enzyme could be deglycosylated with only minimal loss of activity. Mutant enzyme completely lacking glycosylation did not form tetramers. Partial restoration of tetramerization was achieved by the co-expression of normal rat enzyme, provided that the normal rat enzyme supplied at least two subunits to the tetramer.	ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034182, R01GM034182] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM34182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BROT FE, 1978, BIOCHEMISTRY-US, V17, P385, DOI 10.1021/bi00596a001; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GLASER JH, 1973, J LAB CLIN MED, V82, P969; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; HALL CW, 1973, ARCH BIOCHEM BIOPHYS, V155, P32, DOI 10.1016/S0003-9861(73)80006-2; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYLE JW, 1992, GUS PROTOCOLS USING, P189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LEARNED RM, 1981, INITIATION DNA REPLI, P555; LUSIS AJ, 1976, J BIOL CHEM, V251, P7753; ONO M, 1988, J BIOL CHEM, V263, P5884; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; POWELL PP, 1988, BIOCHEM J, V250, P547, DOI 10.1042/bj2500547; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; VARKI A, 1981, J BIOL CHEM, V256, P9937; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; WEITZ G, 1992, J BIOL CHEM, V267, P10039	30	80	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12193	12198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505339				2022-12-25	WOS:A1993LF28400107
J	VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB				VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB			GLYCOPROTEIN-BIOSYNTHESIS IN THE ALG3 SACCHAROMYCES-CEREVISIAE MUTANT .1. ROLE OF GLUCOSE IN THE INITIAL GLYCOSYLATION OF INVERTASE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; LIPID-LINKED OLIGOSACCHARIDE; YEAST EXTERNAL INVERTASE; PROTEIN GLYCOSYLATION; CORE OLIGOSACCHARIDES; GLUCOSYLATION STEPS; 500 MHZ; PATHWAY; IDENTIFICATION; MICROSOMES	Oligosaccharides on invertase restricted to the endoplasmic reticulum (ER) in alg3,sec18 yeast at 37-degrees-C were found to be 20% wild type Man8GlcNAc and 80% Man1alpha-->2Man1alpha-->2Man1alpha-->3(Man1alpha-->6)Man1beta-->4GlcNAc2 (Verostek, M. F., Atkinson, P. H., and Trimble, R. B. (1991) J. Biol. Chem. 266, 5547-5551). These results suggested that alg3 was slightly leaky, but did not address whether the oligosaccharide-lipid Man9GlcNAC2 and Man5GlcNAC2 precursors were glucosylated in alg3 yeast. Therefore, an alg3,sec18,gls1 strain was constructed to delete the GLS1-encoded glucosidase I responsible for trimming the terminal alpha1,2-linked glucose from newly transferred Glc3ManxGlcNAC2 oligosaccharides. Invertase activity was overexpressed 5-10-fold on transforming this strain with a multicopy plasmid (pRB58) carrying the SUC2 gene, and preparative amounts of the ER form of external invertase, derepressed and accumulated at 37-degrees-C, were purified. The N-linked glycans were released by sequential treatment with endo-beta-N-acetylglucosaminidase H (endo H) and peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase. Oligosaccharide pools were sized separately on Bio-Gel P-4, which showed that endo H released about 17% of the carbohydrate as Glc3Man8GlcNAc, while peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase released the remainder as Hex8GlcNAC2 and Man5GlcNAc2 in a 1:4 ratio. Glycan structures were assigned by 500-MHz two-dimensional DQF-COSY H-1 NMR spectroscopy, which revealed that the endo H-resistant Hex8GlcNAc2 pool contained Glc3Man5GlcNAc2 and Man8GlcNAc2 in a 6:4 ratio, the latter a different isomer from that formed by the ER alpha1,2-mannosidase (Byrd, J. C., Tarentino, A. L., Maley, F., Atkinson, P. H., and Trimble, R. B. (1982) J. Biol. Chem. 257, 14657-14666). Recovery of Glc3Man8GlcNAc and not the ER form of Man8GlcNAc provided an internal control indicating the absence of glucosidase I, which was confirmed by incubation of [H-3]Glc3[C-14]Man9GlcNAc with solubilized membranes from either alg3,sec18,gls1 or alg3,sec18,GLS1 strains. Chromatographic analysis of the products showed that [H03]Glc was removed only in the presence of the GLS1 gene product. Thus, the vast majority of the N-linked glycosylation in the ER of alg3 yeast (>75%) occurs by transfer of Man5GlcNAc2 without prior addition of the 3 glucoses normally found on the lipid-linked precursor.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES E524, POB 509, ALBANY, NY 12201 USA; SUNY, SCH PUBL HLTH, ALBANY, NY 12201 USA; MINIST AGR & FISHERIES TECHNOL, UPPER HUTT, NEW ZEALAND	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; SUNY Maritime College					NATIONAL CANCER INSTITUTE [R01CA013402, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NCI NIH HHS [CA13402, CA13330] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; ALVARADO E, 1991, BIOCHEMISTRY-US, V30, P881, DOI 10.1021/bi00218a001; BALLOU L, 1986, P NATL ACAD SCI USA, V83, P3081, DOI 10.1073/pnas.83.10.3081; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; CECCARINI C, 1984, J MOL BIOL, V176, P161, DOI 10.1016/0022-2836(84)90387-5; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHAPMAN A, 1979, J BIOL CHEM, V254, P243; CHU FK, 1978, J BIOL CHEM, V253, P8691; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESMON B, 1984, J BIOL CHEM, V259, P322; Goldstein A, 1975, Methods Enzymol, V42, P504; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KURANDA MJ, 1987, P NATL ACAD SCI USA, V84, P2585, DOI 10.1073/pnas.84.9.2585; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1978, BIOCHIM BIOPHYS ACTA, V539, P218, DOI 10.1016/0304-4165(78)90008-9; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Maurer P H, 1980, Methods Enzymol, V70, P49; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; RAY MK, 1991, J BIOL CHEM, V266, P22818; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VANHALBEEK H, 1980, FEBS LETT, V121, P71; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WANG HY, 1977, BIOTECHNOL BIOENG, V19, P69, DOI 10.1002/bit.260190107; WILLIAMS RS, 1985, J BIOL CHEM, V260, P3334; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	48	50	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12095	12103						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505333				2022-12-25	WOS:A1993LF28400095
J	XIAO, H; DONG, ZM; ODONNELL, M				XIAO, H; DONG, ZM; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .4. CHARACTERIZATION OF CHI AND PSI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; PRIMED TEMPLATE; HOLOENZYME; TAU; MECHANISM; COMPLEX	The gamma complex (gammadeltadelta'chipsi) subassembly of the Escherichia coli replicase initiates processive replication upon assembling the ring-shaped beta subunit around DNA. The beta ring acts as a clamp to hold the replicase down to DNA for highly processive synthesis. In this report we characterize the chi and psi subunits of the gamma complex. Both chi and psi are monomeric, and they associate to form a 1:1 complex. The chi subunit does not form a complex with gamma, but psi binds gamma tightly thereby acting as a bridge to assimilate chi into the gamma complex structure. The psi subunit stimulated the ATPase and replication activities of gamma. The chi subunit only stimulated the activities of gamma when the psi subunit was also present thus reflecting the structure where psi bridges the interaction of chi with gamma.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P176; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1970, HDB BIOCHEMISTRY, pC1; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1993, J BIOL CHEM, V268, P11773	25	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11779	11784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505305				2022-12-25	WOS:A1993LF28400049
J	HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA				HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA			QUANTIFICATION OF P53 PROTEIN IN TUMOR-CELL LINES, BREAST-TISSUE EXTRACTS AND SERUM WITH TIME-RESOLVED IMMUNOFLUOROMETRY	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; PROGNOSTIC FACTORS; SUPPRESSOR GENE; CANCER; MUTATIONS; FREQUENT; EXPRESSION; ANTIBODIES	We have developed a highly sensitive time-resolved immunofluorometric procedure for quantifying mutant or wild-type, human or murine, p53 protein. The method uses monoclonal PAb240 or PAb421 antibodies for capture and a polyclonal rabbit antibody for detection. The final immunocomplex is quantified with an alkaline phosphatase substrate which, when hydrolyzed by the enzyme, forms highly fluorescent long-lived complexes with Tb3+-EDTA. The detection limit is approximately 1 pg of protein per assay. The assay was applied for the quantification of p53 protein in lysates from 23 cell lines and overproducers of mutant protein were identified. Eight hundred cancer patients sera tested negative for the presence of p53. We have also applied the quantitative immunofluorometric procedure for measuring mutant p53 protein in breast tumor extracts specifically prepared for steroid hormone receptor analysis. Sixty-four out of the 264 extracts (24%) were positive for p53. Significant negative correlations between levels of p53 and steroid hormone receptors were found. The proposed analytical methodology simplifies the assessment of p53 status in tumor extracts, has many advantages over immunohistochemical techniques and is proposed as a method of choice for routine clinical use and other investigations involving p53.	TORONTO HOSP,TORONTO WESTERN DIV,DIV CLIN BIOCHEM,399 BATHURST ST,TORONTO M5T 258,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK MED CTR,TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Diamandis, Eleftherios/0000-0002-1589-820X				BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CHRISTOPOULOS TK, 1992, ANAL CHEM, V64, P342, DOI 10.1021/ac00028a004; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAVES RF, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENDERSON IC, 1991, BREAST DISEASES, P332; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOENDERS PG, 1991, CANCER RES, V51, P4544; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1990, SCIENCE, V250, P233; MIDGLEY CA, 1992, IN PRESS J CELL SCI; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MURAKAMI Y, 1991, CANCER RES, V51, P3356; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SINGERLAND J M, 1991, Blood, V77, P1500; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAMURA G, 1991, CANCER RES, V51, P3056; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WINFORDTHOMAS D, 1992, J PATHOL, V166, P329; WINTER SF, 1992, CANCER RES, V52, P4168	49	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502476				2022-12-25	WOS:A1993LE06400013
J	FORGE, V; MINTZ, E; GUILLAIN, F				FORGE, V; MINTZ, E; GUILLAIN, F			CA2+ BINDING TO SARCOPLASMIC-RETICULUM ATPASE REVISITED .1. MECHANISM OF AFFINITY AND COOPERATIVITY MODULATION BY H+ AND MG2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; CALCIUM-BINDING; CONFORMATIONAL TRANSITION; INORGANIC-PHOSPHATE; CA2+-TRANSPORTING ATPASE; DIRECT FLUORESCENCE; TRANSPORT SITE; STOPPED FLOW; PHOSPHORYLATION; MAGNESIUM	H+ and Mg2+ are known to inhibit Ca2+ binding to the transport sites of sarcoplasmic reticulum-ATPase. Evaluation of the affinity for the Ca2+ binding sites requires measurement of the amount of Ca2+ bound to ATPase as a function of the free Ca2+ concentration imposed by a Ca2+ chelator. The choice of the chelator is crucial as it determines the accuracy of the free Ca2+ concentration. At pH > 7, the EGTA affinity for Ca2+ is higher than that of ATPase, inducing artifacts that alter the shape of the binding curves. Thus, we have used 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), whose affinity is unchanged at pH greater-than-or-equal-to 7. Ca2+ binding was studied at equilibrium, from pH 6 to pH 8 and from 0 to 10 mM Mg2+, using EGTA and/or BAPTA and [Ca-45]Ca2+. Under all conditions, the stoichiometry was 2 Ca2+/ATPase. At variance with previous studies, the Hill coefficient was 1.1-2 and higher at pH 6 than at pH 8. In addition, it decreased in the presence of Mg2+. The Ca2+ binding curves were analyzed according to a model in which they result from a sequential binding of two Ca2+, each binding step being modified by H+ and Mg2+. The effect of H+ is described by two steps involving two H+ and one H+, with pK 7 and 7.9, respectively. At pH 6, ATPase must lose two H+ for the first Ca2+ to bind and a third H+ for the second Ca2+ to bind. At pH 9, both Ca2+ bind without any H+ exchange. Mg2+ can bind to all species, except to that saturated with Ca2+. The species having lost two H+ has a higher affinity for Mg2+ (less-than-or-equal-to mM) than the species having bound three H+ (4 mM). The above model allows us to analyze the effects of H+ and Mg2+ at each Ca2+ binding step and to explain the changes in the apparent affinity and cooperativity.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	FORGE, V (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE.							BISHOP JE, 1988, J BIOL CHEM, V263, P1886; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FORGE V, 1993, J BIOL CHEM, V268, P10961; FROUD RJ, 1986, BIOCHEM J, V237, P197, DOI 10.1042/bj2370197; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GIRARDET JL, 1992, FEBS LETT, V296, P103, DOI 10.1016/0014-5793(92)80413-B; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; HENAO F, 1992, J BIOL CHEM, V267, P10302; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P3978, DOI 10.1073/pnas.79.13.3978; HOLGUIN JA, 1986, ARCH BIOCHEM BIOPHYS, V251, P9, DOI 10.1016/0003-9861(86)90045-7; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; IMAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P214, DOI 10.1093/oxfordjournals.jbchem.a123559; IMAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P220, DOI 10.1093/oxfordjournals.jbchem.a123560; INESI G, 1982, Z NATURFORSCH C, V37, P685; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOOMIS CR, 1982, BIOCHEMISTRY-US, V21, P151, DOI 10.1021/bi00530a026; MADEIRA VMC, 1980, ARCH BIOCHEM BIOPHYS, V200, P319, DOI 10.1016/0003-9861(80)90361-6; MAKINOSE M, 1969, EUR J BIOCHEM, V10, P74; MAKINOSE M, 1979, CATION FLUX BIOMEMBR, P89; MARTIN RB, 1992, FEBS LETT, V308, P59, DOI 10.1016/0014-5793(92)81050-V; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MINTZ E, 1990, J BIOL CHEM, V265, P18762; MOUTIN MJ, 1991, J BIOL CHEM, V266, P5580; OGURUSU T, 1991, BIOCHEMISTRY-US, V30, P9966, DOI 10.1021/bi00105a022; PICK U, 1982, J BIOL CHEM, V257, P6120; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1990, J BIOCHEM-TOKYO, V107, P563, DOI 10.1093/oxfordjournals.jbchem.a123087; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526	47	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10953	10960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496159				2022-12-25	WOS:A1993LD46600039
J	VERTEL, BM; WALTERS, LM; FLAY, N; KEARNS, AE; SCHWARTZ, NB				VERTEL, BM; WALTERS, LM; FLAY, N; KEARNS, AE; SCHWARTZ, NB			XYLOSYLATION IS AN ENDOPLASMIC-RETICULUM TO GOLGI EVENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TERMINAL N-ACETYLGALACTOSAMINE; SEMI-INTACT CELLS; CORE PROTEIN; BREFELDIN-A; SUBCELLULAR-LOCALIZATION; CULTURED CHONDROCYTES; RAT CHONDROSARCOMA; CIS-GOLGI; TRANSPORT	The subcellular site of xylosylation, the first carbohydrate modification of the core protein that initiates glycosaminoglycan chain synthesis, was characterized in situ. Methods were developed to combine electron microscopic (EM) autoradiography and the radiolabeling of semi-intact chondrocytes. In the accompanying paper, Kearns et al. (Kearns, A. E., Vertel, B. M., and Schwartz, N. B. (1993) J. Biol. Chem. 268, 11097-11104) presented biochemical and subcellular fractionation studies that utilized semi-intact chondrocytes and radiolabeled UDP sugars to overcome obstacles to the direct analysis of xylosylation. The results suggested that xylosylation begins in the endoplasmic reticulum (ER) and continues in the Golgi. The site of xylosylation was not specified further due to the limitations of subcellular fractionation techniques. The studies described in this report were undertaken to localize these modifications directly in situ. Semi-intact cell preparations were optimized for ultrastructural preservation by modifications of permeabilization methods utilizing nitrocellulose filter overlays. Biochemical analysis demonstrated the exclusive incorporation of UDP-xylose into the cartilage chondroitin sulfate proteoglycan (aggrecan) core protein and 3'-phosphoadenosine 5'-phosphosulfate (PAPS) into the highly modified proteoglycan monomer. Immunolocalization studies showed the equivalence of cytoplasmic subcompartments in normal and semi-intact chondrocytes at the levels of light and electron microscopy. Once the biochemical and morphological equivalence of intact and semi-intact cells was established, EM autoradiographic studies were pursued using UDP-[H-3]xylose and [S-35]PAPS. Based on both qualitative and quantitative data, silver grains resulting from incorporated sulfate were concentrated in the perinuclear Golgi, while those resulting from incorporated xylose were found at the cis or forming face of the Golgi and in vesicular regions of the peripheral cytoplasm associated with the late ER. These data support the view that xylose addition begins in a late ER compartment and continues in intermediate compartments, perhaps including the cis-Golgi.	UNIV HLTH SCI CHICAGO MED SCH,DEPT PHYS THERAPY,N CHICAGO,IL 60064; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Chicago Medical School; University of Chicago; University of Chicago	VERTEL, BM (corresponding author), UNIV HLTH SCI CHICAGO MED SCH,DEPT CELL BIOL & ANAT,3333 GREEN BAY RD,N CHICAGO,IL 60064, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028433] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-17332] Funding Source: Medline; NIDDK NIH HHS [DK-28433] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BUMOL TF, 1982, P NATL ACAD SCI-BIOL, V79, P1245, DOI 10.1073/pnas.79.4.1245; CAHN RD, 1967, METHODS DEVELOPMENTA, P493; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FARQUHAR MG, 1991, INTRACELLULAR TRAFFI, P431; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Hascall V.C., 1991, CELL BIOL EXTRACELLU, P149; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAO CY, 1992, J CELL BIOL, V17, P701; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MAUNSBACH AB, 1966, J ULTRA MOL STRUCT R, V15, P197, DOI 10.1016/S0022-5320(66)80108-9; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; ODONNELL CM, 1988, J BIOL CHEM, V263, P17749; PACIFICI M, 1983, J CELL BIOL, V97, P1724, DOI 10.1083/jcb.97.6.1724; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; RIZZOLO LJ, 1985, J CELL BIOL, V101, P1351, DOI 10.1083/jcb.101.4.1351; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1976, J BIOL CHEM, V251, P3346; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; UPHOLT WB, 1981, ALA J MED SCI, V18, P35; UPHOLT WB, 1979, P NATL ACAD SCI USA, V76, P1261; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; VERTEL BM, 1985, EXP CELL RES, V158, P423, DOI 10.1016/0014-4827(85)90466-5; VERTEL BM, 1984, COLLAGEN REL RES, V4, P1; VERTEL BM, 1989, J CELL BIOL, V109, P1827, DOI 10.1083/jcb.109.4.1827; VERTEL BM, 1987, COLLAGEN REL RES, V7, P57; VERTEL BM, 1985, J CELL BIOCHEM, V27, P215, DOI 10.1002/jcb.240270304; VERTEL BM, 1979, P NATL ACAD SCI USA, V76, P4847; VONDERMARK K, 1977, NATURE, V267, P531, DOI 10.1038/267531a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3	72	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11105	11112						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496173				2022-12-25	WOS:A1993LD46600059
J	RANDAZZO, PA; YANG, YC; RULKA, C; KAHN, RA				RANDAZZO, PA; YANG, YC; RULKA, C; KAHN, RA			ACTIVATION OF ADP-RIBOSYLATION FACTOR BY GOLGI MEMBRANES - EVIDENCE FOR A BREFELDIN A-SENSITIVE AND PROTEASE-SENSITIVE ACTIVATING FACTOR ON GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BOVINE BRAIN; ADENYLATE-CYCLASE; SUCCESSIVE COMPARTMENTS; REGULATORY COMPONENT; GUANINE-NUCLEOTIDES; CHOLERA-TOXIN; PURIFICATION; COFACTOR; ALPHA	Recent evidence has implicated ADP-ribosylation factor (ARF) proteins as critical regulators of the protein secretory pathway, particularly in the endoplasmic reticulum-Golgi pathway. We have examined whether Golgi membranes contain activators of ARF and the consequences of ARF activation and acylation on its membrane association. Two means were used to assess ARF activation. First, guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding to protein was found to be greater when ARF and Golgi were incubated together than when either was incubated alone. These data suggested that ARF . GTPgammaS was formed. This was confirmed by showing that the GTPgammaS-bound protein functioned as a cofactor for cholera toxin-stimulated ADP-ribosylation of G(salpha), a reaction for which activated ARF is a necessary cofactor. Trypsin treatment of Golgi, an inhibitory ARF peptide, and brefeldin A each inhibited Golgi-mediated activation by approximately 70%, demonstrating that a specific protein interaction is required for the majority of the ARF activation. This ARF-activating protein is a strong candidate for the molecular target for brefeldin A. The ubiquitous nature of ARF proteins and their importance in both the exocytic and endocytic pathways may explain the effects of brefeldin A on both exocytic and endocytic membrane traffic in animal cells. A protease-insensitive activation of ARF by Golgi could also be demonstrated and was the dominant activity observed in submicromolar concentrations of magnesium. We believe this to be the lipid-mediated process described previously for purified ARF proteins. ARF activation resulted in tight association of ARF with phospholipid vesicles. Vesicle association required amino-terminal myristoylation of ARF whereas activation did not. These studies indicate that the brefeldin A-sensitive ARF-activating protein and other factors that determine the level of activation of ARF in animal cells are fundamental regulators of membrane traffic in animal cells.	NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,REGULATORY MECHANISMS SECT, BLDG 37, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1988, J BIOL CHEM, V263, P1768; WEISS O, 1989, J BIOL CHEM, V264, P21066	35	126	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9555	9563						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486645				2022-12-25	WOS:A1993LA68900063
J	BOEHM, T				BOEHM, T			ANALYSIS OF MULTIGENE FAMILIES BY DNA FINGERPRINTING OF CONSERVED DOMAINS - DIRECTED CLONING OF TISSUE-SPECIFIC PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; NERVOUS-SYSTEM AXONS; KINASES; IDENTIFICATION; EXPRESSION; RHOMBOTIN; HOMOLOGY; GENES	Little is known about the number of mouse protein tyrosine phosphatases (PTPs) and their developmental and tissue-specific expression patterns. A new procedure based on fingerprinting of amplified catalytic domains detects expression of at least 20 different mouse PTPs during development. The majority of these PTPs show developmentally regulated expression patterns; some display a unique tissue specificity. Diagnostic fragments detected in the fingerprint analysis are used here as specific probes to directly clone two previously unknown ubiquitously expressed PTPs and PTP1C, a protein tyrosine phosphatase highly expressed in thymus RNA. The fingerprinting procedure is also applicable to the analysis of protein tyrosine kinases and may also be used to study the expression pattern of other multigene families.			BOEHM, T (corresponding author), UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,HUGSTETTER STR 55,W-7800 FREIBURG,GERMANY.							BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KREUGER NX, 1992, EMBO J, V89, P7417; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1991, BLOOD, V78, P2222	26	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1385	1390						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479755				2022-12-25	WOS:A1993KY32800033
J	BOTTALICO, LA; KEESLER, GA; FLESS, GM; TABAS, I				BOTTALICO, LA; KEESLER, GA; FLESS, GM; TABAS, I			CHOLESTEROL LOADING OF MACROPHAGES LEADS TO MARKED ENHANCEMENT OF NATIVE LIPOPROTEIN(A) AND APOPROTEIN(A) INTERNALIZATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; ACYL COENZYME-A; ALPHA-2-MACROGLOBULIN RECEPTOR; TRANSFERASE-ACTIVITY; PLASMINOGEN BINDING; HUMAN AORTA; ATHEROSCLEROSIS; PROTEIN; APOLIPOPROTEIN(A)	Lipoprotein(a) levels in the plasma are strongly correlated with atherosclerotic coronary artery disease. Although the mechanism of this effect is not known, the interaction of lipoprotein(a) with macrophages may be important. Previous work has shown that macrophages in culture internalize and degrade native lipoprotein(a) poorly. In the present study, the interaction of Lp(a) with mouse peritoneal and human monocyte-derived macrophages that were cholesterol-loaded, such as occur in atheromata, was investigated. I-125-Lp(a) degradation was increased 4-5-fold in macrophages that had been loaded with cholesterol by incubation with acetyl-LDL for 2-4 days. The enhanced degradation of Lp(a) by foam cells was chloroquine-sensitive and dependent upon the presence of calcium in the extracellular medium. Incubation of the macrophages with acetyl-LDL plus an inhibitor of acyl CoA:cholesterol acyltransferase, which increased the free cholesterol content and decreased the cholesteryl ester content of the cells, resulted in an even greater up-regulation of I-125-Lp(a) degradation (8-23-fold over control macrophages). The interaction of Lp(a) with cholesterol-loaded macrophages involved the apoprotein(a) moiety of Lp(a) since I-125-apoprotein(a), but not I-125-Lp(a-), was degraded to a much greater extent by foam cells compared to control macrophages. The uptake and degradation of Lp(a) in foam cells was not mediated by LDL, scavenger, LDL receptor-related protein (LRP), or plasminogen receptors. Thus, cholesterol loading of macrophages markedly enhances the internalization and lysosomal degradation of Lp(a) and apo(a) by a calcium-dependent receptor activity different from known lipoprotein receptors.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Columbia University; Columbia University; University of Chicago					NHLBI NIH HHS [HL18577, HL21006, HL39703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577, P50HL021006, R01HL039703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BIHAIN BE, 1992, BIOCHEMISTRY-US, V31, P4628, DOI 10.1021/bi00134a013; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FLESS GM, 1986, J BIOL CHEM, V261, P8712; FOWLER S, 1980, ACTA MED SCAND, P151; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HABERLAND ME, 1992, J BIOL CHEM, V267, P4143; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1991, J BIOL CHEM, V266, P21232; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KREMPLER F, 1984, J LIPID RES, V25, P283; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; RAPP JH, 1983, J LIPID RES, V24, P1329; ROSS AC, 1984, J BIOL CHEM, V259, P815; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SNYDER ML, 1992, J BIOL CHEM, V267, P339; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1989, J CLIN INVEST, V84, P1713, DOI 10.1172/JCI114354; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1992, CIRCULATION, V86, P336; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	53	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8569	8573						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473302				2022-12-25	WOS:A1993KX81100032
J	HUSAIN, SS				HUSAIN, SS			FIBRIN AFFINITY OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - EVIDENCE THAT ZN2+ MEDIATES STRONG AND SPECIFIC INTERACTION OF SINGLE-CHAIN UROKINASE WITH FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; AMINO-ACID-SEQUENCE; PRO-UROKINASE; HUMAN-URINE; PROTEOLYTIC CLEAVAGE; ESCHERICHIA-COLI; U937 MONOCYTES; TISSUE; BINDING; PURIFICATION	Interactions of components of the fibrinolytic system with fibrin play a key role in localization and regulation of plasminogen activation at the clot surface. Although interaction of tissue plasminogen activator (tPA) with fibrin is well established, the prevailing view is that urokinase-type plasminogen activator (uPA) does not bind to fibrin. In this report, I show that although there is little or no interaction of single-chain urokinase (Sc-uPA), two-chain urokinase (Tc-uPA), or low molecular weight urokinase (LMW-uPA) with fibrin in the absence of divalent metal cations, Sc-uPA is effectively bound to fibrin in the presence of Zn2+. By comparison, Tc-uPA is poorly bound and LMW-uPA is not bound to fibrin in the presence of the metal ion. The Zn2+-mediated fibrin binding of Sc-uPA is reversible, specific, and saturable. The interaction involves a single class of binding site with dissociation constant of 0.3 muM and stoichiometry of 2.7. Lacking apparent affinity for fibrin, uPA has not been considered to play a role in physiological fibrinolysis. The present study conclusively shows that Sc-uPA possesses a latent affinity for fibrin that is expressed in the presence of Zn2+. These findings raise the possibility that Zn2+ plays a regulatory role in uPA-mediated fibrinolysis by promoting effective localization of Sc-uPA at the clot surface.	HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	HUSAIN, SS (corresponding author), MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114, USA.				NHLBI NIH HHS [HL38178] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038178] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTS RJ, 1989, THROMB HAEMOSTASIS, V62, P699; AKLUGA A, 1975, PLATELETS RECENT ADV, P185; BACHMANN F, 1987, HEMOSTASIS THROMBOSI, P318; BAJPAI A, 1985, BIOCHEM BIOPH RES CO, V133, P475, DOI 10.1016/0006-291X(85)90931-3; BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAWSON RMC, 1986, DATA BIOCH RES, P408; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FOLEY B, 1968, P SOC EXP BIOL MED, V128, P265; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; GUREWICH V, 1983, THROMB HAEMOSTASIS, V50, P386; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HEYNS AD, 1985, BLOOD, V66, P213; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HUSAIN S S, 1990, Fibrinolysis, V4, P121; HUSAIN SS, 1981, P NATL ACAD SCI-BIOL, V78, P4265, DOI 10.1073/pnas.78.7.4265; HUSAIN SS, 1989, BLOOD, V74, P999; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1985, THROMB HAEMOSTASIS, V54, P122; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KASAI S, 1985, J BIOL CHEM, V260, P2377; KRISTENSEN P, 1984, FEBS LETT, V168, P33, DOI 10.1016/0014-5793(84)80201-X; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MANGEL WF, 1991, J BIOL CHEM, V266, P9408; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1975, PROTEASES BIOL CONTR, P901; PRASAD AS, 1988, J CLIN INVEST, V82, P1202, DOI 10.1172/JCI113717; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUMP DC, 1986, J BIOL CHEM, V261, P1274; STUMP DC, 1986, J BIOL CHEM, V261, P1267; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; THORSEN S, 1972, THROMB DIATH HAEMOST, V28, P65; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WIMAN B, 1978, NATURE, V272, P54; WINKLER ME, 1985, BIO-TECHNOL, V3, P990, DOI 10.1038/nbt1185-990; WUN TC, 1982, J BIOL CHEM, V257, P7262; ZAIDI STH, 1990, FIBRINOLYSIS, V4, P160	58	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8574	8579						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473303				2022-12-25	WOS:A1993KX81100033
J	MAO, PL; BEAUCHEMIN, M; BEDARD, PA				MAO, PL; BEAUCHEMIN, M; BEDARD, PA			QUIESCENCE-DEPENDENT ACTIVATION OF THE P20K PROMOTER IN GROWTH-ARRESTED CHICKEN-EMBRYO FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; RETINOBLASTOMA GENE-PRODUCT; HEART MESENCHYMAL CELLS; DNA-BINDING; MESSENGER-RNAS; EXPRESSION; PROTEIN; ENHANCER; TRANSCRIPTION; REPRESSION	We described the synthesis of a quiescence-specific p20K protein in quiescent chicken heart mesenchymal cells and contact-inhibited chicken embryo fibroblasts (Bedard, P.-A., Balk, S. D., Gunther, H. S., Morisi, A., and Erikson, R. L. (1987a) Mol. Cell. Biol. 7, 1450-1459). We now report that the expression of p20K is enhanced in cells rendered quiescent by other conditions of growth arrest such as serum starvation or treatment with hydroxyurea. Chicken embryo fibroblasts transformed by the Rous sarcoma virus also expressed p20K upon serum/medium depletion. In all conditions investigated, the synthesis of p20K was correlated with decreased DNA synthesis, indicating that growth arrest regulates the expression of p20K in fibroblasts. The abundance of p20K mRNAs was elevated in quiescent cells, and the p20K gene was more active in nuclear run-on transcription assays in conditions of growth arrest. The p20K gene was isolated, and the promoter region was analyzed in transient expression assays. Serum starvation increased the activity of the promoter, indicating that the expression of p20K is controlled at least in part at the transcriptional level. Deletion analysis revealed that a region of less than 217 base pairs (bp) is sufficient for quiescence-dependent activity of the promoter. Within this region, a segment of 48 bp was essential to basal and quiescence-induced activity of the promoter in dividing and nondividing cells, respectively. The 48-bp region enhanced the activity of a minimal heterologous promoter in quiescent cells but had no effect in conditions of proliferation, indicating that it functions as a quiescence-responsive unit (QRU). Therefore, the transcription of the p20K gene in quiescent fibroblasts is controlled by the one or several growth-regulated elements located in the 48-bp QRU of the promoter.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALK SD, 1980, P NATL ACAD SCI-BIOL, V77, P6606, DOI 10.1073/pnas.77.11.6606; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Baserga R., 1976, MULTIPLICATION DIVIS; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DODGSON JB, 1979, CELL, V17, P879, DOI 10.1016/0092-8674(79)90328-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MEDRANO EE, 1980, P NATL ACAD SCI-BIOL, V77, P4123, DOI 10.1073/pnas.77.7.4123; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; PARDEE AB, 1975, P NATL ACAD SCI USA, V72, P4994, DOI 10.1073/pnas.72.12.4994; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TANIMURA H, 1992, BIOCHEM BIOPH RES CO, V183, P917, DOI 10.1016/0006-291X(92)90571-2; WANG E, 1985, J CELL BIOL, V101, P1695, DOI 10.1083/jcb.101.5.1695; WANG E, 1985, J CELL BIOL, V100, P545, DOI 10.1083/jcb.100.2.545; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	36	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8131	8139						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463325				2022-12-25	WOS:A1993KW97900078
J	GAUT, JR; HENDERSHOT, LM				GAUT, JR; HENDERSHOT, LM			MUTATIONS WITHIN THE NUCLEOTIDE BINDING-SITE OF IMMUNOGLOBULIN-BINDING PROTEIN INHIBIT ATPASE ACTIVITY AND INTERFERE WITH RELEASE OF IMMUNOGLOBULIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; PEPTIDE-BINDING; GENE-PRODUCT; YEAST; BIP; ASSOCIATION; HOMOLOG; DNAJ; HEMAGGLUTININ	Immunoglobulin-binding protein (BiP), a 70-kDa heat shock protein in the endoplasmic reticulum, binds transiently to nascent proteins, releasing them upon folding and assembly. The in vitro release of bound proteins from BiP requires ATP hydrolysis. Recently, the three-dimensional structure was solved for an ATP-hydrolyzing proteolytic 44-kDa fragment of a 71-kDa heat shock cognate protein, HSC71. Because of the high degree of homology in this region, BiP presumably forms a similar ATP binding structure. Amino-terminal deletions in BiP eliminated ATP-agarose binding. Alteration of a second potential ATP binding site had no effect, suggesting that only the HSC71-like site was capable of ATP binding. Crystallographic data from HSC71 implicated certain amino acids in interactions with the beta-phosphate, gamma-phosphate, and divalent cation of ATP. Mutation of each corresponding residue in BiP (Thr-37, Thr-229, and Glu-201) severely inhibited its ATPase activity. These BiP mutants were still capable of binding ATP and immunoglobulin heavy chains, suggesting that these mutations did not drastically alter the structure of BiP. They did however block the ATP-mediated release of heavy chains from BiP. Our results demonstrate that the structure of BiP in this region must be extremely similar to that elucidated for HSC71 and that mutations of residues proposed to interact with ATP block the ATP-mediated release of bound protein by inhibiting ATP hydrolysis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE CTR HLTH SCI, MED CTR, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 43576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DYSON N, 1989, CANCER CEL, V7, P235; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU AY, 1987, GENE, V54, P33, DOI 10.1016/0378-1119(87)90344-1; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MIYAZAKI T, 1992, J BACTERIOL, V174, P3715, DOI 10.1128/JB.174.11.3715-3722.1992; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILD J, 1992, P NATL ACAD SCI USA, V89, P7139, DOI 10.1073/pnas.89.15.7139; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	48	94	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7248	7255						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463260				2022-12-25	WOS:A1993KV14100063
J	HOCEVAR, BA; BURNS, DJ; FIELDS, AP				HOCEVAR, BA; BURNS, DJ; FIELDS, AP			IDENTIFICATION OF PROTEIN-KINASE-C (PKC) PHOSPHORYLATION SITES ON HUMAN LAMIN-B - POTENTIAL ROLE OF PKC IN NUCLEAR LAMINA STRUCTURAL DYNAMICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GROWTH-FACTOR; ENVELOPE; MITOSIS; INVITRO; SYSTEM; INVOLVEMENT; INTERPHASE; EXPRESSION; SEPARATION	Protein kinase C (PKC) is activated at the nuclear membrane in response to a variety of mitogenic stimuli. In human leukemic cells, the beta(II) PKC isotype is selectively translocated and activated at the nucleus. We recently identified the nuclear envelope component lamin B1 as a major substrate for nuclear PKC both in whole cells and in vitro. Using highly purified human beta(II) PKC and isolated nuclear envelopes from the human promyelocytic (HL60) leukemia cell line, we have now determined the major sites for beta(II) PKC-mediated lamin B phosphorylation. Using a combination of cyanogen bromide cleavage, direct microsequencing, tryptic phosphopeptide, and phosphate release analyses, two major sites of PKC-mediated phosphorylation, Ser395 and Ser405, have been identified. These sites lie within the carboxyl-terminal domain of lamin B immediately adjacent to the central a-helical rod domain. Functionally, beta(II) PKC-mediated phosphorylation of these sites leads to the time-dependent solubilization of lamin B indicative of mitotic nuclear envelope breakdown in vitro. Beta(II) PKC-mediated lamin B phosphorylation is inhibited by 1) a monoclonal antibody directed against the active site of PKC, 2) a PKC pseudosubstrate inhibitor peptide, and 3) a PKC peptide substrate. Two observations indicate that PKC-mediated lamin B phosphorylation and solubilization is due to direct phosphorylation of lamin B by PKC rather than indirect activation of a cdc2 kinase. Neither immunodepletion with p13suc1 Sepharose beads nor the presence of a p34cdc2 kinase peptide substrate had any effect on PKC-mediated lamin B phosphorylation. Therefore, we conclude that beta(II) PKC represents a physiologically relevant lamin kinase that can directly modulate nuclear lamina structure in vitro. Nuclear beta(II) PKC, like p34cdc2 kinase, may function to regulate nuclear lamina structural stability during cell cycle.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, 2119 ABINGTON RD, CLEVELAND, OH 44106 USA; SPHINX PHARMACEUT INC, DURHAM, NC 27707 USA	Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEMENT WM, 1990, CELL REGUL, V1, P315, DOI 10.1091/mbc.1.3.315; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; EGGERT M, 1991, FEBS LETT, V292, P205, DOI 10.1016/0014-5793(91)80868-4; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERACE L, 1984, J CELL SCI, P137; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; OGITA K, 1991, METHOD ENZYMOL, V200, P228; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; SUPRYNOWICZ FA, 1986, J CELL BIOL, V103, P2073, DOI 10.1083/jcb.103.6.2073; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	33	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7545	7552						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463284				2022-12-25	WOS:A1993KV14100104
J	HOGG, PJ; OWENSBY, DA; MOSHER, DF; MISENHEIMER, TM; CHESTERMAN, CN				HOGG, PJ; OWENSBY, DA; MOSHER, DF; MISENHEIMER, TM; CHESTERMAN, CN			THROMBOSPONDIN IS A TIGHT-BINDING COMPETITIVE INHIBITOR OF NEUTROPHIL ELASTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE AFFINITY-CHROMATOGRAPHY; HUMAN-LEUKOCYTE ELASTASE; ENDOTHELIAL-CELLS; CATHEPSIN-G; FIBRONECTIN; DEGRADATION; MATRIX; FIBROBLASTS; PROTEINASES; EQUILIBRIUM	Thrombospondin, a glycoprotein of three identical disulfide-bonded subunits, is a constituent of platelet alpha-granules and a variety of normal and transformed cells and binds to cell surfaces and becomes incorporated into extracellular matrix. It has been implicated in processes such as wound healing and tumor growth and metastasis. In addition, thrombospondin was shown recently to be an inhibitor of the fibrinolytic enzyme, plasmin. In the cause of studying the effects of thrombospondin on other serine proteinases, we found that thrombospondin binds neutrophil elastase in an active-site-dependent manner and competitively inhibits the activity of the enzyme. In a competitive binding assay, neutrophil elastase bound to thrombospondin with a dissociation constant of 17 +/- 7 nM, expressed per mole of thrombospondin trimer, or 52 +/- 20 nM, expressed per mole of thrombospondin subunit. In kinetic studies of the inhibition of the amidolytic activity of neutrophil elastase by thrombospondin, 2.7 +/- 0.3 mol of elastase interacted with 1 mol of thrombospondin trimer with a site-binding constant of 57 +/- 13 nM. Lower limits for the on rate constant of 5 x 10(6) M-1 s-1 and off rate constant of 0.27 s-1 were established. Affinity of binding of neutrophil elastase to thrombospondin was sensitive to ionic strength and calcium ions. Thrombospondin was cleaved by neutrophil elastase, but the site(s) of the limited cleavage are independent of the competitive inhibition of elastase activity by thrombospondin. Neutrophil elastase inactivated with phenylmethylsulfonyl fluoride did not compete with active elastase for binding to thrombospondin, implying that a functional active site is important for the interaction of elastase with thrombospondin. Thrombospondin protected fibronectin from cleavage by neutrophil elastase. In summary, the binding of neutrophil elastase to thrombospondin is tight, reversible, and close enough to the active site of elastase to exclude small synthetic tripeptidyl p-nitroanilide substrates and macromolecular protein substrates. Two potential reactive centers that may be involved in binding elastase have been identified in the calcium-binding type 3 domains of thrombospondin. Neutrophil elastase is the enzyme primarily responsible for degrading and solubilizing connective tissue during inflammatory processes. These findings suggest a previously unsuspected mechanism for regulation of elastase activity at inflammatory sites.	UNIV NEW S WALES, PRINCE WALES HOSP, CTR THROMBOSIS & VASC RES, SYDNEY, NSW 2031, AUSTRALIA; UNIV WISCONSIN, DEPT MED, MADISON, WI 54706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 54706 USA	University of New South Wales Sydney; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Hogg, Philip/0000-0001-6486-2863	NHLBI NIH HHS [HL29586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bieth JG, 1986, REGULATION MATRIX AC, P217; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; HOGG PJ, 1991, J BIOL CHEM, V266, P10953; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1987, MOL IMMUNOL, V24, P797, DOI 10.1016/0161-5890(87)90064-2; HOGG PJ, 1984, ARCH BIOCHEM BIOPHYS, V234, P55, DOI 10.1016/0003-9861(84)90323-0; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JONASSEN IB, 1982, CARLSBERG RES COMMUN, V47, P199, DOI 10.1007/BF02907871; KREIS C, 1989, J IMMUNOL, V143, P1961; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; MAIER K, 1979, J BIOL CHEM, V254, P2555; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MCDONALD JA, 1980, J BIOL CHEM, V255, P8848; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1992, ADV MOL CELL BIOL, V7, P1; MPHERSON J, 1981, J BIOL CHEM, V256, P11330; MURPHYULLRICH JE, 1985, BLOOD, V66, P1098; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NICHOL LW, 1981, BIOCHEMISTRY-US, V20, P4856, DOI 10.1021/bi00520a008; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RICHARDSON M, 1974, FEBS LETT, V45, P11, DOI 10.1016/0014-5793(74)80798-2; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAKLATVALA J, 1980, BIOCHIM BIOPHYS ACTA, V615, P167, DOI 10.1016/0005-2744(80)90020-0; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; SUCHARD SJ, 1991, J IMMUNOL, V146, P3945; SVENDSEN IB, 1982, CARLSBERG RES COMMUN, V47, P45, DOI 10.1007/BF02907796; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VARANI J, 1989, CLIN EXP METASTAS, V7, P265, DOI 10.1007/BF01753679; VOLKER W, 1991, J HISTOCHEM CYTOCHEM, V39, P1385, DOI 10.1177/39.10.1940309; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704	40	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7139	7146						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463250				2022-12-25	WOS:A1993KV14100051
J	ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H				ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H			POTENTIAL VALUE OF INCREASED MYC BUT NOT ERBB2 RNA LEVELS AS A MARKER OF HIGH-RISK MASTOPATHIES	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; C-MYC; ONCOGENE EXPRESSION; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; CARCINOMA INSITU; BENIGN; CELLS; LESIONS; TISSUE	MYC and ERBB2 levels were measured in 38 benign breast diseases using a semiquantitative in situ hybridization technique. Mean levels of MYC and ERBB2 gene expression in benign tissues were similar to those measured in 15 breast cancers with no amplification at the loci concerned. Interestingly, MYC but not ERBB2 RNA levels were increased (t-test, P = 0.03) in benign mastopathies of patients with a first-degree (mother/sister) family history (FH) of breast cancer. Among patients without a first-degree FH, MYC RNA levels were significantly higher (t-test, P = 0.02) during the follicular (preovulatory) than the luteal (post-ovulatory) phase and also significantly higher than levels observed in patients with no menstrual cycle (peri- or postmenopausal) (P = 0.004), indicating an in vivo hormonal regulation of MYC. After exclusion of the first-degree FH patients a higher MYC expression was detected in atypia than in other histological types at the follicular but not at the luteal phase, suggesting an increased sensitivity of these high-risk lesions to estrogens. We propose that in addition to a family history and proliferative atypia, elevated MYC RNA levels during the post-ovulatory phase could potentially be used as a marker of the risk of developing breast cancer. The increase in MYC RNA in high-risk breast diseases also suggests that MYC deregulation might be involved in the early stages of mammary carcinogenesis.	INSERM,U148,UNITE HORMONE & CANC,F-34090 MONTPELLIER,FRANCE; CTR VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; BURCK KB, 1988, ONCOGENES INTRO CONC; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHALBOS D, 1990, JNCI-J NATL CANCER I, V82, P602, DOI 10.1093/jnci/82.7.602; DATI C, 1990, ONCOGENE, V5, P1001; DUBIK D, 1987, CANCER RES, V47, P6517; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; GARCIA M, 1986, CANCER RES, V46, P3734; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LEROY X, 1991, ONCOGENE, V6, P431; LIU E, 1992, ONCOGENE, V7, P1027; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PAGE DL, 1992, BREAST, V1, P3; PARKER CL, 1988, AM J EPIDEMIOL, V128, P467; PAVELIC SP, 1992, CANCER RES, V52, P2597; PETERSEN OW, 1987, CANCER RES, V47, P5748; PIKE MC, 1981, 8 BANB REP; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WALKER KJ, 1992, EUR J CANCER, V28A, P34, DOI 10.1016/0959-8049(92)90379-G; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506	35	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					969	974						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455947				2022-12-25	WOS:A1993KT22000019
J	BLAXTER, ML				BLAXTER, ML			CUTICLE SURFACE-PROTEINS OF WILD-TYPE AND MUTANT CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT BRUGIA-MALAYI; PARASITIC NEMATODES; ASCARIS-SUUM; PANAGRELLUS-REDIVIVUS; DIROFILARIA-IMMITIS; EXCRETORY SYSTEM; COLLAGEN GENE; GLYCOPROTEIN; ANTIGENS; MEMBRANE	The molecular components of the surface of the free-living nematode Caenorhabditis elegans have been identified by surface-specific radioiodination. Four compartments were defined by fractionation of labeled wild type (N2 strain) adult hermaphrodites. Organic solvents extracted cuticular lipids. Homogenization in detergents released a single, non-collagenous, hydrophobic protein. This is not glycosylated and is a heterodimer of 6.5- and 12-kDa subunits. The third compartment, proteins solubilized by reducing agents, included both the cuticular collagens and the heterodimer. Residual material corresponds to the cuticlin fraction. Larval stages showed a similar pattern, except that the dauer larva had an additional 37-kDa detergent-soluble protein. Other species of rhabditid nematodes displayed similar profiles, and comparison with parasitic species suggests that this simple pattern may be primitive in the Nematoda. A C. elegans strain mutant in cuticular collagen (rol-6) had a pattern identical to that of wild type, but another morphological mutant (dpy-6) and several mutants that differ in surface reactivity to antibody and lectins (srf mutants) also had striking differences in surface labeling patterns.			BLAXTER, ML (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, WELLCOME RES CTR PARASIT INFECT, LONDON SW7 2BB, ENGLAND.		Blaxter, Mark/O-2535-2019; Blaxter, Mark L/B-4113-2010	Blaxter, Mark L/0000-0003-2861-949X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ RM, 1989, MOL BIOCHEM PARASIT, V33, P183, DOI 10.1016/0166-6851(89)90032-7; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; BAIRD SE, 1993, IN PRESS NEMATOLOGIC; Barrett J., 1981, BIOCH PARASITIC HELM; Barron G.L., 1977, NEMATODE DESTROYING, VI, P144; BEAMES CG, 1964, EXP PARASITOL, V15, P387, DOI 10.1016/0014-4894(64)90033-5; BETSCHART B, 1990, ACTA TROP, V47, P331, DOI 10.1016/0001-706X(90)90034-W; BIRD AF, 1988, J NEMATOL, V20, P493; BIRD AF, 1987, INT J PARASITOL, V17, P1239, DOI 10.1016/0020-7519(87)90088-9; Bird AF, 1991, STRUCTURE NEMATODES; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNER S, 1974, GENETICS, V77, P71; Chitwood, 1974, INTRO NEMATOLOGY; COOKSON E, 1992, P NATL ACAD SCI USA, V89, P5837, DOI 10.1073/pnas.89.13.5837; COX GN, 1980, GENETICS, V95, P317; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; COX GN, 1990, EXP PARASITOL, V70, P175, DOI 10.1016/0014-4894(90)90098-W; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; COX GN, 1990, ACTA TROP, V47, P269, DOI 10.1016/0001-706X(90)90028-X; DESPOMMIER DD, 1990, EXP PARASITOL, V71, P27, DOI 10.1016/0014-4894(90)90005-W; ENDO BY, 1992, PROTOPLASMA, V166, P67, DOI 10.1007/BF01320145; Findlay J.B.C., 1990, PROTEIN PURIFICATION, P59; FUJIMOTO D, 1981, BIOCHEM BIOPH RES CO, V99, P637, DOI 10.1016/0006-291X(81)91792-7; FUJIMOTO D, 1973, ARCH BIOCHEM BIOPHYS, V157, P1, DOI 10.1016/0003-9861(73)90382-2; GINGER CD, 1967, S BRIT SOC PARASITOL, V7, P17; GOODAY T, 1951, SOIL FRESHWATER NEMA; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; HEMMER RM, 1991, J CELL BIOL, V115, P1237, DOI 10.1083/jcb.115.5.1237; HILL DE, 1990, MOL BIOCHEM PARASIT, V41, P45, DOI 10.1016/0166-6851(90)90095-4; HIMMELHOCH S, 1977, EXP PARASITOL, V41, P118, DOI 10.1016/0014-4894(77)90137-0; HIMMELHOCH S, 1983, EXP PARASITOL, V55, P299, DOI 10.1016/0014-4894(83)90026-7; HO NFH, 1990, MOL BIOCHEM PARASIT, V41, P153, DOI 10.1016/0166-6851(90)90178-O; IBRAHIM MS, 1989, PARASITOLOGY, V99, P89, DOI 10.1017/S0031182000061060; JANSSON HB, 1986, J NEMATOL, V18, P570; JENNINGS AC, 1949, AUST J SCI RES SER B, V2, P408, DOI 10.1071/BI9490408; Jones M. G. K., 1981, Plant parasitic nematodes. Volume III., P255; KENNEDY MW, 1987, MOL BIOCHEM PARASIT, V22, P233, DOI 10.1016/0166-6851(87)90054-5; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KWANLIM GE, 1990, J IMMUNOL, V145, P1912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK CD, 1992, GENETICS, V131, P867; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; Maizels R, 1991, PARASITE ANTIGENS PA; Maizels R. M., 1988, The biology of parasitism. A molecular and immunological approach., P285; MAIZELS RM, 1982, IMMUNOL REV, V61, P109, DOI 10.1111/j.1600-065X.1982.tb00375.x; MAIZELS RM, 1989, MOL BIOCHEM PARASIT, V32, P213, DOI 10.1016/0166-6851(89)90072-8; MALONEY MD, 1991, PARASITOL RES, V77, P294, DOI 10.1007/BF00930904; MARSHALL E, 1986, MOL BIOCHEM PARASIT, V18, P17, DOI 10.1016/0166-6851(86)90046-0; MARSHALL E, 1985, MOL BIOCHEM PARASIT, V15, P295, DOI 10.1016/0166-6851(85)90091-X; MCCLURE MA, 1991, PARASITOLOGY, V103, P421, DOI 10.1017/S0031182000059941; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1992, PARASITOLOGY, V105, P285, DOI 10.1017/S0031182000074217; PHILIPP M, 1980, NATURE, V287, P538, DOI 10.1038/287538a0; POLITZ SM, 1990, P NATL ACAD SCI USA, V87, P2901, DOI 10.1073/pnas.87.8.2901; POLITZ SM, 1992, PARASITOL TODAY, V8, P6, DOI 10.1016/0169-4758(92)90302-I; POLITZ SM, 1987, GENETICS, V117, P467; PREMACHANDRAN D, 1988, J NEMATOL, V20, P70; PRITCHARD DI, 1985, PARASITE IMMUNOL, V7, P575, DOI 10.1111/j.1365-3024.1985.tb00101.x; Proudfoot L., 1991, P1; PROUDFOOT L, 1990, ACTA TROP, V47, P323, DOI 10.1016/0001-706X(90)90033-V; ROSENZWEIG WD, 1985, CAN J MICROBIOL, V31, P693, DOI 10.1139/m85-131; ROTHSTEIN M, 1963, COMP BIOCHEM PHYSIOL, V9, P51, DOI 10.1016/0010-406X(63)90028-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAGER SI, 1979, J IMMUNOL, V123, P2108; SCOTT AL, 1990, ACTA TROP, V47, P339, DOI 10.1016/0001-706X(90)90035-X; SCOTT AL, 1988, EXP PARASITOL, V67, P307, DOI 10.1016/0014-4894(88)90078-1; SEBASTIANO M, 1991, DEV BIOL, V146, P519, DOI 10.1016/0012-1606(91)90253-Y; Selkirk M.E., 1991, P27; SELKIRK ME, 1990, MOL BIOCHEM PARASIT, V42, P31, DOI 10.1016/0166-6851(90)90110-8; SELKIRK ME, 1989, MOL BIOCHEM PARASIT, V32, P229, DOI 10.1016/0166-6851(89)90073-X; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; Vanfleteren J.R., 1980, P47; Ward S., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P503; WHARTON DA, 1990, PARASITOLOGY, V101, P101, DOI 10.1017/S0031182000079804; Wood WB, 1988, NEMATODE CAENORHABDI; WRIGHT KA, 1987, J PARASITOL, V73, P1077, DOI 10.2307/3282284; ZUCKERMAN BM, 1979, EXP PARASITOL, V47, P419, DOI 10.1016/0014-4894(79)90095-X	79	52	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6600	6609						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	8503957				2022-12-25	WOS:A1993KT36800076
J	PAGLIN, S; ROY, R; POLGAR, P				PAGLIN, S; ROY, R; POLGAR, P			CHARACTERIZATION OF HORMONALLY REGULATED AND PARTICULATE-ASSOCIATED PHOSPHOLIPASE-A(2) FROM BOVINE ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; PLATELET-ACTIVATING FACTOR; SMOOTH-MUSCLE CELLS; PULMONARY-ARTERY; CALCIUM; PURIFICATION; BRADYKININ; LINE	Hormonally regulated and particulate-associated phospholipase A2 (PLA2) was detected in endothelial cells from bovine pulmonary artery. The enzyme was solubilized and subjected to initial characterization. PLA2 activity was determined in subcellular fractions from bradykinin (BK)-stimulated and nonstimulated cells by following the release of arachidonic acid (AA) from exogenously added 1-palmitoyl-2-[C-14]arachidonoyl-phosphatidylcholine. Stimulation of cells with BK led to increased PLA2 activity in a particulate fraction (the 92,000 x g pellet of the postnuclear supernatant). The activity in the cytosolic fractions from BK-stimulated and nonstimulated cells was the same. The association of the hormonally regulated PLA2 (HR-PLA2) activity with the particulate fraction was not affected by decreasing the Ca2+ concentrations in the homogenate from 7 muM to 33 nM and therefore was not induced during homogenization by the presence of Ca2+ in the homogenate. The HR-PLA2 activity was Ca2+-dependent and was maximal at submicromolar concentrations of Ca2+. Incubation of the particulate fraction obtained from BK-stimulated and nonstimulated cells with 10 mM n-octyl-beta-D-glucopyranoside resulted in a differential solubilization of the HR-PLA2 activity. Its isoelectric point was determined to be 5.7. HR-PLA2 activity in the octyl glucoside extract of the particulate fraction from stimulated cells co-sedimented in sucrose gradients with the cytosolic PLA2. Their molecular mass was estimated to be 103,000 Da. The extracted enzyme from BK-stimulated cells retained its increased activity toward 1-palmitoyl-2-[1-C-14]arachidonoyl-phosphatidylcholine. However, its activity toward 1-palmitoyl-2-[1-C-14]oleoyl-phosphatidylcholine was equal to the PLA2 activity extracted from nonstimulated cells. Treatment of the cells with 100 nM 12-O-tetradecanoylphorbol-13-acetate resulted in a 20 +/-1.2% (mean +/- S.E., p < 0.01, n = 4) increase in the PLA2 activity in the cytosol but failed to increase PLA2 activity in the particulate fraction. In contrast, addition of 7 muM Ca2+ ionophore A23187 resulted in a 21 +/-0.55% (mean +/- S.E., p < 0.01, n = 5) decrease in the cytosolic activity and a concomitant increase of 68 +/-9.6% (mean +/- S.E., p < 0.05, n = 5) in the particulate-associated activity. We conclude that stimulation of endothelial cells with BK increases the activity of a Ca2+-sensitive high molecular weight isoform of PLA2 which is associated with the particulate fraction. Possible mechanisms of activation are discussed.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Polgar, Peter/0000-0002-9112-1101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025776] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25776] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, FEBS LETT, V234, P283; BUCHAN KW, 1991, BRIT J PHARMACOL, V102, P35, DOI 10.1111/j.1476-5381.1991.tb12128.x; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; BURCH RM, 1989, MOL NEUROBIOL, V3, P155, DOI 10.1007/BF02935629; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAKRABORTI S, 1991, FEBS LETT, V285, P104, DOI 10.1016/0014-5793(91)80735-L; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1986, J BIOL CHEM, V261, P713; Colton T., 1974, STAT MED, V1; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Dennis EA, 1983, ENZYMES, P307; DIEZ E, 1990, J BIOL CHEM, V265, P14654; DOLE VP, 1960, J BIOL CHEM, V235, P2595; FARMER SG, 1991, AM J PHARM, V190, P159; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONG SL, 1982, J BIOL CHEM, V257, P7151; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LOEB GI, 1957, J PHYS CHEM-US, V60, P1633, DOI 10.1021/j150546a009; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MENCONI M, 1984, J CELL PHYSIOL, V120, P163, DOI 10.1002/jcp.1041200209; MENNON NK, 1990, LIFE SCI, V47, P1941; MONCADA S, 1980, PHARMACOL BASIS THER, P668; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PRENTKI M, 1982, J BIOL CHEM, V258, P7597; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RAAFLAUB J, 1956, METHOD BIOCHEM ANAL, V3, P301; RICCUPERO D, 1992, MED INFLAMMATION, V1, P130; SAGE SO, 1989, J BIOL CHEM, V264, P6; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHEELE GA, 1975, J BIOL CHEM, V250, P5375; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIMON W, 1978, ANN NY ACAD SCI, V307, P52; SUNDARAM GS, 1978, J BIOL CHEM, V253, P7703; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11697	11702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505299				2022-12-25	WOS:A1993LF28400038
J	PASCAL, S; TATON, M; RAHIER, A				PASCAL, S; TATON, M; RAHIER, A			PLANT STEROL BIOSYNTHESIS - IDENTIFICATION AND CHARACTERIZATION OF 2 DISTINCT MICROSOMAL OXIDATIVE ENZYMATIC SYSTEMS INVOLVED IN STEROL C4-DEMETHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENERGY INTERMEDIATE; STRUCTURAL REQUIREMENTS; CONFORMATIONAL-ANALYSIS; OBTUSIFOLIOL; CYCLOARTENOL; INHIBITION; CLEAVAGE; ANALOGS; CYCLOEUCALENOL; DERIVATIVES	Membrane-bound enzymatic systems obtained from maize embryos that catalyze the oxidative C4-mono-demethylation of 4,4-dimethyl- and 4alpha-methylsterols have been investigated. Enzymatic assay conditions have been developed for the first time to detect the C4-monodemethylated products formed. The properties of the microsomal systems have been established for cofactor requirements and kinetics. The demethylation process has been interrupted to demonstrate the formation of stable, oxygenated intermediates. In addition to the 3-keto and 3beta-hydroxy-4-monodemethylated products formed, three new sterols have been identified. 3Beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta,19-cyclo-24(24(1))-en-4alpha-hydroxy methyl was identified for the first time as the immediate metabolite of 24-methylenecycloartanol by 4alpha-methyl oxidase in addition to 3beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta, 19-cyclo-24(24(1))-en-4alpha-carboxylic-acid and 3beta-hydroxy-5alpha-stigmasta-7,24(24(1))-dien-4alpha-carboxylic-acid, intermediates involved respectively in the oxidative demethylation of 24-methylenecycloartanol and 24-ethylidenelophenol. Proton nuclear magnetic resonance studies of enzymatically produced 3beta-hydroxy-4beta,14alpha-dimethyl-5alpha-ergosta-9beta,19-cyclo-24(24(1))en-4alpha-carboxylic acid indicate that the 4alpha-methyl group of 24-methylenecycloartanol is oxidized and subsequently removed during its enzymatic conversion to cycloeucalenol. From a series of incubations with 25 natural or synthetic 4,4-dimethyl and 4alpha-methylsterols, a high degree of substrate specificity for the oxidation at C4 of 4,4-dimethyl- and 4alpha-methylsterols was determined. Our results indicate that oxidation of the 4alpha-methyl group of the 4,4-geminal dimethylsterols requires the more flexible and presumably bent conformation of 9beta,19-cyclopropylsterols and the absence of a DELTA24(25) unsaturation, whereas the rigid planar conformation of DELTA7-unsaturated sterols favors oxidation of 4alpha-methylsterols. Distinct strict structural requirements for the oxidation of 4,4-dimethyl- and 4alpha-methylsterols and different sensitivity toward cyanide ions and 3beta,5alpha,6alpha-stigmastatriol, a novel inhibitor of 4alpha-methylsterol C4 oxidase activity, are consistent with the conclusion that two distinct oxidative systems are involved in the removal of the first and second C4-methyl group of phytosterol precursors. Moreover, the present study directly establishes that during the conversion of cycloartenol to phytosterol one C4 dealkylation occurs before the removal of the 14alpha-methyl group.	INST BOT,CNRS,UPR 406,DEPT ENZYMOL CELLULAIRE & MOLEC,INST BIOL MOLEC PLANTES,28 RUE GOETHE,F-67083 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; CATTEL L, 1979, J AM OIL CHEM SOC, V56, P6, DOI 10.1007/BF02671752; FONTENEAU P, 1977, PLANT SCI LETT, V10, P147, DOI 10.1016/0304-4211(77)90122-5; GHISALBERTI EL, 1969, J CHEM SOC CHEM COMM, P1403, DOI 10.1039/c29690001403; GUILHEM J, 1975, Tetrahedron Letters, V34, P2937; HEINTZ R, 1974, J BIOL CHEM, V249, P4267; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOSODA H, 1973, J ORG CHEM, V38, P4209, DOI 10.1021/jo00963a028; KNAPP FF, 1970, J CHEM SOC CHEM COMM, P399, DOI 10.1039/c29700000399; KNAPP FF, 1971, PHYTOCHEMISTRY, V10, P97, DOI 10.1016/S0031-9422(00)90255-3; LENTON JR, 1975, PHYTOCHEMISTRY, V14, P1523, DOI 10.1016/0031-9422(75)85344-1; MAILLOTVERNIER P, 1991, MOL GEN GENET, V231, P33, DOI 10.1007/BF00293818; MILLER WL, 1970, J BIOL CHEM, V245, P5375; MILLER WL, 1971, J BIOL CHEM, V246, P2494; MILON A, 1989, HELV CHIM ACTA, V72, P1, DOI 10.1002/hlca.19890720102; NARULA AS, 1971, TETRAHEDRON, V27, P1119, DOI 10.1016/S0040-4020(01)90859-2; NELSON JA, 1975, BIOORG CHEM, V4, P363, DOI 10.1016/0045-2068(75)90047-4; NES WD, 1988, P NATL ACAD SCI USA, V85, P5759, DOI 10.1073/pnas.85.16.5759; OMURA T, 1964, J BIOL CHEM, V239, P2379; PASCAL S, 1990, BIOCHEM BIOPH RES CO, V172, P98, DOI 10.1016/S0006-291X(05)80178-0; QIN GW, 1989, YOUJI HUAXAE, V9, P263; RAHIER A, 1977, PHYTOCHEMISTRY, V16, P1187, DOI 10.1016/S0031-9422(00)94357-7; RAHIER A, 1986, BIOCHEM BIOPH RES CO, V140, P1064, DOI 10.1016/0006-291X(86)90743-6; RAHIER A, 1984, J BIOL CHEM, V259, P5215; RAHIER A, 1989, EUR J BIOCHEM, V181, P615, DOI 10.1111/j.1432-1033.1989.tb14768.x; RAHIER A, 1986, LIPIDS, V21, P52, DOI 10.1007/BF02534303; RAHMAN R, 1970, J BIOL CHEM, V245, P2667; SANGARE M, 1975, Tetrahedron Letters, V22/23, P1791; SCALLEN TJ, 1971, J BIOL CHEM, V246, P3168; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SHARPLESS KB, 1969, J AM CHEM SOC, V91, P3394, DOI 10.1021/ja01040a065; SHARPLESS KB, 1968, J AM CHEM SOC, V90, P6874, DOI 10.1021/ja01026a073; TATON M, 1987, PESTIC SCI, V21, P269, DOI 10.1002/ps.2780210404; TATON M, 1991, BIOCHEM BIOPH RES CO, V181, P465, DOI 10.1016/S0006-291X(05)81442-1; TATON M, 1986, BIOCHEM BIOPH RES CO, V138, P764, DOI 10.1016/S0006-291X(86)80562-9; TATON M, 1989, EUR J BIOCHEM, V185, P605, DOI 10.1111/j.1432-1033.1989.tb15156.x; TATON M, 1991, BIOCHEM J, V277, P483, DOI 10.1042/bj2770483; TATON M, 1988, PESTIC BIOCHEM PHYS, V30, P178, DOI 10.1016/0048-3575(88)90051-X; TRZASKOS JM, 1985, ENZYMES BIOL MEMBR, V2, P177; YOSHIDA K, 1989, AGR BIOL CHEM TOKYO, V53, P1901, DOI 10.1080/00021369.1989.10869552; 1989, EUR J BIOCHEM, V186, P429	42	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11639	11654						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505296				2022-12-25	WOS:A1993LF28400031
J	SORIMACHI, H; TOYAMASORIMACHI, N; SAIDO, TC; KAWASAKI, H; SUGITA, H; MIYASAKA, M; ARAHATA, K; ISHIURA, S; SUZUKI, K				SORIMACHI, H; TOYAMASORIMACHI, N; SAIDO, TC; KAWASAKI, H; SUGITA, H; MIYASAKA, M; ARAHATA, K; ISHIURA, S; SUZUKI, K			MUSCLE-SPECIFIC CALPAIN, P94, IS DEGRADED BY AUTOLYSIS IMMEDIATELY AFTER TRANSLATION, RESULTING IN DISAPPEARANCE FROM MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ACTIVATED NEUTRAL PROTEASE; MOLECULAR-CLONING; CDNA CLONES; SEQUENCE-ANALYSIS; SKELETAL-MUSCLE; LARGE SUBUNIT; KINASE-C; NUCLEOTIDE-SEQUENCE; BINDING PROTEIN	We previously identified a third type of the calpain large subunit named p94 as a cDNA whose mRNA is expressed exclusively in skeletal muscle at levels approximately 10-fold more abundant than those of the conventional calpain subunit. Rat skeletal muscle fractions were screened by two anti-peptide antibodies raised against two specific sequences in p94, but the p94 protein could not be found. To examine this apparent discrepancy between the amounts of mRNA and protein, wild-type p94 was expressed in COS cells. Although p94 mRNA was expressed normally in COS cells, only very small amounts of the protein and its presumed degradation products were detected by the antibodies described above. A series of COOH-terminal deletion mutants was constructed and expressed in COS cells and L8 cells, a rat myoblast cell line. When IS2, one of the specific regions of p94, was completely eliminated, the truncated p94 proteins were expressed normally, and the amount of the expressed proteins was at least 100-fold higher than with wild-type p94. Moreover, when site-directed mutagenesis was introduced to change the presumed active-site cysteine of p94 to serine or alanine, the mutated p94 proteins were highly expressed like the IS2-deleted mutants. These results indicate the following. 1) The mRNA for p94 is normally transcribed in COS, L8, and muscle cells; 2) the p94 protein becomes active in the cytosol immediately after translation; 3) the p94 protein virtually disappears from cells by autocatalytic degradation; and 4) the p94-specific IS2 region plays an important role in this degradation. In vitro translation experiments support this idea. Furthermore, p94 shows nuclear localization when expressed in COS cells. The physiological function of p94 in muscle is discussed on the basis of the analysis of these transfectants.	NATL INST NEUROSCI, DIV NEUROMUSCULAR RES, KODAIRA, TOKYO 187, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN	National Center for Neurology & Psychiatry - Japan; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	SORIMACHI, H (corresponding author), UNIV TOKYO, INST APPL MICROBIOL, TOKYO 113, JAPAN.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Sorimachi, Hiroyuki/C-6448-2009; Kawasaki, Hiroshi/C-3048-2011; Miyasaka, Masayuki/AAM-6343-2020	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Sorimachi, Hiroyuki/0000-0001-9509-6727; Kawasaki, Hiroshi/0000-0002-2517-159X; 				ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAYTON WR, 1982, BIOCHIM BIOPHYS ACTA, V709, P166, DOI 10.1016/0167-4838(82)90457-5; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; EMORI Y, 1986, J BIOL CHEM, V261, P9465; EMORI Y, 1986, J BIOL CHEM, V261, P9472; FRIEDRICH P, 1990, NEUROSCIENCE, V35, P1, DOI 10.1016/0306-4522(90)90115-K; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MURACHI T, 1989, BIOCHEM INT, V18, P263; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHNO S, 1986, NUCLEIC ACIDS RES, V14, P5559; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; SORIMACHI H, 1990, BIOL CHEM H-S, V371, P171; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SUZUKI K, 1979, FEBS LETT, V104, P355, DOI 10.1016/0014-5793(79)80851-0; SUZUKI K, 1991, BIOMED BIOCHIM ACTA, V50, P483; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V8, P167; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFE FH, 1989, BIOCHIM BIOPHYS ACTA, V998, P236, DOI 10.1016/0167-4838(89)90280-X; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68	52	235	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10593	10605						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486713				2022-12-25	WOS:A1993LB80000089
J	TOBIN, AB; NAHORSKI, SR				TOBIN, AB; NAHORSKI, SR			RAPID AGONIST-MEDIATED PHOSPHORYLATION OF M3-MUSCARINIC-RECEPTORS REVEALED BY IMMUNOPRECIPITATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MUSCARINIC ACETYLCHOLINE-RECEPTOR; INHIBITS PHOSPHOINOSITIDE HYDROLYSIS; NEURO-BLASTOMA CELLS; CHOLINERGIC RECEPTORS; CHICK HEART; TUMOR PROMOTER; DESENSITIZATION; BINDING; ACTIVATION	A specific antiserum against the human m3-muscarinic receptor subtype was made by subcloning a variant region of the third intracellular loop of the m3-receptor (Ser345-Leu463) into a bacterial expression plasmid that produced a fusion protein with glutathione S-transferase. In immunoblot studies this antiserum identified the human m3-receptor expressed in transfected Chinese hamster ovary (CHO) cells (CHO-m3 cells, 1343 fmol/mg protein) as a diffuse band at approximately 97-110 kDa. In vivo labeling of the ATP pool in CHO-m3 cells with [P-32]orthophosphate followed by immunoprecipitation of solubilized m3-receptors revealed that the unstimulated receptor existed in a phosphorylated form. Incubation of CHO-m3 cells with the cholinergic agonist carbachol (1 mM) increased the phosphorylated state of the receptor dramatically, primarily at serine. The time course for agonist-dependent phosphorylation was very rapid occurring within seconds of agonist addition and was maintained for at least 30 min. The muscarinic antagonist atropine (10 muM) inhibited agonist-stimulated phosphorylation. Neither forskolin (10 muM) nor the calcium ionophore, ionomycin (1 muM), had any effect on the state of phosphorylation of the m3-receptor, eliminating a role for cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in the agonist-dependent phosphorylation of m3-receptors. 4Beta-phorbol 12beta-myristate 13alpha-acetate (100 nM) did increase m3-receptor phosphorylation, an effect that was inhibited by the selective protein kinase C inhibitor RO-318220 (10 muM). However, agonist-stimulated m3-receptor phosphorylation was not inhibited by RO-318220 indicating that protein kinase C was not involved in agonist-induced m3-receptor phosphorylation. In conclusion the phosphorylation of m3-receptors, in vivo, was increased following the application of muscarinic agonist or PMA. The response to agonist was mediated via a kinase distinct from protein kinase C, protein kinase A and Ca2+/calmodulin dependent protein kinase, whereas the effect of 4beta-phorbol 12beta-myristate 13alpha-acetate was mediated by protein kinase C.			TOBIN, AB (corresponding author), UNIV LEICESTER,DEPT PHARMACOL & THERAPEUT,POB 138,MED SCI BLDG,UNIV RD,LEICESTER LE1 9HN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK MA, 1990, BIOCHEM BIOPH RES CO, V173, P666, DOI 10.1016/S0006-291X(05)80087-7; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BURGOYNE RD, 1981, FEBS LETT, V127, P144, DOI 10.1016/0014-5793(81)80361-4; BURGOYNE RD, 1980, FEBS LETT, V122, P288, DOI 10.1016/0014-5793(80)80458-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P383; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FISHER SK, 1988, J NEUROCHEM, V50, P984, DOI 10.1111/j.1471-4159.1988.tb03008.x; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HARLOW E, 1984, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HO AKS, 1985, BIOCHEM BIOPH RES CO, V133, P1193, DOI 10.1016/0006-291X(85)91263-X; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LILES WC, 1986, J BIOL CHEM, V261, P5307; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; THOMPSON AK, 1991, J BIOL CHEM, V266, P5004; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VICENTINI LM, 1985, BIOCHEM BIOPH RES CO, V127, P310, DOI 10.1016/S0006-291X(85)80160-1; WALL SJ, 1991, MOL PHARMACOL, V40, P783	36	121	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9817	9823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486662				2022-12-25	WOS:A1993LA68900096
J	GAO, BC; EMOTO, Y; GREENE, L; EISENBERG, E				GAO, BC; EMOTO, Y; GREENE, L; EISENBERG, E			NUCLEOTIDE BINDING-PROPERTIES OF BOVINE BRAIN UNCOATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; PEPTIDE BINDING; COATED VESICLES; CLATHRIN COATS; PROTEINS; HSP70; TRANSLOCATION; DISSOCIATION; SUBFAMILY; ACTIN	Many functions of the 70-kDa heat-shock proteins (hsp70s) appear to be regulated by bound nucleotide. In this study we examined the nucleotide binding properties of purified bovine brain uncoating ATPase, one of the constitutively expressed members of the hsp70 family. We found that uncoating ATPase purified by ATP-agarose column chromatography retained one ADP molecule bound per enzyme molecule which could not be removed by extensive dialysis. Since this bound ADP exchanged rapidly with free ADP or ATP, the inability to remove the bound nucleotide was not due to slow dissociation but rather to strong binding of the nucleotide to the uncoating ATPase. In confirmation of this view, equilibrium dialysis experiments suggested that the dissociation constants for both ADP and ATP were less than 0.1 muM. Schmid et al. (Schmid, S. L., Braell, W. A., and Rothman, J. E. (1985) J. Biol. Chem 260, 10057-10062) suggested that the uncoating ATPase had two sites for bound nucleotide, one specific for ATP and one binding both ATP and ATP analogues but not ADP. In contrast, we found that enzyme with bound ADP did not bind further adenosine 5'-(beta,gamma-imino)triphosphate or dATP, nor did more than one ATP molecule bind per enzyme even in 200 muM free ATP. These results strongly suggest that the enzyme has only one binding site for nucleotide. During steady-state ATP hydrolysis, 85% of the bound nucleotide at this site was determined to be ATP and 15% ADP; this is consistent with the rate of ADP release determined in the exchange experiments noted above, where ADP release was found to be six times faster than the overall rate of ATP hydrolysis.	MED COLL OITA,DEPT PHYSIOL,OITA 87956,JAPAN	Oita University	GAO, BC (corresponding author), NHLBI,CELL BIOL LAB,BLDG 3,RM B1-23,BETHESDA,MD 20892, USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO B, 1992, MOL BIOL CELL, V3, pA58; GAO BC, 1991, J BIOL CHEM, V266, P19565; GREENE LE, 1990, J BIOL CHEM, V265, P6682; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; NOVER L, 1991, HEAT SHOCK RESPONSE, P41; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; WANG N M, 1991, Journal of Cell Biology, V115, p255A; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568	23	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8507	8513						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473294				2022-12-25	WOS:A1993KX81100023
J	SIMONIN, F; POCH, O; DELARUE, M; DEMURCIA, G				SIMONIN, F; POCH, O; DELARUE, M; DEMURCIA, G			IDENTIFICATION OF POTENTIAL ACTIVE-SITE RESIDUES IN THE HUMAN POLY(ADP-RIBOSE) POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBOSE) POLYMERASE; ADP-RIBOSYLATION; CDNA SEQUENCE; DNA; EXPRESSION; PROTEIN; DOMAIN; SYNTHETASE; INVITRO	The carboxyl-terminal catalytic domain of the human poly(ADP-ribose) polymerase (PARP) exhibits sequence homology with the NAD(P)+-dependent leucine and glutamate dehydrogenases. To clarify the role played by some conserved residues between PARP and NAD(P)+-dependent dehydrogenases, point mutations were introduced into the whole enzyme context. Non-conservative mutations of Lys-893 (K893I) and Asp-993 (D993A) completely inactivate human PARP, whereas conservative and nonconservative mutations of Asp-914 (D914E and D914A, respectively) and Lys-953 (K953R and K953I, respectively) partially alter PARP activity. The consequences of conservative substitution of Lys-893 and Asp-993 on the kinetic properties of human poly(ADP-ribose) polymerase enzyme and the polymer it synthesizes suggest that these 2 amino acids are directly involved in the covalent attachment of the first ADP-ribosyl residue from NAD+ onto the acceptor amino acid. In addition, the recent resolution of the three-dimensional structure of the NAD+-linked glutamate dehydrogenase from Clostridium symbiosum (Baker, P. J., Britton, K. L., Engel, P.C., Farrants, G. W., Lilley, K. S., Rice, D. W., and Stillman, T. J. (1992) Proteins 12, 75-86) strongly supports our alignment with leucine and glutamate dehydrogenases and provides an interesting structural framework for the analysis of our results of site-directed mutagenesis.	CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH CANCEROGENESE & MUTAGENESE MOLEC & STRUCT,F-67084 STRASBOURG,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,DIV CELLULAIRE & DEV,UNITE PROPRE RECH MECAN,F-67084 STRASBOURG,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH BIOL STRUCT,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; ATANASSOV C, 1991, CLIN EXP IMMUNOL, V86, P124; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KEITH G, 1990, ANAL BIOCHEM, V157, P4350; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARSISCHKY GT, 1992, ADP RIBOSYLATION REA, P47; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MIWA M, 1982, ADP RIBOSYLATION REA, P43; NIEDERGANG C, 1979, EUR J BIOCHEM, V102, P43, DOI 10.1111/j.1432-1033.1979.tb06261.x; OGATA N, 1980, J BIOL CHEM, V255, P7616; RIQUELME PT, 1979, J BIOL CHEM, V254, P3018; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SIMONIN F, 1991, ANAL BIOCHEM, V195, P226, DOI 10.1016/0003-2697(91)90321-J; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; STILLMAN TJ, 1992, J MOL BIOL, V224, P1181, DOI 10.1016/0022-2836(92)90481-X; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; USHIRO H, 1987, J BIOL CHEM, V262, P2352; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	38	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8529	8535						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473297				2022-12-25	WOS:A1993KX81100026
J	KOCH, WJ; INGLESE, J; STONE, WC; LEFKOWITZ, RJ				KOCH, WJ; INGLESE, J; STONE, WC; LEFKOWITZ, RJ			THE BINDING-SITE FOR THE BETA-GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS ON THE BETA-ADRENERGIC-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BOVINE; FAMILY; PHOSPHOLIPASE-A2; ALPHA	The betagamma subunits of heterotrimeric G proteins play important roles in regulating receptor-stimulated signal transduction processes. Recently appreciated among these is their role in the signaling events that lead to the phosphorylation and subsequent desensitization of muscarinic cholinergic (Haga, K., and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227) and beta-adrenergic (Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992) Science 257, 1264-1267) receptors. Betagamma mediates the membrane targeting of the beta-adrenergic receptor kinase (betaARK), in response to receptor activation, through a specific betaARK-betagamma interaction. This process utilizes the membrane-anchoring properties of the isoprenylated gamma subunit of betagamma. In the present study, we have employed three distinct approaches to identify the region within the carboxyl terminus of betaARK which binds betagamma and thereby results in membrane translocation. We studied the ability of betagamma to enhance the enzymatic activity of a series of truncated mutants of bovine betaARK1, the ability of glutathione S-transferase fusion proteins containing various lengths of the carboxyl terminus of betaARK to bind betagamma subunits, and the ability of synthetic peptides comprised of betaARK sequences to inhibit betagamma activation of betaARK1. We find that the minimal betagamma binding domain of betaARK is localized to a 125-amino acid residue stretch, the distal end of which is located 19 residues from the carboxyl terminus. A single 28-mer peptide (Trp643 to Ser670) derived from this sequence effectively inhibited betagamma activation of betaARK1, with an IC50 of 76 muM. The identification of this ''betagamma binding domain'' on betaARK and the development of peptide inhibitors provide important tools for the study of G protein-coupled receptor desensitization, as well as for the investigation of betagamma activation of other G protein-effector systems.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,BOX 3821,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [4R37-HL16039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WHITEWAY M, 1988, COLD SPRING HARB SYM, V53, P585, DOI 10.1101/SQB.1988.053.01.067	30	448	452	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8256	8260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463335				2022-12-25	WOS:A1993KW97900097
J	WARE, J; RUSSELL, SR; MARCHESE, P; RUGGERI, ZM				WARE, J; RUSSELL, SR; MARCHESE, P; RUGGERI, ZM			EXPRESSION OF HUMAN PLATELET GLYCOPROTEIN-IB-ALPHA IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; MEMBRANE; PROTEINS; COMPLEX; FIBRINOGEN; DOMAIN; GENE; DNA; IX	Platelets are cytoplasmic fragments of megakaryocytes and, therefore, their membrane proteins cannot be manipulated by expression methods in culture. To overcome this limitation, we have expressed human glycoprotein (GP) Ibalpha in transgenic mouse megakaryocytes and found that it was present on the surface of platelets associated with the mouse GP Ibbeta subunit. This finding demonstrates that assembly of the heterooligomeric GP Ib complex occurs through mechanisms conserved across species. In contrast, the receptor function of GP Ib exhibited restricted species specificity, since only the chimeric complex containing human GP Ibalpha bound human von Willebrand factor and supported platelet aggregation mediated by ristocetin. These studies demonstrate the transgenic engineering of a platelet adhesion receptor under control of the human GP Ibalpha promoter and illustrate a new approach to manipulate platelet receptors and study structure-function relationships in hemostasis and thrombosis.	SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-42846, R01 HL050545, R01 HL050545-06, HL-31950] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R37HL042846, R01HL050545, R01HL042846] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRINKHOUS KM, 1983, P NATL ACAD SCI-BIOL, V80, P1463, DOI 10.1073/pnas.80.5.1463; COLLER BS, 1983, BLOOD, V61, P99; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DU XP, 1987, BLOOD, V69, P1524; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARLOW E, 1988, ANTIBODIES LAB MANUA, P319; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; ISHIDA F, 1991, BLOOD, V78, P1722; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MURATA M, 1991, J BIOL CHEM, V266, P15474; NIIYA K, 1987, BLOOD, V70, P475; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; PLOW EF, 1985, BLOOD, V66, P724; RAJAGOPALAN V, 1992, BLOOD, V80, P153; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; RUGGERI ZM, 1992, THROMB HAEMOSTASIS, V67, P594; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHIMOMURA T, 1990, BLOOD, V75, P2349; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WENGER RH, 1989, GENE, V85, P517, DOI 10.1016/0378-1119(89)90446-0; WENGER RH, 1988, BIOCHEM BIOPH RES CO, V156, P389, DOI 10.1016/S0006-291X(88)80853-2; [No title captured]	51	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8376	8382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463345				2022-12-25	WOS:A1993KW97900112
J	YURCHENCO, PD; SUNG, U; WARD, MD; YAMADA, Y; OREAR, JJ				YURCHENCO, PD; SUNG, U; WARD, MD; YAMADA, Y; OREAR, JJ			RECOMBINANT LAMININ-G DOMAIN MEDIATES MYOBLAST ADHESION AND HEPARIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; GLOBULAR DOMAIN; CELL-ADHESION; B-CHAINS; A-CHAIN; INTEGRIN; IDENTIFICATION; SUBUNIT; PROTEIN; POLYMERIZATION	A recombinant mouse cDNA fragment encoding the G domain of the basement membrane laminin A chain was inserted into the eukaryotic baculovirus expression vector pVL1392 modified to produce fusion proteins carrying the rat fibronectin signal. G domain, expressed and secreted as a soluble glycoprotein (rG), was purified to near homogeneity without denaturing conditions. By electron microscopy rG possessed the same globular morphology as found in laminin. rG was cleaved with elastase into two fragments, rG70 and rG50. The latter fragment possessed the identical N terminus as laminin fragment E3 and both shared the same secondary structure by circular dichroism. rG, and rG containing a deletion (residues 2980-3028) rich in basic residues bound to heparin with similar avidity. rG also promoted mouse C2 myoblast cell adhesion and spreading, and evaluation of myoblasts on rG70 and rG50 further revealed that cell spreading was an activity confined to the more proximal sequence of rG70. Antibody specific for rG70 completely blocked cell adhesion to intact laminin in contrast to antibody specific for E3. Finally rG did not inhibit laminin polymerization. These data support the role of G domain in cell and heparin binding, but not laminin self-assembly, and the approach provides a means to further characterize these functions.	ROBERT WOOD JOHNSON MED SCH,DEPT MICROBIOL & MOLEC GENET,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; NIDR,BETHESDA,MD 20892	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36425] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CHARKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; CHEN WY, 1991, J BIOL CHEM, V266, P4081; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; Summers MD, 1987, TEXAS AGR EXPT STATI; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSAO T, 1990, J BIOL CHEM, V265, P5188; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	38	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8356	8365						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463343				2022-12-25	WOS:A1993KW97900110
J	CHANG, CP; ZHAO, J; WIEDMER, T; SIMS, PJ				CHANG, CP; ZHAO, J; WIEDMER, T; SIMS, PJ			CONTRIBUTION OF PLATELET MICROPARTICLE FORMATION AND GRANULE SECRETION TO THE TRANSMEMBRANE MIGRATION OF PHOSPHATIDYLSERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT PROTEINS C5B-9; AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY; SPIN-LABELED PHOSPHOLIPIDS; HUMAN-ERYTHROCYTES; PROCOAGULANT ACTIVITY; BLOOD-PLATELETS; PLASMA-MEMBRANE; LIPID ASYMMETRY; TRANSBILAYER MOVEMENT; ACTIVATED PLATELETS	Activation of human platelets by complement proteins, C5b-9, thrombin plus collagen, or a Ca2+ ionophore results in surface exposure of phosphatidylserine (PS), accompanied by the expression of membrane catalytic activity for the tenase (VIIIaIXa) and prothrombinase (VaXa) coagulation enzyme complexes. The mechanism underlying this surface exposure of PS upon platelet activation remains unresolved. Using fluorescent derivatives of PS (NBD-PS), we have investigated how the transmembrane migration of PS is related to microvesiculation of the platelet plasma membrane and to fusion of storage granules with the plasma membrane. Gel-filtered platelets were incubated with NBD-PS, allowing 90 +/- 10% of the incorporated NBD-PS to accumulate into the inner leaflet of the plasma membrane. Migration of NBD-PS from the inner leaflet to the plasma membrane surface was monitored by time-based flow cytometry, and correlated with the appearance of platelet microparticles and alpha-granule secretion. Platelet activation by C5b-9 or the Ca2+ ionophore, A23187, increased surface exposure of NBD-PS, due to acceleration of the apparent rate of migration from inner to outer plasma membrane leaflets. The onset of this accelerated migration of NBD-PS to the surface coincided with the onset of plasma membrane vesiculation, and the NBD-PS that partitioned into the membrane of the shed microparticle was also rapidly exposed to the surface (t1/2 < 2 min). In addition to a temporal correlation, microparticle formation and the surface exposure of inner leaflet NBD-PS showed a similar requirement for Ca2+. These results demonstrate that agonist-induced microvesiculation of the platelet plasma membrane is accompanied by accelerated migration of a PS analogue from the inner leaflet to the surface of the shed microparticle membrane, suggesting the mechanism by which induction of platelet microparticle formation exposes catalytic surface for tenase and prothrombinase assembly.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,1701 W WISCONSIN AVE,MILWAUKEE,WI 53233; OKLAHOMA MED RES FDN,OKLAHOMA CITY,OK 73104	Versiti Blood Center of Wisconsin; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R29HL040796] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36946, HL40796] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1977, BIOCHEM J, V166, P495, DOI 10.1042/bj1660495; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BODE AP, 1991, BLOOD, V77, P887; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; CONNOR J, 1990, BIOCHEMISTRY-US, V29, P37, DOI 10.1021/bi00453a005; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; EASTMAN SJ, 1992, BIOCHEMISTRY-US, V31, P4262, DOI 10.1021/bi00132a016; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; FOX JEB, 1991, J BIOL CHEM, V266, P13289; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HOPE MJ, 1983, BIOCHEM BIOPH RES CO, V110, P15, DOI 10.1016/0006-291X(83)91253-6; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHATTIL SJ, 1987, BLOOD, V70, P307; SIMS PJ, 1986, BLOOD, V68, P556; SIMS PJ, 1991, IMMUNOL TODAY, V12, P338, DOI 10.1016/0167-5699(91)90012-I; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; TILLY RHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P188, DOI 10.1016/0005-2736(90)90453-U; VANDERMEER BW, 1989, BIOPHYS J, V56, P935, DOI 10.1016/S0006-3495(89)82739-0; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WIEDMER T, 1987, J BIOL CHEM, V262, P13674; WIEDMER T, 1985, J BIOL CHEM, V260, P8014; WIEDMER T, 1986, BLOOD, V68, P875; WIEDMER T, 1991, BLOOD, V78, P2880; WIEDMER T, 1986, BLOOD, V68, P556; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WOLF DE, 1992, BIOCHEMISTRY-US, V31, P2865, DOI 10.1021/bi00126a004; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zwaal R F, 1983, Subcell Biochem, V9, P299	46	125	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7171	7178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463253				2022-12-25	WOS:A1993KV14100055
J	SAIDO, TC; SUZUKI, H; YAMAZAKI, H; TANOUE, K; SUZUKI, K				SAIDO, TC; SUZUKI, H; YAMAZAKI, H; TANOUE, K; SUZUKI, K			INSITU CAPTURE OF MU-CALPAIN ACTIVATION IN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEASE; MEMBRANE-SKELETON; AGGREGATION; INHIBITOR; KINASE	In situ detection of calpain activation in intact cells has not been possible to date. Here we present the first direct evidence, employing a novel approach, that mu-calpain is rapidly activated at cell membranes in platelets upon a rise in intracellular calcium concentration. Immunoelectron microscopy using antibodies capable of distinguishing between the pre- and postautolysis forms of mu-calpain revealed that treatment of platelets with calcium ionophore causes the preautolysis form of the protease to translocate from cytosol to membranes, where it becomes activated by autolysis. This indicates that proteins associated with membranes serve as primary substrates for calpain in cells.	TOKYO METROPOLITAN INST MED SCI,DEPT CARDIOVASC RES,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,3-18-22 HONKOMAGOME,BUNKYO KU,TOKYO 113,JAPAN.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; COLMAN RW, 1990, INTRACELLULAR CALCIU, P211; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; GOLL ED, 1990, INTRACELLULAR CALCIU, P103; HAGIWARA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P201, DOI 10.1016/0003-9861(90)90536-8; HATHAWAY DR, 1990, INTRACELLULAR CALCIU, P91; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SUZUKI H, 1992, HISTOCHEMISTRY, V97, P381, DOI 10.1007/BF00270384; SUZUKI H, 1991, HISTOCHEMISTRY, V96, P31, DOI 10.1007/BF00266758; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TOYOOKA T, 1989, CIRC RES, V64, P407, DOI 10.1161/01.RES.64.2.407; TRUGLIA JA, 1981, BIOCHEM BIOPH RES CO, V100, P814, DOI 10.1016/S0006-291X(81)80247-1; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2	22	104	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7422	7426						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463275				2022-12-25	WOS:A1993KV14100085
J	THON, VJ; KHALIL, M; CANNON, JF				THON, VJ; KHALIL, M; CANNON, JF			ISOLATION OF HUMAN GLYCOGEN BRANCHING ENZYME CDNAS BY SCREENING COMPLEMENTATION IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL COMPLEMENTATION; SACCHAROMYCES-CEREVISIAE; STORAGE-DISEASE; TRANSFORMATION; GENES; MUTATIONS; BINDING	Functional complementation of the Saccharomyces cerevisiae glycogen branching enzyme deficiency was screened to isolate human cDNAs that encode this enzyme. Human hepatoma cell line HepG2-derived cDNA libraries using the pAB23BXN yeast expression vector yielded four cDNAs capable of complementing the glc3::TRP1 glycogen branching enzyme mutation. Complementation was recognized by an altered iodine-staining trait. This illustrates that interspecies complementation can be used to isolate rare plasmids from libraries by screening if there is sufficient resolution. The human and yeast glycogen branching enzymes have a 67% identical amino acid sequence over a major portion of their length. The human gene is on chromosome 3.	UNIV MISSOURI, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia				Cannon, John/0000-0001-6698-176X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040326, R01GM040326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown B. I., 1966, METHOD ENZYMOL, V8, P395; BROWN BI, 1989, AM J HUM GENET, V44, P378; BROWN BI, 1966, P NATL ACAD SCI USA, V56, P725, DOI 10.1073/pnas.56.2.725; BROWN DH, 1961, P NATL ACAD SCI USA, V47, P479, DOI 10.1073/pnas.47.4.479; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; DOUGHERTY KM, 1992, J BIOL CHEM, V267, P871; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Geddes R., 1985, POLYSACCHARIDES, V3, P283; GRAVES DJ, 1982, ENZYMES, V7; GUNJA-SMITH Z, 1977, Journal of Bacteriology, V130, P818; HOWELL RR, 1991, NEW ENGL J MED, V324, P55, DOI 10.1056/NEJM199101033240111; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; ILLINGWORTH B, 1952, J BIOL CHEM, V199, P653; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEDBETTER SA, 1990, GENOMICS, V8, P614, DOI 10.1016/0888-7543(90)90247-R; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Maniatis T., 1982, MOL CLONING; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SELBY R, 1991, NEW ENGL J MED, V324, P39, DOI 10.1056/NEJM199101033240107; SERVIDEI S, 1987, J PEDIATR-US, V111, P51, DOI 10.1016/S0022-3476(87)80341-4; SHERMAN F, 1986, LABORATORY COURSE MA; THON VJ, 1992, J BIOL CHEM, V267, P15224; THON VJ, 1992, THESIS U MISSOURI CO	33	76	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7509	7513						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463281				2022-12-25	WOS:A1993KV14100098
J	OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ				OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ			ALTERNATIVE SPLICING OF THE RBP1 GENE CLUSTERS IN AN INTERNAL EXON THAT ENCODES POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; TRANSCRIPTION FACTOR; PRODUCT; PROTEINS; BINDING; EXPRESSION; CARCINOMA; COMPLEX; IDENTIFICATION	We have isolated cDNA and genomic clones for the human retinoblastoma binding protein 1 (RBP1) gene, and have identified alternative splicing of RBP1 clustered within a 207-nucleotide internal exon. Three of the predicted RPB1 peptides share amino-terminal and carboxy-terminal domains, while a fourth species encodes a distinct carboxy-terminal domain. Functional analysis of these peptides demonstrated that they are capable of precipitating retinoblastoma (RB) protein in vitro from K562 cell lysates, but cannot bind to mutant RB protein. However, each of the RBP1 peptides differed within an internal exon that contains potential casein kinase II and p34cdc2 phosphorylation sites. Immunoblot analysis using polyclonal alpha-RBP1 antiserum revealed that the RBP1 protein is expressed in a wide range of cell lines of differing histologic type and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis predominantly as a 200-kDa protein. Immunohistochemical analysis using the alpha-RBP1 antiserum demonstrated a distinct nuclear staining pattern that was eliminated when the antiserum was preabsorbed with RBP1 peptide. The RBP1 gene encodes a widely expressed 200-kDa nuclear protein and undergoes alternative splicing that predicts a family of RB-binding peptides.	USN HOSP,NCI,NAVY ONCOL BRANCH,BLDG 8,RM 5101,BETHESDA,MD 20889; UNIV HLTH SCI,UNIFORMED SERV,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			kaye, frederic/E-2437-2011					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Battey, 1986, BASIC METHODS MOL BI; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	38	21	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					949	957						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455946				2022-12-25	WOS:A1993KT22000017
J	WELLSKNECHT, MC; HUGGINS, TG; DYER, DG; THORPE, SR; BAYNES, JW				WELLSKNECHT, MC; HUGGINS, TG; DYER, DG; THORPE, SR; BAYNES, JW			OXIDIZED AMINO-ACIDS IN LENS PROTEIN WITH AGE - MEASUREMENT OF O-TYROSINE AND DITYROSINE IN THE AGING HUMAN LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-TRYPTOPHAN FLUORESCENCE; DEPENDENT ACCUMULATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; IDENTIFICATION; COLLAGEN; INVIVO	The concentrations of ortho-tyrosine (o-Tyr) and dityrosine (DT) were measured in noncataractous human lenses in order to assess the role of protein oxidation reactions in the aging of lens proteins. The measurements were conducted by selected ion monitoring-gas chromatography/mass spectrometry using deuterium-labeled internal standards, which provided both high sensitivity and specificity for the quantitation of o-Tyr and DT. Between ages 1 and 78 years, the o-Tyr concentration in lens proteins varied from 0.3 to 0.9 mmol of o-Tyr/mol of Phe (n = 19), while DT ranged from 1 to 3 mumol of DT/mol of Tyr (n = 30). There were no significant changes in levels of o-Tyr with lens age. There was a statistically significant, but only slight, increase in DT in lens proteins with age (approximately 33% increases between ages 1 and 78, r = 0.5, p < 0.01). At the same time, total protein fluorescence, measured at DT wavelengths (E(x) = 317 nm, E(m) = 407 nm), increased 11-fold between ages 1 and 78 and correlated strongly with age (r = 0.82, p < 0.0001). Although the fluorescence maxima of lens proteins were similar to those of DT, DT accounted for less than 1% of the DT-like fluorescence in lens protein at all ages. These observations indicate that oxidation of Phe and Tyr plays a limited role in the normal aging of lens proteins in vivo.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NIDDK NIH HHS [DK25373, DK19971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025373, R01DK019971, R37DK019971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; DILLON J, 1976, NATURE, V259, P422, DOI 10.1038/259422a0; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1991, Z ERNAHRUNGSWISS, V30, P29, DOI 10.1007/BF01910730; GARCIACASTINEIRAS S, 1978, EXP EYE RES, V26, P461, DOI 10.1016/0014-4835(78)90132-X; GARCIACASTINEIRAS S, 1978, SCIENCE, V199, P897, DOI 10.1126/science.622574; GUPTASARMA P, 1992, CURR EYE RES, V11, P1121, DOI 10.3109/02713689209015084; Harding JJ, 1984, EYE B, V1b, P207; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; MCNAMARA MK, 1980, EXP EYE RES, V30, P319, DOI 10.1016/0014-4835(80)90014-7; SATOH K, 1973, EXP EYE RES, V16, P167, DOI 10.1016/0014-4835(73)90311-4; SPECTOR A, 1975, EXP EYE RES, V21, P9, DOI 10.1016/0014-4835(75)90053-6; ZIGLER JS, 1981, TRENDS BIOCHEM SCI, V6, P133	17	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12348	12352						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509374				2022-12-25	WOS:A1993LG65800022
J	DELAHUNTY, MD; STAFFORD, FJ; YUAN, LC; SHAZ, D; BONIFACINO, JS				DELAHUNTY, MD; STAFFORD, FJ; YUAN, LC; SHAZ, D; BONIFACINO, JS			UNCLEAVED SIGNALS FOR GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORING CAUSE RETENTION OF PRECURSOR PROTEINS IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DECAY-ACCELERATING FACTOR; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; SITE-SPECIFIC MUTAGENESIS; CLEAVAGE ATTACHMENT SITE; CELL ANTIGEN RECEPTOR; QA-2 ANTIGEN; THY-1 GLYCOPROTEIN; MOLECULAR-CLONING; PHOSPHOLIPASE-C	Glycosylphosphatidylinositol (GPI)-anchored proteins are generally absent from the surface of cells that are defective in GPI biosynthesis. The current study was undertaken to: (a) examine in detail the intracellular localization and fate of precursors of GPI-anchored proteins in cells that fail to add GPI groups and (b) define structural characteristics of the precursor proteins that determine their intracellular localization. By examining GPI-deficient cells, we show that the uncleaved precursor of the GPI-anchored protein, Q7b, is retained in the cisternae of the endoplasmic reticulum (ER) and is largely lost intracellularly with a half-time of 2-4 h. Only a small amount (1-10%) of a proteolytically cleaved form of the protein is secreted into the medium. In cells competent for GPI anchor addition, mutation of the putative cleavage/attachment site for GPI addition in Q7b results in a similar phenotype of ER retention of the uncleaved precursor. An aspartic acid residue (Asp316) within the Q7b GPI anchoring signal, previously found to be essential for GPI anchor addition (Waneck, G. L., Stein, M. E., and Flavell, R. A. (1988) Science 241, 697-699), is also shown to be critical for ER retention. Information leading to ER retention is transferable to another protein by fusion of the GPI anchoring signals from either Q7b or the GPI-anchored form of the IgG Fc receptor type III. Analysis by sedimentation on sucrose gradients shows that Q7b species retained in the ER are multimeric, whereas species that exit the ER are monomeric. This correlation suggests that the presence of an uncleaved signal for GPI anchoring induces changes in the aggregation state of the precursor proteins, which may lead to their retention in the ER.			DELAHUNTY, MD (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Bonifacino, Juan S./0000-0002-5673-6370				BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLAHERTY L, 1976, IMMUNOGENETICS, V3, P533, DOI 10.1007/BF01576983; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSCH GM, 1988, BLOOD, V72, P1089; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; JOST CR, 1991, BLOOD, V78, P3030; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; MAHONEY JF, 1992, BLOOD, V79, P1400; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MICHAELSON J, 1981, IMMUNOGENETICS, V14, P129, DOI 10.1007/BF00344306; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SHARROW SO, 1989, J IMMUNOL, V142, P3495; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STROYNOWSKI I, 1987, CELL, V50, P759, DOI 10.1016/0092-8674(87)90334-5; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAMI N, 1992, J BIOL CHEM, V267, P1042; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; WADA I, 1991, J BIOL CHEM, V266, P19599; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WANECK GL, 1988, P NATL ACAD SCI USA, V85, P577, DOI 10.1073/pnas.85.2.577; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WIENANDS J, 1992, NATURE, V356, P246, DOI 10.1038/356246a0; WILCOX LA, 1991, BLOOD, V78, P820, DOI 10.1182/blood.V78.3.820.bloodjournal783820; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	65	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12017	12027						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505326				2022-12-25	WOS:A1993LF28400084
J	MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS				MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS			HUMAN ERG-2 PROTEIN IS A PHOSPHORYLATED DNA-BINDING PROTEIN - A DISTINCT MEMBER OF THE ETS FAMILY	ONCOGENE			English	Article							LONG TERMINAL REPEAT; LEUKEMIA-VIRUS; C-FOS; ONCOGENE; GENE; SEQUENCE; ONCOPROTEIN; ACTIVATION; ERYTHROBLASTOSIS; RETROVIRUS-E26	We describe the identification of the ERG-2 gene products using an antibody raised against recombinant human ERG-2 protein. ERG-2 is a nuclear phosphoprotein and binds to purine-rich sequences (C/G)(C/a)GG-AA(G/a)T. ERG-2 protein, with a half-life of 21 h, is considerably more stable than the short-lived ETS-1 or ETS-2 proteins. Its phosphorylation is stimulated by phorbal myristate acetate (PMA), but not by Ca2+ ion-phore treatment. ETS-1 protein is phosphorylated by Ca2+-dependent events, whereas ERG-2 protein is phosphorylated by activation of protein kinase C, suggesting their involvement in distinct signal transduction mechanisms. The expression of ERG-2 protein is restricted to few cell types and is high in early myeloid cells, indicating that it may function at an early stage of hematopoietic lineage determination. The DNA-binding sequence for ERG-2 protein is identified by using a random oligonucleotide selection procedure. The selected sequence is very similar to the binding sequence determined for human ETS-1 using the same method. Like other ets proteins, ERG-2 is a sequence-specific DNA-binding protein and is expressed at higher levels in early myeloid cells than in mature lymphoid cells. These results suggest that it may act as a regulator of genes required for maintenance and/or differentiation of early hematopoietic cells.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INC DYNCORP,PROGRAM RESOURCES,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P1001; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDKE K, 1982, CELL, V31, P643; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	40	42	43	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1559	1566						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502479				2022-12-25	WOS:A1993LE06400019
J	WANG, ZY; LIN, XH; NOBUYOSHI, M; DEUEL, TF				WANG, ZY; LIN, XH; NOBUYOSHI, M; DEUEL, TF			IDENTIFICATION OF A SINGLE-STRANDED DNA-BINDING PROTEIN THAT INTERACTS WITH AN S1 NUCLEASE-SENSITIVE REGION IN THE PLATELET-DERIVED GROWTH-FACTOR A-CHAIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; CARDIAC ACTIN; CODING STRAND; TRANSCRIPTION; SEQUENCES; CONFORMATION; ELEMENTS; ROLES	We previously observed that transcription of the platelet-derived growth factor (PDGF) A-chain gene is enhanced in cells stimulated by PDGF through a serum response element (SRE) in its 5'-flanking sequence. We now show that the region of the SRE is sensitive to S1 nuclease in vitro. We also identify a single-stranded DNA-binding protein in HeLa cell nuclear extracts that binds to the noncoding strand of the PDGF A-chain SRE but not to its double-stranded counterpart or to the single-stranded coding sequence. Competition assays using oligonucleotides with sequence-specific mutations that diminished or eliminated detectable complex formation were used to establish the specificity of this protein/DNA interaction. Remarkably, the sequence-specific single-stranded binding protein binds to this region only when it is highly supercoiled. The data suggest that the single-stranded DNA-binding protein specifically interacts with a highly supercoiled region of the PDGF A-chain promoter and that this interaction may have a role in the transcriptional regulation of this gene.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)								BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAILLARD C, 1988, J VIROL, V62, P2380, DOI 10.1128/JVI.62.7.2380-2385.1988; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GRAYHACK ZJ, 1992, MOL CELL BIOL, V12, P3573; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIN XH, 1992, J BIOL CHEM, V267, P25614; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; SAMBROOK T, 1989, MOL CLONING LABORATO; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WALSH K, 1987, J BIOL CHEM, V262, P9429; WANG ZY, 1992, J BIOL CHEM, V267, P13669; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1991, T ASSOC AM PHYSICIAN, V14, P1; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YAN WA, 1989, EMBO J, V8, P1785; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	35	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10681	10685						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486717				2022-12-25	WOS:A1993LB80000100
J	YAVER, DS; NELSON, H; NELSON, N; KLIONSKY, DJ				YAVER, DS; NELSON, H; NELSON, N; KLIONSKY, DJ			VACUOLAR ATPASE MUTANTS ACCUMULATE PRECURSOR PROTEINS IN A PRE-VACUOLAR COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; H+-ATPASE; YEAST MUTANTS; ALPHA-FACTOR; CARBOXYPEPTIDASE-Y; SECRETORY PATHWAY; PLASMA-MEMBRANE; TRANSPORT; GENE; ACIDIFICATION	The vacuole of the yeast Saccharomyces cerevisiae contains a proton-translocating ATPase that acidifies the vacuolar lumen and generates an electrochemical potential across the vacuole membrane. Strains with chromosomal disruptions of the genes encoding the A, B, and c subunits of the vacuolar ATPase accumulate precursor forms of the vacuolar membrane protein alkaline phosphatase, and the soluble vacuolar hydrolases carboxypeptidase Y and proteinase A. We have found that the intracellular precursors in DELTAvat strains accumulate within the secretory pathway at some point before delivery to the vacuole but after transit to the Golgi complex. Purified vacuoles from DELTAvat cells do not contain the precursor forms of carboxypeptidase Y or alkaline phosphatase. In addition, vacuolar hydrolase-invertase hybrid proteins are inefficiently delivered to the vacuole in DELTAvat strains as demonstrated by vacuole isolation. Further subcellular fractionation to separate organelles indicate that significant amounts of the carboxypeptidase Y-invertase and alkaline phosphatase-invertase hybrid proteins are located in the late Golgi complex and/or post Golgi compartments.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA; ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	University of California System; University of California Davis; Roche Holding				Yaver, Debbie/0000-0003-4150-6756	NIDDK NIH HHS [DK43684] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043684] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P7080, DOI 10.1073/pnas.80.23.7080; FOURY F, 1990, J BIOL CHEM, V265, P18554; Goldstein A, 1975, Methods Enzymol, V42, P504; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HALVORSON H, 1958, BIOCHIM BIOPHYS ACTA, V30, P28, DOI 10.1016/0006-3002(58)90237-3; HIRATA R, 1990, J BIOL CHEM, V265, P6726; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KANE PM, 1989, J BIOL CHEM, V264, P19236; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; PRESTON RA, 1992, GENETICS, V131, P551; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418	46	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10564	10572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486710				2022-12-25	WOS:A1993LB80000085
J	KANAMOTO, R; KAMEJI, T; IWASHITA, S; IGARASHI, K; HAYASHI, S				KANAMOTO, R; KAMEJI, T; IWASHITA, S; IGARASHI, K; HAYASHI, S			SPERMIDINE-INDUCED DESTABILIZATION OF ORNITHINE DECARBOXYLASE (ODC) IS MEDIATED BY ACCUMULATION OF ANTIZYME IN ODC-OVERPRODUCING VARIANT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED-HEPATOCYTES; RAT-LIVER; ALPHA-DIFLUOROMETHYLORNITHINE; ERYTHROLEUKEMIA-CELLS; CASEIN KINASE; PHOSPHORYLATION; DEGRADATION; PUTRESCINE; POLYAMINES; STABILIZATION	The mechanism of spermidine-induced destabilization of ornithine decarboxylase (ODC) was examined in newly isolated ODC-overproducing variant cells by use of an in vitro ODC degrading system. The cells accumulated ODC protein at a level of 2-4% of the total cytosolic protein in the presence of alpha-difluoromethylornithine. Addition of spermidine to the medium accelerated degradation of ODC protein concomitantly with induction of antizyme, a regulatory protein that binds to ODC, inhibiting its activity. Both the acceleration of ODC degradation and the induction of antizyme were inhibited by cycloheximide, but not by actinomycin D. ODC was degraded rapidly in extracts from spermidine-treated cells. The rate of ODC degradation correlated with the amount of antizyme in the extracts, and the degradation activity was abolished by treatment of the extracts with anti-antizyme antibody. Thus, antizyme induced by spermidine was essential for the accelerated degradation of ODC in the cells. ODC was phosphorylated in the cells, probably at serine residue 303 in the first internal PEST region. ODC phosphorylation occurred even when its new synthesis was inhibited by cycloheximide. Antizyme accelerated the degradations of both dephosphorylated ODC and native ODC.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; CHIBA UNIV, FAC PHARMACEUT SCI, YAYOI, CHIBA 260, JAPAN	Chiba University	KANAMOTO, R (corresponding author), JIKEI UNIV SCH MED, DEPT NUTR, MINATO KU, TOKYO 105, JAPAN.			Iwashita, Shintaro/0000-0001-8086-9192; Igarashi, Kazuei/0000-0003-3751-3187				AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Canellakis E S, 1979, Curr Top Cell Regul, V15, P155; FLAMIGNI F, 1990, BIOCHIM BIOPHYS ACTA, V1052, P345, DOI 10.1016/0167-4889(90)90232-3; FLAMIGNI F, 1989, BIOCHEM BIOPH RES CO, V163, P1217, DOI 10.1016/0006-291X(89)91107-8; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HOGAN BLM, 1974, J CELL PHYSIOL, V83, P345, DOI 10.1002/jcp.1040830304; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KAMEJI T, 1982, BIOCHIM BIOPHYS ACTA, V717, P111, DOI 10.1016/0304-4165(82)90387-7; KANAMOTO R, 1991, ARCH BIOCHEM BIOPHYS, V291, P247, DOI 10.1016/0003-9861(91)90130-B; KANAMOTO R, 1987, J BIOL CHEM, V262, P14801; KANAMOTO R, 1986, EUR J BIOCHEM, V154, P539, DOI 10.1111/j.1432-1033.1986.tb09432.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MATSUFUJI S, 1984, J BIOCHEM-TOKYO, V96, P1525, DOI 10.1093/oxfordjournals.jbchem.a134981; MEGGIO F, 1987, BIOCHIM BIOPHYS ACTA, V929, P114, DOI 10.1016/0167-4889(87)90246-1; MEGGIO F, 1984, BIOCHEM BIOPH RES CO, V122, P997, DOI 10.1016/0006-291X(84)91190-2; MITCHELL JLA, 1991, ARCH BIOCHEM BIOPHYS, V290, P143, DOI 10.1016/0003-9861(91)90600-N; MITSUI K, 1990, FEBS LETT, V268, P157, DOI 10.1016/0014-5793(90)80997-W; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1989, EUR J BIOCHEM, V180, P181, DOI 10.1111/j.1432-1033.1989.tb14630.x; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PENG T, 1988, BIOCHEM BIOPH RES CO, V153, P135, DOI 10.1016/S0006-291X(88)81199-9; POULIN R, 1990, J BIOL CHEM, V265, P4025; PROUTY WF, 1976, J CELL PHYSIOL, V89, P65, DOI 10.1002/jcp.1040890107; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOHYAMA Y, 1991, EUR J BIOCHEM, V202, P1327, DOI 10.1111/j.1432-1033.1991.tb16507.x; UTSUNOMIYA K, 1985, Jikeikai Medical Journal, V32, P575; VICEPSMADORE D, 1982, BIOCHIM BIOPHYS ACTA, V717, P305, DOI 10.1016/0304-4165(82)90184-2	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9393	9399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486633				2022-12-25	WOS:A1993LA68900039
J	REICH, NO; MASHHOON, N				REICH, NO; MASHHOON, N			PRESTEADY STATE KINETICS OF AN S-ADENOSYLMETHIONINE-DEPENDENT ENZYME - EVIDENCE FOR A UNIQUE BINDING ORIENTATION REQUIREMENT FOR ECORI DNA METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							METHYLASE	We present the first presteady state kinetic analysis of an S-adenosylmethionine-dependent enzyme. The target enzyme is the bacterial EcoRI DNA methyltransferase, which transfers the methyl group to the second adenine in the DNA sequence GAATTC. The rate constant for conversion of the central complex (enzyme-DNA-S-adenosylmethionine) to products (enzyme-methylated DNA-S-adenosylhomocysteine) (41 +/- 7 s-1) is over 300-fold faster than k(cat), consistent with our demonstration that steps after methyl transfer are rate-limiting (Reich, N. O., and Mashhoon, N. (1991) Biochemistry 30,2933-2939). Methyl transfer at the N6 amino moiety of adenine on each strand requires a single binding orientation.			REICH, NO (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106, USA.							BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; Modrich P., 1982, NUCLEASES, P109; RAZIN A, 1984, DNA METHYLATION BIOC; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1991, NUCLEIC ACIDS RES, V19, P6587, DOI 10.1093/nar/19.23.6587; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REICH NO, 1992, BIOCHEMISTRY-US, V31, P1937, DOI 10.1021/bi00122a006; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0	13	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9191	9193						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486619				2022-12-25	WOS:A1993LA68900010
J	BRACH, MA; GRUSS, HJ; KAISHO, T; ASANO, Y; HIRANO, T; HERRMANN, F				BRACH, MA; GRUSS, HJ; KAISHO, T; ASANO, Y; HIRANO, T; HERRMANN, F			IONIZING-RADIATION INDUCES EXPRESSION OF INTERLEUKIN-6 BY HUMAN FIBROBLASTS INVOLVING ACTIVATION OF NUCLEAR FACTOR-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; DNA DAMAGE; MAMMALIAN-CELLS; MESSENGER-RNA; C-FOS; METALLOTHIONEIN; IRRADIATION; INDUCTION; ELEMENT	We here report that human lung fibroblasts respond to x-ray treatment (XRT) with release of interleukin (IL)-6. Synthesis of IL-6 upon ionizing radiation is preceded by an increase of IL-6 transcript levels resulting from transcriptional activation of the IL-6 gene. Analysis of deleted fragments of the IL-6 promoter indicated that transcriptional activation of the IL-6 promoter was due to enhanced binding activity of the transcription factor nuclear factor (NF)-kappaB. Although AP-1 did not participate in the rapid induction of the IL-6 promoter, its binding activity was also enhanced by XRT. In contrast to binding kinetics observed with NF-kappaB, AP-1 binding following XRT was biphasic with the second peak being dependent on de novo protein synthesis. In contrast, however, NF-IL-6 activity was not enhanced by XRT in fibroblasts. The introduction of both the NF-kappaB- and the AP-1 recognition sequence conferred inducibility by XRT to a heterologous promoter, with reporter gene activity being maximal 24 or 48 h following XRT, respectively. Sequential activation of two distinct transcription factors might thus contribute to synchronize transcriptional activation of different genes participating in the x-ray response.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,DEPT MED ONCOL & APPL MOLEC BIOL,ROBERT ROSSLE KLIN,W-1115 BERLIN,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,W-1115 BERLIN,GERMANY; UNIV FREIBURG KLINIKUM,DEPT HEMATOL & ONCOL,W-7800 FREIBURG,GERMANY; OSAKA UNIV,SCH MED,DIV MOLEC ONCOL,SUITA,OSAKA 565,JAPAN	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Freiburg; Osaka University			Hirano, Toshio/C-8194-2009; Kaisho, Tsuneyasu/B-4130-2012					ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BRACH MA, 1992, BLOOD, V79, P728; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1992, INT J CLIN LAB RES, V22, P143, DOI 10.1007/BF02591414; Bradford MM, 1976, ANAL BIOCHEM, V72, P234; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HALAZONETIS T, 1988, CELL, V55, P924; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Law MP., 1981, ADV RADIAT BIOL, P37; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MANTOVANI L, 1990, FEBS LETT, V270, P152, DOI 10.1016/0014-5793(90)81256-N; PHILLIPS TL, 1972, FRONTIERS RADIATION, V6, P21; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALTHER Z, 1988, J IMMUNOL, V140, P974; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	33	134	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8466	8472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473290				2022-12-25	WOS:A1993KX81100017
J	INMAN, RS; WESSLINGRESNICK, M				INMAN, RS; WESSLINGRESNICK, M			CHARACTERIZATION OF TRANSFERRIN-INDEPENDENT IRON TRANSPORT IN K562 CELLS - UNIQUE PROPERTIES PROVIDE EVIDENCE FOR MULTIPLE PATHWAYS OF IRON UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CADMIUM UPTAKE; SACCHAROMYCES-CEREVISIAE; BOUND IRON; RAT-LIVER; SYSTEM; GROWTH; RETICULOCYTES; HEPATOCYTES; REDUCTION	The present study characterizes the transport of nontransferrin (non-Tf) iron by K562 cells. Accumulation of radiolabel by cells incubated with Fe-55-nitrilotriacetate (NTA) is a saturable process that is time and temperature dependent (Ea approximately 20 kcal/mol). Initial rate analysis of iron influx yields values of V(max) = 855 fmol/min/10(6) cells and apparent K(m) = 0.54 muM. NHCl4 and chloroquine, agents that block cellular acquisition of iron from Tf, do not interfere with assimilation from FeNTA, demonstrating that uptake is truly independent of the Tf-mediated pathway. Furthermore, the inactivation of this transport mechanism by limited proteolytic digestion on ice indicates that specific cell surface proteins are involved. The extent of radiolabel incorporation into heme and ferritin is the same regardless of whether K562 cells acquire iron from Fe-55NTA via the cell surface mechanism or from Fe-55-Tf via receptor-mediated endocytosis. Unlike other Tf-independent iron transport pathways that have been described, the K562 cell transport mechanism is not inhibited by divalent cations such as Ni2+, Co2+, or Mn2+. Uptake from Fe-55NTA can be blocked by Cu2+ but at concentrations >1500-fold molar excess. However, Cd2+ is a fairly specific inhibitor of Fe-55 uptake by K562 cells (IC50 approximately 50 muM). Additionally, the K562 cell transport mechanism is not Ca+2 dependent and does not appear to be regulated by extracellular iron salts, in contrast to features noted for non-Tf iron uptake by fibroblasts (Sturrock, A., Alexander, J., Lamb, J., Craven, C. M., and Kaptan, J. (1991) J. Biol. Chem. 265, 3139-3145; Kaplan, J., Jordan, I., and Sturrock, A. (1991) J. Biol. Chem. 266, 2997-3004). These unique characteristics of the K562 cell uptake mechanism suggest that multiple transport systems function in Tf-independent iron assimilation.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health								BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BASSET P, 1986, CANCER RES, V46, P1644; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; COX TM, 1990, IRON TRANSPORT STORA, P263; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FOULKES EC, 1985, TOXICOLOGY, V37, P117, DOI 10.1016/0300-483X(85)90118-0; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GARTY M, 1986, TOXICOLOGY, V42, P111, DOI 10.1016/0300-483X(86)90002-8; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLUG S, 1988, HUM TOXICOL, V7, P545, DOI 10.1177/096032718800700605; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; MATTIA E, 1984, J BIOL CHEM, V259, P2689; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OKABE T, 1984, P NATL ACAD SCI-BIOL, V81, P453, DOI 10.1073/pnas.81.2.453; STEIN BS, 1986, J BIOL CHEM, V261, P319; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; TITEUX M, 1984, J CELL PHYSIOL, V121, P251, DOI 10.1002/jcp.1041210131; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690; WRIGHT TL, 1986, J BIOL CHEM, V261, P909	30	125	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8521	8528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473296				2022-12-25	WOS:A1993KX81100025
J	OCONNOR, TR; GRAVES, RJ; DEMURCIA, G; CASTAING, B; LAVAL, J				OCONNOR, TR; GRAVES, RJ; DEMURCIA, G; CASTAING, B; LAVAL, J			FPG PROTEIN OF ESCHERICHIA-COLI IS A ZINC FINGER PROTEIN WHOSE CYSTEINE RESIDUES HAVE A STRUCTURAL AND OR FUNCTIONAL-ROLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; TRANSCRIPTION FACTOR-IIIA; BINDING DOMAINS; GENE; REPAIR; POLY(ADP-RIBOSE)POLYMERASE; RECOGNITION; MUTAGENESIS; NICKING	The Fpg protein of Escherichia coli is a DNA repair enzyme with DNA glycosylase, abasic site nicking, and deoxyribose excising activities. Analysis of the amino acid sequence of this protein suggests that the Fpg protein is a zinc finger protein with a Cys-X2-Cys-X16-Cys-X2-Cys motif. Competition experiments show that the Fpg protein substitutes Cu(II), Cd(II), and Hg(II), metal ions classically associated with substitutions in zinc finger proteins. The Fpg protein activities are inhibited following the reaction with a Cys-specific reagent at low protein:reagent ratios, suggesting that these residues are important for the enzymatic activities. Site-directed mutagenesis was used to produce 6 mutant Fpg proteins with Cys --> Gly mutations. Substitution of the zinc in these proteins by Zn-65(II) indicates that all the proteins bind zinc, but the Zn(II) is not retained as strongly in the zinc finger mutants. The mutations in the Fpg protein outside the zinc finger consensus sequence do not eliminate the Fapy-DNA glycosylase and abasic site nicking. One of the Fpg mutant proteins outside the zinc finger has a reduced capacity to release deoxyribose from abasic sites. Cys --> Gly mutations in the zinc finger consensus sequence reduce all three aforementioned activities substantially. The purified Fpg proteins with Cys --> Gly mutations in the zinc finger consensus sequence do not incise DNA at abasic sites with the same efficiency nor mechanism as the native Fpg protein. The wild type Fpg protein and the Fpg proteins mutated outside the zinc finger sequence bind an oligonucleotide with a unique chemically reduced abasic site in a defined sequence as assayed by retention on nitrocellulose filters, whereas the mutant Fpg proteins within the zinc finger sequence do not bind to the same oligonucleotide. Therefore, the disruption of zinc coordination in the zinc finger of the Fpg protein is associated with decreased binding capacity to DNA as well as decreased enzymatic activities.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INST BIOL MOLEC & CELLULAIRE,UPR 9003,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	OCONNOR, TR (corresponding author), INST GUSTAVE ROUSSY,REPARAT LESIONS RADIO & CHIMIOINDUITES GRP,CNRS,URA 147,INSERM,F-94805 VILLEJUIF,FRANCE.			Castaing, Bertrand/0000-0001-5077-8978; O'Connor, Timothy/0000-0001-5848-3592				ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; INAOKA T, 1989, J BIOL CHEM, V264, P2609; IVEY DM, 1990, NUCLEIC ACIDS RES, V18, P5882, DOI 10.1093/nar/18.19.5882; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; LAVAL J, 1990, J CELL BIOCH SA, V14, P24; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MULLER E, 1990, NUCLEIC ACIDS RES, V18, P5969, DOI 10.1093/nar/18.20.5969; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; O'Connor T R, 1989, Ann Ist Super Sanita, V25, P27; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J, 1989, MOL CLONING LABORATO; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857	35	129	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9063	9070						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473347				2022-12-25	WOS:A1993KX81100097
J	THEUNISSEN, HJM; DIJKEMA, R; GROOTENHUIS, PDJ; SWINKELS, JC; DEPOORTER, TL; CARATI, P; VISSER, A				THEUNISSEN, HJM; DIJKEMA, R; GROOTENHUIS, PDJ; SWINKELS, JC; DEPOORTER, TL; CARATI, P; VISSER, A			DISSOCIATION OF HEPARIN-DEPENDENT THROMBIN AND FACTOR-XA INHIBITORY ACTIVITIES OF ANTITHROMBIN-III BY MUTATIONS IN THE REACTIVE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN; ALPHA-1-ANTITRYPSIN; MECHANISM; KINETICS; SERPINS; CELLS	Antithrombin-III (AT-III) is a heparin-dependent inhibitor of thrombin and Factor Xa, two serine proteases that are crucial for blood coagulation. In order to assess whether it would be possible to target AT-III only towards Factor Xa, we replaced parts of the reactive site, or P region, of AT-III by sequences present in prothrombin, a substrate of Factor Xa in the coagulation cascade. We show that replacement of the P3 to P3' region generates the hypothesized phenotype. In fact, point mutation of the P1' site from Ser (present in AT-III) to Ile (present in prothrombin) is sufficient to dissociate heparin-dependent thrombin and Factor Xa inhibitory activities. Interestingly, a combined mutation at P3 and P3' brings about the same dissociation. We show that besides Ile, other amino acids at P1' can lead to the dissociation in inhibitory activity. Amino acids with small side chains (Gly, Ser, Ala, and Thr) have only a marginal effect on the inhibitory activity against either protease. However, larger residues at the P1' position abolish the heparin-dependent antithrombin activity, whereas the heparin-dependent anti-Factor Xa activity is not at all or only moderately affected. These results can be rationalized by a comparison of the x-ray structure and a three-dimensional model of the S1' binding pockets of thrombin and Factor Xa, respectively. It appears that the S1' pocket of Factor Xa leaves much more space for the P1' residue of AT-III than the S1' pocket of thrombin.	ORGANON INT BV, DEPT VASC PHARMACOL, 5340 BH OSS, NETHERLANDS; ORGANON INT BV, DEPT COMP MEDICINAL CHEM, ORGANON SCI DEV GRP, 5340 BH OSS, NETHERLANDS		THEUNISSEN, HJM (corresponding author), ORGANON INT BV, DEPT BIOTECHNOL & BIOCHEM, POB 20, 5340 BH OSS, NETHERLANDS.							BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; Carrell R. W., 1987, THROMB DIATH HAEMO, P1; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IRELAND H, 1991, BRIT J HAEMATOL, V79, P70, DOI 10.1111/j.1365-2141.1991.tb08009.x; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KOYMANS LMH, 1992, IN PRESS RECL TRAV C; LANE DA, 1991, THROMB HAEMOSTASIS, V66, P657; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Muszbek L, 1984, THROMBIN, P83; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1991, THROMB HAEMOSTASIS, V65, P670; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; ZETTLMEISSL G, 1989, J BIOL CHEM, V264, P21153	37	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9035	9040						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473344				2022-12-25	WOS:A1993KX81100093
J	LADENSON, RC; MONSEY, JD; ALLIN, J; SILBERT, DF				LADENSON, RC; MONSEY, JD; ALLIN, J; SILBERT, DF			UTILIZATION OF EXOGENOUSLY SUPPLIED SPHINGOSINE ANALOGS FOR SPHINGOLIPID BIOSYNTHESIS IN CHINESE-HAMSTER OVARY AND MOUSE LM CELL-FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PHOSPHATIDYLSERINE BIOSYNTHESIS; GANGLIOSIDE-MEDIATED MODULATION; EFFICIENT INCORPORATION; BASES; INHIBITION; GROWTH; METABOLISM; RECEPTOR; MEMBRANE; PHOSPHORYLATION	Growth of Chinese hamster ovary and LM cells is inhibited by relatively low concentrations of sphingosine in the culture media. This effect is diminished by an order of magnitude by conversion of this positively charged long-chain amino alcohol to a number of N-acetylated analogues, such as N-acetylsphingosine, N-acetylsphingosine phosphate, and N-acetylsphingosine phosphorylcholine. Synthesis of sphinganine and its incorporation into ceramide, sphingomyelin, and glycosphingolipids (GSL) was monitored using a short pulse of [C-14]serine together with a long pulse of [H-3]galactose. Compared to unsupplemented cultures, growth with 15-30 muM N-acetylsphingosine suppressed incorporation of C-14 radioactivity into ceramide, sphingomyelin, and GSL by 75-95% without accumulation of labeled sphinganine and without any appreciable change in membrane phospholipid or total GSL content. Furthermore, when cells were cultivated with 15 muM [4,5-H-3]N-acetylsphinganine to monitor its utilization for sphingolipid synthesis, considerable loss of radiolabel occurred due to desaturation of sphinganine to sphingosine. Nevertheless, most of the residual label was found in the long-chain base and not the acyl group of sphingomyelin, indicating that the exogenously supplied base was utilized intact for complex lipid synthesis. Radiolabel was also found in ceramide and glycosphingolipid fractions. Thus, established cell lines whose growth is very sensitive to long-chain amino alcohols can be cultivated with sphinganine (sphingosine) analogues at concentrations which suppress endogenous sphinganine production but support continued synthesis of complex sphingolipids.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,660 S EUCLID AVE,BOX 8231,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038540] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1983, J BIOL CHEM, V258, P3051; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FARRER RG, 1990, J BIOL CHEM, V265, P22217; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIGGINS TJ, 1984, J LIPID RES, V25, P1007; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; JUNGALWALA FB, 1983, J LIPID RES, V24, P1380; KUGE O, 1986, J BIOL CHEM, V261, P5790; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; PITTET D, 1987, J BIOL CHEM, V262, P10072; SAITO Y, 1977, P NATL ACAD SCI USA, V74, P3730, DOI 10.1073/pnas.74.9.3730; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; WELTI R, 1989, ANALTECH UPDATE  FAL, P2; WOLF RA, 1985, J LIPID RES, V26, P629	32	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7650	7659						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463295				2022-12-25	WOS:A1993KW97900014
J	MUSZBEK, L; LAPOSATA, M				MUSZBEK, L; LAPOSATA, M			MYRISTOYLATION OF PROTEINS IN PLATELETS OCCURS PREDOMINANTLY THROUGH THIOESTER LINKAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; N-MYRISTOYLTRANSFERASE; COVALENT MODIFICATION; EUKARYOTIC PROTEINS; CELLULAR PROTEINS; PLASMA-MEMBRANE; COA; SPECIFICITY; RECEPTOR; PEPTIDE	We have demonstrated by several lines of evidence that in platelets myristate is linked to proteins predominantly via thioester bonds as is palmitate, and the covalent binding of the two long chain saturated fatty acids to proteins involves the same mechanisms. The first piece of evidence to support the thioester linkage between myristate and proteins is that [H-3]myristate could be removed from proteins via alkaline methanolysis, which disrupts ester bonds but not amide bonds. The second piece of evidence is that unlabeled palmitate, which can form only thioester bonds in physiologic concentrations, competitively inhibits the formation of alkaline methanolysis-sensitive covalent bonds between [H-3]myristate and proteins. Third, by SDS-polyacrylamide gel electrophoresis and fluorography, the patterns of labeled proteins from [H-3]myristate- and [H-3]palmitate-labeled platelets are identical. Fourth, [H-3]myristate-labeled proteins, like [H-3]palmitate-labeled proteins, both release their fatty acid moieties when exposed to hydroxylamine at neutral pH, which disrupts thioester but not hydroxyester bonds. These findings indicate that although the covalent binding of palmitate to proteins was found to occur at a faster rate than that of myristate, protein S fatty acid acylation that occurs posttranslationally is not specific for palmitate.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,CLIN LABS,RM 249,GRAY BLDG,BOSTON,MA 02114; DEBRECEN UNIV MED,SCH MED,DEPT CLIN CHEM,H-4012 DEBRECEN,HUNGARY; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; University of Debrecen; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK43159] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043159] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER M, 1984, J BIOL CHEM, V259, P7245; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BOOYSE FM, 1967, BIOCHIM BIOPHYS ACTA, V145, P188, DOI 10.1016/0005-2787(67)90673-9; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HENNES AR, 1966, NATURE, V210, P839, DOI 10.1038/210839a0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JEMMERSON R, 1987, BIOCHEMISTRY-US, V26, P5703, DOI 10.1021/bi00392a019; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1987, BIOCHEM J, V244, P1; MAGEE AI, 1990, J CELL SCI, V97, P581; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OMARY MB, 1981, J BIOL CHEM, V256, P4715; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WILCOX CA, 1987, BIOCHEMISTRY-US, V26, P1029, DOI 10.1021/bi00378a008	32	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8251	8255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463334				2022-12-25	WOS:A1993KW97900096
J	XU, ZH; BERNLOHR, DA; BANASZAK, LJ				XU, ZH; BERNLOHR, DA; BANASZAK, LJ			THE ADIPOCYTE LIPID-BINDING PROTEIN AT 1.6-A RESOLUTION - CRYSTAL-STRUCTURES OF THE APOPROTEIN AND WITH BOUND SATURATED AND UNSATURATED FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REFINEMENT; PURIFICATION; EXPRESSION; PHOSPHORYLATION; CRYSTALLIZATION; MYELIN	Crystals of the adipocyte lipid-binding protein which diffract to near atomic resolution have been obtained in Na/K phosphate buffer/precipitant system. The structures of the apo-form and the protein with bound oleic acid and stearic acid have been determined and refined to 1.6-angstrom resolution with R-factor around 18%. The conformations of the bound fatty acids are nearly the same. In both cases, the carboxylate group of the ligand interacts directly with Arg126 and Tyr128 indirectly with Arg106 through a water molecule. The hydrocarbon tail sticks out of the protein surface through a hydrophobic patch. Saturated and unsaturated fatty acids bind in essentially the same conformation. The remaining space of the binding pocket is filled with well ordered water molecules interacting with most of the polar side chains. Comparisons between the holo- and apostructures reveal that the hydrophobic patch on the protein surface formed by a helix and several tight turns might serve as a portal for lipid binding. Since the adipocyte lipid-binding protein is phosphorylated at Tyr19 by the insulin receptor kinase, the position of this side chain has been re-evaluated using the coordinates of the holo-forms. It appears that the position of Tyr19 does not change significantly upon the binding of either of the fatty acids.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,COLL BIOL SCI,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 13925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNING MM, 1992, J MOL BIOL, V228, P208; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; BUELT MK, 1990, BIOCHEMISTRY-US, V29, P7408, DOI 10.1021/bi00484a008; BUELT MK, 1991, J BIOL CHEM, V266, P12266; CARTER CW, 1979, J BIOL CHEM, V254, P2219; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P231, DOI 10.1007/BF00231389; HAHN T, 1983, INT TABLES CRYSTALLO, P40; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P808; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; McPherson A, 1982, PREPARATION ANAL PRO; RAO SN, 1980, ACTA CRYSTALLOGR A, V36, P878, DOI 10.1107/S0567739480001854; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SHA RS, 1993, J BIOL CHEM, V268, P7885; STENKAMP RE, 1983, ACTA CRYSTALLOGR B, V39, P697, DOI 10.1107/S0108768183003262; STUMP DG, 1991, J BIOL CHEM, V266, P4622; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UYEMURA K, 1984, NEUROCHEM RES, V9, P1509, DOI 10.1007/BF00964676; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; XU ZH, 1991, J BIOL CHEM, V266, P14367; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	35	160	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7874	7884						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463311				2022-12-25	WOS:A1993KW97900046
J	GENTRYWEEKS, CR; KEITH, JM; THOMPSON, J				GENTRYWEEKS, CR; KEITH, JM; THOMPSON, J			TOXICITY OF BORDETELLA-AVIUM BETA-CYSTATHIONASE TOWARD MC3T3-E1 OSTEOGENIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSSIBLE REGULATORY ROLE; TRACHEAL CYTO-TOXIN; ESCHERICHIA-COLI; L-CANALINE; RHODOPSEUDOMONAS-SPHEROIDES; METHIONINE SYNTHESIS; DERMONECROTIC TOXIN; NUCLEOTIDE-SEQUENCE; PROTEIN SECRETION; GAMMA-SYNTHASE	Bordetella avium is the etiological agent of an upper respiratory disease in birds which, symptomatically and pathologically, resembles bordetellosis in humans. Studies of the virulence of this organism revealed a novel cytotoxic protein, designated osteotoxin, that was lethal for MC3T3-E1 osteogenic cells, fetal bovine trabecular cells, UMR106-01(BSP) rat osteosarcoma cells, and embryonic bovine tracheal cells. The osteotoxin lacked dermonecrotic toxin activity, exhibited no cross-reactivity with antibody against B. avium dermonecrotic toxin, and was non-proteolytic. Osteotoxin (M(r) approximately 80,000 by gel filtration, pI 5.4) was purified to electrophoretic homogeneity from B. avium 197. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and spectrophotometric analyses showed that the native protein was a homodimer and that each of the non-covalently linked subunits (M(r) approximately 41,000) contained one molecule of pyridoxal 5'-phosphate. Microsequencing of the first 32 amino acids from the NH2 terminus allowed the synthesis of two oligonucleotide probes, which, together with polyclonal antibody to the purified protein, facilitated cloning, sequencing, and expression of the osteotoxin gene product in Escherichia coli. The open reading frame encodes a polypeptide of 396 amino acid residues (M(r) = 42,606, calculated pI 5.9), whose sequence exhibits approximately 38% identity (approximately 60% similarity) to pyridoxal 5'-phosphate-dependent beta-cystathionase(s) from E. coli, Salmonella typhimurium, and rat liver. The characteristic motif, TKYXXGHSD, associated with binding the cofactor in these enzymes is also present in osteotoxin. Physicochemical and enzymatic analyses established the coidentity of osteotoxin with beta-cystathionase. The region upstream of the beta-cystathionase (metC) gene in B. avium 197 lacked regulatory sequences (''Met boxes'') described for metC in enteric species, and enzyme production was not repressed by methionine. Incubation of MC3T3-E1 osteogenic cells in medium containing L-[S-35]cystine and purified beta-cystathionase resulted in S-35-labeling of the enzyme and at least one major MC3T3-E1 cell protein (M(r) approximately 50,000). Cytotoxicity can be attributed to: 1) beta-cystathionase-catalyzed cleavage of L-cystine in the medium and formation of reactive sulfane-containing derivative(s), and 2) transfer of sulfane sulfur to metabolically sensitive or structurally important proteins in the osteogenic cells.			GENTRYWEEKS, CR (corresponding author), NIDR,MICROBIAL ECOL LAB,BLDG 30,RM 532,BETHESDA,MD 20892, USA.		Gentry-Weeks, Claudia/J-2248-2017	Gentry-Weeks, Claudia/0000-0002-9214-3193				ABDOLRASULNIA R, 1979, BIOCHIM BIOPHYS ACTA, V567, P135, DOI 10.1016/0005-2744(79)90180-3; ABDOLRASULNIA R, 1980, BIOORG CHEM, V9, P253, DOI 10.1016/0045-2068(80)90026-7; Arp L. H., 1991, Diseases of poultry., P277; ARP LH, 1984, AM J VET RES, V45, P2196; BEELER T, 1976, J BIOL CHEM, V251, P5267; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BURNELL JN, 1977, BIOCHIM BIOPHYS ACTA, V481, P246, DOI 10.1016/0005-2744(77)90157-7; CAVALLINI D., 1960, ENZYMOLOGIA, V22, P161; COOKSON BT, 1989, INFECT IMMUN, V57, P2223, DOI 10.1128/IAI.57.7.2223-2229.1989; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUCHANGE N, 1983, J BIOL CHEM, V258, P4868; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; FETTER AW, 1975, AM J VET RES, V36, P15; FLAVIN M, 1964, J BIOL CHEM, V239, P2212; FLAVIN M, 1962, J BIOL CHEM, V237, P768; FLAVIN M, 1975, METABOLISM SULFUR CO, P457; GENTRYWEEKS CR, 1988, INFECT IMMUN, V56, P1698, DOI 10.1128/IAI.56.7.1698-1707.1988; GILES CJ, 1992, DIS SWINE, P436; GLODE LM, 1981, CANCER RES, V41, P2249; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GRAY JG, 1983, INFECT IMMUN, V42, P350, DOI 10.1128/IAI.42.1.350-355.1983; HARGROVE JL, 1988, J BIOL CHEM, V263, P17262; HARGROVE JL, 1987, J BIOL CHEM, V262, P7351; HORIGUCHI Y, 1991, INFECT IMMUN, V59, P1112, DOI 10.1128/IAI.59.3.1112-1116.1991; INOUE I, 1979, J BIOCHEM-TOKYO, V86, P477, DOI 10.1093/oxfordjournals.jbchem.a132547; KASE H, 1974, AGR BIOL CHEM TOKYO, V38, P2235, DOI 10.1080/00021369.1974.10861488; KATO A, 1966, J BIOCHEM-TOKYO, V59, P40, DOI 10.1093/oxfordjournals.jbchem.a128256; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; KITO K, 1978, J BIOCHEM-TOKYO, V83, P201, DOI 10.1093/oxfordjournals.jbchem.a131892; KRIEGLER MP, 1981, BIOCHEMISTRY-US, V20, P1312, DOI 10.1021/bi00508a042; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; LORY S, 1992, J BACTERIOL, V174, P3423; MARTEL A, 1987, BIOCHEM BIOPH RES CO, V147, P565, DOI 10.1016/0006-291X(87)90968-5; MARTINEAUDOIZE B, 1991, CAN J VET RES, V55, P42; NAGASAWA T, 1984, J BIOL CHEM, V259, P393; NIKASE Y, 1988, PATHOGENESIS IMMUNIT, P211; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; PARK YM, 1989, MOL GEN GENET, V216, P164, DOI 10.1007/BF00332246; Pittman M., 1984, Bergey's Manual of systematic bacteriology. Volume 1, P388; RAHIALA EL, 1971, BIOCHIM BIOPHYS ACTA, V227, P337, DOI 10.1016/0005-2744(71)90065-9; RAHIALA EL, 1973, ACTA CHEM SCAND, V27, P3861, DOI 10.3891/acta.chem.scand.27-3861; ROBEY PG, 1989, ENDOCRIN METAB CLIN, V18, P859, DOI 10.1016/S0889-8529(18)30347-5; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; ROSENTHAL GA, 1990, J BIOL CHEM, V265, P868; ROSENTHAL GA, 1981, EUR J BIOCHEM, V114, P301, DOI 10.1111/j.1432-1033.1981.tb05149.x; ROWBURY RJ, 1966, J GEN MICROBIOL, V42, P155, DOI 10.1099/00221287-42-1-155; SANDY JD, 1975, BIOCHEM J, V150, P245, DOI 10.1042/bj1500245; SILVEIRA D, 1982, RES VET SCI, V33, P37, DOI 10.1016/S0034-5288(18)32356-7; SMITH DJ, 1985, SYNTHETIC COMMUN, V15, P945, DOI 10.1080/00397918508063895; SMITH IK, 1987, METHOD ENZYMOL, V143, P439; Snell E.E., 1970, ENZYMES, V2, P335; SZCZEPKOWSKI TW, 1967, BIOCHIM BIOPHYS ACTA, V139, P469, DOI 10.1016/0005-2744(67)90050-2; TOOHEY JI, 1986, BIOCHEM CELL BIOL, V64, P758, DOI 10.1139/o86-103; TOOHEY JI, 1989, BIOCHEM J, V264, P625, DOI 10.1042/bj2640625; UREN JR, 1979, CANCER TREAT REP, V63, P1073; VALENTINE WN, 1987, P NATL ACAD SCI USA, V84, P1394, DOI 10.1073/pnas.84.5.1394; WEISSBACH H, 1991, MOL MICROBIOL, V5, P1593, DOI 10.1111/j.1365-2958.1991.tb01905.x; WOOD JL, 1980, P SOC EXP BIOL MED, V165, P469, DOI 10.3181/00379727-165-41006; WOOD JL, 1987, METHOD ENZYMOL, V143, P25; WOOD JL, 1982, ADV EXP MED BIOL, V148, P327; WU WH, 1973, J BIOL CHEM, V248, P1696; YAMANISHI T, 1983, J BIOCHEM, V94, P181, DOI 10.1093/oxfordjournals.jbchem.a134328; YAMANISHI T, 1981, J BIOCHEM-TOKYO, V89, P1913, DOI 10.1093/oxfordjournals.jbchem.a133393	66	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7298	7314						17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463265				2022-12-25	WOS:A1993KV14100070
J	INOUE, N; KINOSHITA, T; ORII, T; TAKEDA, J				INOUE, N; KINOSHITA, T; ORII, T; TAKEDA, J			CLONING OF A HUMAN GENE, PIG-F, A COMPONENT OF GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR BIOSYNTHESIS, BY A NOVEL EXPRESSION CLONING STRATEGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; LYMPHOMA-CELLS; RECEPTOR; MUTANT; PROTEINS; ANTIGEN; CDNA; DNA; DEFICIENT; MANNOSE	The glycosylphosphatidylinositol (GPI)-anchored proteins are widely distributed in eukaryotic cells, from yeasts to mammals. A number of proteins, such as glycosyltransferases, are necessary for GPI anchor biosynthesis. Cloning of genes encoding these proteins is required for analyses of their nature and the biosynthetic pathway. Here we report a new method of expression cloning that is applicable to many mutant rodent and human cells, and its application for cloning a human cDNA termed PIG-F (for Phosphatidyl-Inositol-Glycan class F) using a Thy-1-negative mutant murine thymoma cell line of complementation class F. PIG-F takes a part in the step of transfer of ethanolamine phosphate to the GPI intermediate containing three residues of mannose. This expression cloning strategy is applicable to the identification of not only other genes involved in GPI anchor biosynthesis but also human disease-associated genes using mutant mammalian cell lines.	OSAKA UNIV,MICROBIAL DIS RES INST,3-1 YAMADAOKA,SUITA,OSAKA 565,JAPAN; GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN	Osaka University; Gifu University			Kinoshita, Taroh/C-7353-2009					ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAHONEY JF, 1992, BLOOD, V79, P1400; MENON AK, 1992, J BIOL CHEM, V267, P15277; MIYATA T, 1993, IN PRESS SCI; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; PUOTI A, 1991, J BIOL CHEM, V266, P21051; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1990, MOL CELL BIOL, V10, P5027, DOI 10.1128/MCB.10.10.5027; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	31	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6882	6885						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463218				2022-12-25	WOS:A1993KV14100016
J	MAZZEI, GJ; SCHMID, EM; KNOWLES, JKC; PAYTON, MA; MAUNDRELL, KG				MAZZEI, GJ; SCHMID, EM; KNOWLES, JKC; PAYTON, MA; MAUNDRELL, KG			A CA2+-INDEPENDENT PROTEIN-KINASE-C FROM FISSION YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; PURIFICATION; EXPRESSION; GENE	A protein kinase C homologue of Schizosaccharomyces pombe, pkc1+, was isolated from a genomic library by screening with the Saccharomyces cerevisiae PKC1 probe. From its primary sequence and biochemical properties, we conclude that S. pombe pkc1+ encodes a phospholipid-activated Ca2+-independent protein kinase, homologous to the delta/epsilon classes of mammalian protein kinase C. Gene disruption experiments show that pkc1+ is not essential for cell viability; however, overexpression of the protein leads to an abnormal cell morphology and a block in cell separation following mitosis suggestive of a role in cell division. In vitro phosphorylation experiments reveal several potential pkc1+ substrates.	GLAXO INST MOLEC BIOL, 14 CHEMIN AULX, CH-1228 PLAN LES OUATES, SWITZERLAND	GlaxoSmithKline								AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BAZZI MD, 1992, J BIOL CHEM, V267, P22891; BELL RM, 1991, J BIOL CHEM, V266, P4661; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO JF, 1980, P NATL ACAD SCI-BIOL, V77, P7039, DOI 10.1073/pnas.77.12.7039; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAZZEI GJ, 1984, BIOCHEM J, V218, P361, DOI 10.1042/bj2180361; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; ONO Y, 1988, J BIOL CHEM, V263, P6927; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Sambrook J, 1989, MOL CLONING LABORATO; SASAGURI T, 1985, BIOCHEM J, V231, P497, DOI 10.1042/bj2310497; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TURNER RS, 1984, P NATL ACAD SCI-BIOL, V81, P3143, DOI 10.1073/pnas.81.10.3143	27	37	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7401	7406						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463273				2022-12-25	WOS:A1993KV14100082
J	BERNARDO, MM; DAY, DE; HALVORSON, HR; OLSON, ST; SHORE, JD				BERNARDO, MM; DAY, DE; HALVORSON, HR; OLSON, ST; SHORE, JD			SURFACE-INDEPENDENT ACCELERATION OF FACTOR-XII ACTIVATION BY ZINC IONS .2. DIRECT BINDING AND FLUORESCENCE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; COAGULATION FACTOR-XII; HIGH-MR KININOGEN; WASHED HUMAN-PLATELETS; HAGEMAN-FACTOR; BLOOD-COAGULATION; MEDIATED ACTIVATION; CONTACT ACTIVATION; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS	To determine the role of Zn(II)-factor XII interactions in the rate-enhancing effect of Zn(II) on factor XII activation demonstrated in the preceding paper, equilibrium binding of zinc ions to factor XII, and the spectroscopic changes accompanying this binding were investigated. Equilibrium dialysis provided direct evidence for the binding of Zn(II) to factor XII. The binding data were consistent with 7.8 +/- 0.3 zinc ions binding with an indistinguishable K(d) of 91 +/- 6 muM. Binding of Zn(II) was accompanied by a 10% quenching of the intrinsic protein fluorescence and a 2-nm red shift of the wavelength of maximum emission. These spectroscopic changes were specific for factor XII and were not observed with factor XIIa. The Zn(II) concentration dependence of factor XII fluorescence quenching was sigmoid and paralleled the Zn(II)-accelerating effect on factor XII activation by kallikrein and factor XIIa, indicating that the spectral change was reporting Zn(II)-factor XII interactions responsible for the enhanced activation rate. The apparent cooperativity of Zn(II) effects on factor XII fluorescence quenching and activation kinetics, and the apparent noncooperativity in Zn(II) binding to factor XII measured by equilibrium dialysis could be explained by a two-state model in which Zn(II) binding is linked to a conformational change in the protein. The Zn(II)-induced quenching of factor XII fluorescence exhibited a pH dependence consistent with the involvement of histidine residues in the binding of Zn(II). Dynamic quenching of factor XII protein fluorescence by iodide or acrylamide, in the absence and presence of Zn(II), revealed heterogeneity in the environment of the 13 tryptophan residues of factor XII that was markedly reduced by metal ion binding. Together, these results indicate that cooperative interactions of Zn(II) with factor XII induce structural changes in the zymogen that facilitate its proteolytic cleavage and activation.	HENRY FORD HOSP,DIV BIOCHEM RES,EDUC & RES BLDG,RM 3126,2799 W GRAND BLVD,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								BERNARDO MM, 1993, J BIOL CHEM, V268, P12468; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1981, BIOCHEMISTRY-US, V20, P7258, DOI 10.1021/bi00528a032; BOUMA BN, 1986, NEW COMPREHENSIVE BI, V13, P103; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COOL DE, 1987, J BIOL CHEM, V262, P13662; CORNISHBOWDEN A, 1975, J MOL BIOL, V95, P201, DOI 10.1016/0022-2836(75)90390-3; DIXON M, 1964, ENZYMES, P84; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ESPANA F, 1983, J LAB CLIN MED, V102, P487; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIEP MA, 1986, BIOCHEMISTRY-US, V25, P6688, DOI 10.1021/bi00369a054; GRIFFIN JH, 1978, P NATL ACAD SCI USA, V75, P1998, DOI 10.1073/pnas.75.4.1998; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; KAPLAN AP, 1987, BLOOD, V70, P1; KOZIN F, 1988, INFLAMMATION BASIC P, P101; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P379; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MCMILLIN CR, 1974, J CLIN INVEST, V54, P1312, DOI 10.1172/JCI107877; MOOZ ED, 1989, PRACTICAL HDB BIOCH, P34; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; NUIGENS JH, 1989, J BIOL CHEM, V264, P12941; ROSING J, 1985, EUR J BIOCHEM, V151, P531, DOI 10.1111/j.1432-1033.1985.tb09135.x; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P429, DOI 10.1093/oxfordjournals.jbchem.a135077; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SHORE JD, 1989, THROMB HAEMOSTASIS, V62, P15; SILVERBERG M, 1987, BIOCHEM J, V248, P715, DOI 10.1042/bj2480715; SUGO T, 1985, EUR J BIOCHEM, V146, P43, DOI 10.1111/j.1432-1033.1985.tb08617.x; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WOO J, 1984, CLIN DIAGNOSIS MANAG, P161	42	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12477	12483						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509387				2022-12-25	WOS:A1993LG65800039
J	ONRUST, R; ODONNELL, M				ONRUST, R; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .2. CHARACTERIZATION OF DELTA AND DELTA'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOLOENZYME; TAU; MECHANISM; TEMPLATE; SUBUNITS; GAMMA	The gamma complex subassembly (gammadeltadelta'chipsi) of DNA polymerase III holoenzyme couples ATP to assemble the ring-shaped beta subunit around DNA forming a DNA sliding clamp. This beta clamp is needed for highly processive synthesis by the holoenzyme. Here, the delta and delta' subunits of the gamma complex are studied for their structural and functional interaction with each other and with the gamma subunit. Both delta and delta' are monomeric in their native state, and they bind each other tightly to form a 1:1 complex. Neither delta nor delta' alone binds tightly to the gamma subunit. However, as a complex, deltadelta' binds gamma tightly to form a gammadeltadelta' complex. The fact that all three subunits, gamma, delta, and delta' are needed to form a tight complex correlates well with activity assays which show that gamma and delta are capable but inefficient in assembly of the beta ring onto DNA and delta' is needed for an efficient reaction.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P176; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1991, J BIOL CHEM, V266, P21681; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH MH, 1970, HDB BIOCHEMISTRY, pC1; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; XIAO H, 1993, J BIOL CHEM, V268, P11779	23	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11766	11772						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505304				2022-12-25	WOS:A1993LF28400047
J	REDDIGARI, SR; SHIBAYAMA, Y; BRUNNEE, T; KAPLAN, AP				REDDIGARI, SR; SHIBAYAMA, Y; BRUNNEE, T; KAPLAN, AP			HUMAN HAGEMAN-FACTOR (FACTOR-XII) AND HIGH-MOLECULAR-WEIGHT KININOGEN COMPETE FOR THE SAME BINDING-SITE ON HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MR KININOGEN; RELAXING FACTOR; ZINC IONS; ACTIVATION; BRADYKININ; RADIOIMMUNOASSAY; PREKALLIKREIN; ACID	Factor XII (FXII, plasma concentration 375 nM) is a critical member of the plasma contact activation system and is the zymogen form of FXII(a), a serine protease involved in intrinsic coagulation, complement activation, activation of factor VII, and generation of the vasoactive peptide bradykinin. As such its interaction with cells involved in inflammatory pathways can be of physiologic and pathologic significance. We have studied the binding of FXII to cultured human umbilical vein endothelial cells (HUVEC). HUVEC were incubated with I-125-FXII, and cell-bound factor FXII was measured. FXII bound to HUVEC saturably in a zinc-dependent manner. The optimal zinc concentration was 50-60 muM. Binding of labeled FXII was drastically reduced when a 200-fold molar excess of unlabeled FXII was included in the incubation mixture at time zero or when added at 60 min during a 150-min time course experiment. Quantitative binding experiments indicated a dissociation constant of 144 nM with 10-12 million binding sites/endothelial cell. Unlabeled high molecular weight kininogen (HK) inhibited the binding of labeled FXII with a K(i) of 98 nM, whereas unlabeled FXII inhibited the binding of labeled HK to HUVEC with a K(i) of 152 nM. SDS-polyacrylamide gel electrophoresis and autoradiography of cell-bound I-125-FXII showed that factor XII underwent limited proteolysis and the molecular weights of the fragments were similar in size to activated FXII. The cell-bound activated factor XII was also able to activate prekallikrein. These data suggest that (i) FXII binds to HUVEC specifically, saturably, and reversibly in a zinc-dependent manner, (ii) HK and FXII may compete with each other for the same cell-surface receptor/s, and (iii) cell-bound FXII is capable of undergoing activation to FXII(a).	NIPPON ZOKI PHARMACEUT CO LTD,INST BIOACT SCI,DIV NAT PROD 1,HYOGO,JAPAN		REDDIGARI, SR (corresponding author), SUNY,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.							ADAM A, 1985, CLIN CHEM, V31, P423; ARMSTRONG D, 1970, HDB EXPERIMENTAL PHA, V25, P434; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BHARTHA K, 1989, BIOCHEM J, V263, P149; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BOGLE RG, 1991, BIOCHEM BIOPH RES CO, V180, P926, DOI 10.1016/S0006-291X(05)81154-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GINSBERG MH, 1980, J LAB CLIN MED, V95, P497; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; JAFFE EA, 1980, TRANSPL P, V12, P49; KAPLAN AP, 1987, BLOOD, V70, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCEAU F, 1983, GEN PHARMACOL, V14, P209, DOI 10.1016/0306-3623(83)90001-0; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MELONI FJ, 1992, BLOOD, V79, P1233; MORRISON DC, 1974, J EXP MED, V140, P797, DOI 10.1084/jem.140.3.797; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIKAWA K, 1992, BLOOD, V80, P1980; PASKHINA TS, 1979, HDB EXPT PHARM, P609; PLOW EF, 1985, BLOOD, V66, P724; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; REVAK SD, 1974, J CLIN INVEST, V54, P619, DOI 10.1172/JCI107799; SAMUEL M, 1992, J BIOL CHEM, V267, P19691; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHMEIDLERSAPIRO KT, 1991, P NATL ACAD SCI USA, V88, P4382, DOI 10.1073/pnas.88.10.4382; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; SHIMADA T, 1985, J BIOCHEM-TOKYO, V97, P429, DOI 10.1093/oxfordjournals.jbchem.a135077; SILVERBERG M, 1987, BIOCHEM J, V248, P715, DOI 10.1042/bj2480715; SIMIONESCU M, 1988, RECEPTOR MEDIATED TR, P69; SPRAGG J, 1973, ANN NY ACAD SCI, V209, P372, DOI 10.1111/j.1749-6632.1973.tb47541.x; Stewart J.M., 1980, BRADYKININ KALLIDIN, P227; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TOLINS JP, 1991, HYPERTENSION, V17, P909, DOI 10.1161/01.HYP.17.6.909; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WIGGINS RC, 1980, J CLIN INVEST, V65, P197, DOI 10.1172/JCI109651	39	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11982	11987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505323				2022-12-25	WOS:A1993LF28400079
J	SUGIMOTO, M; DENT, J; MCCLINTOCK, R; WARE, J; RUGGERI, ZM				SUGIMOTO, M; DENT, J; MCCLINTOCK, R; WARE, J; RUGGERI, ZM			ANALYSIS OF STRUCTURE-FUNCTION-RELATIONSHIPS IN THE PLATELET MEMBRANE GLYCOPROTEIN IB-BINDING DOMAIN OF VONWILLEBRAND-FACTOR BY EXPRESSION OF DELETION MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; PROTEIN-A; DISEASE; IDENTIFICATION; SEQUENCES; BOTROCETIN; FRAGMENT; SITE; IIB; THROMBOSIS	We have used a series of Escherichia coli-expressed deletion mutants of the glycoprotein (GP) Ib-binding domain of von Willebrand factor (vWF) to study the structural basis of its function. In addition to the prototypic molecule (rvWF441-733), we constructed 11 mutants; seven had deletions of sequence on the amino and/or carboxyl-terminal side of the Cys509-Cys695 intrachain disulfide loop, and four had limited deletions inside the loop. Other cysteine residues in addition to 509 and 695, when present in the corresponding native sequence, were mutated to glycine; all molecules were purified in the oxidized as well as reduced and alkylated state. The smallest species retaining the ability to interact with GP Ib in the absence of modulators was the oxidized rvWF508-696; the latter, as well as rvWF441-696, became inactive after reduction and alkylation. In contrast, all the other fragments with deletions outside of the loop, but extending at least to residue 700, showed better binding to platelets after reduction and alkylation than when the Cys509-Cys695 disulfide bond was oxidized. Any limited deletion of sequence inside the loop caused complete loss of GP Ib-binding function both in the absence or in the presence of botrocetin, and this persisted even after reduction and alkylation. In contrast, all mutants with intact sequence between residues 509 and 695 bound to GP Ib in the presence of botrocetin, regardless of whether the 2 cysteine residues were oxidized or reduced and alkylated. Ristocetin, unlike botrocetin, appeared to have no effect in modulating the binding of any of the expressed fragments to platelets. Our findings suggest that the GP Ib-binding domain of vWF contains multiple interaction sites, but integrity of the sequence 509-695 is important for function.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU RB, 1993, BLOOD, V81, P1263; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1993, J BIOL CHEM, V268, P2821; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; FUJIMURA Y, 1987, BLOOD, V70, P985; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; HANDA M, 1986, J BIOL CHEM, V261, P2579; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NICHOLS TC, 1986, CIRC RES, V59, P15, DOI 10.1161/01.RES.59.1.15; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	41	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12185	12192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505338				2022-12-25	WOS:A1993LF28400106
J	WEBSTER, MK; GOYA, L; FIRESTONE, GL				WEBSTER, MK; GOYA, L; FIRESTONE, GL			IMMEDIATE-EARLY TRANSCRIPTIONAL REGULATION AND RAPID MESSENGER-RNA TURNOVER OF A PUTATIVE SERINE THREONINE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; CELL-CYCLE; 3T3 CELLS; C-FOS; MOUSE FIBROBLASTS; GENE-EXPRESSION; RAT FIBROBLASTS; ONCOGENE; JUN; SEQUENCE	Serine/threonine protein kinases are important regulators of diverse cellular processes including metabolism, proliferation, and differentiation. We have previously identified the cDNA for a 49-kDa serine/threonine kinase, designated sgk, which is transcriptionally responsive to glucocorticoid hormones and serum in epithelial cells. We report here that sgk expression is also rapidly induced by dexamethasone or serum in Rat2 fibroblasts. Nuclear run-on and Northern blot analysis revealed that the induction of sgk mRNA is an immediate-early transcriptional response to serum stimulation of quiescent fibroblasts, which occurs just after the peak in c-jun transcription. In contrast to the glucocorticoid-stimulated sgk expression in Rat2 fibroblasts, the transcriptional induction of sgk by serum was transient and sgk transcripts decayed with a particularly rapid half-life of 20 min. The rapid turnover of sgk, in combination with its immediate-early transcriptional response to serum, suggests a novel mechanism for responding to mitogenic signals during G(o), to S transition and entry into the cell cycle.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BOX 591 LSA, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Goya, Luis/H-5735-2012	Goya, Luis/0000-0001-9449-6200	NCI NIH HHS [CA-05388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; COOK PW, 1988, J BIOL CHEM, V263, P19296; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; Witters LA, 1990, CURR OPIN CELL BIOL, V2, P212, DOI 10.1016/0955-0674(90)90009-4	20	152	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11482	11485						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505283				2022-12-25	WOS:A1993LF28400003
J	FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E				FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E			MUTATION OF THE SERINE 15 PHOSPHORYLATION SITE OF HUMAN P53 REDUCES THE ABILITY OF P53 TO INHIBIT CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							CASEIN KINASE-II; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; GROWTH; GENE; SUPPRESSOR; INVITRO; P53-PROTEIN; EXPRESSION	Overexpression of wild-type p53 prevents cells from entering the S phase of the cell cycle. The amino-terminal transactivation region of p53 is phosphorylated by several protein kinases, including DNA-PK, a nuclear serine/threonine protein kinase that in vitro requires DNA for activity. DNA-PK was recently shown to phosphorylate serines 15 and 37 of human p53 (Lees-Miller et al, 1992. Mol. Cell. Biol., 12, 5041-5049). To prevent phosphorylation at these sites, mutants were constructed that changed the codons for serine 15 or serine 37 to alanine codons. Expression of p53-Ala-37 in stably transformed T98G cells blocked progression of the cells into S phase as well as did the expression of wild-type p53. In contrast, p53-Ala-15 was partially defective in blocking cell cycle progression. Several cell clones transformed with the mutant p53-Ala-15 gene expressed normal levels of p53 mRNA but accumulated little or no detectable p53 protein. However, by using a transient expression system driven by a strong cytomegalovirus promoter, we showed that the inability of p53-Ala-15 to fully block cell cycle progression was not due to inadequate levels of expression or to a failure of the mutant protein to accumulate in the nucleus. These results suggest that phosphorylation of Ser-15 may affect p53 function.	NIH,CELL BIOL LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481; Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA 42866] Funding Source: Medline; NCRR NIH HHS [BRSG S07 RR05417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042866] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JDONEHOWER LA, 1992, NATURE, V356, P215; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLESSIG DF, 1975, J VIROL, V16, P1650, DOI 10.1128/JVI.16.6.1650-1668.1975; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MONTENARH M, 1992, ONCOGENE, V7, P1673; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1984, J VIROL, V51, P559, DOI 10.1128/JVI.51.2.559-562.1984; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V20, P8375; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SILVERMAN L, 1989, J VIROL, V63, P4376, DOI 10.1128/JVI.63.10.4376-4385.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	59	172	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1519	1528						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502477				2022-12-25	WOS:A1993LE06400015
J	LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B				LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B			SIMPLE SEQUENCE REPEAT POLYMORPHISM WITHIN THE P53 GENE	ONCOGENE			English	Note							PROTEIN	This report describes a new polymorphism, in intron 3 of the p53 gene, which consists of a single repeat of 16 nucleotides, absent in the published wild-type p53 gene sequence. In the Caucasian population tested (n = 82), 28% of individuals were heterozygotes for this polymorphism. Using PCR-based analysis, we were able to demonstrate p53 allelic losses in three of six breast tumors from heterozygote patients tested.	INST GUSTAVE ROUSSY,IMMUNOL MOLEC LAB,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ANAT PATHOL LAB C,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94805 VILLEJUIF,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,IMMUNOL LAB,CNRS,URA 1484,F-75006 PARIS,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Lazar, Vladimir/AAQ-2086-2020; Lazar, Vladimir/AAV-2087-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARBONE D, 1991, ONCOGENE, V6, P1691; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; COOPER DN, 1991, HUM GENET, V87, P409; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; SOUSSI T, 1990, ONCOGENE, V5, P945	13	89	92	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1703	1705						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502490				2022-12-25	WOS:A1993LE06400037
J	BIDEN, TJ; DAVISON, AGM; PRUGUE, ML				BIDEN, TJ; DAVISON, AGM; PRUGUE, ML			REGULATION BY MEMBRANE-POTENTIAL OF PHOSPHATIDYLINOSITOL HYDROLYSIS IN PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; INSULIN-SECRETION; B-CELLS; SIGNAL TRANSDUCTION; GLUCOSE; CA-2+; K+; TRISPHOSPHATE; PHOSPHATES	In pancreatic islets stimulated with carbamylcholine (carbachol), hydrolysis of both phosphatidylinositol (PtdIns) and phosphatidylinositol bisphosphate (PtdInsP2) occurs and can be measured as the inositol monophosphates Ins(1)P1, or Ins(4)P1, respectively (Biden, T. J., Prugue, M. L., and Davison, A. G. M. (1992) Biochem. J. 285, 541-549). Our current aim was to establish whether these two events were independently regulated. Rat islets were labeled with either [H-3]inositol or [H-3]arachidonic acid for measurement of InsP1s by high performance liquid chromatography or diacylglycerol by TLC, respectively. The rise in Ins(1)P1 due to carbachol (1 min) was inhibited by 50% by concomitantly raising extracellular KCl ([K+]e) from 6 to 30 mM, thereby depolarizing the islets. Similiar results, obtained in the absence of extracellular Ca2+, exclude the involvement of voltage-gated Ca2+ channels. Conversely, hyperpolarization, by lowering [K+]e to 3 mM, increased by 30% the rise in Ins(1)P1. In fact, over the [K+]e range of 3 to 48 mM, stimulated Ins(1)P1 accumulation was directly proportional to the calculated membrane potential. In contrast, raising [K+]e from 6 to 48 mM exerted no significant effect on carbachol-stimulated Ins(4)P1 levels, and both Ins(1)P1 and Ins(4)P1 were unaffected in the absence of carbachol. rhe rises in Ins(1)P1 (but not Ins(4)P1) were also inhibited by depolarization with the sodium pump inhibitor, ouabain, or the K+ channel blocker, tolbutamide. Stimulated diacylglycerol accumulation and insulin secretion (20 min) showed a biphasic dependency on [K+]e, being less pronounced at 6 mM than at either 3 or 30 mM KCl. This reflects a selective potentiation of PtdIns and PtdInSP2 hydrolysis, due, respectively, to hyperpolarization and the gating of voltage-dependent Ca2+ channels. The differential regulation of these two hydrolytic events is probably important for independent control of the activation of protein kinase C and Ca2+ mobilization and might play a role in modulating the secretory response in vivo.			BIDEN, TJ (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA.		Biden, Trevor/AAW-2829-2021; Davison, Aidan GM/N-3863-2013	Davison, Aidan GM/0000-0002-5618-7068; Biden, Trevor/0000-0001-5211-0234				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIDEN TJ, 1992, BIOCHEM J, V285, P541, DOI 10.1042/bj2850541; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; CAPIOD T, 1987, FEBS LETT, V217, P247, DOI 10.1016/0014-5793(87)80672-5; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; EASOM RA, 1990, J BIOL CHEM, V265, P14938; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; FISHER SK, 1990, MOL PHARMACOL, V38, P54; HENQUIN JC, 1982, J PHYSIOL-LONDON, V332, P529, DOI 10.1113/jphysiol.1982.sp014429; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HERMANS MP, 1989, DIABETES, V38, P198, DOI 10.2337/diabetes.38.2.198; HIGASHIDA H, 1986, NATURE, V323, P333, DOI 10.1038/323333a0; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MEISSNER HP, 1978, FEBS LETT, V94, P87, DOI 10.1016/0014-5793(78)80912-0; MORGAN NG, 1985, BIOCHEM J, V228, P713, DOI 10.1042/bj2280713; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PITTET D, 1990, J BIOL CHEM, V265, P14256; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANA RS, 1986, J BIOL CHEM, V261, P5237; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANDONGEN CJ, 1985, ANAL BIOCHEM, V144, P104, DOI 10.1016/0003-2697(85)90090-9; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; WOLLHEIM CB, 1980, ENDOCRINOLOGY, V107, P924, DOI 10.1210/endo-107-4-924	36	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11065	11072						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496168				2022-12-25	WOS:A1993LD46600053
J	BUTOR, C; DIAZ, S; VARKI, A				BUTOR, C; DIAZ, S; VARKI, A			HIGH-LEVEL O-ACETYLATION OF SIALIC ACIDS ON N-LINKED OLIGOSACCHARIDES OF RAT-LIVER MEMBRANES - DIFFERENTIAL SUBCELLULAR-DISTRIBUTION OF 7-O-ACETYL AND 9-O-ACETYL GROUPS AND OF ENZYMES INVOLVED IN THEIR REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; BOMBARDMENT MASS-SPECTROMETRY; HEPATIC GOLGI FRACTIONS; HUMAN-MELANOMA CELLS; GANGLIOSIDE 9-O-ACETYL-GD3; LIQUID-CHROMATOGRAPHY; ACETYLNEURAMINIC ACID; PURIFICATION; GLYCOPROTEIN; RESIDUES	O-Acetylation of sialic acids has previously been considered an uncommon modification found on certain salivary mucins and neural gangliosides. We show here that glycosidically bound sialic acids from total membranes of rat liver have surprisingly high levels (approximately 20%) of O-acetylation at the 7- or 9-position. This O-acetylation is further enriched in N-linked oligosaccharides but is barely detectable in ganglioside fractions from the same tissue. The position of O-acetylation on the sialic acid side chain varies between different subcellular fractions. In particular, 7-O-acetylation was enriched in lysosomal membranes and 9-O-acetylation in plasma membranes, whereas Golgi membranes contained both types. This distribution fits with the ability of the rat liver sialate:O-acetyltransferase(s) to synthesize both 7- and 9-O-acetyl esters (Diaz, S., Higa, H. H., Hayes, B. K., and Varki, A. (1989) J. Biol. Chem. 264, 19416-19426) and the fact that 7-O-acetyl esters can migrate to the 9-position at physiological temperature but only under neutral or mildly alkaline conditions. Subcellular fractionation shows that sialate:O-acetyltransferase activity directed toward endogenous acceptors is enriched in Golgi fractions, whereas an intralumenal sialic acid-specific O-acetylesterase activity is not. The O-acetyltransferase is labile and difficult to solubilize in the intact state and cannot be assayed with exogenous acceptors. However, a prelabeled [H-3]acetyl intermediate can be solubilized from Golgi membranes with Triton X-100 and is stable for a prolonged time in the cold. In contrast to the transferase, the lumenal esterase is easily released in a stable and water-soluble form from membrane fractions by saponin permeabilization or repeated freeze-thaw. In keeping with this finding, differential subcellular fractionation and continuous sucrose gradients indicate that this enzyme is enriched in lysosomal fractions (see also the accompanying paper (Butor, C., Higa, H. H., and Varki, A. (1993) J. Biol. Chem. 268, 10207-10213). Based upon findings reported in this and previous studies, a model is proposed for the biosynthesis, maturation, and turnover of 7- and 9-O-acetyl esters on the sialic acids of N-linked oligosaccharides that are attached to membrane-bound proteins in the rat liver.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; SAN DIEGO VET AFFAIRS MED CTR, SAN DIEGO, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARMSTRONG JM, 1985, ARCH BIOCHEM BIOPHYS, V238, P619, DOI 10.1016/0003-9861(85)90207-3; BAME KJ, 1986, J BIOL CHEM, V261, P127; BERGERON JJM, 1985, BIOCHIM BIOPHYS ACTA, V821, P393, DOI 10.1016/0005-2736(85)90043-4; BONAFEDE DM, 1989, LIPIDS, V24, P680, DOI 10.1007/BF02535204; BRETZ R, 1980, J CELL BIOL, V84, P87, DOI 10.1083/jcb.84.1.87; BUTOR C, 1993, J BIOL CHEM, V268, P10207; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CORFIELD AP, 1981, BIOCHEM J, V197, P293, DOI 10.1042/bj1970293; DEWALD B, 1973, J BIOL CHEM, V248, P7223; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; HANAOKA K, 1989, J BIOL CHEM, V264, P9842; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HIGA HH, 1987, BIOCHEM BIOPH RES CO, V144, P1099, DOI 10.1016/0006-291X(87)91425-2; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIGA HH, 1989, METHOD ENZYMOL, V179, P409; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; NEUBERGER A, 1973, BIOCHEM J, V133, P623, DOI 10.1042/bj1330623; NEUBERGER A, 1972, BIOCHEM J, V129, P683, DOI 10.1042/bj1290683; OHSUMI Y, 1983, J BIOCHEM, V93, P547; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REUTER G, 1983, EUR J BIOCHEM, V134, P139, DOI 10.1111/j.1432-1033.1983.tb07542.x; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; ROUX L, 1988, J BIOL CHEM, V263, P8879; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SANDERWEWER M, 1982, ADV EXP MED BIOL, V152, P215; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; SCHAUER R, 1970, H-S Z PHYSIOL CHEM, V351, P749, DOI 10.1515/bchm2.1970.351.1.749; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SONNINO S, 1982, ADV EXP MED BIOL, V152, P55; TABAS I, 1979, J BIOL CHEM, V254, P1655; THURIN J, 1985, J BIOL CHEM, V260, P4556; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1986, P NATL ACAD SCI USA, V83, P882, DOI 10.1073/pnas.83.4.882; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1983, J BIOL CHEM, V258, P2465; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WARREN L, 1959, J BIOL CHEM, V234, P1971; WARREN L, 1966, METHOD ENZYMOL, V8, P131	58	79	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10197	10206						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486687				2022-12-25	WOS:A1993LB80000039
J	PAREEK, S; SUTER, U; SNIPES, GJ; WELCHER, AA; SHOOTER, EM; MURPHY, RA				PAREEK, S; SUTER, U; SNIPES, GJ; WELCHER, AA; SHOOTER, EM; MURPHY, RA			DETECTION AND PROCESSING OF PERIPHERAL MYELIN PROTEIN PMP22 IN CULTURED SCHWANN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOOTH DISEASE TYPE-1A; NERVOUS-SYSTEM MYELIN; ARREST-SPECIFIC GENE; SCIATIC-NERVE; GROWTH ARREST; CYCLIC-AMP; EXPRESSION; GLYCOPROTEIN; RECEPTOR; INVITRO	Peripheral myelin protein, 22 kDa (PMP22), is a myelin molecule associated with Schwann cells in peripheral nerves (Snipes, G. J., Suter, U., Welcher, A. A., and Shooter, E. M. (1992) J. Cell Biol. 117, 225-238). Mutations affecting the PMP22 gene have been implicated in the trembler mutation in mice (Suter, U., Welcher, A. A., Ozcelik, T., Snipes, G. J., Kosaras, B., Francke, U., Billings-Gagliardi, S., Sidman, R. L., and Shooter, E. M. (1992) Nature 356, 241-244; Suter, U., Moskow, J. J., Welcher, A. A., Snipes, G. J., Kosaras, B., Sidman, R. L., Buchberg, A. M., and Shooter, E. M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4382-4386) and Charcot-Marie-Tooth Disease in humans (Patel, P. I., Roa, B. B., Welcher, A. A., Schoener-Scott, R., Trask, B. J., Pentao, L., Snipes, G. J., Garcia, C. A., Francke, U., Shooter, E. M., Lupski, J. R., and Suter, U. (1992) Nature genet. 1, 159-165). In this report, we have studied PMP22 production in cultured rat Schwann cells. Schwann cells contain a 1.8-kilobase mRNA transcript coding for PMP22, and its production is up-regulated in vitro by forskolin. Metabolic labeling combined with immunoprecipitation methods using antibodies raised against synthetic peptides of PMP22 reveal that Schwann cells generate the protein from an 18-kDa precursor form which is post-translationally modified by N-linked glycosylation. A second molecule (molecular mass, 48 kDa) that reacted with PMP22 antibodies was also detected in Schwann cells but is not related chemically to PMP22 as determined by pulse-chase labeling. Metabolic labeling of rat sciatic nerve and Western blot analyses of purified rat sciatic nerve myelin reveal that deglycosylation of PMP22 gives rise to an 18-kDa protein similar in size to that in Schwann cells. These results indicate that cultured Schwann cells may provide a good model in which to investigate the production and function of PMP22 and to establish the cellular basis for the protein's involvement in inherited peripheral neuropathies.	MCGILL UNIV,MONTREAL NEUROL INST,3801 UNIV AVE,MONTREAL H3A 2B4,QUEBEC,CANADA; MCGILL UNIV,FAC MED,MONTREAL H3A 2B4,QUEBEC,CANADA; SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROPATHOL,STANFORD,CA 94305	McGill University; McGill University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Stanford University; Stanford University			Suter, Ueli/A-1624-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1983, J BIOL CHEM, V258, P6556; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BARONVANEVERCOOREN A, 1986, DEV NEUROSCI-BASEL, V8, P182, DOI 10.1159/000112252; BROCKES JP, 1980, J NEUROCYTOL, V9, P67, DOI 10.1007/BF01205227; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVISON AN, 1961, BIOCHEM J, V78, P272, DOI 10.1042/bj0780272; DELEON M, 1991, J NEUROSCI RES, V29, P437; EVERLY JL, 1973, J NEUROCHEM, V21, P329, DOI 10.1111/j.1471-4159.1973.tb04253.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; GOULD RM, 1977, J CELL BIOL, V75, P326, DOI 10.1083/jcb.75.2.326; HOOGENDIJK JE, 1991, HUM GENET, V88, P215, DOI 10.1007/BF00206075; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; KITAMURA K, 1981, GLYCOCONJUGATES, P273; LEBLANC AC, 1987, MOL BRAIN RES, V2, P57, DOI 10.1016/0169-328X(87)90021-0; Lees M., 1984, MYELIN, P197; LEMKE G, 1988, DEVELOPMENT, V102, P499; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATA M, 1990, J NEUROCYTOL, V19, P432, DOI 10.1007/BF01188409; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MATTHIEU JM, 1975, BIOCHIM BIOPHYS ACTA, V392, P167, DOI 10.1016/0304-4165(75)90177-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIRSKY R, 1990, DEVELOPMENT, V109, P105; MIRSKY R, 1980, J CELL BIOL, V84, P483, DOI 10.1083/jcb.84.3.483; MITCHELL LS, 1990, J NEUROSCI RES, V27, P125, DOI 10.1002/jnr.490270202; MORELL P, 1989, BASIC NEUROCHEMISTRY, P109; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISON S, 1991, J NEUROCYTOL, V20, P769, DOI 10.1007/BF01187850; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; SAMBROOK J, 1989, MOL CLONING LABORTOR; SCHNEIDER A, 1992, NATURE, V358, P758, DOI 10.1038/358758a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHUMAN S, 1988, J NEUROCHEM, V50, P190, DOI 10.1111/j.1471-4159.1988.tb13248.x; SINGH H, 1976, BIOCHIM BIOPHYS ACTA, V448, P325, DOI 10.1016/0005-2736(76)90246-7; SKRE H, 1974, CLIN GENET, V6, P98; SMITH ME, 1982, J NEUROCHEM, V38, P1044, DOI 10.1111/j.1471-4159.1982.tb05346.x; SMITH ME, 1986, J NEUROCHEM, V47, P924; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SOBUE G, 1986, BRAIN RES, V362, P23, DOI 10.1016/0006-8993(86)91394-6; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; STEFANSSON K, 1982, BRAIN RES, V234, P309, DOI 10.1016/0006-8993(82)90871-X; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; TIMSIT SG, 1992, J NEUROCHEM, V58, P1172, DOI 10.1111/j.1471-4159.1992.tb09378.x; TOMA JG, 1992, J NEUROSCI, V12, P2504; TRAPP BD, 1988, J NEUROSCI, V8, P3515; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WIGGINS RC, 1980, J NEUROCHEM, V34, P627, DOI 10.1111/j.1471-4159.1980.tb11190.x; WOOD JG, 1974, J NEUROCHEM, V22, P627, DOI 10.1111/j.1471-4159.1974.tb04273.x; YAZAKI T, 1992, FEBS LETT, V307, P361, DOI 10.1016/0014-5793(92)80713-Q	56	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10372	10379						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486695				2022-12-25	WOS:A1993LB80000060
J	SJOBERG, ER; VARKI, A				SJOBERG, ER; VARKI, A			KINETIC AND SPATIAL INTERRELATIONSHIPS BETWEEN GANGLIOSIDE GLYCOSYLTRANSFERASES AND O-ACETYLTRANSFERASE(S) IN HUMAN-MELANOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GOLGI; DE-ORTHO-ACETYLATION; ASPARAGINE-LINKED OLIGOSACCHARIDES; BREFELDIN-A; SIALIC-ACID; O-ACETYLATION; CARBOHYDRATE LIGAND; GD3 GANGLIOSIDE; GERMINAL CELLS; UDP-GALACTOSE	The melanoma-associated disialogangliosides 9(7)-O-acetyl-G(D3) and 9(7)-O-acetyl-G(D2) have been structurally well characterized. However, the compartmentalization and sequence of action of the biosynthetic activities responsible for synthesizing these molecules remain obscure. Here, we have studied the spatial and temporal interrelationships among the activities responsible for the later stages of ganglioside biosynthesis and those for O-acetylation in cultured human melanoma cells. First, brefeldin A treatment was used to separate biosynthetic steps into compartments distal or proximal to the transport block imposed by the drug. In keeping with prior reports, G(M2)/G(D2) synthase was consistently rendered inaccessible to its acceptors G(M3) and G(D3). In contrast, the effect on G(D3) biosynthesis was cell line-specific. Synthesis of G(D3) was nearly abrogated in two lines, while it accumulated in a third line. This indicates that the spatial organization of ganglioside processing activities can vary even between similar cell lines. However, in all cell lines studied, the ratio of 9(7)-O-acetyl-G(D3) to G(D3) was not changed by brefeldin A, indicating that the majority of ganglioside O-acetyltransferase activity is co-localized with G(D3) biosynthetic activity in the same Golgi subcompartment(s). As an alternative approach, Golgi-enriched fractions from melanoma cells were incubated with radiolabeled and nonlabeled nucleotide sugars or acetyl-CoA. In these preparations, biosynthesis is dependent upon the co-localization of appropriate sugar nucleotide transporters, glycosyltransferases, and acceptors that are endogenously present within intact topologically correct compartments. Incubations with CMP-Neu5Ac and acetyl-CoA corroborated the results with brefeldin A, co-localizing ganglioside O-acetyltransferase activity in compartments where G(D3) biosynthesis takes place. Analyses with CMP-Neu5Ac and UDP-GalNAc showed that G(D2) and G(D3) synthesis occur in partially overlapping compartments. Labeling with acetyl-CoA and UDP-GalNAc indicated that although labeled acetate can be transferred from acetyl-CoA directly to G(D2), ganglioside O-acetyltransferase activity does not substantially overlap with the biosynthetic compartment(s) for G(D2). Instead, O-acetyl-G(D3) appears to be co-localized with the compartment of G(D2) biosynthesis and serves as an acceptor for G(D2) synthase. Thus, both 9-O-acetyl-G(D3) and G(D2) can be precursors of 9-O-acetyl-G(D2), but apparently in distinct compartments.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BEYER TA, 1979, J BIOL CHEM, V254, P2531; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BRETZ R, 1980, J CELL BIOL, V84, P87, DOI 10.1083/jcb.84.1.87; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CACAN R, 1984, BIOCHEM J, V224, P277, DOI 10.1042/bj2240277; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DAWSON G, 1990, CANCER CELL-MON REV, V2, P327; DAWSON G, 1986, CHEM PHYS LIPIDS, V42, P105, DOI 10.1016/0009-3084(86)90046-0; DAWSON G, 1978, GLYCOCONJUGATES, P287; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIXON SJ, 1987, J CELL BIOL, V105, P1153, DOI 10.1083/jcb.105.3.1153; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1983, METHOD ENZYMOL, V98, P1; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FLEISCHER B, 1989, METHOD ENZYMOL, V174, P173; Ghidoni R, 1984, Adv Exp Med Biol, V174, P307; GHIDONI R, 1980, J BIOL CHEM, V255, P6990; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P6296; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAYES BK, 1992, ANAL BIOCHEM, V201, P140, DOI 10.1016/0003-2697(92)90186-B; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1992, GLYCOBIOLOGY, V2, P137, DOI 10.1093/glycob/2.2.137; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JOHNSTONE SR, 1988, J NEUROCHEM, V51, P1655, DOI 10.1111/j.1471-4159.1988.tb01138.x; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLEIN D, 1987, BIOL CHEM H-S, V368, P1495, DOI 10.1515/bchm3.1987.368.2.1495; KLEIN D, 1987, EUR J BIOCHEM, V167, P417, DOI 10.1111/j.1432-1033.1987.tb13354.x; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LADISCH S, 1984, J CLIN INVEST, V74, P2074, DOI 10.1172/JCI111631; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LEVINE JM, 1984, J NEUROSCI, V4, P820; LIESER M, 1989, BIOCHEM J, V260, P69, DOI 10.1042/bj2600069; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PATON MC, 1986, NATURE, V324, P459; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PODRAZA HM, 1982, BIOCHEMISTRY-US, V21, P3260; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REN S, 1989, CANCER RES, V49, P7051; REN SL, 1992, J BIOL CHEM, V267, P12632; RIBONI L, 1984, J BIOCHEM-TOKYO, V96, P1943, DOI 10.1093/oxfordjournals.jbchem.a135030; RITTER G, 1990, IMMUNOBIOLOGY, V182, P32, DOI 10.1016/S0171-2985(11)80581-4; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUAN S, 1992, CANCER RES, V52, P5725; SAITO M, 1979, J BIOL CHEM, V254, P7845; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P1; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SOMMERS LW, 1982, J BIOL CHEM, V257, P811; SONNINO S, 1982, ADV EXP MED BIOL, V152, P55; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TAATJES DJ, 1991, INT REV CYTOL, V126, P135; TAATJES DJ, 1987, EUR J CELL BIOL, V44, P187; THURIN J, 1985, J BIOL CHEM, V260, P4556; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YUSUF HKM, 1983, P NATL ACAD SCI-BIOL, V80, P7075, DOI 10.1073/pnas.80.23.7075	104	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10185	10196						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486686				2022-12-25	WOS:A1993LB80000038
J	BARDELLE, C; FURIE, B; FURIE, BC; GILBERT, GE				BARDELLE, C; FURIE, B; FURIE, BC; GILBERT, GE			MEMBRANE-BINDING KINETICS OF FACTOR-VIII INDICATE A COMPLEX BINDING PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE UNILAMELLAR VESICLES; COAGULATION FACTOR-VA; PROTEIN-KINASE-C; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; ENZYME COMPLEXES; HUMAN-PLATELETS; MOLECULAR-BASIS; LIGHT CHAIN; SEQUENCES	Factor VIII functions as a component of the tenase enzyme complex upon phospholipid membranes. Factor VIII binds to phosphatidylserine-containing membranes and apparently provides high affinity binding sites for factor IXa upon these membranes. We have characterized the binding kinetics of human factor VIII with phosphatidylserine-containing membranes and directly compared the measured properties with those of factor V. The initial phase of association was evaluated in a stopped-flow apparatus by fluorescence energy transfer from aromatic residues in the protein to dansyl-labeled phosphatidylethanolamine in the vesicles. Association proceeded at an apparent second-order rate of 0.12 muM-1 s-1 for extruded phospholipid vesicles and 0.42 muM-1 s-1 for sonicated vesicles under pseudo-first-order conditions in which the phospholipid concentration determined the rate. Increased temperature resulted in more rapid association, and the effect decreased in the order extruded vesicles > sonicated vesicles > extruded vesicles of dioleoylphospholipids, indicating that the structure of the phospholipid membrane contributes to the activation energy of binding. The binding of fluorescein-labeled factor VIII to membranes supported on glass microspheres (lipospheres) was monitored by flow cytometry. Under conditions in which the factor VIII concentration determined the rate there was rapid initial association at 6.9 muM-1 s-1, accounting for half of the bound factor VIII, and a slower component of 0.87 muM-1 s-1, accounting for the other half. Likewise, the dissociation of factor VIII from liposphere membranes was biphasic with a faster component of 0.010 s-1 and a slower component of 0.0012 s-1. Rates of association and dissociation for factor V were similar to those for factor VIII and were biphasic. These results allow estimation of the size of the phospholipid sites that interact with factors VIII and V and suggest that both proteins bind to membranes via a multistep process in which rapid association is followed by a slower step yielding higher affinity binding.	VET ADM MED CTR W ROXBURY,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132; NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1987, BIOCHEMISTRY-US, V26, P7994, DOI 10.1021/bi00398a067; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BENTAL O, 1991, BLOOD, V78, P180; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN SSH, 1982, J CHROMATOGR, V227, P25, DOI 10.1016/S0378-4347(00)80352-7; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER PA, 1990, BLOOD, V75, P1999; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GOVERSRIEMSLAG JWP, 1992, BIOCHEMISTRY-US, V31, P10000, DOI 10.1021/bi00156a020; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1988, BLOOD, V71, P539; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; SHEETZ M, 1972, BIOCHEMISTRY-US, V24, P4573; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0	37	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8815	8824						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473326				2022-12-25	WOS:A1993KX81100066
J	MORRIS, DP; SOUTE, BAM; VERMEER, C; STAFFORD, DW				MORRIS, DP; SOUTE, BAM; VERMEER, C; STAFFORD, DW			CHARACTERIZATION OF THE PURIFIED VITAMIN-K-DEPENDENT GAMMA-GLUTAMYL CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BONE GLA-PROTEIN; CARBOXYGLUTAMIC ACID; REDUCTASE ACTIVITIES; PROTHROMBIN; WARFARIN; SUBSTRATE; IDENTIFICATION; PROPEPTIDE; INHIBITION	Vitamin K-dependent carboxylase, purified from bovine liver, has properties similar to those reported for the carboxylase activity present in crude, solubilized microsomes. The purified carboxylase was found to possess the vitamin K epoxidase activity, believed to be essential for vitamin K-dependent carboxylation, but did not contain vitamin K epoxide reductase activity. Kinetic studies of the carboxylase done under defined conditions were complicated by the non-Michaelis-Menten kinetic behavior observed for reactions with two of the enzymes substrates, FLEEL and vitamin K1 hydroquinone. Initial rate experiments with the substrate FLEEL demonstrated behavior consistent with substrate inhibition and gave half-maximal activity at 1 mM FLEEL. Experiments with the substrate vitamin K1 hydroquinone also displayed non-Michaelis-Menten kinetics, as maximal activity was reached prematurely in relation to behavior at lower concentrations. Half-maximal activity was observed at 35 mum vitamin K1 hydroquinone. Initial rate experiments with varying (NaHCO3)-C-14 concentration displayed Michaelis-Menten kinetics and gave a K(m(app)) of 0.29 mM. At cosubstrate concentrations chosen to obtain near-maximal activity, initial rate studies with varying (NaHCO3)-C-14 concentration indicated a k(cat) near 1.0 s-1. Removal of the fourth substrate, oxygen, resulted in the loss of more than 99% of carboxylase activity. The sulfhydryl reagent N-ethylmaleimide inhibited carboxylase irreversibly, as did the anticoagulant warfarin.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNIV LIMBURG,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Hasselt University; Maastricht University				Vermeer, Cees/0000-0002-2300-8561	NHLBI NIH HHS [HL06350-30, HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKNER KL, 1992, P NATL ACAD SCI USA, V89, P6242, DOI 10.1073/pnas.89.14.6242; BUITENHUIS HC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P170, DOI 10.1016/0304-4165(90)90072-5; CANFIELD LM, 1987, BIOCHEM BIOPH RES CO, V148, P184, DOI 10.1016/0006-291X(87)91093-X; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; DEMETZ M, 1981, J BIOL CHEM, V256, P843; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FASCO MJ, 1982, J BIOL CHEM, V257, P4894; FIESER L. F., 1939, Journal of the American Chemical Society, V61, P3467, DOI 10.1021/ja01267a072; FRIEDMAN PA, 1976, BIOCHEM BIOPH RES CO, V70, P647, DOI 10.1016/0006-291X(76)91096-2; FURIE B, 1990, BLOOD, V75, P1753; GIRARDOT JM, 1982, ANAL BIOCHEM, V121, P315, DOI 10.1016/0003-2697(82)90486-9; HALL AL, 1982, ARCH BIOCHEM BIOPHYS, V214, P45, DOI 10.1016/0003-9861(82)90006-6; HELGELAND L, 1977, BIOCHIM BIOPHYS ACTA, V499, P181, DOI 10.1016/0304-4165(77)90001-0; HILDEBRANDT EF, 1982, BIOCHEMISTRY-US, V21, P2406, DOI 10.1021/bi00539a020; JONES JP, 1977, J BIOL CHEM, V252, P7738; JONES JP, 1976, BIOCHEM BIOPH RES CO, V72, P589, DOI 10.1016/S0006-291X(76)80081-2; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; LARSON AE, 1981, J BIOL CHEM, V256, P1032; LARSON AE, 1980, FEBS LETT, V118, P95, DOI 10.1016/0014-5793(80)81226-9; MACK DO, 1976, J BIOL CHEM, V251, P3269; MAGNUSSO.S, 1974, FEBS LETT, V44, P189, DOI 10.1016/0014-5793(74)80723-4; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; OLSON RE, 1987, HEMOSTASIS THROMBOSI, P846; PACKER L, 1980, METHOD ENZYMOL, V69, P625; SEGEL EH, 1975, ENZYME KINETICS, P619; SOUTE BAM, 1990, BIOCHIM BIOPHYS ACTA, V1034, P11, DOI 10.1016/0304-4165(90)90146-N; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTTIE J W, 1988, Biofactors, V1, P55; SUTTIE JW, 1986, BIOCHEM PHARMACOL, V35, P2429, DOI 10.1016/0006-2952(86)90472-7; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; SUTTIE JW, 1979, BIOCHEM BIOPH RES CO, V86, P500, DOI 10.1016/0006-291X(79)91742-X; THIJSSEN HHW, 1987, BIOCHEM PHARMACOL, V36, P2753, DOI 10.1016/0006-2952(87)90260-7; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; UOTILA L, 1982, BIOCHEM J, V201, P249, DOI 10.1042/bj2010249; UOTILA L, 1988, ARCH BIOCHEM BIOPHYS, V264, P135, DOI 10.1016/0003-9861(88)90578-4; VERMEER C, 1982, BIOCHIM BIOPHYS ACTA, V714, P361, DOI 10.1016/0304-4165(82)90346-4; VERMEER C, 1984, FEBS LETT, V165, P16, DOI 10.1016/0014-5793(84)80005-8; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; 1981, BIORAD PROTEIN ASSAY, V1069, P2	45	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8735	8742						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473318				2022-12-25	WOS:A1993KX81100055
J	BIETLOT, HP; SCHERNTHANER, JP; MILNE, RE; CLAIRMONT, FR; BHELLA, RS; KAPLAN, H				BIETLOT, HP; SCHERNTHANER, JP; MILNE, RE; CLAIRMONT, FR; BHELLA, RS; KAPLAN, H			EVIDENCE THAT THE CRYIA CRYSTAL PROTEIN FROM BACILLUS-THURINGIENSIS IS ASSOCIATED WITH DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; DELTA-ENDOTOXIN; KURSTAKI; TOXINS; ASSAY	Toxin generated by activation of the Bacillus thuringiensis CryIA(c) crystal protein (protoxin) with bovine trypsin was separated into two components by anion-exchange chromatography. One component (T2) was DNA-associated toxin, and the other was the DNA-free toxin (T1). Only one major protoxin component was observed, and it was found to be associated with DNA. The DNA from the T2 toxin varied in size from 100 to 300 base pairs, whereas the crystal and the solubilized protoxin contained 20-kilobase DNA as the major DNA component. DNase treatment converted the T2 toxin to the DNA-free T1 toxin. In contrast, the DNA in the crystal and the solubilized protoxin was resistant to DNase digestion and was not dissociated from the protein by 1.5 M NaCl. The protoxin and DNA appeared to elute as a complex with a molecular mass of >2 x 10(6) Da on gel-filtration chromatography. No toxin was generated from the protoxin with trypsin after extensive digestion of the protoxin with DNase or dissociation of the DNA by succinylation of the lysine residues. It is proposed that DNA binds to the COOH-terminal half of the crystal protein and is essential for maintaining the conformational integrity required for crystal formation and generation of toxin.	UNIV OTTAWA,DEPT CHEM,140 LOUIS PASTEUR,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa								ANDREWS RE, 1987, CRC CR REV BIOTECHN, V6, P163, DOI 10.3109/07388558709113596; ARONSON AI, 1986, MICROBIOL REV, V50, P1; BIETLOT H, 1989, BIOCHEM J, V260, P87, DOI 10.1042/bj2600087; BIETLOT HPL, 1990, BIOCHEM J, V267, P309, DOI 10.1042/bj2670309; BULLA LA, 1977, J BACTERIOL, V130, P375, DOI 10.1128/JB.130.1.375-383.1977; BULLA LA, 1980, CRC CR REV MICROBIOL, V8, P147, DOI 10.3109/10408418009081124; CAREY PR, 1986, BIOCHIM BIOPHYS ACTA, V872, P169, DOI 10.1016/0167-4838(86)90268-2; CHESTUKHINA GG, 1982, ARCH MICROBIOL, V132, P159, DOI 10.1007/BF00508723; CHOMA CT, 1992, J INVERTEBR PATHOL, V59, P75, DOI 10.1016/0022-2011(92)90114-J; CHOMA CT, 1990, EUR J BIOCHEM, V189, P523, DOI 10.1111/j.1432-1033.1990.tb15518.x; Dulmage H.T., 1981, MICROBIAL CONTROL PE, P193; Fast PG, 1981, MICROBIAL CONTROL PE, p[223, 949]; GRINGORTEN JL, 1990, J INVERTEBR PATHOL, V56, P237, DOI 10.1016/0022-2011(90)90106-G; HOFTE H, 1989, MICROBIOL REV, V53, P242; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Mattes O., 1927, GESELL BEFORD GES NA, V62, P381; NICKERSON KW, 1980, BIOTECHNOL BIOENG, V12, P1305; OHLENBUSCH HH, 1967, J MOL BIOL, V25, P299, DOI 10.1016/0022-2836(67)90143-X; YAMAMOTO T, 1983, ARCH BIOCHEM BIOPHYS, V227, P233, DOI 10.1016/0003-9861(83)90366-1	20	26	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8240	8245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463332				2022-12-25	WOS:A1993KW97900094
J	LINDSTEDT, KA				LINDSTEDT, KA			INHIBITION OF MACROPHAGE-MEDIATED LOW-DENSITY-LIPOPROTEIN OXIDATION BY STIMULATED RAT SEROSAL MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTAMINE-RELEASING ACTIVITY; ATHEROSCLEROTIC LESIONS; DEGRADATION; GRANULES; BASOPHILS; RECEPTOR; LIPOXYGENASE; NEUTROPHILS; METABOLISM; DEPOSITION	Mast cells and macrophages coexist in the human arterial intima where oxidation of low density lipoproteins (LDL) also takes place during atherosclerosis. To investigate whether mast cells play a role in macrophage-mediated oxidation of LDL, a model system was designed in which mast cells and macrophages were cocultured in incubation medium containing LDL. Stimulation of rat serosal mast cells to induce exocytosis of their cytoplasmic granules was found to inhibit macrophage-mediated oxidation of LDL. The inhibitory effect depended on the ability of mast cell-derived histamine, released from the exocytosed granules into the medium, to bind the copper ions necessary for propagation of the macrophage-initiated oxidation of LDL. In addition to binding free copper ions, the mast cell-derived histamine was also capable of inhibiting oxidation of LDL propagated by copper ions bound to the apolipoprotein B component of the LDL particle. The results indicate that mast cells may prevent cell-mediated oxidation of LDL and imply a potentially preventive role for the mast cell in atherosclerosis.			LINDSTEDT, KA (corresponding author), WIHURI RES INST, KALLIOLINNANTIE 4, SF-00140 HELSINKI, FINLAND.							BAGGIOLINI M, 1982, INT ARCH ALLER A IMM, V67, P219, DOI 10.1159/000233022; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; KALYANARAMAN B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P286, DOI 10.1016/0304-4165(90)90090-J; KIKUCHI H, 1981, ANAL BIOCHEM, V115, P109, DOI 10.1016/0003-2697(81)90532-7; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOKKONEN JO, 1990, EUR HEART J, V11, P134, DOI 10.1093/eurheartj/11.suppl_E.134; KOKKONEN JO, 1985, J BIOL CHEM, V260, P4756; KOKKONEN JO, 1987, P NATL ACAD SCI USA, V84, P2287, DOI 10.1073/pnas.84.8.2287; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; KOVANEN PT, 1991, ANN MED, V23, P551, DOI 10.3109/07853899109150517; KUZUYA M, 1992, BIOCHIM BIOPHYS ACTA, V1123, P334, DOI 10.1016/0005-2760(92)90015-N; LINDAHL U, 1979, BIOCHEM J, V182, P189, DOI 10.1042/bj1820189; LINDSTEDT KA, 1993, ARTERIOSCLER THROMB, V13, P23, DOI 10.1161/01.ATV.13.1.23; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; LIU MC, 1986, J IMMUNOL, V136, P2588; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNAIONI PF, 1988, AGENTS ACTIONS, V23, P129, DOI 10.1007/BF02142522; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MITCHINSON MJ, 1985, J PATHOL, V145, P177, DOI 10.1002/path.1711450205; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PARTHASARATHY S, 1990, EUR HEART J, V11, P83, DOI 10.1093/eurheartj/11.suppl_E.83; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SPARROW CP, 1988, J LIPID RES, V29, P745; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STEINBERG D, 1990, ANN NY ACAD SCI, V598, P125, DOI 10.1111/j.1749-6632.1990.tb42284.x; THUESON DO, 1979, J IMMUNOL, V123, P633; TRILLO AA, 1982, ATHEROSCLEROSIS, V43, P259, DOI 10.1016/0021-9150(82)90027-2; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	41	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7741	7746						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463303				2022-12-25	WOS:A1993KW97900026
J	HARRIS, SG; SABIO, I; MAYER, E; STEINBERG, MF; BACKUS, JW; SPARKS, JD; SPARKS, CE; SMITH, HC				HARRIS, SG; SABIO, I; MAYER, E; STEINBERG, MF; BACKUS, JW; SPARKS, JD; SPARKS, CE; SMITH, HC			EXTRACT-SPECIFIC HETEROGENEITY IN HIGH-ORDER COMPLEXES CONTAINING APOLIPOPROTEIN-B MESSENGER-RNA EDITING ACTIVITY AND RNA-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; PURIFICATION; LIVER; IDENTIFICATION; INTESTINE; DEAMINASE; ENZYME; SNRNP	The mechanism for tissue-specific differences in apolipoprotein B (apoB) mRNA editing efficiency is not known. Structural data are presented which demonstrate tissue-specific, quantitative differences in the high order complexes containing apoB mRNA editing activity and RNA-binding proteins. The bulk of rat enterocyte extract editing activity sedimented at 11 S with an additional 5-10% at 60 S. Rat liver extract activity was less abundant and only sedimented at 60 S. Ultraviolet light cross-linking revealed two protein activities of approximately 66 and 44 kDa which specifically associated with apoB RNA substrates and co-sedimented with editing activity. Extracts differed in the cross-linking yield of p66 and p44 and kinetically, enterocyte RNA-protein complexes reached maximum abundance more rapidly than those in liver extracts. Both 60 and 11 S forms of the editing activity redistributed to 27 S during in vitro editosome assembly. The redistribution of editing activities was accompanied by a corresponding redistribution of p66/p44 to 27 S. The data demonstrate that p66 and p44 are common to liver and enterocyte 27 S editosome assembly processes and suggest that differences in both the pre-editosomal assembly state of editing factors and their abundance may be mechanistically important for tissue-specific differences in editing efficiency.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester				Sparks, Janet/0000-0002-0072-766X; Smith, Harold/0000-0001-6257-6791	NCRR NIH HHS [S7RR05403-29] Funding Source: Medline; NHLBI NIH HHS [HL29837-06] Funding Source: Medline; NIDDK NIH HHS [DK 43739-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BACKUS JW, 1990, BIOCHEM BIOPH RES CO, V170, P513, DOI 10.1016/0006-291X(90)92121-F; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CONWAY CG, 1990, MOL CELL BIOL, V9, P5273; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; ECONOMIDIS IV, 1982, P NATL ACAD SCI-BIOL, V79, P1469, DOI 10.1073/pnas.79.5.1469; GARCIA AC, 1992, ARTERIOSCLER THROMB, V12, P172; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HARRIS SG, 1992, BIOCHEM BIOPH RES CO, V183, P899, DOI 10.1016/0006-291X(92)90568-6; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V148, P279, DOI 10.1016/0006-291X(87)91107-7; IPATA PI, 1978, METHOD ENZYMOL, V50, P394; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; LESER GP, 1989, EUR J CELL BIOL, V50, P376; MALATHI VG, 1971, BIOCHIM BIOPHYS ACTA, V238, P377, DOI 10.1016/0005-2787(71)90612-5; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH CN, 1985, FR STUD, V39, P112, DOI 10.1093/fs/39.1.112-a; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VITA A, 1987, ITAL J BIOCHEM, V36, P275; VITA A, 1989, ADV EXP MED BIOL, V253, P71; WEISER MM, 1973, J BIOL CHEM, V248, P2536	36	107	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7382	7392						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463271				2022-12-25	WOS:A1993KV14100080
J	YULE, DI; WU, D; ESSINGTON, TE; SHAYMAN, JA; WILLIAMS, JA				YULE, DI; WU, D; ESSINGTON, TE; SHAYMAN, JA; WILLIAMS, JA			SPHINGOSINE METABOLISM INDUCES CA2+ OSCILLATIONS IN RAT PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; NECROSIS-FACTOR-ALPHA; POLYMORPHONUCLEAR NEUTROPHILS; CALCIUM; HYDROLYSIS; RECEPTORS; SPHINGOSINE-1-PHOSPHATE; PHOSPHATIDYLINOSITOL; CHOLECYSTOKININ; MOBILIZATION	The possibility that sphingosine or a related metabolite could mediate inositol-1,4,5-trisphospate (1,4,5-IP3)-independent Ca2+ release in pancreatic acinar cells was investigated. In intact rat pancreatic acini superfused at 37-degrees-C, sphingosine (10-100 muM) evoked, after a delay of several minutes, an increase in the cytosolic [Ca2+]i which was oscillatory below concentrations of 50 muM. At room temperature no increase in [Ca2+]i was observed. The increase in [Ca2+]i evoked by sphingosine was not inhibited by U73122, and thus was unlikely to be due to phosphatidylinositol (PI) hydrolysis. Furthermore, no PI hydrolysis or 1,4,5-IP3 production was detected on incubation with sphingosine. As metabolism of sphingosine could explain the temperature-dependent action, the effects of sphingosine and related sphingoid bases were tested in permeabilized cells. After a delay of 30 s at 37-degrees-C, sphingosine evoked a slow increase in [Ca2+] into the medium. In contrast, addition of sphingosylphosphorylcholine (SPC) resulted in a rapid increase in [Ca2+]. This response was mimicked by 1,4,5-IP3 but not by addition of sphingosine phosphate 1-10 muM), ceramide (30 muM), or sphingomyelin (50 mug/ml). SPC appeared to induce release of Ca2+ from the same store as 1,4,5-IP3, as SPC failed to evoke any further increase in Ca2+ from cells previously depleted by addition of a maximal concentration of 2,4,5-IP3 or thapsigargin. 1,4,5-IP3 but not SPC-induced Ca2+ release was blocked by heparin, indicating that SPC-induced Ca2+ release was not mediated through the IP3 receptor-channel complex. This study demonstrates that SPC, a sphingosine metabolite, could be responsible for IP3-independent Ca2+ oscillations previously seen in pancreatic acinar cells.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	YULE, DI (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7737 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [DK41225, DK41487] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041225, R01DK041487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, IN PRESS EUR J BIOCH; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GALLONE A, 1991, SCIENCE, V253, P1143; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; METZ DC, 1992, J BIOL CHEM, V267, P20620; OKASAKI T, 1990, J BIOL CHEM, V265, P15823; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG665; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; SHAYMAN JA, 1990, AM J PHYSIOL, V258, pF1282; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	38	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12353	12358						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509375				2022-12-25	WOS:A1993LG65800023
J	GAUSSEM, P; GRAILHE, P; ANGLESCANO, E				GAUSSEM, P; GRAILHE, P; ANGLESCANO, E			SODIUM DODECYL SULFATE-INDUCED DISSOCIATION OF COMPLEXES BETWEEN HUMAN TISSUE-PLASMINOGEN ACTIVATOR AND ITS SPECIFIC INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEIN; MECHANISM; PLASMA; FLUIDS; CELLS; ASSAY	The stability of complexes between serine proteinases and their inhibitors after sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis has been claimed to indicate covalent bond formation. In this work we have investigated the effects of SDS on the stability of complexes between single-chain or two-chain tissue plasminogen activator (t-PA) and its inhibitor (PAI-1). Complexes formed by incubation of t-PA with PAI-1 for 15 min at 22-degrees-C were further incubated with various amounts of SDS before being subjected to SDS-polyacrylamide gel electrophoresis. The molecular species in the gels were identified both by zymography or by autoradiography after immunoblotting with antibodies directed against either t-PA or PAI-1. It was demonstrated that the interaction of SDS with t-PA.PAI-1 complexes before electrophoresis resulted in a transition from the complexed state to the free forms of t-PA and PAI-1 in a time- and dose-dependent manner. The first-order dissociation rate constant in the presence of 35 mm SDS at 22-degrees-C had a k(off) value of 1.4 x 10(-2) min-1, which corresponds to a half-life of 49.5 min. The t-PA released from the complexes was fibrinolytically active, whereas the released PAI-1 inhibited activator-dependent fibrinolysis. In a similar fashion, the well characterized non-acylated pair alpha1-proteinase inhibitor-elastase was dissociated by SDS treatment, confirming the validity of our experimental approach to demonstrate the reversibility of t-PA.PAI-1 complexes. These results demonstrate that SDS-polyacrylamide gel electrophoresis traps the molecular species in the state in which the proteins existed prior to the analysis, and they suggest that under the conditions used, the interaction of t-PA with PAI-1 results in the formation of nonacylated reversible complexes. This phenomenon may be relevant to the pathophysiology of fibrinolysis and to the general mechanism of serine proteinase-inhibitor complex formation.	CHU BICETRE, INSERM, U143, F-94275 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Gaussem, Pascale/AGY-9723-2022; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012; Gaussem, P./ABA-1222-2020; Gaussem, Pascale/ABA-2228-2020	ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Gaussem, P./0000-0002-9139-2147; 				ANGLESCANO E, 1986, ANAL BIOCHEM, V153, P201, DOI 10.1016/0003-2697(86)90082-5; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; FAY WP, 1989, BIOCHEMISTRY-US, V28, P5773, DOI 10.1021/bi00440a011; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GAUSSEM P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P321, DOI 10.1016/0167-4838(91)90076-C; GRAILHE P, 1993, FIBRINOLYSIS, V7, P123, DOI 10.1016/0268-9499(93)90033-R; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1983, P NATL ACAD SCI-BIOL, V80, P6804, DOI 10.1073/pnas.80.22.6804; LINDAHL TL, 1990, BIOCHEM J, V265, P109, DOI 10.1042/bj2650109; LONGSTAFF C, 1992, BLOOD COAGUL FIBRIN, V3, P89, DOI 10.1097/00001721-199202000-00013; MASSON C, 1988, BIOCHEM J, V256, P237, DOI 10.1042/bj2560237; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; NIELSEN LS, 1986, FEBS LETT, V196, P269, DOI 10.1016/0014-5793(86)80261-7; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; SANZO MA, 1987, BIOCHEMISTRY-US, V26, P7443, DOI 10.1021/bi00397a037; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SPRENGERS ED, 1987, BLOOD, V69, P381; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; WAEHNELDT TV, 1975, BIOSYSTEMS, V6, P176, DOI 10.1016/0303-2647(75)90025-8; WAGNER OF, 1986, J BIOL CHEM, V261, P4474; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1984, J BIOL CHEM, V259, P3644	28	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12150	12155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505335				2022-12-25	WOS:A1993LF28400102
J	UCHIDA, T; MATOZAKI, T; MATSUDA, K; SUZUKI, T; MATOZAKI, S; NAKANO, O; WADA, K; KONDA, Y; SAKAMOTO, C; KASUGA, M				UCHIDA, T; MATOZAKI, T; MATSUDA, K; SUZUKI, T; MATOZAKI, S; NAKANO, O; WADA, K; KONDA, Y; SAKAMOTO, C; KASUGA, M			PHORBOL ESTER STIMULATES THE ACTIVITY OF A PROTEIN-TYROSINE-PHOSPHATASE CONTAINING SH(2) DOMAINS (PTP1C) IN HL-60 LEUKEMIA-CELLS BY INCREASING GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTIC DIFFERENTIATION; SIGNAL TRANSDUCTION; SEQUENCE SIMILARITY; INDUCTION; ONCOGENE; KINASES; CD45; SH2; LAR	The affinity-purified antibody to a protein tyrosine phosphatase (PTP) containing two src homology 2 domains (PTP1C) was generated. The antibody recognized two types of PTP1C (PTP1C-alpha and -beta) of which the molecular sizes were 66 (alpha) and 62 kDa (beta), respectively, and these two types were expressed differentially in various cell types. The immune complex phosphatase assay using the antibody demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) and a vitamin D metabolite increased the PTP activity of immunoprecipitated PTP1C to 230 and 150% of control, respectively. By contrast, neither dimethyl sulfoxide nor retinoic acid significantly affected the PTP activity of PTP1C in HL-60 cells. The time course increment by TPA of PTP1C activity was closely correlated with that of the acquisition by HL-60 cells of a macrophage-like phenotype. In addition, TPA increased the amount of PTP1C detected by immunoblotting and immunoprecipitation and raised the level of expression of PTP1C mRNA in HL-60 cells. The increase of PTP1C mRNA induced by TPA treatment was inhibited by cycloheximide, suggesting that new protein synthesis is required for the increase by TPA of PTP1C mRNA expression. Furthermore, TPA increased the rate of transcription of the PTP1C gene without affecting the stability of PTP1C mRNA. These results suggest that (i) two subtypes of PTP1C may exist and function in various cell types, and (ii) TPA stimulates the PTP activity of PTP1C by increasing the transcription rate of PTP1C gene expression. The possible role of PTP1C in the macrophage differentiation will be also discussed.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN; HYOGO MED CTR ADULTS,KITAOHJI,AKASHI 673,JAPAN	Kobe University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; FISHER EH, 1991, SCIENCE, V253, P401; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANK DA, 1986, BIOCHEM BIOPH RES CO, V140, P440, DOI 10.1016/0006-291X(86)91110-1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; MATOZAKI T, 1992, CANCER RES, V352, P1; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; Sambrook J, 1989, MOL CLONING LABORATO; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAETLE R, 1991, LEUKEMIA, V5, P309; TAETLE R, 1987, BLOOD, V70, P852; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0; YAM LT, 1971, AM J CLIN PATHOL, V55, P213; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	32	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11845	11850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505313				2022-12-25	WOS:A1993LF28400059
J	DVIR, A; STEIN, LY; CALORE, BL; DYNAN, WS				DVIR, A; STEIN, LY; CALORE, BL; DYNAN, WS			PURIFICATION AND CHARACTERIZATION OF A TEMPLATE-ASSOCIATED PROTEIN-KINASE THAT PHOSPHORYLATES RNA POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; REPEAT DOMAIN; DNA; INVITRO; IDENTIFICATION; REQUIREMENT; PROMOTER; INVIVO	We have recently shown that a template-associated protein kinase, which phosphorylates the carboxyl-terminal domain (CTD) of RNA polymerase II, is a two-component system. We describe here the purification of these two components to apparent homogeneity from human (HeLa) cell nuclear extract. Kinase component A has a 340-kDa native molecular mass, consists of a single large polypeptide, and contains the kinase active site. Kinase component B, which is identical to the Ku autoantigen, has a 180-kDa native molecular mass, and consists of apparently equimolar 67- and 83-kDa polypeptides. Component B stimulates the activity of component A, and under some conditions, confers DNA dependence on the reaction. The purified kinase converts the CTD to the multiply phosphorylated CTD0 form. Conversion occurs processively, and this processivity is an inherent property of component A. The in vitro phosphorylated CTD0 form contains approximately equimolar phosphoserine and phosphothreonine, but no detectable phosphotyrosine.	UNIV COLORADO,DEPT CHEM & BIOCHEM,CAMPUS BOX 215,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			Stein, Lisa Y./E-6374-2016	Stein, Lisa Y./0000-0001-5095-5022; Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAO DM, 1991, GENE EXPRESSION, V1, P1; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LU H, 1991, P NATL ACAD SCI USA, V88, P1004; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STONE N, 1992, J BIOL CHEM, V267, P6353; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; ZHANG J, 1991, J BIOL CHEM, V266, P2297	48	169	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10440	10447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486698				2022-12-25	WOS:A1993LB80000068
J	DOERING, TL; PESSIN, MS; HOFF, EF; HART, GW; RABEN, DM; ENGLUND, PT				DOERING, TL; PESSIN, MS; HOFF, EF; HART, GW; RABEN, DM; ENGLUND, PT			TRYPANOSOME METABOLISM OF MYRISTATE, THE FATTY-ACID REQUIRED FOR THE VARIANT SURFACE GLYCOPROTEIN MEMBRANE ANCHOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; AFRICAN TRYPANOSOMES; CULTURED FIBROBLASTS; ALPHA-THROMBIN; BRUCEI; BIOSYNTHESIS; PURIFICATION; PROTEIN; IDENTIFICATION; FORM	The trypanosome variant surface glycoprotein (VSG) is anchored to the outer leaflet of the parasite plasma membrane by a glycosyl phosphatidylinositol (GPI). The VSG anchor is unique among GPIs in containing exclusively dimyristoylglycerol as its lipid moiety. Myristate is incorporated into the anchor precursor by sequential deacylation and specific reacylation with myristate. Although myristate is required for the VSG anchor, trypanosomes cannot synthesize this fatty acid and must import their entire supply from the host bloodstream, where it exists in low abundance. Chemical analysis of these parasites reveals that most of their myristate is in VSG protein, with no major lipid storage form. Unexpectedly, when these cells are radiolabeled with [H-3]myristate in culture, most of the label is incorporated into phospholipids, with little into VSG. This apparent contradiction is explained by the fact that trypanosomes in culture medium elongate much of the [H-3]myristate into palmitate and stearate, probably because the medium (with only 5% serum) contains limiting amounts of these fatty acids. In contrast, trypanosomes radiolabeled in whole blood (with higher concentrations of palmitate and stearate) do not modify most of the [H-3]myristate, and instead utilize the major portion of it for GPI synthesis. Our studies suggest that bloodstream trypanosomes have evolved highly efficient means of directing myristate into the GPI biosynthetic pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University				Pessin, Melissa/0000-0003-3990-6494	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021334] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39086] Funding Source: Medline; NIAID NIH HHS [AI21334] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES BN, 1960, J BIOL CHEM, V235, P769; BALDASSARE JJ, 1977, J BIOL CHEM, V252, P8797; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BULOW R, 1986, J BIOL CHEM, V261, P1918; CARAS IW, 1991, CELL BIOL INT REP, V15, P815, DOI 10.1016/0309-1651(91)90035-H; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DETHLOFF LA, 1986, J CHROMATOGR, V382, P79, DOI 10.1016/S0378-4347(00)83506-9; DIXON H, 1971, COMP BIOCHEM PHYSIOL, V39, P247, DOI 10.1016/0305-0491(71)90168-4; DOERING T L, 1990, Methods (Orlando), V1, P288, DOI 10.1016/S1046-2023(05)80330-5; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; DOERING TL, 1993, CELL SURFACE EXTRACE; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1988, SCIENCE, V239, P75; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1990, METHODS, V1, P297; FOX JA, 1986, J BIOL CHEM, V261, P5767; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HERELD D, 1986, J BIOL CHEM, V261, P3813; KORN ED, 1965, J LIPID RES, V6, P43; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MYHER JJ, 1988, J CHROMATOGR, V452, P93, DOI 10.1016/S0021-9673(01)81440-0; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; SAMAD A, 1988, MOL BIOCHEM PARASIT, V29, P159, DOI 10.1016/0166-6851(88)90071-0; SILBERT DF, 1973, BIOCHIM BIOPHYS ACTA, V311, P349, DOI 10.1016/0005-2736(73)90315-5; Spector A A, 1980, Prog Lipid Res, V19, P155; STOLL LL, 1984, IN VITRO CELL DEV B, V20, P732; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TURNER MJ, 1985, CURR TOP MICROBIOL, V117, P23; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VISCARDI RM, 1991, LAB INVEST, V65, P250; WANG LX, 1991, J BIOL CHEM, V266, P13883; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	46	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9215	9222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486622				2022-12-25	WOS:A1993LA68900014
J	KOWALSKI, RJ; WILLIAMS, RC				KOWALSKI, RJ; WILLIAMS, RC			MICROTUBULE-ASSOCIATED PROTEIN 2 ALTERS THE DYNAMIC PROPERTIES OF MICROTUBULE ASSEMBLY AND DISASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIDEO LIGHT-MICROSCOPY; INDIVIDUAL MICROTUBULES; TUBULIN POLYMERIZATION; LIVING CELLS; INSTABILITY; INVITRO; BINDING; ELONGATION; BRAIN; PURIFICATION	The influence of microtubule-associated protein 2 (MAP2) on the dynamics of microtubule assembly and disassembly from axonemal fragments was characterized in vitro in solutions of pure tubulin and varying concentrations of MAP2. A mechanistic description of interactions between MAP2 and individual microtubules was developed from analysis of recorded images obtained by video-enhanced differential-interference-contrast light microscopy. MAP2 decreased the rates and lengths of shortening events and decreased the frequency of transitions between growth and shortening over a wide range of concentrations, thereby producing the increases in net microtubule growth previously described by light-scattering techniques. Increases in rates and lengths of elongation phases, as well as rescue frequencies (i.e. transition from shortening to growth), were observed under conditions in which microtubules are expected to be saturated with MAP2. During early stages of nucleated assembly, MAP2 greatly increased the number of microtubules growing from a given axoneme and caused elongation of ''curved'' structures which may be sheet-like microtubules.	VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025638, T32GM008320] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08320, GM25638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL CW, 1982, METHOD CELL BIOL, V24, P373; BERG HC, 1984, J GEN MICROBIOL, V130, P2915; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1984, J NEUROSCI, V4, P394; CAPLOW M, 1988, J BIOL CHEM, V263, P10344; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; PRYER NK, 1992, J CELL SCI, V103, P965; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SIMON JR, 1990, J CELL SCI, V96, P571; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VALLEE RB, 1977, J BIOL CHEM, V252, P377; VOTER WA, 1984, J BIOL CHEM, V259, P430; WALKER RA, 1991, J CELL BIOL, V114, P73, DOI 10.1083/jcb.114.1.73; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WILLIAMS R C JR, 1992, P151	42	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9847	9855						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486664				2022-12-25	WOS:A1993LA68900099
J	RANDOLPH, RK; SIMON, M				RANDOLPH, RK; SIMON, M			CHARACTERIZATION OF RETINOL METABOLISM IN CULTURED HUMAN EPIDERMAL-KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND MICROSOMES; BINDING-PROTEIN; VITAMIN-A; HUMAN-SKIN; ACYL-COA; TERMINAL DIFFERENTIATION; ACYLTRANSFERASE ACTIVITY; SMALL-INTESTINE; CELL-CULTURE; RAT-LIVER	Retinoids present in cultured human epidermal keratinocytes maintained in medium containing 25 nM retinol were identified and quantitated utilizing reverse-phase gradient high performance liquid chromatography. Total cell retinoid mass and composition averaged 12.59 pmol/mg cell protein +/- 1.86, (mean +/-S.D., n = 5) between strains and was constant with culture age. Long chain fatty acid esters of retinol and 3,4-didehydroretinol comprised greater than 95% of total retinoid, each contributing 77 and 23% of total esters, respectively. In mature stratified cultures, less abundant retinoids included unesterified retinol, 1%, and 3,4-didehydroretinol, 0.5%, retinoic acid, 0.5%, and a retinoid not previously reported in mammalian cells, 3,4-didehydroretinoic acid, 0.3%. This absolute and relative retinoid composition was essentially constant with culture age except that 3,4-didehydroretinoic acid was not detected in 3-4-day-old cultures (16-32 cell colonies), suggesting that keratinocyte differentiation may be related to endogenous changes in production of ''active'' retinoids. Separate pools of retinyl and 3,4-didehydroretinyl esters served as predominant sources of substrate for production of retinoic and 3,4-didehydroretinoic acids, respectively, suggesting that their production may be regulated in dependently.	SUNY STONY BROOK HOSP, SCH DENT MED, LIVING SKIN BANK, STONY BROOK, NY 11794 USA; SUNY, SCH DENT MED, DEPT ORAL BIOL & PATHOL, STONY BROOK, NY 11794 USA; SUNY, SCH MED, DEPT FOOD TECHNOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College								ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; BARUA AB, 1990, METHOD ENZYMOL, V189, P136; Bloch CE, 1921, J HYG-CAMBRIDGE, V19, P283, DOI 10.1017/S0022172400007865; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; Darmon M., 1991, SEMINARS DEV BIOL, V2, P219; DIAMOND L, 1978, LIFE SCI, V23, P1979, DOI 10.1016/0024-3205(78)90229-1; FELL HB, 1953, J PHYSIOL-LONDON, V119, P470, DOI 10.1113/jphysiol.1953.sp004860; FRAZIER G. N., 1931, Archives of Internal Medicine, V48, P507, DOI 10.1001/archinte.1931.00150030158012; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FURR HC, 1990, METHOD ENZYMOL, V189, P85; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Goodman DS, 1984, RETINOIDS, V2, P42; Goodwin GP, 1934, BRIT MED J, V1934, P113, DOI 10.1136/bmj.2.3837.113; Hatch F T, 1968, Adv Lipid Res, V6, P1; HELGERUD P, 1983, J CLIN INVEST, V71, P747, DOI 10.1172/JCI110822; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODAM JR, 1991, J INVEST DERMATOL, V97, P298, DOI 10.1111/1523-1747.ep12480562; HUANG HS, 1965, J BIOL CHEM, V240, P2839; KARASEK M A, 1970, Journal of the Society of Cosmetic Chemists, V21, P925; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROSS AC, 1986, METHOD ENZYMOL, V123, P68, DOI 10.1016/S0076-6879(86)23010-4; ROSS AC, 1982, J LIPID RES, V23, P133; ROSS AC, 1978, J BIOL CHEM, V253, P6591; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SIEGENTHALER G, 1988, EXP CELL RES, V178, P114, DOI 10.1016/0014-4827(88)90383-7; SIEGENTHALER G, 1984, BRIT J DERMATOL, V111, P647, DOI 10.1111/j.1365-2133.1984.tb14147.x; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; UBELS JL, 1990, INVEST OPHTH VIS SCI, V31, P582; VAHLQUIST A, 1988, INT J DERMATOL, V27, P81, DOI 10.1111/j.1365-4362.1988.tb01278.x; VAHLQUIST A, 1982, J INVEST DERMATOL, V79, P94, DOI 10.1111/1523-1747.ep12500033; VAHLQUIST A, 1982, J INVEST DERMATOL, V79, P89, DOI 10.1111/1523-1747.ep12500032; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YOST RW, 1988, J BIOL CHEM, V263, P18693	46	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9198	9205						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486621				2022-12-25	WOS:A1993LA68900012
J	CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A				CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A			CHIMERIC C-JUN CONTAINING AN HETEROLOGOUS HOMODIMERIZATION DOMAIN TRANSFORMS PRIMARY CHICK-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING PROTEIN; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; DIMERIZATION SPECIFICITY; NEGATIVE REGULATION; GENE FAMILY; V-JUN; FOS; ONCOGENE; EXPRESSION	To investigate a possible role for c-Jun homodimers in c-Jun-mediated transformation, we designed two chimeric c-Jun derivatives, called c-Jun(eb1) and c-Jun(gcn4). In these chimeric derivatives the natural dimerization domain of c-Jun was replaced by the heterologous homodimerization domain of the Epstein-Barr virus EB1 or the yeast GCN4 transcription factor. Chick embryo fibroblasts chronically infected with retroviruses expressing c-Jun, c-Jun(eb1) or c-Jun(gcn4) are transformed. Infection with each construction results in sustained growth in low serum and development of colonies from single cells in agar with similar efficiencies. In contrast to c-Jun, c-Jun(eb1) and c-Jun(gcn4) confer additional phenotypic alterations related to in vitro transformation including a condensed cell morphology and ability to develop highly invasive, fast growing colonies in agar. These data suggest that c-Jun homodimers can transform chick embryo fibroblasts and activate cellular functions which influence cell morphology and invasive potential in agar. These findings are consistent with the notion that cellular transformation by c-jun is mediated by c-Jun homodimers.			CASTELLAZZI, M (corresponding author), ECOLE NORMALE SUPER, BIOL MOLEC & CELLULAIRE LAB, CNRS, UMR 49, 46 ALLEE ITALIE, F-69364 LYON, FRANCE.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, ONCOGENE, V5, P929; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1149	1160						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479740				2022-12-25	WOS:A1993KY32800006
J	LOEWY, AG; SANTER, UV; WIECZOREK, M; BLODGETT, JK; JONES, SW; CHERONIS, JC				LOEWY, AG; SANTER, UV; WIECZOREK, M; BLODGETT, JK; JONES, SW; CHERONIS, JC			PURIFICATION AND CHARACTERIZATION OF A NOVEL ZINC-PROTEINASE FROM CULTURES OF AEROMONAS-HYDROPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; BITIS-ARIETANS; GAMMA-CHAIN; D-DIMER; SEQUENCE; FIBRIN; VENOM; CLEAVAGE; FRAGMENTS	While searching for an enzyme capable of breaking epsilon-(gamma-Glu)-Lys isopeptide bonds cross-linking protein chains, we purified a metallo-proteinase which mimics the action of an isopeptidase on the gamma-chain dimers of cross-linked fibrin. The enzyme is present in the growth medium of the bacterium Aeromonas hydrophila, isolated from the intestinal tract of the leech Hirudo medicinalis. It is a 19-kDa protein which specifically hydrolyzes the Gly-Ala peptide bond within the Gly-Gly-Ala sequence, located near the cross-link site in the gamma-chain dimer of fibrin. Substrate specificity studies with a number of synthetic peptides suggest that the enzyme prefers Gly-Gly or acetyl-Gly in the P2 and P1 positions, respectively (Schecter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162). Nonpolar amino acid residues seem to be favored in the P1' and P2' positions. The enzyme contains one atom of zinc and is inhibited by 1,10-phenanthroline, but not by EDTA. Iodoacetate, leupeptin, diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, pepstatin, and alpha2-macroglobulin have no effect on enzyme activity. Disulfide reducing reagents, such as dithiothreitol or 2-mereaptoethanol, inactivate the enzyme completely. The partial amino-terminal sequence shows 46% identity with a zinc metallo-proteinase from a strain of Lysobacter enzymogenes and 69% identity with the LasA protein from Pseudomonas aeruginosa.	CORTECH INC, DENVER, CO 80221 USA		LOEWY, AG (corresponding author), HAVERFORD COLL, DEPT BIOL, HAVERFORD, PA 19041 USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM034503] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 34503] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BASKOVA I P, 1990, Biokhimiya, V55, P674; BASKOVA I P, 1985, Biokhimiya, V50, P424; BASKOVA I P, 1990, Biokhimiya, V55, P771; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P246; CRUSE WBT, 1976, J MOL BIOL, V102, P173, DOI 10.1016/0022-2836(76)90081-4; DAMAGLOU AP, 1976, ATLAS PROTEIN SEQ S2, V5, P98; DARZINS A, 1990, NUCLEIC ACIDS RES, V18, P6444, DOI 10.1093/nar/18.21.6444; DONOVAN JW, 1985, BIOCHEMISTRY-US, V24, P3434, DOI 10.1021/bi00335a007; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1703, DOI 10.1021/bi00627a028; EGEN NB, 1984, TOXICON, V22, P653, DOI 10.1016/0041-0101(84)90005-9; FRANCIS CW, 1988, BLOOD, V71, P1361; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HARSFALVI J, 1991, BIOCHIM BIOPHYS ACTA, V1073, P268, DOI 10.1016/0304-4165(91)90131-Y; HOFMANN T, 1982, BIOCHEM J, V203, P603, DOI 10.1042/bj2030603; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEWY AG, 1991, 15TH INT C BIOCH JER, P61; LOEWY AG, 1990, INT S PEPTIDE INHIBI; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; North M, 1989, PROTEOLYTIC ENZYMES, P105; OZA NB, 1973, INT J PEPT PROT RES, V5, P365; PETERS JE, 1990, J BACTERIOL, V172, P2236, DOI 10.1128/jb.172.5.2236-2240.1990; PURVES L, 1987, BIOCHEMISTRY-US, V26, P4640, DOI 10.1021/bi00389a008; PURVES LR, 1986, S AFR J SCI, V82, P30; PURVES M, 1989, S AFR J SCI, V85, P519; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; ROWBOTHAM B, 1985, Australian and New Zealand Journal of Medicine, V15, P110; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SANTER UV, 1984, CANCER RES, V44, P3730; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHEEHAN JC, 1973, J AM CHEM SOC, V95, P875, DOI 10.1021/ja00784a041; SKOOG DA, 1982, FUNDAMENTALS ANAL CH, P276; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STEWART JM, 1984, LABORATORY TECNIQUES, P85; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001	40	37	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9071	9078						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473348				2022-12-25	WOS:A1993KX81100098
J	PRABAKARAN, D; KIM, P; KIM, KR; ARVAN, P				PRABAKARAN, D; KIM, P; KIM, KR; ARVAN, P			POLARIZED SECRETION OF THROMBOSPONDIN IS OPPOSITE TO THYROGLOBULIN IN THYROID EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; EXTRACELLULAR-MATRIX; SUSPENSION-CULTURE; PROTEINS; FOLLICLES; MEMBRANE; GLYCOPROTEIN; EXOCYTOSIS; COMPONENTS; OCCURS	In addition to thyroglobulin, primary thyrocytes secrete into the culture medium significant quantities of p500, a protein so named because of its M(r) greater-than-or-equal-to 500,000. Epithelial monolayers cultured on porous filters serve as a useful model system in which to study protein secretion. From these monolayers, thyroglobulin, the precursor in thyroid hormonogenesis, was released with apical predominance, while p500 was found mostly in the basolateral medium. Thyrocyte exposure to thyrotropin augmented selectively thyroglobulin but not p500 production. By contrast, exposure to cycloheximide actually augmented p500 production, a response observed for immediate-early proto-oncogenes. Using thyrocyte conditioned medium, the p500 protein was purified to homogeneity. Peptide sequencing of tryptic fragments of purified p500 showed identity to thrombospondin. Immunoprecipitation of thrombospondin from media bathing primary thyrocytes and the FRTL5 cell line quantitatively recovered p500, confirming its identity and indicating an epithelial origin. Gel filtration of secreted thrombospondin eluted at a high molecular weight, suggesting complexation with components of the extracellular matrix. Further, immunofluorescence showed cellular codistribution of thrombospondin and thyroglobulin, although thrombospondin exhibited predominantly an extracellular, basolateral deposition. It seems likely that thrombospondin production by thyrocytes plays a role in the growth or development of the thyroid epithelium.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, CELL & DEV BIOL PROGRAM, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK40344] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040344, R01DK040344] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BERG G, 1975, BIOCHIM BIOPHYS ACTA, V405, P11, DOI 10.1016/0005-2795(75)90309-8; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHAMBARD M, 1984, BIOL CELL, V51, P315, DOI 10.1111/j.1768-322X.1984.tb00310.x; CHAMBARD M, 1990, J MOL ENDOCRINOL, V4, P193, DOI 10.1677/jme.0.0040193; CHANG A, 1989, HDB PHYSL GASTROINTE, V3, P531; DIXIT VM, 1986, P NATL ACAD SCI USA, V83, P5449, DOI 10.1073/pnas.83.15.5449; ERICSON LE, 1981, MOL CELL ENDOCRINOL, V22, P1, DOI 10.1016/0303-7207(81)90098-8; FAYET G, 1982, J CELL BIOL, V93, P479, DOI 10.1083/jcb.93.2.479; FAYET G, 1980, BIOCHIMIE, V62, P27, DOI 10.1016/S0300-9084(80)80367-1; FRATI L, 1974, ARCH BIOCHEM BIOPHYS, V162, P126, DOI 10.1016/0003-9861(74)90111-8; FRAUMAN AG, 1990, ENDOCRIN METAB CLIN, V19, P479, DOI 10.1016/S0889-8529(18)30306-2; GARBI C, 1982, J CELL BIOL, V94, P489, DOI 10.1083/jcb.94.2.489; GARBI C, 1988, J CELL PHYSIOL, V135, P39, DOI 10.1002/jcp.1041350106; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; JAFFE EA, 1985, BLOOD, V65, P79; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KIM PS, 1991, J BIOL CHEM, V266, P12412; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MARRIQ C, 1977, EUR J BIOCHEM, V79, P143, DOI 10.1111/j.1432-1033.1977.tb11792.x; MAUCHAMP J, 1987, ACTA ENDOCRINOL-COP, V115, P220; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; NADLER NJ, 1964, ENDOCRINOLOGY, V74, P333, DOI 10.1210/endo-74-3-333; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; RING P, 1987, CELL TISSUE RES, V247, P505, DOI 10.1007/BF00215743; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1983, BIOCHEMISTRY-US, V22, P2148, DOI 10.1021/bi00278a015; SHIFRIN S, 1982, J BIOL CHEM, V257, P9539; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SMEDS S, 1970, BIOCHEM BIOPH RES CO, V38, P1168, DOI 10.1016/0006-291X(70)90362-1; SPRAY DC, 1987, J CELL BIOL, V105, P541, DOI 10.1083/jcb.105.1.541; STEELE RE, 1986, AM J PHYSIOL, V251, pC136, DOI 10.1152/ajpcell.1986.251.1.C136; STUDER H, 1989, ENDOCR REV, V10, P125, DOI 10.1210/edrv-10-2-125; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TACCHETTI C, 1986, J CELL PHYSIOL, V126, P93, DOI 10.1002/jcp.1041260113; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; WADELEUX P, 1985, BIOCHIM BIOPHYS ACTA, V846, P257, DOI 10.1016/0167-4889(85)90073-4	55	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9041	9048						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473345				2022-12-25	WOS:A1993KX81100094
J	CHUANG, JL; COX, RP; CHUANG, DT				CHUANG, JL; COX, RP; CHUANG, DT			CHARACTERIZATION OF THE PROMOTER-REGULATORY REGION AND STRUCTURAL ORGANIZATION OF E1-ALPHA GENE (BCKDHA) OF HUMAN BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRUP-URINE-DISEASE; MESSENGER-RNA; 5'-FLANKING SEQUENCES; TRANSCRIPTION FACTOR; E1-BETA SUBUNIT; Y393N MUTATION; BOVINE KIDNEY; EXPRESSION; IDENTIFICATION; PURIFICATION	We have isolated genomic clones containing the complete exon 1 and the promoter-regulatory region of the E1alpha gene (BCKDHA) of human branched-chain alpha-keto acid dehydrogenase complex. The cloning was achieved by amplification of a genomic library in the SRB (P2) host strain that allowed the replication of nonstandard DNA structures. The results of this and previous (Dariush, N., Fisher, C. W., Cox, R. P., and Chuang, D. T. (1991) FEBS Lett. 284, 34-38) studies showed that the human E1alpha gene contains 9 exons, and spans at least 55 kilobases (kb). Exon 1 is 135 bp in length, and contains multiple transcription initiation sites at bases +1, +18, and +22. The complete human E1alpha cDNA is, therefore, 1,758 bp in length excluding the poly(A)+ tail, and has 27 nucleotides in the 5'-untranslated region. Sequencing of the 5'-flanking region disclosed the absence of a canonical TATA-box in the vicinity of base -30. Several sets of ''CAAT'' box-like sequences and Spl binding-sites are present. Also present are copies of potential AP-2 binding, fat-specific element 1, fat-specific element 2, glucocorticoid-responsive element, and cAMP-responsive element sequences, as well as multiple sets of direct and inverted repeats. The promoter-regulatory region was characterized using deletion constructs and the luciferase reporter assay. The human hepatoma cells (Hep-G2) and Chinese hamster ovary (CHO) cell lines were used as hosts. The results obtained with Hep-G2 cells indicate that the region for high level transcription is located between bases -320 and -115. Extension of the 5'-end of the insert to beyond base -320 markedly reduces promoter activity. The results strongly suggest the presence of inhibitory elements in the region upstream of base -320. Assays in CHO cells show that the region for high level transcription lies between bases -909 and -115. The variation in the region for high level transcription in Hep-G2 and CHO cells may represent cell-type specific differences in the E1alpha gene promoter function.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CHUANG, JL (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.				NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Battey, 1986, BASIC METHODS MOL BI; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHUANG DT, 1983, BIOCHEM J, V214, P177, DOI 10.1042/bj2140177; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANCIS J, 1960, BIOCHIM BIOPHYS ACTA, V43, P342, DOI 10.1016/0006-3002(60)90448-0; Danner DJ, 1989, METABOLIC BASIS INHE, P671; DARIUSH N, 1991, FEBS LETT, V284, P34, DOI 10.1016/0014-5793(91)80755-R; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FEKETE G, 1989, CYTOGENET CELL GENET, V50, P236, DOI 10.1159/000132768; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER CR, 1991, AM J HUM GENET, V49, P429; FISHER CW, 1989, J BIOL CHEM, V264, P3448; FISHER CW, 1993, AM J HUM GENET, V52, P414; FISHER CW, 1991, BIOCHEM BIOPH RES CO, V174, P804, DOI 10.1016/0006-291X(91)91489-Y; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; HERRING WJ, 1992, BIOCHIM BIOPHYS ACTA, V1138, P236, DOI 10.1016/0925-4439(92)90043-M; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; HU CWC, 1988, J BIOL CHEM, V263, P9007; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KILGORE MW, 1992, MOL CELL ENDOCRINOL, V83, pR9, DOI 10.1016/0303-7207(92)90202-H; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAU KS, 1992, J BIOL CHEM, V267, P24090; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LEACH DRF, 1983, NATURE, V305, P448, DOI 10.1038/305448a0; MARTINI G, 1986, EMBO J, V5, P1849, DOI 10.1002/j.1460-2075.1986.tb04436.x; MATSUDA I, 1990, BIOCHEM BIOPH RES CO, V172, P646, DOI 10.1016/0006-291X(90)90723-Z; MCKEAN MC, 1992, BIOCHIM BIOPHYS ACTA, V1171, P109, DOI 10.1016/0167-4781(92)90149-T; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITSUBUCHI H, 1991, J BIOL CHEM, V266, P14686; NOBUKUNI Y, 1991, J CLIN INVEST, V87, P1862, DOI 10.1172/JCI115209; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; REED LJ, 1980, ENZYME REGULATION ME, P47; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKESHIMA H, 1988, J MOL BIOL, V200, P1, DOI 10.1016/0022-2836(88)90328-2; TANOUE A, 1990, J BIOL CHEM, V265, P11306; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880; YOGANATHAN T, 1992, BIOCHEM J, V285, P721, DOI 10.1042/bj2850721; ZHANG B, 1989, J CLIN INVEST, V83, P1425, DOI 10.1172/JCI114033; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	59	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8309	8316						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463340				2022-12-25	WOS:A1993KW97900104
J	BEHARI, R; BAKER, A				BEHARI, R; BAKER, A			THE CARBOXYL TERMINUS OF ISOCITRATE LYASE IS NOT ESSENTIAL FOR IMPORT INTO GLYOXYSOMES IN AN INVITRO SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL TARGETING SIGNAL; ACYL-COA OXIDASE; MALATE SYNTHASE; ENDOPLASMIC-RETICULUM; PROTEIN TRANSLOCATION; CANDIDA-TROPICALIS; COTYLEDONS; MEMBRANE; IDENTIFICATION; DEHYDROGENASE	A procedure has been established for the isolation of intact and import-competent glyoxysomes from the cotyledons of sunflower (Helianthus annuus) seedlings. Radiolabeled isocitrate lyase (a glyoxysomal matrix protein) was produced by in vitro transcription of the castor bean cDNA and translation of the RNA in a wheat germ lysate. The heterologous isocitrate lyase was imported into isolated sunflower glyoxysomes and protease-protected. Dihydrofolate reductase, a cytoplasmic protein, neither bound to nor imported into the glyoxysomes. Import of isocitrate lyase was not observed when the glyoxysome fraction was replaced by a mitochondrial fraction. The import of isocitrate lyase into glyoxysomes was temperature- and ATP-dependent. Progressive carboxyl-terminal truncations of the isocitrate lyase gene were transcribed and translated to yield polypeptides with the same amino terminus but lacking varying amounts of the carboxyl terminus. All these polypeptides imported with the same characteristics as the full-length protein, suggesting that targeting information must be present within the first 168 amino acids, and, unlike some other peroxisomal proteins, the carboxyl terminus is dispensible for targeting and import.	UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge				Baker, Alison/0000-0003-2181-4057				ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; ATOMI H, 1990, J BIOCHEM-TOKYO, V107, P262, DOI 10.1093/oxfordjournals.jbchem.a123036; BEECHING JR, 1987, PLANT MOL BIOL, V8, P471, DOI 10.1007/BF00017992; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BOWLES DJ, 1976, BIOCHIM BIOPHYS ACTA, V443, P360, DOI 10.1016/0005-2787(76)90500-1; COMAI L, 1989, PLANT CELL, V1, P293, DOI 10.1105/tpc.1.3.293; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; COOPER TG, 1969, J BIOL CHEM, V244, P3507; DEBELLIS L, 1990, PLANTA, V180, P435, DOI 10.1007/BF00198797; DEBELLIS L, 1991, PLANT CELL PHYSIOL, V32, P555; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FANG TK, 1987, PLANTA, V172, P1, DOI 10.1007/BF00403023; FREVERT J, 1980, H-S Z PHYSIOL CHEM, V361, P1557, DOI 10.1515/bchm2.1980.361.2.1557; GERBLING H, 1987, PLANTA, V171, P386, DOI 10.1007/BF00398684; GIETL C, 1986, PLANTA, V167, P87, DOI 10.1007/BF00446373; GIETL C, 1984, PLANTA, V162, P261, DOI 10.1007/BF00397448; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; GRAHAM IA, 1992, PLANT CELL, V4, P349, DOI 10.1105/tpc.4.3.349; GRAY JC, 1978, PHYTOCHEMISTRY, V17, P495, DOI 10.1016/S0031-9422(00)89346-2; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HEUPEL R, 1991, PLANT PHYSIOL, V96, P971, DOI 10.1104/pp.96.3.971; HOCK B, 1966, Z PFLANZENPHYSIOL, V55, P405; Huang A. H. C., 1983, AM SOC PLANT PHYSL M; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KRUSE C, 1981, FEBS LETT, V129, P36, DOI 10.1016/0014-5793(81)80749-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LOOMIS W.D., 1969, METHOD ENZYMOL, V13, P555; LOOMIS WD, 1979, PHYTOCHEMISTRY, V18, P1049, DOI 10.1016/S0031-9422(00)91475-4; MATSUOKA M, 1988, J BACTERIOL, V170, P4528, DOI 10.1128/jb.170.10.4528-4536.1988; MIERNYK JA, 1979, PLANT PHYSIOL, V63, P1068, DOI 10.1104/pp.63.6.1068; Minshull J., 1992, Antisense RNA and DNA., P195; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI H, 1989, FEBS LETT, V244, P163, DOI 10.1016/0014-5793(89)81184-6; NAPIER RM, 1992, J CELL SCI, V102, P261; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; NISHIMURA M, 1986, PLANT PHYSIOL, V80, P313; PEACHEY LD, 1958, J BIOPHYS BIOCHEM CY, V4, P233, DOI 10.1083/jcb.4.3.233; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; RODRIGUEZ D, 1990, PLANT MOL BIOL, V15, P501, DOI 10.1007/BF00019167; SAUTTER C, 1986, PLANTA, V167, P491, DOI 10.1007/BF00391225; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SMALL GM, 1987, MOL CELL BIOL, V7, P1848, DOI 10.1128/MCB.7.5.1848; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; THEIMER RR, 1976, FEBS LETT, V62, P297, DOI 10.1016/0014-5793(76)80079-8; TITUS DE, 1985, J CELL BIOL, V101, P1288, DOI 10.1083/jcb.101.4.1288; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; VEEGER C, 1969, METHOD ENZYMOL, V13, P81, DOI DOI 10.1016/0076-6879(69)13020-7; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	60	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7315	7322						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463266				2022-12-25	WOS:A1993KV14100071
J	SEMENKOVICH, CF; COLEMAN, T; GOFORTH, R				SEMENKOVICH, CF; COLEMAN, T; GOFORTH, R			PHYSIOLOGICAL CONCENTRATIONS OF GLUCOSE REGULATE FATTY-ACID SYNTHASE ACTIVITY IN HEPG2 CELLS BY MEDIATING FATTY-ACID SYNTHASE MESSENGER-RNA STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; INSULIN GENE-EXPRESSION; 3' UNTRANSLATED REGION; PYRUVATE-KINASE GENE; BREAST-CANCER-CELLS; MALIC ENZYME; HORMONAL-REGULATION; LIPOGENIC ENZYMES; MOLECULAR-CLONING; PRIMARY CULTURES	Carbohydrate feeding of animals results in striking increases in hepatic fatty acid synthesis but much of this induction is presumed to be hormone mediated. To clarify the mechanisms responsible for the specific effect of carbohydrate on fatty acid synthesis, the effects of D-glucose on the expression of human fatty acid synthase (FAS) in HepG2 cells cultured in serum-free medium were studied. Northern blots of total RNA from these cells showed a single FAS mRNA band of 9.3 kilobases that was increased 2.7-5.4-fold in the presence of D-glucose. Lactate and citrate but not L-glucose glucose mimicked this effect. Glucose induction of FAS mRNA was time- and concentration-dependent and most of the increase in FAS message was detected within the range of physiologic glucose concentrations. Glucose induction of FAS mRNA, protein synthetic rate, and enzyme activity were similar suggesting that glucose regulates FAS expression at a pretranslational level in this system. Transcription run-off experiments showed that glucose feeding was associated with no change in the FAS transcription initiation rate despite a 5-fold increase in FAS mRNA. FAS mRNA stability as determined by actinomycin D chase was 7-fold greater in the presence of glucose. Differences between FAS mRNA levels in cells grown in the presence versus the absence of glucose were inhibited by cycloheximide but not puromycin, suggesting that glucose regulation of FAS mRNA stability is not dependent on translation. Glucose, at physiologic concentrations and in the absence of hormones, appears to regulate FAS gene expression in HepG2 cells predominantly by mediating FAS mRNA stability.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	SEMENKOVICH, CF (corresponding author), WASHINGTON UNIV, SCH MED,DEPT MED, DIV ATHEROSCLEROSIS NUTR & LIPID RES, 4566 SCOTT AVE, BOX 8046, ST LOUIS, MO 63110 USA.			Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047436] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47436] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BACK DW, 1986, J BIOL CHEM, V261, P4190; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P832, DOI 10.1073/pnas.68.4.832; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHALBOS D, 1991, J BIOL CHEM, V266, P8220; CHALBOS D, 1987, J BIOL CHEM, V262, P9923; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; FUKUDA H, 1992, J BIOCHEM-TOKYO, V111, P25, DOI 10.1093/oxfordjournals.jbchem.a123713; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GIFFHORNKATZ S, 1986, EUR J BIOCHEM, V159, P513, DOI 10.1111/j.1432-1033.1986.tb09916.x; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V15, P6737, DOI 10.1093/nar/15.16.6737; HENTZE MW, 1991, BIOCHIM BIOPHYS ACTA, V1090, P281, DOI 10.1016/0167-4781(91)90191-N; IRITANI N, 1992, J NUTR, V122, P28, DOI 10.1093/jn/122.1.28; IRITANI N, 1992, EUR J BIOCHEM, V205, P433, DOI 10.1111/j.1432-1033.1992.tb16797.x; ISHIDA T, 1983, J CLIN INVEST, V72, P590, DOI 10.1172/JCI111007; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JOYEUX C, 1989, MOL ENDOCRINOL, V3, P681, DOI 10.1210/mend-3-4-681; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KONO T, 1988, VITAM HORM, V44, P103; KRUL ES, 1992, J LIPID RES, V33, P1037; Kumar S, 1981, Methods Enzymol, V71 Pt C, P86, DOI 10.1016/0076-6879(81)71013-9; LEVY R, 1992, J LIPID RES, V33, P1005; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOUIS NA, 1992, J BIOL CHEM, V267, P2287; MEYER S, 1991, EUR J BIOCHEM, V202, P985, DOI 10.1111/j.1432-1033.1991.tb16460.x; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MUSCHEL R, 1986, MOL CELL BIOL, V6, P337, DOI 10.1128/MCB.6.1.337; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SEMENKOVICH CF, 1987, BIOCHEMISTRY-US, V26, P4987, DOI 10.1021/bi00390a016; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SINGER RH, 1973, J MOL BIOL, V78, P321, DOI 10.1016/0022-2836(73)90119-8; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; STAHL H, 1977, EUR J BIOCHEM, V72, P385, DOI 10.1111/j.1432-1033.1977.tb11263.x; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; VOLPE JJ, 1974, P NATL ACAD SCI USA, V71, P889, DOI 10.1073/pnas.71.3.889; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WAKIL SJ, 1966, P NATL ACAD SCI USA, V55, P880, DOI 10.1073/pnas.55.4.880; WELSH M, 1985, J BIOL CHEM, V260, P3590; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; WHITE JJ, 1968, SURGERY, V64, P204; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WU JH, 1990, J BIOL CHEM, V265, P12312; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	70	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6961	6970						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463228				2022-12-25	WOS:A1993KV14100027
J	ABDELGHANY, M; ELSEBAE, AK; SHALLOWAY, D				ABDELGHANY, M; ELSEBAE, AK; SHALLOWAY, D			ALUMINUM-INDUCED NONENZYMATIC PHOSPHO-INCORPORATION INTO HUMAN-TAU AND OTHER PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL NEUROFIBRILLARY DEGENERATION; MICROTUBULE-ASSOCIATED PROTEIN-2; BRAIN CYTOSKELETAL PROTEINS; HUMAN NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; DEPENDENT PHOSPHORYLATION; DIALYSIS ENCEPHALOPATHY; CHEMICAL-PROPERTIES; GAMMA-PHOSPHATE; ACTIN-FILAMENTS	Incubation of purified recombinant human tau protein with aluminum salts at concentrations greater-than-or-equal-to 100 muM induces aggregation of tau that prevents its entry into SDS-polyacrylamide gels and filtration through nylon membranes. This effect is noncovalent and can be reversed by addition of EDTA. However, when incubated along with ATP, GTP, or CTP, aluminum catalyzes a covalent linkage that results in incorporation of the alpha- and gamma-phosphates into the tau protein (phospho-incorporation). The sensitivity to phosphatases and partial hydrolysis and the labeling observed with ATP containing radioisotopes at different positions suggest a novel reaction in which the entire triphosphate moiety is transferred from ATP and linked to tau via an O-linkage to the alpha-phosphate. The aggregation and triphosphorylation phenomena were not catalyzed by divalent or quadrivalent cations, but similar effects were observed with some other trivalent cations. They occurred at aluminum concentrations similar to those found in human brains with Alzheimer's disease, suggesting the possibility that related reactions may have physiological significance in vivo.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University								ABDELGHANY M, 1988, P NATL ACAD SCI USA, V85, P1408, DOI 10.1073/pnas.85.5.1408; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIZZI A, 1986, ACTA NEUROPATHOL, V71, P154, DOI 10.1007/BF00687978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DIAZNIDO J, 1990, NEUROSCI LETT, V110, P221, DOI 10.1016/0304-3940(90)90815-Q; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FATEMI SJA, 1991, BIOCHEM J, V280, P527, DOI 10.1042/bj2800527; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GUY SP, 1991, NEUROSCI LETT, V121, P166, DOI 10.1016/0304-3940(91)90676-K; HEWITT CD, 1991, NEUROPATH APPL NEURO, V17, P47, DOI 10.1111/j.1365-2990.1991.tb00693.x; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; JOHNSON GVW, 1988, BRAIN RES, V456, P95, DOI 10.1016/0006-8993(88)90350-2; JULIEN JP, 1982, J BIOL CHEM, V257, P467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; LANGUI D, 1988, BRAIN RES, V438, P67, DOI 10.1016/0006-8993(88)91324-8; LANGUI D, 1990, ACTA NEUROPATHOL, V80, P649, DOI 10.1007/BF00307634; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LISS L, 1989, ENV CHEM TOXICOLOGY, P317; MACDONALD TL, 1987, SCIENCE, V236, P183, DOI 10.1126/science.3105058; MARKESBERY WR, 1981, ANN NEUROL, V10, P511; Martell A.E., 1989, ENV CHEM TOXICOLOGY, P4; MARTIN RB, 1986, CLIN CHEM, V32, P1797; MARTYN CN, 1989, LANCET, V1, P59; Mason B., 1952, PRINCIPLES GEOCHEMIS; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MCDERMOTT JR, 1978, LANCET, V1, P901, DOI 10.1016/S0140-6736(78)90681-5; MCDERMOTT JR, 1979, NEUROLOGY, V29, P809, DOI 10.1212/WNL.29.6.809; MCLACHLAN DRC, 1986, NEUROBIOL AGING, V7, P525; MESCO ER, 1991, MOL CHEM NEUROPATHOL, V14, P199, DOI 10.1007/BF03159936; MUMA NA, 1988, MOL BRAIN RES, V3, P115, DOI 10.1016/0169-328X(88)90056-3; NISHIDA E, 1981, J BIOCHEM-TOKYO, V90, P575, DOI 10.1093/oxfordjournals.jbchem.a133510; NIXON RA, 1990, J NEUROCHEM, V55, P1950, DOI 10.1111/j.1471-4159.1990.tb05781.x; PERL DP, 1988, MET IONS BIOL SYST, V24, P259; PERL DP, 1982, SCIENCE, V217, P1053, DOI 10.1126/science.7112111; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; SAYRE LM, 1985, BRAIN RES REV, V10, P69, DOI 10.1016/0165-0173(85)90008-6; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SELKOE DJ, 1979, BRAIN RES, V163, P235, DOI 10.1016/0006-8993(79)90352-4; SHEA TB, 1992, J NEUROCHEM, V58, P542, DOI 10.1111/j.1471-4159.1992.tb09753.x; SHEA TB, 1991, NEUROSCI RES COMMUN, V9, P21; Sigel H., 1988, MET IONS BIOL SYST, V24; STERN AJ, 1986, J NEUROPATH EXP NEUR, V45, P361, DOI 10.1097/00005072-198605000-00140; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TRONCOSO JC, 1986, BRAIN RES, V364, P295, DOI 10.1016/0006-8993(86)90842-5; USUKI K, 1991, J BIOL CHEM, V237, P841; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WILLS MR, 1983, LANCET, V2, P29; WISNIEWSKI HM, 1986, NEUROBIOL AGING, V7, P532, DOI 10.1016/0197-4580(86)90103-X; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x; YAMAMOTO H, 1990, J NEUROCHEM, V55, P683, DOI 10.1111/j.1471-4159.1990.tb04187.x; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	66	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11976	11981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505322				2022-12-25	WOS:A1993LF28400078
J	FUKAMIZU, A; SUGIMURA, K; TAKIMOTO, E; SUGIYAMA, F; SEO, MS; TAKAHASHI, S; HATAE, T; KAJIWARA, N; YAGAMI, K; MURAKAMI, K				FUKAMIZU, A; SUGIMURA, K; TAKIMOTO, E; SUGIYAMA, F; SEO, MS; TAKAHASHI, S; HATAE, T; KAJIWARA, N; YAGAMI, K; MURAKAMI, K			CHIMERIC RENIN-ANGIOTENSIN SYSTEM DEMONSTRATES SUSTAINED INCREASE IN BLOOD-PRESSURE OF TRANSGENIC MICE CARRYING BOTH HUMAN RENIN AND HUMAN ANGIOTENSINOGEN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; FRAGMENT-LENGTH-POLYMORPHISMS; EXPRESSION; CELLS	A reaction between enzyme renin and its only natural substrate angiotensinogen is the initial and rate-limiting step for producing a potent vasoconstrictor angiotensin II as the final product of the renin-angiotensin system, a contributory factor in the pathogenesis of hypertension. In order to assess the role of the interaction of human renin with human angiotensinogen in the development of high blood pressure, we have constructed the chimeric renin-angiotensin cascade in mice comprising both human renin and human angiotensinogen as well as the endogenous angiotensin-converting enzyme and angiotensin II receptor by cross-mating separate lines of transgenic mice carrying either the human renin or human angiotensinogen genes. Although each single gene carrier did not develop hypertension despite the observed normal tissue-specific expression of the transgenes, dual gene strains exhibited a chronically sustained increase in blood pressure. Administration of a human renin-specific inhibitor (ES-8891) was effective in reducing the elevated blood pressure only against the cross-mated hybrid mice, but treatment of an angiotensin-converting enzyme inhibitor (captopril) and a selective antagonist (DuP 753) directed at the angiotensin II receptor decreased the basal level of blood pressure even in single gene carriers as well as in dual gene mice. These results clearly demonstrated that the sustained increase in blood pressure of the hybrid mice was initiated by the interaction between the products of the two human genes.	UNIV TSUKUBA, LAB ANIM RES CTR, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	FUKAMIZU, A (corresponding author), UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN.		fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				CORNETTE JC, 1987, ANAL BIOCHEM, V163, P93, DOI 10.1016/0003-2697(87)90097-2; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; DESSIFULGHERI P, 1987, CLIN EXP HYPERTENS A, V9, P1383, DOI 10.3109/10641968709158991; FUKAMIZU A, 1991, BIOCHEM J, V278, P601, DOI 10.1042/bj2780601; FUKAMIZU A, 1989, BIOCHEM BIOPH RES CO, V165, P826, DOI 10.1016/S0006-291X(89)80040-3; GANTEN D, 1992, P NATL ACAD SCI USA, V89, P7806, DOI 10.1073/pnas.89.16.7806; GARDES J, 1982, HYPERTENSION, V4, P185, DOI 10.1161/01.HYP.4.2.185; HATAE T, 1992, BIOMED RES-TOKYO, V13, P381, DOI 10.2220/biomedres.13.381; HIGAKI J, 1988, CLIN SCI, V75, P669, DOI 10.1042/cs0750669; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIM S, 1992, HYPERTENSION, V20, P280, DOI 10.1161/01.HYP.20.3.280; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOKUBU T, 1990, HYPERTENSION, V15, P909, DOI 10.1161/01.HYP.15.6.909; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; MCCAA RE, 1978, CIRC RES, V43, pI32; MENARD J, 1985, J HYPERTENS, V3, pS275; MOORE TJ, 1981, HYPERTENSION, V3, P168, DOI 10.1161/01.HYP.3.2.168; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; NAFTILAN AJ, 1989, HYPERTENSION, V14, P614, DOI 10.1161/01.HYP.14.6.614; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; OLIVER WJ, 1966, P SOC EXP BIOL MED, V122, P923; OPARIL S, 1974, NEW ENGL J MED, V291, P389, DOI 10.1056/NEJM197408222910805; PRINTZ MP, 1977, J BIOL CHEM, V252, P1654; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RHALEB NE, 1991, HYPERTENSION, V17, P480, DOI 10.1161/01.HYP.17.4.480; SIMON D, 1987, CLIN EXP HYPERTENS A, V9, P1333, DOI 10.3109/10641968709158987; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; WARD R, 1990, HYPERTENSION PATHOPH, P81	35	236	242	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11617	11621						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505294				2022-12-25	WOS:A1993LF28400028
J	KUHNE, MR; PAWSON, T; LIENHARD, GE; FENG, GS				KUHNE, MR; PAWSON, T; LIENHARD, GE; FENG, GS			THE INSULIN-RECEPTOR SUBSTRATE-1 ASSOCIATES WITH THE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN; KINASE	The insulin receptor substrate 1 (IRS1) is a protein that is rapidly phosphorylated on tyrosine by the activated insulin receptor. Syp is a recently discovered, broadly expressed phosphotyrosine (Tyr(P)) phosphatase that contains two Src homology 2 (SH2) domains. We have found that insulin treatment of 3T3-L1 adipocytes leads to complex formation between IRS1 and Syp. Syp was detected in immunoadsorbates of IRS1 from extracts of insulin-treated but not basal cells by both immunoblotting and Tyr(P) phosphatase activity. The association of Syp with IRS1 apparently occurs between the SH2 domains of Syp and Tyr(P)-containing sequences of IRS1, since a fusion protein containing only the SH2 domains of Syp bound the Tyr(P) form of IRS1. Unlike the receptors for epidermal and platelet-derived growth factors, which in their activated state bind to the SH2 domains of Syp and elicit phosphorylation of Syp on tyrosine in intact cells, the Tyr(P) form of the insulin receptor did not bind to the SH2 domains of Syp, and no phosphorylation of Syp on tyrosine was detected in insulin-treated 3T3-L1 adipocytes. In combination with other findings these results indicate that IRS1 functions as a docking protein for SH2 domain-containing proteins participating in signaling from the insulin receptor.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1AB, ON, CANADA	Dartmouth College; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORMISANO P, 1991, ENDOCRINOLOGY, V128, P2949, DOI 10.1210/endo-128-6-2949; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FROST SC, 1985, J BIOL CHEM, V260, P2646; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	21	375	383	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11479	11481						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505282				2022-12-25	WOS:A1993LF28400002
J	MADURA, K; DOHMEN, RJ; VARSHAVSKY, A				MADURA, K; DOHMEN, RJ; VARSHAVSKY, A			N-RECOGNIN/UBC2 INTERACTIONS IN THE N-END RULE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; REPAIR GENE RAD6; YEAST SACCHAROMYCES-CEREVISIAE; RNA-PROTEIN TRANSFERASE; SHORT-LIVED PROTEIN; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; CELL-CYCLE; DEGRADATION; TRANSFORMATION	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In the yeast Saccharomyces cerevisiae, substrates of the N-end rule pathway are targeted for degradation by a complex that includes the 225-kDa N-recognin, encoded by UBR1, and the 20-kDa ubiquitin-conjugating enzyme encoded by UBC2. We report that both physical stability and functional activity of the N-recognin . Ubc2 complex require the presence of a highly acidic 23-residue region at the C terminus of Ubc2. Ubc2-C88A, an inactive variant of Ubc2 in which the active-site Cys-88 has been replaced by Ala, is shown to retain the affinity for N-recognin. Expression of Ubc2-C88A inhibits the N-end rule pathway, apparently as a result of competition between Ubc2 and Ubc2-C88A for binding to N-recognin. The two-hybrid (interaction cloning) technique was used to identify a approximately 170-residue C-terminal fragment of the 1,950-residue N-recognin as a Ubc2-interacting domain. We also show that the level of UBR1 mRNA decreases upon overexpression of UBC2. This effect of UBC2 is observed with cells whose UBR1 is expressed from an unrelated promoter but is not observed if UBR1 contains a frameshift mutation, or if the Ubc2 protein lacks its C-terminal acidic region. The N-recognin . Ubc2 complex appears to regulate the expression of N-recognin through changes in the metabolic stability of its mRNA.	CALTECH,DIV BIOL,147-75,PASADENA,CA 91125	California Institute of Technology			Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780	NIA NIH HHS [AG08991] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008991] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BORTS RH, 1986, GENETICS, V113, P551; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1988, J BIOL CHEM, V263, P11155; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANG X, 1991, GENETICS, V130, P285; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MADURA K, 1990, NUCLEIC ACIDS RES, V18, P771, DOI 10.1093/nar/18.4.771; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; NICOLET CM, 1987, YEAST, V3, P149, DOI 10.1002/yea.320030303; PHILLIPS JD, 1993, IN PRESS YEAST; PICKART CM, 1988, UBIQUITIN, P77; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REISS Y, 1988, J BIOL CHEM, V263, P2693; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sherman F., 1986, METHODS YEAST GENETI; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SILVERMAN SJ, 1987, ANAL BIOCHEM, V164, P271, DOI 10.1016/0003-2697(87)90492-1; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; WING SS, 1992, J BIOL CHEM, V267, P6495; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	67	76	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12046	12054						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505328				2022-12-25	WOS:A1993LF28400088
J	CLARK, AC; SINCLAIR, JF; BALDWIN, TO				CLARK, AC; SINCLAIR, JF; BALDWIN, TO			FOLDING OF BACTERIAL LUCIFERASE INVOLVES A NONNATIVE HETERODIMERIC INTERMEDIATE IN EQUILIBRIUM WITH THE NATIVE ENZYME AND THE UNFOLDED SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLTEN GLOBULE STATE; AMINO-ACID SEQUENCE; VIBRIO-HARVEYI; ESCHERICHIA-COLI; ALPHA-SUBUNIT; NUCLEOTIDE-SEQUENCE; BETA-SUBUNIT; LUXB GENE; PROTEIN	Bacterial luciferase is a heterodimeric enzyme that catalyzes the reaction of reduced FMN, O2 and an aliphatic aldehyde to yield the carboxylic acid and an excited flavin that emits blue-green light upon return to ground state. The two subunits of the luciferase from Vibrio harveyi, alpha and beta, have molecular weights of 40,108 and 36,349, respectively; the single active center resides primarily, if not exclusively, on the alpha subunit. We have found that bacterial luciferase can be unfolded in urea-containing 50 mM phosphate buffer, pH 7.0, and refolded by dilution of the urea with final luciferase concentrations of 5-25 mug/ml. We have analyzed the urea-induced equilibrium unfolding of bacterial luciferase by monitoring changes in both the far ultraviolet circular dichroism (predominantly secondary structure) and intrinsic fluorescence emission (predominantly tertiary structure) resulting from incubation in various concentrations of urea at 18-degrees-C for 18-24 h. Both spectral methods indicated a biphasic unfolding transition; the first phase was protein concentration-independent, whereas the second phase was protein concentration-dependent. Equilibrium unfolding curves showed an increase in fluorescence up to 2 M urea followed by a decrease in intensity and red shift of the emission maximum. The ratio of the fluorescence emission in the presence of 2 M urea relative to that in the absence of urea was greater when fluorescence was excited at 295 nm than at 280 nm. The fluorescence increase in the 0-2 M urea range corresponded to the first phase of the biphasic unfolding process. The urea-induced loss of luciferase enzymatic activity appeared to correspond to the first transition observed with the spectroscopic methods, and likewise to be protein concentration-independent. These observations suggested a three-state unfolding mechanism in which the native heterodimeric enzyme rearranges to an inactive heterodimeric species that is well populated, followed by dissociation and unfolding of the alpha and beta subunits. The data were fit to a three-state mechanism using a nonlinear least squares method. At 18-degrees-C in 50 mM phosphate, pH 7.0, the free energy change for the interconversion of the active heterodimer and the inactive heterodimeric species was estimated to be 4.52 +/- 0.30 kcal/mol; the free energy change for the interconversion of the inactive heterodimer and the individual subunits was 19.7 +/- 0.2 kcal/mol. These measurements demonstrate that the equilibrium unfolding of bacterial luciferase proceeds through a well populated inactive heterodimeric species that appears to be partially unfolded and are consistent with the observation (Ziegler, M. M., Goldberg, M. E., Chaffotte, A. F., and Baldwin, T. O. (1993) J. Biol. Chem. 268, 10760-10765) of an inactive heterodimeric intermediate that forms from the individual subunits and precedes the active heterodimeric enzyme on the refolding pathway.	TEXAS A&M UNIV SYST,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843; TEXAS A&M UNIV SYST,INST BIOSCI & TECHNOL,CTR MACROMOLEC DESIGN,COLL STN,TX 77843; TEXAS A&M UNIV SYST,DEPT CHEM,COLL STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BELAS R, 1982, SCIENCE, V218, P791, DOI 10.1126/science.10636771; BORDEN KLB, 1990, BIOCHEMISTRY-US, V29, P3071, DOI 10.1021/bi00464a025; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; CHEN LH, 1989, BIOCHEMISTRY-US, V28, P2684, DOI 10.1021/bi00432a048; CHLUMSKY LJ, 1991, FLAVINS AND FLAVOPROTEINS 1990, P261; COHN DH, 1985, J BIOL CHEM, V260, P6139; COHN DH, 1983, P NATL ACAD SCI-BIOL, V80, P120, DOI 10.1073/pnas.80.1.120; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FUCHS AF, 1991, BIOCHEMISTRY-US, V29, P6598; HASTINGS JW, 1966, BIOLUMINESCENCE PROG, P151; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HURLE MR, 1987, PROTEINS, V2, P54, DOI 10.1002/prot.340020107; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TANDON S, 1986, J BIOL CHEM, V261, P5615; THOMSON JA, 1989, J BIOL CHEM, V264, P11614; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wetlaufer D B, 1981, Adv Protein Chem, V34, P61, DOI 10.1016/S0065-3233(08)60518-5; ZETINA CR, 1980, J MOL BIOL, V137, P401, DOI 10.1016/0022-2836(80)90165-5; ZIEGLER MM, 1981, CURR TOP BIOENERG, V12, P65; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760	45	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10773	10779						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496144				2022-12-25	WOS:A1993LD46600013
J	FORGE, V; MINTZ, E; GUILLAIN, F				FORGE, V; MINTZ, E; GUILLAIN, F			CA2+ BINDING TO SARCOPLASMIC-RETICULUM ATPASE REVISITED .2. EQUILIBRIUM AND KINETIC EVIDENCE FOR A 2-ROUTE MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL TRANSITION; STOPPED FLOW; PHOSPHORYLATION; MAGNESIUM; VESICLES; IONS; CA-2+; DISSOCIATION; PHOSPHATE	The experiments reported in the present paper were designed to check the model proposed for Ca2+ binding in the preceding paper (Forge, V., Mintz, E., and Guillain, F. (1993) J. Biol. Chem. 268,10953-10960). The pH dependence of the Mg2+-induced variation of the intrinsic fluorescence, as well as that of the phosphorylation by P(i), confirmed that there are several species of Ca2+-deprived ATPase. Kinetics of Ca2+ binding as a function of pH suggested that the deprotonated form of the ATPase binds Ca2+ rapidly (k > 50 s-1), whereas the protonated forms bind Ca2+ slowly (1.3-2.7 s-1). At variance with other models which are linear, slow and rapid Ca2+ binding take two different routes, and intermediate pH values and Mg2+, which favors the deprotonated forms, result in biphasic kinetics. Mg2+ binds to all Ca2+-deprived species and to species having one bound Ca2+ but does not bind to ECa2. This is the reason why Mg2+ inhibits Ca2+ binding, and this inhibition is removed in the presence of adenosine-5'-O-(3-thiotriphosphate) which drives Mg2+ into the catalytic site.	CTR ETUD SACLAY,DEPT BIOL CELLULAIRE,CNRS,URA 1290,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	FORGE, V (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,BIOPHYS PROT & MEMBRANES SECT,F-91191 GIF SUR YVETTE,FRANCE.							CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CUENDA A, 1991, FEBS LETT, V283, P273, DOI 10.1016/0014-5793(91)80606-4; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; FORGE V, 1993, J BIOL CHEM, V268, P10953; FROUD RJ, 1986, BIOCHEM J, V237, P197, DOI 10.1042/bj2370197; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1987, J BIOL CHEM, V262, P3025; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1980, ARCH BIOCHEM BIOPHYS, V200, P319, DOI 10.1016/0003-9861(80)90361-6; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEISSNER G, 1981, J BIOL CHEM, V256, P636; MOUTIN MJ, 1990, J BIOL CHEM, V266, P5580; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1982, J BIOL CHEM, V257, P6120; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; YASUOKA K, 1982, J BIOCHEM-TOKYO, V91, P1629, DOI 10.1093/oxfordjournals.jbchem.a133854	32	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10961	10968						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496160				2022-12-25	WOS:A1993LD46600040
J	SMITH, CA; TAYLOR, JS				SMITH, CA; TAYLOR, JS			PREPARATION AND CHARACTERIZATION OF A SET OF DEOXYOLIGONUCLEOTIDE 49-MERS CONTAINING SITE-SPECIFIC CIS-SYN, TRANS-SYN-I, (6-4), AND DEWAR PHOTOPRODUCTS OF THYMIDYLYL(3'-]5')-THYMIDINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; SOLID-PHASE SYNTHESIS; THYMINE DIMER; NUCLEIC-ACIDS; ULTRAVIOLET-RADIATION; ESCHERICHIA-COLI; BUILDING BLOCK; ENDONUCLEASE-V; SKIN-CANCER; DNA	Deoxyoligonucleotide 49-mers containing a central cis-syn, trans-syn-I, (6-4), or Dewar photoproduct of TpT were constructed for use in repair and replication studies by ligation of shorter photoproduct-containing oligonucleotides. A (6-4) product-containing 6-mer was prepared in 3.4% yield by 254 nm irradiation of d(AATTAA) and converted in nearly quantitative yield to the Dewar isomer by irradiation with Pyrex- and Mylar-filtered medium-pressure mercury arc light. d(CGAATTAAGC) containing a site-specific cis-syn or trans-syn-I dimer was prepared via automated solid-phase DNA synthesis utilizing photoproduct building blocks. The photoproduct-containing 49-mers were characterized by their susceptibility to base cleavage and a number of enzymes routinely used to map the sites of DNA photoproduct formation. 1 M piperidine at 90-degrees-C cleaved the Dewar product faster than the (6-4) product, but did not cleave the cyclobutane dimers. The 3' --> 5' exonuclease activity of T4 DNA polymerase was completely blocked by all the lesions except the (6-4) product, which it slowly bypassed. T4 endonuclease V did not cleave the (6-4) or Dewar photoproduct, but unexpectedly cleaved the trans-syn-I dimer at most 1 % the rate of the cis-syn dimer in double-stranded DNA. The trans-syn-I dimer was cleaved at a 50-fold higher rate in double- than in single-stranded DNA. Escherichia coli photolyase was found to be specific for the cis-syn dimer at low concentrations. Implications of this work to methodology for mapping and quantifying DNA photoproducts are also discussed.	WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110	Washington University (WUSTL)				Smith, Colin/0000-0001-5652-0855; Taylor, John-Stephen/0000-0002-8615-7257	NATIONAL CANCER INSTITUTE [R01CA040463] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA40463] Funding Source: Medline; NCRR NIH HHS [1 S10 RR02004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOSE SN, 1983, SCIENCE, V220, P723, DOI 10.1126/science.6836308; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRASH DE, 1985, J BIOL CHEM, V260, P1438; BUTZOW JJ, 1971, BIOCHEMISTRY-US, V10, P2019, DOI 10.1021/bi00787a009; CADET J, 1990, BIOORGANIC PHOTOCHEM, V1, P1; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; CHAN GL, 1986, INT J RADIAT BIOL, V50, P641, DOI 10.1080/09553008614551041; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; Fasman G.D, 1975, HDB BIOCH MOL BIOL N, V1; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HAMILTON KK, 1992, NATURE, V356, P725, DOI 10.1038/356725a0; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; JOHNS HE, 1964, J MOL BIOL, V9, P503, DOI 10.1016/S0022-2836(64)80223-0; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; KONING TMG, 1990, NUCLEIC ACIDS RES, V18, P277, DOI 10.1093/nar/18.2.277; KUMAR S, 1991, NUCLEIC ACIDS RES, V19, P2841, DOI 10.1093/nar/19.11.2841; KUMAR S, 1987, NUCLEIC ACIDS RES, V15, P1199, DOI 10.1093/nar/15.3.1199; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LIU FT, 1978, BIOCHEMISTRY-US, V17, P4865, DOI 10.1021/bi00616a003; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; RYCYNA RE, 1985, NUCLEIC ACIDS RES, V13, P5949, DOI 10.1093/nar/13.16.5949; RYCYNA RE, 1988, BIOCHEMISTRY-US, V27, P3152, DOI 10.1021/bi00409a006; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1990, J CHEM EDUC, V67, P835, DOI 10.1021/ed067p835; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; TAYLOR JS, 1987, J AM CHEM SOC, V109, P2834, DOI 10.1021/ja00243a052; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Wang, 1976, PHOTOCHEM PHOTOBIOL, VTwo; Wang, 1976, PHOTOCHEM PHOTOBIOL	41	119	121	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11143	11151						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496175				2022-12-25	WOS:A1993LD46600064
J	VANADELSBERG, JS; EDWARDS, JC; ALAWQATI, Q				VANADELSBERG, JS; EDWARDS, JC; ALAWQATI, Q			THE APICAL CL/HCO3 EXCHANGER OF BETA-INTERCALATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; KIDNEY EPITHELIAL-CELLS; COLLECTING DUCT; RAT-KIDNEY; ANION-EXCHANGER; MDCK CELLS; H+-ATPASE; BAND-3; ANKYRIN; PROTEIN	There are two types of intercalated cells of the renal collecting duct; one secretes H+ and the other secretes HCO3-. The H+-secreting form has an apical vacuolar H+-ATPase and a basolateral Cl/HCO3 exchanger that cross-reacts with antibodies to band 3, the product of the AE1 gene. The HCO3--secreting form has a basolateral vacuolar H+-ATPase and an apical Cl/HCO3 exchanger, whose identity has not been established previously. Apical membrane vesicles of beta intercalated cells purified from rabbit kidney cortex contain both an electroneutral Cl/HCO3 exchange activity and polypeptides that react with antibodies to band 3 on Western blots. Furthermore, both primary cultures of HCO3--secreting intercalated cells and an immortalized cell line derived from these cells express AE1 and have an apical Cl/HCO3 exchanger. Apical membranes purified from these cells contain a 100-kDa polypeptide that cross-reacts with antibody to the cytoplasmic domain of band 3. These data suggest that the apical Cl/HCO3 exchanger of HCO3--secreting intercalated cells is band 3.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK-01869, DK-20999] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020999, K08DK001869, R01DK020999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; BARTLES JR, 1984, ANAL BIOCHEM, V140, P284, DOI 10.1016/0003-2697(84)90166-0; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CHASE HS, 1988, AM J PHYSIOL, V254, pF374, DOI 10.1152/ajprenal.1988.254.3.F374; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; KOHN OF, 1990, AM J PHYSIOL, V258, pF9, DOI 10.1152/ajprenal.1990.258.1.F9; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LEHIR M, 1982, AM J PHYSIOL, V242, pC117, DOI 10.1152/ajpcell.1982.242.1.C117; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOW PS, 1987, J BIOL CHEM, V262, P4592; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OKUBO K, 1991, J BIOL CHEM, V266, P16420; OSTEDGAARD LS, 1991, P NATL ACAD SCI USA, V88, P981, DOI 10.1073/pnas.88.3.981; SAMBUY Y, 1988, P NATL ACAD SCI USA, V85, P1529, DOI 10.1073/pnas.85.5.1529; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SCHUSTER VL, 1985, J CLIN INVEST, V75, P2056, DOI 10.1172/JCI111925; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANADELSBERG J, 1989, AM J PHYSIOL, V256, pC1004, DOI 10.1152/ajpcell.1989.256.5.C1004; VANADELSBERG J, 1989, METHOD ENZYMOL, V172, P85; WAGNER S, 1987, AM J PHYSIOL, V253, pF213, DOI 10.1152/ajprenal.1987.253.2.F213	35	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11283	11289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496183				2022-12-25	WOS:A1993LD46600083
J	ZHANG, JZ; KUDRYK, B; REDMAN, CM				ZHANG, JZ; KUDRYK, B; REDMAN, CM			SYMMETRICAL DISULFIDE BONDS ARE NOT NECESSARY FOR ASSEMBLY AND SECRETION OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTION; CHAINS; CELLS	Human fibrinogen is a dimer, and each half-molecule is composed of three different polypeptides (Aalpha, Bbeta, and gamma). The two half-molecules are joined together at the amino-terminal ends by three symmetrical disulfide bonds between adjacent Aalpha chains, at position 28, and between adjacent gamma chains at gamma8 and 9. To determine the role of these disulfide bonds in fibrinogen assembly and secretion, site-directed mutagenesis was used to change cysteines of Aalpha28 and gamma8 and 9 to serine, the mutant chains were coexpressed with normal fibrinogen chains in COS cells, and assembly and secretion of fibrinogen were measured. Elimination of the symmetrical disulfide bonds did not affect assembly of tbe chains and dimeric fibrinogen was secreted. Analysis by plasmin digestion indicated that the secreted mutant fibrinogens have a similar structure to normal fibrinogen. Our results indicate that other domains of fibrinogen participate in dimer formation and that the three symmetrical disulfide bonds are not crucial for assembly and secretion of fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FERGUSON EW, 1975, J BIOL CHEM, V250, P7210; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAEKAWA H, 1991, J BIOL CHEM, V266, P11575; MAEKAWA H, 1992, J CLIN INVEST, V90, P67, DOI 10.1172/JCI115857; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; NUSSENZWEIG V, 1961, ANN I PASTEUR PARIS, V100, P377; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; YAMAZUMI K, 1989, J CLIN INVEST, V83, P1590, DOI 10.1172/JCI114056; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21272; ZHANG JZ, 1992, MOL BIOL CELL, V3, P113	30	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11278	11282						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496182				2022-12-25	WOS:A1993LD46600082
J	GELLER, B; ZHU, HY; CHENG, SY; KUHN, A; DALBEY, RE				GELLER, B; ZHU, HY; CHENG, SY; KUHN, A; DALBEY, RE			CHARGED RESIDUES RENDER PRO-OMPA POTENTIAL-DEPENDENT FOR INITIATION OF MEMBRANE TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; SIGNAL-SEQUENCE; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; INNER MEMBRANE; AMINO TERMINUS; OUTER-MEMBRANE; SECA PROTEIN	We have examined the effects of positively and negatively charged residues on the translocation of outer membrane protein A precursor (pro-OmpA) across the bacterial inner membrane. Pro-OmpA does not translocate across the membrane when 2 positively charged residues are inserted immediately after the leader peptide, whereas it does insert when 2 neutral or negatively charged residues are introduced. Using a cell-free translocation system, we show that the membrane potential stimulated the rate of initial insertion of pro-OmpA with negatively charged residues, inhibited pro-OmpA with positively charged residues, and had no effect on neutral pro-OmpA. Thus, acidic residues render pro-OmpA potential-dependent for loop formation, which then initiates the translocation process.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210; UNIV KARLSRUHE,DEPT APPL MICROBIOL,W-7500 KARLSRUHE,GERMANY; OREGON STATE UNIV,DEPT MICROBIOL,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,CORVALLIS,OR 97331	University System of Ohio; Ohio State University; Helmholtz Association; Karlsruhe Institute of Technology; Oregon State University; Oregon State University								ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BANKAITIS VA, 1985, CURR TOP MEMBR TRANS, V24, P105; BASSFORD PJ, 1979, J BACTERIOL, V139, P19, DOI 10.1128/JB.139.1.19-31.1979; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GOLD LM, 1971, METHOD ENZYMOL, V20, P537; ITO K, 1980, J BIOL CHEM, V255, P2123; KATO M, 1992, J BIOL CHEM, V267, P413; KLIONSKY DJ, 1983, J BIOL CHEM, V258, P136; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LU HM, 1991, J BIOL CHEM, V266, P9977; MACINTYRE S, 1990, MOL GEN GENET, V221, P466; Maniatis T., 1982, MOL CLONING; MICHAELIS S, 1982, ANNU REV MICROBIOL, V36, P435, DOI 10.1146/annurev.mi.36.100182.002251; Miller J.H., 1972, EXPT MOL GENETICS; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SILHAVY TJ, 1977, P NATL ACAD SCI USA, V74, P5411, DOI 10.1073/pnas.74.12.5411; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; TANI K, 1989, J BIOL CHEM, V264, P18582; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1988, J BIOL CHEM, V263, P19690; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	44	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9442	9447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486637				2022-12-25	WOS:A1993LA68900047
J	WANG, ZY; QIU, QQ; DEUEL, TF				WANG, ZY; QIU, QQ; DEUEL, TF			THE WILMS-TUMOR GENE-PRODUCT WT1 ACTIVATES OR SUPPRESSES TRANSCRIPTION THROUGH SEPARATE FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-GROWTH; DELETION; EXPRESSION	We recently reported that the putative tumor suppressor gene product WT1 interacts with a 5'-flanking DNA sequence 5'-GCGGGGGCG-3' within the platelet-derived growth factor A-chain gene and abolishes its promoter activity, suggesting that WT1 functions as a transcriptional suppressor of the platelet-derived growth factor A-chain gene. We now show that WT1 functions also as a transcriptional activator. Using chimeric reporter plasmids, we demonstrated that WT1 requires both 5' and 3' binding sites relative to transcription start site for transcriptional repression; however, when WT1 binds to either the 5' or the 3' site alone, WT1 functions to activate transcription. We truncated the wt1 gene and established that amino acid residues 84-179 are required for transcriptional suppression, whereas amino acid residues 180-294 contain a domain that mediates transcriptional activation. These results establish that WT1 has regulatory domains that function either to activate or suppress transcription and suggest the possibility that WT1 functions as an activator and not as a suppressor of selected gene transcription.	WASHINGTON UNIV,SCH MED,DEPT MED,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSSLER M, 1990, NATURE, V343, P774; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1992, NEW BIOL, V4, P97; HUFF V, 1991, AM J HUM GENET, V48, P997; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIN XH, 1992, J BIOL CHEM, V267, P25614; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1992, J BIOL CHEM, V267, P21999	23	185	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9172	9175						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486616				2022-12-25	WOS:A1993LA68900005
J	CHEN, XS; FUNK, CD				CHEN, XS; FUNK, CD			STRUCTURE-FUNCTION PROPERTIES OF HUMAN PLATELET 12-LIPOXYGENASE - CHIMERIC ENZYME AND INVITRO MUTAGENESIS STUDIES	FASEB JOURNAL			English	Note						LIPOXYGENASE; ARACHIDONIC ACID; MUTAGENESIS; IRON-BINDING DOMAIN	SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; AMINO-ACID SEQUENCE; HUMAN 5-LIPOXYGENASE; MOLECULAR-CLONING; SOYBEAN LIPOXYGENASE-1; ARACHIDONATE 12-LIPOXYGENASE; POSITIONAL SPECIFICITY; ACTIVE-SITE; EXPRESSION	Mutant and chimeric lipoxygenases were expressed in human embryonal kidney 293 cells to assess the importance of amino acids and domains for catalytic activity and positional specificity of molecular oxygen insertion. Histidines 360, 365, and 540, when changed to glutamine residues, completely abolished human platelet 12-lipoxygenase activity. Altered histidines at positions 355, 383, and 392 retained enzymatic activity. The former three histidines could possibly serve as ligands for the catalytically essential non-heme iron atom. Amino acids adjacent (residues 398-417) to the five centrally located histidines conserved among all plant and animal lipoxygenases controlled to a limited extent the positional specificity of oxygenation of 12-lipoxygenase. Variant A417I and the triple variant K416Q/A417I/V418M, designed to introduce 15-lipoxygenase substitutions, transformed the platelet 12-lipoxygenase that synthesizes exclusively 12-hydro(pero)xy-eicosatetraenoic acid (12-H(P)ETE) to an enzyme capable of 10-20% 15-lipoxygenation. When all amino acids between positions 398-429 of 12-lipoxygenase had the corresponding 15-lipoxygenase sequence, the enzyme made 66% 15-lipoxygenase products. The latter enzyme had markedly reduced enzyme activity, though, indicating an apparent shift in the optimal alignment of substrate at the active site for hydrogen atom abstraction. The platelet enzyme could not be altered to form 5-lipoxygenase products by similar manipulations of sequence within this region. Chimeric enzymes consisting of an NH2-terminal segment from one lipoxygenase and the COOH terminus from another lipoxygenase or large substitutions resulted in nonfunctional enzymes. NH2-terminal extensions, but not short deletions, could be tolerated functionally. These studies provide some new insights into lipoxygenase structure-function in the absence of an unresolved three-dimensional structure.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002710, R01HL046017] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46017, K04 HL02710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1991, ADV PROSTAG THROMB L, V21, P33; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2592, DOI 10.1073/pnas.86.8.2592; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1991, PROSTAGLANDINS LEUKO, P97; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGHTON JE, 1989, NATURE, V338, P172, DOI 10.1038/338172a0; ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1990, J BIOL CHEM, V265, P16300; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NAVARATNAM S, 1988, BIOCHIM BIOPHYS ACTA, V956, P70, DOI 10.1016/0167-4838(88)90299-3; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; STECZKO J, 1992, BIOCHEMISTRY-US, V31, P4053, DOI 10.1021/bi00131a022; STECZKO J, 1992, BIOCHEM BIOPH RES CO, V186, P686, DOI 10.1016/0006-291X(92)90801-Q; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; YENOFSKY RL, 1988, MOL GEN GENET, V211, P215, DOI 10.1007/BF00330597; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; ZHANG Y, 1991, J AM CHEM SOC, V113, P5162, DOI 10.1021/ja00014a004; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	40	55	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1993	7	8					694	701		10.1096/fasebj.7.8.8500694	http://dx.doi.org/10.1096/fasebj.7.8.8500694			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	LE290	8500694				2022-12-25	WOS:A1993LE29000012
J	HATA, A; RIDINGER, DN; SUTHERLAND, S; EMI, M; ZHANG, SH; MYERS, RL; REN, KS; CHENG, T; INOUE, I; WILSON, DE; IVERIUS, PH; LALOUEL, JM				HATA, A; RIDINGER, DN; SUTHERLAND, S; EMI, M; ZHANG, SH; MYERS, RL; REN, KS; CHENG, T; INOUE, I; WILSON, DE; IVERIUS, PH; LALOUEL, JM			BINDING OF LIPOPROTEIN-LIPASE TO HEPARIN - IDENTIFICATION OF 5 CRITICAL RESIDUES IN 2 DISTINCT SEGMENTS OF THE AMINO-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC TRIGLYCERIDE LIPASE; HUMAN POSTHEPARIN PLASMA; RADIATION INACTIVATION; MOLECULAR-PROPERTIES; ADIPOSE-TISSUE; BOVINE-MILK; SECONDARY-STRUCTURE; KINETIC-PROPERTIES; PANCREATIC LIPASE; CDNA SEQUENCE	Binding to heparan sulfate governs many aspects of the physiological action and regulation of the lipolytic enzyme, lipoprotein lipase (LPL). In an attempt to identify the structural determinants which mediate this interaction, basic residues in three segments of the primary sequence of human LPL (residues 147-151, 279-282, and 292-304) were replaced with alanine, either singly or in various combinations, and variant proteins were subjected to affinity chromatography on heparin-Superose. Five basic residues in two distinct segments of the primary sequence were critical determinants of the high affinity for heparin manifested by the active enzyme (R279, K280, R282, K296, R297). By contrast, no such evidence could be detected for basic residues in the first cluster (K147, K148) or for other basic residues in the third cluster (K292, R294, K304), while the evidence for K300 was unresolved. The conformation of this heparin-binding domain can be inferred by reference to the three-dimensional structure of the homologous enzyme, pancreatic lipase (Winkler, F. K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774). Affinity of the active enzyme for heparin could not be reduced below a threshold, suggesting that other heparin-binding determinants exist elsewhere in the molecule, as supported by recently published evidence (Davis, R. C., Wong, H., Nikazy, J., Wang, K., Han, Q., and Schotz, M. C. (1992) J. Biol. Chem. 267, 21499-21504).	UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, VET AFFAIRS MED CTR, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, DIV SOCIAL MED, SALT LAKE CITY, UT 84132 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL39593, HL45753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL145753, R01HL045753, R01HL039593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHBY P, 1978, BIOCHEM J, V171, P305, DOI 10.1042/bj1710305; ATKINS EDT, 1976, HEPARIN CHEM CLIN US, P21; AUGUSTIN J, 1978, J BIOL CHEM, V253, P2912; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSON G, 1981, EUR J BIOCHEM, V113, P547, DOI 10.1111/j.1432-1033.1981.tb05097.x; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; BENGTSSON G, 1979, BIOCHIM BIOPHYS ACTA, V575, P471, DOI 10.1016/0005-2760(79)90118-8; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; BENSADOU.A, 1974, J BIOL CHEM, V249, P2220; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CHOAY J, 1989, ANN NY ACAD SCI, V556, P61; CHOAY J, 1980, THROMB RES, V18, P573, DOI 10.1016/0049-3848(80)90356-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CLARKE AR, 1983, BIOCHIM BIOPHYS ACTA, V747, P130, DOI 10.1016/0167-4838(83)90131-0; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; EGELRUD T, 1972, J BIOL CHEM, V247, P6212; EHNHOLM C, 1974, BIOCHIM BIOPHYS ACTA, V360, P68, DOI 10.1016/0005-2760(74)90180-5; EMI M, 1990, J BIOL CHEM, V265, P5910; GARFINKEL AS, 1972, J LIPID RES, V13, P63; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HATA A, 1992, J BIOL CHEM, V267, P20132; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; Iverius P H, 1986, Methods Enzymol, V129, P691; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KEMPNER ES, 1991, METHOD ENZYMOL, V197, P280; Kinnunen P.K.J., 1984, P307; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; OLIVECRONA T, 1971, BIOCHEM BIOPH RES CO, V43, P524, DOI 10.1016/0006-291X(71)90645-0; OLIVECRONA T, 1982, EUR J BIOCHEM, V124, P629, DOI 10.1111/j.1432-1033.1982.tb06640.x; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1467; QUINN D, 1983, PROG LIPID RES, V22, P35, DOI 10.1016/0163-7827(83)90003-6; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; Smith L.C., 1984, P263; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; VANNIER C, 1989, J BIOL CHEM, V264, P13199; WALLINDER L, 1982, BIOCHIM BIOPHYS ACTA, V711, P107, DOI 10.1016/0005-2760(82)90015-7; WANG CS, 1983, BIOCHIM BIOPHYS ACTA, V754, P142, DOI 10.1016/0005-2760(83)90155-8; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YANG CY, 1989, J BIOL CHEM, V264, P16822	64	105	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8447	8457						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473288				2022-12-25	WOS:A1993KX81100015
J	JACKSON, DG; WINDLE, HJ; VOORHEIS, HP				JACKSON, DG; WINDLE, HJ; VOORHEIS, HP			THE IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF 2 INVARIANT SURFACE GLYCOPROTEINS LOCATED BENEATH THE SURFACE-COAT BARRIER OF BLOOD-STREAM FORMS OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; GENE-EXPRESSION SITE; DISTINCT ACID-PHOSPHATASES; POLYACRYLAMIDE GELS; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; T-BRUCEI; AFRICAN TRYPANOSOMES; LEISHMANIA-DONOVANI; ANTIGENIC VARIATION	Two new polypeptides, termed ISG70 and ISG64, have been found in Trypanosoma brucei, using enzyme-catalyzed radioiodination techniques. Both are externally disposed integral membrane glycoproteins, containing N-linked carbohydrate chains. No structural homology was detected between ISG70, ISG64, or the variant surface glycoprotein (VSG) when assessed by 1) comparative peptide mapping, 2) immunoprecipitation analysis, and 3) lectin affinity chromatography. ISG70 occurred in 5.1 x 10(4) copies/cell and has been purified 880-fold from detergent extracts of plasma membranes by a procedure that includes gel filtration, lectin affinity chromatography, and preparative SDS-polyacrylamide gel electrophoresis. ISG70 Was present only in bloodstream forms and was specifically detected in six different cloned variants from the Molteno Institute trypanosomal antigen type (MITat) serodeme of T. brucei and from the single cloned variant of the International Laboratory for Research on Animal Diseases trypanosomal antigen type (ILTat) serodeme that was examined. Rabbits with chronic infections of T. brucei displayed circulating antibodies against ISG70. Both the immunogenicity of ISG70 and its invariant nature suggest that it may be useful in the development of an effective serodiagnostic test. Furthermore, its stage-specific location combined with its invariant nature implies that its function is strictly related to a physiological role required for the parasite's residence in its mammalian host.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND	Trinity College Dublin				, david/0000-0002-4133-9364				ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; BEAT DA, 1984, J PROTOZOOL, V31, P541, DOI 10.1111/j.1550-7408.1984.tb05499.x; BERBEROF M, 1991, MOL CELL BIOL, V11, P1473, DOI 10.1128/MCB.11.3.1473; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; BULOW R, 1986, J BIOL CHEM, V261, P1918; BURGESS DE, 1985, INFECT IMMUN, V50, P893, DOI 10.1128/IAI.50.3.893-899.1985; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; CULLY DF, 1986, MOL BIOCHEM PARASIT, V21, P189, DOI 10.1016/0166-6851(86)90022-8; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; FAHEY JL, 1978, HDB EXPT IMMUNOLOGY; FOX JA, 1986, J BIOL CHEM, V261, P5767; GIBBS CP, 1988, MOL BIOCHEM PARASIT, V28, P197, DOI 10.1016/0166-6851(88)90004-7; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GOTTLIEB M, 1981, EXP PARASITOL, V52, P117, DOI 10.1016/0014-4894(81)90067-9; GRAB DJ, 1987, J CELL BIOL, V105, P737, DOI 10.1083/jcb.105.2.737; HAND ES, 1962, J AM CHEM SOC, V84, P3505, DOI 10.1021/ja00877a017; HASSAN HF, 1987, MOL BIOCHEM PARASIT, V23, P285, DOI 10.1016/0166-6851(87)90035-1; HERELD D, 1986, J BIOL CHEM, V261, P3813; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P51, DOI 10.1016/0166-6851(89)90199-0; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; JACKSON DG, 1985, BIOCHEM J, V230, P195, DOI 10.1042/bj2300195; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; JACKSON DG, 1984, J BIOL CHEM, V260, P5179; JOHNSON JG, 1977, J PROTOZOOL, V24, P587, DOI 10.1111/j.1550-7408.1977.tb01020.x; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOOTER JM, 1988, GENE, V69, P1, DOI 10.1016/0378-1119(88)90372-1; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; MANCINI PE, 1982, BIOCHIM BIOPHYS ACTA, V688, P399, DOI 10.1016/0005-2736(82)90351-0; Markwell M. A. K., 1978, ANAL BIOCHEM, V87, P207; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MCLAUGHLIN J, 1986, MOL CELL BIOCHEM, V70, P177, DOI 10.1007/BF00229432; MCLAUGHLIN J, 1987, EXP PARASITOL, V64, P1, DOI 10.1016/0014-4894(87)90002-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY NB, 1987, MOL STRATEGIES PARAS, P449; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OWEN P, 1985, ENTEROBACTERIAL SURF, P237; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; REINWALD E, 1981, BIOCHIM BIOPHYS ACTA, V668, P119, DOI 10.1016/0005-2795(81)90155-0; REMALEY AT, 1985, J BIOL CHEM, V260, P880; REVELARD P, 1990, NUCLEIC ACIDS RES, V18, P7299, DOI 10.1093/nar/18.24.7299; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; ROVIS L, 1984, ACTA TROP, V41, P227; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SIEGEL MB, 1983, METHOD ENZYMOL, V93, P3; SMILEY BL, 1990, MOL CELL BIOL, V10, P6436, DOI 10.1128/MCB.10.12.6436; SON HJ, 1989, MOL BIOCHEM PARASIT, V33, P59, DOI 10.1016/0166-6851(89)90042-X; STEIGER RF, 1980, EUR J BIOCHEM, V105, P163, DOI 10.1111/j.1432-1033.1980.tb04486.x; TACK LO, 1977, BIOCHEMISTRY-US, V16, P3746, DOI 10.1021/bi00636a003; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TAYLOR DW, 1977, PARASITOLOGY, V74, P47, DOI 10.1017/S0031182000047521; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOORHEIS HP, 1977, BIOCHEM J, V164, P15, DOI 10.1042/bj1640015; VOORHEIS HP, 1979, BIOCHEM J, V180, P11, DOI 10.1042/bj1800011; VOORHEIS HP, 1980, EUR J BIOCHEM, V113, P223, DOI 10.1111/j.1432-1033.1980.tb06160.x; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WILLIAMS AF, 1988, ANN REV BIOCH, V57, P285; WYNS L, 1978, NUCLEIC ACIDS RES, V5, P2345, DOI 10.1093/nar/5.7.2345; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	69	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8085	8095						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463323				2022-12-25	WOS:A1993KW97900073
J	ALTSCHULER, D; LAPETINA, EG				ALTSCHULER, D; LAPETINA, EG			MUTATIONAL ANALYSIS OF THE CAMP-DEPENDENT PROTEIN KINASE-MEDIATED PHOSPHORYLATION SITE OF RAP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP/GTP EXCHANGE PROTEIN; PUTATIVE EFFECTOR DOMAIN; INTACT HUMAN-PLATELETS; BOVINE BRAIN CYTOSOL; RAS GENE-PRODUCT; SMG P21; CATALYZED PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY	Rap1b, a member of the Ras superfamily of low molecular weight GTP-binding proteins, can be phosphorylated by cAMP-dependent protein kinase (protein kinase A). The experiments presented here were undertaken to determine the precise site of this phosphorylation. Because the Rap1 proteins are highly homologous, there are no specific antibodies able to discriminate between them. To overcome this problem, we used a transient expression system of a fused protein containing in the NH2 terminus an epitope for a known antibody. Using this system, the transfected protein was expressed at a high level and was localized in a perinuclear structure, as previously reported for the endogenous Rap1 proteins. The mutational analysis of Rap1b revealed Ser179 as the residue involved in the protein kinase A-mediated phosphorylation. The presence of a Lys179 instead of the wild-type Ser179 (resembling the Rap1a sequence) rendered Ser180 a better substrate for phosphorylation caused by protein kinase A. The mobility shift of Rap1b in SDS gels, observed in cells that were stimulated with agonists that increase cAMP, was caused, at least in part, by the phosphorylation of Rap1b.			ALTSCHULER, D (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BABACID M, 1987, ANNU REV BIOCHEM, V56, P779; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COBITZ AR, 1989, P NATL ACAD SCI USA, V86, P858, DOI 10.1073/pnas.86.3.858; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; Maniatis T., 1982, MOL CLONING; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAIKUMAR P, 1988, ONCOGENE RES, V3, P213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WINEGAR DA, 1991, J BIOL CHEM, V266, P4375; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	47	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7527	7531						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463283				2022-12-25	WOS:A1993KV14100101
J	SCHNITZER, JE; BRAVO, J				SCHNITZER, JE; BRAVO, J			HIGH-AFFINITY BINDING, ENDOCYTOSIS, AND DEGRADATION OF CONFORMATIONALLY MODIFIED ALBUMINS - POTENTIAL ROLE OF GP30 AND GP18 AS NOVEL SCAVENGER RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TREATED SERUM-ALBUMIN; ALDEHYDE-MODIFIED PROTEINS; SINUSOIDAL LIVER-CELLS; RAT-LIVER; CAPILLARY ENDOTHELIUM; MICROVASCULAR ENDOTHELIUM; MACROPHAGE RECEPTOR; BONE-MARROW; TRANSCYTOSIS	Scavenger receptors interact with a variety of modified proteins, mediate their endocytosis and degradation, and may play an important role in protein catabolism and pathogenic processes such as atherosclerosis, aging, and diabetes. Many scavenger receptors have been detected kinetically but few such binding proteins have actually been identified. Recently, we found that two membrane-associated proteins, gp30 and gp18, interact more avidly with albumins conformationally modified by chemical means or by surface adsorption to colloidal gold particles than with native albumin. In this study, we show that gp30 and gp18 behave similarly to other known scavenger receptors. Competition studies indicate a similar ligand binding profile to other known scavenger receptors. Polyanionic molecules (dextran sulfate, fucoidan, polyglutamic acid, polyinosinic acid, heparin) and modified albumins such as formaldehyde-treated or maleylated albumin (Malbovine serum albumin) competed with albumin conjugated to colloidal gold particles (A-Au) for the blotting of gp30 and gp18. A-Au and Mal-bovine serum albumin bound cultured endothelial cells with high affinity. Modified and native albumins were each internalized, but only modified albumins were then released degraded. Inhibition studies revealed that only the same molecules that were effective in blocking A-Au blotting of gp30 and gp18, also inhibited A-Au degradation. Addition of the lysosomotropic agent chloroquine resulted in more than 70% inhibition of degradation. Differential processing of A-Au by cultured smooth muscle and endothelial cells along with fibroblasts was observed in a manner consistent with gp30 and gp18 expression. Cumulatively, these results suggest that gp30 and gp18 may mediate the high affinity binding, endocytosis, and degradation of conformationally modified albumins but not native albumin.			SCHNITZER, JE (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,INST BIOMED ENGN,DEPT MED & PATHOL,DIV CELLULAR & MOLEC MED,0651,LA JOLLA,CA 92093, USA.		Bravo, Jose/F-8861-2015	Bravo, Jose/0000-0001-5752-2406	NHLBI NIH HHS [HL43278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAVO J, 1992, FASEB J, V6, pA1322; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUMBASIREVIC V, 1990, J SUBMICR CYTOL PATH, V22, P135; DEBRUYN PPH, 1985, CELL TISSUE RES, V240, P1; DRESEL HA, 1985, EMBO J, V4, P1157, DOI 10.1002/j.1460-2075.1985.tb03754.x; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; FAUSTMANN PM, 1992, J NEUROIMMUNOL, V35, P79; GALIS Z, 1988, EUR J CELL BIOL, V47, P358; GEOFFROY JS, 1984, J ULTRA MOL STRUCT R, V89, P223, DOI 10.1016/S0022-5320(84)80039-8; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HABERLAND ME, 1986, J CLIN INVEST, V77, P681, DOI 10.1172/JCI112362; HORIUCHI S, 1985, J BIOL CHEM, V260, P475; HORIUCHI S, 1985, J BIOL CHEM, V260, P482; HORIUCHI S, 1985, J BIOL CHEM, V260, P53; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NEEPER M, 1992, J BIOL CHEM, V267, P14988; OTTNAD E, 1990, BIOCHEM J, V265, P689, DOI 10.1042/bj2650689; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; RADOFF S, 1991, DIABETES, V40, P1731, DOI 10.2337/diabetes.40.12.1731; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH48, DOI 10.1152/ajpheart.1992.263.1.H48; SCHNITZER JE, 1992, FASEB J, V6, pA2083; SCHNITZER JE, 1992, MOL BIOL CELL, V3, P59; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKATA K, 1988, J BIOL CHEM, V263, P14819; VIA DP, 1985, J BIOL CHEM, V260, P7379; VILLASCHI S, 1986, MICROVASC RES, V32, P190, DOI 10.1016/0026-2862(86)90053-1; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; Waldmann T. A., 1977, ALBUMIN STRUCTURE FU, P255; YEDGAR S, 1983, AM J PHYSIOL, V244, pE101, DOI 10.1152/ajpendo.1983.244.1.E101	43	132	135	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7562	7570						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463286				2022-12-25	WOS:A1993KV14100106
J	SALT, DE; WAGNER, GJ				SALT, DE; WAGNER, GJ			CADMIUM TRANSPORT ACROSS TONOPLAST OF VESICLES FROM OAT ROOTS - EVIDENCE FOR A CD2+/H+ ANTIPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-PUMPING ATPASE; BETA-VULGARIS L; MEMBRANE-VESICLES; CALCIUM-TRANSPORT; CA2+/H+ ANTIPORT; SUSPENSION CELLS; ACRIDINE-ORANGE; SYSTEM DRIVEN; BINDING; TOBACCO	Cadmium accumulates in the vacuole of plant cells, but the mechanism driving its transport across the vacuole membrane is not understood. Here we present evidence for Cd2+ transport via a Cd2+/H+ antiport activity into tonoplast-enriched vesicles isolated from oat roots. Experimentally, accumulation of Cd2+ into vesicles could be driven by DELTApH generated by either V-type ATPase or artificially using nigericin to exchange K+ and H+ in K+-loaded vesicles. When tonoplast-enriched vesicles were separated on a linear sucrose gradient, NO3--sensitive ATPase, total MgATPase, and DELTApH-dependent Cd2+ transport equilibrated at 1.11 g/ml, the density of tonoplast membrane. Cd2+ accumulation in vesicles was accompanied by efflux of protons in a Cd2+ concentration-dependent manner characteristic of an antiport activity. The DELTApH-dependent Cd2+ accumulation process showed saturation kinetics with a K(m(app)) of 5.5 muM. Thus the process is a candidate for transport of Cd2+ from the cytoplasm to the vacuolar sap under conditions of low as well as high Cd2+ exposure.	UNIV KENTUCKY,DEPT AGRON,PLANT PHYSIOL,BIOCHEM MOLEC BIOL PROGRAM,N212F,AGR SCI BLDG N,LEXINGTON,KY 40546	University of Kentucky			Salt, David E/B-3864-2009					BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761; BLACKFORD S, 1990, J BIOL CHEM, V265, P9617; BLUMWALD E, 1986, PLANT PHYSIOL, V80, P727, DOI 10.1104/pp.80.3.727; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH DR, 1986, PLANT PHYSIOL, V80, P549, DOI 10.1104/pp.80.2.549; CATALDO DA, 1981, PLANT PHYSIOL, V68, P835, DOI 10.1104/pp.68.4.835; CHANSON A, 1991, J PLANT PHYSIOL, V137, P471, DOI 10.1016/S0176-1617(11)80319-6; CHURCHILL KA, 1984, PLANT PHYSIOL, V76, P490, DOI 10.1104/pp.76.2.490; CHURCHILL KA, 1983, PLANT PHYSIOL, V71, P610, DOI 10.1104/pp.71.3.610; CHURCHILL KA, 1983, PLANT PHYSIOL, V73, P921, DOI 10.1104/pp.73.4.921; DABIN P, 1978, PLANT SOIL, V50, P329, DOI 10.1007/BF02107182; DUPONT FM, 1990, PLANT PHYSIOL, V94, P179, DOI 10.1104/pp.94.1.179; GIANNINI JL, 1991, PLANT SCI, V74, P203, DOI 10.1016/0168-9452(91)90047-C; GOGARTENBOEKELS M, 1985, J PLANT PHYSIOL, V118, P309, DOI 10.1016/S0176-1617(85)80190-5; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HOPPS H, 1974, GEOCHEMISTRY ENV, V1, P6; JOYCE DC, 1988, PLANT PHYSIOL, V88, P1097, DOI 10.1104/pp.88.4.1097; KAESTNER KH, 1988, J BIOL CHEM, V263, P1282; KAREZ CS, 1990, PLANT CELL ENVIRON, V13, P483, DOI 10.1111/j.1365-3040.1990.tb01326.x; KROTZ RM, 1989, PLANT PHYSIOL, V91, P780, DOI 10.1104/pp.91.2.780; LEIGH RA, 1980, PLANTA, V150, P222, DOI 10.1007/BF00390830; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; PEEREBOOMSTEGEMAN JHJC, 1989, ECOTOX ENVIRON SAFE, V18, P93, DOI 10.1016/0147-6513(89)90095-X; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; RANDALL SK, 1987, METHOD ENZYMOL, V148, P123; RYAN JA, 1982, ENVIRON RES, V28, P251, DOI 10.1016/0013-9351(82)90128-1; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SCHUMAKER KS, 1985, PLANT PHYSIOL, V79, P1111, DOI 10.1104/pp.79.4.1111; SZE H, 1982, PLANT PHYSIOL, V70, P498, DOI 10.1104/pp.70.2.498; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; SZE H, 1981, P NATL ACAD SCI-BIOL, V78, P5578, DOI 10.1073/pnas.78.9.5578; TUKENDORF A, 1990, PLANT SCI, V70, P155, DOI 10.1016/0168-9452(90)90129-C; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; WAGNER GJ, 1986, PLANT PHYSIOL, V82, P274, DOI 10.1104/pp.82.1.274; WAGNER GJ, 1983, BIOCHIM BIOPHYS ACTA, V728, P267, DOI 10.1016/0005-2736(83)90479-0; WAGNER GJ, 1989, UCLA S MOL CELL BIOL, V98, P325; WANG YZ, 1985, J BIOL CHEM, V260, P434	38	168	185	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12297	12302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509367				2022-12-25	WOS:A1993LG65800014
J	ROTTMAN, JN; GORDON, JI				ROTTMAN, JN; GORDON, JI			COMPARISON OF THE PATTERNS OF EXPRESSION OF RAT INTESTINAL FATTY-ACID BINDING-PROTEIN HUMAN GROWTH-HORMONE FUSION GENES IN CULTURED INTESTINAL EPITHELIAL-CELL LINES AND IN THE GUT EPITHELIUM OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; MOUSE SMALL-INTESTINE; A-I GENE; TRANSCRIPTION FACTORS; SEQUENCE-ANALYSIS; DIFFERENTIATION; DNA; LOCALIZATION; CACO-2; MEMBER	The intestinal fatty acid binding protein gene (Fabpi) provides a good model system for studying how gene transcription is regulated in enterocytes as a function of their differentiation program and location along the duodenal-to-colonic axis. We have compared and contrasted the transcriptional activity of four fusion genes composed of elements from the 5'-nontranscribed domain of rat Fabpi linked to the human growth hormone gene (I-FABP/hGH) in transgenic mice and in five primate epithelial cell lines derived from intestine, liver, kidney, and cervix. Nucleotides -103 to +28 of rat Fabpi are able to direct appropriate lineage-specific and geographic patterns of hGH expression in transgenic mice. I-FABP-103 to +28/hGH is preferentially expressed in Caco-2 cells, which emulate some of the features of differentiated small intestinal enterocytes after they reach confluence. However, other I-FABP/hGH fusion genes that exhibit differentiation-dependent changes in their expression along the crypt-to-villus axis do not manifest the same pattern of differentiation-dependent change in activity in this cell line. Correlation of their patterns of expression in vivo and ex vivo suggest that nonproliferating Caco-2 cells mimic some of the features of the transcriptional regulatory environment of enterocytes located in the upper crypt. Nucleotides -103 to +28 of rat Fabpi contain one copy of a repeated 14-base pair element that is conserved in the orthologous mouse and human genes and represented in several other homologous and nonhomologous genes, which are expressed in villus-associated enterocytes. This element binds to two members of the steroid hormone receptor superfamily of transcription factors produced in enterocytes and Caco-2 cells: hepatic nuclear factor-4 (HNF-4) and apolipoprotein regulatory protein-1 (ARP-1). Co-transfection studies performed in Caco-2 cells and in a monkey kidney cell line (CV-1) that lacks endogenous pools of ARP-1 and HNF-4 suggest that ARP-1 and HNF-4 can function to activate I-FABP-103 to +28/hGH+3 through their interactions with the 14-base pair element. This activation appears to be affected by elements located between nucleotides -277 and -104 and other transcription factors.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS GS, 1992, J CELL SCI, V101, P219; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FORMAN B M, 1990, New Biologist, V2, P587; GEY GO, 1952, CANCER RES, V12, P264; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSET E, 1984, AM J PHYSIOL, V247, pC260, DOI 10.1152/ajpcell.1984.247.3.C260; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUO CF, 1990, DEVELOPMENT, V109, P473; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MAHRAOUI L, 1992, AM J PHYSIOL, V263, pG312, DOI 10.1152/ajpgi.1992.263.3.G312; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; PINTO M, 1983, BIOL CELL, V47, P323; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; RUBIN DC, 1989, P NATL ACAD SCI USA, V86, P1278, DOI 10.1073/pnas.86.4.1278; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHIELDS HM, 1986, J LIPID RES, V27, P549; SIMON TC, 1993, IN PRESS J BIOL CHEM; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	61	76	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11994	12002						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505324				2022-12-25	WOS:A1993LF28400081
J	SCHAEFER, A; STOCKER, U; MARQUARDT, H				SCHAEFER, A; STOCKER, U; MARQUARDT, H			CALCIUM IONOPHORE-INDUCED TRANSIENT DOWN-REGULATION OF C-MYB MESSENGER-RNA LEVELS IN FRIEND-ERYTHROLEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION; DIMETHYL SULFOXIDE; GENE-EXPRESSION; GLOBIN GENES; MURINE; COMMITMENT; DIMETHYLSULFOXIDE; ERYTHROPOIETIN; HEMOGLOBIN; FRAGMENTS	The effects of calcium ionophores A23187 and ionomycin on the c-myb and c-myc mRNA levels have been investigated in the Friend erythroleukemia cell line F4-6 using Northern blot analysis. Treatment of the cells with 0.5-4 muM A23187 or 1-4 muM ionomycin induced a concentration-dependent decrease in c-myb mRNA; this decrease was abolished by EGTA. c-myc mRNA levels were only moderately affected. After 12-24 h of calcium ionophore exposure, c-myb mRNA returned to pretreatment levels. No similar decrease in c-myb mRNA was seen with the sodium ionophore monensin (up to 16 muM). The dimethyl sulfoxide-induced suppression of c-myb and also of c-myc mRNA levels was not prevented in Ca2+-free medium and thus appeared Ca2+-independent. A23187 and ionomycin were capable of inducing beta-globin mRNA synthesis in F4-6 cells. Prolonged calcium ionophore exposure, however, strongly reduced cell viability and resulted only in a slight hemoglobin increase at lower concentrations. These results suggest that a rise in [Ca2+]i may be a signal leading to a transient decrease in c-myb mRNA and the initiation of erythroid differentiation in Friend cells. The transient suppression of c-myb mRNA levels represents a common feature of the action of dimethyl sulfoxide and calcium ionophores.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,W-2000 HAMBURG 13,GERMANY	Fraunhofer Gesellschaft	SCHAEFER, A (corresponding author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,W-2000 HAMBURG 13,GERMANY.							BRIDGES K, 1981, J CELL BIOL, V90, P542, DOI 10.1083/jcb.90.2.542; BUSFIELD SJ, 1992, BLOOD, V80, P412; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DANISH R, 1992, ONCOGENE, V7, P901; FALETTO DL, 1985, J BIOL CHEM, V260, P4884; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; HENSOLD JO, 1991, BLOOD, V77, P1362; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; LACHMAN HM, 1984, NATURE, V310, P249; LACHMAN HM, 1985, P NATL ACAD SCI USA, V82, P5223; LANNIGAN DA, 1985, J BIOL CHEM, V260, P7322; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; LEVENSON R, 1983, J CELL BIOCHEM, V21, P1, DOI 10.1002/jcb.240210102; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; OSTERTAG W, 1972, NATURE-NEW BIOL, V239, P231, DOI 10.1038/newbio239231a0; PATEL HR, 1992, J BIOL CHEM, V267, P21300; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REUBEN RC, 1980, BIOCHIM BIOPHYS ACTA, V605, P325, DOI 10.1016/0304-419X(80)90015-3; SCHAEFER A, 1984, J CELL PHYSIOL, V119, P335, DOI 10.1002/jcp.1041190312; SCHAEFER A, 1992, LEUKEMIA, V6, P828; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMITH RL, 1982, J BIOL CHEM, V257, P773; SPIVAK JL, 1992, EXP HEMATOL, V20, P283; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIEMEIER DC, 1978, CELL, V14, P237, DOI 10.1016/0092-8674(78)90110-1; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TSIFTSOGLOU AS, 1981, J CELL PHYSIOL, V108, P327, DOI 10.1002/jcp.1041080306; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; YEH LA, 1983, J BIOL CHEM, V258, P6567	38	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10876	10880						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496152				2022-12-25	WOS:A1993LD46600027
J	ANIENTO, F; ROCHE, E; CUERVO, AM; KNECHT, E				ANIENTO, F; ROCHE, E; CUERVO, AM; KNECHT, E			UPTAKE AND DEGRADATION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE BY RAT-LIVER LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; MICROSCOPIC LOCALIZATION; POLYACRYLAMIDE GELS; CYTOSOLIC PROTEINS; UBIQUITIN; PROTEOLYSIS; PATHWAY; CELLS; INHIBITORS; SYSTEM	The molecular mechanisms involved in the degradation of individual cellular proteins are probably unique and characteristic. We have investigated in rat liver the degradation of glyceraldehyde-3-phosphate dehydrogenase, an abundant cytosolic enzyme of the glycolytic pathway. Immunoblot analysis of isolated liver lysosomes from rats treated with lysosomal inhibitors show that this protein is degraded, at least in part, by a lysosomal pathway. This pathway was further investigated by incubating the enzyme with lysosomes in a cell-free system, followed by proteolysis measurements, sodium dodecyl sulfate-polyacrylamide gel electrophoresis of lysosomes, and electron microscopic immunocytochemistry. We postulate that the degradative mechanism of glyceraldehyde-3-phosphate dehydrogenase includes a temperature-dependent lysosomal pathway, different from classical nonspecific macroautophagy. The postulated pathway involves: binding of the enzyme to the lysosomal membrane, entry into the lysosomal matrix, and degradation. This cell-free system, which can also incorporate in vitro synthesized proteins, should allow further advances toward clarifying the complex signals that regulate protein degradation as well as its close interrelationship with protein synthesis.	INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA, AMADEO SABOYA 4, E-46010 VALENCIA, SPAIN				Knecht, Erwin/A-9366-2014; Roche, Enrique/V-5738-2017; Company, Fernando Aniento/G-9781-2015; Knecht, Erwin/K-2432-2014	Roche, Enrique/0000-0001-5128-1672; Company, Fernando Aniento/0000-0003-3553-585X; Knecht, Erwin/0000-0002-7208-3832; Cuervo, Ana Maria/0000-0002-0771-700X				AHLBERG J, 1982, LAB INVEST, V47, P523; AHLBERG J, 1985, EXP MOL PATHOL, V42, P78, DOI 10.1016/0014-4800(85)90020-6; BENDAYAN M, 1989, COLLOIDAL GOLD PRINC, V1, P33; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P466; Beynon R.J., 1989, PROTEOLYTIC ENZYMES, P241; BOHLEY P, 1987, NEW COMPR BIOCH, V16, P307; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BONNER WD, 1955, METHOD ENZYMOL, V1, P722, DOI 10.1016/0076-6879(55)01126-9; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOWERS WE, 1967, J CELL BIOL, V32, P325, DOI 10.1083/jcb.32.2.325; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FINDLAY J, 1958, BIOCHEM J, V69, P467, DOI 10.1042/bj0690467; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROPPER R, 1991, J BIOL CHEM, V266, P3602; Harrison J., 1976, P1; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; KNECHT E, 1986, FEBS LETT, V206, P339, DOI 10.1016/0014-5793(86)81008-0; KNECHT E, 1978, CELL TISSUE RES, V193, P473; KNECHT E, 1986, J HISTOCHEM CYTOCHEM, V34, P913, DOI 10.1177/34.7.3519755; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Kun E, 1979, Methods Enzymol, V55, P115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; MARZELLA L, 1980, EXP CELL RES, V129, P460, DOI 10.1016/0014-4827(80)90515-7; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; Nuzum CT, 1976, UREA CYCLE, P325; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Rivett A.J., 1990, Essays in Biochemistry, V25, P39; ROCHE E, 1987, FEBS LETT, V221, P231, DOI 10.1016/0014-5793(87)80931-6; ROCHE E, 1987, BIOCHEM BIOPH RES CO, V142, P680, DOI 10.1016/0006-291X(87)91468-9; ROCHE E, 1989, CURRENT TRENDS STUDY, V2, P285; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STEER CJ, 1991, INTRACELLULAR TRAFFI; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umezawa H, 1976, Methods Enzymol, V45, P678; VARGAS JL, 1990, EUR J BIOCHEM, V188, P99, DOI 10.1111/j.1432-1033.1990.tb15376.x; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WINKLER JR, 1984, J BIOL CHEM, V259, P5369; WOLF DH, 1992, EXPERIENTIA, V48, P117, DOI 10.1007/BF01923505; YAMAZAKI K, 1989, HEPATOLOGY, V10, P877, DOI 10.1002/hep.1840100522	56	126	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10463	10470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486700				2022-12-25	WOS:A1993LB80000071
J	SCUDDER, P; DOOM, JP; CHUENKOVA, M; MANGER, ID; PEREIRA, MEA				SCUDDER, P; DOOM, JP; CHUENKOVA, M; MANGER, ID; PEREIRA, MEA			ENZYMATIC CHARACTERIZATION OF BETA-D-GALACTOSIDE ALPHA-2,3-TRANS-SIALIDASE FROM TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; ALPHA-2->6 SIALYLTRANSFERASE; INFECTION INVITRO; NEURAMINIDASE; SURFACE; OLIGOSACCHARIDES; TRYPOMASTIGOTES; CELLS; GLYCOPROTEIN; COLOSTRUM	The substrate specificity, physico-chemical, and kinetic properties of the trans-sialidase from Trypanosoma cruzi have been investigated. The enzyme demonstrates activity towards a wide range of saccharide, glycolipid, and glycoprotein acceptors which terminate with a beta-linked galactose residue, and synthesizes exclusively an alpha2-3 sialosidic linkage. Oligosaccharides which terminate in Galbeta1-4(Fucalpha1-3)GlcNAc, Galbeta1-3(Fucalpha1-4)GlcNAc, or Galalpha1- are not acceptor-substrates. The enzyme utilizes alpha2,3-linked sialic acid when the donor species is an oligosaccharide and can also transfer, at a low rate, sialic acid from synthetic alpha-sialosides such as p-nitrophenyl-alpha-N-acetylneuraminic acid, but NeuAcalpha2-3Galbeta1-4(Fucalpha1-3)Glc is not a donor-substrate. The trans-sialidase has an apparent pH optimum of 7.9 and a temperature optimum of 13-degrees-C. The kinetic properties of the enzyme suggest that the trans-sialylation reaction may occur via a rapid equilibrium random or steady-state ordered mechanism. A method for immobilizing the enzyme is described together with examples of its use for the synthesis of oligosaccharide and glycoprotein precursors of sialyl-Lewis(a) and sialyl-Lewis(x).	MONSANTO CO,CTR PHYS SCI,ST LOUIS,MO 63198; NEW ENGLAND MED CTR,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111	Monsanto; Tufts Medical Center	SCUDDER, P (corresponding author), MONSANTO CO,DIV PROT BIOCHEM,GLYCOSCI GRP,800 N LINDBERGH BLVD,ST LOUIS,MO 63167, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; CAVALLESCO R, 1988, J IMMUNOL, V140, P617; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HANFLAND P, 1975, CHEM PHYS LIPIDS, V15, P105, DOI 10.1016/0009-3084(75)90035-3; LIBBY P, 1986, J CLIN INVEST, V77, P127, DOI 10.1172/JCI112266; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGER ID, 1992, BIOCHEMISTRY-US, V31, P10724, DOI 10.1021/bi00159a012; PARDI AJ, 1992, EMBO J, V11, P1705; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PEREIRA MEA, 1983, SCIENCE, V219, P1444, DOI 10.1126/science.6338592; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PRIOLI RP, 1992, MOL BIOCHEM PARASIT, V52, P85, DOI 10.1016/0166-6851(92)90038-L; REARICK JI, 1979, J BIOL CHEM, V254, P4444; ROSENBERG I, 1991, MOL BIOCHEM PARASIT, V46, P303, DOI 10.1016/0166-6851(91)90054-A; SCHAUER R, 1983, H-S Z PHYSIOL CHEM, V364, P1053, DOI 10.1515/bchm2.1983.364.2.1053; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCUDDER P, 1987, EUR J BIOCHEM, V168, P585, DOI 10.1111/j.1432-1033.1987.tb13457.x; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; Smith D F, 1978, Methods Enzymol, V50, P169; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845	28	108	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9886	9891						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486668				2022-12-25	WOS:A1993LA68900104
J	CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA				CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA			EXPRESSION CDNA CLONING OF A SERINE KINASE TRANSFORMING GENE	ONCOGENE			English	Article							ENDOCRINE NEOPLASIA TYPE-2A; DEPENDENT PROTEIN-KINASE; OKADAIC ACID; TUMOR PROMOTER; ONCOGENE; CELLS; CHROMOSOME-10; PHOSPHORYLATION; INTERLEUKIN-1; HYBRIDIZATION	By ectopic expression of cDNAs derived from a Ewing sarcoma cell line in NIH3T3 celts, we isolated a transforming gene (est). Sequence analysis revealed homology to the cot oncogene, which encodes a novel serine kinase. Whereas the cot product was truncated at its carboxy-terminal end as a result of gene rearrangement during transfection, est encodes the normal cot product. Thus, this gene can be activated as an oncogene by overexpression as well as by gene rearrangement. NIH3T3 cells transfected with est formed progressively growing colonies in soft agar and were tumorigenic in nude mice. The 3.2-kb est transcript was expressed at low level in both human fibroblasts and epithelial cells. Addition of the tumor promoter, okadaic acid (OA), or cytokine, interleukin 1 (IL-1), but not serum or platelet-derived growth factor (PDGF), induced increased expression of the est transcript. Using fluorescence in situ hybridization, we localized the est gene to the short arm of human chromosome 10 at band p11.2.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,1E24,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Maniatis T., 1982, MOL CLONING; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAROD SA, 1992, AM J HUM GENET, V51, P469; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P292; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SIMPSON NE, 1991, CYTOGENET CELL GENET, V58, P428, DOI 10.1159/000133170; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	33	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1329	1333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479752				2022-12-25	WOS:A1993KY32800026
J	ABBAS, A; LABBEBOIS, R				ABBAS, A; LABBEBOIS, R			STRUCTURE-FUNCTION STUDIES OF YEAST FERROCHELATASE - IDENTIFICATION AND FUNCTIONAL-ANALYSIS OF AMINO-ACID SUBSTITUTIONS THAT INCREASE V(MAX) AND THE K(M) FOR BOTH SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; SACCHAROMYCES-CEREVISIAE; ERYTHROPOIETIC PROTOPORPHYRIA; COPROPORPHYRINOGEN OXIDASE; MOUSE FERROCHELATASE; LIVER-FERROCHELATASE; MITOCHONDRIAL IRON; HEME-BIOSYNTHESIS; MOLECULAR-CLONING; INHIBITION	The molecular basis of the ferrochelatase defects was investigated in two ''protoporphyric'' and partially heme-deficient yeast mutants. Ferrochelatase, a mitochondrial inner membrane-bound enzyme, catalyzes the incorporation of ferrous iron into protoporphyrin, the last step in protoheme biosynthesis. The mutant cells made normal amounts of normal-sized ferrochelatase, as detected by immunoblotting. The mutations were identified by sequencing the mutant hem15 alleles amplified in vitro from mutant strains genomic DNA. A single nucleotide change, causing an amino acid substitution, was found in each mutant. Substitution of the conserved Ser-169 by Phe caused a 10-fold increase in V(max) and a 45- and 35-fold increase in the K(M) for protoporphyrin and metal, respectively. Replacement of Ser-174 by Pro produced the same effects, but to a lesser degree. There was a good correlation between the ferrochelatase defects measured in vitro and the heme synthesis deficiencies estimated in vivo. The decreased in vivo heme synthesis is probably due to the lower affinity of the mutant enzymes for iron. We propose that the region identified by the two close mutations contributes to the binding domains of metal and protoporphyrin.	UNIV PARIS 07,INST JACQUES MONOD,BIOCHIM PORPHYRINES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; BLOM C, 1990, BIOCHIM BIOPHYS ACTA, V1039, P339, DOI 10.1016/0167-4838(90)90268-K; BLOOMER JR, 1987, J BIOL CHEM, V262, P667; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1981, BIOCHIMIE, V63, P463, DOI 10.1016/S0300-9084(81)80022-3; CAMADRO JM, 1982, BIOCHIM BIOPHYS ACTA, V707, P280, DOI 10.1016/0167-4838(82)90362-4; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1989, BIOCHIM BIOPHYS ACTA, V999, P7, DOI 10.1016/0167-4838(89)90021-6; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DEMATTEIS F, 1985, BIOCHEM J, V226, P537, DOI 10.1042/bj2260537; EIDE D, 1992, J BIOL CHEM, V267, P20774; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HONEYBOURNE CL, 1979, FEBS LETT, V98, P207, DOI 10.1016/0014-5793(79)80185-4; KENG T, 1987, P NATL ACAD SCI USA, V84, P9113, DOI 10.1073/pnas.84.24.9113; KURLANDZKA A, 1985, J GEN MICROBIOL, V131, P2909; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; MCCLUSKEY SA, 1989, MOL PHARMACOL, V36, P608; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MOODY MD, 1985, J BACTERIOL, V161, P1074, DOI 10.1128/JB.161.3.1074-1079.1985; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; NORDMANN Y, 1990, BIOSYNTHESIS HEME CH, P491; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; RYTKA J, 1984, BIOCHEM J, V218, P405, DOI 10.1042/bj2180405; SHERMAN F, 1986, LABORATORY COURSE MA; STRAKA JG, 1991, AM J HUM GENET, V48, P72; TAKETANI S, 1982, EUR J BIOCHEM, V127, P443; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TAKETANI S, 1981, J BIOL CHEM, V256, P2748; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; TANGERAS A, 1986, BIOCHIM BIOPHYS ACTA, V882, P77, DOI 10.1016/0304-4165(86)90058-9; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; URBANGRIMAL D, 1981, MOL GEN GENET, V183, P85, DOI 10.1007/BF00270144; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	39	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8541	8546						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473299				2022-12-25	WOS:A1993KX81100028
J	GHIVIZZANI, SC; MADSEN, CS; HAUSWIRTH, WW				GHIVIZZANI, SC; MADSEN, CS; HAUSWIRTH, WW			INORGANELLO FOOTPRINTING - ANALYSIS OF PROTEIN-BINDING AT REGULATORY REGIONS IN BOVINE MITOCHONDRIAL-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; TRANSCRIPTION FACTOR-I; LIGHT-STRAND PROMOTER; MOUSE L-CELLS; HEAVY-STRAND; ACCURATE INITIATION; PRECISE ASSIGNMENT; GENE-EXPRESSION; REPLICATION; RNA	Detailed study of mammalian mitochondrial transcriptional and replicative mechanisms is currently limited to in vitro analyses, requiring isolation and reassembly of functional components to mimic the in vivo process. To complement these studies and begin understanding the intracellular function of mitochondrial DNA (mtDNA) regulatory regions, we developed in organello footprinting to investigate protein-DNA interactions within the mitochondrion. Using a methylation protection technique and mitochondria isolated from bovine brain tissue, we analyzed five domains believed critical for regulating mtDNA function. Near equivalent protein-DNA interactions were seen upstream of both light and heavy strand RNA start sites at positions consistent with those observed for human mitochondrial transcription factor 1 DNA binding in vitro. Downstream of the 16 S rRNA gene, a high level of protein occupancy was detected within the bovine homologue of the human tridecamer sequence required for attenuation of transcription in vitro. Immediately upstream of the origin of heavy strand replication, a novel site of protein-mtDNA interaction was observed within conserved sequence block 1, suggesting its potential as a regulatory element involved in initiation of heavy strand DNA synthesis. Unlike regions associated with the origin of heavy strand replication, protein-mtDNA interaction was not detected at the origin of light strand replication or within flanking tRNA genes.	UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIGMS NIH HHS [GM34825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BARATGUERIDE M, 1989, EUR J BIOCHEM, V183, P297, DOI 10.1111/j.1432-1033.1989.tb14928.x; BECKWITH B, 1985, WOMEN HEALTH, V10, P1, DOI 10.1300/J013v10n01_01; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BERK AJ, 1976, J MOL BIOL, V100, P85, DOI 10.1016/S0022-2836(76)80036-8; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANG DD, 1986, MOL CELL BIOL, V6, P3262, DOI 10.1128/MCB.6.9.3262; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1986, MOL CELL BIOL, V6, P3253, DOI 10.1128/MCB.6.9.3253; CHAPPELL JB, 1963, BIOCHEM SOC S, V23, P39; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; FISHER RP, 1989, GENE DEV, V3, P2202, DOI 10.1101/gad.3.12b.2202; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GELFAND R, 1981, MOL CELL BIOL, V4, P1605; GHIVIZZANI SC, 1993, IN PRESS J MOL EVOL; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; HEHMAN GL, 1992, P NATL ACAD SCI USA, V89, P8562, DOI 10.1073/pnas.89.18.8562; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HIXSON JE, 1986, J BIOL CHEM, V261, P2384; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; JACKSON KL, 1956, J GEN PHYSIOL, V40, P47, DOI 10.1085/jgp.40.1.47; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KING TC, 1987, J BIOL CHEM, V262, P6204; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; MARTENS PA, 1979, J MOL BIOL, V135, P327, DOI 10.1016/0022-2836(79)90440-6; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIGNOTTE F, 1990, EUR J BIOCHEM, V194, P561, DOI 10.1111/j.1432-1033.1990.tb15653.x; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NICK H, 1985, NATURE, V313, P795, DOI 10.1038/313795a0; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; SACCONE C, 1991, J MOL EVOL, V33, P83, DOI 10.1007/BF02100199; Sambrook J, 1989, MOL CLONING LABORATO; SEKIYA T, 1980, GENE, V11, P53; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TAPPER DP, 1982, J MOL BIOL, V162, P1, DOI 10.1016/0022-2836(82)90159-0; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; TOPPER JN, 1989, MOL CELL BIOL, V9, P1200, DOI 10.1128/MCB.9.3.1200; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WONG TW, 1985, J BIOL CHEM, V260, P1530; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0	65	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8675	8682						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473311				2022-12-25	WOS:A1993KX81100047
J	PAIGE, LA; NADLER, MJS; HARRISON, ML; CASSADY, JM; GEAHLEN, RL				PAIGE, LA; NADLER, MJS; HARRISON, ML; CASSADY, JM; GEAHLEN, RL			REVERSIBLE PALMITOYLATION OF THE PROTEIN-TYROSINE KINASE P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; FATTY-ACID ACYLATION; CYTOPLASMIC DOMAINS; PALMITIC ACID; POSTTRANSLATIONAL MODIFICATION; VIRUS GLYCOPROTEINS; CELLULAR PROTEINS; CYSTEINE MOTIFS; LYMPHOCYTES-T; RAS PROTEINS	The myristoylated protein-tyrosine kinase, p56lck, is expressed predominantly in T cells where it is believed to play a role in T cell activation. We observed a 56-kDa protein that became metabolically labeled in intact T lymphoid cells that were incubated with either [H-3] myristate or [H-3]palmitate. This protein was identified as p56lck based on its specific immunoprecipitation with polyclonal antisera to p56lck, by induction of a shift in its electrophoretic mobility following treatment of cells with 12-O-tetradecanoylphorbol-13-acetate and by co-chromatography with p56lck on protamine-agarose. Characterization of the two acylation events revealed that, in contrast to the p56lck-associated radioactivity from [H-3]myristate-labeled cells, the p56lck-associated radioactivity from [H-3]palmitate-labeled cells was susceptible to cleavage by neutral hydroxylamine and was not blocked by inhibitors of protein synthesis. Pulse-chase analyses revealed that the labeling of p56lck with [H-3]palmitate, but not [H-3]myristate, was reversible. The presence of covalently attached palmitate on p56lck from [H-3]palmitate-labeled cells was verified by thin-layer chromatography following acid hydrolysis of the acylated protein. 2-Hydroxymyristate, which is metabolically activated to form a potent inhibitor of protein myristoylation, specifically inhibited the acylation of p56lck with [H-3]myristate without affecting its labeling with [H-3]palmitate. These studies indicate that p56lck is both a cotranslationally myristoylated and post-translationally palmitoylated protein.	PURDUE UNIV,DEPT MEDICINAL CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907; OHIO STATE UNIV,COLL PHARM,COLUMBUS,OH 43210	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University System of Ohio; Ohio State University				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R55CA045667, R01CA045667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008298, R01GM048099] Funding Source: NIH RePORTER; NCI NIH HHS [CA45667] Funding Source: Medline; NIGMS NIH HHS [GM48099, 5 T32 GM08298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADAM M, 1988, ARCH BIOCHEM BIOPHYS, V264, P553, DOI 10.1016/0003-9861(88)90321-9; ALVEREZ E, 1990, J BIOL CHEM, V265, P16644; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CRISE B, 1992, J BIOL CHEM, V267, P13593; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; GLYNN JP, 1964, CANCER RES, V24, P502; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HURLEY TR, 1989, ONCOGENE, V4, P265; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1988, J CELL BIOCHEM, V37, P347, DOI 10.1002/jcb.240370403; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1989, J IMMUNOL, V142, P2430; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OMARY MB, 1981, J BIOL CHEM, V256, P4715; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SPECTOR AA, 1986, METHOD ENZYMOL, V128, P320; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; TAMANOI F, 1988, J CELL BIOCHEM, V36, P261, DOI 10.1002/jcb.240360307; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	47	141	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8669	8674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473310				2022-12-25	WOS:A1993KX81100046
J	CHEN, JJ; PEDERSON, DS				CHEN, JJ; PEDERSON, DS			A DISTAL HEAT-SHOCK ELEMENT PROMOTES THE RAPID RESPONSE TO HEAT-SHOCK OF THE HSP26 GENE IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; TRANSCRIPTIONAL REGULATION; SYNERGISTIC ACTIVATION; BINDING-PROTEIN; TATA ELEMENTS; DNA TOPOLOGY; 70 GENE; CHROMATIN; SEQUENCES; EXPRESSION	Induction of heat shock genes is mediated by heat shock factor (HSF). Our recent genomic footprinting experiments demonstrate that HSF binds constitutively to perfect and imperfect heat shock elements (HSEs) in the HSP26 gene in yeast. Site-directed mutagenesis of the single perfect HSE, previously reported to not be involved in regulating gene expression, significantly reduces the rate of response of the gene to heat shock. However, the same mutation only slightly reduced the rate of accumulation of HSP26 mRNA during heat shock. Genomic footprinting experiments indicate that this lag in response to heat shock is due to the failure of HSF to bind efficiently to the mutated HSE. The rate of response to heat shock of synthetic promoters containing one, two, three, or seven perfect HSEs was similar to that observed for the wild-type HSP26 gene. These results suggest that the rate of response to heat shock is correlated with HSF occupancy of HSEs, rather than the number of HSEs in a promoter. As with the wild-type and mutant HSP26 genes, the rate of accumulation of mRNA from synthetic promoters increased only moderately with an increase in the number of HSEs. These results suggest that as few as two HSE.HSF complexes are sufficient to saturate HSF's target in the basal transcription apparatus.			CHEN, JJ (corresponding author), UNIV VERMONT,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05401, USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; BOSSIER P, 1989, GENE, V78, P323, DOI 10.1016/0378-1119(89)90234-5; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; GREENE JM, 1990, MOL CELL BIOL, V10, P1319, DOI 10.1128/MCB.10.4.1319; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GURLEY WB, 1991, BIOCHEMISTRY-US, V30, P1, DOI 10.1021/bi00215a001; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LEE MS, 1992, IN PRESS P NATL ACAD; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; MORIMOTO RI, 1989, UCLA S MOL CELL BIOL, V96, P83; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; PARK HO, 1989, MOL CELL BIOL, V9, P2025, DOI 10.1128/MCB.9.5.2025; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; Ptashne M., 1986, A GENETIC SWITCH; RIDDIHOUGH G, 1986, EMBO J, V5, P1653, DOI 10.1002/j.1460-2075.1986.tb04408.x; Sambrook J, 1989, MOL CLONING LABORATO; SHUEY DJ, 1986, J BIOL CHEM, V261, P7934; SIGURDSON DC, 1981, MOL GEN GENET, V183, P59, DOI 10.1007/BF00270139; SIKORSKI RS, 1989, GENETICS, V122, P19; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; SUSEK RE, 1990, MOL CELL BIOL, V10, P6362, DOI 10.1128/MCB.10.12.6362; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	49	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7442	7448						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463277				2022-12-25	WOS:A1993KV14100088
J	MIKI, M; IIO, T				MIKI, M; IIO, T			KINETICS OF STRUCTURAL-CHANGES OF RECONSTITUTED SKELETAL-MUSCLE THIN-FILAMENTS OBSERVED BY FLUORESCENCE RESONANCE ENERGY-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C; TROPOMYOSIN-TROPONIN; CALCIUM-BINDING; MYOSIN SUBFRAGMENT-1; PROTEOLYTIC FRAGMENTS; I COMPLEX; ACTIN; ATPASE; CA-2+; CONTRACTION	Fluorescence resonance energy transfer was measured between probes attached to Troponin-I and actin in the reconstituted skeletal muscle thin filament. Cys-133 on TnI was labeled with 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid, and Lys-61 on actin was labeled with fluorescein 5-isothiocyanate. A large difference in the efficiency of resonance energy transfer was observed between the presence (0.55) and absence (0.76) of Ca2+, which corresponds to the change in the distance of 0.53 nm and is in good accordance with a previous report (Miki, M. (1990) Eur. J. Biochem. 187, 155-162). The fluorescence titration curve of this reconstituted thin filament was measured versus free Ca2+ concentration under physiological conditions in the presence of 8 mM MgCl2. The transfer efficiency changed sharply between pCa 6.9 and 5.75, with a midpoint at pCa 6.25, suggesting that a conformational change of thin filaments occurs with a highly cooperative mode. The time course of this conformational change was followed by measuring the fluorescence intensity change (energy transfer efficiency change) of the labeled reconstituted thin filament after rapid decrease or increase of free Ca2+ concentration with a stopped-flow fluorometer. When the free Ca2+ concentration was increased in the presence of 5 mM MgCl2, the fluorescence intensity increased (the transfer efficiency decreased) with a rate constant of 530 +/- 170 s-1 at 20-degrees-C. On the other hand, when the free Ca2+ concentration was decreased, the fluorescence intensity decreased with a rate constant of 43 +/- 5 s-1. The results indicate that the conformational change observed by fluorescence resonance energy transfer corresponds well to the regulation mechanism by troponin-tropomyosin on the reconstituted skeletal muscle thin filament.	NAGOYA UNIV,DEPT PHYS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Nagoya University	MIKI, M (corresponding author), FUKUI UNIV,DEPT APPL CHEM & BIOTECHNOL,BUNKYO 3-CHOME,FUKUI 910,JAPAN.							AKIYAMA S, 1985, B CHEM SOC JPN, V58, P2192, DOI 10.1246/bcsj.58.2192; BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BOTTS J, 1984, P NATL ACAD SCI-BIOL, V81, P2060, DOI 10.1073/pnas.81.7.2060; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; CUMMINS P, 1973, BIOCHEM J, V133, P765, DOI 10.1042/bj1330765; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DOSREMEDIOS CG, 1987, J MUSCLE RES CELL M, V8, P97, DOI 10.1007/BF01753986; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; EBASHI S, 1968, J BIOCHEM-TOKYO, V64, P465, DOI 10.1093/oxfordjournals.jbchem.a128918; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY HE, 1972, COLD SPRING HARB SYM, V37, P362; IIO T, 1988, J BIOCHEM-TOKYO, V104, P306, DOI 10.1093/oxfordjournals.jbchem.a122462; IIO T, 1978, J BIOCHEM-TOKYO, V83, P961, DOI 10.1093/oxfordjournals.jbchem.a132024; IIO T, 1982, J BIOCHEM-TOKYO, V92, P1141, DOI 10.1093/oxfordjournals.jbchem.a134030; ISHIWATA S, 1972, J MOL BIOL, V68, P511, DOI 10.1016/0022-2836(72)90103-9; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; MIKI M, 1989, J BIOCHEM-TOKYO, V106, P651, DOI 10.1093/oxfordjournals.jbchem.a122911; MIKI M, 1992, J MUSCLE RES CELL M, V13, P132, DOI 10.1007/BF01874150; MIKI M, 1987, EUR J BIOCHEM, V164, P229, DOI 10.1111/j.1432-1033.1987.tb11015.x; MIKI M, 1990, EUR J BIOCHEM, V187, P155, DOI 10.1111/j.1432-1033.1990.tb15289.x; MIKI M, 1991, BIOCHEMISTRY-US, V30, P5625, DOI 10.1021/bi00236a042; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SIN IL, 1978, BIOCHEM BIOPH RES CO, V82, P1132, DOI 10.1016/0006-291X(78)90304-2; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAO T, 1989, BIOCHEMISTRY-US, V28, P5902, DOI 10.1021/bi00440a029; TAO T, 1983, BIOCHEMISTRY-US, V22, P3059, DOI 10.1021/bi00282a006; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; WAKABAYASHI T, 1975, J MOL BIOL, V93, P477, DOI 10.1016/0022-2836(75)90241-7; WNUK W, 1984, J BIOL CHEM, V259, P9017; ZOT HG, 1987, J MUSCLE RES CELL M, V8, P428, DOI 10.1007/BF01578432	45	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7101	7106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463245				2022-12-25	WOS:A1993KV14100045
J	VOELKER, DR				VOELKER, DR			THE ATP-DEPENDENT TRANSLOCATION OF PHOSPHATIDYLSERINE TO THE MITOCHONDRIA IS A PROCESS THAT IS RESTRICTED TO THE AUTOLOGOUS ORGANELLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED ANIMAL-CELLS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID-SYNTHESIS; ENDOPLASMIC-RETICULUM; SUBCELLULAR MEMBRANES; CULTURED FIBROBLASTS; LIPID-COMPOSITION; GOLGI-APPARATUS; TRANSPORT	The general properties of phosphatidylserine synthesis and translocation to the inner mitochondrial membrane which occur in both intact and permeabilized cells are now shown to occur in cells that are disrupted by shearing. In disrupted cells the synthesis of phosphatidylserine requires ATP and is blocked by preventing Ca2+ sequestration. The translocation of nascent phosphatidylserine to the mitochondria also requires ATP in disrupted cells. Using disrupted cells it is possible to test whether the translocation of nascent phosphatidylserine to the mitochondria is restricted to autologous mitochondrial acceptors or is possible with heterologous mitochondrial acceptors. To examine the nature of the transport process, a donor and acceptor population of cells were prepared. The donor cells were poisoned with hydroxylamine which irreversibly inactivates phosphatidylserine decarboxylase and will prevent the conversion of nascent phosphatidylserine to phosphatidylethanolamine. The acceptor cells were not treated with hydroxylamine so that any phosphatidylserine generated in the donor cell that reached the inner mitochondrial membrane of the acceptor cells would be decarboxylated to form phosphatidylethanolamine. Disrupted donor cells were pulse labeled with [H-3]serine for 40 min to permit the synthesis of [H-3] phosphatidylserine, and then further incorporation of radiolabel was arrested by chelating Ca2+. When the prelabeled disrupted donor cells were mixed with disrupted acceptor cells the latter failed to decarboxylate the nascent phosphatidylserine. In control experiments the addition of hydroxylamine-poisoned cells did not alter the transfer of nascent phosphatidylserine to autologous mitochondria present in unpoisoned cells. These results indicate that the ATP-dependent translocation of phosphatidylserine to the mitochondria is a process that is restricted to the autologous organelle.			VOELKER, DR (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206, USA.				NIGMS NIH HHS [GM32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; HELMS JB, 1990, J BIOL CHEM, V265, P20027; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KASS GEN, 1989, J BIOL CHEM, V264, P16965; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; OHTA A, 1981, J BIOL CHEM, V256, P2219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	24	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7069	7074						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463240				2022-12-25	WOS:A1993KV14100040
J	SHARMA, SV				SHARMA, SV			MELITTIN-INDUCED HYPERACTIVATION OF PHOSPHOLIPASE-A2 ACTIVITY AND CALCIUM INFLUX IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; A431 CELLS; MEMBRANE; PROTEINS; VENOM; DIACYLGLYCEROL; FACILITATION; FLUORESCENCE; LIPOXYGENASE; FIBROBLASTS	The activated ras oncogene is a key mediator of cellular transformation and is present in a wide variety of primary human neoplasms. The biochemical role of the ras oncogene in cellular transformation is at present unclear, and hence approaches to control its activities in transformed cells have met with limited success. Previous studies have demonstrated the ability of melittin, a 26 amino acid amphipathic peptide from bee venom, to specifically counterselect for cells in culture that express high levels of the ras oncogene product. The biochemical basis for this counterselection is currently unknown. This study demonstrates the ability of melittin to hyperactivate phospholipase A2 (PLA2) in ras-transformed cells by the mediation of enhanced influx of calcium ions (Ca2+). This hyperactivation of PLA2 and Ca2+ mobilization in ras-transformed cells by melittin is mimicked by the calcium ionophore, A23187. Both melittin- and A23187-mediated PLA2 hyperactivation require Ca2+. However, the action of melittin is strongly dependent on extracellular Ca2+, whereas that of A23187 is not. Melittin-induced Ca2+ influx and PLA2 hyperactivation is inhibited by manganese ions (Mn2+). These studies reveal a close correlation between the extent of PLA2 hyperactivation and Ca2+ mobilization, suggesting a causal relationship.			SHARMA, SV (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P155, DOI 10.1016/0005-2736(87)90165-9; BOS JL, 1989, CANCER RES, V49, P4682; CHANG JP, 1988, J BIOL CHEM, V263, P18614; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FLETCHER JE, 1991, BIOCHEM CELL BIOL, V69, P274, DOI 10.1139/o91-042; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1989, G PROTEINS MEDIATORS; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; METZ SA, 1986, BIOCHEM PHARMACOL, V35, P3371, DOI 10.1016/0006-2952(86)90438-7; MIX LL, 1984, BIOCHEM BIOPH RES CO, V119, P69, DOI 10.1016/0006-291X(84)91619-X; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MUFSON RA, 1979, NATURE, V280, P73; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; ROZENGURT E, 1981, CELL, V23, P781, DOI 10.1016/0092-8674(81)90442-6; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SESSA G, 1969, J BIOL CHEM, V244, P3575; SHAH GV, 1990, ENDOCRINOLOGY, V127, P613, DOI 10.1210/endo-127-2-613; SHARMA SV, 1992, ONCOGENE, V7, P193; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; VINCENTINI LM, 1984, J BIOL CHEM, V259, P6912; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUNES R, 1977, ARCH BIOCHEM BIOPHYS, V183, P105, DOI 10.1016/0003-9861(77)90424-6	46	54	56	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					939	947						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455945				2022-12-25	WOS:A1993KT22000016
J	ZAKERI, ZF; QUAGLINO, D; LATHAM, T; LOCKSHIN, RA				ZAKERI, ZF; QUAGLINO, D; LATHAM, T; LOCKSHIN, RA			DELAYED INTERNUCLEOSOMAL DNA FRAGMENTATION IN PROGRAMMED CELL-DEATH	FASEB JOURNAL			English	Article						APOPTOSIS; PROGRAMMED CELL DEATH; ENDONUCLEASE; MANDUCA SEXTA; DNA	RAT VENTRAL PROSTATE; GENE-EXPRESSION; APOPTOSIS; ACTIVATION; INDUCTION; ENDONUCLEASE; INVOLVEMENT; TRANSCRIPTS; LYMPHOCYTES; REGRESSION	DNA fragmentation was evaluated in three instances of programmed cell death, interdigital cell death in embryonic mouse limbs, and metamorphic death of both the labial glands and intersegmental muscle in the tobacco hornworm Manduca sexta. In the mouse, we evaluated both developmental cell death and expanded-range cell death induced by retinoic acid. The status of DNA was examined in several ways. Nuclei were examined by electron microscopy and Feulgen staining. Quantitative assessment of total DNA content in Feulgen-stained degenerating nuclei was made for the gland. In the labial gland, DNA content does not drop during the early phases of cell death; nor is an endonucleolytic ladder seen when DNA was examined by ethidium bromide staining or prelabeling with [H-3]thymidine. Only by using end labeling of DNA could we detect DNA fragmentation at a very late stage in cell death, day 4 of the collapse of the gland. In contrast, WEHI 7.1 lymphoma cells display an early and extensive ladder after treatment with glucocorticoids. In mouse limb, for which cell death follows a more classic apoptotic morphology, a ladder is likewise not seen. We conclude that activation of an endonuclease is neither a trigger nor a necessary or defining component of the early phases of developmental programmed cell death, and that reported failure by others to find such a ladder may depend on limitations in the system that is under investigation.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA; CUNY QUEENS COLL, DEPT BIOL, FLUSHING, NY 11367 USA; UNIV MODENA, DEPT PATHOL, I-41100 MODENA, ITALY; CUNY, GRAD CTR, FLUSHING, NY 11367 USA	Saint John's University; City University of New York (CUNY) System; Queens College NY (CUNY); Universita di Modena e Reggio Emilia; City University of New York (CUNY) System			Quaglino, Daniela/A-9381-2010	Quaglino, Daniela/0000-0002-4302-5078	NIA NIH HHS [R01 AG-10101] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010101] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akai H., 1984, P323; ALLES AJ, 1989, TERATOLOGY, V40, P163, DOI 10.1002/tera.1420400210; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BEAULATION J, 1977, J MORPHOL, V154, P39, DOI 10.1002/jmor.1051540104; BEAULATON J, 1982, INT REV CYTOL, V79, P215, DOI 10.1016/S0074-7696(08)61675-7; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARONLESLIE LAM, 1991, J STEROID BIOCHEM, V40, P661, DOI 10.1016/0960-0760(91)90288-G; CARSON DA, 1988, ADV ENZYME REGUL, V27, P395, DOI 10.1016/0065-2571(88)90028-3; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1984, J IMMUNOL, V132, P38; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; DOWD DR, 1991, J BIOL CHEM, V266, P18423; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOLDMAN AS, 1983, P SOC EXP BIOL MED, V174, P239; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1991, MOL BASIS CELL DEATH, P5; Lockshin R A, 1965, J Insect Physiol, V11, P803, DOI 10.1016/0022-1910(65)90159-9; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; LOCKSHIN RA, 1974, J ULTRA MOL STRUCT R, V46, P43, DOI 10.1016/S0022-5320(74)80021-3; LOCKSHIN RA, 1979, TISSUE CELL, V11, P803, DOI 10.1016/0040-8166(79)90033-8; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; LOCKSHIN RA, 1965, J INSECT PHYSL, V11, P605; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P831, DOI 10.1016/0022-1910(65)90186-1; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; MONTEMAYOR ME, 1990, FEBS LETT, V276, P219, DOI 10.1016/0014-5793(90)80546-U; NAEGELE JR, 1991, P NATL ACAD SCI USA, V88, P330, DOI 10.1073/pnas.88.2.330; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PRICE JM, 1977, AM J ANAT, V149, P353, DOI 10.1002/aja.1001490304; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; SENSIBAR JA, 1990, PROSTATE, V16, P263, DOI 10.1002/pros.2990160310; TASHIRO Y, 1968, J CELL BIOL, V38, P574, DOI 10.1083/jcb.38.3.574; TILLY JL, 1991, ENDOCRINOLOGY, V129, P2799, DOI 10.1210/endo-129-5-2799; UMANSKY SR, 1991, APOPTOSIS MOL BASIS, P193; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; ZAKERI Z, 1990, Cell Biology International Reports, V14, P171, DOI 10.1016/0309-1651(90)90786-X	42	188	189	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1993	7	5					470	478		10.1096/fasebj.7.5.8462789	http://dx.doi.org/10.1096/fasebj.7.5.8462789			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KV351	8462789				2022-12-25	WOS:A1993KV35100012
J	BOHINSKI, RJ; HUFFMAN, JA; WHITSETT, JA; LATTIER, DL				BOHINSKI, RJ; HUFFMAN, JA; WHITSETT, JA; LATTIER, DL			CIS-ACTIVE ELEMENTS CONTROLLING LUNG CELL-SPECIFIC EXPRESSION OF HUMAN PULMONARY SURFACTANT PROTEIN-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ENHANCER; TRANSGENIC MICE; FETAL LUNG; CHROMATIN; RECEPTOR; LOCUS; LIVER; ORGANIZATION; INITIATOR; INTERACT	Human surfactant protein B (SPB) is a 79-aminoacid hydrophobic protein that enhances the surface active properties of pulmonary surfactant. SPB is expressed in nonciliated bronchiolar and alveolar type II cells of the respiratory epithelium, and its expression increases markedly late in gestation. In the present study, a human pulmonary adenocarcinoma cell line, H441, was used in both functional and biochemical assays to identify DNA sequences controlling lung cell-specific expression of the SPB gene. DNase I hypersensitive studies demonstrated two distinct regions of lung cell-specific hypersensitivity located proximal to the SPB promoter and within the eighth intron of the gene. To functionally define these DNA sequences, a series of plasmid vectors were constructed in which segments of the human SPB gene and 5'-flanking sequence were linked to a CAT reporter gene and assayed for expression in lung and nonlung cell lines. Whereas far upstream and intronic sequences did not contain enhancer-like elements, a 259-base pair DNA segment (base pair -218 to +41) was sufficient to support lung cell-specific expression. DNase I footprinting demonstrated that this pulmonary epithelial cell-specific promoter fragment contained five nuclear protein-binding sites, two of which bound lung cell-specific nuclear protein complexes. These results suggest that the pulmonary epithelial cell-specific expression of SPB is determined, in part, by both ubiquitous and cell type-specific protein-DNA interactions within the proximal promoter region.	CHILDRENS HOSP MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011725] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038859, P01HL041496, R01HL038859] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38859, HL41496] Funding Source: Medline; NICHD NIH HHS [HD11725] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALAM J, 1991, BIOTECHNIQUES, V10, P423; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; COCHRANE CG, 1991, SCIENCE, V254, P566, DOI 10.1126/science.1948032; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EISSENBERG JC, 1985, ANNU REV GENET, V19, P485, DOI 10.1146/annurev.genet.19.1.485; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAZDAR AF, 1990, CANCER RES, V50, P5481; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGWOOD S, 1991, ANNU REV PHYSIOL, V53, P375; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; Miller JH., 1972, EXPT MOL GENETICS; MIRKOVITCH J, 1991, GENE DEV, V5, P83, DOI 10.1101/gad.5.1.83; MOON AM, 1991, BLOOD, V77, P2272; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; OREILLY MA, 1989, BIOCHIM BIOPHYS ACTA, V1011, P140, DOI 10.1016/0167-4889(89)90201-2; OREILLY MA, 1991, AM J PHYSIOL, V260, pL37, DOI 10.1152/ajplung.1991.260.2.L37; OREILLY MA, 1989, AM J PHYSIOL, V257, pL385, DOI 10.1152/ajplung.1989.257.6.L385; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RISSE G, 1989, EMBO J, V8, P2825; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STAHLMAN MT, 1992, J HISTOCHEM CYTOCHEM, V40, P1471, DOI 10.1177/40.10.1527371; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WERT SE, 1993, IN PRESS DEV BIOL; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	52	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11160	11166						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496176				2022-12-25	WOS:A1993LD46600066
J	DIECI, G; DUIMIO, L; CODAZABETTA, F; SPRAGUE, KU; OTTONELLO, S				DIECI, G; DUIMIO, L; CODAZABETTA, F; SPRAGUE, KU; OTTONELLO, S			A NOVEL RNA POLYMERASE-III TRANSCRIPTION FACTOR FRACTION THAT IS NOT REQUIRED FOR TEMPLATE COMMITMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSFER-RNA; GENE-TRANSCRIPTION; FACTOR-TFIIIB; COMPLEXES; BINDING; DNA; POLYPEPTIDE; COMPONENTS; INITIATION; PURIFICATION	We have identified and partially characterized a novel class III transcription factor fraction (TFIIIE) from yeast nuclear extracts. TFIIIE is functionally distinct from the standard yeast transcription factor fractions, TFIIIB and TFIIIC. It is also different from either of the TFIIIB subfractions, B' and B''. TFIIIE is essential for specific transcription of both tRNA and 5 S RNA genes, its activity is sensitive to proteinase K, and it exhibits an apparent sedimentation coefficient of 4.0 S when analyzed on glycerol gradients. In the case of a tRNA gene, TFIIIE does not play a role in the formation of stable preinitiation complexes containing TFIIIB and TFIIIC. It is required for single as well as multiple rounds of transcription, however. Thus, TFIIIE is involved in the utilization of stable transcription complexes, but its action is not restricted to reinitiation events.	UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY; UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Parma; University of Oregon			Dieci, Giorgio/B-3434-2012	Dieci, Giorgio/0000-0002-8792-3961	NIGMS NIH HHS [GM25388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; FLORES O, 1992, J BIOL CHEM, V267, P2786; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; HUIBREGTSE JM, 1987, MOL CELL BIOL, V7, P3212, DOI 10.1128/MCB.7.9.3212; JOHNSON DL, 1989, MOL CELL BIOL, V9, P2018, DOI 10.1128/MCB.9.5.2018; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; OEI SL, 1990, J BIOL CHEM, V265, P7485; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SCHULTZ LD, 1976, P NATL ACAD SCI USA, V73, P1029, DOI 10.1073/pnas.73.4.1029; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Sentenac A, 1982, MOL BIOL YEAST SACCH, P561; Shoyab M, 1979, Methods Enzymol, V68, P199; STILMAN DJ, 1985, J MOL BIOL, V815, P451; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	40	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11199	11207						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496177				2022-12-25	WOS:A1993LD46600072
J	MILNE, CA; SEGALL, J				MILNE, CA; SEGALL, J			MAPPING REGIONS OF YEAST TRANSCRIPTION FACTOR-IIIA REQUIRED FOR DNA-BINDING, INTERACTION WITH TRANSCRIPTION FACTOR-IIIC, AND TRANSCRIPTION ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; 5-S RNA GENE; XENOPUS 5S-RNA GENE; SINGLE ZINC FINGER; 5S RNA; POLYMERASE-III; FACTOR-TAU; DELETION MUTANTS; FACTOR TFIIIA; PROTEIN	TFIIIA, a site-specific DNA-binding protein containing nine zinc finger motifs, is an RNA polymerase III transcription factor responsible for the assembly of a transcription complex on the 5 S RNA gene. We have analyzed the effect of deleting various regions of yeast TFIIIA on its ability to bind to the internal control region of the yeast 5 S RNA gene, to recruit TFIIIC into the TFIIIA.DNA complex and to promote in vitro transcription of the 5 S RNA gene. A truncated polypeptide containing only the three amino-terminal zinc fingers retained the ability to bind specifically to the internal control region of the 5 S RNA gene. The TFIIIA.DNA complex formed with this three zinc finger module was able to recruit TFIIIC but could not promote transcription. An 81-amino acid domain, which interrupts the repeating zinc finger motifs between fingers 8 and 9, was found to be essential for the transcription activity of the protein. Removal of the carboxyl-terminal region of yeast TFIIIA that extends beyond the ninth zinc finger motif had no effect on the in vitro activities of the protein. Extending the carboxyl-terminal deletion to include the ninth zinc finger led to reduced transcription activity. We speculate that the ninth zinc finger serves to anchor the carboxyl-terminal portion of TFIIIA on the 5 S RNA gene, correctly orienting the 81-amino acid domain to serve its role in promoting transcription. Removal of the region of the protein amino-terminal to the first zinc finger motif was without effect. Extending the amino-terminal deletion to include the first zinc finger appeared to decrease the affinity of TFIIIA for DNA without affecting the specificity of the protein-DNA interaction. The resultant TFIIIA.DNA complex was defective in recruiting TFIIIC and did not support transcription.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto								ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CAREY MF, 1986, J BIOL CHEM, V261, P4309; CHALLICE JM, 1989, J BIOL CHEM, V264, P20060; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P1607; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HANAS JS, 1989, NUCLEIC ACIDS RES, V17, P9861, DOI 10.1093/nar/17.23.9861; HAYES J, 1989, J BIOL CHEM, V264, P6009; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON DL, 1989, MOL CELL BIOL, V9, P2018, DOI 10.1128/MCB.9.5.2018; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; OLSON MV, 1981, NATURE, V291, P464, DOI 10.1038/291464a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SEGALL J, 1986, J BIOL CHEM, V261, P1578; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; TAYLOR MJ, 1985, J BIOL CHEM, V260, P4531; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG CK, 1989, J BIOL CHEM, V264, P1092; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WOYCHIK NA, 1992, P NATL ACAD SCI USA, V89, P3999, DOI 10.1073/pnas.89.9.3999; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	69	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11364	11371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496187				2022-12-25	WOS:A1993LD46600094
J	SMITH, MT; EMERICH, DW				SMITH, MT; EMERICH, DW			ALANINE DEHYDROGENASE FROM SOYBEAN NODULE BACTEROIDS - KINETIC MECHANISM AND PH STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-CAPSULATA	The kinetic mechanism of alanine dehydrogenase from soybean nodule bacteroids was studied by initial velocity experiments with or without product inhibitors, dead-end inhibitors, or alternate substrates. Without inhibitors, double-reciprocal plots of initial velocity experiments showed intersecting lines, indicating a sequential mechanism. These initial velocity experiments also revealed rapid-equilibrium ordered binding of NH4+ prior to pyruvate. When NAD was varied at changing-fixed concentrations of L-alanine, a nonlinear, concave down double-reciprocal plot was obtained. Substrate inhibition by pyruvate or L-alanine with cosubstrates varied was uncompetitive giving further support to an ordered mechanism. Product inhibition studies showed that both NAD and NADH and pyruvate and L-alanine were competitive. This suggested a Theorell-Chance mechanism. When product inhibition by L-alanine was studied with NH4+ varied in a series of experiments at increasing concentrations of pyruvate, the inhibition was eliminated, as expected for a Theorell-Chance mechanism. Furthermore, when NADH, NH4+, and pyruvate were varied simultaneously, maintaining their concentrations at a constant ratio to each other, an infinite V(max) was obtained. pH studies of the kinetic parameters indicated that NH4+, rather than NH3, was the true substrate that binds to a residue on the enzyme with a pK of 8.1. In conclusion, the kinetic mechanism at pH 8.5 was determined to be a Ter-Bi Theorell-Chance. In the amination direction, the substrates add in the order: NADH, NH4+, pyruvate, with NH4+ binding in rapid-equilibrium. In the reverse direction, NAD adds first, followed by L-alanine.	UNIV MISSOURI,DEPT BIOCHEM,117 SCHWEITZER HALL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia								CABALLERO FJ, 1985, J BACTERIOL, V162, P804, DOI 10.1128/JB.162.2.804-809.1985; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W. W, 1970, ENZYMES, V2, P1; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; CROW VL, 1987, APPL ENVIRON MICROB, V53, P1885, DOI 10.1128/AEM.53.8.1885-1892.1987; DUNN SD, 1973, CAN J MICROBIOL, V19, P1493, DOI 10.1139/m73-243; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3820, DOI 10.1021/bi00410a045; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3826, DOI 10.1021/bi00410a046; GATES CA, 1988, BIOCHEMISTRY-US, V27, P3834, DOI 10.1021/bi00410a047; GOLDMAN DS, 1959, BIOCHIM BIOPHYS ACTA, V34, P527, DOI 10.1016/0006-3002(59)90305-1; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5655, DOI 10.1021/bi00523a003; GRIMSHAW CE, 1981, BIOCHEMISTRY-US, V20, P5650, DOI 10.1021/bi00523a002; MCCOWEN SM, 1974, J BACTERIOL, V118, P590, DOI 10.1128/JB.118.2.590-597.1974; MULLER P, 1982, Z NATURFORSCH C, V37, P927; MURRELL JC, J GEN MICROBIOL, V129, P1197; Neet K E, 1980, Methods Enzymol, V64, P139; OHASHIMA T, 1979, EUR J BIOCHEM, V100, P29, DOI 10.1111/j.1432-1033.1979.tb02030.x; ROWELL P, 1976, ARCH MICROBIOL, V107, P115, DOI 10.1007/BF00446830; SCHIMERLIK MI, 1977, BIOCHEMISTRY-US, V16, P571, DOI 10.1021/bi00623a002; SMITH MT, 1991, THESIS U MISSOURI; TOLXDORFFNEUTZLING R, 1982, FEMS MICROBIOL LETT, V13, P155; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	22	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10746	10753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496141				2022-12-25	WOS:A1993LD46600009
J	WU, YN; MIKULSKI, SM; ARDELT, W; RYBAK, SM; YOULE, RJ				WU, YN; MIKULSKI, SM; ARDELT, W; RYBAK, SM; YOULE, RJ			A CYTOTOXIC RIBONUCLEASE - STUDY OF THE MECHANISM OF ONCONASE CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN PLACENTAL RIBONUCLEASE; TOXIC LECTINS ABRIN; DIPHTHERIA-TOXIN; RANA-CATESBEIANA; P-30 PROTEIN; TUMOR-CELLS; RICIN; INHIBITOR; JAPONICA	Onconase, or P-30, is a protein initially purified from extracts of Rana pipiens oocytes and early embryos based upon its anticancer activity both in vitro and in vivo. It is a basic single-chain protein with an apparent molecular mass of 12,000 daltons and is homologous to RNase A. In cultured 9L glioma cells, onconase inhibits protein synthesis with an IC50 of about 10(-7) M. The inhibition of protein synthesis correlates with cell death determined by clonogenic assays. I-125-Labeled onconase binds to specific sites on cultured 9L glioma cells. Scatchard analysis of the binding data shows that onconase appears to bind to cells with two different affinities, one with a K(d) of 6.2 x 10(-8) and another of 2.5 x 10(-7) M. Each cell could bind about 3 x 10(5) molecules of onconase at each of the two affinity sites. The low affinity K(d) is similar to the IC50 for onconase toxicity. Onconase also demonstrates a saturability of cytotoxicity at a concentration that would saturate the low affinity binding site. Incubation at 4-degrees-C increased the binding of onconase to cells relative to 37-degrees-C binding and also increased the sensitivity of cells to onconase toxicity, indicating that receptor binding may be an initial step in cell toxicity. Onconase cytotoxicity can be blocked by metabolic inhibitors, NaN3 and 2-deoxyglucose, and cytotoxicity is potentiated 10-fold by monensin. Ribonuclease activity appears necessary for onconase toxicity because alkylated onconase, which only retains 2% of the ribonuclease activity, was at least 100-fold less potent in inhibiting protein synthesis in cells. Onconase inhibition of protein synthesis in 9L cells coincides with the degradation of cellular 28 S and 18 S rRNA. In contrast to RNase A, onconase is resistant to two RNase inhibitors, placental ribonuclease inhibitor and Inhibit-Ace(TM). Northern hybridization with placental ribonuclease inhibitor cDNA probe indicates that 9L glioma cells contain endogenous placental ribonuclease inhibitor mRNA. Based on these results, we propose that onconase toxicity results from onconase binding to cell surface receptors, internalization to the cell cytosol where it degrades ribosomal RNA, inhibiting protein synthesis and causing cell death.	ALFACELL CORP,BLOOMFIELD,NJ 07003		WU, YN (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892, USA.							ANFINSEN CB, 1954, J BIOL CHEM, V207, P201; ARDELT W, 1991, J BIOL CHEM, V266, P245; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLANK A, 1981, BIOCHEMISTRY-US, V20, P2261, DOI 10.1021/bi00511a030; BREGNI M, 1986, CANCER RES, V46, P1208; COLLIER RJ, 1988, IMMUNOTOXINS, P25; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DIJKSTRA J, 1978, BIOCHIM BIOPHYS ACTA, V521, P363, DOI 10.1016/0005-2787(78)90278-2; ENDO Y, 1987, J BIOL CHEM, V262, P5908; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HONJO T, 1968, J BIOL CHEM, V243, P3553; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JOHNSON EA, 1961, BIOMETRICS, V17, P79, DOI 10.2307/2527497; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KAMIYA Y, 1990, J BIOCHEM-TOKYO, V108, P139, DOI 10.1093/oxfordjournals.jbchem.a123153; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KIM K, 1965, J BACTERIOL, V90, P1557, DOI 10.1128/JB.90.6.1557-1562.1965; KRAFT N, 1970, BIOCHIM BIOPHYS ACTA, V217, P164, DOI 10.1016/0005-2787(70)90133-4; KYNER D, 1979, EUR J BIOCHEM, V99, P395, DOI 10.1111/j.1432-1033.1979.tb13268.x; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEWIS M T, 1989, Protein Sequences and Data Analysis, V2, P101; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1990, CELL TISSUE KINET, V23, P237, DOI 10.1111/j.1365-2184.1990.tb01119.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEWTON DL, 1992, J BIOL CHEM, V267, P19572; NITTA K, 1987, CANCER RES, V47, P4877; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; OLSNES S, 1976, J BIOL CHEM, V251, P3985; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; ROTH JS, 1962, BIOCHIM BIOPHYS ACTA, V61, P903, DOI 10.1016/0926-6550(62)90007-5; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; VANTIELMENKVELD GJ, 1982, J BACTERIOL, V150, P490, DOI 10.1128/JB.150.2.490-497.1982; WATSON DH, 1979, NATURE, V278, P278; YOULE RJ, 1993, IN PRESS CRIT REV TH	46	235	247	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10686	10693						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486718				2022-12-25	WOS:A1993LB80000101
J	MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S				MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S			LACK OF C-JUN EXPRESSION IN A TRANSFORMED-CELL LINE ISOLATED BY GLUCOCORTICOID PROMOTION OF RAS-TRANSFECTED RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article							GROWTH ARREST; DNA-BINDING; ONCOGENE; DOMAIN; COOPERATION; ACTIVATION; REQUIRES; PROTEINS; RECEPTOR; HORMONE	Rat embryo fibroblasts (REFs) are inefficiently transformed by the T24-ras oncogene. A contributing factor to cellular resistance to transformation is the limited tolerance to p21-ras oncoprotein expression. Here we present data suggesting that long-term glucocorticoid treatment of ras oncogene-transfected REFs results in increased tolerance to p21-ras oncoproteins, leading to expression of the transformed phenotype. Stably transformed cell lines that expressed high levels of H-ras and could be maintained in the absence of hormone were isolated. In three out of four tines studied, the AP-1-dependent collagenase gene was expressed at a low level. In one of these lines, low collagenase expression was paralleled by lack of c-jun mRNA. Immunochemical analysis revealed that progression to hormone independence was not paralleled by mutations in the p53 gene. We propose that a decreased expression of AP-1-driven genes may result in increased tolerance to p21-ras oncoprotein.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CUZIN F, 1984, CANCER CELL, V2, P109; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOTTO GP, 1985, NATURE, V318, P472; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1987, ONCOGENE, V1, P47; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, ONCOGENE, V6, P669; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, VIROLOGY, V179, P78, DOI 10.1016/0042-6822(90)90276-W; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MARTENS I, 1988, P NATL ACAD SCI USA, V85, P5571, DOI 10.1073/pnas.85.15.5571; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUINN CO, 1990, J BIOL CHEM, V265, P22342; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUBIN E, 1992, CANCER RES, V52, P878; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMASHITA T, 1988, INT J CANCER, V42, P930, DOI 10.1002/ijc.2910420624; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	53	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1303	1309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479751				2022-12-25	WOS:A1993KY32800023
J	GIULIVI, C; DAVIES, KJA				GIULIVI, C; DAVIES, KJA			DITYROSINE AND TYROSINE OXIDATION-PRODUCTS ARE ENDOGENOUS MARKERS FOR THE SELECTIVE PROTEOLYSIS OF OXIDATIVELY MODIFIED RED-BLOOD-CELL HEMOGLOBIN BY (THE 19-S) PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; COLI GLUTAMINE-SYNTHETASE; MIXED-FUNCTION OXIDATION; OXYGEN RADICALS; ESCHERICHIA-COLI; DENATURED PROTEINS; MULTICATALYTIC PROTEASE; HORSERADISH-PEROXIDASE; MAMMALIAN-CELLS; SKELETAL-MUSCLE	Cells exposed to oxidative stress have been shown previously to exhibit both protein oxidation and increased proteolysis. Experiments conducted with purified proteins in vitro have indicated that oxidatively modified proteins may be selectively degraded by intracellular proteases, but a definitive cause-and-effect relationship has not been demonstrated previously in intact cells. Several investigators have proposed that oxidatively modified proteins are selectively degraded within cells, but the possibility that oxidants may activate intracellular proteases (directly or indirectly) to catalyze the indiscriminate degradation of undamaged proteins has not been discounted. Armed with the knowledge that dityrosine is a specific product of protein oxidation, we undertook a series of experiments to test the hypothesis that oxidized proteins undergo selective intracellular degradation. Our results demonstrate that dityrosine is produced in the hemoglobin molecule when red blood cells are exposed to a continuous flux of hydrogen peroxide (H2O2). The dityrosine so produced is only released from the hemoglobin by proteolysis and is stable to prolonged incubation with cell extracts. Inhibitors of proteolysis have no effect on dityrosine production but do effectively prevent dityrosine release. Proteasome (the 670-kDa multicatalytic proteinase complex, that we have previously called macroxyproteinase or MOP (Pacifici, R. E., Salo, D. C., and Davies, K. J. A. (1989) Free Radical Biol. & Med. 7, 521-526; Salo, D. C., Pacifici, R. E., Lin, S. W., Giulivi, C., and Davies, K. J. A. (1990) J. Biol. Chem. 265, 11919-11927; Pacifici, R. E., and Davies, K. J. A. (1991) Gerontology 37, 166-180) appears responsible for dityrosine release during the selective degradation of oxidatively modified proteins in red blood cells and red cell extracts. We conclude that the elevated rates of proteolysis observed in response to oxidative stress do, indeed, reflect selective degradation of oxidatively modified (damaged) proteins. Despite a relatively low production rate, dityrosine has a high fluorometric quantum yield and is, of course, a specific product of protein oxidation. As an apparently stable metabolic end product, dityrosine may prove to be an extremely valuable (cellular or urinary) marker or index of organismal oxidative stress.	ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,47 NEW SCOTLAND AVE,ALBANY,NY 12208; UNIV SO CALIF,INST TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT BIOCHEM,LOS ANGELES,CA 90033	Albany Medical College; University of Southern California; University of Southern California			Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435; Davies, Kelvin/0000-0001-7790-3003	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R56ES003598, R23ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKHAYAT O, 1987, P NATL ACAD SCI USA, V84, P1595, DOI 10.1073/pnas.84.6.1595; ANDERSEN SO, 1964, BIOCHIM BIOPHYS ACTA, V93, P213, DOI 10.1016/0304-4165(64)90289-2; ARMON T, 1990, J BIOL CHEM, V265, P20723; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P225, DOI 10.1016/0891-5849(88)90016-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DAVIES KJA, 1988, INT COMMITTEE PROTEO, P3; DAVIES KJA, 1990, CELLULAR ANTIOXIDANT, P123; DAVIES KJA, 1985, CELLULAR MOL ASPECTS, P15; DAVIES KJA, 1988, LIPID PEROXIDATION B, P101; DAVIES KJA, 1981, OXIDATIVE DAMAGE REP; DAVIES KJA, 1988, ROLE OXYGEN RADICALS, P169; DEAN RT, 1985, BIOCHEM BIOPH RES CO, V126, P1082, DOI 10.1016/0006-291X(85)90296-7; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GARCIACASTINEIRAS S, 1978, SCIENCE, V199, P897, DOI 10.1126/science.622574; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1988, INT COMMITTEE PROTEO, P4; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KIKUGAWA K, 1991, LIPIDS, V26, P922, DOI 10.1007/BF02535978; LABELLA F, 1967, BIOCHEM BIOPH RES CO, V26, P748, DOI 10.1016/S0006-291X(67)80137-2; LABELLA F, 1968, BIOCHEM BIOPH RES CO, V30, P333, DOI 10.1016/0006-291X(68)90746-8; LEHRER SS, 1967, BIOCHEMISTRY-US, V6, P757, DOI 10.1021/bi00855a017; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MISRA HP, 1972, J BIOL CHEM, V247, P6960; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; ORLOWSKI M, 1988, BIOCHEM J, V255, P751; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PACIFICI RE, 1988, FASEB J, V2, pA1007; PACIFICI RE, 1991, OXIDATIVE DAMAGE & REPAIR, P364; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PENNELL RB, 1964, RED BLOOD CELL, P53; PRTZ WA, 1983, INT J RADIAT BIOL, V44, P183; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIVETT AJ, 1989, BIOCHEM J, V263, P625, DOI 10.1042/bj2630625; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; RYTER SW, 1990, BIOL OXIDATION SYSTE, V2, P929; SALO DC, 1990, J BIOL CHEM, V265, P11919; SALO DC, 1988, FREE RADICAL BIO MED, V5, P335, DOI 10.1016/0891-5849(88)90105-0; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TEW D, 1988, J BIOL CHEM, V263, P17880; URSINI F, 1990, PROTEIN METABOLISM A, P373; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	76	179	189	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8752	8759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473319				2022-12-25	WOS:A1993KX81100057
J	HU, NM; MILLS, DA; HUCHZERMEYER, B; RICHTER, ML				HU, NM; MILLS, DA; HUCHZERMEYER, B; RICHTER, ML			INHIBITION BY TENTOXIN OF COOPERATIVITY AMONG NUCLEOTIDE BINDING-SITES ON CHLOROPLAST COUPLING FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; FACTOR-I; BETA-SUBUNIT; EPSILON-SUBUNIT; ATP SYNTHASE; CONFORMATION; HYDROLYSIS; ACTIVATION; MECHANISM	Tentoxin, a cyclic tetrapeptide produced by the fungus Alternaria tenuis, is a potent inhibitor of the chloroplast coupling factor 1 from certain sensitive species of plants. We have shown that the beta subunit is at least partly responsible for conferring sensitivity to the toxin. This was confirmed by Avni et al. (Avni, A., Anderson, J. D., Holland, N., Rochaix, J-D., Gromet-Elhanan, Z., and Edelman, M. (1992) Science 257, 1245-1247) who demonstrated the importance for tentoxin sensitivity of an acidic amino acid residue at position 83 in the beta subunit sequence. In this paper we show that the Ca2+-ATPase and Mg2+-ATPase activities of CF1 lacking the delta and epsilon subunits, CF1(-deltaepsilon), were fully sensitive to tentoxin, even after the gamma subunit is cleaved by trypsin into several smaller fragments. We also show that the isolated reconstitutively active beta subunit of CF1 does not effectively compete with CF1(-deltaepsilon) for tentoxin binding. The results suggest that tight tentoxin binding requires the presence of at least the alpha and beta subunits but is independent of the delta and epsilon subunits. Tentoxin inhibited the release of a tightly bound molecule of ADP from CF1, which was induced by the binding of the ATP analogue adenylyl-beta,gamma-imidodiphosphate (AMP-PNP). AMP-PNP was shown previously (Shapiro, A. B., and McCarty, R. E. (1990) J. Biol. Chem. 265, 4340-4347) to cause two adenine nucleotide binding sites on CF1, sites 1 and 3, to switch their properties, possibly as part of an alternating site catalytic cooperativity mechanism (Boyer, P. D. (1989) FASEB J. 3, 2164-2178). It is proposed that the effect of tentoxin on catalytic cooperativity in CF1 results from tentoxin binding at an interface between alpha and beta subunits, preventing transfer of information between different nucleotide binding sites on the enzyme.	UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045; HANNOVER SCH VET MED,INST BOT,W-3000 HANNOVER 1,GERMANY	University of Kansas; University of Veterinary Medicine Hannover, Foundation			Huchzermeyer, Bernhard/AAF-5071-2020					ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ANTHON GE, 1983, BIOCHIM BIOPHYS ACTA, V723, P358, DOI 10.1016/0005-2728(83)90041-5; ARANA JL, 1982, J BIOL CHEM, V257, P1125; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BAIRD BA, 1976, J BIOL CHEM, V251, P6953; BARZVI D, 1983, FEBS LETT, V160, P233, DOI 10.1016/0014-5793(83)80973-9; BARZVI D, 1984, BIOCHIM BIOPHYS ACTA, V765, P340, DOI 10.1016/0005-2728(84)90174-9; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1981, BIOCHEMISTRY-US, V20, P6298, DOI 10.1021/bi00525a003; CERIONE RA, 1981, BIOCHEMISTRY-US, V20, P3359, DOI 10.1021/bi00515a008; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; DUNCAN TM, 1986, FEBS LETT, V208, P1, DOI 10.1016/0014-5793(86)81519-8; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; FROMME P, 1992, Z NATURFORSCH C, V47, P239; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GROMETELHANAN G, 1992, BIOCHIM BIOPHYS ACTA, V1102, P379; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LECKBAND D, 1987, BIOCHEMISTRY-US, V26, P2306, DOI 10.1021/bi00382a035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MILLS DA, 1990, CURRENT PROGR PHOTOS, V3, P6; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; NALIN CM, 1977, BIOCHEMISTRY-US, V24, P2318; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; RICHTER ML, 1987, PROGR PHOTOSYNTHESIS, V3, P53; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHOSHAN V, 1979, J BIOL CHEM, V254, P8808; SNYDER B, 1985, BIOCHEMISTRY-US, V24, P2324, DOI 10.1021/bi00330a030; SNYDER B, 1984, BIOCHEMISTRY-US, V23, P5787, DOI 10.1021/bi00319a018; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; STEELE JA, 1977, BIOCHIM BIOPHYS ACTA, V459, P347, DOI 10.1016/0005-2728(77)90036-6; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; YU F, 1985, ARCH BIOCHEM BIOPHYS, V238, P61, DOI 10.1016/0003-9861(85)90140-7	51	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8536	8540						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473298				2022-12-25	WOS:A1993KX81100027
J	JONES, DA; CARLTON, DP; MCINTYRE, TM; ZIMMERMAN, GA; PRESCOTT, SM				JONES, DA; CARLTON, DP; MCINTYRE, TM; ZIMMERMAN, GA; PRESCOTT, SM			MOLECULAR-CLONING OF HUMAN PROSTAGLANDIN ENDOPEROXIDE SYNTHASE TYPE-II AND DEMONSTRATION OF EXPRESSION IN RESPONSE TO CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; MESSENGER-RNA; PROSTACYCLIN SYNTHESIS; PHORBOL ESTER; G/H SYNTHASE; HEME-BINDING; CYCLOOXYGENASE; GENE; STIMULATION; ENCODES	Prostaglandin endoperoxide synthase (PHS) catalyzes the committed step in the biosynthesis of prostaglandins and thromboxane. We recently observed dissociation of PHS activity and enzyme mass measured in an immunoassay of endothelial cells exposed to tumor necrosis factor. These data and observations by others suggested that endothelial cells express an alternate PHS. We now report the molecular cloning of human PHS type II from an endothelial cell cDNA library. The protein encoded by this cDNA shares 61% identity with the human PHS I. Southern analysis demonstrated a single copy of PHS II and we found a polymorphism in approximately 5% of the population. PHS II mapped to chromosome 1, in contrast to PHS I, which is on chromosome 9. The PHS II cDNA hybridized strongly to a 4.3-kilobase (kb) message from endothelial cells. Stimulation of the cells with tumor necrosis factor, phorbol 12-myristate 13-acetate, lipopolysaccharide, or interleukin-1 increased mRNA levels for PHS II, and this change correlated well with increased prostacyclin biosynthesis. Cycloheximide induced PHS II mRNA without a corresponding activity increase demonstrating that translation of the 4.3-kb message is required for increased prostacyclin biosynthesis. We conclude that expression of PHS II may have important pathophysiological effects in the vasculature.			JONES, DA (corresponding author), UNIV UTAH, NORA ECCLES HARRISON CARDIOVASC RES TRAINING INST, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA.				NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034127, R01HL044525, R37HL044525] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA42014] Funding Source: Medline; NHLBI NIH HHS [HL34127, HL44525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; CARLTON DP, 1992, CLIN RES, V40, pA193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Fourney R.M., 1988, FOCUS, V10, P5; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INGERMANWOJENSKI CM, 1988, PROSTAGLANDINS, V36, P127, DOI 10.1016/0090-6980(88)90300-0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAGGART RT, 1985, P NATL ACAD SCI USA, V82, P6240, DOI 10.1073/pnas.82.18.6240; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	36	700	724	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9049	9054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473346				2022-12-25	WOS:A1993KX81100095
J	LI, KH; TAMAI, K; TAN, EML; UITTO, J				LI, KH; TAMAI, K; TAN, EML; UITTO, J			CLONING OF TYPE-XVII COLLAGEN - COMPLEMENTARY AND GENOMIC DNA-SEQUENCES OF MOUSE 180-KILODALTON BULLOUS PEMPHIGOID ANTIGEN (BPAG2) PREDICT AN INTERRUPTED COLLAGENOUS DOMAIN, A TRANSMEMBRANE SEGMENT, AND UNUSUAL FEATURES IN THE 5'END OF THE GENE AND THE 3'-UNTRANSLATED REGION OF THE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; EXPRESSION; AUTOANTIGEN; CHAIN; SKIN	Thus far, 16 distinct vertebrate collagens (types I-XVI) have been delineated. In this study, we have cloned a mouse collagenous protein, the 180-kDa bullous pemphigoid antigen (BPAG2). Isolation of overlapping clones, together with 5' and 3' rapid amplification of cDNA ends, allowed delineation of the entire coding sequence. The 5' and 3' ends of the mRNA transcripts were confirmed by primer extension and anchored reverse transcription polymerase chain reaction analyses. The deduced polypeptide contained 1,433 amino acids, including a collagenous domain that consisted of 13 separate segments. Computer analysis of the deduced amino acid sequence demonstrated the presence of a membrane-associated segment. Examination of the 5' end of the BPAG2 gene revealed that the 295-base pair (bp) exon 1 contained two segments of (T)13AA and TT(A)11, whereas exon 2 was shown to contain the translation initiation codon. The 3' end of the mRNA transcript identified two 6-bp inverted repeat sequences that could form a stem for a 30-bp hairpin loop followed by a series of U residues. Comparison of mouse and human BPAG2 sequences demonstrated 86% homology and the unit of evolutionary period of 4.2 million years. In summary, we have cloned full-length mouse BPAG2 cDNA sequences that encode a collagenous polypeptide. We propose that this polypeptide be designated as the alpha1-chain of type XVII collagen.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST,RM 450,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1990, J INVEST DERMATOL, V95, P252, DOI 10.1111/1523-1747.ep12484863; BERNARD P, 1992, J INVEST DERMATOL, V99, P174, DOI 10.1111/1523-1747.ep12616797; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTIANO AM, 1992, HUM MOL GENET, V1, P475, DOI 10.1093/hmg/1.7.475; Chu Mon-Li, 1993, P149; COPELAND NG, 1993, GENOMICS, V15, P180, DOI 10.1006/geno.1993.1027; DENG G, 1981, NUCLEIC ACIDS RES, V9, P4173, DOI 10.1093/nar/9.16.4173; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; FAZIO MJ, 1988, LAB INVEST, V58, P270; Frohman MA, 1990, PCR PROTOCOLS GUIDE; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GIUDICE GJ, 1991, CLIN RES, V39, P478; HART GW, 1979, J BIOL CHEM, V254, P9747; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABIB RS, 1986, J IMMUNOL, V136, P1231; LI K, 1991, J BIOL CHEM, V266, P24064; LI K, J INVEST DERMATOL, V99, P258; MARCHANT JK, 1991, P NATL ACAD SCI USA, V88, P1560, DOI 10.1073/pnas.88.4.1560; MORRISON LH, 1988, J CLIN INVEST, V81, P2023, DOI 10.1172/JCI113554; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Piez K.A., 1976, BIOCH COLLAGENS, P1; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1992, NEW ENGL J MED, V326, P540; RYYNANEN J, 1991, J INVEST DERMATOL, V97, P562, DOI 10.1111/1523-1747.ep12481896; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; UITTO J, 1992, J INVEST DERMATOL, V98, P391, DOI 10.1111/1523-1747.ep12499822; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAGATA M, 1991, J CELL BIOL, V115, P209, DOI 10.1083/jcb.115.1.209	46	173	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8825	8834						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473327				2022-12-25	WOS:A1993KX81100067
J	NACHTIGAL, MW; NICKEL, BE; CATTINI, PA				NACHTIGAL, MW; NICKEL, BE; CATTINI, PA			PITUITARY-SPECIFIC REPRESSION OF PLACENTAL MEMBERS OF THE HUMAN GROWTH-HORMONE GENE FAMILY - A POSSIBLE MECHANISM FOR LOCUS REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC SOMATOMAMMOTROPIN; 5'-FLANKING REGION; HUMAN-PROLACTIN; TUMOR-CELLS; EXPRESSION; BINDING; TRANSCRIPTION; ACTIVATION; SEQUENCES; EVOLUTION	Five members of the human growth hormone (GH) gene family are located at a single locus on chromosome 17. Growth hormone is expressed in the pituitary under the control of the tissue-specific factor Pit 1/GHF-1, and chorionic somatomammotropin (CS) -A, -B, and -L, as well as placental GH variant, are expressed specifically in the placental syncytiotrophoblast. Despite this specificity in vivo, the CS-A promoter can bind Pit 1/GHF-1 and allow CS-A promoter activity in pituitary tumor cells after gene transfer. We have identified and characterized PSF sequences associated with only the placental members in the GH/CS locus which repress placental promoter activity >90% in transfected pituitary cells. These sequences do not significantly affect promoter function in placental cells after gene transfer. Repressor activity correlates with binding of protein at two sites (PSF-A and PSF-B) with pituitary, but not placental, nuclear extracts. Competition studies suggest an interaction between PSF and Pit 1/GHF-1 proteins. These results indicate that PSF protein can repress CS-A promoter activity in a tissue-specific manner in vitro and provide a possible mechanism by which expression of placental members of the GH family are inhibited in the pituitary in vivo.	UNIV MANITOBA,DEPT PHYSIOL,770 BANNATYNE AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba				Nachtigal, Mark/0000-0003-3291-8628				BALDWIN AS, 1990, DNA PROTEIN ENG TECH, V2, P73; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTINI PA, 1986, DNA-J MOLEC CELL BIO, V5, P503, DOI 10.1089/dna.1.1986.5.503; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DAVIDSON RL, 1966, P NATL ACAD SCI USA, V56, P1437, DOI 10.1073/pnas.56.5.1437; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DUCKWORTH ML, 1993, IN PRESS TROPHOBLAST; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; HJELLE BL, 1982, NUCLEIC ACIDS RES, V10, P3459, DOI 10.1093/nar/10.11.3459; IMMONS DM, 1990, GENE DEV, V4, P695; JACKSONGRUSBY LL, 1988, ENDOCRINOLOGY, V122, P2462, DOI 10.1210/endo-122-6-2462; JONES BK, 1992, 74TH M END SOC SAN A; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEMAIGRE FP, 1989, DNA-J MOLEC CELL BIO, V8, P149, DOI 10.1089/dna.1.1989.8.149; LEW AM, 1991, NUCLEIC ACIDS RES, V19, P6329, DOI 10.1093/nar/19.22.6329; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NACHTIGAL MW, 1993, IN PRESS TROPHOBLAST; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; NICKEL BE, 1991, MOL CELL BIOCHEM, V106, P181; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	35	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8473	8479						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473291				2022-12-25	WOS:A1993KX81100018
J	SALEHZADA, T; SILHOL, M; STEFF, AM; LEBLEU, B; BISBAL, C				SALEHZADA, T; SILHOL, M; STEFF, AM; LEBLEU, B; BISBAL, C			2',5'-OLIGOADENYLATE-DEPENDENT RNASE-L IS A DIMER OF REGULATORY AND CATALYTIC SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; INTACT-CELLS; CONSTITUTIVE EXPRESSION; MONOCLONAL-ANTIBODIES; 2-5A-DEPENDENT RNASE; 2-5A SYNTHETASE; ACTIVATION; ENZYME; ENDONUCLEASE; DERIVATIVES	The subunit composition of RNase L, a key enzyme in the interferon system, has been characterized. RNase L was purified from human Daudi cells on a column of 2-5A-Sepharose and used to immunize Balb/c mice. A specific monoclonal antibody which recognizes a protein of 80 kDa has been isolated. This protein has been characterized and shown to be an RNA-binding protein with nuclease activity which is associated with, but distinct from, the 80-kDa 2-5A-binding protein known previously as RNase L. It is therefore proposed that the 2-5A-dependent RNase L is a complex of two distinct subunits: an 80-kDa RNA-binding protein (i.e. the catalytic subunit) and an 80-kDa 2-5A-binding protein (i.e. the regulatory subunit).	UNIV MONTPELLIER 2,BIOCHIM PROT LAB,CNRS,URA 1191,F-34095 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Bisbal, Catherine/I-6984-2016	Bisbal, Catherine/0000-0003-1086-020X; Steff, Ann-Muriel/0000-0002-9817-6164				BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BAYARD B, 1986, BIOCHEMISTRY-US, V25, P3730, DOI 10.1021/bi00360a038; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; CHARACHON G, 1990, BIOCHEMISTRY-US, V29, P2550, DOI 10.1021/bi00462a017; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; FLOYDSMITH G, 1982, J BIOL CHEM, V257, P8584; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; GALABRU J, 1985, J GEN VIROL, V66, P711, DOI 10.1099/0022-1317-66-4-711; GALEN FX, 1984, J CLIN INVEST, V74, P723, DOI 10.1172/JCI111488; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PIECHACZYK M, 1985, HYBRIDOMA, V4, P361, DOI 10.1089/hyb.1985.4.361; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SALEHZADA T, 1991, ANAL BIOCHEM, V196, P410, DOI 10.1016/0003-2697(91)90486-D; SALEHZADA T, 1991, J BIOL CHEM, V266, P5808; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1981, EUR J BIOCHEM, V115, P79; SILVERMAN RH, 1985, INTERFERON 3J, P177; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4340; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571	27	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7733	7740						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463302				2022-12-25	WOS:A1993KW97900025
J	CASTEELS, P; AMPE, C; JACOBS, F; TEMPST, P				CASTEELS, P; AMPE, C; JACOBS, F; TEMPST, P			FUNCTIONAL AND CHEMICAL CHARACTERIZATION OF HYMENOPTAECIN, AN ANTIBACTERIAL POLYPEPTIDE THAT IS INFECTION-INDUCIBLE IN THE HONEYBEE (APIS-MELLIFERA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPROVED ANTIMICROBIAL ACTIVITY; SYNTHETIC MAGAININ ANALOGS; GRAM-NEGATIVE BACTERIA; AMINO-ACID-SEQUENCE; CELL-FREE IMMUNITY; HYALOPHORA-CECROPIA; ESCHERICHIA-COLI; OUTER-MEMBRANE; SARCOPHAGA-PEREGRINA; INSECT IMMUNITY	As part of our ongoing search for novel antimicrobial agents and their use in singular or combined drug therapy, we have isolated a series of polypeptides from the lymph fluid of honeybees. These polypeptides are synthesized de novo, following experimental infection of the insect with live Escherichia coli cells, and confer a broad-spectrum antibacterial defense to the host. We have dissected this humoral ''immune'' system into its constituent components. In addition to the previously characterized apidaecins and abaecin, we also isolated a member of the defensin family of peptide antibiotics and, now, a novel 93-amino acid long, cationic polypeptide, termed hymenoptaecin. Detailed analysis established the complete chemical structure, including a 2-pyrrolidone-5-carboxylic acid at the N terminus, and indicated major differences with all known antibacterial polypeptides. Under physiological conditions, it inhibits viability of Gram-negative and Gram-positive bacteria, including several human pathogens. Lethal effects against E. coli are secondary to sequential permeabilization of outer and inner membrane. In combination, the six-constituent ''peptide antibiotics'' of bee lymph provide wide-spectrum antibacterial protection in vitro by virtue of complementarity rather than synergism.	CORNELL UNIV,GRAD SCH MED SCI,ITHACA,NY 14853; PLANT GENET SYST NV,GHENT,BELGIUM; STATE UNIV GHENT,DEPT ZOOPHYSIOL,B-9000 GHENT,BELGIUM	Cornell University; Bayer AG; Bayer CropScience; Ghent University	CASTEELS, P (corresponding author), MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ampe, Christophe/B-5534-2012					AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; ANDO K, 1987, BIOCHEMISTRY-US, V26, P226, DOI 10.1021/bi00375a030; BANGALORE N, 1990, J BIOL CHEM, V265, P13584; BANKS J G, 1986, Biotechnology and Applied Biochemistry, V8, P103; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; Borror DJ, 1981, INTRO STUDY INSECTS; BULET P, 1991, J BIOL CHEM, V266, P24520; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1990, RES IMMUNOL, V141, P957; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; DELORENZO V, 1985, ANTIMICROB AGENTS CH, V27, P666, DOI 10.1128/AAC.27.4.666; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIMARCQ JL, 1990, EMBO J, V9, P2507, DOI 10.1002/j.1460-2075.1990.tb07430.x; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; ENGSTROM A, 1984, EMBO J, V3, P2065, DOI 10.1002/j.1460-2075.1984.tb02092.x; ENGSTROM P, 1984, EMBO J, V3, P3347, DOI 10.1002/j.1460-2075.1984.tb02302.x; FAYE I, 1975, INFECT IMMUN, V12, P1426, DOI 10.1128/IAI.12.6.1426-1438.1975; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GUDMUNDSSON GH, 1991, J BIOL CHEM, V266, P11510; HANCOCK REW, 1984, ANTIMICROB AGENTS CH, V26, P48, DOI 10.1128/AAC.26.1.48; HOFFMANN JA, 1990, RES IMMUNOL, V141, P910, DOI 10.1016/0923-2494(90)90192-2; HOLDEN C, 1989, SCIENCE, V246, P754, DOI 10.1126/science.2814497; Joklik WK, 1992, ZINSSER MICROBIOLOGY; KEPPI E, 1989, ARCH INSECT BIOCHEM, V10, P229, DOI 10.1002/arch.940100306; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1988, J IMMUNOL METHODS, V108, P153, DOI 10.1016/0022-1759(88)90414-0; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; MATIN A, 1989, ANNU REV MICROBIOL, V43, P293, DOI 10.1146/annurev.mi.43.100189.001453; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; Metchnikoff I, 1893, LECT COMP PATHOLOGY; NATORI S, 1977, J INSECT PHYSIOL, V23, P1169, DOI 10.1016/0022-1910(77)90149-4; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; OKADA M, 1985, BIOCHEM J, V229, P453, DOI 10.1042/bj2290453; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; Paillot A, 1920, CR SOC BIOL, V83, P278; RIVIERE LR, 1991, TECHNIQUES PROTEIN C, V2, P171; RUSSELL AD, 1991, UNDERSTANDING ANTIBA; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P545, DOI 10.1128/JB.108.1.545-552.1971; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; SPACH G, 1989, BIOCHIMIE, V71, P11, DOI 10.1016/0300-9084(89)90126-0; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; TEMPST P, 1986, J CHROMATOGR, V359, P403, DOI 10.1016/0021-9673(86)80094-2; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; URRUTIA R, 1989, FEBS LETT, V247, P17, DOI 10.1016/0014-5793(89)81230-X; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; WESTERHOFF HV, 1989, P NATL ACAD SCI USA, V86, P6597, DOI 10.1073/pnas.86.17.6597; WICKER C, 1990, J BIOL CHEM, V265, P22493; WRIGHT SD, 1981, J IMMUNOL, V127, P1146; Zernoff V, 1928, CR SOC BIOL, V99, P315	69	227	249	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7044	7054						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463238				2022-12-25	WOS:A1993KV14100037
J	SHNEIDER, BL; MOYER, MS				SHNEIDER, BL; MOYER, MS			CHARACTERIZATION OF ENDOGENOUS CARRIER-MEDIATED TAUROCHOLATE EFFLUX FROM XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER CANALICULAR MEMBRANE; ACID TRANSPORT-SYSTEM; RAT-LIVER; FUNCTIONAL EXPRESSION; VESICLES; CLONING	Taurocholate efflux was studied in Xenopus laevis oocytes and is consistent with a carrier-mediated process. This carrier can be competitively inhibited and trans stimulated by glycocholate. Transport is also trans stimulated by taurochenodeoxycholate and S-hexylglutathione, but not taurolithocholate or daunomycin, reflecting a range of specificity including substrates of both the hepatic canalicular bile acid transporter and the multispecific organic anion transporter. In addition, ATP added to the outside of the oocyte results in an increase in the maximal velocity of this transport process. The physiologic function of this endogenous carrier is not known, but it may act as a generalized system for the efflux of potentially toxic organic anions.			SHNEIDER, BL (corresponding author), YALE UNIV, SCH MED,DEPT PEDIAT, DIV PEDIAT GASTROENTEROL HEPATOL,333 CEDAR ST, BOX 3333, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042673] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 07388] Funding Source: Medline; NIGMS NIH HHS [GM 42673] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1991, HEPATOLOGY, V14, P655, DOI 10.1016/0270-9139(91)90053-X; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BEAN BP, 1990, J NEUROSCI, V10, P1; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEBER R, 1992, J NEUROCHEM, V58, P1165; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; KLINGENBERG M, 1989, METHOD ENZYMOL, V171, P12; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; Reisin I. L., 1992, Journal of General Physiology, V100, p33A; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; UCHIDA S, 1991, J BIOL CHEM, V266, P9605; WANG HC, 1991, INT J BIOCHEM, V23, P271	18	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6985	6988						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463231				2022-12-25	WOS:A1993KV14100030
J	TURK, B; KRIZAJ, I; KRALJ, B; DOLENC, I; POPOVIC, T; BIETH, JG; TURK, V				TURK, B; KRIZAJ, I; KRALJ, B; DOLENC, I; POPOVIC, T; BIETH, JG; TURK, V			BOVINE STEFIN-C, A NEW MEMBER OF THE STEFIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-PROTEINASE-INHIBITOR; AMINO-ACID-SEQUENCE; EGG-WHITE CYSTATIN; HUMAN POLYMORPHONUCLEAR GRANULOCYTES; RAY CRYSTAL-STRUCTURE; LOW-MOLECULAR WEIGHT; CATHEPSIN-B; CHICKEN CYSTATIN; COVALENT CHROMATOGRAPHY; PROTEASE INHIBITOR	Four low M(r) cysteine proteinase inhibitors with different pI values were isolated from bovine thymus using alkaline activation of the gland homogenate, affinity chromatography on carboxymethyl-papain-Sepharose, gel filtration on Sephadex G-50, ion-exchange chromatography on a DEAE-cellulose column and a fast protein liquid chromatography Mono Q column, and hydrophobic chromatography on a TSK Phenyl-5 PW column. One of the inhibitors was identified both as the monomeric and dimeric forms of stefin B. Two others, called cysteine proteinase inhibitor-1 and cysteine proteinase inhibitor-2, were N terminally blocked and most likely belong to the stefin family. The complete amino acid sequence of the last inhibitor, namely bovine stefin C, was determined. The inhibitor consisted of 101 amino acids and its M(r) was calculated to be 11,546. It exhibits considerable sequence homology with other inhibitors from the stefin family. It was identified as the first tryptophane-containing stefin and it had a prolonged N terminus. The four inhibitors had similar inhibitory activities on cysteine proteinases. They were fast-acting inhibitors of papain and cathepsin L (k(ass) greater-than-or-equal-to 1.8 x 106 M-1 s-1) and formed very tight complexes with the enzymes (K(i) less-than-or-equal-to 180 pM). In contrast, they were relatively poor inhibitors of cathepsin B (K(i) > 100 nM).	J STEFAN INST, DEPT SPECT, LJUBLJANA, SLOVENIA; UNIV LOUIS PASTEUR, ENZYMOL LAB, INSERM, U237, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE	Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	TURK, B (corresponding author), J STEFAN INST, DEPT BIOCHEM, JAMOVA 39, 61111 LJUBLJANA, SLOVENIA.			Turk, Boris/0000-0002-9007-5764				ABE K, 1988, J BIOL CHEM, V263, P7655; ABE K, 1987, J BIOL CHEM, V262, P16793; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BODE W, 1988, INTRACELLULAR PROTEO, P297; BROCKLEHURST K, 1973, BIOCHEM J, V133, P573, DOI 10.1042/bj1330573; BRZIN J, 1982, FEBS LETT, V138, P193, DOI 10.1016/0014-5793(82)80439-0; BRZIN J, 1983, H-S Z PHYSIOL CHEM, V364, P1475, DOI 10.1515/bchm2.1983.364.2.1475; BUTTLER PJG, 1972, METHOD ENZYMOL, V25, P191; GREEN GDJ, 1984, BIOCHEM J, V218, P939, DOI 10.1042/bj2180939; HIRADO M, 1984, J BIOCHEM-TOKYO, V96, P51, DOI 10.1093/oxfordjournals.jbchem.a134828; HIRADO M, 1985, FEBS LETT, V186, P41, DOI 10.1016/0014-5793(85)81335-1; HIRADO M, 1981, BIOCHIM BIOPHYS ACTA, V669, P21, DOI 10.1016/0005-2795(81)90218-X; HUSAIN SS, 1969, BIOCHEM J, V114, P279, DOI 10.1042/bj1140279; JARVINEN M, 1978, J INVEST DERMATOL, V71, P114, DOI 10.1111/1523-1747.ep12546165; JARVINEN M, 1982, BIOCHIM BIOPHYS ACTA, V708, P210, DOI 10.1016/0167-4838(82)90222-9; JERALA R, 1990, BIOL CHEM H-S, V371, P157; KONDO H, 1990, J BIOL CHEM, V265, P15832; KOPITAR M, 1989, BIOL CHEM H-S, V370, P1145, DOI 10.1515/bchm3.1989.370.2.1145; KOTNIK M, 1986, CYSTEINE PROTEINASES, P43; KRIZAJ I, 1992, FEBS LETT, V298, P237, DOI 10.1016/0014-5793(92)80066-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenarcic B., 1986, CYSTEINE PROTEINASES, P473; LINDAHL P, 1988, BIOCHEMISTRY-US, V27, P5074, DOI 10.1021/bi00414a019; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; MACHLEIDT W, 1983, H-S Z PHYSIOL CHEM, V364, P1481, DOI 10.1515/bchm2.1983.364.2.1481; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; NIKAWA T, 1989, FEBS LETT, V255, P309, DOI 10.1016/0014-5793(89)81112-3; NYCANDER M, 1990, BIOCHEM J, V271, P281, DOI 10.1042/bj2710281; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; RITONJA A, 1985, BIOCHEM BIOPH RES CO, V131, P1187, DOI 10.1016/0006-291X(85)90216-5; STROP P, 1981, J CHROMATOGR, V207, P55; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TAKEDA A, 1983, J BIOCHEM, V94, P811, DOI 10.1093/oxfordjournals.jbchem.a134423; TAKIO K, 1983, BIOCHEM BIOPH RES CO, V115, P902, DOI 10.1016/S0006-291X(83)80020-5; TAKIO K, 1984, BIOCHEM BIOPH RES CO, V121, P149, DOI 10.1016/0006-291X(84)90699-5; TCHOUPE JR, 1991, BIOCHIM BIOPHYS ACTA, V1076, P149, DOI 10.1016/0167-4838(91)90232-O; THIELE U, 1990, BIOL CHEM H-S, V371, P125; TURK B, 1992, BIOL CHEM H-S, V373, P441, DOI 10.1515/bchm3.1992.373.2.441; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; WAKAMATSU N, 1984, J BIOL CHEM, V259, P3832; ZVONAR T, 1979, CROAT CHEM ACTA, V52, P411	53	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7323	7329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463267				2022-12-25	WOS:A1993KV14100072
J	LEE, J; MORGAN, JR; TOMPKINS, RG; YARMUSH, ML				LEE, J; MORGAN, JR; TOMPKINS, RG; YARMUSH, ML			PROLINE-MEDIATED ENHANCEMENT OF HEPATOCYTE FUNCTION IN A COLLAGEN GEL SANDWICH CULTURE CONFIGURATION	FASEB JOURNAL			English	Note						PROLINE; CIS-HYDROXYPROLINE; COLLAGEN; HEPATOCYTES; ALBUMIN; PRIMARY CULTURE	CELL-MATRIX INTERACTIONS; RAT HEPATOCYTES; AMINO-ACIDS; POLYPEPTIDES; LIPOGENESIS; PROCOLLAGEN	Isolated rat primary hepatocytes were cultured between two layers of gelled collagen in a sandwich configuration that reinstates the cellular polarity necessary for long-term function in vitro. Maintenance of hepatocyte function, as measured by the secretion of albumin, was shown to be dependent on both the sandwich gel configuration and the continued presence of L-proline in the culture media. Cis-hydroxyproline, an analog of proline known to prevent the proper folding of triple helical collagen molecules, inhibited the response of sandwiched hepatocytes to proline in a dose-dependent and reversible manner. The addition of cis-hydroxyproline to cultures established for 7 days also resulted in the inhibition of hepatocyte function. These data support the hypothesis that continued collagen synthesis by hepatocytes is critical for hepatocyte function in the sandwich gel configuration.	MASSACHUSETTS GEN HOSP, SURG SERV, BOSTON, MA 02114 USA; SHRINERS BURNS INST, SURG SERV, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	LEE, J (corresponding author), RUTGERS STATE UNIV, DEPT CHEM & BIOCHEM ENGN, BRETT BOWERS RD, PISCATAWAY, NJ 08854 USA.			Morgan, Jeffrey/0000-0002-7546-3443; Yarmush, Martin/0000-0003-4986-8444	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1991, BIOCHEM J, V273, P57, DOI 10.1042/bj2730057; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; DIEGELMANN RF, 1983, SCIENCE, V219, P1343, DOI 10.1126/science.6828863; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; FELDHOFF RC, 1977, J BIOL CHEM, V252, P3611; Hay E. D., 1981, CELL BIOL EXTRACELLU; HOUCK KA, 1985, IN VITRO CELL DEV B, V21, P121, DOI 10.1007/BF02620953; HUTSON SM, 1987, AM J PHYSIOL, V252, pE291, DOI 10.1152/ajpendo.1987.252.3.E291; JIMENEZ S, 1974, ARCH BIOCHEM BIOPHYS, V163, P459, DOI 10.1016/0003-9861(74)90502-5; LEE JW, 1992, BIOTECHNOL BIOENG, V40, P298, DOI 10.1002/bit.260400214; MOORE DH, 1982, HEPATOLOGY TXB LIVER, P137; Nakane M. B., 1978, IMMUNOFLUORESCENCE R, P215; NEUMAN RE, 1949, ARCH BIOCHEM, V24, P289; Peterkofsky B, 1982, IMMUNOCHEMISTRY EXTR, VII, P19; RUOSLAHTI E, 1988, LIVER BIOL PATHOBIOL, P739; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SUGDEN MC, 1984, BIOCHIM BIOPHYS ACTA, V798, P368, DOI 10.1016/0304-4165(84)90111-9; UITTO J, 1974, BIOCHIM BIOPHYS ACTA, V336, P234, DOI 10.1016/0005-2795(74)90401-2; UITTO VJ, 1978, ARCH BIOCHEM BIOPHYS, V185, P214, DOI 10.1016/0003-9861(78)90161-3; YARMUSH ML, 1992, ANN NY ACAD SCI, V665, P238, DOI 10.1111/j.1749-6632.1992.tb42588.x; [No title captured]	26	44	47	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1993	7	6					586	591		10.1096/fasebj.7.6.8472895	http://dx.doi.org/10.1096/fasebj.7.6.8472895			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472895				2022-12-25	WOS:A1993KY00900013
J	GAO, PQ; SIMS, SH; CHANG, DC; DEISSEROTH, AB				GAO, PQ; SIMS, SH; CHANG, DC; DEISSEROTH, AB			INTERFERON-GAMMA PRIMING EFFECTS IN THE ACTIVATION AND DEACTIVATION OF ISGF3 IN K562 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC PROGENITOR CELLS; INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; ALPHA-INTERFERON; SYNTHETASE GENE; TRANSCRIPTIONAL ACTIVATOR; STIMULATED TRANSCRIPTION; PROMOTER ELEMENT; RESPONSE ELEMENT	ISGF3 is a major protein factor which mediates the transcriptional activation of interferon-inducible genes. ISGF3 is composed of two subunits, ISGF3gamma and ISGF3alpha, which are stimulated by interferon-gamma (IFN-gamma) and interferon-alpha (IFN-alpha), respectively. In this paper, the effect of pretreatment of IFN-gamma on the response of K562 cells to IFN-alpha, termed ''gamma-priming,'' is examined. Using techniques of gene transfection and mobility shift assay, we studied the gamma-priming effects on the kinetics of appearance and disappearance of (i) the protein product of a luciferase reporter gene driven by an IFN-inducible promoter and (ii) the binding of ISGF3 to the interferon-stimulated response element. We found that exposure of cells to IFN-gamma prior to IFN-alpha greatly increased both the levels and the rate of ISGF3 binding activity during the early phase of IFN-alpha treatment and caused the amount of ISGF3 bound to the interferon-stimulated response element to decrease more rapidly with time during the later phase. Such effects were reflected also on the kinetics of expression of the interferon-inducible luciferase gene induced by IFN-alpha. In order to understand the basis of these gamma-priming effects, we use an in vitro reconstitution method to examine the kinetics of the subcomponents of ISGF3 in response to different IFN treatments in K562 cells. It was found that gamma-priming not only increased the levels of ISGF3gamma, but it also stimulated both the rates of rise and fall of the activated alpha-component of ISGF3. A molecular model is proposed to explain these findings.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; GENOSYS BIOTECHNOL INC,THE WOODLANDS,TX 77381; HONG KONG UNIV SCI & TECHNOL,DEPT BIOL,HONG KONG,HONG KONG	University of Texas System; UTMD Anderson Cancer Center; Hong Kong University of Science & Technology			Chang, Donald/AAV-7180-2021		NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49639-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON P, 1982, J BIOL CHEM, V257, P1301; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BRANCA AA, 1982, J BIOL CHEM, V257, P13291; BROXMEYER HE, 1985, J IMMUNOL, V135, P2502; CARLOSTELLA C, 1988, BLOOD, V72, P1293; CHANG DC, 1989, BIOPHYS J, V56, P641, DOI 10.1016/S0006-3495(89)82711-0; CHANG DC, 1988, B AM PHYS SOC, V33, P297; CHANG DC, 1989, ELECTROPORATION ELEC, P215; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; CZARNIECKI CW, 1984, J VIROL, V49, P490, DOI 10.1128/JVI.49.2.490-496.1984; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GOETSCHY JF, 1989, J VIROL, V63, P2616, DOI 10.1128/JVI.63.6.2616-2622.1989; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HORISBERGER MA, 1987, J INTERFERON RES, V7, P331, DOI 10.1089/jir.1987.7.331; HUBBELL HR, 1987, J BIOL RESP MODIF, V6, P141; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KURZROCK R, 1987, BLOOD, V70, P943; KUSARI J, 1986, MOL CELL BIOL, V6, P2062, DOI 10.1128/MCB.6.6.2062; KUSARI J, 1987, MOL CELL BIOL, V7, P528, DOI 10.1128/MCB.7.1.528; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LARNER AC, 1986, J BIOL CHEM, V261, P453; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PINE R, 1989, MOL CELL BIOL, V9, P3533, DOI 10.1128/MCB.9.8.3533; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; RAEFSKY EL, 1985, J IMMUNOL, V135, P2507; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STRIFE A, 1990, CHRONIC MYELOGENOUS; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; VAIMAN D, 1990, FEBS LETT, V265, P12, DOI 10.1016/0014-5793(90)80871-F; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VISANI G, 1988, BLUT, V57, P41, DOI 10.1007/BF00320633	53	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12380	12387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509377				2022-12-25	WOS:A1993LG65800027
J	NAKAMURA, S; TAKASAKI, H; KOBAYASHI, K; KATO, A				NAKAMURA, S; TAKASAKI, H; KOBAYASHI, K; KATO, A			HYPERGLYCOSYLATION OF HEN EGG-WHITE LYSOZYME IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE CHAINS; PROTEIN GLYCOSYLATION; CARBOXYPEPTIDASE-Y; ACID-PHOSPHATASE; GLYCOPROTEINS; INHIBITORS	The large molecular size of N-glycosylated lysozyme with a polymannose chain was predominantly expressed in the yeast carrying the lysozyme expression plasmid in 9-fold greater secretion compared with the wild type. Complementary DNA encoding hen egg white lysozyme was subjected to site-directed mutagenesis to obtain the Asn-X-Ser/Thr sequence that is the signal for asparagine-linked (N-linked) glycosylation. At positions 49, 67, 70, and 103, the signal for N-linked glycosylation was created. Only the mutant lysozyme whose glycine 49 was substituted with asparagine was expressed in the two types of glycosylated forms, a small oligomannose chain (Man18GlcNAc2)-linked form and a large polymannose chain (Man310GlcNAc2)-linked form, whereas other mutants were not glycosylated. The secreted amount of polymannosyl lysozyme was much higher than that of the oligomannosyl lysozyme. Both types of glycosylated lysozymes were susceptible to endo-beta-N-acetyl-glucosaminidase cleavage of their carbohydrate chains. The average molecular masses of oligomannosyl and polymannosyl lysozymes were 18 and 71 kDa, respectively. The length of the polymannose chain was found to be 200-350 residues/molecule of lysozyme according to the estimation of the molecular mass distribution by low angle laser light scattering measurements. The protein conformation estimated by CD analysis was completely conserved in these glycosylated lysozymes. The enzymatic activities of oligomannosyl and polymannosyl lysozymes were 100 and 91%, respectively, of wild-type protein when glycol chitin was used as a substrate. In addition, the polymannosyl lysozyme revealed remarkable heat stability in that no coagulation was observed under conditions in which the wild-type lysozyme coagulated. Thus, this novel glycoprotein can be used as a reporter in studies of the processing and sorting of glycoproteins and as a model of the expression of foreign genes in yeast for the construction of stable enzymes.	YAMAGUCHI UNIV,DEPT BIOCHEM,YAMAGUCHI 753,JAPAN; UBE COLL,DEPT FOOD & NUTR,YAMAGUCHI 755,JAPAN	Yamaguchi University								BALLOU CE, 1974, SCIENCE, V184, P127, DOI 10.1126/science.184.4133.127; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BARBARIC S, 1984, ARCH BIOCHEM BIOPHYS, V234, P567, DOI 10.1016/0003-9861(84)90305-9; CHU FK, 1985, BIOCHEMISTRY-US, V24, P6125, DOI 10.1021/bi00343a014; CHU FK, 1982, ARCH BIOCHEM BIOPHYS, V214, P134, DOI 10.1016/0003-9861(82)90015-7; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; IMOTO T, 1971, AGR BIOL CHEM TOKYO, V35, P1154, DOI 10.1080/00021369.1971.10860050; ITOH H, 1983, J BACTERIOL, V153, P163; KATO A, 1992, BIOSCI BIOTECH BIOCH, V56, P1424, DOI 10.1271/bbb.56.1424; KATO A, 1992, BIOCHIM BIOPHYS ACTA, V1159, P22, DOI 10.1016/0167-4838(92)90070-T; KUKAGAI I, 1989, J BIOCH, V105, P946; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; MIZUNAGA T, 1982, J BIOCHEM, V91, P191, DOI 10.1093/oxfordjournals.jbchem.a133676; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PARRY RM, 1965, P SOC EXP BIOL MED, V119, P384; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH WL, 1974, BIOCHEMISTRY-US, V13, P355, DOI 10.1021/bi00699a021; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOHE A, 1981, J BACTERIOL, V145, P1421, DOI 10.1128/JB.145.3.1421-1424.1981; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	27	64	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12706	12712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509405				2022-12-25	WOS:A1993LG65800071
J	THORVALDSEN, JL; SEWELL, AK; MCCOWEN, CL; WINGE, DR				THORVALDSEN, JL; SEWELL, AK; MCCOWEN, CL; WINGE, DR			REGULATION OF METALLOTHIONEIN GENES BY THE ACE1 AND AMT1 TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATION SEQUENCES; SUPEROXIDE-DISMUTASE GENE; DNA-BINDING PROTEIN; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; CANDIDA-GLABRATA; COPPER RESISTANCE; SHUTTLE VECTORS; EXPRESSION; CLONING	The AMT1 metalloregulatory trans-acting factor from Candida glabrata was found to functionally mimic the ACE1 metalloregulatory trans-acting factor from Saccharomyces cerevisiae in the copper-induced expression of the chromosomal S. cerevisiae metallothionein gene. Plasmid constructs with promoters of various metal-inducible genes fused to the bacterial beta-galactosidase (lacZ) reporter gene were used in S. cerevisiae to evaluate the roles of ACE1 and AMT1 in mediating metal-stimulated expression. Promoters from the S. cerevisiae CUP1 gene and Cu,Zn-superoxide dismutase (SOD1) and from the C. glabrata MT genes MTI, MTIIa, and MTIIb were used. The ACE1 factor was effective in the metalloregulation of the two S. cerevisiae promoters, CUP1 and SOD1, but of only one C. glabrata promoter, MTI. AMT1 was found to be effective in the metalloregulation of all three C. glabrata MT promoters and the two S. cerevisiae promoters tested. The regulation mediated by both ACE1 and AMT1 was copper-dependent and copper-specific. Episomally expressed SWI5, a distinct trans-acting factor of S. cerevisiae, enhanced only the basal expression from promoters. The SWI5 enhancement was not metal dependent. In conclusion, AMT1 and ACE1 are functionally homologous in metal-specific regulation, AMT1 appears to be more promiscuous than ACE1 in this function.	UNIV UTAH,MED CTR,DEPT BIOCHEM,SALT LAKE CITY,UT 84132; UNIV UTAH,MED CTR,DEPT MED,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Sewell, Andrew/GPT-4220-2022	Sewell, Andrew/0000-0003-3194-3135	NCI NIH HHS [T32 CA 09602] Funding Source: Medline; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CULOTTA VC, 1989, P NATL ACAD SCI USA, V86, P8377, DOI 10.1073/pnas.86.21.8377; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; EVANS CF, 1990, MOL CELL BIOL, V10, P426, DOI 10.1128/MCB.10.1.426; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GORMAN JA, 1986, GENE, V48, P13, DOI 10.1016/0378-1119(86)90347-1; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HU S, 1990, New Biologist, V2, P544; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; JEYAPRAKASH A, 1991, MOL GEN GENET, V225, P363, DOI 10.1007/BF00261675; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; MANTIATIS T, 1982, MOL CLONING LABORATO; MEHRA RK, 1992, GENE, V113, P119, DOI 10.1016/0378-1119(92)90678-I; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; MEHRA RK, 1992, GENE, V114, P75, DOI 10.1016/0378-1119(92)90709-X; MEHRA RK, 1990, J BIOL CHEM, V265, P6369; MEHRA RK, 1989, J BIOL CHEM, V264, P19747; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	40	55	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12512	12518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509391				2022-12-25	WOS:A1993LG65800044
J	JONES, LR; FIELD, LJ				JONES, LR; FIELD, LJ			RESIDUES 2-25 OF PHOSPHOLAMBAN ARE INSUFFICIENT TO INHIBIT CA2+ TRANSPORT ATPASE OF CARDIAC SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC STIMULATION; CA-2+ PUMP; PHOSPHORYLATION; VESICLES; CA-2+-ATPASE; VENTRICLES; RESOLUTION; PROTEIN; SITE; MICE	We have used sarcoplasmic reticulum (SR) vesicles isolated from AT-1 cardiomyocytes to examine the mechanism of phospholamban (PLB) inhibition of the Ca2+ pump of cardiac SR. By immunoblotting with monoclonal antibodies, we observed that these SR vesicles contained a normal amount of the cardiac isoform of the Ca2+ pump (SERCA 2) but only a trace level of PLB. A monoclonal antibody that recognized amino acid residues 9-17 of PLB had no significant effect on Ca2+ transport by AT-1 SR vesicles, but it increased Ca2+ transport into mouse ventricular SR vesicles greater than 10-fold by reversing PLB inhibition of SERCA 2 at low ionized Ca2+ concentration. To further explore the domains of PLB responsible for SERCA 2 inhibition, we examined the effect of a PLB synthetic peptide consisting of amino acid residues 2-25 on Ca2+ uptake by AT-1 SR vesicles. Even at concentrations as high as 0.44 mM, no significant effect of the peptide was observed. Based on these results, we conclude that the cytoplasmic domain of PLB, containing the phosphorylation sites, by itself is insufficient to inhibit the Ca2+ pump and that the transmembrane region, which stabilizes the pentamer, is also essential for Ca2+ transport regulation.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	JONES, LR (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453, R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06308, HL28556, HL45453] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHIESI M, 1989, FEBS LETT, V244, P240; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1985, J BIOL CHEM, V260, P7721; JONES LR, 1981, J BIOL CHEM, V256, P1809; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WEGENER AD, 1986, J BIOL CHEM, V261, P5154; XU ZC, 1989, J BIOL CHEM, V264, P16644	27	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11486	11488						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505284				2022-12-25	WOS:A1993LF28400004
J	RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG				RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG			WILD-TYPE P53 INDUCED APOPTOSIS IN A BURKITT-LYMPHOMA (BL) LINE THAT CARRIES MUTANT P53	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; TUMOR-ANTIGEN; PROTEIN; GROWTH; TRANSLOCATION; LOCALIZATION; ASSOCIATION; MUTATIONS; INDUCTION	All Burkitt lymphoma (BL) biopsies and cell lines carry a c-myc/Ig translocation. The resulting constitutive activation of c-myc is regarded as an essential factor for the progressive growth of the tumor cells. At least 60% of BL cell lines carry a mutated p53 gene as well. It has been shown that the growth of mutant p53 carrying tumor cells could be inhibited by the introduction of wild-type p53. In order to examine whether this also applies to the presumably 'myc-driven' BL cell, we have transfected the Epstein-Barr virus (EBV) negative BL41 cell line with a temperature sensitive p53 mutant (p53-Val135) that expresses p53 with a largely mutant conformation at 37.5-degrees-C and mostly wild-type conformation at 32-degrees-C. At 37.5-degrees-C, the p53-Val135 transfected cells behaved like the parental or neo transfected control cells. However, expression of exogenous wild-type p53 at 32-degrees-C resulted in a rapid reduction of the number of viable cells white the parental and neo control cells remained unaffected. Cell death was due to apoptosis as shown by chromatin and nuclear condensation and specific DNA fragmentation. The first signs of apoptosis were evident after 10 h at 32-degrees-C and after 3 days 90-100% of the cells had undergone apoptosis. These findings indicate an incompatibility between expression of wild-type p53 and progressive growth of BL cells if their neoplastic development has included a p53 mutation. The question whether apoptosis was induced in by the wild-type protein per se or by the contradictory signals of a constitutively activated c-myc and wild-type p53 needs further investigation.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021; Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; 	NCI NIH HHS [5R01 CA14054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P553; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASEY G, 1991, ONCOGENE, V6, P1791; CHENG J, 1992, CANCER RES, V52, P222; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; ISAACS WB, 1991, CANCER RES, V51, P4716; LANE DP, 1979, NATURE, V351, P453; LENIOR GM, 1985, IARC SCI PUBL, V60, P309; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHALUSKY G, 1991, P NATL ACAD SCI USA, V88, P8982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; TORSTEINSDOTTIR S, 1989, INT J CANCER, V43, P273, DOI 10.1002/ijc.2910430219; VOSS H, 1992, Methods in Molecular and Cellular Biology, V3, P30; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	144	146	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1495	1500						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502475				2022-12-25	WOS:A1993LE06400012
J	TSAI, SC; ADAMIK, R; HAUN, RS; MOSS, J; VAUGHAN, M				TSAI, SC; ADAMIK, R; HAUN, RS; MOSS, J; VAUGHAN, M			EFFECTS OF BREFELDIN-A AND ACCESSORY PROTEINS ON ASSOCIATION OF ADP-RIBOSYLATION FACTOR-I, FACTOR-III, AND FACTOR-5 WITH GOLGI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; NUCLEOTIDE-BINDING; CHOLERA-TOXIN; BOVINE BRAIN; ACTIVATOR; STIMULATION; EXPRESSION; VESICLES; MEMBRANE; CELLS	ADP-ribosylation factors (ARFs) are approximately 20-kDa guanine nucleotide-binding proteins initially identified by their ability to enhance in vitro cholera toxin-catalyzed ADP-ribosylation and subsequently shown to participate in vesicular transport in the Golgi and other cellular compartments. By cDNA and genomic cloning, at least six mammalian ARFs were identified. Brefeldin A (BFA) disrupts Golgi membranes and inhibits binding of soluble high molecular weight proteins to Golgi fractions. We examined the effects of BFA on binding of ARF1, -3, and -5 to a Golgi fraction in the presence of an ATP-regenerating system and a fraction of soluble, high molecular weight, accessory proteins (SAP), presumably containing complexes identified by others as coatomers that are involved in vesicular transport. ARF binding in all instances was dependent on guanosine 5'-O-(3-thiotriphosphate) and increased by the ATP-regenerating system. Binding of ARF1 and -3, but not ARF5, was enhanced by SAP. BFA inhibited the SAP-dependent, but not the SAP-independent, binding of ARF1 and -3. It had no effect on the increment in binding produced by an ATP-regenerating system. B36, an inactive derivative of BFA, did not inhibit SAP-dependent binding of ARF1 and -3. Binding of ARF5, which was SAP-independent, was not affected by BFA. These observations are consistent with the conclusion that mammalian ARFs differ in their dependence on accessory proteins for interaction with Golgi and, perhaps, other cellular membranes and that BFA specifically inhibits SAP-dependent ARF binding.			TSAI, SC (corresponding author), NHLBI,CELLULAR METAB LAB,RM 5N-307,BLDG 10,BETHESDA,MD 20892, USA.							BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FLEISCHER B, 1974, METHOD ENZYMOL, V31, P181; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUNZ BC, 1990, FASEB J, V4, P167; LEE CM, 1992, J BIOL CHEM, V267, P9028; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	38	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10820	10825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496147				2022-12-25	WOS:A1993LD46600020
J	ALGATE, PA; MCCUBREY, JA				ALGATE, PA; MCCUBREY, JA			AUTOCRINE TRANSFORMATION OF HEMATOPOIETIC-CELLS RESULTING FROM CYTOKINE MESSAGE STABILIZATION AFTER INTRACISTERNAL-A PARTICLE TRANSPOSITION	ONCOGENE			English	Article							DEPENDENT HEMATOPOIETIC-CELLS; C-MOS ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; INTERLEUKIN-3 GENE; MURINE INTERLEUKIN-3; GROWTH-FACTORS; HOMEOBOX GENE; MALIGNANT TRANSFORMATION; TYROSINE PHOSPHORYLATION	Cell lines that no longer require exogenous interleukin 3 (IL-3) for growth were isolated from an IL-3-dependent cell tine that possesses characteristics of early lymphoid cells. Unlike the parental cells (FL5.12), these autocrine transformed lines (FL-IL3-R) constitutively secreted IL-3, were rearranged at the IL-3 locus and formed tumors upon injection into syngeneic mice. The rearrangement and IL-3 expression resulted from the transposition of an intracisternal A particle (IAP) provirus into the 3' untranslated region of the IL-3 gene. This region contained ATTTA sequence motifs that have been associated with cytokine and oncogene mRNA instability. IL-3 transcripts from the autocrine transformed cell lines had a longer half-life than similar transcripts isolated from either phorbol ester-stimulated T cells or the WEHI-3B myelomonocytic cell line. IAP proviral transposition did not alter the transcription rate of the IL-3 gene in FL-IL3-R cells. Therefore, IAP proviral transposition can activate IL-3 gene expression by prolonging mRNA stability, and this mechanism can contribute to the autocrine transformation of the hemopoietic cells.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS DK, 1988, BIOCHEM BIOPH RES CO, V154, P991, DOI 10.1016/0006-291X(88)90237-9; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; Ihle J N, 1989, Year Immunol, V5, P59; IHLE JN, 1987, J IMMUNOL, V138, P3051; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY J, 1983, J VIROL, V45, P950, DOI 10.1128/JVI.45.3.950-955.1983; MCCUBREY JA, 1990, BLOOD, V76, P63; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VANBEVEREN C, 1980, P NATL ACAD SCI-BIOL, V77, P3307; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901; 1991, PROMEGA PROTOCOLS AP, P90	73	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1221	1232						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479745				2022-12-25	WOS:A1993KY32800013
J	CHANDRA, R; SALMON, ED; ERICKSON, HP; LOCKHART, A; ENDOW, SA				CHANDRA, R; SALMON, ED; ERICKSON, HP; LOCKHART, A; ENDOW, SA			STRUCTURAL AND FUNCTIONAL DOMAINS OF THE DROSOPHILA NCD MICROTUBULE MOTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN HEAVY-CHAIN; CHROMOSOME SEGREGATION; ELECTRON-MICROSCOPY; LEUCINE ZIPPER; BINDING; ATPASE; IDENTIFICATION; POLYPEPTIDES; CLEAVAGE	Nonclaret disjunctional (ncd) is a kinesin-related microtubule motor protein that is required for proper chromosome distribution in Drosophila. Despite its sequence similarity to kinesin heavy chain, ncd translocates with the opposite polarity as kinesin, toward microtubule minus ends. We have expressed different regions of the protein in bacteria and analyzed the proteins for function. Results indicate that ncd consists of three domains: a basic, proline-rich N-terminal ''tail,'' a central alpha-helical coiled-coil stalk, and a C-terminal motor domain. The ncd N terminus proteins bundle microtubules in motility assays and show ATP-independent binding to microtubules in solution. Truncated proteins, lacking the tail but containing the predicted motor domain and differing lengths of the stalk, did not support microtubule gliding in in vitro assays but showed microtubule-stimulated MgATPase activity in solution. Addition of a nonspecific N terminus to two of the truncated proteins restored directional gliding and rotation of microtubules in motility assays, demonstrating that these properties map to the predicted mechanochemical domain of ncd. Physical properties of the C terminus proteins indicate that the stalk region is important for dimerization and that the ncd protein probably exists and functions as a dimer.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; MARIE CURIE INST, SURREY RH8 0TL, ENGLAND	University of North Carolina; University of North Carolina Chapel Hill; Duke University	CHANDRA, R (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHANDRA R, 1993, IN PRESS METHODS CEL, V69; CHANDRA R, 1993, IN PRESS J CELL SCI, V104; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; DAVIS DG, 1969, GENETICS, V61, P577; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HATSUMI M, 1992, J CELL SCI, V103, P1013; HATSUMI M, 1992, J CELL SCI, V101, P547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HODGES R S, 1992, Current Biology, V2, P122, DOI 10.1016/0960-9822(92)90241-2; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KIMBLE M, 1983, J CELL SCI, V62, P301; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEWIS EB, 1952, GENETICS, V37, P600; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sturtevant AH, 1929, Z WISS ZOOL ABT A, V135, P323; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; Wald H, 1936, GENETICS, V21, P264; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YAMAMOTO AH, 1989, EMBO J, V8, P3543, DOI 10.1002/j.1460-2075.1989.tb08526.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	48	154	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9005	9013						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473343				2022-12-25	WOS:A1993KX81100090
J	HAMAMOTO, T; YAMAMOTO, M; NORDFANG, O; PETERSEN, JGL; FOSTER, DC; KISIEL, W				HAMAMOTO, T; YAMAMOTO, M; NORDFANG, O; PETERSEN, JGL; FOSTER, DC; KISIEL, W			INHIBITORY PROPERTIES OF FULL-LENGTH AND TRUNCATED RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR (TFPI) - EVIDENCE THAT THE 3RD KUNITZ-TYPE DOMAIN OF TFPI IS NOT ESSENTIAL FOR THE INHIBITION OF FACTOR-VIIA-TISSUE FACTOR COMPLEXES ON CELL-SURFACES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; EXTRINSIC PATHWAY; BLOOD-COAGULATION; FACTOR-XA; DIRECTED MUTAGENESIS; PURIFICATION; PLASMA; INITIATION; MECHANISM; BINDING	Human tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that consists of three tandem Kunitz-type inhibitor domains flanked by a negatively charged NH2 terminus and a positively charged COOH-terminal tail. Previous studies have shown that the first and second Kunitz-type domains in TFPI are involved in the inhibition of factor VIIa and factor Xa activity, respectively. In the present study, we have compared the inhibitory properties of full-length recombinant TFPI and a truncated form of TFPI lacking the third Kunitz-type domain and COOH-terminal tail (TFPI1-161) with respect to inhibition of factor VIIa-tissue factor complexes on the surface of a human bladder carcinoma cell line J82. Full-length TFPI and TFPI1-161 were kinetically indistinguishable with respect to neutralization of the proteolytic activity of preformed complexes of factor VIIa-tissue factor on the J82 cell surface in the absence of factor Xa. Equimolar amounts of factor Xa augmented the anticoagulant activity of both preparations of TFPI to the same extent, and both preparations of TFPI were equally effective in inhibiting factor VIIa-tissue factor amidolytic activity in solution phase. In addition, plasma concentrations of both forms of TFPI, in stoichiometric complex with factor Xa, inhibited cell surface factor VIIa-tissue factor proteolytic activity markedly faster than plasma levels of antithrombin III, even in the presence of 1 unit/ml heparin. The results of displacement studies suggested slight differences in the affinity of the two TFPI molecules for the cell surface in that approximately 5% of a VIIa.TF.Xa.TFPI1-161 quaternary complex on J82 cells was displaceable from the cell surface by high concentrations of factor VIIa (10-100 nM), whereas only 1-2% of a VIIa.TF.Xa.TFPI complex was displaceable under comparable conditions. Pretreatment of the cells with TFPI/Xa alone or together with R152E factor VII, followed by factor VIIa treatment, revealed significant differences in the two TFPI forms with respect to the degree with which offered factor VIIa could restore factor X activation on the cell surface. These differences notwithstanding, our collective findings indicate that the third Kunitz-type domain and/or COOH-terminal tail of TFPI is not essential for the inhibition of cell surface factor VIIa-tissue factor complexes and suggests that TFPI1-161 may be a useful therapeutic agent in the treatment of thromboembolic episodes.	UNIV NEW MEXICO, SCH MED, DEPT PATHOL, BLOOD SYST RES FDN LAB, ALBUQUERQUE, NM 87131 USA; NOVO NORDISK AS, GENTOFTE, DENMARK; ZYMOGENET INC, SEATTLE, WA 98105 USA	University of New Mexico; Novo Nordisk; Zymogenet Inc.					NHLBI NIH HHS [HL35246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1988, BLOOD, V71, P335; BUSBY SJ, 1988, CURRENT ADV VITAMIN, P173; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Engvall E, 1980, Methods Enzymol, V70, P419; FOSTER DC, 1991, BIOCHEMISTRY-US, V30, P367, DOI 10.1021/bi00216a009; GEMMELL CH, 1990, BLOOD, V76, P2266; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEDNER U, 1983, J CLIN INVEST, V71, P1836, DOI 10.1172/JCI110939; HEDNER U, 1988, LANCET, V2, P1193; KAZAMA Y, 1993, BLOOD, V81, P676; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO S, 1987, BLOOD, V70, P1947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIK BG, 1989, AM J HEMATOL, V32, P232, DOI 10.1002/ajh.2830320315; MAHONEY WC, 1980, EUR J BIOCHEM, V105, P545, DOI 10.1111/j.1432-1033.1980.tb04531.x; Maniatis T., 1982, MOL CLONING; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NOVOTNY WF, 1989, J BIOL CHEM, V264, P18832; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAPAPORT SI, 1989, BLOOD, V73, P359; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SANDERS NL, 1985, BLOOD, V66, P204; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; WARNCRAMER BJ, 1988, THROMB HAEMOSTASIS, V60, P453; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1992, CIRCULATION, V86, P815; WUN TC, 1988, J BIOL CHEM, V263, P6001; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	39	76	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8704	8710						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473315				2022-12-25	WOS:A1993KX81100051
J	HARROCH, S; GOTHELF, Y; WATANABE, N; REVEL, M; CHEBATH, J				HARROCH, S; GOTHELF, Y; WATANABE, N; REVEL, M; CHEBATH, J			INTERLEUKIN-6 ACTIVATES AND REGULATES TRANSCRIPTION FACTORS OF THE INTERFERON REGULATORY FACTOR FAMILY IN M1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; TERMINAL DIFFERENTIATION; INDUCIBLE ENHANCER; SYNTHETASE GENE; NUCLEAR FACTOR; GROWTH ARREST; IRF-1; IFN; ELEMENTS	Activation of (2'-5') A synthetase gene expression in interleukin-6 (IL-6)-treated myeloleukemic M1 cells correlates with protein binding to the interferon response sequence enhancer (IRS). A new interferon response sequence complex, F6, is induced by IL-6 independently of interferon and is identified here as comprising the interferon regulatory factor-1 (IRF-1) and IRF-2, by use of specific antibodies in DNA mobility shift assays with probes containing IRF binding sites. IRF-1 and IRF-2 have, respectively, positive and negative transcriptional effects on interferon-beta and interferon-inducible genes. In the IL-6-treated M1 or cells, IRF-1 binding is activated early and maximally at 1 h, whereas the onset of IRF-2 binding is delayed. In a cell variant M1res, where (2'-5') A synthetase is no more induced, IRF-2 binding is constitutive, and IRF-1 binding is not seen before or after IL-6 treatment. In sensitive M1or cells, IL-6 rapidly induces IRF-1 mRNA, but in M1res cells, IRF-1 mRNA is constitutively high and not changed by IL-6. IRF-2 mRNA levels are also constitutive and not inducible by IL-6 even in M1or cells. The dissociation between induction of mRNAs and of protein binding observed suggests that the activity of the IRF proteins is regulated by IL-6. Transcripts of a third member of the IRF gene family, ICSBP, encoding a protein known to act as repressor, were found to be strongly down-regulated by IL-6. The rapid activation of IRF-1 and the modulation of the other transcription factors of this family may play a role in the early phase of IL-6 action on the M1 cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Chebath, Judith/0000-0002-8151-7428				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BICKEL M, 1990, Cytokine, V2, P238, DOI 10.1016/1043-4666(90)90023-M; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHIU CP, 1989, J IMMUNOL, V142, P1909; COHEN B, 1991, CYTOKINE, V3, P83, DOI 10.1016/1043-4666(91)90027-B; COHEN B, 1989, NUCLEIC ACIDS RES, V17, P1679, DOI 10.1093/nar/17.4.1679; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GIVON T, 1992, BLOOD, V79, P2392; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOTHELF Y, 1991, LYMPHOKINE CYTOK RES, V10, P369; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LEVY D, 1990, New Biologist, V2, P923; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MAEKAWA T, 1990, INT J CANCER, V45, P353, DOI 10.1002/ijc.2910450224; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; NATSUKA S, 1992, BLOOD, V79, P460; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; ONOZAKI K, 1989, CANCER RES, V49, P3602; PIEN R, 1992, J VIROL, V66, P4470; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAMJI DP, 1992, IL6 PHYSIOPATHOLOGY, P55; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; REVEL M, 1989, ANN NY ACAD SCI, V557, P144; REVEL M, 1989, EXPERIENTIA, V45, P549, DOI 10.1007/BF01990505; SAMAL B, 1990, LEUKEMIA RES, V14, P575, DOI 10.1016/0145-2126(90)90010-7; SHABO Y, 1990, LEUKEMIA, V4, P797; SHABO Y, 1988, BLOOD, V72, P2070; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEISZ A, 1992, J BIOL CHEM, V267, P25589	40	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9092	9097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473349				2022-12-25	WOS:A1993KX81100100
J	HATA, A; AKITA, Y; SUZUKI, K; OHNO, S				HATA, A; AKITA, Y; SUZUKI, K; OHNO, S			FUNCTIONAL DIVERGENCE OF PROTEIN-KINASE-C (PKC) FAMILY MEMBERS - PKC-GAMMA DIFFERS FROM PKC-ALPHA AND PKC-BETA-II AND NPKC-EPSILON IN ITS COMPETENCE TO MEDIATE-12-O-TETRADECANOYL PHORBOL 13-ACETATE (TPA)-RESPONSIVE TRANSCRIPTIONAL ACTIVATION THROUGH A TPA-RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; FOS GENE; DISTINCT FORMS; SERUM FACTORS; RAT-BRAIN; EXPRESSION; JUN; RECEPTOR; ONCOGENE; AP-1	We have established an assay system where overexpression of a specific protein kinase C (PKC) type caused by introduction of the respective cDNA results in the enhancement of a cell response: the transcriptional activation of a set of genes in response to PKC activators such as 12-O-tetradecanoylphorbol 13-acetate (TPA). When monitored by the expression of a reporter gene containing the chloramphenicol acetyltransferase gene fused downstream of a synthetic TPA response element (TRE) or a serum response element (SRE), the overexpression of cPKCalpha and betaII or nPKCepsilon all resulted in the enhancement of transcriptional activation through both TRE and SRE. On the other hand, PKCgamma activates TRE only very weakly, although it activates SRE in a similar manner to the other PKC members examined. The overexpression of cPKCalpha and -betaII or nPKCepsilon, but not cPKCgamma, resulted in the enhanced expression of the endogenous c-jun gene, which contains TRE in the 5'-upstream, promoter region. The gel mobility shift assay showed that the activation of PKCgamma, as well as PKCalpha and -betaII and nPKCepsilon, causes the increase in TRE-binding proteins, suggesting that transcriptional activation through TRE requires an additional step, which is not activated by PKCgamma, such as a qualitative change in TRE-binding or in TRE-associating proteins. This finding provides not only a rationale to explain the presence of multiple PKC family members, but also permits the dissection of the complex cellular signaling cascade involving PKC family members.	TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269				AKITA Y, 1990, J BIOL CHEM, V265, P354; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1989, J BIOL CHEM, V264, P6404; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONNO Y, 1989, J BIOCHEM-TOKYO, V106, P673, DOI 10.1093/oxfordjournals.jbchem.a122915; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAIDO TC, 1992, BIOCHEMISTRY-US, V31, P482, DOI 10.1021/bi00117a026; SAKAI M, 1989, CANCER RES, V49, P5633; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	57	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9122	9129						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473351				2022-12-25	WOS:A1993KX81100105
J	SILBERSTEIN, DS; MCDONOUGH, S; MINKOFF, MS; BALCEWICZSABLINSKA, MK				SILBERSTEIN, DS; MCDONOUGH, S; MINKOFF, MS; BALCEWICZSABLINSKA, MK			HUMAN EOSINOPHIL CYTOTOXICITY-ENHANCING FACTOR - EOSINOPHIL-STIMULATING AND DITHIOL REDUCTASE ACTIVITIES OF BIOSYNTHETIC (RECOMBINANT) SPECIES WITH COOH-TERMINAL DELETIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; AMINO-ACID SEQUENCE; SCHISTOSOMA-MANSONI; U937 CELLS; FACTOR ADF; PURIFICATION; THIOREDOXIN; CLEAVAGE; NEUTROPHILS; MONOKINES	U937 cells produce eosinophil cytotoxicity-enhancing factor (ECEF) polypeptides of 14 and 10 kDa that have identical NH2-terminal amino acid sequences. The 10-kDa form has greater eosinophil-stimulating activity (half-maximal at >20-fold lower concentration). We considered the hypothesis that there is a precursor-product relationship between the 14- and 10-kDa species. Recombinant 14-kDa 104-amino acid ECEF (rECEF-104) had a slight stimulatory effect on eosinophil cytotoxic function at concentrations of 160 nm and above. In contrast, two species, rECEF-80 and rECEF-84, representing cleavage products of approximately 10 kDa had substantial statistically significant cytotoxicity-enhancing activity at concentrations as low as 10 pm. This evidence demonstrates the potential to generate the high-activity ECEF species by proteolytic cleavage of the 104-amino acid species. Another feature of this cytokine is the sequence from amino acids 31 to 34, which constitutes the conserved and active site of the enzyme thioredoxin. When tested for dithiol reductase enzymatic activity, rECEF-104 was active in a dose- and time-dependent manner, whereas the truncated forms of the molecule had no dithiol reductase activity. Thus the eosinophil-stimulating functions of the molecule do not correlate with its enzymatic activity. The evidence shows that the enzymatic activity is not essential for the initial interaction of ECEF with the eosinophil, and it suggests that the ECEF molecule functions by means of two discrete mechanisms.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028525, R01AI022532] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28525, AI-22532] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCEWICZSABLINSKA MK, 1991, J IMMUNOL, V147, P2170; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; DESSEIN AJ, 1986, J IMMUNOL, V136, P3829; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECH K, 1990, CURRENT PROTOCOLS MO; LENZI HL, 1985, CELL IMMUNOL, V94, P333, DOI 10.1016/0008-8749(85)90257-6; LINSLEY PS, 1990, MOL CELL BIOL, V10, P1882, DOI 10.1128/MCB.10.5.1882; MATSUDA M, 1991, J IMMUNOL, V147, P3837; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; RIMSKY L, 1986, J IMMUNOL, V136, P3304; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILBERSTEIN DS, 1990, HYBRIDOMA, V9, P237, DOI 10.1089/hyb.1990.9.237; SILBERSTEIN DS, 1987, J IMMUNOL, V138, P3042; SILBERSTEIN DS, 1989, J IMMUNOL, V143, P979; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; VADAS MA, 1979, J IMMUNOL, V122, P1228; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506	21	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9138	9142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473353				2022-12-25	WOS:A1993KX81100107
J	SIRAWARAPORN, W; CAO, M; SANTI, DV; EDMAN, JC				SIRAWARAPORN, W; CAO, M; SANTI, DV; EDMAN, JC			CLONING, EXPRESSION, AND CHARACTERIZATION OF CRYPTOCOCCUS-NEOFORMANS DIHYDROFOLATE-REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIS3 REGULATORY SEQUENCES; ACID BIOSYNTHETIC GENES; X-RAY STRUCTURE; SACCHAROMYCES-CEREVISIAE; PNEUMOCYSTIS-CARINII; SYNTHESIZED INVITRO; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; GCN4 PROTEIN; METHOTREXATE	The Cryptococcus neoformans dihydrofolate reductase (DHFR) gene has been isolated from cDNA and genomic DNA libraries. The 690-base pair coding sequence codes for a 25,152-Da protein, which is the largest monofunctional DHFR yet reported. The gene contains two introns, and several putative regulatory sequences have been identified. The coding sequence was placed in a pUC-based expression vector, which expresses C. neoformans DHFR in Escherichia coli at a level of about 5% of the total soluble extract. The expressed DHFR was purified to homogeneity by methotrexate-Sepharose affinity chromatography, followed by anion exchange chromatography on Q-Sepharose. On SDS-polyacrylamide gel electrophoresis, the purified enzyme migrates as a single protein with apparent mass of 28 kDa. The molecular weight, as determined by electrospray mass spectral analysis, and the amino-terminal sequence are in accord with what was predicted from the DNA sequence. Steady state kinetic parameters, effects of pH, salts, and inhibition constants of several anti-folates have been determined.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HORMONE RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; MAHIDOL UNIV,FAC SCI,DEPT BIOCHEM,BANGKOK 10400,THAILAND	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mahidol University					NIAID NIH HHS [AI 29312, AI 30261] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029312] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRWEILER PM, 1988, J BACTERIOL, V170, P3301, DOI 10.1128/jb.170.7.3301-3304.1988; Armstrong D, 1988, Ann N Y Acad Sci, V544, P443, DOI 10.1111/j.1749-6632.1988.tb40442.x; BACCANARI DP, 1989, J BIOL CHEM, V264, P1100; BARCLAY BJ, 1988, GENE, V63, P175, DOI 10.1016/0378-1119(88)90523-9; BENNETT JE, 1979, NEW ENGL J MED, V301, P126, DOI 10.1056/NEJM197907193010303; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Bodey G P, 1988, Ann N Y Acad Sci, V544, P431, DOI 10.1111/j.1749-6632.1988.tb40441.x; BURCHALL JJ, 1983, INHIBITION FOLATE ME, P55; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; EDMAN JC, 1989, P NATL ACAD SCI USA, V86, P8625, DOI 10.1073/pnas.86.22.8625; FLING ME, 1988, GENE, V63, P165, DOI 10.1016/0378-1119(88)90522-7; FUTTERMAN S, 1957, J BIOL CHEM, V228, P1031; GRANT IH, 1986, AM J MED, V81, P59, DOI 10.1016/0002-9343(86)90515-2; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; KOZAK M, 1983, MICROBIOL REV, V47, P1; KWONCHUNG KJ, 1978, 4TH P INT C MYC, P204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS DA, 1978, J BIOL CHEM, V253, P6946; MATTHEWS DA, 1977, SCIENCE, V197, P452, DOI 10.1126/science.17920; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; Parker R, 1987, MOL BIOL RNA NEW PER, P133; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RHODES JC, 1985, SABOURAUDIA, V23, P77; Rippon J. W., 1988, MED MYCOLOGY; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Sirawaraporn W, 1991, Protein Expr Purif, V2, P313, DOI 10.1016/1046-5928(91)90088-Z; SIRAWARAPORN W, 1988, MOL BIOCHEM PARASIT, V31, P79, DOI 10.1016/0166-6851(88)90147-8; WILLIAMS JW, 1981, BIOCHEMISTRY-US, V20, P6024, DOI 10.1021/bi00524a016; 1908, LANCET, V8600, P1434	32	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8888	8892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473332				2022-12-25	WOS:A1993KX81100075
J	GREEN, DW; SUN, HW; PLAPP, BV				GREEN, DW; SUN, HW; PLAPP, BV			INVERSION OF THE SUBSTRATE-SPECIFICITY OF YEAST ALCOHOL-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPUTER-GRAPHICS; ACTIVE-SITE; MUTAGENESIS; MECHANISM; BINDING; SUBUNIT	The relationship between the size of the substrate binding pocket and the catalytic reactivities with varied alcohols was studied with the Saccharomyces cerevisiae alcohol dehydrogenase I (ScADH) and compared with the liver enzymes from horse (EqADH, EE isoenzyme) and monkey (MmADHalpha, alpha-isoenzyme). The yeast enzyme is most active with ethanol, and its activity decreases as the size of the alcohol is increased, whereas the activities of the liver enzymes increase with larger alcohols. The substrate pocket in ScADH was enlarged by single substitutions of Thr-48 to Ser (T48S), Trp-57 to Met (W57M), and Trp-93 to Ala (W93A), and a double change, T48S:W93A, and a triple, T48S:W57M:W93A. The T48S enzyme has the same pattern of activity (V/K) as wild-type ScADH for linear primary alcohols. The W57M enzymes have lowered reactivity with primary and secondary alcohols. The W93A and r48S:W93A enzymes resemble MmADHalpha in having an inverted specificity pattern for primary alcohols, being 3- and 10-fold more active on hexanol and 350- and 540-fold less active on ethanol, and are as reactive as the liver enzymes with long chain primary alcohols. The three Ala-93 enzymes also acquired weak activity on branched chain alcohols and cyclohexanol.	UNIV IOWA,DEPT BIOCHEM,4-370 BOWEN SCI BLDG,IOWA CITY,IA 52242	University of Iowa			Plapp, Bryce V/F-6353-2010		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006223] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06223] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CORNELL NW, 1983, PHARMACOL BIOCHEM BE, V18, P215, DOI 10.1016/0091-3057(83)90174-0; CREASER EH, 1990, PROTEIN ENG, V3, P523, DOI 10.1093/protein/3.6.523; DALZIEL K, 1966, BIOCHEM J, V100, P34, DOI 10.1042/bj1000034; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; DICKENSON CJ, 1975, BIOCHEM J, V147, P541, DOI 10.1042/bj1470541; DICKINSO.FM, 1967, BIOCHEM J, V104, P165, DOI 10.1042/bj1040165; DICKINSON FM, 1967, NATURE, V214, P31, DOI 10.1038/214031a0; DICKINSON FM, 1973, BIOCHEM J, V131, P261, DOI 10.1042/bj1310261; EKLUND H, 1987, EUR J BIOCHEM, V167, P185, DOI 10.1111/j.1432-1033.1987.tb13322.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; GANZHORN AJ, 1988, J BIOL CHEM, V263, P5446; HAYES JE, 1954, J BIOL CHEM, V207, P225; HOOG JO, 1992, EUR J BIOCHEM, V205, P519, DOI 10.1111/j.1432-1033.1992.tb16808.x; HORJALES E, 1985, J BIOL CHEM, V260, P5445; HURLEY TD, 1992, BIOCHEM BIOPH RES CO, V183, P93, DOI 10.1016/0006-291X(92)91613-U; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JORNVALL H, 1978, J BIOL CHEM, V253, P8414; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE KM, 1988, BIOCHEMISTRY-US, V27, P3528, DOI 10.1021/bi00409a060; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LIGHT DR, 1992, J BIOL CHEM, V267, P12592; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; PARK DH, 1992, J BIOL CHEM, V267, P5527; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENA M, 1989, US BIOCH CORP EDITOR, V15, P23; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; STOEN CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; Sund H., 1963, ENZYMES, V7, P25; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WILLS C, 1979, EUR J BIOCHEM, V99, P323, DOI 10.1111/j.1432-1033.1979.tb13260.x; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	66	75	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7792	7798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463307				2022-12-25	WOS:A1993KW97900035
J	SUN, WL; GODSON, GN				SUN, WL; GODSON, GN			BINDING AND PHASING OF ESCHERICHIA-COLI SINGLE-STRANDED DNA-BINDING PROTEIN BY THE SECONDARY STRUCTURE OF PHAGE-G4 ORIGIN OF COMPLEMENTARY-DNA STRAND SYNTHESIS (G4ORIC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; NUCLEOTIDE-SEQUENCES; MUTATIONAL ANALYSIS; BACTERIOPHAGE-G4 ORIGIN; DEOXYRIBONUCLEIC-ACID; RNA-POLYMERASE; G4 ORIGIN; COMPLEXES; MUTANTS; PRIMASE	The origin of phage G4 DNA complementary strand synthesis (G4ori(c)) consists of three stem-loop structures (stem loops I, II, and III) that have been proposed as a recognition site for primase during primer RNA (pRNA) synthesis (Godson, G. N., Barrell, B. G., Staden, R., and Fiddes, J. C. (1978) Nat. New Biol. 276, 236-247; Fiddes, J. C., Barrell, B. G., and Godson, G. N. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 1081-1085; Sims, J., Capon, D., and Dressler, D. (1979) J. Biol. Chem. 254, 12615-12628). It is generally considered that the double-stranded DNA stem-loop structure is not coated with Escherichia coli single-stranded DNA-binding protein (SSB), but is recognized by primase as naked DNA (Kornberg, A., and Baker, J. (1992) DNA Replication, 2nd Ed., p. 280, W. H. Freeman & Co., New York). Using small G4ori(c) single-stranded DNA fragments of various sizes (302, 278, 149, and 100 nucleotides) consisting of the core 100-nucleotide stem-loop region plus differing lengths of 3'- and 5'-flanking sequence as substrates for gel retardation and DNase I and micrococcal nuclease digestion, we show that under conditions of pRNA synthesis, two SSB tetramers bind to the stem-loop structure. With increasing lengths of 5'- and 3'-flanking sequence, more SSB tetramers are added. Regardless of the number of SSB tetramers bound, however, the region of DNA containing the pRNA initiation site is always left accessible to nuclease digestion. In situ copper-phenanthroline footprinting of individual gel shift assembly intermediates shows that on the 302-nucleotide G4ori(c), the first two SSB tetramers assemble at random, but the addition of more SSB tetramers results in formation of a unique structure. In this structure, SSB tetramers protect both sides of stem loop III plus the intervening region between stem loops III and I, but leave most of stem loop I and the CTG pRNA initiation site accessible to copper-phenanthroline. Primase can only synthesize pRNA when the stem-loop structure is saturated with SSB and presumably in the unique configuration. The G4ori(c) stem-loop structure therefore appears to dictate the phasing of SSB to leave a primase recognition site as free DNA.	NYU MED CTR,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016	New York University					NIGMS NIH HHS [GM 32898] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; CHASE JW, 1984, J BIOL CHEM, V259, P805; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; FIDDES JC, 1978, P NATL ACAD SCI USA, V75, P1081, DOI 10.1073/pnas.75.3.1081; GODSON GN, 1978, NATURE, V276, P236, DOI 10.1038/276236a0; GODSON GN, 1990, GENE AMST, V100, P59; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HIASA H, 1989, GENE, V84, P17, DOI 10.1016/0378-1119(89)90134-0; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HIRAO I, 1989, NUCLEIC ACIDS RES, V17, P2223, DOI 10.1093/nar/17.6.2223; HIRAO I, 1990, BIOCHIM BIOPHYS ACTA, V1087, P199, DOI 10.1016/0167-4781(90)90205-G; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; KODAIRA K, 1989, BIOCHIM BIOPHYS ACTA, V1007, P359, DOI 10.1016/0167-4781(89)90160-7; KODAIRA KI, 1990, MOL GEN GENET, V220, P240; KORNBERG A, 1992, DNA REPLICATION, P280; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P5346, DOI 10.1021/bi00521a040; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAMBERT PF, 1987, GENE, V53, P257, DOI 10.1016/0378-1119(87)90014-X; LAMBERT PF, 1986, J VIROL, V58, P450, DOI 10.1128/JVI.58.2.450-458.1986; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MARSHALL LE, 1981, BIOCHEMISTRY-US, V20, P244, DOI 10.1021/bi00505a003; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1990, J BIOL CHEM, V265, P15134; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; NAKANO K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P43, DOI 10.1016/0167-4781(90)90020-3; SAKAI H, 1988, GENE, V71, P323; SAKAI H, 1987, GENE, V53, P265; SAKAI H, 1985, BIOCHIM BIOPHYS ACTA, V826, P30, DOI 10.1016/S0167-4781(85)80005-1; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SIMS J, 1980, P NATL ACAD SCI-BIOL, V77, P900, DOI 10.1073/pnas.77.2.900; SIMS J, 1979, J BIOL CHEM, V254, P2615; SMITH DW, 1989, CHROMOSOMES EUCARYOT, V2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UEDA K, 1985, J BIOL CHEM, V260, P5804; UEDA K, 1992, BIOSCI BIOTECH BIOCH, V56, P394, DOI 10.1271/bbb.56.394; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZECHEL K, 1975, J BIOL CHEM, V250, P4684	44	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8026	8039						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463320				2022-12-25	WOS:A1993KW97900066
J	SANCHEZLOPEZ, R; ALEXANDER, CM; BEHRENDTSEN, O; BREATHNACH, R; WERB, Z				SANCHEZLOPEZ, R; ALEXANDER, CM; BEHRENDTSEN, O; BREATHNACH, R; WERB, Z			ROLE OF ZINC-BINDING-ENCODED AND HEMOPEXIN DOMAIN-ENCODED SEQUENCES IN THE SUBSTRATE-SPECIFICITY OF COLLAGENASE AND STROMELYSIN-2 AS REVEALED BY CHIMERIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; EPIDERMAL GROWTH-FACTOR; IV COLLAGENASE; CYSTEINE SWITCH; DIRECTED MUTAGENESIS; TISSUE INHIBITOR; RAT FIBROBLASTS; INDUCED TRANSIN; MESSENGER-RNA; GENE FAMILY	The relationship of enzyme structure to substrate specificity for the matrix metalloproteinases interstitial collagenase and stromelysin-2 has been investigated by analysis of the cleavage specificity of recombinant human collagenase-stromelysin-2 hybrid proteins and C terminally truncated collagenase and stromelysin-2. Two series of chimeric proteins were devised by progressive substitution of exon-encoded domains. The recombinant proteins were expressed in COS-7 cells as protein A-fusion proteins and purified on an IgG affinity matrix. Treatment with 4-aminophenylmercuric acetate released active metalloproteinase of the sizes predicted for the chimeric proteins. Active forms of both the chimeric protein series and the short form enzymes expressed both casein- and gelatin-degrading activities. Like stromelysin, the catalytic activity of stromelysin-2 was contained in the N-terminal domain (encoded by exons 1-5) and was apparently independent of the C-terminal domain (encoded by exons 6-10). Only full-length collagenase displayed a triple helicase (collagenolytic) activity; no combination of N- or C-terminal collagenase domains fused with stromelysin-2 domains had such activity. This suggests that the triple helicase activity is a composite of elements derived from both halves of the collagenase molecule. C terminally truncated collagenase (exons 1-5) and a hybrid of collagenase exons 1-5 and stromelysin-2 exons 6-10 cleaved denatured type I collagen (gelatin) to generate diagnostic peptides in gelatin fingerprint assays. When exon 5 (the exon encoding the zinc-binding domain) was derived from stromelysin-2, the enzyme specificity in the finger-print assay changed to that of native stromelysin-2. In contrast, when exon 5 was derived from collagenase, the specificity reflected that of the parent enzyme. Our data also suggest that mismatching of exons 2 and 5 destabilizes the enzyme, presumably by altering the geometry of the propeptide-zinc-binding site interaction. We conclude that the loss of triple helicase collagenolytic activity is not accompanied by a shift to the broad specificity characteristic of stromelysin. Rather, the zinc-binding domain confers a distinct cleavage specificity on each metalloproteinase.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Breathnach, Richard/K-7599-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023539] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 23539] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ALLAN JA, 1991, J CELL SCI, V99, P789; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN B, 1988, BIOCHEMISTRY-US, V27, P6751, DOI 10.1021/bi00418a016; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FISHER SJ, 1992, IN PRESS EXTRACELLUL; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GROSS J, 1974, BIOCHEM BIOPH RES CO, V61, P555; GRUNDSTROM T, 1985, NUCLEIC ACIDS RES, V13, P3305, DOI 10.1093/nar/13.9.3305; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; JENNE D, 1991, BIOCHEM BIOPH RES CO, V176, P1000, DOI 10.1016/0006-291X(91)90381-G; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Maniatis T., 1982, MOL CLONING; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nagase H, 1992, Matrix Suppl, V1, P421; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; PARK AJ, 1991, J BIOL CHEM, V266, P1584; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; QUINN CO, 1990, J BIOL CHEM, V265, P22342; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SAUS J, 1988, J BIOL CHEM, V263, P6742; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888	52	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7238	7247						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463259				2022-12-25	WOS:A1993KV14100062
J	ELDAR, H; BENAV, P; SCHMIDT, US; LIVNEH, E; LISCOVITCH, M				ELDAR, H; BENAV, P; SCHMIDT, US; LIVNEH, E; LISCOVITCH, M			UP-REGULATION OF PHOSPHOLIPASE-D ACTIVITY-INDUCED BY OVEREXPRESSION OF PROTEIN-KINASE C-ALPHA - STUDIES IN INTACT SWISS/3T3 CELLS AND IN DETERGENT-SOLUBILIZED MEMBRANES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE BREAKDOWN; GROWTH-FACTOR; SIGNAL TRANSDUCTION; COMMON MECHANISM; 3T3 FIBROBLASTS; HYDROLYSIS; DIACYLGLYCEROL; ACTIVATION; PHOSPHATIDYLETHANOLAMINE; GENERATION	The role of protein kinase C in the mechanism of phospholipase D activation by platelet-derived growth factor and 12-O-tetradecanoylphorbol-13-acetate was studied in Swiss/3T3 fibroblasts that overexpress protein kinase C-alpha. Production of [H-3]phosphatidylpropanol (specific product of the phospholipase D-catalyzed transphosphatidylation reaction) was determined in cells which were prelabeled with [H-3]oleic acid. Accumulation of [H-3]phosphatidylpropanol in response to platelet-derived growth factor and 12-O-tetradecanoylphorbol-13-acetate was 2-3-fold greater in protein kinase C-alpha-overexpressing SF1.4 cells compared with the vector control cells, SC1. Basal [H-3] phosphatidylpropanol production also was 2-fold higher in SF1.4 cells than in SC1 cells. Hence, -fold stimulation of basal phospholipase D activity by platelet-derived growth factor and 12-O-tetradecanoyl-phorbol-13-acetate was comparable in the two cell lines and was not significantly altered by the overexpression of protein kinase C-alpha. Similarly, overexpression of protein kinase C-alpha did not affect either the kinetics of phospholipase D activation nor its dependence on platelet-derived growth factor or 12-O-tetradecanoylphorbol-13-acetate concentration. In vitro assay of phospholipase D activity in membranes isolated from the cells, utilizing exogenous [H-3]phosphatidylcholine as a substrate, revealed nearly 2-fold higher phospholipase D activity in SF1.4 cell membranes. Kinetic analysis of detergent-solubilized phospholipase D activity indicated that the apparent V(max) and K(m) of phospholipase D derived from SF1.4 and SF3.2 (protein kinase C-alpha-overexpressing) cells are significantly higher than those of phospholipase D from control cells. These results indicate that in Swiss/3T3 cells overexpression of protein kinase C-alpha elevates basal and agonist-stimulated phospholipase D activity in intact cells as well as phospholipase D activity in vitro. These data are consistent with the hypothesis that overexpression of protein kinase C-alpha up-regulates phospholipase D, leading to a constitutive higher level of enzyme activity. Thus, protein kinase C-alpha may play a role in regulating phospholipase D expression.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686				BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1990, BIOCHEM SOC T, V18, P484, DOI 10.1042/bst0180484; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DANIN M, 1993, LIPID METABOLISM SIG; ELDAR H, 1990, J BIOL CHEM, V265, P13290; EXTON JH, 1990, J BIOL CHEM, V265, P1; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1989, J BIOL CHEM, V264, P1483; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; Raber J, 1991, Eur Cytokine Netw, V2, P281; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; WAKELAM MJO, 1991, BIOCHEM SOC T, V19, P321, DOI 10.1042/bst0190321; WARTMANN M, 1991, CELL REGUL, V2, P491, DOI 10.1091/mbc.2.6.491	28	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12560	12564						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509396				2022-12-25	WOS:A1993LG65800051
J	FEENER, EP; BACKER, JM; KING, GL; WILDEN, PA; SUN, XJ; KAHN, CR; WHITE, MF				FEENER, EP; BACKER, JM; KING, GL; WILDEN, PA; SUN, XJ; KAHN, CR; WHITE, MF			INSULIN STIMULATES SERINE AND TYROSINE PHOSPHORYLATION IN THE JUXTAMEMBRANE REGION OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVITY; BETA-SUBUNIT; THREONINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HEPATOMA-CELLS; AMINO-ACIDS; AUTOPHOSPHORYLATION; IDENTIFICATION; RESIDUES; DOMAIN	Insulin-stimulated autophosphorylation of the cytoplasmic juxtamembrane region of the human insulin receptor was examined by Tricine/SDS-PAGE. Various mutant receptor molecules were used to identify two tryptic phosphopeptides associated with the juxtamembrane region which accounts for 15% of the autophosphorylation of partially purified insulin receptor. These phosphopeptides were immunoprecipitated with an antipeptide antibody against the juxtamembrane sequence and were phosphorylated exclusively on tyrosine. Substitution of both Tyr960 and Tyr953 with alanine eliminated insulin-stimulated phosphorylation of the juxtamembrane region without affecting tyrosine autophosphorylation in the C terminus or regulatory regions. Monosubstitution of Tyr960 with phenylalanine or alanine reduced phosphorylation in the juxtamembrane region by more than 50%, and manual Edman degradation indicated that Tyr960 was phosphorylated in wild-type receptor. In vivo, phosphorylation of the juxtamembrane region accounts for one-third of the insulin receptor phosphorylation and contains both phosphoserine and phosphotyrosine. Deletion of Tyr960 and 11 adjacent amino acids eliminated insulin-stimulated phosphorylation of the juxtamembrane region. Substitution of Tyr960 reduced this phosphorylation by more than 50%. The insulin receptor also undergoes serine phosphorylation outside of the juxtamembrane region which depends on the presence of Tyr1151. Together with our previous studies, this report suggests that phosphorylation of Tyr960 may play an important role in signal transduction by the insulin receptor.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	FEENER, EP (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036433, R55DK038712, R01DK033201, R29DK038712, R01DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, DK 38712, DK 36433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CHOU CK, 1987, J BIOL CHEM, V262, P1842; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HERRERA R, 1985, P NATL ACAD SCI USA, V82, P7899, DOI 10.1073/pnas.82.23.7899; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P21804; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	41	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11256	11264						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496180				2022-12-25	WOS:A1993LD46600079
J	FERNANDEZCHECA, JC; OOKHTENS, M; KAPLOWITZ, N				FERNANDEZCHECA, JC; OOKHTENS, M; KAPLOWITZ, N			SELECTIVE INDUCTION BY PHENOBARBITAL OF THE ELECTROGENIC TRANSPORT OF GLUTATHIONE AND ORGANIC-ANIONS IN RAT-LIVER CANALICULAR MEMBRANE-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOBILIARY TRANSPORT; HEPATIC GLUTATHIONE; MUTANT RATS; EFFLUX; HEPATOCYTES; INHIBITION; CONJUGATE; HYPERBILIRUBINEMIA; METHIONINE; KINETICS	Glutathione is excreted into bile via a low affinity, electrogenic, ATP-independent transport system which is cis-inhibited and trans-stimulated by certain organic anions (Fernandez-Checa, J. C., Takikawa, H., Horie, T., Ookhtens, M., and Kaplowitz N. (1992) J. Biol. Chem. 267, 1667-1673). This transport system differs from the sinusoidal carrier in several respects, such as affinity for transport and inhibitor specificity. Another differential aspect is the selective increase by phenobarbital pretreatment of GSH excretion into bile without changing the sinusoidal release into blood. To determine if phenobarbital induces the GSH transporter in the canalicular membrane and if this is reflected in the induction of organic anion transport, we have used rat liver canalicular (cLPM) and sinusoidal (bLPM) enriched membrane vesicles from liver of control (saline) and phenobarbital-treated rats. cLPM vesicles prepared from phenobarbital-pretreated rats exhibited a significant, 46% increase in V(max) for transport (9.02 +/- 0.3 versus 6.17 +/- 0.5 nmol/mg/15 s) without a change in the K(m) for GSH transport (14.0 +/- 1.1 versus 16.7 +/- 2.7 mM, respectively). Kinetic parameters for GSH transport in bLPM vesicles remained unchanged after phenobarbital treatment versus control (V(max), 4.67 +/- 0.2 versus 4.77 +/- 0.2 nmol/mg/15 s; K(m), 7.79 +/- 0.8 versus 6.95 +/- 0.8 mM, respectively). Phenobarbital treatment increased the electrogenic transport of [S-35]sulfobromophthalein (BSP) (5 and 50 muM) but not the electrogenic uptake of [C-14] glycocholic acid (10 and 200 muM). In addition, the ATP-dependent transport of [S-35]BSP, [H-3]leukotriene C4, and [C-14]glycocholic acid into cLPM vesicles was not altered by phenobarbital treatment. The ATP-independent transport of [S-35]BSP in cLPM was cis-inhibited and trans-stimulated by GSH, supporting the view that BSP and GSH share a common multispecific transporter. Thus, among the various canalicular transport systems, the multispecific electrogenic organic anion and GSH transport system is selectively induced by phenobarbital treatment.	UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033	University of Southern California	FERNANDEZCHECA, JC (corresponding author), UNIV BARCELONA,HOSP CLIN & PROV,SERV BIOQUIM,UNIDAD HIGADO,VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990	NIDDK NIH HHS [DK 30312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030312, R37DK030312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1984, J BIOL CHEM, V259, P9355; AWASTHI YC, 1981, BLOOD, V58, P733; BALATORI N, 1989, AM J PHYSIOL, V256, pG22; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; Fiske CH, 1925, J BIOL CHEM, V66, P375; GARCIARUIZ C, 1992, J BIOL CHEM, V267, P22256; Hatefi Y, 1978, Methods Enzymol, V53, P21; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; NISHIDA T, 1992, HEPATOLOGY, V16, P149; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10836	10841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496149				2022-12-25	WOS:A1993LD46600022
J	HOLMBERGBETSHOLTZ, I; LUND, E; BJORKHEM, I; WIKVALL, K				HOLMBERGBETSHOLTZ, I; LUND, E; BJORKHEM, I; WIKVALL, K			STEROL 27-HYDROXYLASE IN BILE-ACID BIOSYNTHESIS - MECHANISM OF OXIDATION OF 5-BETA-CHOLESTANE-3-ALPHA,7-ALPHA,12-ALPHA,27-TETROL INTO 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER-MITOCHONDRIA; ALCOHOL-DEHYDROGENASE; CYTOCHROME-P-450; 5-BETA-CHOLESTANE-3-ALPHA; 7-ALPHA; 26-HYDROXYLATION; 12-ALPHA-TRIOL; HYDROXYLASES; ADRENODOXIN; CONVERSION	The sequence of reactions catalyzed by sterol 27-hydroxylase (CYP27) in the oxidation of 5beta-cholestane-3alpha,7alpha,12alpha,27-tetrol into 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid was studied with apparently homogeneous preparations of the cytochrome P-450 from rabbit liver mitochondria. Conditions are described for the formation and characterization of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-27-al as an enzymatically generated intermediate in the oxidation process. Incubation of 5beta-cholestane-3alpha,7alpha,12alpha-triol or 5beta-cholestane-3alpha,7alpha,12alpha,27-tetrol with sterol 27-hydroxylase in (O2)-O-18 atmosphere resulted in the incorporation of one or two (O2)-O-18 atoms in the carboxyl group of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. Similar incubations with 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-27-al resulted in the incorporation of one O-18 atom in the 27-carboxyl group. The results strongly indicate that the sterol 27-hydroxylase performs multiple monooxygenations in the conversion of 5beta-cholestane-3alpha,7alpha,12alpha-triol into 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. The following reaction sequence (Reaction 1) at carbon 27 is proposed.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	HOLMBERGBETSHOLTZ, I (corresponding author), UNIV UPPSALA,DEPT PHARMACEUT BIOCHEM,S-75123 UPPSALA,SWEDEN.			Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXEN E, 1992, BIOCHEM J, V287, P725, DOI 10.1042/bj2870725; BATTA AK, 1983, J LIPID RES, V24, P94; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1974, BIOCHEM BIOPH RES CO, V57, P870, DOI 10.1016/0006-291X(74)90627-5; BJORKHEM I, 1985, NEW COMPREHENSIVE BI, V12, P231; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHU JW, 1973, J BIOL CHEM, V248, P2089; CRONHOLM T, 1970, EUR J BIOCHEM, V16, P373, DOI 10.1111/j.1432-1033.1970.tb01091.x; DAHLBACK H, 1990, BIOCHEM BIOPH RES CO, V167, P391, DOI 10.1016/0006-291X(90)92034-W; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V157, P30, DOI 10.1016/S0006-291X(88)80006-8; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V153, P267, DOI 10.1016/S0006-291X(88)81217-8; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P354, DOI 10.1016/0165-6147(89)90007-2; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; HANSON RF, 1980, J BIOL CHEM, V255, P1483; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; HUME R, 1984, EUR J BIOCHEM, V140, P583, DOI 10.1111/j.1432-1033.1984.tb08142.x; JONSSON KH, 1990, CHEM-BIOL INTERACT, V75, P267, DOI 10.1016/0009-2797(90)90070-4; KELLIS JT, 1987, J BIOL CHEM, V262, P8840; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OKUDA A, 1983, J BIOL CHEM, V258, P2899; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OKUDA K, 1968, BIOCHEM BIOPH RES CO, V33, P788, DOI 10.1016/0006-291X(68)90229-5; OKUDA K, 1970, BIOCHIM BIOPHYS ACTA, V222, P141; OMURA T, 1964, J BIOL CHEM, V239, P2379; SJOVALL J, 1985, BIOCHIM BIOPHYS ACTA, V836, P8, DOI 10.1016/0005-2760(85)90213-9; WAHLEN E, 1989, J LIPID RES, V30, P1847; WIKVALL K, 1984, J BIOL CHEM, V259, P3800; WOOD AW, 1988, J BIOL CHEM, V263, P17322	30	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11079	11085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496170				2022-12-25	WOS:A1993LD46600055
J	TANAKA, S; SAITO, K; REED, JC				TANAKA, S; SAITO, K; REED, JC			STRUCTURE-FUNCTION ANALYSIS OF THE BCL-2 ONCOPROTEIN - ADDITION OF A HETEROLOGOUS TRANSMEMBRANE DOMAIN TO PORTIONS OF THE BCL-2-BETA PROTEIN RESTORES FUNCTION AS A REGULATOR OF CELL-SURVIVAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR LYMPHOMA; MONOCLONAL-ANTIBODY; MEMBRANE PROTEIN; GENE; EXPRESSION; DEATH; MITOCHONDRIAL; APOPTOSIS; GROWTH; LINES	The bcl-2 gene can potentially encode 26-and 22-kDa proteins that differ only in their carboxyl tails because of an alternative splicing mechanism. The larger of these proteins contains a hydrophobic transmembrane domain within its carboxyl terminus, resides (at least in part) in mitochondrial membranes and has been shown to prolong cell survival by blocking programmed cell death (also termed ''apoptosis''). To explore the function of the shorter 22-kDa Bcl-2 protein that lacks a transmembrane domain, DNAs encoding p26-Bcl-2-alpha or p22-Bcl-2-beta were expressed in an interleukin-3 (IL-3)-dependent hematopoietic cell line 32D. In contrast to p26-Bcl-2alpha that markedly prolonged cell survival, p22-Bcl-2-beta did not extend the survival of 32D cells when cultured in the absence of IL-3. Expression in 32D cells of a chimeric DNA that fused portions of the open reading frame common to Bcl-2-alpha and Bcl-2-beta (amino-acids 1-195) with sequences encoding the transmembrane and cytosolic domains of the IL-2 receptor-a protein resulted in production of a Bcl-2/IL-2R fusion protein that was capable of prolonging 32D cell survival in the setting of IL-3 withdrawal. Based on fractionation of cells to produce crude heavy membrane, light membrane, nuclei, and cytosolic preparations, much of the p22-Bcl-2-beta protein appeared to reside in the cytosol, whereas Bcl-2-alpha and the Bcl-2/IL-2R chimeric proteins were found exclusively in fractions that also contained the inner mitochondrial membrane protein F1-beta-ATPase. Taken together, these findings demonstrate the importance of membrane association for the function and intracellular targeting of the apoptosis-blocking Bcl-2 protein. Furthermore, despite the strong evolutionary conservation of the carboxyl regions of Bcl-2-alpha proteins observed previously for mammalian and avian species, these data suggest that a heterologous transmembrane domain can be substituted without loss of function.	LA JOLLA CANC RES FDN, CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN Y, 1991, J HISTOCHEM CYTOCHEM, V39, P635, DOI 10.1177/39.5.2016513; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKLEWIS I, 1985, EXP HEMATOL, V13, P304; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVANS WH, 1987, BIOL MEMBRANES PRACT, P1; FUJII J, 1989, J BIOL CHEM, V264, P12950; HAMILTON MS, 1991, LEUKEMIA, V5, P768; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORTON R, 1989, GENE, V27, P61; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KUO LM, 1986, BIOCHIM BIOPHYS ACTA, V848, P247, DOI 10.1016/0005-2728(86)90047-2; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MAVILIO F, 1989, ONCOGENE, V4, P301; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NUNEZ G, 1990, J IMMUNOL, V144, P3602; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANHAESEBROECK B, 1993, IN PRESS ONCOGENE; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	43	184	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10920	10926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496157				2022-12-25	WOS:A1993LD46600034
J	CISNEROS, RJ; ZAPF, JW; DUNLAP, RB				CISNEROS, RJ; ZAPF, JW; DUNLAP, RB			STUDIES OF 5-FLUORODEOXYURIDINE-5'-MONOPHOSPHATE BINDING TO CARBOXYPEPTIDASE A-INACTIVATED THYMIDYLATE SYNTHASE FROM LACTOBACILLUS-CASEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX; SYNTHETASE; COVALENT; 5-FLUORO-2'-DEOXYURIDYLATE; SITE	The binding of 5-fluorodeoxyuridylate (FdUMP) to carboxypeptidase-inactivated thymidylate synthase obtained from methotrexate-resistant Lactobacillus casei was investigated using [H-3]FdUMP in a trichloroacetic acid precipitation assay and by F-19 nuclear magnetic resonance spectroscopy. The cleavage of 1 valine residue from the carboxyl terminus of one of the identical subunits of the enzyme dimer correlates with complete loss of thymidylate synthesis (Aull, J. L., Loeble, R. B., and Dunlap, R. B. (1974) J. Biol. Chem. 249, 1167-1172). We have further investigated the phenomenon of carboxypeptidase A-dependent inactivation of thymidylate synthase by employing immobilized carboxypeptidase A in order to facilitate the isolation and characterization of the inactivated enzyme. The time course of carboxypeptidase treatment of thymidylate synthase has been profiled by the spectrophotometric assay, tritium release assay, trichloroacetic acid precipitation assay (covalent adduct analysis), F-19 nuclear magnetic resonance spectroscopy, and amino acid analysis. The techniques utilized in this study yielded results which showed that the completely inactivated enzyme (failure to catalyze thymidylate formation) continued to catalyze both covalent FdUMP-enzyme interactions and the formation of the covalent inhibitory ternary complex with the cofactor, 5,10-methylenetetrahydrofolate, although to a reduced extent, thus effectively uncoupling these processes from thymidylate synthesis activity.	UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R01CA015645] Funding Source: NIH RePORTER; NCI NIH HHS [CA 15645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULL JL, 1974, J BIOL CHEM, V249, P1167; AULL JL, 1974, MICROCHEM J, V19, P210, DOI 10.1016/0026-265X(74)90076-9; BYRD RA, 1978, J AM CHEM SOC, V100, P7478, DOI 10.1021/ja00492a007; CISNEROS R J, 1988, Drugs of the Future, V13, P859; CISNEROS RJ, 1990, ANAL BIOCHEM, V186, P202, DOI 10.1016/0003-2697(90)90067-J; CROMWELL LD, 1969, BIOCHEMISTRY-US, V8, P4735, DOI 10.1021/bi00840a012; DRECHSLER ER, 1959, J BIOL CHEM, V234, P2627; DUNLAP RB, 1971, BIOCHEMISTRY-US, V10, P88, DOI 10.1021/bi00777a014; FINERMOORE JS, 1990, BIOCHEMISTRY-US, V29, P6977, DOI 10.1021/bi00482a005; FOLK JE, 1963, J BIOL CHEM, V238, P3895; FOLK JE, 1963, J BIOL CHEM, V238, P3884; GALIVAN J, 1977, ARCH BIOCHEM BIOPHYS, V184, P346, DOI 10.1016/0003-9861(77)90361-7; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KUMEL G, 1979, J CHROMATOGR, V172, P221, DOI 10.1016/S0021-9673(00)90957-9; LEWIS CA, 1980, BIOCHEMISTRY-US, V19, P116, DOI 10.1021/bi00542a018; LEWIS CA, 1981, TOPICS MOL PHARM, P160; LOMAX MIS, 1967, J BIOL CHEM, V242, P109; LYON JA, 1975, CANCER BIOCHEM BIOPH, V1, P121; MALEY GF, 1979, J BIOL CHEM, V254, P1288; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MCFADDEN BA, 1968, BIOCHEMISTRY-US, V7, P3574, DOI 10.1021/bi00850a035; MOFFAT K, 1973, J BIOL CHEM, V248, P6387; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE MA, 1986, J BIOL CHEM, V261, P2745; MOORE MA, 1986, BIOCHEMISTRY-US, V25, P3311, DOI 10.1021/bi00359a034; RUTTER WJ, 1961, J BIOL CHEM, V236, P3193; SANTI DV, 1984, FOLATES PTERINS, P345; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; Zakrzewski S F, 1980, Methods Enzymol, V66, P529	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10102	10108						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486679				2022-12-25	WOS:A1993LB80000026
J	HUSTEN, EJ; TAUSK, FA; KEUTMANN, HT; EIPPER, BA				HUSTEN, EJ; TAUSK, FA; KEUTMANN, HT; EIPPER, BA			USE OF ENDOPROTEASES TO IDENTIFY CATALYTIC DOMAINS, LINKER REGIONS, AND FUNCTIONAL INTERACTIONS IN SOLUBLE PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE AMIDATION; MESSENGER-RNA; ENZYME; CELLS; PURIFICATION; EXPRESSION; PITUITARY; SEQUENCE; INTERMEDIATE; BIOSYNTHESIS	The production of alpha-amidated peptides is accomplished through the sequential action of two enzymes, peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), that are contained within the bifunctional peptidylglycine alpha-amidating monooxygenase (PAM) protein. Tissue-specific alternative splicing and endoproteolysis are known to generate both soluble and integral membrane mono- and bifunctional PAM proteins. In order to investigate the functional consequences of these differences we purified PAM-3, a soluble 95-kDa bifunctional form of the enzyme, from the spent medium of stably transfected hEK-293 cells. Using NH2-terminal sequence analysis of products of limited endoproteolysis and antibody cross-reactivity we identified protease-sensitive regions at the NH2 terminus, between the 35-kDa PHM and 42-kDa PAL domains and at the COOH terminus of the protein. Endoproteolytic removal of the COOH-terminal region from the bifunctional PAM-3 protein shifted the pH optimum of PHM to a more alkaline pH, increased the turnover number (k(cat)) of PHM and decreased its K(M) for alpha-N-acetyl-Tyr-Val-Gly; the catalytic properties of PAL were not altered. Since peptide amidation can be a rate-limiting step in the biosynthesis of neuropeptides, similar increases in PHM activity in vivo may play an important role in regulating the extent of peptide alpha-amidation.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,WOOD BASIC SCI BLDG,RM 907,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT DERMATOL,BALTIMORE,MD 21205; MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114	Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949, F32DK008504] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 00098] Funding Source: Medline; NIDDK NIH HHS [DK 32949, DK 08504] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDRY GA, 1990, J BIOL CHEM, V265, P17694; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; DUNCAN K, 1987, BIOCHEM J, V246, P375, DOI 10.1042/bj2460375; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; GLAUDER J, 1990, BIOCHEM BIOPH RES CO, V169, P551, DOI 10.1016/0006-291X(90)90366-U; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1991, BIOCHEMISTRY-US, V30, P6189, DOI 10.1021/bi00239a016; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIM HS, 1992, J BIOL CHEM, V267, P7177; MAINS RE, 1991, MOL ENDOCRINOL, V5, P187, DOI 10.1210/mend-5-2-187; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MEHTA NM, 1988, ARCH BIOCHEM BIOPHYS, V261, P44, DOI 10.1016/0003-9861(88)90102-6; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MURTHY ASN, 1986, J BIOL CHEM, V261, P1815; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAMBURINI PP, 1990, INT J PEPT PROT RES, V35, P153; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, V114, P571	38	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9709	9717						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486658				2022-12-25	WOS:A1993LA68900082
J	BALDARI, CT; HEGUY, A; TELFORD, JL				BALDARI, CT; HEGUY, A; TELFORD, JL			CALCIUM-DEPENDENT CYCLOSPORINE-A-SENSITIVE ACTIVATION OF THE INTERLEUKIN-2 PROMOTER BY P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PROTEIN-KINASE; T-CELL RECEPTOR; CD4; EXPRESSION; COMPLEX; ANTIGEN; PHOSPHORYLATION; P56LCK	T-cell antigen receptor engagement results in suboptimal activation of protein kinase C and a prolonged increase in intracellular free calcium concentration. These signals, in combination with stimulation via accessory molecules usually supplied by the antigen presenting cell, activate expression of interleukin-2 (IL-2) and initiate autocrine growth. The lymphocyte-specific tyrosine kinase p56lck is physically associated with CD4 and is brought into close proximity of the intracellular domain of the antigen receptor by CD4 recognition of the major histocompatibility complex during antigen presentation. p56lck activation enhances and may be essential for antigen receptor signaling. We report that a constitutively active form of p56lck delivers a signal which contributes to IL-2 promoter activation. The signal substituted for a calcium-mobilizing signal in a Jurkat cell model of T-cell activation. The activation was sensitive to EGTA and cyclosporin A, indicating that p56lck functions at an early stage of the calcium-mediated pathway. The transcription factor NF-AT mediated, at least in part, the p56lck activation of IL-2 expression. In addition, activated p56lck synergized with constitutively active p21Ha-ras, which can replace protein kinase C activation, resulting in activation of NF-AT in the absence of external signals.	IMMUNOBIOL RES INST SIENA,VIA FIORENTINA 1,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUT BIOL,I-53100 SIENA,ITALY	University of Siena			Telford, John Laird/ABG-8144-2020	Baldari, Cosima/0000-0002-4414-6744				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SEFTON BM, 1991, ONCOGENE, V6, P683; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0	31	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8406	8409						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473282				2022-12-25	WOS:A1993KX81100007
J	BROWN, ED; WOOD, JM				BROWN, ED; WOOD, JM			CONFORMATIONAL CHANGE AND MEMBRANE ASSOCIATION OF THE PUTA PROTEIN ARE COINCIDENT WITH REDUCTION OF ITS FAD COFACTOR BY PROLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PYRUVATE OXIDASE; SALMONELLA-TYPHIMURIUM; OXIDATION-REDUCTION; DEHYDROGENASE; BINDING; ENZYME; FLAVOPROTEINS; PURIFICATION; ACTIVATION	The PutA protein is both the put repressor and a membrane-bound enzyme with proline and DELTA1-pyrroline-5-carboxylate dehydrogenase activities. The conditions required for association of purified PutA protein with membrane vesicles suggested that a redox switching mechanism might determine the proportion of PutA protein functioning as a dehydrogenase (Wood, J. M. (1987) Proc. Natl. Acad. Sci. USA 84,373-377). The FAD cofactor was released from the PutA protein with 1 M KBr at neutral pH. The apoprotein retained DELTA1-pyrroline-5-carboxylate dehydrogenase and DNA binding but not proline dehydrogenase activity. Reconstitution with FAD fully restored proline dehydrogenase activity. Proline at a concentration of 0.11 mm caused half-maximal bleaching of the FAD in PutA. Chymotryptic digestion of the PutA protein in the presence and absence of proline demonstrated that the persistence of a 119-kDa protein fragment was characteristic of the reduced protein. Identical digestion patterns were obtained from the apoprotein in the presence and absence of proline. The quantity of the 119-kDa fragment produced varied with proline concentration, yielding a midpoint of 0.056 mm proline. The fraction of PutA protein associated with membrane vesicles was also a function of proline concentration, yielding a titration midpoint of 0.10 mm proline. Membrane binding was thus coincident with both flavin reduction and a change in protein conformation.	UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT MICROBIOL, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BUCHANAN BB, 1983, FUNCTIONS GLUTATHION, P231; DENDINGER S, 1970, J BACTERIOL, V103, P144, DOI 10.1128/JB.103.1.144-152.1970; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1986, BIOCHEM J, V239, P1; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; Husain M, 1978, Methods Enzymol, V53, P429; Kierkegaard P., 1971, FLAVINS FLAVOPROTEIN, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALOY SR, 1987, ESCHERICHIA COLI SAL, V1, P1513; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASSEY V, 1966, J BIOL CHEM, V241, P3417; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P262; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PUST S, 1989, BIOCHEMISTRY-US, V28, P516, DOI 10.1021/bi00428a016; RUSSELL P, 1977, J BIOL CHEM, V252, P7877; SANNER C, 1991, EUR J BIOCHEM, V196, P663, DOI 10.1111/j.1432-1033.1991.tb15863.x; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SCHROCK HL, 1977, J BIOL CHEM, V252, P5990; SCHROCK HL, 1980, BIOCHIM BIOPHYS ACTA, V614, P215, DOI 10.1016/0005-2744(80)90182-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P6789, DOI 10.1021/bi00370a010; WEIMAR W R, 1975, P1; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373; WOOD JM, 1987, BIOCHEM CELL BIOL, V65, P507, DOI 10.1139/o87-065; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	37	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8972	8979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473341				2022-12-25	WOS:A1993KX81100086
J	KINOSIAN, HJ; SELDEN, LA; ESTES, JE; GERSHMAN, LC				KINOSIAN, HJ; SELDEN, LA; ESTES, JE; GERSHMAN, LC			NUCLEOTIDE BINDING TO ACTIN - CATION DEPENDENCE OF NUCLEOTIDE DISSOCIATION AND EXCHANGE-RATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT METAL-ION; MONOMERIC ACTIN; ADENOSINE 5'-TRIPHOSPHATE; ATP-ACTIN; ADP-ACTIN; KINETICS; AFFINITY; POLYMERIZATION; FLUORESCENCE; MECHANISM	We have reinvestigated nucleotide binding to actin in order to resolve conflicts regarding the mechanism of nucleotide dissociation and exchange. We present evidence that supports a mechanism for nucleotide binding to actin in which the tightly bound divalent cation (Ca2+ or Mg+) directly interacts with the bound nucleotide. The dissociation rates of ATP or ADP from actin are limited by the dissociation of the high affinity divalent cation from actin and vary inversely with free Ca2+ or free Mg2+ concentration. The divalent cation concentration range over which attenuation of the ATP dissociation takes place is about 100-fold greater for Mg2+ than that for Ca2+ due to the much slower association rate constant for Mg2+ compared with Ca2+. The relative affinity for ATP versus ADP is 200:1 for Ca-actin in 100 muM free [Ca2+], and 4:1 for Mg-actin in 100 muM free [Mg2+]. Actin without a tightly bound divalent cation has about a 3-fold greater affinity for ATP than ADP. At constant free divalent cation concentration, the rate of nucleotide exchange on actin is described by competitive binding kinetics.	VET AFFAIRS SAMUEL S STRATTON MED CTR,RES SERV,151-B,HOLLAND AVE,ALBANY,NY 12208; VET AFFAIRS SAMUEL S STRATTON MED CTR,MED SERV,ALBANY,NY 12208; ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208; ALBANY MED COLL,DEPT MED,ALBANY,NY 12208	Albany Medical College; Albany Medical College					NIGMS NIH HHS [GM 32007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BREMER A, 1992, Current Opinion in Cell Biology, V4, P20, DOI 10.1016/0955-0674(92)90054-G; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; ESTES JE, 1987, J BIOL CHEM, V262, P4952; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GERSHMAN LC, 1991, J BIOL CHEM, V266, P76; GERSHMAN LC, 1989, BIOCHIM BIOPHYS ACTA, V995, P109, DOI 10.1016/0167-4838(89)90068-X; GERSHMAN LC, 1986, BIOCHEM BIOPH RES CO, V135, P607, DOI 10.1016/0006-291X(86)90036-7; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.biophys.21.1.49; KINOSIAN HJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P151, DOI 10.1016/0167-4838(91)90052-2; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; MANNHERZ HG, 1992, J BIOL CHEM, V267, P11661; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NEIDL C, 1979, EUR J BIOCHEM, V101, P163; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P8613, DOI 10.1021/bi00423a016; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; SELDEN LA, 1986, J MUSCLE RES CELL M, V7, P215, DOI 10.1007/BF01753554; SELDEN LA, 1987, FEBS LETT, V217, P89, DOI 10.1016/0014-5793(87)81249-8; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; STROHMAN RC, 1962, J BIOL CHEM, V237, P363; STRZELECKAGOLASZEWSKA H, 1985, EUR J BIOCHEM, V147, P331, DOI 10.1111/j.1432-1033.1985.tb08754.x; SZENTGYORGYI A, 1951, CHEM MUSCULAR CONTRA, P146; THAMES KE, 1974, BIOCHEM BIOPH RES CO, V60, P1252, DOI 10.1016/0006-291X(74)90333-7; UE K, 1992, EUR J BIOCHEM, V203, P493, DOI 10.1111/j.1432-1033.1992.tb16574.x; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; WAECHTER F, 1977, EUR J BIOCHEM, V74, P227, DOI 10.1111/j.1432-1033.1977.tb11385.x; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; WANGER M, 1983, FEBS LETT, V162, P112, DOI 10.1016/0014-5793(83)81059-X; WEST JJ, 1971, BIOCHEMISTRY-US, V10, P3547, DOI 10.1021/bi00795a009	39	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8683	8691						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473312				2022-12-25	WOS:A1993KX81100048
J	MUKAI, K; IMAI, M; SHIMADA, H; ISHIMURA, Y				MUKAI, K; IMAI, M; SHIMADA, H; ISHIMURA, Y			ISOLATION AND CHARACTERIZATION OF RAT CYP11B GENES INVOLVED IN LATE STEPS OF MINERALOCORTICOID AND GLUCOCORTICOID SYNTHESES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSTERONE SYNTHASE CYTOCHROME-P-450; BOVINE ADRENOCORTICAL MITOCHONDRIA; MOUSE STEROID 11-BETA-HYDROXYLASE; ADRENAL-CORTEX; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; P-450(11-BETA) GENES; MAMMALIAN-CELLS; PROMOTER REGION; EXPRESSION	We isolated and characterized four forms of ra CYP11B genes, which were tentatively name CYP11B1,-B2,-B3, and-B4. Genomic Southern analyses indicated that the members of the rat CYP11 gene subfamily were confined to these four genes; among them, CYP11B1 and -B2 encoded steroid 11beta-hydroxylase and aldosterone synthase, respectively, while CYP11B3 was a gene highly homologous to CYP11B1 without a known expression product. By being devoid of a region spanning two exons conserved in the other three, CYP11B4 was presumably a pseudogene. In the nucleotide sequences, CYP11B1, -B3, and -B4 showed 95-96 and 93-100% identities in the coding and 0.5-kilobase 5'-flanking regions, respectively. However, the homology between the nucleotide sequences of one of the three and CYP11B2 was rather low, about 90 and 50% in the coding and 0.5-kilobase 5'-flanking regions, respectively. As a whole, CYP11B2 rather than CYP11B1, -B3, or -B4 was more homologous to CYP11B genes of other animals such as cow and human. In transient transfection experiments using mouse adrenocortical Y1 cells and chloramphenicol acetyltransferase gene constructs, the 0.5-kilobase 5'-flanking region of CYP11B1 had a 4- and 10-fold higher promoter activity than the corresponding regions of CYP11B2 and-B3, respectively. The possible presence of a suppressive element(s) was noted in the upstream of the 0.5-kilobase region of CYP11B1. Although a variant of cAMP-responsive element, which was present in rat CYP11B2 and all known CYP11B genes of other animals, was modified in rat CYP11B1 and -B3 genes, dibutyryl cAMP stimulated all the promoter activities of the 5'-flanking regions of the rat genes by 3-fold.	KEIO UNIV, SCH MED,DEPT BIOCHEM,35 SHINANOMACHI,SHINJUKU KU, TOKYO 160, JAPAN	Keio University				Mukai, Kuniaki/0000-0002-9590-5077				BIGLIERI EG, 1987, ANN NY ACAD SCI, V512, P426, DOI 10.1111/j.1749-6632.1987.tb24978.x; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMAINABA H, 1987, CELL STRUCT FUNCT, V12, P173, DOI 10.1247/csf.12.173; HASHIMOTO T, 1989, J BIOCHEM-TOKYO, V105, P676, DOI 10.1093/oxfordjournals.jbchem.a122725; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; IKUSHIRO SI, 1992, J BIOL CHEM, V267, P1464; IMAI M, 1990, FEBS LETT, V263, P299, DOI 10.1016/0014-5793(90)81398-8; IMAI M, 1992, J BIOCHEM-TOKYO, V111, P440, DOI 10.1093/oxfordjournals.jbchem.a123776; KAWAMOTO T, 1990, FEBS LETT, V269, P345, DOI 10.1016/0014-5793(90)81190-Y; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KIRITA S, 1990, J BIOCHEM, V108, P1030, DOI 10.1093/oxfordjournals.jbchem.a123302; KIRITA S, 1988, J BIOCHEM-TOKYO, V104, P683, DOI 10.1093/oxfordjournals.jbchem.a122533; LAUBER M, 1987, J STEROID BIOCHEM, V26, P693, DOI 10.1016/0022-4731(87)91041-7; LAUBER M, 1989, ARCH BIOCHEM BIOPHYS, V274, P109, DOI 10.1016/0003-9861(89)90421-9; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; MORNET E, 1989, J BIOL CHEM, V264, P20961; MOROHASHI K, 1990, J BIOCHEM, V107, P635, DOI 10.1093/oxfordjournals.jbchem.a123099; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V102, P559, DOI 10.1093/oxfordjournals.jbchem.a122089; MOROHASHI KI, 1990, J BIOCHEM-TOKYO, V108, P1050, DOI 10.1093/oxfordjournals.jbchem.a123304; MOUW AR, 1989, J BIOL CHEM, V264, P1305; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; Muller J., 1988, REGULATION ALDOSTERO; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; NONAKA Y, 1991, EUR J BIOCHEM, V202, P897, DOI 10.1111/j.1432-1033.1991.tb16449.x; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OGISHIMA T, 1989, J BIOCHEM-TOKYO, V105, P497, DOI 10.1093/oxfordjournals.jbchem.a122694; QUINN SJ, 1988, ANNU REV PHYSIOL, V50, P409, DOI 10.1146/annurev.ph.50.030188.002205; RICE DA, 1989, J BIOL CHEM, V264, P14011; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WADA A, 1985, J BIOCHEM-TOKYO, V98, P245, DOI 10.1093/oxfordjournals.jbchem.a135264; YABU M, 1991, HISTOCHEMISTRY, V96, P391, DOI 10.1007/BF00315995; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P3556; YANAGIBASHI K, 1988, J STEROID BIOCHEM, V29, P665	51	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9130	9137						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473352				2022-12-25	WOS:A1993KX81100106
J	COLLEN, D; SCHLOTT, B; ENGELBORGHS, Y; VANHOEF, B; HARTMANN, M; LIJNEN, HR; BEHNKE, D				COLLEN, D; SCHLOTT, B; ENGELBORGHS, Y; VANHOEF, B; HARTMANN, M; LIJNEN, HR; BEHNKE, D			ON THE MECHANISM OF THE ACTIVATION OF HUMAN PLASMINOGEN BY RECOMBINANT STAPHYLOKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE MUTAGENIZED PLASMINOGEN; T-PA; PURIFICATION; EXPRESSION; PROTEIN	The mechanism of activation of human plasminogen by recombinant staphylokinase (STAR) was studied using the active site titrant p-nitrophenyl-p'-guanidinobenzoate (NPGB). NPGB prevented active site exposure in equimolar mixtures of plasminogen and STAR but reacted stoichiometrically with mixtures preincubated in the absence of titrant. Active site generation occurred progressively, with a marked initial lag phase followed by an exponential growth phase, and was associated with the conversion of single-chain plasminogen to two-chain plasmin. Incubation of mixtures of plasminogen and STAR with catalytic amounts (<0.2% molar ratio) of preformed plasmin.STAR complex or of urokinase shortened the lag hase, whereas catalytic amounts (5% molar ratio) of the plasmin inhibitor alpha2-antiplasmin delayed active site generation. The following kinetic model for the activation of plasminogen (P) by STAR (S) fits the experimental data, [GRAPHICS] and is described by [GRAPHICS] or [GRAPHICS] In this model, plasminogen and STAR produce an inactive complex (P.S), in which active plasmin.STAR (p.S) is generated in a rate limiting step, which is accelerated by plasminogen activators and delayed by plasmin inhibitors. At room temperature in a 0.1 M Veronal buffer, pH 8.3, containing 0.1 M arginine, the data are adequately fitted by the integrated equation with k1 = 4.0 x 10(-7) s-1 and k2 = 1.3 x 10(-2) muM-1 s-1. The k1 value could be explained by contamination of the plasminogen preparation with 3 ppm plasmin, converted by S to p.S. It is concluded that STAR activates plasminogen via a mechanism which differs in several essential aspects from that of streptokinase.	CATHOLIC UNIV LEUVEN,PHYS BIOCHEM LAB,B-3000 LOUVAIN,BELGIUM; INST MOLEC BIOTECHNOL,O-6900 JENA,GERMANY	KU Leuven	COLLEN, D (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,O&N,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Lijnen, Roger/AAA-4085-2020					BEHNKE D, 1987, MOL GEN GENET, V210, P528, DOI 10.1007/BF00327208; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1992, FIBRINOLYSIS, V6, P232, DOI 10.1016/0268-9499(92)90076-T; COLLEN D, 1992, IN PRESS CIRCULATION; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICSON R, 1977, CHEM ABSTR, V86, P202; GAFFNEY PJ, 1985, THROMB HAEMOSTASIS, V53, P134; GERLACH D, 1988, ZBL BAKT-INT J MED M, V269, P314; KANAI K, 1986, BIOL ABSTR, V81, P748; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1964, AM J PHYSIOL, V207, P1049, DOI 10.1152/ajplegacy.1964.207.5.1049; LEWIS JH, 1964, AM J PHYSIOL, V207, P1044, DOI 10.1152/ajplegacy.1964.207.5.1044; LEWIS JH, 1951, AM J PHYSIOL, V166, P594, DOI 10.1152/ajplegacy.1951.166.3.594; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; LIJNEN HR, 1990, THROMB HAEMOSTASIS, V64, P61; MATSUO O, 1990, BLOOD, V76, P925; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NELLES L, 1987, J BIOL CHEM, V262, P10855; SWEET B, 1965, CLIN SCI, V29, P375; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	26	93	95	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8284	8289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463338				2022-12-25	WOS:A1993KW97900101
J	STOJILKOVIC, SS; KUKULJAN, M; TOMIC, M; ROJAS, E; CATT, KJ				STOJILKOVIC, SS; KUKULJAN, M; TOMIC, M; ROJAS, E; CATT, KJ			MECHANISM OF AGONIST-INDUCED [CA2+]I OSCILLATIONS IN PITUITARY GONADOTROPHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; CALCIUM OSCILLATIONS; INOSITOL TRISPHOSPHATE; CA-2+ OSCILLATIONS; TUMOR PROMOTER; THAPSIGARGIN; HORMONE; ACTIVATION; MOBILIZATION; METABOLISM	Gonadotropin-releasing hormone (GnRH) activates oscillatory Ca2+ signaling in pituitary gonadotrophs at a frequency (up to 25 min-1) that is dose-dependent and is determined by the degree of receptor-mediated inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) formation. Similar dose-dependent and frequency-modulated Ca2+ oscillations were elicited by intracellular administration of Ins(1,4,5)P3 and its nonhydrolyzable analogs, consistent with models in which Ins(1,4,5)P3 levels determine the frequency of Ca2+ oscillations but do not fluctuate in synchrony with [Ca2+]i. At constant agonist concentrations, Ca2+ spiking varied in amplitude, with a number of progressively larger transients before the onset of maximal oscillations, followed by a gradual decrease in spike amplitude that was accompanied by an increase in spiking frequency. The decline in the amplitude and increase in frequency of Ca2+ transients during stimulation by GnRH were not related to a decrease in the propagation of the Ca2+ signal within the cell but were associated with gradual depletion of the agonist-sensitive Ca2+ pool. Once initiated, the pattern of Ca2+ spiking was not altered by blockade of receptor occupancy, by inhibition of phospholipase C, or by reduction of extracellular [Ca2+]. Also, the endoplasmic reticulum (Ca2+)-ATPase blocker, thapsigargin, could substitute for Ins(1,4,5)P3, in initiating the oscillatory Ca2+ response. These findings indicate that although the Ins(1,4,5)P3 concentration determines the pattern of transients at the initiation of the oscillatory Ca2+ signal, maintenance of the signal does not require a sustained rise in Ins(1,4,5)P3. Since the frequency of Ca2+ oscillations is also influenced by depletion of luminal [Ca2+], it is possible that the Ins(1,4,5)P3-sensitive channels in the endoplasmic reticulum are tonically inhibited by high intraluminal Ca2+ levels and that Ins(1,4,5)P3 surmounts such inhibition by promoting Ca2+ discharge. When a critical level of Ca2+ discharge is attained, repetitive Ca2+ transients are generated by an autocatalytic mechanism in which a sustained rise in Ins(1,4,5)P3 is not an essential requirement.	NIDDKD,CELL BIOL & GENET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	STOJILKOVIC, SS (corresponding author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,BLDG 49,RM 6A-36,BETHESDA,MD 20892, USA.		Tomic, Melanija/C-3371-2016					BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; CHANG JP, 1988, J BIOL CHEM, V263, P18614; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; ELY JA, 1991, J BIOL CHEM, V266, P18635; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; IIDA T, 1991, MOL ENDOCRINOL, V5, P949, DOI 10.1210/mend-5-7-949; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LEONG DA, 1991, J BIOL CHEM, V266, P9016; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RAWLINGS SR, 1991, J BIOL CHEM, V266, P22755; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1990, SCIENCE, V248, P1662; SWILLENS S, 1990, BIOCHEM J, V271, P835, DOI 10.1042/bj2710835; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; YULE DI, 1992, J BIOL CHEM, V267, P13830	32	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7713	7720						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463300				2022-12-25	WOS:A1993KW97900022
J	LEBIVIC, A; GARCIA, M; RODRIGUEZBOULAN, E				LEBIVIC, A; GARCIA, M; RODRIGUEZBOULAN, E			RICIN-RESISTANT MADIN-DARBY CANINE KIDNEY-CELLS MISSORT A MAJOR ENDOGENOUS APICAL SIALOGLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; CYTOPLASMIC DOMAIN; SURFACE POLARITY; GOLGI-COMPLEX; LINE; MECHANISM; PHENOTYPE	gp114 is a major sialoglycoprotein expressed on the apical membrane of Madin-Darby canine kidney (MDCK) II cells. We investigated its distribution in two lectin-resistant mutant cell lines derived from MDCKII cells, MDCKII-RCA(r) and MDCKII-ConA(r) cells. gp114 was present on the apical membrane of MDCKII-ConA(r) cells but was predominantly basolateral in MDCKII-RCA(r) cells. No change of polarity was observed for several apical and basolateral markers in this cell line. Reversal of polarity of gp114 mainly resulted from a modification of its intracellular sorting. gp114 showed altered endocytosis in MDCKII-RCA(r) cells. In MDCKII cells gp114 was slowly endocytosed, whereas in MDCKII-RCA(r) cells endocytosis of gp114 was highly increased. Using mannosidase I and II inhibitors we found that N-glycosylation only slightly affects gp114 sorting and endocytosis. Our results suggest that gp114 or an associated component in MDCK-RCA(r) fails to express apical information or that a mutation creates a basolateral sorting signal which could be related to endocytic signals.	CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA	Cornell University	LEBIVIC, A (corresponding author), FAC SCI LUMINY, URA 179, F-13288 MARSEILLE 9, FRANCE.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34107, R01 GM034107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BRANDLI AW, 1990, J CELL BIOL, V111, P2909, DOI 10.1083/jcb.111.6.2909; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GRAEVE L, 1989, J CELL BIOL, V109, P2809, DOI 10.1083/jcb.109.6.2809; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SAMBUY Y, 1988, P NATL ACAD SCI USA, V85, P1529, DOI 10.1073/pnas.85.5.1529; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623	39	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6909	6916						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463221				2022-12-25	WOS:A1993KV14100020
J	OKAMOTO, K; WAKAMIYA, M; NOJI, S; KOYAMA, E; TANIGUCHI, S; TAKEMURA, R; COPELAND, NG; GILBERT, DJ; JENKINS, NA; MURAMATSU, M; HAMADA, H				OKAMOTO, K; WAKAMIYA, M; NOJI, S; KOYAMA, E; TANIGUCHI, S; TAKEMURA, R; COPELAND, NG; GILBERT, DJ; JENKINS, NA; MURAMATSU, M; HAMADA, H			A NOVEL CLASS OF MURINE POU GENE PREDOMINANTLY EXPRESSED IN CENTRAL-NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER RNA; TRANSCRIPTION FACTOR; DNA-BINDING; DOMAIN; PROTEIN; SEQUENCE; OCT-1; CELLS; DROSOPHILA; REGION	A mouse gene (referred to as Emb) encoding a novel class of POU domain is described. The Emb POU domain shares only 40-50% homology to that of any other POU proteins. Nonetheless, the Emb POU domain can bind to the octamer sequence like other POU domains. Emb is a single-copy gene, located on the distal region of mouse chromosome 15. It is expressed in embryo throughout post-implantation stages, where the most prominent expression is seen in developing central nervous system. In the adult, it is highly expressed in brain, whereas weaker expression can be detected in other organs such as testis, skeletal muscle, and kidney. The expression in adult brain is most evident in neurons of hypocampus formation. Two types of Emb mRNA are expressed in brain; one type encodes a protein of 301 amino acids residues, whereas the other codes for a protein with two extra amino acids residues added at the amino-terminal end of POU domain. These two mRNA species are generated by alternative splicing by utilizing an unusual splice acceptor site: CCTCCCTCTG/. Emb mRNA expressed in testis, on the other hand, encodes a smaller protein lacking most of the amino-terminal region.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, HONGO 7-3-1, BUNKYO KU, TOKYO 113, JAPAN; OKAYAMA UNIV, SCH DENT, DEPT BIOCHEM, OKAYAMA 700, JAPAN; TORANOMON GEN HOSP, OKINAKA MEM RES INST, TOKYO 113, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	University of Tokyo; Okayama University; Toranomon Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BRANNAN CI, 1992, GENOMICS, V13, P1075, DOI 10.1016/0888-7543(92)90021-J; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; Green EL, 1981, GENETICS PROBABILITY, P77; Green MC., 1989, GENETIC VARIANTS STR, P12; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON WA, 1990, NATURE, V343, P467, DOI 10.1038/343467a0; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WARING GL, 1990, DEV BIOL, V142, P1, DOI 10.1016/0012-1606(90)90146-A; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	32	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7449	7457						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463278				2022-12-25	WOS:A1993KV14100089
J	RANSOHOFF, RM; HAMILTON, TA; TANI, M; STOLER, MH; SHICK, HE; MAJOR, JA; ESTES, ML; THOMAS, DM; TUOHY, VK				RANSOHOFF, RM; HAMILTON, TA; TANI, M; STOLER, MH; SHICK, HE; MAJOR, JA; ESTES, ML; THOMAS, DM; TUOHY, VK			ASTROCYTE EXPRESSION OF MESSENGER-RNA ENCODING CYTOKINES IP-10 AND JE/MCP-1 IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS	FASEB JOURNAL			English	Note						CHEMOATTRACTANTS; ASTROCYTES; DEMYELINATION; CYTOKINES; IP-10; JE/MCP-1; INSITU HYBRIDIZATION	MYELIN PROTEOLIPID PROTEIN; HUMAN ENDOTHELIAL-CELLS; MONOCYTE CHEMOATTRACTANT; MULTIPLE-SCLEROSIS; INTERFERON; GENE; IDENTIFICATION; SYNTHESIZE; SECRETION; INDUCTION	Mononuclear leukocytes preferentially accumulate in the central nervous system (CNS) during the course of experimental autoimmune encephalomyelitis (EAE). To address factors that govern leukocyte trafficking in EAE, we monitored expression of mRNAs encoding IP-10 and JE/MCP-1, which are members of a family of chemoattractant cytokines. A transient burst of IP-10 and JE/MCP-1 mRNA accumulation in the CNS occurred, in close relation to the onset of histologic and clinical disease. In situ hybridizations showed, unexpectedly, that astrocytes were the major source of mRNAs encoding IP-10 and JE/MCP-1. These observations implicate astrocyte-derived cytokines as potential chemoattractants for inflammatory cells during EAE.	CLEVELAND CLIN FDN,DIV PATHOL & LAB MED,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,NEUROPATHOL SECT,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation	RANSOHOFF, RM (corresponding author), CLEVELAND CLIN FDN,RES INST,MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & NEUROL,DEPT MOLEC BIOL,CLEVELAND,OH 44195, USA.		Hamilton, Thomas A/A-7756-2009	Hamilton, Thomas/0000-0002-9817-242X	NHLBI NIH HHS [HL29582] Funding Source: Medline; NINDS NIH HHS [NSKO8-01265, NS 29095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029095, K08NS001265] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; FIERZ W, 1985, J IMMUNOL, V134, P3785; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FONTANA A, 1984, LYMPHOKINE RES, V3, P11; FREI K, 1985, J IMMUNOL, V135, P4044; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KIES MW, 1984, EXPT ALLERGIC ENCEPH; Lassmann H, 1983, COMP NEUROPATHOLOGY; LEE SC, 1990, J NEUROPATH EXP NEUR, V49, P122, DOI 10.1097/00005072-199003000-00005; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MERRILL JE, 1992, P NATL ACAD SCI USA, V89, P574, DOI 10.1073/pnas.89.2.574; NARUMI S, 1992, J LEUKOCYTE BIOL, V52, P27, DOI 10.1002/jlb.52.1.27; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1992, IN PRESS AM J PATHOL; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; RANSOHOFF RM, 1991, ARCH NEUROL-CHICAGO, V48, P1244, DOI 10.1001/archneur.1991.00530240048017; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; SAFIRSTEIN R, 1991, AM J PHYSIOL, V261, pF1095, DOI 10.1152/ajprenal.1991.261.6.F1095; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SOBEL RA, 1990, J NEUROPATH EXP NEUR, V49, P468, DOI 10.1097/00005072-199009000-00002; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANGURI P, 1990, J BIOL CHEM, V265, P15049; VANGURI P, 1992, 23RD ANN M AM SOC NE; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449	36	478	494	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1993	7	6					592	600		10.1096/fasebj.7.6.8472896	http://dx.doi.org/10.1096/fasebj.7.6.8472896			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KY009	8472896				2022-12-25	WOS:A1993KY00900014
J	BLONDELGUINDI, S; FOURIE, AM; SAMBROOK, JF; GETHING, MJH				BLONDELGUINDI, S; FOURIE, AM; SAMBROOK, JF; GETHING, MJH			PEPTIDE-DEPENDENT STIMULATION OF THE ATPASE ACTIVITY OF THE MOLECULAR CHAPERONE BIP IS THE RESULT OF CONVERSION OF OLIGOMERS TO ACTIVE MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; GLUCOSE-REGULATED PROTEIN; SHOCK COGNATE PROTEIN; ENDOPLASMIC-RETICULUM; HEAT-SHOCK; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEINS; MAMMALIAN-CELLS; HEMAGGLUTININ	The molecular chaperone BiP purified from bovine liver (bBiP) exhibits a low basal level of ATPase activity that can be stimulated 3-6-fold by synthetic peptides (Flynn, G. C., Chappell, T. G., and Rothman, J. E. (1989) Science 245, 385-390). By contrast, recombinant murine BiP (rBiP) purified to homogeneity following expression in Escherichia coli exhibits a higher basal level of ATPase activity and is much less stimulated by synthetic peptides. Nondenaturing gel electrophoresis showed that rBiP is predominantly monomeric, while bBiP exists in multiple forms probably corresponding to differentially modified monomeric, dimeric, and higher oligomeric species. Some, but not all, synthetic peptides cause conversion of the oligomeric and modified species of bBiP to a monomeric form. We propose that the peptide-dependent ATPase stimulation observed for BiP reflects the conversion of inactive oligomeric and/or modified species into active monomers.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CARLSSON L, 1983, P NATL ACAD SCI-BIOL, V80, P4664, DOI 10.1073/pnas.80.15.4664; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KIM PS, 1991, J BIOL CHEM, V266, P12412; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1989, J CELL SCI, P115; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIN AY, 1984, P NATL ACAD SCI-BIOL, V81, P988, DOI 10.1073/pnas.81.4.988; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MORRISON SL, 1975, J IMMUNOL, V114, P655; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEU HC, 1965, J BIOL CHEM, V240, P3685; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	44	147	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12730	12735						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509407				2022-12-25	WOS:A1993LG65800075
J	EHRIG, T; MUHOBERAC, BB; BREMS, D; BOSRON, WF				EHRIG, T; MUHOBERAC, BB; BREMS, D; BOSRON, WF			MONOMERS OF HUMAN BETA(1)BETA(1) ALCOHOL-DEHYDROGENASE EXHIBIT ACTIVITY THAT DIFFERS FROM THE DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; KINETIC CHARACTERIZATION; ESCHERICHIA-COLI; DISSOCIATION; ISOENZYMES; OXIDATION; PHOSPHOFRUCTOKINASE; SUBSTITUTIONS; PURIFICATION; ISOZYMES	A previously unreported enzymatic activity is described for monomers of the beta1beta1 isoenzyme of human alcohol dehydrogenase that were prepared from dimeric enzyme by freeze-thaw in liquid nitrogen. Whereas the dimeric enzyme has optimal activity at low substrate concentrations (2.5 mM ethanol, 50 muM NAD+; ''low K(m)'' activity), the monomer has its highest activity at high substrate concentrations (1.5 M ethanol, 2.5 mM NAD+; ''high K(m)'' activity). While the activity of the monomer does not appear to be saturated at 1.5 M ethanol, its maximal activity at this high ethanol concentration exceeds the V(max) of the dimer by about 3-fold. The apparent K(m) of NAD+ with monomers is 270 muM, and no activity could be detected with nicotinamide mononucleotide as cofactor. During gel filtration the high K(m) activity elutes at a lower apparent molecular weight position than the dimer. The kinetics of monomer-to-dimer reassociation are consistent with a second-order process with a rate constant of 240 M-1 s-1. The reassociation rate is markedly enhanced by the presence of NAD+. During refolding of beta1beta1 following denaturation in 6 M guanidine hydrochloride, an enzyme species with high K(m) activity and spectral properties similar to the freeze-thaw monomer is observed, indicating that a catalytically active monomer is an intermediate in the refolding pathway. The enzymatic activity of the monomers implies that the intersubunit contacts of beta1beta1 are not crucial in establishing a catalytically competent enzyme. However, the differences in specific activity and K(m) between monomer and dimer suggest that dimerization may serve to modulate the catalytic properties.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MED SCI BLDG 405,635 BARNHILL DR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285; INDIANA UNIV PURDUE UNIV,PURDUE UNIV SCI,DEPT CHEM,INDIANAPOLIS,IN 46205	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis					NIAAA NIH HHS [R37 AA07117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA007117] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSSON L, 1979, EUR J BIOCHEM, V94, P557, DOI 10.1111/j.1432-1033.1979.tb12925.x; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; Branden C.-I., 1975, ENZYMES, V11, P103; BRIGANTI F, 1989, BIOCHEMISTRY-US, V28, P5374, DOI 10.1021/bi00439a009; BROMBERG JP, 1984, PHYSICAL CHEM, P889; BUHLER R, 1982, FEBS LETT, V144, P135, DOI 10.1016/0014-5793(82)80586-3; BURNS DL, 1982, J BIOL CHEM, V257, P8638; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; EHRIG T, 1992, FEBS LETT, V300, P283, DOI 10.1016/0014-5793(92)80864-D; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; FONG WP, 1987, BIOCHEMISTRY-US, V26, P5733, DOI 10.1021/bi00392a023; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; GHELIS C, 1982, PROTEIN FOLDING, P470; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1987, ENZYME, V37, P5; KAPLAN NO, 1960, ENZYMES, V3, P147; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; MARDH G, 1986, P NATL ACAD SCI USA, V83, P2836; MARSH EN, 1989, BIOCHEM J, V260, P353, DOI 10.1042/bj2600353; PIETRUSZKO R, 1972, ARCH BIOCHEM BIOPHYS, V153, P279, DOI 10.1016/0003-9861(72)90446-8; SHORE JD, 1966, ARCH BIOCHEM BIOPHYS, V117, P375, DOI 10.1016/0003-9861(66)90425-5; STONE CL, 1989, J BIOL CHEM, V264, P11112; STONE CL, 1993, J BIOL CHEM, V268, P892; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11721	11726						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505301				2022-12-25	WOS:A1993LF28400041
J	GUREVICH, VV; BENOVIC, JL				GUREVICH, VV; BENOVIC, JL			VISUAL ARRESTIN INTERACTION WITH RHODOPSIN - SEQUENTIAL MULTISITE BINDING ENSURES STRICT SELECTIVITY TOWARD LIGHT-ACTIVATED PHOSPHORYLATED RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; BETA-ADRENERGIC-RECEPTOR; ROD OUTER SEGMENTS; 48-KDA PROTEIN; PHOTORECEPTOR-MEMBRANES; PHOTOEXCITED RHODOPSIN; ALPHA-TRANSDUCIN; BOVINE RETINA; MESSENGER-RNA; INVITRO	Visual arrestin plays an important role in regulating light responsiveness via its ability to specifically bind to the phosphorylated and light-activated form of rhodopsin. Previously, we utilized an in vitro translation system to express and characterize the full-length (404 amino acids) and two truncated forms of visual arrestin. Here we have extended these studies to include a total of 33 different truncation and deletion mutants of arrestin, ranging from 69 to 391 amino acids in length. Mutants were produced by cutting within the open reading frame of the bovine arrestin cDNA with selective restriction enzymes followed by in vitro translation of the transcribed truncated mRNAs. Mutant arrestin binding to dark, light-activated, dark phosphorylated, and light-activated phosphorylated rhodopsin as well as to opsin, phosphoopsin, and truncated rhodopsin was then extensively characterized. In addition, the sensitivity of arrestin/rhodopsin interactions to conditions of increasing ionic strength was measured. These studies suggest the localization of multiple functional domains within the arrestin molecule that include: 1) a ''phosphorylation recognition'' domain, which interacts with the phosphorylated carboxyl terminus of rhodopsin, was localized predominately between residues 158-185; 2) an ''activation recognition'' domain, which interacts with those portions of the rhodopsin molecule that change conformation upon light activation, was found to consist of at least three regions within the first 191 residues of the arrestin molecule; 3) a hydrophobic interaction domain, localized between residues 191 and 365, appears to be mobilized upon binding of arrestin to activated phosphorylated rhodopsin; 4) a regulatory domain, localized in the COOH-terminal region of arrestin (residues 365-391), was found to play a role in controlling the conformational change in arrestin necessary for mobilization of the hydrophobic interaction domain; and 5) The NH2 terminus of arrestin (residues 2-16) was found to be important for interacting with the regulatory COOH-terminal region as well as maintaining the conformation of the NH2-terminal half of arrestin. A mechanism which ensures strict arrestin binding selectivity toward phosphorylated light-activated rhodopsin is proposed.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE T, 1989, FEBS LETT, V247, P307, DOI 10.1016/0014-5793(89)81358-4; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; CHEN CY, 1993, J BIOL CHEM, V268, P7825; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GEIGER T, 1988, EUR J BIOCHEM, V175, P181, DOI 10.1111/j.1432-1033.1988.tb14181.x; GUREVICH VV, 1989, BIOL MEMBRANY, V6, P647; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN P A, 1989, Investigative Ophthalmology and Visual Science, V30, P170; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; OLATE J, 1988, J BIOL CHEM, V263, P10394; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P4201; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; POGOZHEVA ID, 1989, BIOL MEMBRANY, V6, P1248; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZOZULYA SA, 1989, Patent No. 1547313	53	264	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11628	11638						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505295				2022-12-25	WOS:A1993LF28400030
J	DEYEBRA, L; BALLESCA, JL; VANRELL, JA; BASSAS, L; OLIVA, R				DEYEBRA, L; BALLESCA, JL; VANRELL, JA; BASSAS, L; OLIVA, R			COMPLETE SELECTIVE ABSENCE OF PROTAMINE-P2 IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR BASIC-PROTEINS; HUMAN-SPERM; NUCLEOTIDE-SEQUENCE; HUMAN-SPERMATOZOA; INFERTILE MEN; HISTONE HYPERACETYLATION; MOUSE; GENE; INVITRO	Male sterility due to abnormal sperm morphology or motion has been widely reported, although relatively little has been published on the sperm nuclear protein abnormalities. We report the first cases worldwide of infertile patients having a complete selective absence of protamine P2 in the sperm nucleus. This provides a selective phenotype that will aid understanding of the mechanisms of synthesis, processing, or function of the P2 protamines. In addition, it is of marked immediate relevance to medicine as it allows the diagnosis of this type of human male sterility and the opportunity to understand the basis of this defect.	UNIV BARCELONA, FAC MED, MOLEC GENET RES GRP, DIAGONAL 643, E-08028 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, PUIGVERT FDN, E-08025 BARCELONA, SPAIN; HOSP CLIN BARCELONA, OBSTET & GYNECOL UNIT, E-08036 BARCELONA, SPAIN	University of Barcelona; Fundacio Puigvert; University of Barcelona; Hospital Clinic de Barcelona			Oliva, Rafael/C-9741-2009	Oliva, Rafael/0000-0003-4876-2410				ADROER R, 1992, NUCLEIC ACIDS RES, V20, P609, DOI 10.1093/nar/20.3.609; AIMAN J, 1979, NEW ENGL J MED, V300, P223, DOI 10.1056/NEJM197902013000503; ARKHIS A, 1991, EUR J BIOCHEM, V200, P387, DOI 10.1111/j.1432-1033.1991.tb16196.x; AUGER J, 1990, INT J ANDROL, V13, P452, DOI 10.1111/j.1365-2605.1990.tb01052.x; BACH O, 1990, ANDROLOGIA, V22, P217; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; BALHORN R, 1988, EXPERIENTIA, V44, P52, DOI 10.1007/BF01960243; BALHORN R, 1992, ARCH BIOCHEM BIOPHYS, V296, P384, DOI 10.1016/0003-9861(92)90588-N; Balhorn R., 1989, P366; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; BELLVE AR, 1988, BIOCHEMISTRY-US, V27, P2890, DOI 10.1021/bi00408a034; BELOKOPYTOVA IA, 1993, MOL REPROD DEV, V34, P53, DOI 10.1002/mrd.1080340109; BIANCHI F, 1992, BIOCHEM BIOPH RES CO, V182, P540, DOI 10.1016/0006-291X(92)91766-J; BIBBINS PE, 1992, FERTIL STERIL, V57, P402; BLANCHARD Y, 1990, ANDROLOGIA, V22, P549; BOWER PA, 1987, BIOL REPROD, V37, P479, DOI 10.1095/biolreprod37.2.479; BROWN DB, 1992, YALE J BIOL MED, V65, P29; BUNICK D, 1990, EXP CELL RES, V188, P147, DOI 10.1016/0014-4827(90)90290-Q; BUSTOSOBREGON E, 1983, ANDROLOGIA, V15, P468; CANTU JM, 1981, HUM GENET, V59, P380, DOI 10.1007/BF00295476; CHAGANTI RSK, 1980, AM J HUM GENET, V32, P833; CHAUVIERE M, 1992, EUR J BIOCHEM, V204, P759, DOI 10.1111/j.1432-1033.1992.tb16691.x; CHEVAILLIER P, 1987, LANCET, V2, P806; COLLEU D, 1988, ARCH ANDROLOGY, V21, P155, DOI 10.3109/01485018808986737; DADOUNE JP, 1988, ANDROLOGIA, V19, P433; DEBRAEKELEER M, 1991, HUM REPROD, V6, P245, DOI 10.1093/oxfordjournals.humrep.a137315; DEYEBRA L, 1993, ANAL BIOCHEM, V209, P201, DOI 10.1006/abio.1993.1104; DOMENJOUD L, 1988, NUCLEIC ACIDS RES, V16, P7733, DOI 10.1093/nar/16.15.7733; DOMENJOUD L, 1990, GENOMICS, V8, P127, DOI 10.1016/0888-7543(90)90234-L; DOMENJOUD L, 1991, ANDROLOGIA, V23, P333; ELSEVIER SM, 1991, EUR J BIOCHEM, V196, P167, DOI 10.1111/j.1432-1033.1991.tb15800.x; EVENSON DP, 1980, SCIENCE, V210, P1131, DOI 10.1126/science.7444440; FLORKEGERLOFF S, 1984, ANDROLOGIA, V16, P187; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GUSSE M, 1986, BIOCHIM BIOPHYS ACTA, V884, P124, DOI 10.1016/0304-4165(86)90235-7; Hecht N.B., 1989, P396; HURET JL, 1986, ARCH ANDROLOGY, V16, P97, DOI 10.3109/01485018608986928; JAGER S, 1990, ARCH ANDROLOGY, V25, P253, DOI 10.3109/01485019008987614; JEGOU B, 1991, P NATL ACAD SCI USA, V88, P8710, DOI 10.1073/pnas.88.19.8710; Kasinsky H. E., 1989, HISTONES OTHER BASIC, P73; KREMLING H, 1992, BIOCHIM BIOPHYS ACTA, V1132, P133, DOI 10.1016/0167-4781(92)90003-I; LEE C, 1991, MOL REPROD DEV, V30, P154, DOI 10.1002/mrd.1080300212; LEE CH, 1987, NUCLEIC ACIDS RES, V15, P7639, DOI 10.1093/nar/15.18.7639; LESCOAT D, 1988, ARCH ANDROLOGY, V20, P35, DOI 10.3109/01485018808987050; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; MAIER WM, 1990, NUCLEIC ACIDS RES, V18, P1249, DOI 10.1093/nar/18.5.1249; MCKAY DJ, 1986, EUR J BIOCHEM, V156, P5, DOI 10.1111/j.1432-1033.1986.tb09540.x; MCKAY DJ, 1985, BIOSCIENCE REP, V5, P383, DOI 10.1007/BF01116555; MEYER JM, 1992, HISTOPATHOLOGY, V21, P25; MEZQUITA C, 1985, CHROMOSOMAL PROTEINS, P315; NAVARRO J, 1990, HUM REPROD, V5, P227, DOI 10.1093/oxfordjournals.humrep.a137076; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; OLIVA R, 1989, J BIOL CHEM, V264, P12472; OLIVA R, 1989, J BIOL CHEM, V264, P17627; OLIVA R, 1987, J BIOL CHEM, V262, P17016; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PASTEUR X, 1992, ANAL QUANT CYTOL, V14, P96; PAVLOU SN, 1991, J CLIN ENDOCR METAB, V73, P1360, DOI 10.1210/jcem-73-6-1360; PIRHONEN A, 1990, BIOCHIM BIOPHYS ACTA, V1039, P177, DOI 10.1016/0167-4838(90)90183-G; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; QUERALT R, 1991, NUCLEIC ACIDS RES, V19, P5786, DOI 10.1093/nar/19.20.5786; RETIEF JD, 1993, IN PRESS J MOL EVOL, V36; SAUTIERE P, 1988, J BIOL CHEM, V263, P11059; SAUTIERE P, 1984, EUR J BIOCHEM, V144, P121, DOI 10.1111/j.1432-1033.1984.tb08439.x; SCAGLIA HE, 1991, J ANDROL, V12, P273; SCHILL WB, 1991, HUM REPROD, V6, P969, DOI 10.1093/oxfordjournals.humrep.a137471; SCHLEGEL PN, 1991, FERTIL STERIL, V55, P235; SCHLUTER G, 1992, GENOMICS, V14, P377, DOI 10.1016/S0888-7543(05)80229-0; SNYDER PJ, 1990, NEW ENGL J MED, V323, P54; STANKER LH, 1992, MOL REPROD DEV, V33, P481, DOI 10.1002/mrd.1080330415; TANHAUSER SM, 1989, NUCLEIC ACIDS RES, V17, P4395, DOI 10.1093/nar/17.11.4395; TOBITA T, 1983, BIOCHIM BIOPHYS ACTA, V744, P141, DOI 10.1016/0167-4838(83)90083-3; UEDA H, 1991, ARCH HISTOL CYTOL, V54, P401, DOI 10.1679/aohc.54.401; VANBEEK MEAB, 1992, J REPROD FERTIL, V94, P327, DOI 10.1530/jrf.0.0940327; WINKFEIN R J, 1991, Journal of Cell Biology, V115, p89A	76	159	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10553	10557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486708				2022-12-25	WOS:A1993LB80000083
J	FENSTERMAKER, RA; POPTIC, E; BONFIELD, TL; KNAUSS, TC; CORSILLO, L; PISKURICH, JF; KAETZEL, CS; JENTOFT, JE; GELFAND, C; DICORLETO, PE; KAETZEL, DM				FENSTERMAKER, RA; POPTIC, E; BONFIELD, TL; KNAUSS, TC; CORSILLO, L; PISKURICH, JF; KAETZEL, CS; JENTOFT, JE; GELFAND, C; DICORLETO, PE; KAETZEL, DM			A CATIONIC REGION OF THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) A-CHAIN (ARG(159)-LYS(160)-LYS(161)) IS REQUIRED FOR RECEPTOR-BINDING AND MITOGENIC ACTIVITY OF THE PDGF-AA HOMODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; BOVINE LUTEINIZING-HORMONE; HAMSTER OVARY CELLS; MESANGIAL CELLS; MESSENGER-RNAS; BETA GENES; ONC GENE; B-CHAIN; V-SIS; DIMERIZATION	Platelet-derived growth factor-AA and -BB homodimers and -AB heterodimers bind with high affinity to the platelet-derived growth factor (PDGF) alpha-receptor. Basic polypeptides such as polylysine and protamine sulfate compete with PDGF for receptor binding, suggesting a role for ligand positive charge in the binding interaction. A pentapeptide amino acid sequence with a cationic tripeptide core is perfectly conserved between the A- and B-chains (Val158-Arg159-Lys160-Lys161-Pro162) and was therefore considered as a possible alpha-receptor-binding domain. We have investigated the functional importance of positive charge within this region of the PDGF A-chain by using site-directed mutagenesis to convert the cationic core amino acids to the acidic sequence triglutamic acid. cDNAs encoding wild-type (PDGF-AA(wt) and charge mutant (PDGF-AA(cm)) proteins were expressed following stable transfection of Chinese hamster ovary cells. Proper assembly and secretion of PDGF-AA(cm) was verified by metabolic labeling with [S-35]cysteine, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis analysis under nonreducing and reducing conditions. PDGF-AA(cm) was secreted as two major species of disulfide-linked A-chain homodimers identical in molecular mass to those observed for PDGF-AA(wt) (32 and 35 kDa). Secreted PDGF-AA(wt) and PDGF-AA(cm) proteins were purified to homogeneity and subjected to structural and functional analyses. Compared to purified PDGF-AA(wt), PDGF-AA(cm) displayed a marked reduction in both binding affinity for PDGF alpha-receptors and mitogenic activity in Swiss 3T3 cells. Large reductions were also observed in the ability of semi-purified PDGF-AA(cm) to stimulate calcium influx and the production of inositol phosphates. Measurement of circular dichroism spectra of highly purified PDGF-AA(cm) and PDGF-AA(wt) revealed no significant difference in secondary structure. Collectively, these results indicate that the cationic Arg159-Lys160-Lys161 region plays a critical role in the biological activity of PDGF-AA by direct participation in ligand binding to the PDGF alpha-receptor.	DEPT VET AFFAIRS MED CTR,DIV RES,10701 E BLVD,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NEUROSURG,CLEVELAND,OH 44106; CLEVELAND CLIN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation				Kaetzel, Charlotte/0000-0001-7546-0085				BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; DALLAFAVERA R, 1982, SCIENCE, V218, P686, DOI 10.1126/science.6291150; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; ENGSTROM J, 1992, J BIOL CHEM, V267, P16581; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HASSID A, 1986, AM J PHYSIOL, V251, pF1018; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG JS, 1982, J BIOL CHEM, V257, P8130; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KAETZEL DM, 1988, J BIOL CHEM, V263, P6344; KAETZEL DM, 1985, P NATL ACAD SCI USA, V82, P7280, DOI 10.1073/pnas.82.21.7280; KAETZEL DM, 1989, MOL ENDOCRINOL, V3, P1765, DOI 10.1210/mend-3-11-1765; KELLY JD, 1991, J BIOL CHEM, V266, P8987; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; NILSON JH, 1983, J BIOL CHEM, V258, P2087; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PINZANI M, 1991, AM J PHYSIOL, V260, pC485, DOI 10.1152/ajpcell.1991.260.3.C485; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1986, ACTA MED SCAND S, V715, P33; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; VOGEL S, 1989, BIOCHEMISTRY-US, V28, P2961, DOI 10.1021/bi00433a033; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1986, ACTA MED SCAND S, V715, P19	47	26	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10482	10489						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486701				2022-12-25	WOS:A1993LB80000073
J	RINI, JM; HARDMAN, KD; EINSPAHR, H; SUDDATH, FL; CARVER, JP				RINI, JM; HARDMAN, KD; EINSPAHR, H; SUDDATH, FL; CARVER, JP			X-RAY CRYSTAL-STRUCTURE OF A PEA LECTIN-TRIMANNOSIDE COMPLEX AT 2.6 ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING SPECIFICITY; LEAST-SQUARES REFINEMENT; CONCANAVALIN-A; METHYL 3,6-DI-O-(ALPHA-D-MANNOPYRANOSYL)-ALPHA-D-MANNOPYRANOSIDE; 6-A RESOLUTION; LENTIL-LECTINS; PISUM-SATIVUM; PROTEINS; OLIGOSACCHARIDES; SITE	The x-ray crystal structure of pea lectin, in complex with a methyl glycoside of the N-linked-type oligosaccharide trimannosyl core, methyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside, has been solved by molecular replacement and refined at 2.6-angstrom resolution. The R factor is 0.183 for all data in the 8.0 to 2.6 angstrom resolution range with an average atomic temperature factor of 26.1 angstrom2. Strong electron density for a single mannose residue is found in the monosaccharide-binding site suggesting that the trisaccharide binds primarily through one of the terminal alpha-linked mannose residues. The complex is stabilized by hydrogen bonds involving the protein residues Asp-81, Gly-99, Asn-125, Ala-217, and Glu-218, and the carbohydrate oxygen atoms O3, O4, O5, and O6. In addition, the carbohydrate makes van der Waals contacts with the protein, involving Phe-123 in particular. These interactions are very similar to those found in the monosaccharide complexes with concanavalin A and isolectin 1 of Lathyrus ochrus, confirming the structural relatedness of this family of proteins. Comparison of the pea lectin complex with the unliganded pea lectin and concanavalin A structures indicates differences in the conformation and water structure of the unliganded binding sites of these two proteins. Furthermore, a correlation between the position of the carbohydrate oxygen atoms in the complex and the bound water molecules in the unliganded binding sites is found. Binding of the trimannose core through a single terminal monosaccharide residue strongly argues that an additional fucose-binding site is responsible for the high affinity pea lectin-oligosaccharide interactions.	UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; UPJOHN CO, KALAMAZOO, MI 49001 USA; GEORGIA INST TECHNOL, SCH CHEM & BIOCHEM, ATLANTA, GA 30332 USA	University of Toronto; DuPont; Pfizer; University System of Georgia; Georgia Institute of Technology	RINI, JM (corresponding author), UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA.							AGARWAL RC, 1978, ACTA CRYSTALLOGR A, V34, P791, DOI 10.1107/S0567739478001618; ALLEN AK, 1976, BIOCHEM J, V155, P127, DOI 10.1042/bj1550127; BECKER JW, 1976, NATURE, V259, P406, DOI 10.1038/259406a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; CARVER JP, 1985, BIOPOLYMERS, V24, P49, DOI 10.1002/bip.360240106; CARVER JP, 1989, CIBA F SYMP, V145, P6; CARVER JP, 1993, IN PRESS PURE APPL C; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6676, DOI 10.1021/bi00395a017; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DEBRAY H, 1984, FEBS LETT, V157, P257; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DEREWENDA ZS, 1981, ACTA CRYSTALLOGR A, V37, P407, DOI 10.1107/S0567739481000879; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HARDMAN KD, 1976, BIOCHEMISTRY-US, V15, P1120, DOI 10.1021/bi00650a026; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAIFU R, 1975, CARBOHYD RES, V40, P111, DOI 10.1016/S0008-6215(00)82673-7; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KUNDROT CE, 1987, ACTA CRYSTALLOGR B, V43, P544, DOI 10.1107/S0108768187097349; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LIENER IE, 1986, LECTINS PROPERTIES F, P33; Lis H, 1991, CURR OPIN STRUC BIOL, V1, P741, DOI 10.1016/0959-440X(91)90173-Q; MEEHAN EJ, 1982, J BIOL CHEM, V257, P13278; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAYMENT I, 1977, J APPL CRYSTALLOGR, V10, P365, DOI 10.1107/S0021889877013703; RINI JM, 1987, BIOCHEM CELL BIOL, V65, P338, DOI 10.1139/o87-043; RINI JM, 1986, J MOL BIOL, V189, P259, DOI 10.1016/0022-2836(86)90399-2; RINI JM, 1989, T AM CRYSTALLOGR ASS, V25, P51; RINI JM, 1987, THESIS U TORONTO TOR; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STUBBS ME, 1986, J BIOL CHEM, V261, P6141; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TROWBRIDGE IS, 1974, J BIOL CHEM, V249, P6004; VANWAUWE JP, 1975, BIOCHIM BIOPHYS ACTA, V379, P456, DOI 10.1016/0005-2795(75)90152-X; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WINNIK FM, 1982, CARBOHYD RES, V103, P15, DOI 10.1016/S0008-6215(82)80004-9; YAMAMOTO K, 1982, CARBOHYD RES, V110, P283, DOI 10.1016/0008-6215(82)84010-X	56	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10126	10132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486683				2022-12-25	WOS:A1993LB80000030
J	ARROYO, AG; GARCIAPARDO, A; SANCHEZMADRID, F				ARROYO, AG; GARCIAPARDO, A; SANCHEZMADRID, F			A HIGH-AFFINITY CONFORMATIONAL STATE ON VLA INTEGRIN HETERODIMERS INDUCED BY AN ANTI-BETA-1 CHAIN MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GPIIB-IIIA; FIBROBLASTIC CELLS; RECEPTOR AFFINITY; DIVALENT-CATIONS; BINDING DOMAIN; IIB-IIIA; T-CELLS; FIBRONECTIN; ADHESION; LIGAND	The VLA integrin subfamily includes receptors for extracellular matrix proteins as well as receptors involved in cell-cell adhesive interactions. We have previously described the up-regulation of VLA integrin-mediated cell attachment to different ligands by the anti-beta1 TS2/16 monoclonal antibody (mAb) (Arroyo, A. G., Sanchez-Mateos, P., Campanero, M. R., Martin-Padura, I., Dejana, E., and Sanchez-Madrid, F. (1992) J. Cell Biol. 117, 659-670). In this report, we have investigated the mechanism involved in this regulatory effect. The anti-beta1-mediated regulatory effect on cell adhesion did not require ''de novo'' protein synthesis, since it was not affected by pretreatment with either cycloheximide or actinomycin D. To quantitate the effect of the regulatory anti-beta1 TS2/16 mAb on the affinity of VLA-5 for its ligand, an RGD-containing fragment of fibronectin (FN80), we performed binding studies of radiolabeled soluble FN80 to U-937 cells. The affinity of VLA-5 for FN80 was enhanced about 4-fold in the presence of TS2/16 mAb (K(d) = 0.98 +/-0.07 muM) compared to the functionally irrelevant anti-beta1 Alex 1/4 mAb (K(d) = 4.23 +/- 0.92 muM), whereas no alteration in the number of binding sites was observed. Indeed, the anti-beta1 TS2/16 mAb is inducing this high affinity state on VLA heterodimers by a direct change on the conformation of these receptors as demonstrated by affinity chromatography analysis using extracellular matrix proteins covalently bound to Sepharose. The yield of VLA-5 fibronectin receptor bound to FN80-Sepharose columns was strongly increased upon treatment of U-937 cell lysates with mAb TS2/16. Moreover, higher concentrations of EDTA were required for eluting the VLA-5 integrin from this matrix. This up-regulatory effect was also observed with F(ab')2 and Fab fragments of the anti-beta1 TS2/16 mAb, and was also exerted on the purified VLA-5 receptor. Similarly, the yield of VLA-2 retained on a collagen I-Sepharose column was dramatically increased by pretreatment of A375 melanoma cell lysates with the mAb TS2/16. Altogether, these results indicate that the interaction of VLA beta1 heterodimers with their ligands can be regulated by switching between differently active conformations inherent to the alphabeta1 receptors.	UNIV AUTONOMA MADRID,HOSP PRINCESA,SECC IMMUNOL,C DIEGO LEON 62,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,MADRID 6,SPAIN	Autonomous University of Madrid; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Arroyo, Alicia G./L-2796-2014; Garcia Pardo, Angeles/G-5987-2015; Sanchez-Madrid, Francisco/M-7889-2016	Arroyo, Alicia G./0000-0002-1536-3846; Garcia Pardo, Angeles/0000-0001-5577-2954; Sanchez-Madrid, Francisco/0000-0001-5303-0762				AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANCHEZMADRID F, 1992, SEMIN CELL BIOL, V3, P119; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	38	110	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9863	9868						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486666				2022-12-25	WOS:A1993LA68900101
J	BIRD, GSJ; ROSSIER, MF; OBIE, JF; PUTNEY, JW				BIRD, GSJ; ROSSIER, MF; OBIE, JF; PUTNEY, JW			SINUSOIDAL OSCILLATIONS IN INTRACELLULAR CALCIUM REQUIRING NEGATIVE FEEDBACK BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CYTOSOLIC CALCIUM; LACRIMAL CELLS; PHORBOL-ESTER; HORMONE; ACETYLCHOLINE; STIMULATION; HEPATOCYTES; TRANSIENT	Stimulation of mouse lacrimal acinar cells with submaximal concentrations of the muscarinic agonist, methacholine, resulted in an increase in intracellular calcium ([Ca2+]i), which took the form of sinusoidal oscillations. These oscillations were relatively constant (approximately 4-5/min) regardless of the methacholine concentration, suggesting that the oscillations arise from an oscillating negative feedback in the signal transduction pathway. This negative feedback appears to involve oscillations in protein kinase C activity because the oscillations were prevented by activation, inhibition, or down-regulation of protein C. Activation of protein kinase C with phorbol esters inhibited the methacholine-induced [Ca2+]i signal and formation of the Ca2+ mobilizing messenger, inositol 1,4,5-trisphosphate. [Ca2+]i signals elicited by intracellular introduction of inositol phosphates did not oscillate and were not affected by activators or inhibitors of protein kinase C. Thus, the constant frequency [Ca2+]i oscillations appear to result from a negative feedback loop involving inhibition of inositol trisphosphate production by protein kinase C.			BIRD, GSJ (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021; Rossier, Michel/AAW-2895-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748; 				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; COOPER RH, 1985, J BIOL CHEM, V260, P3281; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12, P61, DOI 10.1016/0143-4160(91)90008-3; DRUMMOND AH, 1985, NATURE, V315, P752, DOI 10.1038/315752a0; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELPER JR, 1988, J BIOL CHEM, V263, P7610; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, J PHYSIOL-LONDON, V394, P239, DOI 10.1113/jphysiol.1987.sp016868; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; TAN YP, 1991, J PHYSIOL-LONDON, V433, P357, DOI 10.1113/jphysiol.1991.sp018430; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	32	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8425	8428						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473285				2022-12-25	WOS:A1993KX81100012
J	TAKAHASHI, Y; CAMPBELL, EA; HIRATA, Y; TAKAYAMA, T; LISTOWSKY, I				TAKAHASHI, Y; CAMPBELL, EA; HIRATA, Y; TAKAYAMA, T; LISTOWSKY, I			A BASIS FOR DIFFERENTIATING AMONG THE MULTIPLE HUMAN MU-GLUTATHIONE S-TRANSFERASES AND MOLECULAR-CLONING OF BRAIN GSTM5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-STILBENE OXIDE; LUNG-CANCER; RAT-BRAIN; GENE DELETION; EXPRESSION; SUSCEPTIBILITY; ISOENZYMES; MARKER; LIVER; IDENTIFICATION	Specific cDNA probes and antisera were employed to interpret genetic polymorphisms of human Mu-class glutathione S-transferases and to provide a basis for identifying individual forms in human tissues. A cDNA probe that cross-hybridized with various human and rodent Mu-glutathione S-transferase transcripts, hybridized with at least three discrete components by Northern analysis of RNA from human tissue. The smallest (1.3 kb) transcript was identified as the one that encodes GSTM3-3 subunits. A form designated GSTM5, was cloned from a human brain cDNA library and its sequence determined. The open reading frame of GSTM5 shared a high degree of homology with the sequences of other Mu-class glutathione S-transferases, but its 846-nucleotide 3'-noncoding region was unique and considerably larger than that of any of the other Mu forms. Specific synthetic peptide antigens were utilized to distinguish among Mu-class glutathione S-transferases in different tissues of representative individuals. The primary hepatic transcript was that encoding GSTM1-1 with much lesser amounts of GSTM3-3, but livers were devoid of GSTM2-2, and GSTM5-5. Immunoblots confirmed that null-phenotype individuals lacked the GSTM1 gene rather than its GSTM2 homologue that is nearly identical in its exon sequences. The null phenotype therefore was conspicuous in liver, where GSTM1-1 ordinarily was the predominant Mu transcript, but brain and testis contained all four forms. A general strategy was devised to distinguish among and assign primary structures to individual glutathione S-transferases from human tissue.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM07128] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ M, 1988, J BIOL CHEM, V263, P17627; ABRAMOVITZ M, 1987, J BIOL CHEM, V262, P7770; ABRAMOVITZ M, 1989, HEPATOLOGY, V9, P235, DOI 10.1002/hep.1840090212; BOARD PG, 1981, FEBS LETT, V135, P12, DOI 10.1016/0014-5793(81)80933-7; BROCKMOLLER J, 1992, BIOCHEM PHARMACOL, V43, P647, DOI 10.1016/0006-2952(92)90591-6; CAMMER W, 1989, J NEUROCHEM, V52, P876, DOI 10.1111/j.1471-4159.1989.tb02536.x; CAMPBELL E, 1990, J BIOL CHEM, V265, P9188; CARMICHAEL J, 1988, CARCINOGENESIS, V9, P1617, DOI 10.1093/carcin/9.9.1617; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; Erickson B. W., 1976, PROTEINS, VII, P255; GUPTA S, 1990, CLIN CHEM ENZYM COMM, V3, P115; HECKBERT SR, 1992, J NATL CANCER I, V84, P414, DOI 10.1093/jnci/84.6.414; HUSSEY AJ, 1991, BIOCHEM J, V273, P323, DOI 10.1042/bj2730323; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JENSSON H, 1985, METHOD ENZYMOL, V113, P504; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; Listowsky Irving, 1993, P397; LIU YH, 1991, CARCINOGENESIS, V12, P2269, DOI 10.1093/carcin/12.12.2269; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; ROOTS I, 1992, CLIN INVESTIGATOR, V70, P307; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDEGARD J, 1985, HUM GENET, V69, P66, DOI 10.1007/BF00295531; SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; SEIDEGARD J, 1988, CARCINOGENESIS, V9, P1211; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; STROHMEYER T, 1992, J UROLOGY, V147, P1424, DOI 10.1016/S0022-5347(17)37586-9; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; SUZUKI T, 1991, BIOCHEM J, V274, P405, DOI 10.1042/bj2740405; TAYLOR JB, 1991, BIOCHEM J, V274, P87; THEODORE C, 1985, BIOCHEM J, V225, P375, DOI 10.1042/bj2250375; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TSUCHIDA S, 1990, J BIOL CHEM, V265, P7150; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WIENCKE JK, 1990, CANCER RES, V50, P1585; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533	45	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8893	8898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473333				2022-12-25	WOS:A1993KX81100076
J	BORELLINI, F; GLAZER, RI				BORELLINI, F; GLAZER, RI			INDUCTION OF SP1-P53 DNA-BINDING HETEROCOMPLEXES DURING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-DEPENDENT PROLIFERATION IN HUMAN ERYTHROLEUKEMIA CELL-LINE TF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; MYELOID LEUKEMIC-CELLS; C-JUN EXPRESSION; GENE-EXPRESSION; SYNERGISTIC ACTIVATION; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; T-ANTIGEN; WILD-TYPE; PROTEINS	The involvement of Sp1 in regulating cell proliferation in myeloid leukemia cells was determined by measuring the levels and DNA binding activity of Spl in TF-1 cells, a human erythroleukemia cell line dependent on granulocyte/macrophage colony-stimulating factor (GM-CSF) for viability and cell growth. DNA binding of Sp1 to a specific double-stranded oligodeoxynucleotide was increased markedly in a dose-dependent manner in proliferating cells in response to GM-CSF compared with growth-arrested or apoptotic cells. Competition experiments and mobility shift interference assays with antibodies against Sp1 as well as wild-type or mutant p53 indicated that GM-CSF-inducible DNA-binding complexes contained both Sp1 and p53 and that these heterocomplexes bound to both p53- and Sp1-binding sequences with high affinity. Immunoprecipitation of nuclear extracts with a p53 antibody indicated that Sp1 was associated as a heterocomplex with p53. Formation of this complex was dependent on the level of p53 since p53 was more abundant in proliferating cells and decreased upon induction of growth arrest and apoptosis by withdrawal of GM-CSF while Sp1 levels remained unchanged. These results suggest that the association of Sp1 with p53 may represent a novel mechanism of growth regulation in cytokine-dependent leukemia cells.	GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,4 RES CT,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,LOMBARDI CANC RES CTR,WASHINGTON,DC 20007	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [R01CA054231] Funding Source: NIH RePORTER; NCI NIH HHS [CA54231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1992, EXP HEMATOL, V20, P391; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KREISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11; KREISS SA, 1988, J VIROL, V62, P4737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHABO Y, 1990, LEUKEMIA, V4, P797; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; STEIN G, 1989, P NATL ACAD SCI USA, V86, P1865, DOI 10.1073/pnas.86.6.1865; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; UEDA K, 1987, J BIOL CHEM, V262, P17432; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG W, 1992, ONCOGENE, V7, P1039	49	163	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7923	7928						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463313				2022-12-25	WOS:A1993KW97900053
J	KAMEYAMA, K; HAGA, K; HAGA, T; KONTANI, K; KATADA, T; FUKADA, Y				KAMEYAMA, K; HAGA, K; HAGA, T; KONTANI, K; KATADA, T; FUKADA, Y			ACTIVATION BY G-PROTEIN BETA-GAMMA-SUBUNITS OF BETA-ADRENERGIC AND MUSCARINIC RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; GTP-BINDING; ADENYLYL CYCLASE; INHIBITION; RHODOPSIN; FAMILY; PURIFICATION; EXPRESSION; TRANSDUCIN; HEART	We have shown previously that GTP-binding regulatory protein (G protein) betagamma subunits stimulate the agonist- or light-dependent phosphorylation of muscarinic acetylcholine receptors (mAChRs) and rhodopsin by a protein kinase partially purified from porcine brain (mAChR kinase) but not the phosphorylation of rhodopsin by rhodopsin kinase (Haga, K., and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227). We report here that the mAChR kinase phosphorylates beta-adrenergic receptors (beta-ARs) purified from bovine lung in an agonist-dependent manner, and the phosphorylation is also stimulated by G protein betagamma subunits. We also report that recombinant beta-adrenergic receptor kinase 1 (beta-ARK1) expressed in COS-7 cells phosphorylates mAChRs (human m2 subtype) and rhodopsin in an agonist- or light-dependent manner, respectively, and that this phosphorylation is stimulated by G protein betagamma subunits. By contrast, the betagamma subunits do not stimulate the phosphorylation of mAChRs or rhodopsin by a beta-ARK1 mutant lacking a part of the carboxyl-terminal region which is present in beta-ARKs but not in rhodopsin kinase. These results indicate that the beta-ARK1 is the same as or very similar to the mAChR kinase but is distinguished from the rhodopsin kinase with respect to activation by the betagamma subunits and that the extra carboxyl-terminal sequence in beta-ARKs is required for the stimulation by the betagamma subunits.	TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Tokyo Institute of Technology; Kyoto University	KAMEYAMA, K (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.		吉孝, 深田/G-5090-2014					BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1990, RECEPTOR BIOCH PRACT, P125; CARON MG, 1979, J BIOL CHEM, V254, P2923; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA K, 1985, J BIOL CHEM, V260, P7927; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KONTANI K, 1992, ARCH BIOCHEM BIOPHYS, V294, P527, DOI 10.1016/0003-9861(92)90720-H; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARKER EM, 1991, J BIOL CHEM, V266, P519; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Sambrook J, 1989, MOL CLONING LABORATO; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211	27	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7753	7758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463305				2022-12-25	WOS:A1993KW97900028
J	DESJARDIN, LE; TIMMERS, AMM; HAUSWIRTH, WW				DESJARDIN, LE; TIMMERS, AMM; HAUSWIRTH, WW			TRANSCRIPTION OF PHOTORECEPTOR GENES DURING FETAL RETINAL DEVELOPMENT - EVIDENCE FOR POSITIVE AND NEGATIVE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN IRBP; RNA POLYMERASE-II; MESSENGER-RNA; SEQUENCE-ANALYSIS; BOVINE RHODOPSIN; RAT RETINA; EXPRESSION; MOUSE; ACTIVATION; CELLS	Rod photoreceptor outer segments are elaborated at approximately 6 months gestation in the cow coinciding with a dramatic increase in mRNAs encoding many visual transduction and associated proteins. Nuclear run-on determination of relative transcription rates demonstrates that gene expression follows three distinct patterns. Opsin, S-antigen, and transducin are all minimally detectable at 5.2 months gestation and increase throughout development. Only opsin demonstrates an additional sharp increase in transcriptional activity which resembles a positive gene-specific enhancer that is first effective between 6.3 and 7.4 months gestation. In contrast, interphotoreceptor retinoid binding protein (IRBP) transcription is already at 43% of its adult level at 5.2 months gestation. To further understand these differences, the relative contributions of initiation and elongation to nuclear run-on signals were examined using either Sarkosyl or ammonium sulfate. Transcriptional rates for S-antigen and transducin were not affected, however, opsin was reduced approximately 4-fold and IRBP was increased approximately 2-fold. Opsin is therefore likely to be initiated de novo during the run-on reaction and responds to a gene-specific positive regulator. The increase in IRBP transcription rate suggests the removal of an elongation inhibitory factor and supports the idea that a negative regulatory element may be involved in controlling IRBP expression.	UNIV FLORIDA,DEPT OPHTHALMOL,POB 100284 JHMHC,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL EYE INSTITUTE [R01EY009358, R01EY007864] Funding Source: NIH RePORTER; NEI NIH HHS [EY07864, EY09358, EY07132] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMOV I, 1982, SCIENCE, V217, P265, DOI 10.1126/science.6178160; ALEMANY J, 1989, J BIOL CHEM, V264, P17559; BARNSTABLE CJ, 1991, PROGR RETINAL RES, V10, P45; BISTNER SI, 1973, AM J VET RES, V34, P7; BORST DE, 1989, J BIOL CHEM, V264, P1115; BOWES C, 1987, EXP EYE RES, V45, P467, DOI 10.1016/S0014-4835(87)80058-1; BUTTERWORTH PH, 1971, EUR J BIOCHEM, V23, P229, DOI 10.1111/j.1432-1033.1971.tb01613.x; CARTERDAWSON L, 1986, DEV BIOL, V116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chomczynski P, 1987, ANAL BIOCH, V162, P156; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P158; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DURNAM DM, 1983, ANAL BIOCH, V131; GARIGLIO P, 1974, FEBS LETT, V44, P330, DOI 10.1016/0014-5793(74)81170-1; GONZALEZFERNANDEZ F, 1990, J CELL BIOL, V111, P2775, DOI 10.1083/jcb.111.6.2775; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GREEN MH, 1975, EUR J BIOCHEM, V53, P217, DOI 10.1111/j.1432-1033.1975.tb04060.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; HAUSWIRTH WW, 1992, EXP EYE RES, V54, P661, DOI 10.1016/0014-4835(92)90021-J; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOLLYFIELD JG, 1985, INVEST OPHTH VIS SCI, V26, P58; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; JOHNSON AT, 1985, J COMP NEUROL, V233; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; KUO CH, 1986, MOL BRAIN RES, V1, P251, DOI 10.1016/0169-328X(86)90031-8; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LEMISCHKA I, 1982, NATURE, V300, P330, DOI 10.1038/300330a0; LIOU GI, 1986, VISION RES, V26, P1645, DOI 10.1016/0042-6989(86)90052-0; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OZANICS V, 1982, OCULAR ANATOMY EMBRY, P54; PORRELLO K, 1991, J HISTOCHEM CYTOCHEM, V39, P171, DOI 10.1177/39.2.1987260; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sambrook J, 1989, MOL CLONING LABORATO; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; SCHEER U, 1978, CELL, V13, P535, DOI 10.1016/0092-8674(78)90327-6; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; STRYER L, 1991, J BIOL CHEM, V266, P10711; TIMMERS AM, 1993, IN PRESS EXP EYE RES, V57; TOLUNAY HE, 1984, P NATL ACAD SCI-BIOL, V81, P5916, DOI 10.1073/pnas.81.19.5916; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANVEEN T, 1986, FEBS LETT, V208, P133, DOI 10.1016/0014-5793(86)81547-2; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; YU FL, 1972, BIOCHIM BIOPHYS ACTA, V272, P119, DOI 10.1016/0005-2787(72)90039-1; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	56	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6953	6960						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463227				2022-12-25	WOS:A1993KV14100026
J	SMITH, A; ALAM, J; ESCRIBA, PV; MORGAN, WT				SMITH, A; ALAM, J; ESCRIBA, PV; MORGAN, WT			REGULATION OF HEME OXYGENASE AND METALLOTHIONEIN GENE-EXPRESSION BY THE HEME ANALOGS, COBALT-PROTOPORPHYRIN, AND TIN-PROTOPORPHYRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENT COMPETITIVE INHIBITOR; PIG ALVEOLAR MACROPHAGES; MOUSE HEPATOMA-CELLS; MESSENGER-RNA; NEONATAL HYPERBILIRUBINEMIA; TRANSCRIPTIONAL REGULATION; HEAVY-METALS; RAT-LIVER; 3T3 CELLS; I GENE	Two heme analogs, cobalt- and tin-protoporphyrin (CoPP and SnPP, respectively) have been used to probe the heme-hemopexin interaction, hemopexin receptor binding, and the mechanism of regulation of heme oxygenase (HO) and metallothionein-1 (MT-1) gene expression by hemopexin. Both CoPP and SnPP are HO inhibitors and hemopexin binds SnPP (Morgan, W. T., Alam, J., Deaciuc, V., Muster, P., Tatum, F. M., and Smith, A. (1988) J. Biol. Chem. 263, 8226-8231) and CoPP. The association of CoPP with hemopexin produces characteristic changes in the absorbance spectrum of CoPP and quenches the intrinsic fluorescence of hemopexin. Binding of CoPP is tight (K(d) ca. 3 x 10(-7) M) although of lower affinity than heme itself (K(d) < pM); and CoPP binding, like heme, produces conformational changes in hemopexin shown by an increase in the molar ellipticity at 233 nm and affords protection from proteolysis of the hinge region between the two structural domains of hemopexin. The coordination of the central cobalt atom is predicted to be similar to that of heme and to involve His56 and His127 of rabbit hemopexin. Furthermore, CoPP-hemopexin, like SnPP-hemopexin, binds to the hemopexin receptor as shown by competitive inhibition studies with radioactive heme-hemopexin. The effect of free heme analogs and their hemopexin complexes on HO and MT gene regulation was investigated and compared with the extent of induction by heme and heme-hemopexin. Free CoPP is a more effective inducer of HO steady state mRNA levels than free heme and produces a 5-fold increase within 1 h compared to only a 2-fold increase with heme, but free SnPP (up to 10 muM) produces no detectable increase in HO mRNA. In contrast, by 3 h heme-hemopexin and SnPP-hemopexin increase HO mRNA levels 11- and 6-fold, respectively; but the CoPP-hemopexin complex causes no detectable change in HO mRNA levels. The complexes of hemopexin with heme or either of the two heme analogs are effective inducers of metallothionein (MT) mRNA. Induction of MT mRNA by heme-hemopexin is rapid, increasing 4-fold within 1 h and 14-fold by 3-4 h. Strikingly, an even more rapid and slightly more extensive induction of MT mRNA is seen in response to either CoPP- or SnPP-hemopexin complexes, with MT mRNA rising 8-fold within 1 h. In contrast, free heme and the free analogs are far less effective inducers, increasing MT mRNA levels and in vitro transcription rates only 3-4-fold and declining after 2-3 h. The uptake of SnPP by Hepa cells is facilitated by hemopexin but interestingly, binding to hemopexin significantly retards the uptake of CoPP. Both free CoPP and SnPP alone are accumulated by cells at 37-degrees-C. In conclusion, since CoPP-hemopexin binds to the hemopexin receptor yet CoPP uptake is minimal, and since MT mRNA levels are induced, while those of HO are not, occupation of the hemopexin receptor alone appears to be sufficient to influence intracellular events, such as a signaling pathway, important for MT gene transcription.	ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,NEW ORLEANS,LA 70121	Ochsner Health System	SMITH, A (corresponding author), UNIV MISSOURI,SCH BIOL SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X; Escriba, Pablo/0000-0001-9795-182X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037463] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37463] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDERSON KE, 1984, J PHARMACOL EXP THER, V228, P327; ARIZONO K, 1991, J ENVIRON SCI HEAL A, V26, P941, DOI 10.1080/10934529109375676; BECKER RC, 1991, CARDIOLOGY, V78, P257, DOI 10.1159/000174792; CALTABIANO MM, 1986, J BIOL CHEM, V261, P3381; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; ISHIZAWA S, 1983, J BIOL CHEM, V258, P4220; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; MAINES MD, 1976, BIOCHEM J, V154, P125, DOI 10.1042/bj1540125; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; MORGAN WT, 1988, J BIOL CHEM, V263, P8220; MORGAN WT, 1993, J BIOL CHEM, V268, P6256; MORGAN WT, 1975, ANN NY ACAD SCI, V244, P624; MULLER RM, 1987, J BIOL CHEM, V262, P6795; PIMSTONE NR, 1971, J CLIN INVEST, V50, P2042, DOI 10.1172/JCI106697; PIMSTONE NR, 1971, J EXP MED, V133, P1264, DOI 10.1084/jem.133.6.1264; REN YF, 1992, FASEB J, V6, pA71; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; SHIBAHARA S, 1979, ARCH BIOCHEM BIOPHYS, V197, P607, DOI 10.1016/0003-9861(79)90285-6; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; SMITH A, 1985, BIOCHEM J, V231, P663, DOI 10.1042/bj2310663; SMITH A, 1991, BIOCHEM J, V276, P417, DOI 10.1042/bj2760417; SMITH A, 1988, J BIOL CHEM, V263, P5224; SMITH A, 1990, EUR J CELL BIOL, V53, P234; SMITH A, 1984, J BIOL CHEM, V259, P2049; SMITH A, 1988, BIOCHEM J, V256, P941, DOI 10.1042/bj2560941; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TAKETANI S, 1988, BIOCHEM INT, V17, P665; TENHUNEN R, 1970, J LAB CLIN MED, V75, P410; YONETANI T, 1974, J BIOL CHEM, V249, P682; 1991, FASEB J, V6, P71	44	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7365	7371						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463269				2022-12-25	WOS:A1993KV14100078
J	BERNARDO, MM; DAY, DE; OLSON, ST; SHORE, JD				BERNARDO, MM; DAY, DE; OLSON, ST; SHORE, JD			SURFACE-INDEPENDENT ACCELERATION OF FACTOR-XII ACTIVATION BY ZINC IONS .1. KINETIC CHARACTERIZATION OF THE METAL-ION RATE ENHANCEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; ATOMIC-ABSORPTION SPECTROPHOTOMETRY; PROTEIN-PROTEIN INTERACTIONS; WASHED HUMAN-PLATELETS; COAGULATION FACTOR-XII; HIGH-MR KININOGEN; BLOOD-COAGULATION; CONTACT ACTIVATION; ENDOTHELIAL-CELLS; HAGEMAN-FACTOR	The effect of zinc ions (Zn(II)) on the activation of factor XII in the absence of a procoagulant surface was investigated by initial velocity kinetic studies at I = 0.15, pH 7.4, and 25-degrees-C. Zinc ions at concentrations greater than 160 muM potentiated 99-fold the k(cat)/K(M) for the activation of factor XII by kallikrein and, at an optimum concentration of 110 muM, accelerated 140-fold the apparent k(cat)/K(M) for factor XII autoactivation. High molecular weight kininogen had no effect on either metal-potentiated reaction. Analysis of the factor XII concentration dependence of initial activation rates revealed that Zn(II), at levels that saturate the effect, accelerates kallikrein activation of factor XII by lowering Km (from 52 to 7.3 muM) and raising k(cat) (from 2.6 to 31 min-1). For the autocatalytic activation reaction of factor XII in the presence of optimal Zn(II), apparent K(M) and k(cat) values of 2.4 muM and 0.041 min-1, respectively, were determined, but these parameters were not resolvable in the absence of the metal ion. Zinc ions minimally affected kallikrein enzymatic activity and inhibited factor XIIa enzymatic activity with K(I) values of 20-40 muM, suggesting that the rate-enhancing effects of the metal ion are due to interactions with the substrate (factor XII) rather than with the enzyme. The Zn(II) inhibition of factor XIIa enzymatic activity accounted for a decreased Zn(II) enhancement of factor XII autoactivation at high metal ion concentrations (> 110 muM). The Zn(II) concentration dependence of the acceleration of factor XII activation reactions were sigmoid and characterized by Hill coefficients of 3.3-4.3, suggesting that cooperative binding of at least four zinc ions to factor XII was responsible for the Zn(II) potentiating effect. The Zn(II) enhancement of the rates of factor XII activation decreased both above and below pH 7.4 with midpoint pH values of 6.5-7.0 and 8.0, consistent with histidine and possibly water ligands mediating Zn(II) binding to the protein. Despite an apparent weaker binding of Zn(II) to factor XII at pH 6.5, indistinguishable maximum accelerating effects of the metal ion were observed at saturation at this pH, indicating that the increased positive charge of factor XII resulting from protonation at the lower pH did not mimic the effect of Zn(II) binding. These results imply that zinc ions induce a conformational change in factor XII that makes it a better substrate for its enzyme activators.	HENRY FORD HOSP,DIV BIOCHEM RES,EDUC & RES BLDG,RM 3126,2799 W GRAND BLVD,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; BERINI L, 1983, COORDINATION CHEM ME, P1; BERNARDO MM, 1993, J BIOL CHEM, V268, P12477; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOCK PE, 1983, J BIOL CHEM, V258, P5079; BOCK PE, 1985, J BIOL CHEM, V260, P2434; BOCK PE, 1981, BIOCHEMISTRY-US, V20, P7258, DOI 10.1021/bi00528a032; BOUMA BN, 1986, NEW COMPREHENSIVE BI, V13, P103; CHAMBERS JL, 1974, BIOCHEM BIOPH RES CO, V59, P70, DOI 10.1016/S0006-291X(74)80175-0; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FLASCHKA HA, 1959, EDTA TITRATIONS, P63; FOLEY B, 1968, P SOC EXP BIOL MED, V128, P266; GORDON PR, 1982, AM J CLIN NUTR, V35, P113, DOI 10.1093/ajcn/35.1.113; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; HEYNS AD, 1985, BLOOD, V66, P213; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KAPLAN AP, 1987, BLOOD, V70, P1; KIEM J, 1979, CLIN CHEM, V25, P705; KOZIN F, 1988, INFLAMMATION BASIC P, P101; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; NEMERSON Y, 1988, BLOOD, V71, P1; NUJENS JH, 1989, J BIOL CHEM, V264, P12941; PRASAD AS, 1970, J LAB CLIN MED, V76, P416; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; Segel I., 1975, ENZYME KINETICS, P371; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; SHORE JD, 1987, BIOCHEMISTRY-US, V26, P2250, DOI 10.1021/bi00382a027; SHORE JD, 1989, THROMB HAEMOSTASIS, V62, P15; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1983, J BIOL CHEM, V258, P8215; TANS G, 1986, NEW COMPREHENSIVE BI, V13, P59; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; VALLEE BL, 1983, ZINC ENZYMES, P3; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WARD NI, 1979, ANAL CHIM ACTA, V105, P185, DOI 10.1016/S0003-2670(01)83750-8; WHITEHOUSE RC, 1983, CLIN CHEM, V29, P1974; WHITEHOUSE RC, 1982, CLIN CHEM, V28, P475; WOO J, 1984, CLIN DIAGNOSIS MANAG, P161	51	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12468	12476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509386				2022-12-25	WOS:A1993LG65800038
J	SANTAMBROGIO, P; LEVI, S; COZZI, A; ROVIDA, E; ALBERTINI, A; AROSIO, P				SANTAMBROGIO, P; LEVI, S; COZZI, A; ROVIDA, E; ALBERTINI, A; AROSIO, P			PRODUCTION AND CHARACTERIZATION OF RECOMBINANT HETEROPOLYMERS OF HUMAN FERRITIN H-CHAIN AND L-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN; HUMAN-LIVER; APOFERRITIN; CELLS; ISOFERRITINS; MECHANISM; HETEROGENEITY; EXPRESSION; SITE	Vertebrate ferritins are iron storage proteins composed by 24 subunits of one or more types. The recombinant homopolymers of human ferritin H- and L-type chains differ in iron uptake and in physical stability, but the properties of heteropolymers with various proportions of H- and L-type chains cannot be predicted. Present study shows that unfolded human ferritin Hand L- type chains renature under similar conditions to form homopolymers indistinguishable from the native ones and that, when mixed, the unfolded H and L chains renature to form heteropolymers with restricted heterogeneity and with the expected H:L ratios. Seven of these ferritins with different H:L ratios were analyzed; electrophoretic mobility, immunological reactivity, and stability to guanidine denaturation varied as predicted, based on the homopolymers. In contrast, the rate of iron uptake, monitored by the variation of absorbance at 310 nm, increased in the ferritins that ranged in H chain content from 0 to 35%; further increments in H chains had no additional effect. This finding indicates that, under the present conditions, only a limited number of H chains are needed for the maximum rate of ferritin iron uptake. Variations of L- and H-type chains in vivo may thus have biological relevance.	UNIV MILAN, DEPT BIOMED SCI & TECHNOL, I-20132 MILAN, ITALY; CNR, IST TECHNOL BIOMED AVANZATI, I-20131 MILAN, ITALY; UNIV BRESCIA, INST CHEM, I-25124 BRESCIA, ITALY; UNIV MILAN, SCI INST SAN RAFFAELE, DEPT BIOL & TECHNOL RES, I-20132 MILAN, ITALY	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Brescia; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			arosio, paolo/E-6817-2010; Cozzi, Anna/AAN-3821-2020; levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992; albertini, alberto/0000-0002-7989-649X				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1976, CANCER RES, V36, P1735; AROSIO P, 1989, IRON IMMUNITY CANCER, P55; BOYD D, 1985, J BIOL CHEM, V260, P1755; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; CAZZOLA M, 1983, BLOOD, V62, P1078; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GERL M, 1987, EUR BIOPHYS J BIOPHY, V15, P103, DOI 10.1007/BF00257503; GERL M, 1988, BIOCHEMISTRY-US, V27, P4089, DOI 10.1021/bi00411a027; GERL M, 1987, BIOL CHEM H-S, V368, P387, DOI 10.1515/bchm3.1987.368.1.387; HARRISON PM, 1968, NATURE, V220, P578, DOI 10.1038/220578a0; HARRISON PM, 1987, BIOCHEM SOC T, V15, P744, DOI 10.1042/bst0150744; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LAWSON DM, 1990, THESIS U SHEFFIELD S; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LIAU G, 1991, J BIOL CHEM, V266, P18819; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; OTSUKA S, 1981, BIOCHEMISTRY-US, V20, P5226, DOI 10.1021/bi00521a020; RUGGERI G, 1984, FERRITINS ISOFERRITI, P67; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; STEFANINI S, 1987, BIOCHEMISTRY-US, V26, P1831, DOI 10.1021/bi00381a007; STEFANINI S, 1982, BIOCHEMISTRY-US, V21, P2293, DOI 10.1021/bi00539a004; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VEZZONI P, 1986, BRIT J HAEMATOL, V62, P105, DOI 10.1111/j.1365-2141.1986.tb02905.x; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; YABLONSKI MJ, 1992, BIOCHEMISTRY-US, V31, P9680, DOI 10.1021/bi00155a022	37	156	162	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12744	12748						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509409				2022-12-25	WOS:A1993LG65800077
J	STUDWELLVAUGHAN, PS; ODONNELL, M				STUDWELLVAUGHAN, PS; ODONNELL, M			DNA POLYMERASE-III ACCESSORY PROTEINS .5. THETA ENCODED BY HOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOLOENZYME; PURIFICATION; SUBUNIT; IDENTIFICATION; REPLICATION	The polIII core subassembly of DNA polymerase III holoenzyme is composed of the alpha (DNA polymerase), epsilon (editing exonuclease), and theta subunits. We have identified holE encoding theta (8.6 kDa) at 40.4 min, expressed and purified 300 mg of theta, and have studied its function by constituting the polIII core from pure alpha, epsilon, and theta subunits. The theta subunit binds the epsilon proofreader tightly, but it does not form a detectable complex with alpha. The epsilon subunit also binds to alpha (Maki, H., and Kornberg, A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4389-4392). Hence, the subunit arrangement of the polIII core is linear, alphaepsilontheta. Interaction of theta with epsilon slightly stimulated epsilon in excision of a 3' terminal mismatched nucleotide, suggesting a possible role for theta in fidelity.	CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,DEPT MICROBIOL,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,HEARST RES FDN,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Cornell University; Howard Hughes Medical Institute					NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUTLAG D, 1969, BIOCHEM BIOPH RES CO, V37, P982, DOI 10.1016/0006-291X(69)90228-9; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DONG ZM, 1993, J BIOL CHEM, V268, P11758; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KORNBERG A, 1991, DNA REPLICATION, P176; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1983, P NATL ACAD SCI-BIOL, V80, P7137, DOI 10.1073/pnas.80.23.7137; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI H, 1987, UCLA S MOL CELL BIOL, V127, P63; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ROWEN L, 1979, J BIOL CHEM, V253, P758; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH M, 1989, HDB BIOCH, pC1; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; WICKNER W, 1974, J BIOL CHEM, V249, P6244	29	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11785	11791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505306				2022-12-25	WOS:A1993LF28400050
J	IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S				IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S			USE OF THE 2-HYBRID SYSTEM TO IDENTIFY THE DOMAIN OF P53 INVOLVED IN OLIGOMERIZATION	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; PROTEINS BIND; SEQUENCE; TRANSFORMATION; IDENTIFICATION; MUTATIONS; ONCOGENE	We used a yeast-based genetic assay, the two-hybrid system, to characterize the domain of the tumor-suppressor p53 involved in oligomerization. This assay relies on the reconstitution of the function of a transcriptional activator, the yeast GAL4 protein, via the interaction of a protein fused to the DNA-binding domain of GAL4 with a protein fused to the transcriptional activation domain of GAL4. We show by a reconstruction experiment that this approach could detect the interaction of p53 deleted for its N-terminal activation domain with SV40 large T antigen. We then searched a library of human proteins present as activation domain hybrids for proteins that can interact with the hybrid of p53 with the DNA-binding domain. This search identified 36 plasmids containing the p53 gene, representing 10 different classes. These results provide an additional in viro demonstration of p53 oligomerization. The smallest p53 fragment identified from screening the library contained only amino acids 331-393, indicating that this small C-terminal fragment is sufficient to mediate oligomerization. In addition, a mutant p53 protein could bind to the wild-type protein in this assay, providing support for the idea that mutant forms of p53 act in a dominant-negative manner through C-terminal oligomerization with the wild type.	SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794; SUNY,GRAD PROGRAM MOLEC & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NCI NIH HHS [CA54699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Miller J.H., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	32	171	200	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1693	1696						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502489				2022-12-25	WOS:A1993LE06400035
J	GALLWITZ, WE; MUNDY, GR; LEE, CH; QIAO, M; ROODMAN, GD; RAFTERY, M; GASKELL, SJ; BONEWALD, LF				GALLWITZ, WE; MUNDY, GR; LEE, CH; QIAO, M; ROODMAN, GD; RAFTERY, M; GASKELL, SJ; BONEWALD, LF			5-LIPOXYGENASE METABOLITES OF ARACHIDONIC-ACID STIMULATE ISOLATED OSTEOCLASTS TO RESORB CALCIFIED MATRICES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; BONE-RESORPTION; LEUKOTRIENE SYNTHESIS; LIPOXYGENASE; RELEASE; INVITRO; CYCLOOXYGENASE; EXPRESSION; RECEPTOR; ANTIGENS	Bone resorption requires cooperation between osteoclasts and mononuclear accessory cells by mechanisms which have not been elucidated. Since multinucleated cells in giant cell tumors of bone have many phenotypic and functional characteristics of normal osteoclasts, we have examined the interaction between the bone-resorbing multinucleated cells and the distinct mono-nuclear stromal cells from these tumors. We have found that these mononuclear cells produce an activity which stimulates both giant cells from giant cell tumors and rodent osteoclasts to resorb bone in vitro. We have identified the activity and found that it represents several products of the 5-lipoxygenase pathway of arachidonic acid metabolism, namely 5-hydroxyeicosatetraenoic acid and the leukotrienes. These data indicate that 5-lipoxygenase metabolites stimulate isolated osteoclasts to resorb bone in vitro and may represent a mechanism by which mononuclear stromal cells in human giant cell tumors communicate with the giant cells. In addition, these results may explain a possible mechanism for communication between accessory cells and osteoclasts involved in normal bone resorption.	UNIV TEXAS, HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL & METAB, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine			Bonewald, Lynda/Q-3638-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039529] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39529] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHANASOU NA, 1989, BRIT J CANCER, V59, P491, DOI 10.1038/bjc.1989.102; BALAZY M, 1986, ANAL CHEM, V58, P1098, DOI 10.1021/ac00297a026; BAND L, 1985, J CLIN INVEST, V76, P374; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CHAMBERS TJ, 1983, CALCIFIED TISSUE INT, V35, P566, DOI 10.1007/BF02405095; CHAMBERS TJ, 1987, J CELL PHYSIOL, V132, P90, DOI 10.1002/jcp.1041320112; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; COLLINS JL, 1989, J DENT RES, V109, P1817; COLLINS JL, 1987, J DENT RES, V66, P1771; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; ELATTAR TMA, 1983, J ORAL PATHOL MED, V12, P7; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDRING SR, 1986, CLIN ORTHOP RELAT R, P59; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HORTON MA, 1985, CANCER RES, V45, P5663; HUANG FC, 1990, J MED CHEM, V33, P1194, DOI 10.1021/jm00166a017; HUANG FC, 1989, J MED CHEM, V32, P1836, DOI 10.1021/jm00128a027; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KHANDWALA A, 1987, BIOCHEM PHARMACOL, V36, P663, DOI 10.1016/0006-2952(87)90717-9; KOMIYA S, 1990, CLIN ORTHOP RELAT R, P304; LING L, 1988, ARCH PATHOL LAB MED, V112, P65; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MCSHEEHY PM, 1987, J IMMUNOL, V138, P775; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; MEGHJI S, 1988, PROSTAG OTH LIPID M, V36, P139, DOI 10.1016/0090-6980(88)90301-2; MOHAMMED AH, 1989, AM J ORTHOD DENTOFAC, V95, P231, DOI 10.1016/0889-5406(89)90053-X; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; OREFFO ROC, 1990, ENDOCRINOLOGY, V126, P3069, DOI 10.1210/endo-126-6-3069; OREFFO ROC, 1993, IN PRESS CLIN ORTHOP; OURSLER MJ, 1991, J BONE MINER RES, V6, P375; PARKER CW, 1987, ANNU REV IMMUNOL, V5, P65, DOI 10.1146/annurev.iy.05.040187.000433; PERRY HM, 1987, CALCIFIED TISSUE INT, V40, P298, DOI 10.1007/BF02555265; RAFTERY MJ, 1992, BIOL MASS SPECTROM, V21, P509, DOI 10.1002/bms.1200211008; RAISZ LG, 1984, BONE MINERAL RES ANN, V2, P286; REID GK, 1990, J BIOL CHEM, V265, P19818; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; SANDY JR, 1989, BONE MINER, V5, P155, DOI 10.1016/0169-6009(89)90093-7; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; VANINWEGEN RG, 1987, J PHARMACOL EXP THER, V241, P117; ZAMBONINZALLONE A, 1988, ANAT EMBRYOL, V159, P68; ZIBOH VA, 1986, CANCER RES, V46, P600	46	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10087	10094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486677				2022-12-25	WOS:A1993LB80000024
J	SAMBASIVAM, H; RASSOULI, M; MURRAY, RK; NAGPURKAR, A; MOOKERJEA, S; AZADI, P; DELL, A; MORRIS, HR				SAMBASIVAM, H; RASSOULI, M; MURRAY, RK; NAGPURKAR, A; MOOKERJEA, S; AZADI, P; DELL, A; MORRIS, HR			STUDIES ON THE CARBOHYDRATE MOIETY AND ON THE BIOSYNTHESIS OF RAT C-REACTIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLCHOLINE-BINDING-PROTEIN; ACUTE PHASE RESPONSE; AMYLOID-P-COMPONENT; SERUM; ACID; RABBIT; SECRETION	Rat C-reactive protein (CRP) is a pentameric glycoprotein composed of five apparently identical monomers, two of which form a disulfide-linked dimer (Rassouli, M., Sambasivam, H., Azadi, P., Dell, A., Morris, H. R., Nagpurkar, A., Mookerjea, S., and Murray, R. K. (1992) J. Biol. Chem. 267, 2947-2954). In this study, the nature of the oligosaccharide chain of rat CRP was investigated by fast atom bombardment-mass spectrometry (FAB-MS), and general features of its biosynthetic pathway were also analyzed. FAB-MS, electrospray-mass spectrometry, and linkage analysis demonstrated that each monomer of rat CRP contained one oligosaccharide chain, predominantly a disialylated biantennary structure, attached to Asn-128. The biosynthesis of rat CRP was studied by immunoprecipitation of CRP synthesized in vitro and by cultured hepatocytes. The results revealed that each monomer of rat CRP was synthesized individually as a single-chain precursor with a cleavable signal sequence. The translocated species was sensitive to digestion by endoglycosidase H (endo H), indicating that it possessed a high mannose oligosaccharide. Rat CRP acquired the ability to bind to phosphorylcholine-Sepharose and to form the dimeric and oligomeric species prior to acquiring resistance to endo H. Studies using tunicamycin revealed that the N-linked oligosaccharide present in rat CRP was not required for formation of its dimeric component, oligomerization, ability to bind to phosphorylcholine, or secretion. The non-glycosylated rat CRP, however, was still able to bind to phosphorylcholine-Sepharose and to be secreted by hepatocytes.	MEM UNIV NEWFOUNDLAND, DEPT BIOCHEM, ST JOHNS A1B 3X9, NEWFOUNDLAND, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	Memorial University Newfoundland; University of Toronto; Imperial College London								AMATAYAKULCHANT.S, 1990, GLYCONJUGATE J, V7, P440; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALTZ ML, 1982, ANN NY ACAD SCI, V389, P49, DOI 10.1111/j.1749-6632.1982.tb22125.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS J, 1984, BIOCHIM BIOPHYS ACTA, V799, P97, DOI 10.1016/0304-4165(84)90281-2; DEBEER FC, 1982, IMMUNOLOGY, V45, P55; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; GEWURZ H, 1982, HOSP PRACT, V17, P67; GIULIAN GG, 1985, FED PROC, V44, P686; GRZELCZAK ZF, 1983, CAN J BIOCHEM CELL B, V61, P1233, DOI 10.1139/o83-159; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACINTYRE SS, 1983, BIOCHEM J, V210, P707, DOI 10.1042/bj2100707; MACINTYRE SS, 1988, METHOD ENZYMOL, V163, P383; NAGPURKAR A, 1988, BIOCHIM BIOPHYS ACTA, V967, P76, DOI 10.1016/0304-4165(88)90190-0; NAGPURKAR A, 1981, J BIOL CHEM, V256, P7440; PRESPER KA, 1985, ENZYMOLOGY POSTTRANS, P59; RANDELL E, 1990, BIOCHIM BIOPHYS ACTA, V1034, P281, DOI 10.1016/0304-4165(90)90051-W; RASSOULI M, 1992, J BIOL CHEM, V267, P2947; ROBEY FA, 1983, J BIOL CHEM, V258, P3889; SAXENA U, 1985, CAN J BIOCHEM CELL B, V63, P1014, DOI 10.1139/o85-126; SEMPLE E, 1987, BIOCHEM BIOPH RES CO, V148, P449, DOI 10.1016/0006-291X(87)91132-6; SYIN C, 1986, J BIOL CHEM, V261, P5473; TUCCI A, 1983, J IMMUNOL, V131, P2416	28	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10007	10016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486673				2022-12-25	WOS:A1993LB80000014
J	HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D				HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D			2 POTENTIALLY ONCOGENIC CYCLINS, CYCLIN-A AND CYCLIN-D1, SHARE COMMON PROPERTIES OF SUBUNIT CONFIGURATION, TYROSINE PHOSPHORYLATION AND PHYSICAL ASSOCIATION WITH THE RB PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; HISTONE-H1 KINASE-ACTIVITY; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CANDIDATE ONCOGENE; CDC2; MITOSIS; P34CDC2; TRANSFORMATION	Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene. Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene. However, the specific enzymatic activities and, hence, the precise biochemical mechanisms through which cyclins function to govern cell cycle progression remain unresolved. In the present study we have investigated the coordinate interactions between these two potentially oncogenic cyclins, cyclin-dependent protein kinase subunits (cdks) and the Rb tumor-suppressor protein. The distribution of cyctin D isoforms was modulated by serum factors in primary fetal rat lung epithelial cells. Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro. In synchronized human osteosarcoma cells, cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1, a Cdk-binding subunit. Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity. Immobilized, recombinant cyclins A and D1 were found to associate with cellular proteins in complexes that contain the p105Rb protein. This study identifies several common aspects of cyclin biochemistry, including tyrosine phosphorylation and the potential to interact directly or indirectly with the Rb protein, that may ultimately relate membrane-mediated signaling events to the regulation of gene expression.	UNIV SO CALIF, SCH MED, CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULMUNOL, LOS ANGELES, CA 90054 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90054 USA	Children's Hospital Los Angeles; University of Southern California; Baylor College of Medicine; University of Southern California	HALL, FL (corresponding author), UNIV SO CALIF, SCH MED, CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA.			Harper, Jeffrey/0000-0002-6944-7236	NHLBI NIH HHS [HL-44977, HL-44060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044977, R01HL044060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARBONAROHALL D, 1993, IN PRESS ONCOGENE; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HARADA S, 1991, ONCOGENE, V6, P461; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POST M, 1988, AM REV RESPIR DIS, V137, P525, DOI 10.1164/ajrccm/137.3.525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; TAMURA T, 1990, ONCOGENE, V5, P1259; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARBURTON D, 1989, J APPL PHYSIOL, V66, P901, DOI 10.1152/jappl.1989.66.2.901; WILLIAMS RT, 1992, ONCOGENE, V7, P423; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	60	73	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1377	1384						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479754				2022-12-25	WOS:A1993KY32800032
J	OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P				OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P			MUTATION OF A PHOSPHORYLATION SITE IN THE DNA-BINDING DOMAIN IS REQUIRED FOR REDOX-INDEPENDENT TRANSACTIVATION OF AP1-DEPENDENT GENES BY V-JUN	ONCOGENE			English	Article							C-JUN; FOS; ONCOGENE; INVITRO; REGION; AP-1	The ability of the nuclear onocprotein Jun to activate transcription is controlled both by level of DNA binding and by the activity of its transactivation domain. Control of DNA binding is achieved by two mechanisms: phosphorylation and redox regulation. Mutation of Ser-226 inhibits phosphorylation of the DNA binding, resulting in enhanced DNA-binding and transactivation activity of Jun. In contrast, mutation of Cys-252, which is the target for repression of DNA-binding activity under oxidative conditions, results in a strong decrease of Jun-specific activation of transcription. However, transactivation by c-Jun-Cys-252 is fully restored upon mutation of Ser-226. Both mutations are also found in the oncogenic counterpart of c-Jun, v-Jun, and are the only differences between these proteins in the DNA-binding domain, suggesting that v-Jun escapes down-modulation of DNA binding by both mechanisms. However, inhibition of phosphorylation of Ser-226 is absolutely required for the ability of v-Jun to activate transcription of AP-1-dependent genes in a redox-independent manner.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH, INST GENET, POSTFACH 3640, W-7500 KARLSRUHE 1, GERMANY; BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, WOLFSON LAB MOLEC PATHOL, GLASGOW G61 1BD, SCOTLAND	Helmholtz Association; Karlsruhe Institute of Technology; Beatson Institute			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Gillespie, David/0000-0002-6338-0544				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FRAME MC, 1991, ONCOGENE, V6, P205; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479739				2022-12-25	WOS:A1993KY32800005
J	HERSHBERGER, PA; MITA, BC; TRIPATARA, A; DEHASETH, PL				HERSHBERGER, PA; MITA, BC; TRIPATARA, A; DEHASETH, PL			INTERFERENCE BY P(R)-BOUND RNA-POLYMERASE WITH P(RM) FUNCTION-INVITRO - MODULATION BY THE BACTERIOPHAGE-LAMBDA CI PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; POSITIVE CONTROL; GENE-REGULATION; RIGHT OPERATOR; PRM PROMOTER; REPRESSOR; MECHANISM; INITIATION; STEPS; OR3	Activation of the weak P(RM) promoter by cI protein is an essential process in the establishment of lysogeny. Much evidence has accumulated that cI protein binds cooperatively to the operators O(R)1 and O(R)2 and that protein at the O(R)2 site contacts RNA polymerase to facilitate open complex formation at the P(RM) promoter. We had shown previously in vitro that RNA polymerase situated at the nearby P(R) promoter could interfere with open complex formation at P(RM) and that an additional mechanism Of P(RM) activation in vitro involved cI-mediated RNA polymerase exclusion from P(R). Here we further characterize this second indirect mode of activation. We demonstrate that addition of cI and inactivation of the P(R) Promoter activate open complex formation at P(RM) similarly over the temperature range from 37 to 20-degrees-C in which the extent of activation decreases from 8- to 2-fold. We also show that the binding of cI protein to O(R)1 is sufficient to effect an increase in the rate of synthesis of abortive RNA products at P(RM). This result is difficult to explain based on direct cI-RNA polymerase contacts alone but is readily interpreted in terms of our previously proposed model involving the exclusion of an interfering RNA polymerase from binding at P(R).	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University				Hershberger, Pamela/0000-0003-0030-6520	NIGMS NIH HHS [GM 31808] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; Ptashne M., 1986, A GENETIC SWITCH; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; WOODY ST, 1993, J MOL BIOL, V229, P37, DOI 10.1006/jmbi.1993.1006	14	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8943	8948						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473337				2022-12-25	WOS:A1993KX81100082
J	GIBBS, JB; POMPLIANO, DL; MOSSER, SD; RANDS, E; LINGHAM, RB; SINGH, SB; SCOLNICK, EM; KOHL, NE; OLIFF, A				GIBBS, JB; POMPLIANO, DL; MOSSER, SD; RANDS, E; LINGHAM, RB; SINGH, SB; SCOLNICK, EM; KOHL, NE; OLIFF, A			SELECTIVE-INHIBITION OF FARNESYL-PROTEIN TRANSFERASE BLOCKS RAS PROCESSING INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID; A-FACTOR; FARNESYLTRANSFERASE; P21RAS; YEAST; IDENTIFICATION; GENE; GERANYLGERANYLTRANSFERASE; EXPRESSION; INVITRO	The ras oncogene product, Ras, is synthesized in vivo as a precursor protein that requires post-translational processing to become biologically active and to be capable of transforming mammalian cells. Farnesylation appears to be a critical modification of Ras, and thus inhibitors of the farnesyl-protein transferase (FPTase) that catalyzes this reaction may block ras-dependent tumorigenesis. Three structural classes of FPTase inhibitors were identified: (alpha-hydroxyfarnesyl)phosphonic acid, chaetomellic acids, and zaragozic acids. By comparison, these compounds were weaker inhibitors of geranylgeranyl-protein transferases. Each of these inhibitors was competitive with respect to farnesyl diphosphate in the FPTase reaction. All compounds were assayed for inhibition of Ras processing in Ha-ras-transformed NIH3T3 fibroblasts. Ras processing was inhibited by 1 muM (alpha-hydroxyfarnesyl)phosphonic acid. Neither chaetomellic acid nor zaragozic acid were active in this assay. These results are the first demonstration that a small organic chemical selected for inhibition of FPTase can inhibit Ras processing in vivo.	MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065	Merck & Company	GIBBS, JB (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DECLUE JE, 1991, CANCER RES, V51, P712; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GILL M, 1982, PHYTOCHEMISTRY, V21, P1786, DOI 10.1016/S0031-9422(82)85063-2; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JOLY A, 1991, J BIOL CHEM, V266, P13495; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LIU WC, 1992, J ANTIBIOT, V45, P454, DOI 10.7164/antibiotics.45.454; LOWRY D, 1992, SEMINARS CANCER BIOL, V3, P167; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILING HC, 1990, SCIENCE, V247, P318; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	40	278	320	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7617	7620						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463291				2022-12-25	WOS:A1993KW97900005
J	ENENKEL, C; WOLF, DH				ENENKEL, C; WOLF, DH			BLH1 CODES FOR A YEAST THIOL AMINOPEPTIDASE, THE EQUIVALENT OF MAMMALIAN BLEOMYCIN HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEINASE YSCE; MOLECULAR-CLONING; EUKARYOTIC CELLS; MUTANTS; PROTEOLYSIS; ENZYME; GENE; PEPTIDASE; SURVIVAL	We have cloned the BLH1 gene of the yeast Saccharomyces cerevisiae coding for a peptidase with significant homology to rabbit bleomycin hydrolase. Bleomycin is a glycopeptide antibiotic used for the treatment of human cancers. The antitumor activity of the drug is limited by its metabolic inactivation caused by bleomycin hydrolase. a member of the cysteine protease family. The open reading frame of BLH1 consists of 1,449 base pairs encoding a 55.4-kDa protein consistent with the molecular mass found in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The consensus sequence within the active site region of cysteine proteases is conserved in the yeast enzyme. Biochemical studies on the purified enzyme confirm its classification as a thiol protease. The nonvacuolar enzyme has a molecular mass of 220 kDa, suggesting a homotetrameric structure. It exhibits an aminopeptidase activity with broad substrate specificity. Biochemical and genetic linkage data give evidence that the BLH1 and the LAP3 (Trumbly, R. J., and Bradley, G. (1983) J. Bacteriol. 156, 36-48) encoded aminopeptidases are identical. Deletion of the BLH1 gene is not lethal under normal growth conditions. However, blh1 mutants show hypersensitivity to bleomycin, indicating that bleomycin hydrolase is able to inactivate bleomycin in vivo and to protect cells from bleomycin-induced toxicity.	UNIV STUTTGART,INST BIOCHEM,PFAFFENWALDRING 55,W-7000 STUTTGART 80,GERMANY	University of Stuttgart								ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; ACHSTETTER T, 1983, ARCH BIOCHEM BIOPHYS, V226, P292, DOI 10.1016/0003-9861(83)90296-5; ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; ARRIGO AP, 1988, NATURE, V331, P190; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHLER M, 1992, THESIS U STUTTGART, P106; Carter S.K., 1985, BLEOMYCIN CHEMOTHERA, P3; CHANG YH, 1989, J BIOL CHEM, V264, P6979; CHANG YH, 1992, J BIOL CHEM, V267, P8007; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CUEVA R, 1989, FEBS LETT, V259, P125, DOI 10.1016/0014-5793(89)81510-8; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FREY J, 1978, BIOCHIM BIOPHYS ACTA, V527, P31, DOI 10.1016/0005-2744(78)90253-X; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GARCIAALVAREZ N, 1991, EUR J BIOCHEM, V202, P993, DOI 10.1111/j.1432-1033.1991.tb16461.x; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1992, J BIOL CHEM, V267, P25709; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; HILT W, 1993, J BIOL CHEM, V268, P3479; HILT W, 1992, MOL MICROBIOL, V6, P2437; HIRSCH HH, 1988, EUR J BIOCHEM, V173, P589, DOI 10.1111/j.1432-1033.1988.tb14040.x; Hirsch HH., 1989, MOL CELL BIOL YEASTS, P134; JONES EW, 1991, J BIOL CHEM, V266, P7963; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZO JS, 1987, METABOLISM ACTION AN, P194; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; MOORE CW, 1991, J BACTERIOL, V173, P3605, DOI 10.1128/jb.173.11.3605-3608.1991; NISHIMURA C, 1989, BIOCHEM BIOPH RES CO, V163, P788, DOI 10.1016/0006-291X(89)92291-2; NISHIMURA C, 1987, BIOCHEMISTRY-US, V26, P1574, DOI 10.1021/bi00380a013; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROSE B, 1979, J BACTERIOL, V139, P220, DOI 10.1128/JB.139.1.220-224.1979; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMKE RT, 1970, ANNU REV BIOCHEM, V39, P929, DOI 10.1146/annurev.bi.39.070170.004433; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; Sherman F., 1986, METHODS YEAST GENETI; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; UMEZAWA H, 1979, BLEOMYCIN CHEM BIOCH, P24; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WOLF DH, 1992, EXPERIENTIA, V48, P117, DOI 10.1007/BF01923505; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975; WOLF DH, 1986, MICROBIOL SCI, V3, P107; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	57	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7036	7043						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463237				2022-12-25	WOS:A1993KV14100036
J	HAMAWY, MM; MERGENHAGEN, SE; SIRAGANIAN, RP				HAMAWY, MM; MERGENHAGEN, SE; SIRAGANIAN, RP			TYROSINE PHOSPHORYLATION OF PP125(FAK) BY THE AGGREGATION OF HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTORS REQUIRES CELL ADHERENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BASOPHILIC LEUKEMIA-CELLS; VIRUS-TRANSFORMED CELLS; PROTEIN KINASE-C; SIGNAL TRANSDUCTION; HISTAMINE-RELEASE; PHORBOL ESTER; 2H3 CELLS; CALCIUM SIGNAL; INTEGRIN; TALIN	The aggregation of the high affinity IgE receptor (FcespilsonRI) in adherent rat basophilic leukemia (RBL-2H3) cells induces the tyrosine phosphorylation of several proteins. We examined whether focal adhesion-associated tyrosine kinase, pp125FAK, is one of these proteins. Anti-pp125FAK monoclonal antibody immunoblotted and precipitated a 115-kDa tyrosine-phosphorylated protein. In the absence of FcepsilonRI aggregation, pp125FAK was tyrosine-phosphorylated only in adherent cells. Aggregating FcepsilonRI in adherent cells markedly enhanced tyrosine phosphorylation of pp125FAK. This increase was detectable within 1 min of FcepsilonRI aggregation and was maximal by 15 min. In contrast, in nonadherent cells FcepsilonRI aggregation did not induce tyrosine phosphorylation of pp125FAK. The enhanced influx of calcium by calcium ionophore or the activation of protein kinase C by phorbol myristate acetate induced tyrosine phosphorylation of pp125FAK only in adherent cells. Thus, FcepsilonRI-induced tyrosine phosphorylation of pp125FAK could be mediated by the activation of protein kinase C and/or the induction of calcium influx. The data indicate that cell adherence is essential for FcepsilonRI-induced tyrosine phosphorylation of pp125FAK.			HAMAWY, MM (corresponding author), NIDR,IMMUNOL LAB,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.							BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORVATH AR, 1990, ONCOGENE, V5, P1349; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; SAHARA N, 1990, J HISTOCHEM CYTOCHEM, V38, P975, DOI 10.1177/38.7.1693935; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1988, INFLAMMATION BASIC P, P513; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; STRACKE ML, 1987, MOL IMMUNOL, V24, P347, DOI 10.1016/0161-5890(87)90176-3; TAPLEY P, 1989, ONCOGENE, V4, P325; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WERTH DK, 1984, J BIOL CHEM, V259, P5264; WHITE KN, 1988, J IMMUNOL, V141, P942; YU KT, 1991, J BIOL CHEM, V266, P22564; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	48	115	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6851	6854						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463210				2022-12-25	WOS:A1993KV14100008
J	KOZMA, SC; MCGLYNN, E; SIEGMANN, M; REINHARD, C; FERRARI, S; THOMAS, G				KOZMA, SC; MCGLYNN, E; SIEGMANN, M; REINHARD, C; FERRARI, S; THOMAS, G			ACTIVE BACULOVIRUS RECOMBINANT P70(S6K) AND P85(S6K) PRODUCED AS A FUNCTION OF THE INFECTIOUS RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 PHOSPHORYLATION SITES; DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; SWISS MOUSE 3T3-CELLS; RIBOSOMAL PROTEIN-S6; 3T3 CELLS; RAT-LIVER; CATALYTIC SUBUNIT; MAP2 KINASE; LATE PHASE	Rat p70s6k and p85s6k have been expressed in baculovirus recombinants propagated in Sf9 insect cells. Surprisingly, both recombinant isoforms were active without coinfection of other kinases which lie upstream in the signaling pathway. Treatment of either recombinant form with phosphatase 2A leads to immediate inactivation in the absence of phosphatase inhibitors. Further studies show that the same four major Ser/Thr-Pro sites associated with p70s6k activation following mitogenic stimulation in vivo are also the four major sites phosphorylated in both the p70s6k and p85s6k during the infection process. It is proposed that the production of phosphorylated and activated recombinant p70s6k and p85s6k is due to activation of a host cell signaling pathway which is triggered by viral infection. In support of this hypothesis, wild-type virus-, but not mock-infected cells, exhibit the multiple phosphorylation of a ribosomal protein which migrates similar to ribosomal protein S6 on two-dimensional-polyacrylamide gels and extracts from these same cells contain elevated levels of S6 kinase activity.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND; CIBA GEIGY AG, DIV PHARMACEUT, RES DEPT, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis			Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1991, J BIOL CHEM, V266, P22770; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARMANN B, 1990, FEBS LETT, V273, P248, DOI 10.1016/0014-5793(90)81096-7; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; JAKUBOWICZ T, 1987, EUR J BIOCHEM, V168, P371, DOI 10.1111/j.1432-1033.1987.tb13429.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1991, METHOD ENZYMOL, V200, P268; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; SUMMERS M, 1987, B15555 TEX AGR EXP S; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; THOMAS G, 1978, J BIOL CHEM, V253, P1101; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOODGETTJR, 1992, CURR BIOL, V2, P357	46	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7134	7138						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463249				2022-12-25	WOS:A1993KV14100050
J	MENDELOW, M; PROROK, M; SALERNO, A; LAWRENCE, DS				MENDELOW, M; PROROK, M; SALERNO, A; LAWRENCE, DS			ATPASE-PROMOTING DEAD-END INHIBITORS OF THE CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR DICHROIC EVIDENCE; CATALYTIC SUBUNIT; CONFORMATIONAL CHANGE; SITE INTERACTIONS; BOVINE HEART; HEXOKINASE; MECHANISM; SEQUENCE; TYROSINE; FAMILY	The cAMP-dependent protein kinase is a bifunctional enzyme, catalyzing the phosphorylation of the serine and threonine residues in peptides and proteins (kinase activity) as well as the phosphorylation of water (ATPase activity). We have found that several peptides, which serve as inhibitors of the kinase reaction, will either maintain or enhance the ATPase reaction catalyzed by the enzyme. Positively charged dipeptides (e.g. Arg-Arg), as well as small guanidino-containing compounds (e.g. guanethidine) block protein kinase activity yet enhance ATPase activity up to 3.5-fold over that exhibited by the enzyme in the absence of these compounds. In contrast, several non-phosphorylatable peptides, whose primary sequences are based on that of a known substrate (i.e. Leu-Arg-Arg-Ala-Ser-Leu-Gly), such as Leu-Arg-Arg-Ala-Ala-Leu-Gly, Leu-Arg-Arg-Ala-Phe-Leu-Gly, and Leu-Arg-Arg-Ala-Tyr-Leu-Gly, have little or no effect on the rate of the kinase-catalyzed hydrolysis of ATP. An exception to the latter observation is Leu-Arg-Arg-Ala-Cys-Leu-Gly, a cysteine-containing peptide that promotes the protein kinase-catalyzed ATPase reaction by 2.2-fold. We have also found that peptides that possess relatively large amino acid side chain moieties immediately following the arginine dyad (i.e. such as Phe, Tyr, Cys, or Asn at Xaa in Leu-Arg-Arg-Xaa-Ala-Leu-Gly) sharply reduce the rate of enzyme-catalyzed ATP hydrolysis. This suggests that in the presence of peptides containing an -Arg-Arg-Ala- sequence, the enzyme-bound gamma-phosphate of ATP is relatively accessible to water. In contrast, when the the latter alanine moiety is replaced by a larger residue, access by water to ATP appears to be hindered. These results indicate that certain structural features associated with the substrate or substrate analog have a profound influence on the manner by which these species interact with the protein kinase. Furthermore, the work described herein demonstrates that it is possible to block the physiologically important kinase reaction and simultaneously promote the energetically wasteful ATPase reaction.	SUNY Buffalo, DEPT CHEM, ACHESON HALL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; ARMSTRONG RN, 1979, P NATL ACAD SCI USA, V76, P722, DOI 10.1073/pnas.76.2.722; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3606, DOI 10.1021/bi00434a068; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHT WB, 1989, BIOCHEMISTRY-US, V28, P5728, DOI 10.1021/bi00440a005; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P415; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; MOLL GW, 1976, J BIOL CHEM, V251, P3993; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1991, BIOCHEMISTRY-US, V30, P2549, DOI 10.1021/bi00223a036; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1984, BIOCHEMISTRY-US, V23, P968, DOI 10.1021/bi00300a026; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SHOHAM M, 1982, BIOCHIM BIOPHYS ACTA, V705, P380, DOI 10.1016/0167-4838(82)90260-6; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; ZHENG JH, 1991, METHOD ENZYMOL, V200, P508	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12289	12296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509366				2022-12-25	WOS:A1993LG65800013
J	YAMADA, M; SUMI, K; MATSUSHITA, K; ADACHI, O; YAMADA, Y				YAMADA, M; SUMI, K; MATSUSHITA, K; ADACHI, O; YAMADA, Y			TOPOLOGICAL ANALYSIS OF QUINOPROTEIN GLUCOSE-DEHYDROGENASE IN ESCHERICHIA-COLI AND ITS UBIQUINONE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACINETOBACTER-CALCOACETICUS; PYRROLOQUINOLINE QUINONE; NUCLEOTIDE-SEQUENCE; GENE FUSIONS; CLONING; DNA; VECTORS; SIGNALS; PROTEIN; CHAIN	Topological structure of quinoprotein glucose dehydrogenase in the inner membrane of Escherichia coli was determined by constructing protein fusions with alkaline phosphatase or beta-galactosidase. Analysis of the fusions revealed that the dehydrogenase possesses five membrane-spanning segments, and the N-terminal and C-terminal portions resided at the cytoplasmic and periplasmic side of the membrane, respectively. These results agreed with the hydropathy profile based on its primary structure. The topological structure suggests that the predicted binding site of the prosthetic group pyrroloquinoline quinone is located at the periplasmic side and that the amino acid residues corresponding to those that were presumed to interact with ubiquinone in one subunit of mitochondrial NADH dehydrogenase also occur at the periplasmic side. When the purified glucose dehydrogenase and cytochrome o ubiquinol oxidase were reconstituted together with ubiquinone into liposomes, a membrane potential could be generated by the electron transfer at the site of the ubiquinol oxidase but not of the dehydrogenase. These results suggest that glucose dehydrogenase has a ubiquinone reacting site close to the periplasmic side of the membrane, and thus its electron transfer to ubiquinone appears to be incapable of forming a proton electrochemical gradient across the inner membrane of E. coli.	YAMAGUCHI UNIV,SCH MED,DEPT PHARMACOL,YAMAGUCHI 753,JAPAN	Yamaguchi University	YAMADA, M (corresponding author), YAMAGUCHI UNIV,FAC AGR,DEPT BIOL CHEM,1677-1 YOSHIDA,YAMAGUCHI 753,JAPAN.			Yamada, Mamoru/0000-0003-4354-7324				AMEYAMA M, 1986, AGR BIOL CHEM TOKYO, V50, P49, DOI 10.1080/00021369.1986.10867348; AMEYAMA M, 1981, FEBS LETT, V130, P179, DOI 10.1016/0014-5793(81)81114-3; BIVILLE F, 1991, J GEN MICROBIOL, V137, P1775, DOI 10.1099/00221287-137-8-1775; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; CLETONJANSEN AM, 1988, NUCLEIC ACIDS RES, V16, P6228, DOI 10.1093/nar/16.13.6228; CLETONJANSEN AM, 1990, J BACTERIOL, V172, P6308, DOI 10.1128/jb.172.11.6308-6315.1990; CLETONJANSEN AM, 1989, MOL GEN GENET, V217, P430, DOI 10.1007/BF02464914; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FRIEDRICH T, 1990, FEBS LETT, V265, P37, DOI 10.1016/0014-5793(90)80878-M; HOMMES RWJ, 1984, FEMS MICROBIOL LETT, V24, P329, DOI 10.1016/0378-1097(84)90274-X; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; MACHLIN SM, 1988, J BACTERIOL, V170, P4739, DOI 10.1128/jb.170.10.4739-4747.1988; Malymy M., 1966, METHODS ENZYMOLOGY, V9, P639, DOI [10.1016/0076-6879(66)09129-8, DOI 10.1016/0076-6879(66)09129-8]; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUSHITA K, 1989, J BIOCHEM, V105, P633, DOI 10.1093/oxfordjournals.jbchem.a122716; MATSUSHITA K, 1987, J BACTERIOL, V169, P205, DOI 10.1128/jb.169.1.205-209.1987; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MESSING J, 1983, METHOD ENZYMOL, V101, P20; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAMADA M, 1984, EUR J BIOCHEM, V140, P249, DOI 10.1111/j.1432-1033.1984.tb08095.x; YAMADA M, 1993, J BACTERIOL, V175, P568, DOI 10.1128/JB.175.2.568-571.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12812	12817						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509415				2022-12-25	WOS:A1993LG65800086
J	HEDDI, A; LESTIENNE, P; WALLACE, DC; STEPIEN, G				HEDDI, A; LESTIENNE, P; WALLACE, DC; STEPIEN, G			MITOCHONDRIAL-DNA EXPRESSION IN MITOCHONDRIAL MYOPATHIES AND COORDINATED EXPRESSION OF NUCLEAR GENES INVOLVED IN ATP PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-SUBUNIT; NUCLEOTIDE TRANSLOCATOR GENE; MUSCLE ADP/ATP TRANSLOCATOR; KEARNS-SAYRE SYNDROME; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; POINT MUTATION; TRANSCRIPTION; INVITRO	The expression of nuclear and mitochondrial oxidative phosphorylation (OXPHOS) genes was examined in the skeletal muscle of patients with Kearns-Sayre syndrome (KSS), myoclonic epilepsy associated with ragged red fibers (MERRF), and myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and compared with controls. In KSS muscle, mtDNA transcripts outside the deletion were elevated, while those within the deletion were reduced according to the percentage of deleted mtDNA molecules. In MERRF and MELAS muscle, mitochondrial transcripts levels were increased, but the increase was greater in MERRF muscle. The processing of mtDNA transcripts was reduced in all pathogenic muscles. This was true for full-length heavy and light strand transcripts as well as for the 16 S rRNA + tRNA(Leu) + ND1 transcript. However, the tRNA(Lys) level was reduced in all three muscles. In MELAS muscle, our results are not consistent with an impairment of transcription termination at the end of the 16 S mitochondrial rRNA. Finally, the transcription of the nuclear ATPsyn.beta and ANT1 genes was induced in parallel with the high level of mtDNA transcripts in MERRF and MELAS muscle, but was repressed in KSS muscle. The results demonstrate that the expression of nuclear and cytoplasmic OXPHOS genes is coordinated and that OXPHOS gene expression increases to compensate for respiratory deficiency. The repression of nuclear genes in KSS muscle could be a consequence of the segmental distribution of deleted mtDNA molecules in muscle cells.	CNRS, CTR GENET MOLEC & CELLULAIRE, UNITE MIXTE RECH 106, 43 BLVD 11 NOVEMBRE 1918, F-69622 VILLEURBANNE, FRANCE; CHRU, INSERM, U298, F-49033 ANGERS, FRANCE; EMORY UNIV, SCH MED, DEPT GENET & MOLEC MED, ATLANTA, GA 30322 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Emory University					NHLBI NIH HHS [HL45572] Funding Source: Medline; NINDS NIH HHS [NS21328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BATTINI R, 1987, J BIOL CHEM, V262, P4355; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KAGAWA Y, 1990, INT J BIOCHEM, V22, P219; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KU DH, 1990, J BIOL CHEM, V265, P16060; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; NAKASE H, 1990, AM J HUM GENET, V46, P418; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; NELSON I, 1992, NEUROPEDIATRICS, V23, P199, DOI 10.1055/s-2008-1071341; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316	38	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12156	12163						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505336				2022-12-25	WOS:A1993LF28400103
J	KAUFMAN, RJ; MURTHARIEL, P; PITTMAN, DD; DAVIES, MV				KAUFMAN, RJ; MURTHARIEL, P; PITTMAN, DD; DAVIES, MV			CHARACTERIZATION OF WILD-TYPE AND SER(53) MUTANT EUKARYOTIC INITIATION FACTOR-4E OVEREXPRESSION IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; INFECTED HELA-CELLS; MESSENGER-RNA; TRANSLATIONAL CONTROL; SECONDARY STRUCTURE; 5'-TERMINAL 7-METHYLGUANOSINE; STIMULATES PHOSPHORYLATION; INTERNAL INITIATION; GROWTH-FACTOR; FACTOR 4E	Eukaryotic translation initiation factor 4E (eIF-4E) is one component of the m7G-cap-binding protein complex eIF-4F and is required for cap-dependent translation initiation. The phosphorylation state of eIF-4E correlates with increased activity and a major phosphorylation site resides at serine 53. To further evaluate the role of eIF-4E phosphorylation, eIF-4E wild-type and two Ser53 mutants, Ser53Ala and Ser53Asp, were expressed at high level, representing almost 2% of the total cell protein, by transient transfection of COS-1 monkey cells. (PO4)-P-32 metabolic labeling of transfected cells demonstrated both Ser53 mutants were phosphorylated at an alternate serine residue. [S-35] Methionine pulse-labeling demonstrated that the wild-type and both Ser53 mutants were equally incorporated into the eIF-4F complex. The effect of wild-type and Ser53 mutant overexpression on cap-dependent translation initiation and internal translation initiation was monitored by cotransfection with an expression vector encoding a dicistronic mRNA for which the 5' cistron is translated in a cap-dependent manner, and the 3' cistron is translated by internal ribosome binding. Unexpectedly, overexpression of the wild-type or either mutant did not affect the efficiency of either cap-dependent or internal initiation. These results demonstrate that phosphorylation of eIF-4E at residue 53 is not required for interaction with p220 and suggest that Ser'' phosphorylation may not be required for cap-dependent translation initiation in this system.			KAUFMAN, RJ (corresponding author), GENET INST INC,CAMBRIDGE,MA 02140, USA.							ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P4895; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1741; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LLOYD RE, 1988, VIROLOGY, V123, P60; LOCKARD RE, 1978, NUCLEIC ACIDS RES, V5, P2850; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; ROSE JK, 1976, NATURE, V262, P32, DOI 10.1038/262032a0; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1977, P NATL ACAD SCI USA, V74, P4288, DOI 10.1073/pnas.74.10.4288; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YAN RQ, 1992, J BIOL CHEM, V267, P23226	57	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11902	11909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505316				2022-12-25	WOS:A1993LF28400067
J	LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL				LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL			DETECTION OF C-MOS PROTOONCOGENE EXPRESSION IN HUMAN-CELLS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; KINASE-ACTIVITY; MEIOTIC MATURATION; TRANSFORMING GENE; XENOPUS OOCYTES; CDC2 PROTEIN; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; HUMAN NEUROBLASTOMAS	Although the human c-mos proto-oncogene has been characterized for more than a decade, very little is known about its protein product and its expression in somatic cells. We generated three human c-mos-specific antisera and report here the detection of c-mos protein in a human neuroblastoma cell line, SK-N-BE2 (BE2). Both Western (immuno-) blot and immunoprecipitation analyses detected a p37 as the major form and p40 and p35 as minor forms of the c-mos protein. Using Northern blot analysis, 3.5- and 1.7-kb c-mos messages were detected. Using a highly sensitive method that combines reverse transcription and the polymerase chain reaction (RT-PCR), c-mos RNA was detected in all the human samples examined. With Western blot analysis, we further showed that c-mos proteins are expressed in cervical carcinoma-derived cell lines. This ubiquitous expression of low levels of c-mos suggests a fundamental role for the c-mos proto-oncogene.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LI, CCH (corresponding author), INC DYNCORP,PROGRAM RESOURCES,BIOL CARCINOGENESIS & DEV PROGRAM,POB B,BLDG 567,ROOM 202,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011		NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COFFIN JM, 1981, J VIROL, V40, P953, DOI 10.1128/JVI.40.3.953-957.1981; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DANOS O, 1984, CANCER CELLS ONCOGEN, V2, P291; DIAMOND SL, 1990, J CELL PHYSL, V143, P3641; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; KESHET E, 1988, ONCOGENE, V2, P235; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LI CCH, 1987, J VIROL, V61, P2684, DOI 10.1128/JVI.61.9.2684-2690.1987; LI CCH, 1990, PAPILLOMAVIRUSES, P119; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PARKAR MH, 1988, CANCER LETT, V43, P185, DOI 10.1016/0304-3835(88)90169-3; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, ONCOGENE HDB, P195; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YEE C, 1985, AM J PATHOL, V119, P361; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	65	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1685	1691						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502488				2022-12-25	WOS:A1993LE06400034
J	TSAI, LH; LEES, E; FAHA, B; HARLOW, E; RIABOWOL, K				TSAI, LH; LEES, E; FAHA, B; HARLOW, E; RIABOWOL, K			THE CDK2 KINASE IS REQUIRED FOR THE G1-TO-S TRANSITION IN MAMMALIAN-CELLS	ONCOGENE			English	Article							P34CDC2 PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; CYCLIN-A; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATION SITES; CDC28 MUTATION; G1 PHASE; GENE; MITOSIS	In the cell cycle of fission and budding yeast, the p34cdc2/cDC28 kinase is required for both the G1-to-S and G2-to-M phase transitions. In vertebrates, the homologous p34cdc2 kinase is required for G2-to-M phase transitions but appears to be dispensible for DNA synthesis. We have investigated the function of a related kinase, p33cdk2, using serum-stimulated quiescent human fibroblasts. While the p33cdk2 protein was expressed at constant levels throughout the cell cycle, p33cdk2 kinase activity was first detected a few hours prior to the onset of DNA synthesis. Microinjection of anti-p33cdk2 antibodies blocked cells from entering S phase. Pre-adsorbtion of these antibodies with cdk2 protein abrogated their blocking effect suggesting that the G1 arrest caused by these antibodies is cdk2-specific. These results indicate that p33cdk2 is required for the G1-to-S phase transition in mammalian cells. We also show evidence to suggest that the cyclin E/p33cdk2 complex is likely to be required for entry into S phase since the timing of the cyclin E-associated kinase activity was coincident with that of p33cdk2 and preclearing of either component abolished the majority of the histone H1 kinase activity present in the lysates harvested from the late G1.	UNIV CALGARY, SO ALBERTA CANC RES CTR, DEPT MED BIOCHEM, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary	TSAI, LH (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BLDG 149, 13TH ST, BOSTON, MA 02129 USA.				NCI NIH HHS [CA55339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FAHA B, 1992, PEZCOLLER F S, V3, P107; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FERNANDEZ A, 1991, EXP CELL RES, V195, P468, DOI 10.1016/0014-4827(91)90398-E; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STARK H, 1989, PEPTIDES, V10, P717, DOI 10.1016/0196-9781(89)90102-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	64	327	340	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1593	1602						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502482				2022-12-25	WOS:A1993LE06400023
J	REINHARDT, D; MANN, K; NISCHT, R; FOX, JW; CHU, ML; KRIEG, T; TIMPL, R				REINHARDT, D; MANN, K; NISCHT, R; FOX, JW; CHU, ML; KRIEG, T; TIMPL, R			MAPPING OF NIDOGEN BINDING-SITES FOR COLLAGEN TYPE-IV, HEPARAN-SULFATE PROTEOGLYCAN, AND ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; DENSITY LIPOPROTEIN-RECEPTOR; BASEMENT-MEMBRANE COLLAGEN; STRUCTURAL CHARACTERIZATION; LAMININ; PROTEIN; ENTACTIN; COMPLEX; PURIFICATION; GLYCOPROTEIN	Recombinant nidogen fragments comprising the globular domains G1 plus G2, the rod-like domain, and the rod connected to the globe G3 were prepared from the culture media of transfected human cell clones. In addition, domains G1 and G2 were separated from each other after cleavage with chymotrypsin. The purified fragments were characterized by N-terminal sequences, electrophoresis, electron microscopy, and radioimmunoassays and the cell clones by Northern hybridization. Transfection with a construct comprising a large part of domain G3 showed high mRNA levels but no secreted protein, indicating a protein folding problem. All these fragments were used as soluble and/or immobilized ligands in binding assays. This demonstrated major binding sites on domain G2 for collagen IV and heparan sulfate proteoglycan. Affinity chromatography on zinc- and cobalt-loaded columns showed binding of domains G2 and G3 and the rod. Protein binding, but not metal binding, was abolished by reduction and alkylation of nidogen. This allowed for the isolation of several zinc-binding tryptic peptides, four from G2, two from the rod, and one from the G3 domain. Most of these short peptides contained several histidines that are likely to mediate binding. Zinc inhibited efficiently G3-mediated nidogen binding to laminin at 4-degrees-C (IC50 approximately 5 muM) but less at higher temperatures. Similarly, zinc inhibited binding to collagen IV and proteoglycan at low temperatures but not at high (37-degrees-C) temperatures. This indicates a complex modulation of nidogen binding to other basement membrane proteins by some, but not all, transition metals. Whether the particularly striking effects shown for zinc are of biological relevance remains to be established.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV COLOGNE, DEPT DERMATOL, W-5000 COLOGNE, GERMANY; THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT DERMATOL, PHILADELPHIA, PA 19107 USA	Max Planck Society; University of Cologne; Jefferson University; Jefferson University			Reinhardt, Dieter P/A-3102-2008; Mann, Karlheinz/C-4254-2008	Reinhardt, Dieter P/0000-0001-6535-9872; 				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FALCHUK KH, 1987, PRINCIPLES INTERNAL, P418; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GERL M, 1991, EUR J BIOCHEM, V202, P167, DOI 10.1111/j.1432-1033.1991.tb16358.x; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HASSELL JR, 1991, J BIOL CHEM, V266, P22939; JACKSON MJ, 1989, ZINC HUMAN BIOL, P1; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NAGAYOSHI T, 1989, DNA-J MOLEC CELL BIO, V8, P581, DOI 10.1089/dna.1989.8.581; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PAULSSON M, 1986, EUR J BIOCHEM, V156, P467, DOI 10.1111/j.1432-1033.1986.tb09605.x; REINHARDT D, 1992, UNTERSUCHUNGEN STRUK; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SMITH MC, 1990, ACS SYM SER, V427, P168; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; Williams RJP., 1989, ZINC HUMAN BIOL, P15, DOI 10.1007/978-1-4471-3879-2_2; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	39	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10881	10887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496153				2022-12-25	WOS:A1993LD46600028
J	RUSVAI, E; NARAYFEJESTOTH, A				RUSVAI, E; NARAYFEJESTOTH, A			A NEW ISOFORM OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE IN ALDOSTERONE TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MINERALOCORTICOID RECEPTOR; CORTICOSTEROID 11-BETA-DEHYDROGENASE; RAT-KIDNEY; LOCALIZATION; LIVER; SPECIFICITY; EXPRESSION; PROTECTOR; CLONING; GENE	11beta-Hydroxysteroid dehydrogenase has been proposed to play an important role in aldosterone target cells by degrading endogenous glucocorticoids, thus allowing aldosterone to bind to the relatively nonselective mineralocorticoid receptor. The physiologically important species of this enzyme in renal aldosterone target cells appears to be kinetically and antigenically distinct from the previously characterized liver enzyme. Here we show that 11beta-steroid dehydrogenase in the microsomal fraction of isolated renal collecting duct cells has a K(m) for corticosterone of 25.9 +/- 2.4 nM, about 100 times lower than the rat liver enzyme. Surprisingly, the collecting duct enzyme utilizes almost exclusively NAD as cofactor versus NADP used by the liver form. Conversion of corticosterone to 11-dehydrocorticosterone is 2.6 +/- 0.5 and 0.07 +/- 0.01 fmol/min/mg protein with 100 muM of NAD and NADP, respectively, demonstrating a 37.4 +/- 3.5-fold preference for NAD versus NADP. There is practically no conversion of 11-dehydrocorticosterone to corticosterone either with NADH or NADPH, indicating that in collecting duct cells the enzyme operates only in the direction of oxygenation. In addition, 11beta-steroid dehydrogenase activity is dose dependently inhibited by the end product 11-dehydrocorticosterone while the liver enzyme does not show end product inhibition. We conclude that renal collecting duct cells, the major physiological targets of aldosterone, are protected from circulating glucocorticoids by a hitherto undescribed enzyme of the 11-dehydrogenase family, which differs from the known liver enzyme in having a significantly higher affinity for corticosterone and a different cofactor requirement.	DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03756	Dartmouth College					NIDDK NIH HHS [DK 39523, DK 41841] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK041841] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BONVALET JP, 1990, J CLIN INVEST, V86, P832, DOI 10.1172/JCI114781; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FEJESTOTH G, 1987, AM J PHYSIOL, V253, pF1303; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; KROZOWSKI Z, 1990, ENDOCRINOLOGY, V127, P3009, DOI 10.1210/endo-127-6-3009; KROZOWSKI Z, 1992, J BIOL CHEM, V267, P2569; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; MERCER WR, 1992, ENDOCRINOLOGY, V130, P540, DOI 10.1210/en.130.1.540; MOISAN MP, 1992, MOL ENDOCRINOL, V6, P1082, DOI 10.1210/me.6.7.1082; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MONDER C, 1991, BIOCHIM BIOPHYS ACTA, V1115, P23, DOI 10.1016/0304-4165(91)90006-3; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; NARAYFEJESTOTH A, 1990, AM J PHYSIOL, V259, pF672, DOI 10.1152/ajprenal.1990.259.4.F672; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; STEWART PM, 1991, ENDOCRINOLOGY, V128, P2129, DOI 10.1210/endo-128-4-2129; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WALKER BR, 1992, ENDOCRINOLOGY, V131, P970, DOI 10.1210/en.131.2.970	23	244	245	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10717	10720						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496139				2022-12-25	WOS:A1993LD46600005
J	KOJIMA, I; MOGAMI, H; SHIBATA, H; OGATA, E				KOJIMA, I; MOGAMI, H; SHIBATA, H; OGATA, E			ROLE OF CALCIUM ENTRY AND PROTEIN-KINASE-C IN THE PROGRESSION ACTIVITY OF INSULIN-LIKE GROWTH FACTOR-I IN BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-THYROID CELLS; DNA-SYNTHESIS; INFLUX; INVOLVEMENT; INHIBITORS	We previously reported that insulin-like growth factor-I (IGF-I) stimulated calcium entry (Kojima, I., Matsunaga, H., Kurokawa, K., Ogata, E., and Nishimoto, I. (1988) J. Biol. Chem. 263, 16561-16567) and production of 1,2-diacylglycerol in IGF-responsive ''primed competent'' Balb/c 3T3 cells (Kojima, I., Kitaoka, M., and Ogata, E. (1990) J. Biol. Chem. 265, 16846-16850). The present study was conducted to determine a role of protein kinase C (PKC) in the progression activity of IGF-I. To monitor the activity of PKC in intact cells, we measured phosphorylation of a synthetic KRTLRR peptide, a substrate of PKC, immediately after the permeabilization of the cells with digitonin. When 1 nM IGF-I was added to primed competent cells, KRTLRR peptide phosphorylation was augmented. IGF-I induced more than 2-fold increase in KRTLRR peptide phosphorylation that was blocked by PKC19-36, a pseudosubstrate of PKC, which blocks the activity of the kinase, and Ro31-8220, an inhibitor of PKC. The phosphorylation remained elevated for up to 6 h. To assess the role of PKC in cell cycle progression, IGF-I-induced nuclear labeling was measured in the presence of Ro31-8220. Ro31-8220 reduced the rate of entrance into S phase when added in the first quarter of the G1 phase, but did not affect cell cycle progression when added at the second quarter or later. In contrast, reduction of extracellular calcium completely blocked cell cycle progression when done in the first, second, and third quarter but had no effect in the last quarter. These results indicate that IGF-I persistently activates PKC in primed competent cells, but the activation is required only for the initiation of progression. We conclude that IGF-I promotes cell cycle progression by calcium-dependent mechanisms that are largely independent of PKC.	JAPANESE FDN CANC RES,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research	KOJIMA, I (corresponding author), GUNMA UNIV,INST ENDOCRINOL,CELL BIOL RES UNIT,3-39-15 SHOWA MACHI,MAEBASHI,GUNMA 371,JAPAN.							BOYNTON AL, 1985, EXP CELL RES, V160, P197, DOI 10.1016/0014-4827(85)90248-4; BRENNERGATI L, 1988, J CLIN INVEST, V82, P1144, DOI 10.1172/JCI113672; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O	12	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10003	10006						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486672				2022-12-25	WOS:A1993LB80000013
J	BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ				BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ			OVEREXPRESSION OF CYCLIN-D1 IN MOUSE SKIN CARCINOGENESIS	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; HARVEY-RAS ONCOGENE; MESSENGER-RNA; CANDIDATE ONCOGENE; PAPILLOMAS; TUMORS; GENE; CARCINOMAS; MICE; HETEROZYGOSITY	Recent studies have provided evidence suggesting that disruption of cyclin function may play a critical role in tumorigenesis. Cyclin D1, a putative G1 cyclin previously isolated in human parathyroid adenomas (designated PRAD1) and mouse macrophages (designated Cyl1), has been implicated in various neoplasias including breast and squamous cell carcinomas (SCC). The role of cyclin altered regulation in the different stages of tumor progression has not been studied in a well defined animal model system. In the study presented here, Cyl1 was mapped to the distal end of mouse chromosome 7 and found to be dramatically overexpressed in skin SCC. In premalignant stages of tumor development, early papillomas showed basal Cyl1 transcript levels, whereas overexpression was observed in most advanced papillomas. These findings suggest that altered expression of cyclin D1 plays a critical role in mouse skin carcinogenesis and may be related to the acquisition of autonomous growth by papillomas. Further studies on the role of cyclin D1 in the mouse model system should prove valuable for understanding the multistep basis of tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV RES, SCI PK,POB 389, SMITHVILLE, TX 78957 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Oak Ridge National Laboratory				Robles, Ana/0000-0001-5019-4374	NCI NIH HHS [CA42157, CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1991, CANCER RES, V51, P1045; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIANCHI AB, 1993, IN PRESS MAMMALIAN G, V4; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS F, 1983, ENVIRON HEALTH PERSP, V50, P309, DOI 10.2307/3429562; BURNS FJ, 1976, CANCER RES, V36, P1422; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FISCHER SM, 1988, CANCER RES, V48, P658; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HENNINGS H, 1985, J NATL CANCER I, V74, P735; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JOHNSON DK, 1989, P NATL ACAD SCI USA, V86, P8862, DOI 10.1073/pnas.86.22.8862; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KIDD VJ, 1992, MOL CARCINOGEN, V5, P95, DOI 10.1002/mc.2940050203; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY AL, 1987, INT J CANCER, V39, P261, DOI 10.1002/ijc.2910390223; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUGGERI B, 1991, CANCER RES, V51, P6615; SLAGA T J, 1989, P1; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; VANDIERENDONCK JH, 1991, AM J PATHOL, V138, P1165; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	47	116	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1127	1133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479737				2022-12-25	WOS:A1993KY32800003
J	NEILSON, EG; KALLURI, R; SUN, MJ; GUNWAR, S; DANOFF, T; MARIYAMA, M; MYERS, JC; REEDERS, ST; HUDSON, BG				NEILSON, EG; KALLURI, R; SUN, MJ; GUNWAR, S; DANOFF, T; MARIYAMA, M; MYERS, JC; REEDERS, ST; HUDSON, BG			SPECIFICITY OF GOODPASTURE AUTOANTIBODIES FOR THE RECOMBINANT NONCOLLAGENOUS DOMAINS OF HUMAN TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLOMERULAR-BASEMENT-MEMBRANE; ALPHA-2(IV) COLLAGEN; ALPHA-3(IV) CHAIN; ALPORT SYNDROME; IDENTIFICATION; LOCALIZATION; ANTIGEN; ALPHA-1-CHAIN; ALPHA-1(IV); ALPHA-5(IV)	Type IV collagen has recently emerged as a family composed of five known chains (alpha1-alpha5), each of which contains a carboxyl-terminal noncollagenous domain (NC1) of approximately 230 amino acids. The NC1 domain of the alpha3(IV) chain is the probable target for autoantibodies in patients with Goodpasture syndrome (GP), as evidenced from studies employing bovine type IV collagen. In the present experiments, the specificity of GP antibodies for the five NC1 domains of human type IV collagen was determined by using recombinant NC1 domains as the antigen. cDNAs encoding each NC1 domain were expressed in E. coli as fusion proteins with a 6-histidine amino-terminal leader. The recombinant NC1 monomers ralpha1(IV), ralpha2(IV), ralpha3(IV), ralpha4(IV), and ralpha5(IV) were purified by affinity chromatography to the fusion protein using a nickel resin column, and then characterized by electrophoresis and immunoblot analysis using chain-specific peptide antibodies. The specificity of GP antibodies from four patients to these recombinant proteins was then further evaluated by immunoblot analysis and enzyme-linked immunosorbent assay measurements. The GP antibodies reacted strongly with the ralpha3(IV) NC1 domain but were not reactive when tested against the other four recombinant monomers. In contrast, neither antisera from patients with two other forms of autoimmune disease (anti-tubular basement membrane disease and Wegener's syndrome) nor normal control sera bound to any of the recombinant NC1 moieties. These results unambiguously establish that GP antibodies are specifically targeted to the NC1 domain of the alpha3(IV) chain of human type IV collagen. The findings also establish a methodology for large scale preparation of ralpha3(IV) NC1 domain for use in diagnostic tests and development of therapeutic procedures and offer a strategy for the elucidation of a more complete GP epitope by site-directed mutagenesis.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,39TH & RAINBOW BLVD,KANSAS CITY,KS 66103; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV PENN,PENN CTR MOLEC STUDIES KIDNEY DIS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Kansas; University of Kansas Medical Center; Howard Hughes Medical Institute; Yale University; University of Pennsylvania; University of Pennsylvania			Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030280, R37DK030280, T32DK007006] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20553] Funding Source: Medline; NIDDK NIH HHS [DK-30280, DK-07006] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HUDSON B, 1991, PATHOBIOCHEMISTRY, P17; HUDSON BG, 1993, KIDNEY INT, V43, P135, DOI 10.1038/ki.1993.22; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KARP S, 1993, IN PRESS J IMMUNOL; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; MYERS JC, 1987, J BIOL CHEM, V262, P9231; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; QUINONES S, 1992, J BIOL CHEM, V267, P19780; SAUS J, 1989, J BIOL CHEM, V264, P6318; SAUS J, 1988, J BIOL CHEM, V263, P13374; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1987, FEBS LETT, V225, P188; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P3838, DOI 10.1073/pnas.81.12.3838; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	30	94	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8402	8405						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473281				2022-12-25	WOS:A1993KX81100006
J	VERCESI, AE; MORENO, SNJ; BERNARDES, CF; MEINICKE, AR; FERNANDES, EC; DOCAMPO, R				VERCESI, AE; MORENO, SNJ; BERNARDES, CF; MEINICKE, AR; FERNANDES, EC; DOCAMPO, R			THAPSIGARGIN CAUSES CA2+ RELEASE AND COLLAPSE OF THE MEMBRANE-POTENTIAL OF TRYPANOSOMA-BRUCEI MITOCHONDRIA INSITU AND OF ISOLATED RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM HOMEOSTASIS; CA-2+ TRANSPORT; SUPEROXIDE ANION; ARSENAZO-III; CRUZI; PERMEABILIZATION; GENERATION; NIGERICIN	Thapsigargin, previously reported to release Ca2+ from non-mitochondrial stores of different cell types, as well as nigericin, were found, when used at high concentrations, to release Ca2+ and collapse the membrane potential of Trypanosoma brucei bloodstream and procyclic trypomastigotes mitochondria in situ. At similarly high concentrations (>10 muM), thapsigargin was also found to release Ca2+ and collapse the membrane potential of isolated rat liver mitochondria. These results indicate that care should be taken when attributing the effects of thapsigargin in intact cells to the specific inhibition of the sarcoplasmic and endoplasmic reticulum Ca2+-ATPase family of calcium pumps. In addition, we have found no evidence for an increase in intracellular Ca2+ by release of the ion from intracellular stores by nigericin, measuring changes in cytosolic Ca2+ by dual wavelength spectrofluorometry in fura-2-loaded T. brucei bloodstream trypomastigotes or measuring Ca2+ transport in digitonin-permeabilized cells.	UNIV ILLINOIS,DEPT VET PATHOBIOL,2001 S LINCOLN AVE,URBANA,IL 61801; UNIV ESTADUAL CAMPINAS,DEPT BIOQUIM,BR-13081 CAMPINAS,SP,BRAZIL	University of Illinois System; University of Illinois Urbana-Champaign; Universidade Estadual de Campinas			Vercesi, Aníbal E/C-8767-2012	Vercesi, Anibal Eugenio/0000-0001-6671-7125				CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1989, ARCH BIOCHEM BIOPHYS, V272, P122, DOI 10.1016/0003-9861(89)90202-6; DOCAMPO R, 1983, J BIOL CHEM, V258, P4920; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FERGUSON SM, 1971, J BIOL CHEM, V246, P5645; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; KLINE D, 1992, J BIOL CHEM, V267, P17624; MARKIN VS, 1975, J MEMBRANE BIOL, V25, P23, DOI 10.1007/BF01868566; METZ DC, 1992, J BIOL CHEM, V267, P20620; MORENO SNJ, 1992, J BIOL CHEM, V267, P6020; MORENO SNJ, 1992, MOL BIOCHEM PARASIT, V52, P251, DOI 10.1016/0166-6851(92)90057-Q; MORENO SNJ, 1984, J BIOL CHEM, V259, P4609; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; RUBEN L, 1992, EXP PARASITOL, V74, P332, DOI 10.1016/0014-4894(92)90157-6; RUBEN L, 1991, J BIOL CHEM, V266, P24351; Scarpa A, 1979, Methods Enzymol, V56, P301; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORO M, 1987, J MEMBRANE BIOL, V95, P1, DOI 10.1007/BF01869625; VERCESI AE, 1990, MOL BIOCHEM PARASIT, V42, P119, DOI 10.1016/0166-6851(90)90119-7; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463	27	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8564	8568						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473301				2022-12-25	WOS:A1993KX81100031
J	BRANTLEY, RE; SMERDON, SJ; WILKINSON, AJ; SINGLETON, EW; OLSON, JS				BRANTLEY, RE; SMERDON, SJ; WILKINSON, AJ; SINGLETON, EW; OLSON, JS			THE MECHANISM OF AUTOOXIDATION OF MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; CARBON-MONOXIDE; LIGAND-BINDING; DISTAL HISTIDINE; SYNTHETIC GENE; AUTOXIDATION; HEMOGLOBIN; OXYMYOGLOBIN; DISPLACEMENT	Time courses for the autooxidation of native and mutant sperm whale and pig myoglobins were measured at 37-degrees-C in the presence of catalase and superoxide dismutase. In sperm whale myoglobin, His64(E7) was replaced with Gln, Gly, Ala, Val, Thr, Leu, and Phe; Val68(E11) was replaced with Ala, Ile, Leu, and Phe; Leu29(B10) was replaced with Ala, Val, and Phe. In pig myoglobin, His64(E7) was replaced with Val; Val68(E11) was replaced with Thr and Ser; Thr67(E10) was replaced with Ala, Val, Glu, and Arg; Lys45(CD3) was replaced with Ser, Glu, His, and Arg. The observed pseudo-first order rate constants varied over 4 orders of magnitude, from 58 h-1 (H64A) to 0.055 h-1 (native) to 0.005 h-1 (L29F) at 37-degrees-C, pH 7, in air. The dependences of the observed autooxidation rate constant on oxygen concentration and pH were measured for native and selected mutant myoglobins. In the native proteins and in most mutants still possessing the distal histidine, autooxidation occurs through a combination of two mechanisms. At high [O2], direct dissociation of the neutral superoxide radical (HO2) from oxymyoglobin dominates, and this process is accelerated by decreasing pH. At low [O2], autooxidation occurs by a bimolecular reaction between molecular oxygen and deoxymyoglobin containing a weakly coordinated water molecule. The neutral side chain of the distal histidine (His64) inhibits autooxidation by hydrogen bonding to bound oxygen, preventing both HO2 dissociation and the oxidative bimolecular reaction with deoxymyoglobin. Replacement of His64 by amino acids incapable of hydrogen bonding to the bound ligand markedly increases the rate of autooxidation and causes the superoxide mechanism to predominate. Increasing the polarity of the distal pocket by substitution of Val68 with Ser and Thr accelerates autooxidation, presumably by facilitating protonation of the Fe(II) . O2 complex. Increasing the net anionic charge at the protein surface in the vicinity of the heme group also enhances the rate of autooxidation. Decreasing the volume of the distal pocket by replacing small amino acids with larger aliphatic or aromatic residues at positions 68 (E11) and 29 (B10) inhibits autooxidation markedly by decreasing the accessibility of the iron atom to solvent water molecules.	RICE UNIV, WM KECK CTR COMPUTAT BIOL, HOUSTON, TX 77251 USA; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	Rice University; University of York - UK	BRANTLEY, RE (corresponding author), RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA.			Wilkinson, Anthony/0000-0003-4577-9479; Smerdon, Stephen/0000-0001-5688-8465; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, T32GM008280] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47020] Funding Source: Medline; NIGMS NIH HHS [GM-08280, GM-35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BRANTLEY RE, 1992, THESIS W MARSH RICE; Brooks J, 1935, PROC R SOC SER B-BIO, V118, P560, DOI 10.1098/rspb.1935.0072; BROWN WD, 1969, J BIOL CHEM, V244, P6696; CARRELL RW, 1978, RED CELL PROGR CLIN, V21, P687; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; COLETTA M, 1985, J BIOL CHEM, V260, P4151; EDMUNDSO.AB, 1965, NATURE, V205, P883, DOI 10.1038/205883a0; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; GEORGE P, 1952, BIOCHEM J, V51, P418, DOI 10.1042/bj0510418; GUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; HERRERA AER, 1974, BIOCHIM BIOPHYS ACTA, V336, P318, DOI 10.1016/0005-2795(74)90410-3; MISRA HP, 1972, J BIOL CHEM, V247, P6960; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; Olson J S, 1981, Methods Enzymol, V76, P631; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PHILLIPS SEV, 1981, XRAY STRUCTURE DEOXY; QUILLIN ML, 1992, BIOPHYS J, V61, P2687; RIFKIND JM, 1974, BIOCHEMISTRY-US, V13, P2475, DOI 10.1021/bi00709a003; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SATOH Y, 1981, J BIOL CHEM, V256, P272; SHIKAMA K, 1978, EUR J BIOCHEM, V91, P407, DOI 10.1111/j.1432-1033.1978.tb12693.x; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; SPRINGER BA, 1989, THESIS U ILLINOIS UR; TEW D, 1988, J BIOL CHEM, V263, P17880; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WALLACE WJ, 1974, FEBS LETT, V43, P33, DOI 10.1016/0014-5793(74)81099-9; WALLACE WJ, 1979, BIOCH CLIN ASPECTS O, P69; WATKINS JA, 1985, BIOCHEM BIOPH RES CO, V132, P742, DOI 10.1016/0006-291X(85)91195-7; WAZAWA T, 1992, BIOPHYS J, V63, P544, DOI 10.1016/S0006-3495(92)81608-9; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; WITTENBERG JB, 1981, METHOD ENZYMOL, V76, P31; ZHU L, 1992, J MOL BIOL, V224, P207, DOI 10.1016/0022-2836(92)90584-7	42	344	350	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6995	7010						16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463233				2022-12-25	WOS:A1993KV14100032
J	CHAPLINE, C; RAMSAY, K; KLAUCK, T; JAKEN, S				CHAPLINE, C; RAMSAY, K; KLAUCK, T; JAKEN, S			INTERACTION CLONING OF PROTEIN-KINASE-C SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHORYLATION SITE DOMAIN; FOCAL CONTACTS; ALPHA-ADDUCIN; IDENTIFICATION; FIBROBLASTS; PURIFICATION; ASSOCIATION; ACTIVATION; BINDING; MARCKS	We have previously used an overlay assay technique to detect proteins that interact with protein kinase C (PKC) (Hyatt, S. L., Klauck, T., and Jaken, S. (1990) Mol. Carcinogenesis 3, 45-53). In some cases, binding proteins were also identified as substrates. Therefore, we used the overlay assay approach to screen a rat kidney lambdagt11 cDNA library to isolate and identify additional PKC substrates. Two clones have now been characterized. 35A is the rat homologue of the myristoylated alanine-rich C kinase substrate (MARCKS)-related F52 cDNA, whereas 35H is a partial cDNA with substantial homology to the 3' end of beta-adducin. Both cDNAs encode proteins that bind phosphatidylserine (PS) and are substrates for PKC. Phosphorylation decreased both PS and PKC binding activities. Both proteins contain high density positive charge domains similar to that found in the major PKC substrate MARCKS. These results demonstrate that PKC interactions with certain substrate proteins are of sufficiently high affinity to facilitate their isolation via interaction cloning.			JAKEN, S (corresponding author), W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946, USA.				NATIONAL CANCER INSTITUTE [P01CA037589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NCI NIH HHS [CA465330, CA37589] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; DONG LQ, 1991, AM J PHYSIOL, V261, pF679, DOI 10.1152/ajprenal.1991.261.4.F679; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; HYATT SL, 1991, J CELL BIOCHEM, V15, P158; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; JAKEN S, 1992, PROTEIN KINASE C CUR, P237; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; WASEEM A, 1990, J CELL SCI, V96, P93; WOLF M, 1986, J BIOL CHEM, V261, P3327	32	111	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6858	6861						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463212				2022-12-25	WOS:A1993KV14100010
J	SGROI, D; VARKI, A; BRAESCHANDERSEN, S; STAMENKOVIC, I				SGROI, D; VARKI, A; BRAESCHANDERSEN, S; STAMENKOVIC, I			CD22, A B-CELL-SPECIFIC IMMUNOGLOBULIN SUPERFAMILY MEMBER, IS A SIALIC ACID-BINDING LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MOLECULE N-CAM; ADHESION MOLECULE; LEUKOCYTE ADHESION; MEMBRANE-PROTEIN; SPERM RECEPTOR; CDNA; ENDOTHELIUM; CLONING; FAMILY	The B lymphocyte cell surface receptor CD22 is an adhesion molecule that can mediate binding to several leukocyte subsets. The first CD22 ligand to be identified was the receptor-linked phosphotyrosine phosphatase CD45, but several lines of evidence suggest that CD22 may interact with multiple counter receptors on adjacent lymphocytes. In the present work, we show that in addition to CD45, a soluble CD22-immunoglobulin fusion protein (CD22Rg) recognizes several other distinct lymphocyte sialoglycoproteins. CD22-mediated adhesion is dependent upon the presence of sialic acids on ligands. CD22Rg is observed to bind specifically to a 115-kDa sialoglycoprotein in COS cells transfected with an alpha-2,6-sialyltransferase cDNA, but not in COS cells transfected with unrelated cDNA clones, indicating that at least some CD22-mediated interactions require presentation of sialic acid in an alpha-2,6 linkage by CD22 ligands. In all cases, truncation of the side chain of sialic acids by mild periodate oxidation abolishes recognition by CD22Rg. Direct binding of CD22Rg to lymphoid cells also requires sialic acids and their side chains. Taken together, these observations indicate that CD22 is a sialic acid-binding lectin and may define a novel functional subset of immunoglobulin superfamily adhesion molecules.	MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego			Sgroi, Dennis/AAV-2487-2021		NCI NIH HHS [CA55735] Funding Source: Medline; NIGMS NIH HHS [GM43257, GM32373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373, R01GM043257, R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED H, 1989, J BIOL CHEM, V264, P18673; ARIGA T, 1987, J BIOL CHEM, V262, P848; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CAHAN LD, 1980, VIROLOGY, V103, P505, DOI 10.1016/0042-6822(80)90208-1; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P3037, DOI 10.1073/pnas.83.9.3037; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOLLENBAUGH D, 1992, EMBO J, V11, P4314; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEDBETTER JA, 1985, J IMMUNOL, V135, P1819; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MARKWELL MAK, 1980, P NATL ACAD SCI-BIOL, V77, P5693, DOI 10.1073/pnas.77.10.5693; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NORGARDKE, 1993, IN PRESS; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; POWELL LD, 1993, J BIOL CHEM, V268, P7019; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; RUTISHAUSER U, 1989, NEUROBIOLOGY GLYCOCO, P347; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TIEMEYER M, 1990, J BIOL CHEM, V265, P11990; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	58	214	219	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7011	7018						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463234				2022-12-25	WOS:A1993KV14100033
J	LIU, ZR; THOMPSON, KS; TOWLE, HC				LIU, ZR; THOMPSON, KS; TOWLE, HC			CARBOHYDRATE REGULATION OF THE RAT L-TYPE PYRUVATE-KINASE GENE REQUIRES 2 NUCLEAR FACTORS - LF-A1 AND A MEMBER OF THE C-MYC FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POST-TRANSCRIPTIONAL REGULATION; MAJOR LATE PROMOTER; DNA-BINDING; ACTIVATES TRANSCRIPTION; LIVER; EXPRESSION; PROTEIN; UPSTREAM; GLUCOSE; REGIONS	Transcription of the L-type pyruvate kinase (L-PK) gene is induced in response to increased carbohydrate metabolism in the liver. We have demonstrated previously that a segment of the 5'-flanking region of the L-PK gene between -183 and -96 is necessary and sufficient for the glucose response in primary hepatocytes. To explore the protein factors that are involved in carbohydrate regulation, we have performed mutational analyses and in vitro binding studies of this segment. Sequences critical for the glucose response were mapped from -171 to -124. This segment contains the consensus binding sites for two nuclear transcription factors: LF-A1 and MLTF. Both factors are capable of binding to the corresponding L-PK sites in vitro. Mutational and functional analyses indicated that LF-A1 is indeed involved in glucose induction of the L-PK gene. The PK MLTF-like site consists of two imperfect CACGTG motifs, the core binding site for a family of transcription factors related to c-myc. Unexpectedly, mutations in either motif that resulted in defective glucose stimulation retained in vitro binding to MLTF. Furthermore, an authentic MLTF binding site from the adenovirus major late promoter was not functionally interchangeable with the natural sequence. These data indicate that binding of MLTF, in presence of LF-A1, is not capable of supporting the glucose response. Conversion of either imperfect motif to CACGTG within the context of the mutations disrupting the opposite site restored the response to elevated glucose. Thus, the factor that recognizes the PK MLTF-like site and participates in mediating the carbohydrate response of the L-PK gene appears to be a member of the c-myc family distinct from MLTF.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK 26919] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCUS AC, 1970, ANAL BIOCHEM, V37, P53, DOI 10.1016/0003-2697(70)90257-5; BACK DW, 1986, J BIOL CHEM, V261, P4190; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HROMAS R, 1986, NUCLEIC ACIDS RES, V14, P4837, DOI 10.1093/nar/14.12.4837; INOUE H, 1984, J BIOCHEM-TOKYO, V96, P1457, DOI 10.1093/oxfordjournals.jbchem.a134974; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; NOGUCHI T, 1991, BIOCHEM BIOPH RES CO, V181, P259, DOI 10.1016/S0006-291X(05)81411-1; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STROBL W, 1989, J BIOL CHEM, V264, P1190; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; YAMADA K, 1990, J BIOL CHEM, V265, P19885	37	123	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12787	12795						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509413				2022-12-25	WOS:A1993LG65800083
J	MARSTON, SB; REDWOOD, CS				MARSTON, SB; REDWOOD, CS			THE ESSENTIAL ROLE OF TROPOMYOSIN IN COOPERATIVE REGULATION OF SMOOTH-MUSCLE THIN FILAMENT ACTIVITY BY CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; HEAVY-MEROMYOSIN; MYOSIN SUBFRAGMENT-1; TROPONIN-TROPOMYOSIN; CA-2+ REGULATION; F-ACTIN; BINDING; SKELETAL; CALMODULIN; INHIBITION	We compared the mechanisms by which caldesmon inhibits actin and actin-tropomyosin activation of myosin subfragment 1 (S1) MgATPase activity. Caldesmon always inhibited actin activation by displacing S1 . ADP . P(i) from actin and inhibition required at least 0.7 caldesmon molecules bound per actin for 90% inhibition. Caldesmon inhibited actin-tropomyosin without any displacement of S1 . ADP . P(i); thus it inhibits a rate-limiting step. Inhibition is highly cooperative, requiring no more than one caldesmon bound per 10 actins for 90% inhibition of activation by actin and smooth muscle tropomyosin. The degree of cooperativity is defined by the tropomyosin since inhibition by skeletal tropomyosin requires up to one caldesmon bound per 4 actins for 90% inhibition under identical conditions. Both noncooperative inhibition of actin and cooperative, tropomyosin-dependent, inhibition are manifested by a fragment of caldesmon containing only the C-terminal 99 amino acids (658C), although this fragment does not itself bind to tropomyosin. The functional properties of 658C are very similar to striated muscle troponin I, consequently we propose a similar mechanism for tropomyosin-dependent regulation by caldesmon. Caldesmon binding switches actin-tropomyosin to the ''off'' or ''weak'' state and Ca2+/calmodulin binding to caldesmon blocks this switch and thus reactivates the actin filament.			MARSTON, SB (corresponding author), NATL HEART & LUNG INST, DEPT CARDIAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.			Marston, Steven/0000-0001-6054-6070				BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HILL TL, 1981, BIOPHYS J, V35, P99, DOI 10.1016/S0006-3495(81)84777-7; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; MARSTON SB, 1984, J MUSCLE RES CELL M, V5, P559, DOI 10.1007/BF00713261; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MARSTON SB, 1988, BIOCHEM BIOPH RES CO, V155, P197, DOI 10.1016/S0006-291X(88)81068-4; MARSTON SB, 1991, BIOCHEM J, V279, P1; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PRITCHARD K, 1993, BIOCHEM BIOPH RES CO, V190, P668, DOI 10.1006/bbrc.1993.1100; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1982, J MOL BIOL, V157, P275, DOI 10.1016/0022-2836(82)90234-0; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	34	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12317	12320						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509369				2022-12-25	WOS:A1993LG65800017
J	ROBERTSON, MW				ROBERTSON, MW			PHAGE AND ESCHERICHIA-COLI EXPRESSION OF THE HUMAN HIGH-AFFINITY IMMUNOGLOBULIN-E-RECEPTOR ALPHA-SUBUNIT ECTODOMAIN - DOMAIN LOCALIZATION OF THE IGE-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; FILAMENTOUS PHAGE; VARIABLE DOMAINS; MAST-CELLS; ANTIBODY; CHAIN; RAT; PROTEINS; GENE; LIBRARIES	The high affinity IgE receptor is a multisubunit complex that participates in IgE-dependent activation of mast cells and basophils. The IgE-binding portion of the receptor resides exclusively in the alpha-subunit and specifically within the 180 residues of the mature extracytoplasmic portion. In this study the contiguous two-domain human alpha-subunit has been displayed on the surface of a filamentous bacteriophage in a form that specifically binds both human and murine IgE but not other isotypes. Phage display of the individual immunoglobulin-like domains reveals that the IgE-binding portion resides exclusively in the COOH-terminal domain and that this domain appears to bind IgE with lower affinity than the comparably displayed two-domain fragment. Phage display results using a chimeric rat-human alpha-subunit fragment suggest that structural elements within the NH2-terminal domain are necessary to impart high affinity IgE binding activity to the alpha-chain ectodomain. The two-domain human receptor fragment was also expressed in a soluble form from Escherichia coli and purified in one step by affinity chromatography. The solution binding of the purified receptor fragment to IgE was measured by fluorescence quench which afforded an approximate equilibrium affinity constant of 2 x 10(9) M-1 together with a stoichiometry of 1 receptor molecule/molecule of IgE. The complementary approach of phage display and E. coli expression used in this study represents a useful strategy for further analysis of discrete receptor epitope(s) that contribute to IgE binding activity.			ROBERTSON, MW (corresponding author), MRC,CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CONRAD DH, 1983, J IMMUNOL, V130, P327; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DAY LA, 1969, J MOL BIOL, V39, P265, DOI 10.1016/0022-2836(69)90316-7; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EISEN HN, 1964, METHOD MED RES, V10, P155; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEMPSTEAD BL, 1981, J BIOL CHEM, V256, P717; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JUNG V, 1990, NUCLEIC ACIDS RES, V18, P6156, DOI 10.1093/nar/18.20.6156; KANELLOPOULOS J, 1979, J BIOL CHEM, V254, P7691; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KULCZYCKI A, 1979, J BIOL CHEM, V254, P3187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LIU FT, 1980, J IMMUNOL, V124, P2728; LIU FT, 1988, P NATL ACAD SCI USA, V85, P5639, DOI 10.1073/pnas.85.15.5639; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MENDOZA G, 1976, NATURE, V264, P548, DOI 10.1038/264548a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PECOUD AR, 1981, J IMMUNOL, V126, P1624; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RISKE F, 1991, J BIOL CHEM, V266, P11245; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; TEPLER I, 1989, J BIOL CHEM, V264, P5912; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WEBSTER RE, 1985, VIRUS STRUCTURE ASSE, P235	46	72	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12736	12743						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509408				2022-12-25	WOS:A1993LG65800076
J	VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB				VEROSTEK, MF; ATKINSON, PH; TRIMBLE, RB			GLYCOPROTEIN-BIOSYNTHESIS IN THE ALG3 SACCHAROMYCES-CEREVISIAE MUTANT .2. STRUCTURE OF NOVEL MAN6-10GLCNAC2 PROCESSING INTERMEDIATES ON SECRETED INVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; LIPID-LINKED OLIGOSACCHARIDES; YEAST EXTERNAL INVERTASE; PROTEIN GLYCOSYLATION; CORE OLIGOSACCHARIDES; ELONGATION; DEFICIENT; CELLS	Alg3 yeast mutants synthesize endoglycosidase H-resistant oligosaccharides whose precursor for elongation is Man1alpha-->2Man1alpha-->2Man1alpha-->3(Man1alpha--> 6) Man1beta-->4GlcNAc2 (Verostek, M. F., Atkinson, P. H., and Trimble, R. B. (1991) J. Biol. Chem. 266, 5547-5551). To characterize alg3 glycan elongation in vivo, oligosaccharides on alg3,sec18 invertase synthesized and secreted at 26-degrees-C were released with peptide-N4-N-acetyl-beta-glucosaminyl asparagine amidase and purified by Bio-Gel P-4 chromatography. Large (Man>30GlcNAc2) and intermediate (Man5-10GlcNAc2) sized oligosaccharides were pooled separately, and the smaller ones were exchanged with (H2O)-H-2 for one- and two-dimensional DQF-COSY H-1 NMR analyses at 500 MHz. Although there was no detectable substitution of the terminal alpha1,6-core-linked mannose, addition of alpha1,6-, alpha1,2-, and alpha1,3-mannoses to the alpha1,3-linked core branch of a majority of the Man5 precursor was analogous to core-filling reactions seen on wild type invertase glycans (Trimble, R. B., and Atkinson, P. H. (1986) J. Biol. Chem. 261, 9815-9824). Two additional types of oligosaccharide structures were found; those which retained glucose and those consistent with mannan elongation. Glucose retention appeared to be due to inefficient trimming from minor glucosylated intermediates, while mannan elongation was by extension of a new alpha1,6-linked branch from the alpha1,3-core-linked residue as seen in wild-type core oligosaccharides (Hernandez, L. M., Ballou, L., Alvarado, E., Gillece-Castro, B. L., Burlingame, A. L., and Ballou, C. E. (1989) J. Biol. Chem. 264, 11849-11856) or mnnl,mnn2,mnn10 processing intermediates (Ballou, L., Alvarado, E., Tsai, P-k., Dell, A., and Ballou, C. E. (1989) J. Biol. Chem. 264, 11857-11864). Thus, the alpha1,6-linked branch additions which form Man9GlcNAc2-PP-dolichol from Man5GlcNAc2-PP-dolichol appear to provide important structural information enabling efficient recognition by the endoplasmic reticulum-glucosyltransferases forming oligosaccharide-lipid as well as the glucosidases involved in early trimming reactions, but the alg3 mutant documents that they are unnecessary for normal yeast man-nan elongation.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES E524, POB 509, ALBANY, NY 12201 USA; MINIST AGR & FISHERIES TECHNOL, UPPER HUTT, NEW ZEALAND; SUNY, SCH PUBL HLTH, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; SUNY Maritime College					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA013402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NCI NIH HHS [CA13402, CA13330] Funding Source: Medline; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; ALVARADO E, 1991, BIOCHEMISTRY-US, V30, P881, DOI 10.1021/bi00218a001; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; CHAPMAN A, 1979, CELL, V17, P509, DOI 10.1016/0092-8674(79)90259-9; CHU FK, 1978, J BIOL CHEM, V253, P8691; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldstein A, 1975, Methods Enzymol, V42, P504; GOPAL PK, 1987, P NATL ACAD SCI USA, V84, P8824, DOI 10.1073/pnas.84.24.8824; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1979, J BIOL CHEM, V254, P2754; MCLEAN C, 1973, ANAL BIOCHEM, V55, P72, DOI 10.1016/0003-2697(73)90291-1; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; TSAI PK, 1984, J BIOL CHEM, V259, P3805; TSAI PK, 1984, P NATL ACAD SCI-BIOL, V81, P6340, DOI 10.1073/pnas.81.20.6340; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	42	33	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12104	12115						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	8505334				2022-12-25	WOS:A1993LF28400096
J	COLAMONICI, OR; DOMANSKI, P				COLAMONICI, OR; DOMANSKI, P			IDENTIFICATION OF A NOVEL SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR LOCALIZED TO HUMAN CHROMOSOME-21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-INTERFERON; GAMMA-INTERFERON; CELLS; ANTIBODIES; EXPRESSION; CLONING; BINDING; GENE; CDNA	Expression in mouse cells of the cloned human IFN alpha receptor (IFNalphaR) subunit selectively confers response and binding to human IFNalpha8, indicating that other subunits are involved in IFNalpha binding. We report here that a new monoclonal antibody (mAb), termed IFNaRbeta1, recognizes a novel IFNalphaR subunit different from the one recently cloned and distinct from the alpha subunit recognized by the IFNalphaR3 mAb. The IFNaRbeta1 mAb blocks the biological effect of seven different Type I IFNs. Immunoprecipitations after cell surface iodination demonstrate that the IFNaRbeta1 mAb recognizes a protein with a molecular mass of 100 kDa in Daudi and U-266 cells that express normal IFNalphaR. However, a 55-kDa protein instead of the 100-kDa product was immunoprecipitated in the IFNalpha-resistant U-937 cell line that express the variant form of the receptor. We also demonstrate that the gene that codes for this novel IFNalphaR subunit maps to human chromosome 21, as do the cloned IFNalphaR subunit and the alpha subunit, indicating the existence of a locus on this chromosome that regulates binding for Type I IFNs.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago								BENOIT P, 1993, J IMMUNOL, V150, P707; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MEISTER A, 1986, J GEN VIROL, V67, P1633, DOI 10.1099/0022-1317-67-8-1633; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHULMAN LM, 1984, VIROLOGY, V137, P422, DOI 10.1016/0042-6822(84)90235-6; TAN YH, 1976, NATURE, V260, P141, DOI 10.1038/260141a0; TAN YH, 1974, SCIENCE, V186, P61, DOI 10.1126/science.186.4158.61; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; ZOON KC, 1984, PHARMACOL THERAPEUT, V24, P259, DOI 10.1016/0163-7258(84)90037-8	23	100	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10895	10899						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496154				2022-12-25	WOS:A1993LD46600030
J	PATE, E; FRANKSSKIBA, K; WHITE, H; COOKE, R				PATE, E; FRANKSSKIBA, K; WHITE, H; COOKE, R			THE USE OF DIFFERING NUCLEOTIDES TO INVESTIGATE CROSS-BRIDGE KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKINNED MUSCLE-FIBERS; RABBIT PSOAS FIBERS; SKELETAL-MUSCLE; ADENOSINE-TRIPHOSPHATASE; FORCE GENERATION; RANA-TEMPORARIA; CONTRACTION; PHOSPHATE; DISSOCIATION; MECHANISM	We have investigated the ability of the nucleotides GTP, CTP, and 1-N-etheno-2-aza-ATP (aza-ATP) to support contraction of chemically skinned rabbit psoas fibers. Working at 10-degrees-C, millimolar concentrations of all nucleotides relaxed fibers in the absence of calcium. In active fibers, GTP served as a very poor substrate, with isometric tension, isometric GTPase rate, and maximum shortening velocity (V(max)) all less than 10% of those obtained with ATP. Aza-ATP was only a slightly better substrate. CTP, on the other hand, was an effective substrate with mechanical parameters which were 65-100% those obtained with ATP, and with a hydrolysis rate that exceeded that of ATP. For all three ligands, V(max) followed Michaelis-Menten saturation behavior with values for K(m) which were from 2.5 to 12 times greater than that for ATP, showing that the analogs bound slowly to myosin in the fibers. Increasing concentrations of orthophosphate inhibited tension with CTP, to a lesser extent with aza-ATP, but not at all with GTP. A combination of the mechanical data obtained in fibers with the kinetic data obtained in solution (White, H. D., Belknap, B., and Jiang, W. (1993) J. Biol. Chem. 268, 10039-10045) is used to better define the actomyosin interaction in fibers.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; EASTERN VIRGINIA MED SCH,DEPT BIOCHEM,NORFOLK,VA 23501; WASHINGTON STATE UNIV,DEPT PURE & APPL MATH,PULLMAN,WA 99164; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Eastern Virginia Medical School; Washington State University; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41776, HL32145] Funding Source: Medline; NIAMS NIH HHS [AR39643] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032145, R01HL041776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039643] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABBOTT RH, 1970, PFLUG ARCH EUR J PHY, V321, P223, DOI 10.1007/BF00588443; BELKNAP B, 1989, Biophysical Journal, V55, p269A; BELKNAP B, 1992, Biophysical Journal, V61, pA440; BLUM JJ, 1955, ARCH BIOCHEM BIOPHYS, V55, P486, DOI 10.1016/0003-9861(55)90428-8; BRENNER B, 1986, BIOPHYS J, V50, P685, DOI 10.1016/S0006-3495(86)83509-3; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P10490, DOI 10.1073/pnas.88.23.10490; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1980, BIOCHEMISTRY-US, V19, P2265, DOI 10.1021/bi00551a042; COOKE R, 1979, BIOPHYS J, V28, P241, DOI 10.1016/S0006-3495(79)85174-7; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; COOKE R, 1988, J PHYSIOL-LONDON, V395, P77, DOI 10.1113/jphysiol.1988.sp016909; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; ECCLESTON JF, 1979, BIOCHEMISTRY-US, V18, P2896, DOI 10.1021/bi00580a034; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; FERENCZI MA, 1982, BASIC BIOL MUSCLES C, P91; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HASSELBACH W, 1956, BIOCHIM BIOPHYS ACTA, V20, P355, DOI 10.1016/0006-3002(56)90297-9; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIBBERD MG, 1985, SCIENCE, V228, P1317, DOI 10.1126/science.3159090; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOMSHER E, 1990, ANNU REV PHYSIOL, V52, P875, DOI 10.1146/annurev.ph.52.030190.004303; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; JAMES E, 1966, J BIOL CHEM, V241, P4758; JULIAN FJ, 1981, J PHYSIOL-LONDON, V311, P201, DOI 10.1113/jphysiol.1981.sp013581; KAWAI M, 1986, J MUSCLE RES CELL M, V7, P421, DOI 10.1007/BF01753585; KAWAI M, 1989, BIOPHYS J, V55, P595, DOI 10.1016/S0006-3495(89)82857-7; KIELLEY WW, 1956, J BIOL CHEM, V219, P95; KOMADA T, 1986, J BIOCHEM-TOKYO, V99, P1465; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; PATE E, 1988, BIOPHYS J, V53, pA568; PATE E, 1991, BIOPHYS J, V59, P598, DOI 10.1016/S0006-3495(91)82275-5; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; PATE E, 1992, AM J PHYSIOL, V262, pC1039; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SLEEP J, 1986, BIOCHEMISTRY-US, V25, P1149, DOI 10.1021/bi00353a030; SMITH SJ, 1985, J BIOL CHEM, V260, P5156; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TONOMURA Y, 1973, MUSCLE PROTEINS MUSC, P259; WALKER JW, 1992, J BIOL CHEM, V267, P2459; WEBER A, 1969, J GEN PHYSIOL, V53, P781, DOI 10.1085/jgp.53.6.781; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YOUNT RG, 1963, J BIOL CHEM, V238, P1708	50	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10046	10053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486676				2022-12-25	WOS:A1993LB80000019
J	PATEL, SS; HINGORANI, MM				PATEL, SS; HINGORANI, MM			OLIGOMERIC STRUCTURE OF BACTERIOPHAGE-T7 DNA PRIMASE HELICASE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-4 PROTEIN; ATP HYDROLYSIS; REPLICATION; MECHANISM; COMPONENT; SEQUENCE; HEXAMERS; ANTIGEN; RHO	The oligomeric structure of bacteriophage T7 gene 4 helicase/primase proteins was investigated using protein cross-linking and high pressure gel-filtration chromatography. Studies were carried out with both 4A' and 4B proteins. 4A' is a M64L mutant of 4A which has similar helicase and primase activities as the wild-type mixture of 4A and 4B proteins (Patel, S. S., Rosenberg, A. H., Studier, F. W., and Johnson, K. A. (1992) J. Biol. Chem. 267, 15013-15021), and 4B is the smaller protein which has only helicase activity. Chemical cross-linking of 4A' and 4B proteins with dimethyl suberimidate resulted in cross-linked species ranging from dimers to hexamers and beyond. The cross-linking time course, however, indicated that hexamers were the predominant species to accumulate in both 4A' and 4B proteins. The effect of MgNTP and DNA binding on oligomerization of the gene 4 proteins was investigated using high pressure gel-filtration chromatography at increasing protein concentrations. In the absence of added ligands, close to 100 muM protein-concentrations were required to form stable oligomers beyond dimers. However, in the presence of Mg-beta,gamma-methylene deoxythymidine triphosphate (nonhydrolyzable analog of dTTP), 4A' and 4B proteins assembled into stable hexamers at protein concentrations less than 8 muM. Addition of single-stranded DNA further stabilized the hexamer structure. Therefore, in the presence of a 60-nucleotide-long single-stranded DNA, hexamers were observed at protein concentrations as low as 0.2 muM. Nuclease protection experiments indicated that the 4A' and 4B hexamers protect about 60-65 bases of single-stranded DNA.			PATEL, SS (corresponding author), OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210, USA.							ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5247; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; PATEL SS, 1992, J BIOL CHEM, V267, P15013; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEO YS, 1991, J BIOL CHEM, V266, P13161; Valdes R Jr, 1979, Methods Enzymol, V61, P125; WANG EH, 1991, VIROLOGY, V184, P399, DOI 10.1016/0042-6822(91)90858-9; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, J BIOL CHEM, V254, P1997	29	118	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10668	10675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486715				2022-12-25	WOS:A1993LB80000098
J	ZHANG, H; GAO, YG; VANDERMAREL, GA; VANBOOM, JH; WANG, AHJ				ZHANG, H; GAO, YG; VANDERMAREL, GA; VANBOOM, JH; WANG, AHJ			SIMULTANEOUS INCORPORATIONS OF 2 ANTICANCER DRUGS INTO DNA - THE STRUCTURES OF FORMALDEHYDE-CROSS-LINKED ADDUCTS OF DAUNORUBICIN-D(CG(ARAC)GCG) AND DOXORUBICIN-D(CA(ARAC)GTG) COMPLEXES AT HIGH-RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; RNA; ARABINOSYLCYTOSINE; DAUNORUBICIN; NOGALAMYCIN; DAUNOMYCIN; PROSPECTS; LEUKEMIA	Anthracycline antibiotics (notably daunorubicin (DAU) and doxorubicin (DOX)) and nucleoside analog arabinosylcytosine (araC or (a)C) are important anticancer drugs. They are sometimes used together in the treatment of certain cancers. Both classes of compounds act by blocking DNA replication and transcription. To probe whether both drugs can be incorporated simultaneously into DNA and the possible structural consequences, we carried out x-ray diffraction analyses of the complexes between DAU/DOX and araC-containing DNA hexamers cross-linked with formaldehyde. The crystal structures were determined to high resolution (DAU-CG(a)CGCG, 1.2 angstrom, space group P4(1)2(1)2, R = 0.182, 3275 reflections; DOX-CA(a)CGTG, 1.5 angstrom, space group C2, R = 0.175, 3359 reflections), and they are similar to those of the previously studied DAU- and DOX-DNA complexes, despite different crystal packings. Two DAU/DOX molecules intercalate at both ends of the helix with their amino sugars in the minor groove. As in the structure of DAU-CGCGCG (Wang, A. H.-J., Gao, Y.-G., Liaw, Y.-C., and Li, Y. K. (1991) Biochemistry 30, 3812-3815), a covalent methylene bridge (from formaldehyde) between the N3' of daunosamine and the N2 of the guanine is formed in both adducts. In DOX-CA(a)CGTG, the two halves are slightly different with a root-mean-square deviation of 0.322 angstrom between them. The O-14 hydroxyls of the intercalated DOXs are within hydrogen bond distances to the O2P atoms of the A2p((a)C3) and A8p((a)C9) steps. The O2P-hydroxyl group from araC does not affect the binding of DAU-DOX or the conformation of the drug-DNA complexes. The results suggest that three major drug modifications on DNA, i.e., intercalation, covalent bond formation, and nucleoside analog incorporation, can coexist in the same DNA molecule without difficulty. When they occur in close proximity in DNA, they may provide an additive inhibitory effect for the target enzymes.	LEIDEN UNIV,GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	Leiden University; Leiden University - Excl LUMC; University of Illinois System; University of Illinois Urbana-Champaign	WANG, AHJ (corresponding author), UNIV ILLINOIS,DIV BIOPHYS,URBANA,IL 61801, USA.				NATIONAL CANCER INSTITUTE [R01CA052506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041612] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52506] Funding Source: Medline; NIGMS NIH HHS [GM-41612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, CURR OPIN STRUC BIOL; ARAI T, 1979, TETRAHEDRON LETT, P2355; ARORA SK, 1991, J BIOMOL STRUCT DYN, V6, P489; DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241; DEVROOM E, 1988, NUCLEIC ACIDS RES, V16, P2987, DOI 10.1093/nar/16.7.2987; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; GAO YG, 1991, BIOCHEMISTRY-US, V30, P9922, DOI 10.1021/bi00105a016; GAO YG, 1991, P NATL ACAD SCI USA, V88, P4845, DOI 10.1073/pnas.88.11.4845; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; HAGHBIN M, 1974, CANCER-AM CANCER SOC, V33, P1491, DOI 10.1002/1097-0142(197406)33:6<1491::AID-CNCR2820330604>3.0.CO;2-#; HENDRICKSON WA, 1979, BIOMOLECULAR STRUCTU, P43; ISHIGURO K, 1978, BIOCHEMISTRY-US, V17, P2545, DOI 10.1021/bi00606a014; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KEATING MJ, 1982, JAMA-J AM MED ASSOC, V248, P2481, DOI 10.1001/jama.248.19.2481; KIMURA K, 1990, AGR BIOL CHEM TOKYO, V54, P1645, DOI 10.1080/00021369.1990.10870198; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUFE DW, 1985, SEMIN ONCOL, V12, P34; LIAW YC, 1989, BIOCHEMISTRY-US, V28, P9913, DOI 10.1021/bi00452a006; Lown J.W., 1988, ANTHRACYCLINE ANTHRA; MIKITA T, 1988, BIOCHEMISTRY-US, V27, P4698, DOI 10.1021/bi00413a018; PROPST CL, 1992, NUCLEIC ACID TARGETE; PULLMAN B, 1990, MOL BASIS SEPECIFICI; RABINOVICH D, 1984, ACTA CRYSTALLOGR A, V40, P195, DOI 10.1107/S010876738400043X; Rosik LO, 1990, BIOCONJUGATE CHEM, V1, P251, DOI 10.1021/bc00004a004; SAKAI R, 1992, P NATL ACAD SCI USA, V89, P11456, DOI 10.1073/pnas.89.23.11456; SYGUSCH J, 1976, ACTA CRYSTALLOGR B, V32, P1139, DOI 10.1107/S0567740876004834; TAKAHASHI A, 1992, CHEM PHARM BULL, V40, P1313, DOI 10.1248/cpb.40.1313; TENG MK, 1989, BIOCHEMISTRY-US, V28, P4923, DOI 10.1021/bi00438a001; TOUGARD P, 1974, ACTA CRYSTALLOGR B, V30, P86, DOI 10.1107/S0567740874002251; UEDA I, 1984, ACTA CRYSTALLOGR C, V40, P1578, DOI 10.1107/S0108270184008775; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; WANG AHJ, 1984, SCIENCE, V225, P1115, DOI 10.1126/science.6474168; WANG AHJ, 1991, BIOCHEMISTRY-US, V30, P3812, DOI 10.1021/bi00230a002; WARPEHOSKI MA, 1988, CHEM RES TOXICOL, V1, P315, DOI 10.1021/tx00006a001; WESTENDORF J, 1989, CANCER RES, V49, P5262; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035; ZHANG H, 1992, BIOPOLYMERS, V32, P1559, DOI 10.1002/bip.360321113	38	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10095	10101						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486678				2022-12-25	WOS:A1993LB80000025
J	ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP				ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP			STRUCTURAL DETERMINANTS OUTSIDE OF THE LEUCINE ZIPPER INFLUENCE THE INTERACTIONS OF CREB AND ATF-2 - INTERACTION OF CREB WITH ATF-2 BLOCKS E1A ATF-2 COMPLEX-FORMATION	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN; T7 RNA-POLYMERASE; DNA-BINDING; RESPONSE ELEMENT; ENHANCER BINDING; TRANSCRIPTION; EXPRESSION; DOMAINS; ZINC; ADENOSINE-3',5'-MONOPHOSPHATE	Dimerization of leucine zipper-containing proteins has been associated characteristically with the formation of a coiled-coil structure between two compatible leucine zipper motifs. In the present study we demonstrate the association of the leucine zipper of cAMP response element-binding protein (CREB) with a zinc finger motif of ATF-2. The association of the CREB leucine zipper with the ATF-2 zinc finger is stabilized if the ATF-2 leucine zipper is intact, implying that the preferred interactive structure of ATF-2 juxtaposes the amino-terminal zinc finger motif of this protein with the carboxy-terminal leucine zipper of this same protein. Furthermore, we demonstrate that the association of the CREB leucine zipper with the ATF-2 zinc finger in vitro blocks the association of the adenoviral E1a protein with ATF-2. Similarly, overexpression of full-length CREB, or a truncated version of this protein corresponding to the carboxy-terminal 74 amino acids that make up the DNA-binding and dimerization domains, can block the ATF-2-mediated transcriptional stimulation by E1a in vivo. Mutation of the ATF-2 zinc finger motif stimulates DNA binding of this protein, and abolishes interactions with E1a and CREB proteins. These results demonstrate that the structural conformation of ATF-2 is critical for DNA binding and protein-protein interactions and, further, that leucine zippers can mediate protein-protein interactions with structural motifs other than leucine zippers.	UNIV COLORADO,SCH MED,CTR CANC,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,SCH PHARM,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV ENDOCRINOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen C Y, 1991, Protein Expr Purif, V2, P402, DOI 10.1016/1046-5928(91)90101-N; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT KJ, 1991, ONCOGENE, V6, P2019; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZU YL, 1991, J BIOL CHEM, V266, P24134	33	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1161	1174						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479741				2022-12-25	WOS:A1993KY32800007
J	HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U				HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U			THE PHYSIOLOGY OF BCL-2 EXPRESSION IN MURINE B-LYMPHOCYTES	ONCOGENE			English	Article							MONOCLONAL-ANTIBODY; POPULATION-DYNAMICS; GENE-EXPRESSION; TRANSGENIC MICE; CELL SURVIVAL; MOUSE; RECEPTORS; SELECTION; APOPTOSIS; PROTEIN	Quantitation of bcl-2 gene expression in B-lineage lymphocytes from normal adult mice allows the identification of four cell populations, characterized by successive three- to fivefold increases in average mRNA levels: bone marrow pre-B cells, bone marrow B cells, splenic B cells and long-lived splenic B cells. Thus, in line with previous experiments using overexpression systems, a correlation between longevity and levels of bcl-2 mRNA exists also in the physiology of B-lineage cells. The data are compatible with a quantitative regulation of expression, possibly determined at selective differentiation steps. No difference in bcl-2 expression was detected by comparing splenic IgD+ with IgD- B cells, while distinctly low levels of bcl-2 mRNA were scored in peritoneal CD5+ and CD5- B cells. These observations indicate that the reported persistence of peritoneal B cells may be controlled by mechanisms other than bcl-2 gene expression.	INST PASTEUR,CNRS,URA 359,UNITE IMMUNOBIOL,25 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			freitas, antonio/A-2482-2013	Hibner, Urszula/0000-0002-5520-7311; Haury, Matthias/0000-0002-1796-1479; Coutinho, Antonio/0000-0002-0857-9227; freitas, antonio/0000-0001-6392-7178				ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ANDRADE L, 1989, EUR J IMMUNOL, V19, P1117, DOI 10.1002/eji.1830190623; BRUCE J, 1981, J IMMUNOL, V127, P2496; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; Coutinho A, 1992, Int Rev Immunol, V8, P173, DOI 10.3109/08830189209055572; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Freitas A A, 1989, Int Immunol, V1, P342, DOI 10.1093/intimm/1.4.342; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; FREITAS AA, 1986, IMMUNOL REV, V91, P5, DOI 10.1111/j.1600-065X.1986.tb01482.x; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KINCADE PW, 1981, J IMMUNOL METHODS, V42, P17, DOI 10.1016/0022-1759(81)90220-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVY M, 1987, EUR J IMMUNOL, V17, P295, DOI 10.1002/eji.1830170223; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANSON SD, 1977, J IMMUNOL METHODS, V18, P225, DOI 10.1016/0022-1759(77)90176-4; NERGRINI G, 1987, CELL, V49, P455; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROCHA B, 1983, J IMMUNOL, V131, P2158; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Thomas-Vaslin V, 1989, Int Immunol, V1, P237, DOI 10.1093/intimm/1.3.237; THOMASVASLIN V, 1990, INT IMMUNOL, V2, P74; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YEH TM, 1991, INT IMMUNOL, V3, P1329, DOI 10.1093/intimm/3.12.1329	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1257	1262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479747				2022-12-25	WOS:A1993KY32800017
J	FRELIN, C; BREITTMAYER, JP; VIGNE, P				FRELIN, C; BREITTMAYER, JP; VIGNE, P			ADP INDUCES INOSITOL PHOSPHATE-INDEPENDENT INTRACELLULAR CA2+ MOBILIZATION IN BRAIN CAPILLARY ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; SMOOTH-MUSCLE CELLS; BRILLIANT BLUE-G; EXTRACELLULAR ATP; CALCIUM MOBILIZATION; CA-2+ MOBILIZATION; REACTIVE BLUE-2; PHOSPHOLIPASE-C; TUMOR PROMOTER; THAPSIGARGIN	The action of adenine and uracyl nucleotides on rat brain capillary endothelial cells was investigated. ATP, UTP, and adenosine 5'-O-(3-thiotrisphosphate) activated phospholipase C and induced large increases in [Ca2+]i. ADP had a different action. At low concentrations (<10 muM), ADP induced the mobilization of a thapsigargin-sensitive intracellular Ca2+ store in the absence of measurable production of inositol phosphates. At larger concentrations (>30 mum), ADP activated phospholipase C. The actions of ATP and ADP and of UTP and ADP were additive. Those of ATP and UTP were not. In the presence of ATP or UTP, the dose-response curve for ADP action on [Ca2+]i was monophasic and corresponded to the high affinity responses. Finally, we observed that ADP did not desensitize cells to the actions of ATP and UTP. In contrast, cross-desensitization of the actions of ATP and UTP were observed. It is concluded that two types of receptors account for the actions of nucleotides: (i) a nucleotide that recognizes ATP and UTP and that is positively coupled to phospholipase C; and (ii) an ADP-specific receptor that induces the mobilization of a thapsigargin-sensitive intracellular Ca2+ pool in a manner independent of the formation of inositol phosphates.	UNIV NICE,FAC MED,INSERM,U343,F-06034 NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	FRELIN, C (corresponding author), CNRS 660,INST PHARMACOL MOLEC & CELLULAIRE,ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE.							AMBLER SK, 1987, MOL PHARMACOL, V32, P376; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BODIN P, 1991, BRIT J PHARMACOL, V103, P1203, DOI 10.1111/j.1476-5381.1991.tb12324.x; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; DUBYAK GR, 1985, J BIOL CHEM, V260, P653; GONZALEZ FA, 1989, J CELL PHYSIOL, V141, P606, DOI 10.1002/jcp.1041410320; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HOPWOOD AM, 1987, EUR J PHARMACOL, V136, P49, DOI 10.1016/0014-2999(87)90777-1; HOUSTON DA, 1987, J PHARMACOL EXP THER, V241, P501; INOUE K, 1991, BRIT J PHARMACOL, V102, P851, DOI 10.1111/j.1476-5381.1991.tb12265.x; KENNEDY C, 1985, EUR J PHARMACOL, V107, P161, DOI 10.1016/0014-2999(85)90055-X; KUROKI M, 1989, BIOCHIM BIOPHYS ACTA, V1012, P103, DOI 10.1016/0167-4889(89)90017-7; LEE HC, 1989, J BIOL CHEM, V264, P1608; MARSAULT R, 1992, J NEUROCHEM, V59, P942, DOI 10.1111/j.1471-4159.1992.tb08334.x; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; MIHARA S, 1989, FEBS LETT, V259, P79, DOI 10.1016/0014-5793(89)81499-1; NEEDHAM L, 1987, EUR J PHARMACOL, V134, P199, DOI 10.1016/0014-2999(87)90166-X; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; SAGE SO, 1986, BIOCHEM BIOPH RES CO, V136, P1124, DOI 10.1016/0006-291X(86)90450-X; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SOLTOFF SP, 1989, BIOCHEM BIOPH RES CO, V165, P1279, DOI 10.1016/0006-291X(89)92741-1; STUBBS EB, 1992, J IMMUNOL, V148, P2242; STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; VERMA A, 1990, BIOCHEM BIOPH RES CO, V172, P811, DOI 10.1016/0006-291X(90)90747-B; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; VIGNE P, 1992, BIOCHEM BIOPH RES CO, V183, P640, DOI 10.1016/0006-291X(92)90530-X; WILSON DB, 1985, J BIOL CHEM, V260, P3496; WOLF BA, 1986, J BIOL CHEM, V261, P3501	39	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8787	8792						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473322				2022-12-25	WOS:A1993KX81100062
J	KOGURE, K; SHINOHARA, Y; TERADA, H				KOGURE, K; SHINOHARA, Y; TERADA, H			EVOLUTION OF THE TYPE-II HEXOKINASE GENE BY DUPLICATION AND FUSION OF THE GLUCOKINASE GENE WITH CONSERVATION OF ITS ORGANIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; CLONED CDNA; ALPHA-FETOPROTEIN; TERMINAL HALVES; ISOZYME; ALBUMIN; CELL	The type I, II, and III isozymes of mammalian hexokinase (100 kDa) all consist of a duplicated, highly homologous peptide sequence, each half of which is very similar to that of glucokinase (type IV hexokinase, 50 kDa) and yeast hexokinase (50 kDa). We isolated a genomic clone of type II hexokinase that contained five exons encoding the C-terminal region of type II hexokinase. The positions of intron insertions of the isolated clone were found to be identical with those of the glucokinase gene, indicating that the type II hexokinase gene arose from the glucokinase gene. Furthermore, we prepared two DNA fragments of the type II hexokinase gene amplified from total genomic DNA. The exons in these fragments were found to be constructed by linkage of the coding region of the last exon and second exon of the glucokinase gene, indicating that the hexokinase gene arose by fusion of two glucokinase genes. These results clearly show that the mammalian hexokinase gene evolved from the glucokinase gene by gene duplication and fusion with conservation of the gene organization.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,SHOMACHI-1,TOKUSHIMA 770,JAPAN	Tokushima University								ANDREONE TL, 1989, J BIOL CHEM, V264, P363; GORIN MB, 1981, J BIOL CHEM, V256, P1954; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7	17	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8422	8424						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473284				2022-12-25	WOS:A1993KX81100011
J	MISHIMA, K; TSUCHIYA, M; NIGHTINGALE, MS; MOSS, J; VAUGHAN, M				MISHIMA, K; TSUCHIYA, M; NIGHTINGALE, MS; MOSS, J; VAUGHAN, M			ARD-1, A 64-KDA GUANINE NUCLEOTIDE-BINDING PROTEIN WITH A CARBOXYL-TERMINAL ADP-RIBOSYLATION FACTOR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ADENYLATE-CYCLASE; REGULATORY COMPONENT; MESSENGER-RNA; BOVINE BRAIN; GTP; EXPRESSION; ACTIVATION; MECHANISM; ACID	Clones referred to as ARD 1 were isolated from human and rat cDNA libraries. ARD 1 genes encode a putative 64-kDa protein that contains an 18-kDa ADP-ribosylation factor (ARF) domain at the carboxyl terminus and is much larger than the other monomeric approximately 20-kDa guanine nucleotide-binding ARF proteins thus far identified. ARD 1 mRNAs of 3.7 and 4.1 kilobases were detected in all rat tissues as well as in mouse and rabbit brain, human fibroblasts, and human neuroblastoma cells but not in HL-60 cells. Based on sequence identities, ARD 1 is highly conserved between rat and human. The ARF domain of ARD 1 contains the consensus sequences believed to be involved in guanine nucleotide binding, which are conserved in the ARFs and other GTP-binding proteins. Recombinant ARD 1 or the ARF domain of ARD 1, which lacks the 15 amino acids corresponding to the amino-terminal regions of ARFs stimulated, in a GTP-dependent manner, cholera toxin ADP-ribosyltransferase activity in the presence of 0.3% Tween 20. It had no effect in the presence of SDS, dimyristoylphosphatidylcholine/cholate, or cardiolipin. These observations are consistent with the conclusion that the amino-terminal region of ARF proteins is not required for activation of cholera toxin. In addition, the characteristic features of ARF proteins may be found as domains of larger mammalian proteins.			MISHIMA, K (corresponding author), NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CM, 1992, J BIOL CHEM, V267, P9028; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MISHIMA K, 1992, J BIOL CHEM, V267, P24109; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	46	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8801	8807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473324				2022-12-25	WOS:A1993KX81100064
J	YOON, JK; LAU, LF				YOON, JK; LAU, LF			TRANSCRIPTIONAL ACTIVATION OF THE INDUCIBLE NUCLEAR RECEPTOR GENE NUR77 BY NERVE GROWTH-FACTOR AND MEMBRANE DEPOLARIZATION IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; C-FOS TRANSCRIPTION; DNA-BINDING SITE; NGFI-B; INDUCTION; CAMP; SUPERFAMILY; EXPRESSION	nur77 is an immediate-early gene inducible by nerve growth factor or membrane depolarization in the rat pheochromocytoma cell line PC12 and by serum growth factors in fibroblasts. The nur77-encoded protein is a member of the steroid/thyroid hormone receptor superfamily and can act as a potent transcription activator. The induction of nur77 in PC12 cells is rapid and transient, with kinetics similar to those of the c-fos protooncogene. Induction does not require de novo protein synthesis. Whereas transcriptional activation of c-fos by nerve growth factor in PC12 cells requires a 20-base pair serum response element in its promoter, there is no such sequence in the nur77 promoter. To understand the mechanism for the activation of nur77, we have analyzed the inducibility of a series of transfected nur77 minigenes using an S1 nuclease protection assay. We identified the sequence 22-86 nucleotides upstream of the transcription start site as necessary and sufficient for nur77 induction by nerve growth factor and membrane depolarization in PC12 cells. Sequences farther upstream enhance the induction. Analysis of base substitution mutations allowed us to identify three sequence elements within this region that are essential for induction. These sequence elements include two copies of an AP1-like element and a GC-rich sequence. Unlike transcriptional activation of c-fos, the sequence requirements for the activation of nur77 by nerve growth factor and membrane depolarization cannot be readily separated. Taken together, our data suggest that activation of nur77 and c-fos by nerve growth factor occurs through different mechanisms in PC12 cells.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS IJ, 1991, MOL ENDOCRINOL, V5, P854, DOI 10.1210/mend-5-6-854; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; METZ R, 1991, ONCOGENE, V6, P2165; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Treisman R, 1990, Semin Cancer Biol, V1, P47; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	51	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9148	9155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473354				2022-12-25	WOS:A1993KX81100109
J	BRISTOL, JA; FURIE, BC; FURIE, B				BRISTOL, JA; FURIE, BC; FURIE, B			PROPEPTIDE PROCESSING DURING FACTOR-IX BIOSYNTHESIS - EFFECT OF POINT MUTATIONS ADJACENT TO THE PROPEPTIDE CLEAVAGE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLATION RECOGNITION SITE; GAMMA-CARBOXYLATION; HUMAN PROALBUMINS; MOLECULAR-BASIS; YEAST; CELLS; IDENTIFICATION; PROHORMONE; EXPRESSION; PROTEASE	Factor IX is synthesized in a precursor form with a propeptide that contains the gamma-carboxylation recognition site, an element which directs the post-translational gamma-carboxylation of adjacent glutamic acid residues. After protein synthesis, the propeptide is cleaved to yield the mature Factor IX. To study propeptide processing, anti-proFactor IX antibodies were prepared using a synthetic peptide based upon the sequence of the Factor IX propeptide. Immunoaffinity-purified anti-proFactor IX antibodies were reactive with Factor IX Cambridge, a mutant form of Factor IX containing the propeptide, but were not reactive with Factor IX. These antibodies were used to examine the proteolytic processing of forms of Factor IX containing point mutations at P6, P3, P2, P1, P1', P2', and P3' adjacent to the propeptide cleavage site in order to determine the requirement of each of these amino acids for propeptide cleavage. Furthermore, the hierarchy of different pairs of basic residues at positions P1 and P2 was analyzed. The mutated cDNA constructs were expressed in Chinese hamster ovary cells. Propeptide processing was examined using intrinsically labeled Factor IX immunoprecipitated with either anti-proFactor IX antibodies or anti-Factor IX:total antibodies, and the Factor IX species were separated by SDS-gel electrophoresis. Under the expression conditions employed, the propeptide of wild type Factor IX was almost completely removed, whereas Factor IX mutated to threonine at P1 was not cleaved. The percentage of propeptide cleaved varied with the amino acid sequences of residues P2 and P1, respectively: Lys-Arg (93%), Arg-Arg (66%), Thr-Arg (33%), Arg-Lys (19%), Lys-Lys (10%), and Lys-Thr (<1%). Apart from alterations of basic amino acids at P1 and P2, nonconservative mutations at P6 and P3 decreased propeptide cleavage, whereas conservative mutations at P3, P1', P2', or P3' resulted in cleavage efficiencies approximately equal to that for wild type Factor IX. These results indicate that the preference of paired basic residues at P1 and P2 is similar to other endopeptidases active toward proteins secreted through the constitutive pathway and that the propeptide residues NH2-terminal to these paired basic residues are important in defining enzyme-substrate binding.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; SACKLER SCH GRAD BIOMED SCI, BOSTON, MA 02111 USA	Tufts University; Tufts University	BRISTOL, JA (corresponding author), NEW ENGLAND MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NHLBI NIH HHS [HL38216, HL42433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038216, R01HL038216] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHSTETTER T, 1985, EMBO J, V4, P173, DOI 10.1002/j.1460-2075.1985.tb02333.x; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRENNAN SO, 1989, MOL BIOL MED, V6, P87; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANFORD PA, 1991, PROTEIN ENG, V4, P319; HARLOW E, 1988, ANTIBODIES LABORATOR; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBER P, 1990, J BIOL CHEM, V265, P12467; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LOH YP, 1987, ANN NY ACAD SCI, V493, P292, DOI 10.1111/j.1749-6632.1987.tb27214.x; MCCRACKEN A A, 1984, Biotechniques, V2, P82; MEULIEN P, 1990, PROTEIN ENG, V3, P629, DOI 10.1093/protein/3.7.629; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; ODA K, 1990, J BIOCHEM-TOKYO, V108, P549, DOI 10.1093/oxfordjournals.jbchem.a123240; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; RATCLIFFE JV, 1991, BLOOD, V78, pA180; REHEMTULLA A, 1992, BLOOD, V79, P2349; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WARE J, 1989, J BIOL CHEM, V264, P11401; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4935; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	52	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7577	7584						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463288				2022-12-25	WOS:A1993KV14100108
J	LING, P; ROBERTS, RM				LING, P; ROBERTS, RM			UTEROFERRIN AND INTRACELLULAR TARTRATE-RESISTANT ACID-PHOSPHATASES ARE THE PRODUCTS OF THE SAME GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; PLACENTAL IRON TRANSPORT; N-TERMINAL SEQUENCE; PIG ALLANTOIC FLUID; PORCINE UTEROFERRIN; BEEF SPLEEN; HUMAN OSTEOCLASTOMAS; PURPLE PHOSPHATASE; MOLECULAR-CLONING; BOVINE SPLEEN	Uteroferrin (Uf) is a purple acid phosphatase with a bi-iron center. It is the major secretory product of the porcine uterus under the influence of progesterone and supplies iron to the developing fetuses during pregnancy. Tartrate-resistant acid phosphatases (TRAP) are clearly similar to Uf in many of their properties but are generally located intracellularly in lysosomes. To determine whether Uf and intracellular TRAP are distinct gene products, cDNA for the TRAP from pig spleen were compared with Uf cDNA. Although no full-length cDNA for the former were isolated, a TRAP cDNA of 1.1 kilobases was identical in nucleotide sequence to a Uf cDNA (1.42 kilobases) in the region of overlap, which included the entire 3'-end of the transcript and most of the open reading frame. TRAP purified from porcine spleen also had an NH2-terminal amino acid sequence that corresponded to that of Uf purified from uterine secretions and was also similar in sequence to intracellular TRAP isolated from tissues of other species, including ones from human osteoclastomas and spleen. Finally, Southern hybridization analysis with two probes specific for exons 1 and 2 of the Uf gene strongly suggested the presence of only a single gene for acid phosphatases of this class in the pig. A similar analysis performed on human DNA with an exon-specific probe for human TRAP was also consistent with a single gene. It is concluded that the difference in trafficking between a secreted TRAP, such as Uf, and TRAP located in lysosomes is not the result of distinctive primary sequence of the polypeptides and that the variability within species ascribed to such enzymes is most likely the result of minor posttranslational changes.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021980] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21980] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN SH, 1989, J BONE MINER RES, V4, P47; ANDERSON TR, 1986, ARCH BIOCHEM BIOPHYS, V247, P131, DOI 10.1016/0003-9861(86)90541-2; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; ANTANAITIS BC, 1985, J BIOL CHEM, V260, P751; BASHA SMM, 1979, BIOL REPROD, V20, P431, DOI 10.1095/biolreprod20.3.431; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; BECK JL, 1984, BIOCHIM BIOPHYS ACTA, V791, P357, DOI 10.1016/0167-4838(84)90347-9; CAMPBELL HD, 1973, BIOCHEM BIOPH RES CO, V54, P1498, DOI 10.1016/0006-291X(73)91155-8; CHEN TT, 1975, BIOL REPROD, V13, P304, DOI 10.1095/biolreprod13.3.304; CLARK SA, 1989, J BONE MINER RES, V4, P399; COUSO R, 1986, J BIOL CHEM, V261, P6326; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; DAVIS JC, 1981, BIOCHEMISTRY-US, V20, P4062, DOI 10.1021/bi00517a018; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; DREXLER HG, 1983, BLUT, V47, P105; DUCSAY CA, 1986, J ANIM SCI, V62, P706, DOI 10.2527/jas1986.623706x; ECHETEBU ZO, 1987, CLIN CHEM, V33, P1832; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; EKRYLANDER B, 1991, J BONE MINER RES, V6, P365; HARA A, 1984, J BIOCHEM, V95, P67, DOI 10.1093/oxfordjournals.jbchem.a134603; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYMAN AR, 1991, BIOCHEM J, V277, P631, DOI 10.1042/bj2770631; HAYMAN AR, 1989, BIOCHEM J, V261, P601, DOI 10.1042/bj2610601; HUNT DF, 1987, BIOCHEM BIOPH RES CO, V144, P1154, DOI 10.1016/0006-291X(87)91432-X; KATAYAMA I, 1972, AM J PATHOL, V69, P471; KEOUGH DT, 1980, BIOCHEM BIOPH RES CO, V94, P600, DOI 10.1016/0006-291X(80)91274-7; KETCHAM CM, 1989, J BIOL CHEM, V264, P557; KETCHAM CM, 1992, J BIOL CHEM, V267, P11654; KETCHAM CM, 1985, J BIOL CHEM, V260, P5768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM KW, 1976, CLIN CHIM ACTA, V70, P289, DOI 10.1016/0009-8981(76)90431-9; LAM KW, 1990, CLIN BIOCHEM, V23, P335, DOI 10.1016/0009-9120(90)80065-Q; LANG L, 1984, J BIOL CHEM, V259, P4663; LAU KHW, 1985, J BIOL CHEM, V260, P4653; LAU KHW, 1991, INT J BIOCHEM, V23, P1237, DOI 10.1016/0020-711X(91)90222-9; LI C, 1973, J LAB CLIN MED, V82, P446; LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901; LORD DK, 1990, EUR J BIOCHEM, V189, P287, DOI 10.1111/j.1432-1033.1990.tb15488.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; NUTTLEMAN PR, 1990, J BIOL CHEM, V265, P12192; RENEGAR RH, 1982, BIOL REPROD, V27, P1247, DOI 10.1095/biolreprod27.5.1247; ROBERTS RM, 1986, FED PROC, V45, P2513; ROBERTS RM, 1988, J REPROD FERTIL, V82, P875, DOI 10.1530/jrf.0.0820875; ROBINSON DB, 1980, J BIOL CHEM, V255, P5864; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS PTK, 1985, J BIOL CHEM, V260, P3658; SCHINDELMEISER J, 1987, HISTOCHEMISTRY, V87, P13, DOI 10.1007/BF00518719; SCHLOSNAGLE DC, 1976, J BIOL CHEM, V251, P4680; SIMMEN RCM, 1988, MOL ENDOCRINOL, V2, P253, DOI 10.1210/mend-2-3-253; SIMMEN RCM, 1989, DNA-J MOLEC CELL BIO, V8, P543, DOI 10.1089/dna.1989.8.543; STEPAN JJ, 1990, BIOCHEM BIOPH RES CO, V168, P792, DOI 10.1016/0006-291X(90)92391-C; STEPAN JJ, 1989, BIOCHEM BIOPH RES CO, V165, P1027; VINCENT JB, 1991, BIOCHEMISTRY-US, V30, P3025, DOI 10.1021/bi00226a007; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P5263, DOI 10.1021/bi00138a004; WHITAKER KB, 1989, CLIN CHEM, V35, P86	61	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6896	6902						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463220				2022-12-25	WOS:A1993KV14100018
J	MORO, O; LAMEH, J; SADEE, W				MORO, O; LAMEH, J; SADEE, W			SERINE-RICH AND THREONINE-RICH DOMAIN REGULATES INTERNALIZATION OF MUSCARINIC CHOLINERGIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; NEUROBLASTOMA-CELLS; CYTOPLASMIC DOMAIN; RHODOPSIN KINASE; AMINO-ACIDS; ENDOCYTOSIS; AGONIST; DESENSITIZATION; SEQUESTRATION; FIBROBLASTS	Upon agonist exposure, most membrane receptors internalize into the cell as part of an adaptation process. Receptor domains that mediate internalization have been defined for several receptor classes, e.g. growth factor and transport receptors, but not yet for any of the numerous members of the family of G protein-coupled receptors (GPCRs), having seven putative transmembrane helices. With the use of deletion mutations, we previously showed that a small region in the middle of the third intracellular loop (i3) appears to be required for the agonist-induced internalization of the Hm1 muscarinic cholinergic receptor (Lameh, J., Philip, M., Sharma, Y. K., Moro, O., Ramachandran, J., and Sadee, W. (1992) J. Biol. Chem. 267, 13406-13412). Using point mutations, we now demonstrate that domain 286-292 (ESLTSSE) is required, with TSS playing a crucial role. Although the i3 loops of GPCRs share minimal overall sequence identity, even among closely related subtypes, small domains containing multiple S/T residues are also present in several other GPCRs, e.g. peptide, catechol, and all the muscarinic cholinergic receptor subtypes. S/T --> A mutations in analogous i3 domains also prevented receptor internalization in the case of Hm3 and attenuated internalization of Hm2. We propose that an S/T-rich domain in the i3 loop, possibly via phosphorylation reactions, regulates one pathway of GPCR internalization.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MORO, O (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.				NIGMS NIH HHS [GM 43102] Funding Source: Medline; NIMH NIH HHS [K21 MH 00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FELIPO V, 1990, J BIOL CHEM, V265, P9599; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HOOVER RK, 1990, J PHARMACOL EXP THER, V253, P185; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LAMEH J, 1990, PHARMACEUT RES, V7, P1213, DOI 10.1023/A:1015969301407; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHVARTZ I, 1987, J BIOL CHEM, V262, P17046; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; THIES RS, 1990, J BIOL CHEM, V265, P10132; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; VANTOL HHM, 1992, NATURE, V358, P119	29	109	110	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6862	6865						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463213				2022-12-25	WOS:A1993KV14100011
J	HAUN, RS; MOSS, J; VAUGHAN, M				HAUN, RS; MOSS, J; VAUGHAN, M			CHARACTERIZATION OF THE HUMAN ADP-RIBOSYLATION FACTOR-III PROMOTER - TRANSCRIPTIONAL REGULATION OF A TATA-LESS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; CHOLERA-TOXIN; MAMMALIAN-CELLS; MESSENGER-RNA; PLASMID DNA; SEQUENCE; EXPRESSION; GENE; INITIATION; ACTIVATOR	The 5'-flanking region of the human ADP-ribosylation factor 3 gene contains the features of a housekeeping gene. It lacks a TATA or CAAT box, has several GC boxes within a highly GC-rich region, and utilizes multiple transcription initiation sites. The cis-acting elements involved in regulating expression of the gene were identified by transient transfections of IMR-32 neuroblastoma cells. Reporter plasmids were modified to facilitate construction of defined promoter deletions linked to chloramphenicol acetyltransferase or luciferase using ligation-independent cloning. Transfection analyses indicated that sequences within 58 base pairs of the transcription initiation site were necessary for full expression, in particular a sequence containing the 10-base pair palindrome TCTCGCGAGA. Electrophoretic mobility shift assays performed with IMR-32 nuclear extracts demonstrated that a DNA-binding protein, termed TLTF, bound to an oligonucleotide containing this palindrome. Competition experiments showed that mutations within the core of the palindrome abolished in vitro binding and that the same protein bound to a 5'-proximal sequence. Expression of the promoter containing a mutated palindrome was reduced dramatically, consistent with the conclusion that this region functions in vivo to control expression of the ARF3 gene.			HAUN, RS (corresponding author), NHLBI,CELLULAR METAB LAB,BLDG 10,RM 5N307,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; LEE CM, 1992, J BIOL CHEM, V267, P9028; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8793	8800						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473323				2022-12-25	WOS:A1993KX81100063
J	LITOSCH, I; SULKHOLUTSKAYA, I; WENG, C				LITOSCH, I; SULKHOLUTSKAYA, I; WENG, C			G-PROTEIN-MEDIATED INHIBITION OF PHOSPHOLIPASE-C ACTIVITY IN A SOLUBILIZED MEMBRANE PREPARATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY COMPONENT; GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; ACTIVATION; ANTIBODIES	In solubilized bovine brain membrane preparations AlF4- (20 muM AlCl3 plus 10 mM NaF) and 50 nM guanosine 5-O-(2-thiotriphosphate) (GTPgammaS) promoted a rapid but transient inhibition of phospholipase C (PLC) activity. Maximal inhibition was evident within 7 min of incubation, followed by reversal of inhibition. In contrast, 10 muM GTPgammaS did not induce inhibition of PLC activity but rather produced a time-dependent stimulation of PLC activity. GTPgammaS-dependent inhibition of PLC activity was concentration-dependent with half-maximal inhibition at 1 nM. Inhibition was antagonized by guanosine 5-O-(2-thiodiphosphate (GDPbetaS). Pertussis toxin delayed the onset of inhibition by GTPgammaS but did not prevent the inhibitory effect. Alpha(o)-GTPgammaS or alpha(o)-GDP had little effect on PLC activity. Alpha(i)-GTPgammaS and alpha(i)-GDP produced a 15% inhibition of PLC activity. Betagamma subunits did not inhibit basal PLC activity but did attenuate the net degree of inhibition due to GTPgammaS. Inhibition was associated with a decrease in the Ca2+ sensitivity of PLC. Preincubation of membranes with anti-PLC-beta1 antibody, but not anti-PLC-gamma1 or anti-PLC-delta1, prevented the GTPgammaS-mediated inhibition of PLC. These studies implicate PLC-beta1 as an effector system that is under negative modulation by a G protein-dependent mechanism.			LITOSCH, I (corresponding author), UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101, USA.				NIDDK NIH HHS [DK37007] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037007] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATADA T, 1984, J BIOL CHEM, V259, P3578; KATADA T, 1979, J BIOL CHEM, V254, P469; LEE CH, 1992, J BIOL CHEM, V267, P16044; LITOSCH I, 1989, BIOCHEM J, V261, P245, DOI 10.1042/bj2610245; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH RM, 1974, CRITICAL STABILITY C, V1, P1; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150	30	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8692	8697						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473313				2022-12-25	WOS:A1993KX81100049
J	NEYA, S; FUNASAKI, N; SATO, T; IGARASHI, N; TANAKA, N				NEYA, S; FUNASAKI, N; SATO, T; IGARASHI, N; TANAKA, N			STRUCTURAL-ANALYSIS OF THE MYOGLOBIN RECONSTITUTED WITH IRON PORPHINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PROTON NMR-SPECTROSCOPY; CRYSTALLOGRAPHIC REFINEMENT; PROSTHETIC GROUP; HEME POCKET; METMYOGLOBIN; RESOLUTION; PORPHYRINS; APOMYOGLOBIN; HEMOPROTEINS	Sperm whale apomyoglobin was complexed with iron porphine to examine the influence of completely removed heme side chains on the entire molecular structure. Paramagnetic NMR peak from the proximal histidine of the deoxy protein ensured formation of the iron-histidine bond. Porphine pyrrole-proton NMR signals of the cyanmet and deoxy derivatives are unusually sharp single lines manifesting rapid heme rotation about the iron-histidine bond. X-ray crystallographic structure of the cyanmet derivative, determined with a final R factor of 0.21 for 11,808 independent reflections ranging from 7 to 1.8 angstrom, was resolved at 1.8 angstrom resolution. The result confirmed 1:1 coupling between apomyoglobin and iron porphine. The cyano ligand adopts a bent configuration with an Fe-C-N angle of 127-degrees and a Fe-CN distance of 1.89 angstrom. The overall globin structure and side chain conformations are remarkably similar to those of native myoglobin despite intensive disruption of the original heme-globin interactions. The native apoprotein structure unexpectedly conserved even after iron porphine insertion demonstrates that the complex polypeptide fold of holomyoglobin is more inherent in the amino acid sequence than is generally believed.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology	NEYA, S (corresponding author), KYOTO PHARMACEUT UNIV,DEPT PHYS CHEM,KYOTO 607,JAPAN.							ADLER AD, 1970, J INORG NUCL CHEM, V32, P2443, DOI 10.1016/0022-1902(70)80535-8; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, V21, P436, DOI 10.1126/science.178.4058.296; BRESLOW E, 1967, J BIOL CHEM, V242, P4149; BROWN KL, 1979, INORG CHIM ACTA, V37, pL153; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CHANCE B, 1966, J MOL BIOL, V17, P525, DOI 10.1016/S0022-2836(66)80162-6; CHANG CK, 1984, ARCH BIOCHEM BIOPHYS, V213, P366; CHEN BML, 1972, J AM CHEM SOC, V94, P4144, DOI 10.1021/ja00767a015; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; DEATHERAGE JF, 1976, J MOL BIOL, V106, P678; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; FALK JE, 1964, PORPHYRINS METALLOPO, P242; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; Fischer H, 1936, LIEBIGS ANN CHEM, V521, P157; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FRYDMAN L, 1989, J AM CHEM SOC, V111, P7001, DOI 10.1021/ja00200a016; GOFF H, 1977, J AM CHEM SOC, V99, P6599, DOI 10.1021/ja00462a022; GOFF H, 1980, J AM CHEM SOC, V102, P3252, DOI 10.1021/ja00529a065; Goff H. M., 1983, IRON PORPHYRINS 1, P237; HARRISON SC, 1965, J BIOL CHEM, V240, P299; HAUKSSON JB, 1990, J AM CHEM SOC, V112, P6198, DOI 10.1021/ja00173a006; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; JOHNSON RD, 1983, J AM CHEM SOC, V105, P7205, DOI 10.1021/ja00362a050; KROL S, 1959, J ORG CHEM, V24, P2064; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; LECOMTE JTJ, 1990, BIOCHEMISTRY-US, V29, P11057, DOI 10.1021/bi00502a007; LI XY, 1991, J PHYS CHEM-US, V95, P4268, DOI 10.1021/j100164a020; MOMENTEAU M, 1985, J CHEM SOC PERK T 1, P61, DOI 10.1039/p19850000061; NEYA S, 1989, BIOCHIM BIOPHYS ACTA, V996, P226, DOI 10.1016/0167-4838(89)90251-3; NEYA S, 1987, J BIOL CHEM, V262, P6725; NEYA S, 1988, BIOCHIM BIOPHYS ACTA, V952, P150, DOI 10.1016/0167-4838(88)90110-0; NEYA S, 1988, J BIOL CHEM, V263, P8810; POULOS TL, 1978, J BIOL CHEM, V253, P3730; RADZISZEWSKI JG, 1991, J PHYS CHEM-US, V95, P1963, DOI 10.1021/j100158a015; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; Rothgeb T M, 1978, Methods Enzymol, V52, P473; Sano S., 1979, PORPHYRINS, V7, P377; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SATO T, 1992, BIOCHIM BIOPHYS ACTA, V1121, P1, DOI 10.1016/0167-4838(92)90329-C; SCHEIDT WR, 1981, CHEM REV, V81, P543, DOI 10.1021/cr00046a002; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; WEISS C, 1965, J MOL SPECTROSC, V16, P415, DOI 10.1016/0022-2852(65)90132-3; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; WUTHRICH K, 1970, STRUCT BOND, V8, P53; ZHANG K, 1991, BIOCHEMISTRY-US, V30, P9116, DOI 10.1021/bi00101a030	48	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8935	8942						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473336				2022-12-25	WOS:A1993KX81100081
J	NAKAHARA, K; TANIMOTO, T; HATANO, K; USUDA, K; SHOUN, H				NAKAHARA, K; TANIMOTO, T; HATANO, K; USUDA, K; SHOUN, H			CYTOCHROME-P-450-55A1 (P-450DNIR) ACTS AS NITRIC-OXIDE REDUCTASE EMPLOYING NADH AS THE DIRECT ELECTRON-DONOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-OXYSPORUM; INDUCIBLE CYTOCHROME-P-450; PARACOCCUS-DENITRIFICANS; FUNGUS; PURIFICATION; CDNA; SEQUENCE; CLONING	Cytochrome P-450dNIR (P-450dNIR), involved in the fungal denitrification by Fusarium oxysporum, was purified to homogeneity. The cytochrome P-450 (P-450) exhibited a potent nitric oxide (NO) reductase activity to form nitrous oxide (N2O) employing NADH but not NADPH as the sole effective electron donor. The apparent maximum turnover rate against NO was estimated as high as 31,500 min-1. The stoichiometry of the reaction between NO:NADH:N2O was 2:1:1. The reaction required neither an artificial electron-carrying mediator nor other proteinaceous components. An anaerobic incubation of ferric P-450dNIR.NO complex, but not of free ferric P-450dNIR, resulted in rapid reduction of the P-450, indicating that P-450dNIR.NO complex was reduced directly by NADH. Spectral changes during catalytic turnover indicated that decomposition of the ferrous P-450.NO complex might be rate-limiting. The reaction was not inhibited by carbon monoxide at all, suggesting that the free ferrous P-450 is not formed during turnover. On the basis of these results a possible reaction mechanism was considered. The present results demonstrated not only the unique reaction catalyzed by P-450, but also the first P-450-dependent reaction where the electron transport from NAD(P)H to P-450 is not supported by other components. Now that the physiological function of P-450 55A1 (P-450dNIR) has been found, we propose to alter the trivial name to P-450nor.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba				Nakahara, Kazuhiko/0000-0002-7313-6879				CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; Dean, 1985, LANGES HDB CHEM, P3; DERMASTIA M, 1991, J BIOL CHEM, V266, P10899; FANG GH, 1986, NUCLEIC ACIDS RES, V14, P8061, DOI 10.1093/nar/14.20.8061; FERGUSON SJ, 1987, TRENDS BIOCHEM SCI, V12, P354, DOI 10.1016/0968-0004(87)90164-2; GOTOH O, 1993, IN PRESS CYTOCHROME; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; ISHIHARA S, 1990, J BIOCHEM-TOKYO, V108, P899, DOI 10.1093/oxfordjournals.jbchem.a123310; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; OMURA T, 1964, J BIOL CHEM, V239, P2370; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; SATO R, 1978, CYTOCHROME P450, P23; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1989, AGR BIOL CHEM TOKYO, V53, P2153, DOI 10.1080/00021369.1989.10869624; SHOUN H, 1991, J BIOL CHEM, V266, P11078; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; TANIMOTO T, 1992, BIOSCI BIOTECH BIOCH, V56, P2058, DOI 10.1271/bbb.56.2058; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	25	236	244	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8350	8355						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463342				2022-12-25	WOS:A1993KW97900109
J	ORTI, E; HU, LM; MUNCK, A				ORTI, E; HU, LM; MUNCK, A			KINETICS OF GLUCOCORTICOID RECEPTOR PHOSPHORYLATION IN INTACT-CELLS - EVIDENCE FOR HORMONE-INDUCED HYPERPHOSPHORYLATION AFTER ACTIVATION AND RECYCLING OF HYPERPHOSPHORYLATED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; RAT-LIVER; COMPLEXES; MODEL	Glucocorticoid receptors are basally phosphorylated in the absence of hormone and become hyperphosphorylated after hormone treatment of intact cells. To determine the Sequence of changes which the receptor undergoes following hormone binding, we analyzed the kinetics of receptor phosphorylation in WEHI-7 mouse thymoma cells and in stably transfected Chinese hamster ovary cells that overexpress the mouse receptor. No major differences were found between these two cell types. Cells were preincubated with P-32(i) and [S-35] methionine to label the receptors metabolically. The phosphate content of the receptor protein was determined from the ratio of P-32 to S-35 in radioactive gel slices after immunopurification and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Hormone-induced increases in phosphorylation were seen as early as 5 min after adding hormone and persisted for 20 h. Analysis of newly formed cytosolic and nuclear-bound activated (DNA-binding) receptors showed that activation precedes hyperphosphorylation. Nonactivated receptors, both unliganded and hormone-liganded, also became hyperphosphorylated but more slowly than activated receptors. The rate of receptor dephosphorylation, determined by chasing with unlabeled P(i), was much slower than the rate of phosphorylation or of hormone dissociation and appeared to be slightly increased by agonists and by the antagonist RU486 (which does not cause hyperphosphorylation). Mutant WEHI-7 cells lacking cAMP-dependent protein kinase activity gave basal and hormone-induced receptor phosphorylation indistinguishable from wild type cells. We conclude that (a) the substrate for hormone-dependent hyperphosphorylation is the activated hormone-receptor complex; (b) most hyperphosphorylated receptors are recycled and reutilized in hyperphosphorylated form; (c) control of receptor phosphorylation may not be cell-specific; (d) cAMP-dependent protein kinase is not involved directly or indirectly in phosphorylating major sites on the receptor in vivo.	DARTMOUTH COLL, HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHYSIOL, 1 MED CTR DR, HANOVER, NH 03756 USA	Dartmouth College					FIC NIH HHS [1F05 TW03923-01] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline; NIDDK NIH HHS [DK03535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003535] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GOVINDAN MV, 1980, EUR J BIOCHEM, V108, P47, DOI 10.1111/j.1432-1033.1980.tb04694.x; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; MENDEL DB, 1990, PROG CLIN BIOL RES, V322, P97; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MENDEL DB, 1987, J BIOL CHEM, V262, P5644; MUNCK A, 1984, J BIOL CHEM, V259, P820; ORTI E, 1989, J BIOL CHEM, V264, P231; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; ORTI E, 1989, J BIOL CHEM, V264, P9728; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; REXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067	20	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7779	7784						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463306				2022-12-25	WOS:A1993KW97900033
J	BUTTICE, G; KURKINEN, M				BUTTICE, G; KURKINEN, M			A POLYOMAVIRUS ENHANCER A-BINDING PROTEIN-3 SITE AND ETS-2 PROTEIN HAVE A MAJOR ROLE IN THE 12-O-TETRADECANOYLPHORBOL-13-ACETATE RESPONSE OF THE HUMAN STROMELYSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHORBOL-ESTER; C-FOS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATION; COLLAGENASE GENE; BASAL EXPRESSION; KINASE-C; INDUCTION	The expression of stromelysin, a major matrix metalloproteinase of connective tissues, is regulated by several cytokines, growth factors, protooncogenes as well as by 12-O-tetradecanoylphorbol-13-acetate (TPA). The human stromelysin gene promoter contains an activator protein-1 (Fos/Jun) binding site at -70, which is required for basal expression but is not necessary for the TPA response. In this study, using promoter deletion mutants in transient gene transfection experiments, we first identify the sequence from -220 to -202 as necessary for the TPA response of the stromelysin gene. Further, among the restriction fragments from the 1.3-kilobase long promoter, only the proximal fragment (-274 to -101) conferred a TPA response on the heterologous thymidine kinase gene promoter. The -220 to -202 sequence contains two copies of a motif similar to the polyomavirus enhancer A-binding protein-3 (PEA-3) site, which binds the Ets family of oncoproteins and transcription factors. Point mutations of either one of the two PEA-3 sites, in the 1.3-kilobase long stromelysin promoter context, reduced basal gene expression. However, only the mutation of the proximal, but not the distal PEA-3 site, significantly inhibited the TPA response. In cotransfection experiments, the Ets-2 protein transactivated the stromelysin promoter and the promoter proximal fragment containing the PEA-3 sites but not the promoters containing mutated PEA-3 sites. These data suggest that the PEA-3 site, but not the activator protein-1 site, and Ets-2 protein have a major role in the TPA induction of the human stromelysin gene transcription.			BUTTICE, G (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854, USA.			Buttice', Giovanna/0000-0001-6550-5585	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24442] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ALITALO R, 1990, BLOOD, V75, P1974; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Blasi F, 1990, Semin Cancer Biol, V1, P117; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRINCKERHOFF CE, 1990, J BIOL CHEM, V265, P22262; BRUGGE J, 1991, ORIGINS HUMAN CANCER; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO HN, 1991, ONCOGENE, V6, P705; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOI JK, 1991, MOL CELL BIOL, V11, P4473, DOI 10.1128/MCB.11.9.4473; COUSIN E, 1991, NUCLEIC ACIDS RES, V19, P3881, DOI 10.1093/nar/19.14.3881; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GARDNER DP, 1990, FEBS LETT, V269, P288, DOI 10.1016/0014-5793(90)81178-Q; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKUDA A, 1989, J BIOL CHEM, V264, P16919; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; QUINONES S, 1989, J BIOL CHEM, V264, P8339; ROCHFORD R, 1990, MOL CELL BIOL, V10, P4996, DOI 10.1128/MCB.10.9.4996; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATO H, 1992, ONCOGENE, V7, P77; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; TREISMAN R, 1990, CANCER BIOL, V1, P47; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; VENKITARAMAN AR, 1989, NUCLEIC ACIDS RES, V17, P3314, DOI 10.1093/nar/17.8.3314; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991	70	121	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7196	7204						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463255				2022-12-25	WOS:A1993KV14100058
J	DOUGHERTY, BA; VANDERIJN, I				DOUGHERTY, BA; VANDERIJN, I			MOLECULAR CHARACTERIZATION OF HASB FROM AN OPERON REQUIRED FOR HYALURONIC-ACID SYNTHESIS IN GROUP-A STREPTOCOCCI - DEMONSTRATION OF UDP-GLUCOSE DEHYDROGENASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT CAPSULAR POLYSACCHARIDES; GROUP-B STREPTOCOCCUS; PSEUDOMONAS-AERUGINOSA; COMMON ORGANIZATION; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; VIRULENCE; SEQUENCE; PROTEINS; GENE	The membrane-associated hyaluronate synthase produces capsular hyaluronate in group A streptococci by the alternate addition of UDP-N-acetylglucosamine and UDP-glucuronic acid. Previous studies identified a locus required for hyaluronate synthase activity and suggested that a gene involved in the production of UDP-glucuronic acid (UDP-glucose dehydrogenase) also mapped to the locus. In the present study the putative UDP-glucose dehydrogenase gene (hasB) was cloned and the DNA sequence determined. The hasB gene product was shown to have global similarity with AlgD, a dehydrogenase, which catalyzes the production of GDP-mannuronic acid for the alginate capsule of Pseudomonas aeruginosa. Regions of local homology have been identified which apparently correspond to the NAD-binding and enzyme active sites of HasB and AlgD. In order to show that hasB expression correlated with UDP-glucose dehydrogenase activity, the hasB gene was cloned under control of the T7 promoter. Hyperexpression of hasB resulted in a protein of approximately 47 kDa and high levels of UDP-glucose dehydrogenase activity were observed. These data demonstrate that hasB encodes the UDP-glucose dehydrogenase of group A streptococci.	WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [T32-AI-07401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBUS A, 1991, INFECT IMMUN, V59, P1008, DOI 10.1128/IAI.59.3.1008-1014.1991; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLEWELL DB, 1986, ANNU REV MICROBIOL, V40, P635, DOI 10.1146/annurev.mi.40.100186.003223; DERETIC V, 1991, MOL MICROBIOL, V5, P1577, DOI 10.1111/j.1365-2958.1991.tb01903.x; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; FEINGOLD DS, 1981, TRENDS BIOCHEM SCI, V6, P103, DOI 10.1016/0968-0004(81)90038-4; FRANZEN B, 1981, BIOCHEM J, V199, P599, DOI 10.1042/bj1990599; FROSCH M, 1991, MOL MICROBIOL, V5, P1251, DOI 10.1111/j.1365-2958.1991.tb01899.x; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; KROLL JS, 1989, J BACTERIOL, V171, P3343, DOI 10.1128/jb.171.6.3343-3347.1989; KUYPERS JM, 1989, INFECT IMMUN, V57, P3058, DOI 10.1128/IAI.57.10.3058-3065.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MARKOVITZ A, 1977, SURFACE CARBOHYDRATE, P415; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUBENS CE, 1987, P NATL ACAD SCI USA, V84, P7208, DOI 10.1073/pnas.84.20.7208; SCHILLER JG, 1976, BIOCHIM BIOPHYS ACTA, V453, P418, DOI 10.1016/0005-2795(76)90137-9; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; SCOTT JR, 1992, J BACTERIOL, V174, P6005, DOI 10.1128/JB.174.19.6005-6010.1992; SILVER RP, 1984, J BACTERIOL, V157, P568, DOI 10.1128/JB.157.2.568-575.1984; SMITH EE, 1961, J BIOL CHEM, V236, P2179; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU, 1959, AUSTRIAN R, V110, P585; WATSON DA, 1990, INFECT IMMUN, V58, P3135, DOI 10.1128/IAI.58.9.3135-3138.1990; WECKBECKER G, 1983, ANAL BIOCHEM, V132, P405, DOI 10.1016/0003-2697(83)90027-1; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	36	109	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7118	7124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463246				2022-12-25	WOS:A1993KV14100047
J	HAUN, RS; TSAI, SC; ADAMIK, R; MOSS, J; VAUGHAN, M				HAUN, RS; TSAI, SC; ADAMIK, R; MOSS, J; VAUGHAN, M			EFFECT OF MYRISTOYLATION ON GTP-DEPENDENT BINDING OF ADP-RIBOSYLATION FACTOR TO GOLGI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; CHOLERA-TOXIN; NUCLEOTIDE-BINDING; MEMBRANE ATTACHMENT; ADENYLATE-CYCLASE; BOVINE BRAIN; EXPRESSION; TRANSPORT; ACTIVATOR; VESICLES	ADP-ribosylation factors (ARFs), a family of approximately 20-kDa guanine nucleotide-binding proteins that activate cholera toxin ADP-ribosyltransferase in vitro, have been implicated in intracellular protein trafficking and are thought to cycle between cytosolic and membrane compartments. Although isolated predominantly as soluble proteins, ARFs associate with membranes and phospholipids in a GTP-dependent manner. In contrast to other small GTP-binding proteins, ARFs are NH2 terminally myristoylated. Using a bacterial expression system, recombinant myristoylated and non-myristoylated human ARF5 were produced to investigate the role of myristoylation in its association with Golgi. The recombinant ARFs (myristoylated and non-myristoylated) exhibited similar biochemical activity as measured by GTP binding and in vitro activation of cholera toxin. Myristoylated ARF5, however, demonstrated a temperature- and GTP-dependent association with Golgi membranes, whereas non-myristoylated ARF did not bind to Golgi under any of the experimental conditions. These data indicate that myristoylation is necessary, although not sufficient, for membrane attachment, but is not necessary for activation of cholera toxin.			HAUN, RS (corresponding author), NHLBI, CELLULAR METAB LAB, BLDG 10, RM 5N307, BETHESDA, MD 20892 USA.							BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Fleischer B, 1974, Methods Enzymol, V31, P180; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HAUN RS, 1992, GENE, V112, P37, DOI 10.1016/0378-1119(92)90300-E; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUNZ BC, 1990, FASEB J, V4, pA2077; LEE CM, 1992, J BIOL CHEM, V267, P9028; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SERVENTI IM, 1993, IN PRESS J BIOL CHEM; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SIMONDS WF, 1989, BIOCHEM BIOPH RES CO, V164, P46, DOI 10.1016/0006-291X(89)91680-X; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	43	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7064	7068						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463239				2022-12-25	WOS:A1993KV14100039
J	FURLOW, JD; MURDOCH, FE; GORSKI, J				FURLOW, JD; MURDOCH, FE; GORSKI, J			HIGH-AFFINITY BINDING OF THE ESTROGEN-RECEPTOR TO A DNA RESPONSE ELEMENT DOES NOT REQUIRE HOMODIMER FORMATION OR ESTROGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; TRANSCRIPTIONAL REGULATION; GLUCOCORTICOID RECEPTOR; LIGAND-BINDING; UTERINE CELLS; RAT UTERUS; DIMERIZATION; ANTIESTROGEN; COMPLEXES; GENE	We have developed an antibody-based DNA binding assay to study the effects of the absence or presence of an estrogen receptor agonist and two antagonists on the thermodynamic binding parameters for estrogen receptor binding to a consensus estrogen response element in vitro. We first demonstrate that antibodies raised against a region of the estrogen receptor directly adjacent to the DNA-binding domain do not interfere with the receptor's ability to preferentially bind to the vitellogenin estrogen response element in plasmid DNA. Exploiting this property to develop a quantitative DNA binding assay, we demonstrate that estrogen is not required for high affinity binding of the receptor for an oligonucleotide containing this element, nor do antiestrogens alter this interaction. In addition, we find that 1 mol of estrogen receptor is complexed with high affinity to 1 mol of vitellogenin estrogen response element, instead of two estrogen receptors/response element as would be predicted if estrogen receptor homodimer formation was required for high affinity DNA binding. Our data best fit a model in which the active estrogen receptor form is a monomer or heterodimer, but not a homodimer, and the regulatory role of estrogen on the estrogen receptor is the induction of protein-protein, but not protein-DNA, interactions.	UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				MURDOCH, FERN/0000-0001-5724-9681	NCI NIH HHS [CA18110] Funding Source: Medline; NICHD NIH HHS [HD08192, HD07259] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD008192, R01HD008192, T32HD007259] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA018110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY A, 1980, J BIOL CHEM, V255, P2729; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK JH, 1978, J BIOL CHEM, V253, P7630; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DARWISH H, 1991, J BIOL CHEM, V266, P551; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GORSKI J, 1976, ANNU REV PHYSIOL, V38, P425, DOI 10.1146/annurev.ph.38.030176.002233; GRODY WW, 1982, ENDOCR REV, V3, P141, DOI 10.1210/edrv-3-2-141; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HANSEN JC, 1986, J BIOL CHEM, V261, P13990; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLER MA, 1985, ENDOCRINOLOGY, V117, P515, DOI 10.1210/endo-117-2-515; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURDOCH FE, 1991, BIOCHEMISTRY-US, V30, P10838, DOI 10.1021/bi00109a005; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; MURDOCH FE, 1992, 74TH ANN M END SOC S, P114; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; PEALE FV, 1988, P NATL ACAD SCI USA, V85, P1038, DOI 10.1073/pnas.85.4.1038; REESE JC, 1992, NUCLEIC ACIDS RES, V19, P6505; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SAKAI D, 1984, BIOCHEMISTRY-US, V23, P3541, DOI 10.1021/bi00310a024; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WALENT JH, 1990, ENDOCRINOLOGY, V126, P2383, DOI 10.1210/endo-126-5-2383; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WILLIAMS D, 1972, P NATL ACAD SCI USA, V69, P3464, DOI 10.1073/pnas.69.11.3464	47	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12519	12525						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509392				2022-12-25	WOS:A1993LG65800045
J	HUGGINS, TG; WELLSKNECHT, MC; DETORIE, NA; BAYNES, JW; THORPE, SR				HUGGINS, TG; WELLSKNECHT, MC; DETORIE, NA; BAYNES, JW; THORPE, SR			FORMATION OF O-TYROSINE AND DITYROSINE IN PROTEINS DURING RADIOLYTIC AND METAL-CATALYZED OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-TRYPTOPHAN FLUORESCENCE; OXYGEN RADICALS; AMINO-ACIDS; HUMAN LENS; DEGRADATION; IDENTIFICATION; CONSEQUENCES; BITYROSINE; TURNOVER; DAMAGE	To evaluate their usefulness as chemical indicators of cumulative oxidative damage to proteins, we studied the kinetics and extent of formation of ortho-tyrosine (o-Tyr), dityrosine (DT), and dityrosine-like fluorescence (E(x) = 317 nm, E(m) = 407 nm) in the model proteins RNase and lysozyme exposed to radiolytic and metal-catalyzed (H2O2/Cu2+) oxidation (MCO). Although there were protein-dependent differences, o-Tyr, DT, and fluorescence increased coordinately during oxidation of the proteins in both oxidation systems. The contribution of DT to total dityrosine-like fluorescence in oxidized proteins varied from 2-100%, depending on the protein, type of oxidation, and extent of oxidative damage. In proteins exposed to MCO, DT typically accounted for >50% of the fluorescence at DT wavelengths. These studies indicate that o-Tyr and DT should be useful chemical markers of cumulative exposure of proteins to MCO in vitro and in vivo.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; RICHLAND MEM HOSP,DEPT MED PHYS,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019971, R01DK025373, R01DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19971, DK-25373] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AESCHBACH R, 1976, BIOCHIM BIOPHYS ACTA, V439, P292, DOI 10.1016/0005-2795(76)90064-7; AHMED MU, 1986, J BIOL CHEM, V261, P4889; AUGUSTEYN RC, 1981, MECHANISMS CATARACT, P71; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOGUTA G, 1983, INT J RADIAT BIOL, V43, P249, DOI 10.1080/09553008314550301; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; DAUGHERTY A, 1991, ROLE OXIDATION PATHO; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DIZDAROGLU M, 1983, INT J RADIAT BIOL, V2, P185; Fricke H., 1966, RADIATION DOSIMETRY, V2, P167; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GARCIACASTINEIRAS S, 1978, EXP EYE RES, V26, P461, DOI 10.1016/0014-4835(78)90132-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAYAISHI O, 1989, MED BIOCH CHEM ASPEC; HUNT JV, 1991, FREE RADICAL RES COM, V12-3, P115, DOI 10.3109/10715769109145775; KAREM L, 1990, J BIOL CHEM, V265, P11581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; SPADARO AC, 1979, ANAL BIOCHEM, V96, P317, DOI 10.1016/0003-2697(79)90587-6; SPECTOR A, 1975, EXP EYE RES, V21, P9, DOI 10.1016/0014-4835(75)90053-6; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; USHIJIMA Y, 1984, BIOCHEM BIOPH RES CO, V125, P916, DOI 10.1016/0006-291X(84)91370-6; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348	27	201	205	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12341	12347						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509373				2022-12-25	WOS:A1993LG65800021
J	VADLAMUDI, RK; JI, TH; BULLA, LA				VADLAMUDI, RK; JI, TH; BULLA, LA			A SPECIFIC BINDING-PROTEIN FROM MANDUCA-SEXTA FOR THE INSECTICIDAL TOXIN OF BACILLUS-THURINGIENSIS SUBSP BERLINER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BUTTERFLY PIERIS-BRASSICAE; DELTA-ENDOTOXINS; ENTOMOCIDAL PROTOXIN; CRYSTAL PROTEINS; HIGH-AFFINITY; IDENTIFICATION; MIDGUT; VESICLES; SEQUENCE	Biopesticides based on the bacterium Bacillus thuringiensis have attracted wide attention as safe alternatives to chemical pesticides. In this paper, we report, for the first time, the identification and purification of a single binding protein from a lepidopteran insect, Manduca sexta, that is specific for a cryIA toxin of B. thuringiensis. The purified protein appeared as a single band of 210 kDa on a two-dimensional gel, had a pI of approximately 5.5, and stained with Schiff's reagent. The band material was sensitive to proteolytic digestion and was rich with acidic amino acids, indicating its protein nature. Radiolabeled toxin bound to the protein with a K(d) value of 708 pm and could be specifically blocked by unlabeled toxin but not by toxins from other subspecies of B. thuringiensis. This study lays the groundwork to clone the toxin binding protein and to determine the molecular mechanism(s) of toxin action.	UNIV WYOMING, DEPT MOLEC BIOL, POB 3944, LARAMIE, WY 82071 USA	University of Wyoming				Bulla, Lee/0000-0003-1789-7021				ARONSON AI, 1986, MICROBIOL REV, V50, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLA LA, 1981, J BIOL CHEM, V256, P3000; BULLA LA, 1977, J BACTERIOL, V130, P375, DOI 10.1128/JB.130.1.375-383.1977; CHILCOTT CN, 1988, J GEN MICROBIOL, V134, P2551; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HURLEY JM, 1987, APPL ENVIRON MICROB, V126, P961; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SG, 1985, BIOCHEM BIOPH RES CO, V126, P953, DOI 10.1016/0006-291X(85)90278-5; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LILLEY M, 1980, J GEN MICROBIOL, V118, P1; LUTHY P, 1984, PATHOGENESIS INVERTE, P223; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCPHERSON SA, 1988, BIO-TECHNOL, V6, P61, DOI 10.1038/nbt0188-61; ODDOU P, 1991, EUR J BIOCHEM, V202, P673, DOI 10.1111/j.1432-1033.1991.tb16422.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TYRELL DJ, 1981, J BACTERIOL, V145, P1052, DOI 10.1128/JB.145.2.1052-1062.1981; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WABIKO H, 1985, APPL ENVIRON MICROB, V49, P706, DOI 10.1128/AEM.49.3.706-708.1985; WABIKO H, 1986, DNA-J MOLEC CELL BIO, V5, P305, DOI 10.1089/dna.1986.5.305; WADA HG, 1979, J BIOL CHEM, V254, P2629; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3	32	154	178	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12334	12340						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509372				2022-12-25	WOS:A1993LG65800020
J	AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M				AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M			THE HEPATITIS-B VIRUS (HBV) PX TRANSACTIVATES THE C-FOS PROMOTER THROUGH MULTIPLE CIS-ACTING ELEMENTS	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; X-GENE PRODUCT; EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; ENHANCER ELEMENT; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; TRANSCRIPTIONAL ACTIVATION; MEDIATE INDUCTION; TRANSGENIC MICE	The hepatitis B virus (HBV) X protein (pX) stimulates transcription regulated by cis-acting elements that control many viral and cellular genes, including the c-myc and the c-fos proto-oncogenes. Using several c-fos promoter deletion mutants, we found the serum-responsive element (SRE) located at -315, the modified TPA-responsive element located at -296 (fos-AP-1 binding site, FAP) and the region spanning from nucleotide -220 to -120, which contains an NF1-like site and several stretches of sequence homologous to the AP-2 consensus binding sites, to be responsive to pX. pX does not modify the pattern of the retarded complexes bound to the SRE/FAP region which, in our system, appears to be occupied by SRE-binding factors. The activation of the SRE does not involve complex formation between SRE-binding factors and pX, it is not associated with an increase in serum response factor binding to the SRE and it does not determine changes in SRE mobility-shift pattern.	POLICLIN UMBERTO L,MED CLIN 1,I-00161 ROME,ITALY; POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome			Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BALSANO C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P572; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUSCHER M, 1988, ONCOGENE, V3, P301; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Curran T, 1988, ONCOGENE HDB, P307; DEJAN A, 1986, NATURE, V322, P70; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P2083; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KONIG H, 1989, EMBO J, V8, P2259; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILSTON T, NATURE, V336, P396; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	69	69	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502480				2022-12-25	WOS:A1993LE06400020
J	HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK				HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK			THE CONSISTENT 13Q14 TRANSLOCATION BREAKPOINT SEEN IN CHRONIC B-CELL LEUKEMIA (BCLL) INVOLVES DELETION OF THE D13S25 LOCUS WHICH LIES DISTAL TO THE RETINOBLASTOMA PREDISPOSITION GENE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DEFINITION; CHROMOSOME-13; ABNORMALITIES; HYBRID	Structural rearrangements involving chromosome 13 are frequently seen in B-cell chronic lymphocytic leukaemia. The presence of reciprocal translocations involving 13q14 in 10-15% of cases pinpoints the location of a gene important in leukaemogenesis. In order to characterise the exact location of the 13q14 breakpoint, somatic cell hybrids were constructed between mouse 3T3 cells and leukaemic cells from 5 patients with translocations involving chromosome 13. Hybrid pairs were isolated which carried either of the two derivative chromosomes carrying subsections of 13 and the position of the breakpoint investigated using a series of probes along the length of the chromosome. In all cases the translocation breakpoint lay distal to the 13q14.1 breakpoint region associated with rhabdomyosarcoma tumours and proximal to the D13S31 locus which lies in 13q14.3. In three translocations the RB1 gene was deleted as a result of the translocation but in at least one other case the BCLL breakpoint did not involve the RB1 gene, which consistently cosegregated in hybrids carrying other proximal markers. The D13S25 probe, which lies between RB1 and D13S31, however, was deleted in the translocation retaining RB1. It appears therefore that deletion of a gene(s) in this 2Mbp region is a critical event in some cases of BCLL tumorigenesis.	INST CHILD HLTH,ONCOL GRP,ICRF,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,ENGLAND	University of London; University College London				Hawthorn, Lesleyann/0000-0001-8179-0937; Cowell, John/0000-0002-2079-5950				ABBOTT C, 1991, GENOMICS, V9, P73, DOI 10.1016/0888-7543(91)90222-Z; BOWCOCK AM, 1991, GENOMICS, V11, P517, DOI 10.1016/0888-7543(91)90058-M; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; COWELL JK, 1987, BRIT J CANCER, V55, P661, DOI 10.1038/bjc.1987.135; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1992, ANN ONCOL, V3, P693, DOI 10.1093/oxfordjournals.annonc.a058319; COWELL JK, 1992, HUMAN CYTOGENETICS P, P202; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; HOGG A, 1992, ONCOGENE, V7, P1444; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LUI Y, 1992, GENES CHROMS CANCER, V45, P250; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; MITCHELL CD, 1991, ONCOGENE, V6, P89; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORRIS CM, 1991, GENE CHROMOSOME CANC, V3, P455, DOI 10.1002/gcc.2870030607; NICHOLS J, 1992, BLOOD, V80, P2953; OSCIER D, 1990, BLOOD, V76, P241; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; Sambrook J, 1989, COLD SPRING HARBOR L, V3	21	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1415	1419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502470				2022-12-25	WOS:A1993LE06400003
J	STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D				STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D			ABSENCE OF A PAUSED TRANSCRIPTION COMPLEX FROM THE C-MYC P2-PROMOTER OF THE TRANSLOCATION CHROMOSOME IN BURKITTS-LYMPHOMA CELLS - IMPLICATION FOR THE C-MYC P1/P2 PROMOTER SHIFT	ONCOGENE			English	Article							RNA-POLYMERASE-II; EPSTEIN-BARR-VIRUS; 1ST EXON; B-CELL; STRUCTURAL ALTERATIONS; VARIANT TRANSLOCATION; CHROMATIN STRUCTURE; SOMATIC MUTATION; HL60 CELLS; GENE	We have shown recently that pausing of RNA polymerase II (pol II) at the transcription start site regulates expression from the P2 promoter of the proto-oncogene c-myc. RNAs initiated at the P2 promoter usually contribute > 80% to steady-state c-myc RNA levels in normal cells. In Burkitt's lymphoma (BL) cells c-myc is chromosomally translocated to an immunoglobulin (1g) gene and preferentially transcribed from the upstream P1 promoter. We have studied the activity of c-myc promoters in two BL cell lines with high expression of P1 RNA. Kinetic nuclear run-on experiments show that the initiation rate at the c-myc P1 promoter in BL2 and BL60 cells is not increased compared with control BJAB cells, whereas the number of paused polymerases at the P2 promoter is greatly diminished. The translocation c-myc gene of BL60 cells was cloned and stably transfected into the BL cell line Raji. The transfected c-myc gene regained the ability to form a paused transcription complex at the c-myc P2 promoter. The data suggest that a paused polymerase at the c-myc P2 promoter impedes transcription from the upstream P1 promoter on a normal c-myc gene. The c-myc gene on the translocation chromosome in BL cells has lost the ability to retain pol II at the P2 promoter, probably by interaction with elements of the adjacent Ig gene locus.	FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOLEK BIOL & TUMORGENET, MARCHIONINISTR 25, D-81377 MUNICH, GERMANY				Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ALLEN RW, 1987, J BIOL CHEM, V262, P649; APEL TW, 1992, ONCOGENE, V7, P1267; ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1990, ONCOGENE, V5, P1397; FLORES O, 1989, J BIOL CHEM, V264, P8913; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HOROWITZ H, 1982, NUCLEIC ACIDS RES, V10, P5447, DOI 10.1093/nar/10.18.5447; JOOS S, 1992, HUM MOL GENET, V1, P625, DOI 10.1093/hmg/1.8.625; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOHLHUBER F, 1993, IN PRESS ONCOGENE; KRUGER W, 1987, J MOL BIOL, V195, P31, DOI 10.1016/0022-2836(87)90325-1; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACY J, 1987, P NATL ACAD SCI USA, V84, P5838, DOI 10.1073/pnas.84.16.5838; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Lenoir G M, 1985, IARC Sci Publ, P309; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NISHIKURA K, 1985, P NATL ACAD SCI USA, V82, P2900, DOI 10.1073/pnas.82.9.2900; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PLET A, 1992, ONCOGENE, V7, P1847; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZEIDLER R, 1992, THESIS L MAXIMILIANS; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	82	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1437	1447						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502472				2022-12-25	WOS:A1993LE06400006
J	BROWNBRIDGE, GG; LOWE, PN; MOORE, KJM; SKINNER, RH; WEBB, MR				BROWNBRIDGE, GG; LOWE, PN; MOORE, KJM; SKINNER, RH; WEBB, MR			INTERACTION OF GTPASE-ACTIVATING PROTEINS (GAPS) WITH P21(RAS) MEASURED BY A NOVEL FLUORESCENCE ANISOTROPY METHOD - ESSENTIAL ROLE OF ARG-903 OF GAP IN ACTIVATION OF GTP HYDROLYSIS ON P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; GENE-PRODUCT; NEUROFIBROMATOSIS GENE; MECHANISM; DOMAIN; NUCLEOTIDES; MUTANTS; CLONING; SITE	Ras GTPase activating proteins (GAPs) contain an invariant motif, -FLR-, within the most conserved region of their catalytic domains. Certain mutations in this motif have greatly reduced activity (Skinner, R. H., Bradley, S., Brown, A. L., Johnson, N. J., Rhodes, S., Stammers, D. K., and Lowe, P. N. (1991) J. Biol. Chem. 266, 14163-14166), but it was not determined whether the reduced activity was due to loss of binding or impaired catalysis. In order to address this question, we have developed a simple physical method to study formation of GAP.p21ras complexes. This utilizes the increase of fluorescence anisotropy upon binding of GAP to p21ras complexed with 2'(3')-O-(N-methylanthraniloyl) (mant) derivatives of guanine nucleotides. Dissociation constants obtained for the catalytic domains of either p120-GAP (GAP-344) or neurofibromin (NF1-GRD) with normal and Leu-61 p21ras proteins are comparable with those obtained by kinetic methods. In the course of these studies, we found, in contrast to previous observations, that both GAP and NF1-GRD can weakly activate the GTPase of Leu-61 mutant p21, showing that Gln-61 is not absolutely required for the stimulation of GTPase activity by GAPs. The fluorescence anisotropy method allowed us to show that mutation of Arg-903, within the FLR motif of GAP, can result in protein defective in catalysis but not in binding to p21ras. These data suggest a direct role for this residue in catalyzing GTP hydrolysis on p21ras, possibly by contributing a catalytic group to the p21 active site. This method is independent of the catalytic activity of the proteins, and so it could be extended generally to the measurement of binding of effector molecules, exchange factors, or other macromolecules to guanine nucleotide-binding proteins.	NATL INST MED RES,DIV PHYS BIOCHEM,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	MRC National Institute for Medical Research; GlaxoSmithKline; Wellcome Research Laboratories				Webb, Martin/0000-0002-0134-9621				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; ECCLESTON JF, 1989, NATO ADV SCI I A-LIF, V165, P87; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HAZLETT TL, 1990, BIOPHYS J, V57, pA289; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JAMESON DM, 1984, FLUORESCEIN HAPTEN I, P23; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MOORE KJM, 1992, PHILOS T ROY SOC B, V336, P49, DOI 10.1098/rstb.1992.0043; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; REENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	37	78	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10914	10919						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496156				2022-12-25	WOS:A1993LD46600033
J	ZIEGLER, MM; GOLDBERG, ME; CHAFFOTTE, AF; BALDWIN, TO				ZIEGLER, MM; GOLDBERG, ME; CHAFFOTTE, AF; BALDWIN, TO			REFOLDING OF LUCIFERASE SUBUNITS FROM UREA AND ASSEMBLY OF THE ACTIVE HETERODIMER - EVIDENCE FOR FOLDING INTERMEDIATES THAT PRECEDE AND FOLLOW THE DIMERIZATION STEP ON THE PATHWAY TO THE ACTIVE FORM OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; BACTERIAL LUCIFERASE; VIBRIO-HARVEYI; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; BETA-SUBUNIT; LUXB GENE; BIOLUMINESCENCE; RENATURATION	Conditions have been established that allow reversible refolding of luciferase from 5 M urea. The kinetics of formation of the active enzyme showed a concentration-independent lag, suggesting the existence of intermediate structures on the pathway of refolding. The rate of approach to the final level of activity was strongly concentration-dependent at protein concentrations below 10 mug/ml, but at concentrations above about 20 mug/ml, the rate of approach to the final activity value did not change with concentration. The concentration dependence presumably reflects the second-order step yielding the heterodimeric structure. The finding that at concentrations above 20 mug/ml, the rate becomes insensitive to concentration suggests that under these conditions, some step subsequent to dimerization becomes rate-limiting. When the refolding reaction was initiated by dilution out of 5 M urea at 50 mug/ml followed at various times by a secondary dilution to a final concentration of 5 mug/ml, it was found that the increase in activity continued at the rate characteristic of the higher protein concentration for a period of about 1-2 min following the dilution before slowing to the rate expected for the lower protein concentration. These observations indicate that there are inactive heterodimeric species that form from assembly of the individual subunits and that these species must undergo further folding to yield the active heterodimeric species. At protein concentrations of 5-50 mug/ml, the final yield of active enzyme was about 65-85%, decreasing at higher and lower concentrations. At higher concentrations, aggregation probably accounts for the limit in recovery, whereas at lower concentrations, it appears that the reduced yield of activity is due to the competing process of the folding of one or both individual subunits into some form incompetent to interact with each other. These experiments demonstrate the existence of slow steps in the refolding of luciferase subunits from urea and the formation of the active heterodimeric structure, both preceding and following the dimerization. Furthermore, the failure of protein at low concentrations to efficiently reassemble into the active heterodimer is consistent with the prior finding that luciferase subunits produced independently in Escherichia coli fold into conformations that cannot interact to form the active heterodimer upon mixing (Waddle, J. J., Johnston, T. C., and Baldwin, T. O. (1987) Biochemistry 26, 4917-4921).	TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLL STN, TX 77843 USA; TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, CTR MACROMOLEC DESIGN, COLL STN, TX 77843 USA; INST PASTEUR, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					FIC NIH HHS [1 FO6 TW016066-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN TO, 1993, J BIOL CHEM, V268, P10766; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1979, P NATL ACAD SCI USA, V76, P4887, DOI 10.1073/pnas.76.10.4887; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BELAS R, 1982, SCIENCE, V218, P791, DOI 10.1126/science.10636771; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CLARK AC, 1993, J BIOL CHEM, V268, P10773; COHN DH, 1985, J BIOL CHEM, V260, P6139; FRIEDLAND J, 1967, P NATL ACAD SCI USA, V58, P2336, DOI 10.1073/pnas.58.6.2336; FRIEDLAND J, 1967, BIOCHEMISTRY-US, V9, P2893; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLDBERG ME, 1985, TRENDS BIOCHEM SCI, V10, P388, DOI 10.1016/0968-0004(85)90066-0; GOLDBERG ME, 1980, PROTEIN FOLDING, P469; GUNSALUSMIGUEL A, 1972, J BIOL CHEM, V247, P398; HASTINGS JW, 1969, BIOCHEMISTRY-US, V8, P4681, DOI 10.1021/bi00840a004; HASTINGS JW, 1966, BIOLUMINESCENCE PROG, P151; Hastings JW., 1978, METHOD ENZYMOL, V57, P135; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1991, IND UNIV C, P137; JOHNSTON TC, 1986, J BIOL CHEM, V261, P4805; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MEIGHEN EA, 1970, BIOCHEMISTRY-US, V9, P4949; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; ORSINI G, 1978, J BIOL CHEM, V253, P3453; SINCLAIR JF, 1993, IN PRESS BIOCHEMISTR, V32; SUGIHARA J, 1988, BIOCHEMISTRY-US, V27, P2872, DOI 10.1021/bi00408a031; TU SC, 1977, J BIOL CHEM, V252, P803; TU SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P342, DOI 10.1016/0003-9861(77)90120-5; TU SC, 1978, METHOD ENZYMOL, V57, P171; WADDLE J, 1991, BIOCHEM BIOPH RES CO, V178, P1188, DOI 10.1016/0006-291X(91)91018-8; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WADDLE JJ, 1990, THESIS TEXAS AM U CO; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; ZIEGLER MM, 1981, CURR TOP BIOENERG, V12, P65	40	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10760	10765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	8496142				2022-12-25	WOS:A1993LD46600011
J	MINAMI, Y; KAWASAKI, H; SUZUKI, K; YAHARA, I				MINAMI, Y; KAWASAKI, H; SUZUKI, K; YAHARA, I			THE CALMODULIN-BINDING DOMAIN OF THE MOUSE 90-KDA HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLUCOCORTICOID RECEPTOR; GEL-ELECTROPHORESIS; ACTIN-FILAMENTS; PURIFICATION; HSP90; QUANTITATION; ANTIBODIES; QUANTITIES; MEMBRANE	The mouse 90-kDa heat shock protein (HSP90) and Ca2+-calmodulin were cross-linked at an equimolar ratio using a carbodiimide zero-length cross-linker. To identify the calmodulin-binding domain(s) of HSP90, CNBr-cleaved peptide fragments of HSP90 were mixed with Ca2+-calmodulin and cross-linked. Amino acid sequence determination revealed that an HSP90alpha-derived peptide starting at the 486th amino acid residue was contained in the cross-linked products, which contains a calmodulin-binding motif (from Lys500 to Ile520). A similar motif is present also in HSP90beta (from Lys491 to Val511). The synthetic peptides corresponding to these putative calmodulin-binding sequences were found to be cross-linked with Ca2+-calmodulin and to prevent the cross-linking of HSP90 and Ca2+-calmodulin. Both HSP90alpha and HSP90beta bind Ca2+. The HSP90 peptides bind HSP90 and thereby inhibit the binding of Ca2+. In addition, the HSP90 peptides augment the self-oligomerization of HSP90 induced at elevated temperatures. These results suggest that the calmodulin-binding domain of HSP90 might interact with another part of the same molecule and that Ca2+-calmodulin might modulate the structure and function of HSP90 through abolishing the intramolecular interaction.	TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,HONKOMAGOME 3-18-22,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science			Kawasaki, Hiroshi/C-3048-2011	Kawasaki, Hiroshi/0000-0002-2517-159X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KANG HS, 1991, J BIOL CHEM, V266, P5643; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KELLEY PM, 1982, MOL CELL BIOL, V2, P267, DOI 10.1128/MCB.2.3.267; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KLEE CB, 1980, PROTEIN PHOSPHORYLAT, P61; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1989, J CELL PHYSIOL, V140, P601, DOI 10.1002/jcp.1041400327; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SCHUH S, 1985, J BIOL CHEM, V260, P4292; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	36	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9604	9610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486648				2022-12-25	WOS:A1993LA68900069
J	LEHNER, R; KUKSIS, A				LEHNER, R; KUKSIS, A			TRIACYLGLYCEROL SYNTHESIS BY AN SN-1,2(2,3)-DIACYLGLYCEROL TRANSACYLASE FROM RAT INTESTINAL MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; ACYLTRANSFERASE ACTIVITY; ACID LIPASE; PURIFICATION; PROTEINS; LIVER	A membrane-associated sn-1,2(2,3)-diacylglycerol transacylase activity was purified 550-fold from the microsomes of rat intestinal villus cells. The enzyme was solubilized with the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and was isolated and purified by sequential chromatography on hydroxylapatite, an anion exchanger, Affi-Gel heparin and Cibacron blue A-agarose. SDS-polyacrylamide gel electrophoresis revealed two major closely migrating polypeptides of apparent molecular mass of 50 and 52 kDa. Incubation of the isolated enzyme with sn-1,2(2,3)dioleoyl-[2-H-3]glycerol yielded trioleoyl[2-H-3]glycerol and 2-oleoyl[2-H-3]glycerol. The synthesis of triacylglycerols was independent of acyl-CoA, as indicated by the absence of incorporation of radioactivity from [1-C-14]oleoyl-CoA into mono-, di-, or triacylglycerols under these conditions. The transacylase did not hydrolyze triacylglycerols readily and was not affected by the acyltransferase inhibitors, N-ethylmaleimide and 4,4'-diisothiocy-anostilbene-2,2'-disulfonate, while the lipase/hydrolase inhibitors NaF, phenylmethylsulfonyl fluoride, and diethyl p-nitrophenyl phosphate caused partial inactivation. The enzyme was specific toward 1(3)-positions of rac 1,2-diacylglycerols but did not utilize the -1,3-diacylglycerols or other neutral lipid esters effectively and was not capable of removing fatty acids from phosphatidylcholine or of transfer of fatty acids from X (unspecified enantiomer)- 1,2-diacylglycerol to lysophosphatidylcholine. Since the diacylglycerol transacylation did not lead to accumulation of either sn-1,2- or sn-2,3-diacylglycerols during incubation with the racemates, it is concluded that both sn-1,2- and sn-2,3-s are utilized at similar rates.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA	University of Toronto				Lehner, Richard/0000-0002-6008-1805				BERGE RK, 1980, EUR J BIOCHEM, V111, P67; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; COLEMAN RA, 1985, BIOCHIM BIOPHYS ACTA, V834, P180, DOI 10.1016/0005-2760(85)90154-7; FAROOQUI AA, 1980, J CHROMATOGR, V184, P335, DOI 10.1016/S0021-9673(00)89004-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; ITABASHI Y, 1990, J LIPID RES, V31, P1711; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; MYHER JJ, 1979, CAN J BIOCHEM CELL B, V57, P117, DOI 10.1139/o79-015; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAO RH, 1990, BIOCHIM BIOPHYS ACTA, V1043, P273, DOI 10.1016/0005-2760(90)90027-U; RAO RH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P19, DOI 10.1016/0005-2760(90)90089-G; SANJANWALA M, 1989, BIOCHIM BIOPHYS ACTA, V1006, P203, DOI 10.1016/0005-2760(89)90197-5; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V133, P574, DOI 10.1016/0006-291X(85)90944-1; WAITE M, 1973, J BIOL CHEM, V248, P7985; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1991, J LIPID RES, V32, P1173	22	88	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8781	8786						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473321				2022-12-25	WOS:A1993KX81100061
J	SCEARCE, LM; LAZ, TM; HAZEL, TG; LAU, LF; TAUB, R				SCEARCE, LM; LAZ, TM; HAZEL, TG; LAU, LF; TAUB, R			RNR-1, A NUCLEAR RECEPTOR IN THE NGFI-B NUR77 FAMILY THAT IS RAPIDLY INDUCED IN REGENERATING LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE EXPRESSION; GROWTH-FACTOR; GENETIC RESPONSE; SUPERFAMILY; CELLS; IDENTIFICATION; SEQUENCE; MEMBER; CDNA; TRANSCRIPTION	Liver regeneration following partial hepatectomy provides one of the few systems for analysis of mitogenesis in the fully developed, intact animal. Immediate-early growth response genes, induced in the absence of prior protein synthesis, play an important regulatory role in the regenerative process. During screening of a subtracted cDNA library of immediate-early genes induced during liver regeneration, a novel member of the thyroid/steroid receptor superfamily, RNR-1 (regenerating liver nuclear receptor), was identified. This gene is not expressed in quiescent liver but is rapidly induced following partial hepatectomy and is specific to hepatic growth as it is not induced in other mitogen-treated cells. RNR-1 is also expressed in brain. A full-length cDNA clone of RNR-1 encodes a 66-kDa, 597-amino acid protein as verified by in vitro translation in reticulocyte lysate. RNR-1 is highly homologous to r-NGFI-B/m-Nur77 particularly in the DNA binding (94%) and putative ligand binding (59%) domains. Using a mobility shift assay, we have shown that RNR-1 specifically binds to the NGFI-B DNA half-site and forms a complex very similar in size to the Nur77 complex, suggesting that RNR-1 also may bind as a monomer. Consistent with this finding, the A box region important in mediating half-site binding is 100% conserved between r-NGFI-B/m-Nur77. Both RNR-1 and Nur77 strongly transactivate a reporter driven by a consensus r-NGFI-B/Nur77 binding site, and their effect together is additive. As both the RNR-1 and r-NGFI/m-nur77 genes are induced during liver regeneration, it is very possible that RNR-1 acts concomitantly with r-NGFI/m-Nur77 in regulating the expression of delayed-early genes during liver regeneration.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,PHILADELPHIA,PA 19104; UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612	Howard Hughes Medical Institute; University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHANG CS, 1987, NUCLEIC ACIDS RES, V15, P9603, DOI 10.1093/nar/15.22.9603; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAUSTO N, 1989, LAB INVEST, V60, P4; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERBOMEL P, 1984, CELL, V39, P6563; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MOHN KL, 1990, J BIOL CHEM, V265, P21914; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P393; PARKER MG, 1991, NUCLEAR HORMONE RECE; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAUB R, 1987, J BIOL CHEM, V262, P10893; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	38	117	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8855	8861						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473329				2022-12-25	WOS:A1993KX81100071
J	MASSIA, SP; RAO, SS; HUBBELL, JA				MASSIA, SP; RAO, SS; HUBBELL, JA			COVALENTLY IMMOBILIZED LAMININ PEPTIDE TYR-ILE-GLY-SER-ARG (YIGSR) SUPPORTS CELL SPREADING AND COLOCALIZATION OF THE 67-KILODALTON LAMININ RECEPTOR WITH ALPHA-ACTININ AND VINCULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TO-SUBSTRATE CONTACTS; EXTRACELLULAR-MATRIX; A-CHAIN; INTERFERENCE-REFLECTION; MULTIDOMAIN PROTEIN; SYNTHETIC PEPTIDE; ENDOTHELIAL-CELLS; MULTIPLE RECEPTORS; NEURITE OUTGROWTH	The laminin-based nonapeptide Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg (CDPGYIGSR) and pentapeptide Tyr-Ile-Gly-Ser-Arg (YIGSR) have been previously demonstrated to support the attachment of several cell types and to competitively bind to the 67-kDa high affinity laminin receptor. Cell attachment, but not spreading, on substrates containing adsorbed CDPGYIGSR or YIGSR was observed. In this report we describe YIGSR-mediated attachment and spreading of a wide variety of cell types. GYIGSRY promoted cell spreading and stress fiber formation when it was covalently immobilized through the amino-terminal Gly residue, used as a spacer arm. Spreading was not observed when adsorbed YIGSR peptide was used. Functionally blocking antiserum directed against the 67-kDa and related laminin-binding proteins blocked human foreskin fibroblast (HFF) spreading, but not attachment, on covalently grafted GYIGSRY substrates. However, functionally blocking antisera directed against the vitronectin receptor, integrin alpha(v)beta3, and the fibronectin receptor, integrin alpha5beta1, did not affect HFF spreading on these substrates. When HFFs spread on these substrates, the 67-kDa laminin receptor co-localized with the cytoplasmic proteins alpha-actinin and vinculin into discrete structures. These results suggest that the adhesion ligand YIGSR is solely sufficient for cell spreading when it is conformationally constrained by covalent attachment to a solid substrate, at least when attached via its amino terminus. Furthermore, the role of the 67-kDa laminin receptor in recognition of this ligand and mediating cell attachment is confirmed in this study. This report also provides the first evidence for direct or indirect association of this receptor with vinculin and alpha-actinin when YIGSR-mediated cell spreading occurs.	UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712; UNIV TEXAS,DEPT MECH ENGN,AUSTIN,TX 78712; UNIV TEXAS,DIV BIOL SCI,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456				ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ABERCROMBIE M, 1975, EXP CELL RES, V92, P57, DOI 10.1016/0014-4827(75)90636-9; BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; BROWN SS, 1983, P NATL ACAD SCI-BIOL, V80, P5927, DOI 10.1073/pnas.80.19.5927; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; CODY RL, 1986, EXP CELL RES, V165, P107, DOI 10.1016/0014-4827(86)90536-7; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; DAVIS CM, 1991, EXP CELL RES, V193, P262, DOI 10.1016/0014-4827(91)90095-C; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEATH JP, 1978, J CELL SCI, V29, P197; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUARD TK, 1986, AM J PATHOL, V123, P365; HUBBELL JA, 1991, BIO-TECHNOL, V9, P568, DOI 10.1038/nbt0691-568; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; IZZARD CS, 1980, J CELL SCI, V42, P81; IZZARD CS, 1976, J CELL SCI, V21, P129; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MASSIA SP, 1992, J BIOL CHEM, V267, P10133; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; MERCURIO AM, 1991, BIOESSAYS, V13, P469, DOI 10.1002/bies.950130907; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; PALM SL, 1985, BIOCHEMISTRY-US, V24, P7753, DOI 10.1021/bi00347a038; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; TANDON NN, 1991, BIOCHEM J, V274, P535, DOI 10.1042/bj2740535; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1983, TRENDS BIOCHEM SCI, V8, P207, DOI 10.1016/0968-0004(83)90213-X; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WEHLAND J, 1979, J CELL SCI, V37, P259; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YANNARIELLOBROWN J, 1988, J CELL BIOL, V106, P1773, DOI 10.1083/jcb.106.5.1773; YOON PS, 1987, J IMMUNOL, V138, P259; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	81	164	179	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8053	8059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463322				2022-12-25	WOS:A1993KW97900069
J	NDUBUKA, C; LI, Y; RUBIN, CS				NDUBUKA, C; LI, Y; RUBIN, CS			EXPRESSION OF A KINASE ANCHOR PROTEIN-75 DEPLETES TYPE-II CAMP-DEPENDENT PROTEIN-KINASES FROM THE CYTOPLASM AND SEQUESTERS THE KINASES IN A PARTICULATE POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT; GOLGI-COMPLEX; BRAIN; IDENTIFICATION; ISOFORMS; CLONING; GENE; RII	A kinase anchor proteins (AKAPs) have a C-terminal binding site for the regulatory subunit (RIIbeta) of cAMP-dependent protein kinase IIbeta (PKAIIbeta) and an N-terminal domain that mediates the targeting and attachment of the anchor protein to intracellular structures. In vitro biochemical studies and recent in situ immunocytochemical analysis (Glantz, S. B., Amat, J. A., and Rubin, C. S. (1992) Mol. Biol. Cell 3, 1215-1228) suggest that AKAPs anchor PKAIIbeta at specific sites in the dendritic cytoskeleton of neurons. This arrangement would place PKAIIbeta in proximity with its substrates and create ''target sites'' for cAMP actions. The foregoing model predicts that (a) RII subunits are freely accessible to AKAPs, (b) PKAII holoenzymes, as well as RII subunits, are anchored, and (c) changes in the level of AKAP can alter the intracellular distribution of type II PKAs. We have addressed these previously untested propositions by overexpressing bovine AKAP75 in a human cell line (HEK293). Non-transfected cells express a low level of endogenous AKAP79, and approximately 90% of RIIalpha and RIIbeta subunits are isolated in the cell cytosol. In contrast, stably transfected cells, which express a 10-fold excess of AKAP75, sequester >90% of their RII subunits in a particulate pool. Catalytic subunits are also transferred to this pool. AKAP75 accumulates in a cell compartment with biochemical properties characteristic of cytoskeleton. Thus, AKAPs have access to and avidly bind cytoplasmic type II PKAs. Moreover, an increase in AKAP content can alter the particulate/cytoplasmic distribution of PKAIIbeta and PKAIIalpha.			NDUBUKA, C (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM22792, GM 7288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; LEISER M, 1986, J BIOL CHEM, V261, P1904; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9565; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; STEIN JC, 1987, J BIOL CHEM, V262, P3002; THEURKAUF W, 1983, J BIOL CHEM, V257, P3284	23	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7621	7624						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463292				2022-12-25	WOS:A1993KW97900006
J	REZAIE, AR; NEUENSCHWANDER, PF; MORRISSEY, JH; ESMON, CT				REZAIE, AR; NEUENSCHWANDER, PF; MORRISSEY, JH; ESMON, CT			ANALYSIS OF THE FUNCTIONS OF THE 1ST EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF FACTOR-X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CALCIUM-BINDING; PROTEIN-C; BLOOD-COAGULATION; ACTIVATION; REGION; PROTHROMBIN; SITE; THROMBIN; FRAGMENT	Upon activation, factor X participates in the prothrombin activation complex. Similar to 4-carboxyglutamic acid (Gla)-domainless protein C, the Gla-domainless factor X (GDFX) contains a high affinity Ca2+-binding site critical for the function of these molecules. In the case of protein C, we recently demonstrated that the high affinity Ca2+-binding site critical for activation is outside the first epidermal growth factor (EGF) homology domain. To examine if this is also true for factor X, we have expressed in human 293 cells a deletion mutant of factor X (E2FX) which lacks the entire Gla region as well as the NH2-terminal EGF homology region of factor X. Direct binding studies by equilibrium dialysis indicate that E2FX contains a single Ca2+-binding site with a dissociation constant (K(d)) of 154 +/- 48 muM. The functional properties of E2FX are equivalent or improved over those of GDFX. For instance, the factor X coagulant protein of Russell's viper venom activates E2FX three times faster than recombinant GDFX. Kinetic analysis of prothrombin activation in the absence of membranes indicates that activated GDFX and E2FX bind to factor Va with equal affinity (K(d) = 4.1 muM). The Ca2+ concentration required for half-maximal prothrombin activation rates in the above activation system shifted from 721 +/- 113 muM for activated GDFX to 193 +/- 64 muM for activated E2FX. GDFX and E2FX activation rates with the soluble tissue factor-factor VIIa complex were identical as was the Ca2+ dependence of the reaction. We conclude that E2FX retains a high affinity Ca2+-binding site and that the first EGF homology domain does not appear to have a positive functional role in the GDFX molecule. However, Ca2+ occupancy of the Ca2+-binding site in the first EGF domain of intact factor X may be essential for optimal prothrombin activation.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center			Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569	NHLBI NIH HHS [R01 HL29807, F32 HL08710, R01 HL47014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, F32HL008710, R01HL047014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1973, THESIS WASHINGTON U; Esmon N L, 1987, Dev Biol Stand, V67, P75; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; MANN KG, 1990, BLOOD, V76, P1; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; MORITA T, 1984, J BIOL CHEM, V259, P5698; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1991, BLOOD, V78, P1637; SUGO T, 1984, J BIOL CHEM, V259, P5705; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WILDGOOSE P, 1988, BIOCHEM BIOPH RES CO, V152, P1207, DOI 10.1016/S0006-291X(88)80413-3	33	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8176	8180						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463328				2022-12-25	WOS:A1993KW97900085
J	MOSER, B; DEWALD, B; BARELLA, L; SCHUMACHER, C; BAGGIOLINI, M; CLARKLEWIS, I				MOSER, B; DEWALD, B; BARELLA, L; SCHUMACHER, C; BAGGIOLINI, M; CLARKLEWIS, I			INTERLEUKIN-8 ANTAGONISTS GENERATED BY N-TERMINAL MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; RESPIRATORY BURST; RECEPTOR-BINDING; EXPRESSION; CHEMOTAXIS; EXOCYTOSIS; RESIDUES; CELLS	We have previously shown that the residues Glu4-Leu5-Arg6 (ELR) preceding the first cysteine at the N terminus of the 72-residue form of interleukin-8 (IL-8) are essential for receptor binding and neutrophil activation (Clark-Lewis, I., Schumacher, C., Baggiolini, M., and Moser, B. (1991) J. Biol. Chem. 266, 23128-23134). We have now synthesized a series of analogs of IL-8(4-72), the truncated form of IL-8 with the N-terminal sequence ELRC, as potential IL-8 antagonists. Among 26 analogs with deletions or amino acid replacements in the ELR region several inhibited IL-8 function. The most potent were IL-8(6-72), with Arg6 at the N terminus, and IL-8,AAR(7-72) with N-terminal Ala4-Ala5 instead of Glu4-Leu5. They inhibited IL-8 receptor binding, exocytosis (IC50 0.3 muM), as well as chemotaxis and the respiratory burst. Inhibition was restricted to responses elicited by IL-8, GROalpha, or NAP-2, and no effect was observed when the unrelated agonists fMet-Leu-Phe or C5a were used as stimuli. These results demonstrate that selective antagonists that prevent or attenuate the action of IL-8 and its related chemotactic cytokines are obtained by modification of the ELR sequence at the N terminus.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia	MOSER, B (corresponding author), UNIV BERN,THEODOR KOCHER INST,POB 99,CH-3000 BERN,SWITZERLAND.			Moser, Bernhard/0000-0002-4354-4572				BAGGIOLINI M, 1991, BIOCHEM SOC T, V19, P55, DOI 10.1042/bst0190055; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COLDITZ I, 1989, AM J PATHOL, V134, P755; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; LEONARD EJ, 1991, J INVEST DERMATOL, V96, P690, DOI 10.1111/1523-1747.ep12470612; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; MOSER B, 1991, J BIOL CHEM, V266, P10666; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; STOECKLE M Y, 1990, New Biologist, V2, P313; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; ZOJA C, 1991, AM J PATHOL, V138, P991	19	138	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7125	7128						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463247				2022-12-25	WOS:A1993KV14100048
J	ANDERSON, JW; PULLEN, K; GEORGES, F; KLEVIT, RE; WAYGOOD, EB				ANDERSON, JW; PULLEN, K; GEORGES, F; KLEVIT, RE; WAYGOOD, EB			THE INVOLVEMENT OF THE ARGININE-17 RESIDUE IN THE ACTIVE-SITE OF THE HISTIDINE-CONTAINING PROTEIN, HPR, OF THE PHOSPHOENOLPYRUVATE - SUGAR PHOSPHOTRANSFERASE SYSTEM OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYL TRANSFER-REACTIONS; PHOSPHOCARRIER PROTEIN; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; ENZYME-I; BACTERIAL PHOSPHOENOLPYRUVATE; STAPHYLOCOCCUS-AUREUS; DIRECTED MUTAGENESIS; N-ACETYLGLUCOSAMINE; TERTIARY STRUCTURE	Histidine-containing protein, HPr, of the Escherichia coli phosphoenolpyruvate:sugar phosphotransferase system has an active site His-15 that is phosphorylated to form N(delta1)-P-histidine. The nearby conserved residue, Arg-17, has been replaced by: lysine, histidine, glutamate, glycine, serine, and cysteine. All mutations resulted in impairment of the phosphoacceptor function of HPr with enzyme I: k(cat)/K(m) values between 6% (Ser-17) and 0.1% (Glu-17), relative to wild type. Several sugar-specific enzymes II had different responses. Both the V(max) and K(m) of enzyme II(N-acetylglucosamine) were altered, while for enzyme II(mannose) only K(m) was affected, except for R17E. For both enzymes, k(cat)/K(m) values were between 0.5 and 3%, with R17E being 10-fold lower. Except for R17E, minimal effects were observed for enzyme II(mannitol). These results suggest that there are different rate-limiting steps in the enzymes II. Phosphohydrolysis properties and the pK(a) values for His-15 and phosphorylated His-15 determined by NMR for both wild type and mutant HPrs suggest that Arg-17 is partly responsible for the instability of P-His-15 and the depressed pK(a) values in wild type HPr. Other feature(s) of the tertiary structure influence the protonation of His-15 and the phosphohydrolysis properties of phosphorylated His-15.	UNIV SASKATCHEWAN, DEPT BIOCHEM, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; NATL RES COUNCIL CANADA, INST PLANT BIOTECHNOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA	University of Saskatchewan; University of Washington; University of Washington Seattle; National Research Council Canada					NIDDK NIH HHS [DK-35187] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK035187, R01DK035187] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ANDERSON JW, 1992, BIOCHEM CELL BIOL, V70, P242, DOI 10.1139/o92-036; BENKOVIC SJ, 1971, J AM CHEM SOC, V93, P4009, DOI 10.1021/ja00745a032; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2996, DOI 10.1021/bi00581a014; EISERMANN R, 1991, EUR J BIOCHEM, V197, P9, DOI 10.1111/j.1432-1033.1991.tb15875.x; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; ERNI B, 1989, J BIOL CHEM, V264, P18733; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; GRENIER FC, 1986, J CELL BIOCHEM, V31, P97, DOI 10.1002/jcb.240310203; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HAYS JB, 1973, J BIOL CHEM, V248, P941; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; JENCKS WP, 1965, J AM CHEM SOC, V87, P3199, DOI 10.1021/ja01092a035; JIA Z, 1992, THESIS U SASKATCHEWA; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; KALBITZER HR, 1991, BIOCHEMISTRY-US, V30, P11186, DOI 10.1021/bi00110a024; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY S, 1990, GENE, V86, P27, DOI 10.1016/0378-1119(90)90110-D; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MATEUCCI MD, 1981, J AM CHEM SOC, V103, P3186; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MISSET O, 1982, BIOCHEMISTRY-US, V21, P3139; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; PRASAD L, 1993, J BIOL CHEM, V268, P10705; REIZER J, 1992, J BIOL CHEM, V267, P9158; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SHARMA S, 1992, THESIS U SASKATCHEWA; STOCK JB, 1982, J BIOL CHEM, V257, P4543; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; TITGEMEYER F, 1991, THESIS U OSNABRUCK; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; WAYGOOD EB, 1980, CAN J BIOCHEM CELL B, V58, P40, DOI 10.1139/o80-006; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1986, BIOCHEMISTRY-US, V25, P4085, DOI 10.1021/bi00362a015; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WAYGOOD EB, 1989, FEMS MICROBIOL LETT, V63, P43, DOI 10.1016/0168-6445(89)90007-7; WAYGOOD EB, 1988, BIOCHEM CELL BIOL, V66, P76, DOI 10.1139/o88-010; WAYGOOD EB, 1987, SUGAR TRANSPORT META, P235; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	61	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12325	12333						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509371				2022-12-25	WOS:A1993LG65800019
J	HAMMEL, KE; JENSEN, KA; MOZUCH, MD; LANDUCCI, LL; TIEN, M; PEASE, EA				HAMMEL, KE; JENSEN, KA; MOZUCH, MD; LANDUCCI, LL; TIEN, M; PEASE, EA			LIGNINOLYSIS BY A PURIFIED LIGNIN PEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS PHANEROCHAETE-CHRYSOSPORIUM; C-13 NMR-SPECTROSCOPY; WHITE-ROT FUNGI; VERATRYL ALCOHOL; DEGRADING BASIDIOMYCETE; MANGANESE PEROXIDASE; MODEL-COMPOUND; FREE-RADICALS; STEADY-STATE; OXALIC-ACID	The lignin peroxidases (LiPs) of white-rot basidiomycetes are generally thought to catalyze the oxidative cleavage of polymeric lignin in vivo. However, direct evidence for such a role has been lacking. In this investigation, C-14- and C-13-labeled synthetic lignins were oxidized with a purified isozyme of Phanerochaete chrysosporium LiP. Gel permeation chromatography of the radiolabeled polymers showed that LiP catalyzed their cleavage to give soluble lower-M(r) products. To a lesser extent, the enzyme also polymerized the lignins to give soluble higher-M(r) products. This result is attributable to the fact that purified LiP, unlike the intact fungus, provides no mechanism for the removal of lignin fragments that are susceptible to repolymerization. LiP catalysis also gave small quantities of insoluble, perhaps polymerized, lignin, but in lower yield than intact P. chrysosporium does. C-13 NMR experiments with C-13-labeled polymer showed that LiP cleaved it between C(alpha) and C(beta) of the propyl side chain to give benzylic aldehydes at C(alpha), in agreement with the cleavage mechanism hypothesized earlier. The data show that LiP catalysis accounts adequately for the initial steps of ligninolysis by P. chrysosporium in vivo.	PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIV PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	HAMMEL, KE (corresponding author), US FOREST SERV, FOREST PROD LAB, MADISON, WI 53705 USA.		Hammel, Kenneth/G-1890-2011	Hammel, Kenneth/0000-0002-2935-5847				ADLER E, 1977, WOOD SCI TECHNOL, V11, P169, DOI 10.1007/BF00365615; AKAMATSU Y, 1990, FEBS LETT, V269, P261, DOI 10.1016/0014-5793(90)81169-O; Allan GG, 1971, LIGNINS OCCURRENCE F, P511; BLANCHETTE RA, 1991, ANNU REV PHYTOPATHOL, V29, P381, DOI 10.1146/annurev.py.29.090191.002121; BLANCHETTE RA, 1989, APPL ENVIRON MICROB, V55, P1457, DOI 10.1128/AEM.55.6.1457-1465.1989; CAI DY, 1989, BIOCHEM BIOPH RES CO, V162, P464, DOI 10.1016/0006-291X(89)92020-2; Chen C. L., 1985, BIOSYNTHESIS BIODEGR, P535; CHUA MGS, 1983, HOLZFORSCHUNG, V37, P55, DOI 10.1515/hfsg.1983.37.2.55; CHUA MGS, 1982, HOLZFORSCHUNG, V36, P165, DOI 10.1515/hfsg.1982.36.4.165; CONNORS WJ, 1980, HOLZFORSCHUNG, V34, P80, DOI 10.1515/hfsg.1980.34.3.80; DANIEL G, 1989, APPL ENVIRON MICROB, V55, P874; Evans C. S., 1991, Biodegradation, V2, P93, DOI 10.1007/BF00114599; FAIX O, 1985, HOLZFORSCHUNG, V39, P203, DOI 10.1515/hfsg.1985.39.4.203; FURNISS BS, 1989, VOGELS TXB PRACTICAL, P695; GAGNAIRE D, 1977, MAKROMOL CHEM, V178, P1477; GALLIANO H, 1991, ENZYME MICROB TECH, V13, P478, DOI 10.1016/0141-0229(91)90005-U; GARCIA S, 1987, APPL ENVIRON MICROB, V53, P2384, DOI 10.1128/AEM.53.10.2384-2387.1987; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; GOLDSCHMID O, 1954, ANAL CHEM, V26, P1421, DOI 10.1021/ac60093a009; GORING DAI, 1971, LIGNINS OCCURRENCE F, P741; HAEMMERLI SD, 1986, FEMS MICROBIOL LETT, V35, P33, DOI 10.1111/j.1574-6968.1986.tb01494.x; HAIDER K, 1985, HOLZFORSCHUNG, V39, P23, DOI 10.1515/hfsg.1985.39.1.23; HAMMEL KE, 1986, P NATL ACAD SCI USA, V83, P3708, DOI 10.1073/pnas.83.11.3708; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HAMMEL KE, 1986, J BIOL CHEM, V261, P6948; HAMMEL KE, 1985, J BIOL CHEM, V260, P8348; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; KERN HW, 1989, HOLZFORSCHUNG, V43, P375, DOI 10.1515/hfsg.1989.43.6.375; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KIRK TK, 1975, P NATL ACAD SCI USA, V72, P2515, DOI 10.1073/pnas.72.7.2515; KIRK TK, 1975, HOLZFORSCHUNG, V29, P56, DOI 10.1515/hfsg.1975.29.2.56; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KIRK TK, 1978, ARCH MICROBIOL, V117, P277, DOI 10.1007/BF00738547; KIRK TK, 1970, ACTA CHEM SCAND, V24, P3379, DOI 10.3891/acta.chem.scand.24-3379; KIRK TK, 1990, METHOD ENZYMOL, V188, P159; KIRK TK, 1988, METHOD ENZYMOL, V161, P65; KOFUJITA H, 1991, MOKUZAI GAKKAISHI, V37, P555; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; MIKI K, 1986, BIOCHEMISTRY-US, V25, P4790, DOI 10.1021/bi00365a011; MILLIS CD, 1989, BIOCHEMISTRY-US, V28, P8484, DOI 10.1021/bi00447a032; NEWMAN J, 1986, HOLZFORSCHUNG, V40, P369, DOI 10.1515/hfsg.1986.40.6.369; ODIER E, 1988, BIOCHIMIE, V70, P847, DOI 10.1016/0300-9084(88)90117-4; ORTH AB, 1991, APPL ENVIRON MICROB, V57, P2591, DOI 10.1128/AEM.57.9.2591-2596.1991; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; PERIE FH, 1991, APPL ENVIRON MICROB, V57, P2240; POPP JL, 1990, BIOCHEMISTRY-US, V29, P10475, DOI 10.1021/bi00498a008; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; ROBERT D, 1989, HOLZFORSCHUNG, V43, P323, DOI 10.1515/hfsg.1989.43.5.323; RUEL K, 1991, APPL ENVIRON MICROB, V57, P374, DOI 10.1128/AEM.57.2.374-384.1991; Ruel K., 1985, BIOSYNTHESIS BIODEGR, P441; RUTTIMANN C, 1992, BIOTECHNOL APPL BIOC, V16, P64; RUTTIMANN C, 1992, BIOTECHNOLOGY PULP P, P243; SARKANEN S, 1991, J BIOL CHEM, V266, P3636; SCHOEMAKER HE, 1985, FEBS LETT, V183, P7, DOI 10.1016/0014-5793(85)80942-X; SCHUERCH C, 1952, J AM CHEM SOC, V74, P5061, DOI 10.1021/ja01140a020; SHIMADA M, 1981, ARCH MICROBIOL, V129, P321, DOI 10.1007/BF00414706; SREBOTNIK E, 1988, APPL ENVIRON MICROB, V54, P2608, DOI 10.1128/AEM.54.11.2608-2614.1988; STRUBE RE, 1963, ORG SYNTH, V4, P417; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1990, APPL ENVIRON MICROB, V56, P2540, DOI 10.1128/AEM.56.8.2540-2544.1990; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; TUOR U, 1992, BIOCHEMISTRY-US, V31, P4986, DOI 10.1021/bi00136a011; UMEZAWA T, 1989, MOKUZAI GAKKAISHI, V35, P1014; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WARIISHI H, 1991, BIOCHEM BIOPH RES CO, V176, P269, DOI 10.1016/0006-291X(91)90919-X; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; YAU WW, 1979, MODERN SIZE EXCLUSIO, P315; YOKOTA S, 1990, HOLZFORSCHUNG, V44, P271, DOI 10.1515/hfsg.1990.44.4.271	73	222	232	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12274	12281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509364				2022-12-25	WOS:A1993LG65800011
J	ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V				ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V			THE CORE PROMOTER REGION OF THE P-GLYCOPROTEIN GENE IS SUFFICIENT TO CONFER DIFFERENTIAL RESPONSIVENESS TO WILD-TYPE AND MUTANT P53	ONCOGENE			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; EXPRESSION; CELLS; DNA; TISSUES; SUPPRESSOR; SEQUENCE; PRODUCT	The overexpression of P-glycoprotein is thought to be responsible for resistance to chemotherapy in some non-responsive cancers. The mechanism by which P-glycoprotein is overexpressed in human tumors is poorly understood. However, several lines of evidence suggest that the major regulatory mechanism of P-glycoprotein overexpression in human tumors is at the transcriptional level. During tumor progression one of the most commonly observed alterations is mutation of the p53 tumor-suppressor gene. It has been shown that the p53 protein plays a role in transcriptional regulation. To gain insight into the effect p53 protein may have on P-glycoprotein promoter activity, we transiently co-transfected plasmids containing the hamster pgp1 or human mdr1 promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene with plasmids encoding either wild-type or mutant p53 protein into Chinese hamster ovary (CHO) cells. In this report, we show that wild-type p53 protein represses P-glycoprotein promoter activity, while mutant forms of p53 protein enhance P-glycoprotein promoter activity. Furthermore, we present data which indicate that the transcriptional regulatory effects of p53 are mediated through interactions with pgp1/mdr1 core promoter sequences. These findings have implications for our understanding of the molecular mechanism(s) by which p53 protein functions as a transcriptional regulator of gene expression. In addition, our results suggest a mechanism by which P-glycoprotein may be overexpressed in human cancers that also express mutant forms of p53 protein.	UNIV TORONTO,ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X	NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMADA H, 1988, CANCER RES, V48, P4926; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HIRT B, 1967, J MOL BIOL, V26, P363; JARRELL KA, 1991, P NATL ACAD SCI USA, V88, P102, DOI 10.1073/pnas.88.1.102; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MA DDF, 1987, LANCET, V1, P135; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	40	144	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502478				2022-12-25	WOS:A1993LE06400016
J	TADAKI, DK; NIYOGI, SK				TADAKI, DK; NIYOGI, SK			THE FUNCTIONAL IMPORTANCE OF HYDROPHOBICITY OF THE TYROSINE AT POSITION 13 OF HUMAN EPIDERMAL GROWTH-FACTOR IN RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; KINASE-ACTIVITY; RESIDUES; EGF; LEUCINE-47; H-1-NMR; DOMAIN	The tyrosine at position 13 of epidermal growth factor (EGF) has been implicated as playing a role in receptor binding due to its close proximity to the critical arginine 41 residue as well as its high degree of conservation in EGF and EGF-like proteins that can bind to the EGF receptor. Site-directed mutagenesis of tyrosine 13 in human EGF (hEGF) was employed to examine the role of this residue in ligand-receptor interaction. The removal of the hydroxyl moiety of the tyrosine by substitution with phenylalanine had little effect on the binding, indicating that it is not involved in any crucial hydrogen bonds with either the receptor or with other regions of the EGF molecule. The substitution of the aromatic tyrosine side-chain with the nonpolar leucine side-chain caused the receptor affinity to decrease only slightly, indicating that aromaticity of the amino acid at this site is also not critical. Substitutions with other hydrophobic residues, isoleucine, valine, and alanine, resulted in a significant decrease in receptor affinity as a function of decreasing hydrophobicity. Substitution of tyrosine 13 with the polar residues histidine and arginine markedly decreased receptor binding affinity, and complete removal of the side-chain by substitution with glycine dramatically lowered the binding affinity to 0.3% as compared to wild type. Analysis of three hEGF mutants, Tyr13-->Leu, Tyr13-->Arg, and Tyr13-->Gly, by circular dichroism showed that the major structural features of hEGF were not significantly altered. The results demonstrate that the decreased receptor affinities of these hEGF mutants are due to disruption of the functional contribution(s) of the tyrosine 13 residue rather than alteration(s) in the overall structural integrity. Overall, the results suggest that the tyrosine 13 side-chain plays a critical role in receptor binding by contributing to hydrophobic receptor-ligand interactions.	OAK RIDGE NATL LAB,DIV BIOL,UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,POB 2009,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,PROTEIN ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory					NCI NIH HHS [CA 50735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAMPION SR, 1993, J BIOL CHEM, V268, P1742; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1985, METHOD ENZYMOL, V109, P107; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; ENGLER DA, 1991, MOL CELL BIOL, V11, P2425, DOI 10.1128/MCB.11.5.2425; HELMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HOMMEL U, 1991, BIOCHEMISTRY-US, V30, P8891, DOI 10.1021/bi00100a024; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P554, DOI 10.1093/oxfordjournals.jbchem.a122307; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MAYO KH, 1986, BIOCHEM J, V239, P13, DOI 10.1042/bj2390013; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; MONTELIONE GT, 1986, P NATL ACAD SCI USA, V83, P8594, DOI 10.1073/pnas.83.22.8594; MOY FJ, 1989, P NATL ACAD SCI USA, V86, P9836, DOI 10.1073/pnas.86.24.9836; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; TADAKI DK, 1991, FASEB J, V5, pA1183; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	33	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10114	10119						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	8486681				2022-12-25	WOS:A1993LB80000028
J	FABER, PW; VANROOIJ, HCJ; SCHIPPER, HJ; BRINKMANN, AO; TRAPMAN, J				FABER, PW; VANROOIJ, HCJ; SCHIPPER, HJ; BRINKMANN, AO; TRAPMAN, J			2 DIFFERENT, OVERLAPPING PATHWAYS OF TRANSCRIPTION INITIATION ARE ACTIVE ON THE TATA-LESS HUMAN ANDROGEN RECEPTOR PROMOTER - THE ROLE OF SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; RIBONUCLEIC-ACID; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING; DNA; ACTIVATION; SPECIFICITY; PROTEINS; COMPLEX	In this study, the minimal promoter requirements of the TATA-less human androgen receptor (hAR) gene promoter are described. The hAR promoter is characterized by a short GC-box (-59/-32) and a long homopurine stretch (-117/-60). Two major transcription initiation sites, AR transcription initiation site I (AR-TIS I, (+1/2/3)) and AR transcription initiation site II (AR-TIS II, (+12/13)) are located in a 13-base pair region (Faber, P. W., van Rooij, H. C. J., van der Korput, J. A. G. M., Baarends, W. M., Brinkmann, A. O., Grootegoed, J. A., and Trapman, J. (1991) J. Biol. Chem. 266, 10743-10749). Transient transfection of COS cells with hAR promoter deletion and mutant constructs, followed by RNA isolation and S1 nuclease protection analysis showed that the process of transcription initiation through AR-TIS I and AR-TIS II is regulated by different promoter sequences. The GC-box directed initiation from AR-TIS II but did not affect AR-TIS I utilization, which is dependent upon sequences between positions -5 and +57. Band shift analysis identified the transcription factor Sp1 as the protein interacting with the GC-box. A single Sp1 binding sequence was found to be present in the GC-box. Footprint analysis confirmed the interaction of Sp1 with this sequence. The differential initiation through AR-TIS I and AR-TIS II was substantiated by the introduction of point mutations in the Sp1 binding sequence: only mutations that specifically abolished Sp1 binding interfered with AR-TIS II utilization, but all mutations left AR-TIS I initiation intact.	ERASMUS UNIV,DEPT ENDOCRINOL & REPROD,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	FABER, PW (corresponding author), ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS.							BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; Battey, 1986, BASIC METHODS MOL BI; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRINKMANN AO, 1992, CANCER SURV, V14, P95; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coffey D S, 1987, Prog Clin Biol Res, V239, P1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FABER PW, 1991, J BIOL CHEM, V266, P10743; FABER PW, 1991, BIOCHEM J, V278, P269, DOI 10.1042/bj2780269; GOODRICH JA, 1991, TRENDS BIOCHEM SCI, V16, P394, DOI 10.1016/0968-0004(91)90162-O; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KASAI Y, 1992, MOL CELL BIOL, V12, P2884, DOI 10.1128/MCB.12.6.2884; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAKANE KK, 1991, ENDOCRINOLOGY, V129, P1093, DOI 10.1210/endo-129-2-1093; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615	41	116	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9296	9301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486625				2022-12-25	WOS:A1993LA68900025
J	ROSS, FP; CHAPPEL, J; ALVAREZ, JI; SANDER, D; BUTLER, WT; FARACHCARSON, MC; MINTZ, KA; ROBEY, PG; TEITELBAUM, SL; CHERESH, DA				ROSS, FP; CHAPPEL, J; ALVAREZ, JI; SANDER, D; BUTLER, WT; FARACHCARSON, MC; MINTZ, KA; ROBEY, PG; TEITELBAUM, SL; CHERESH, DA			INTERACTIONS BETWEEN THE BONE-MATRIX PROTEINS OSTEOPONTIN AND BONE SIALOPROTEIN AND THE OSTEOCLAST INTEGRIN ALPHA-V-BETA-3 POTENTIATE BONE-RESORPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; AMINO-ACID-SEQUENCE; CELL-ADHESION; VITRONECTIN RECEPTOR; RAT BONE; ALPHA-V; PHOSPHORYLATED GLYCOPROTEIN; MONONUCLEAR PHAGOCYTES; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR	We have investigated the mechanism by which osteoclasts adhere to and resorb bone. We show that these cells express beta1 and beta3 integrins which are involved in attachment to purified bone matrix proteins. Binding to osteopontin and bone sialoprotein is mediated by alpha(v)beta3, while a beta1 integrin is responsible for attachment to fibronectin. Both the rapid attachment by osteoclasts to intact bone particles and their subsequent resorption are blocked by a monoclonal antibody directed to the alpha(v)beta3 complex but not by an antibody against beta1 integrins. Attachment of osteoclasts to bone is also inhibited with soluble osteopontin, Arg-Gly-Asp-containing peptides derived from both osteopontin and bone sialoprotein, or a monospecific polyclonal antibody against osteopontin. We conclude that both osteoclast adherence to bone and subsequent resorption of its matrix are dependent on interactions between the bone matrix proteins osteopontin and/or bone sialoprotein and the integrin alpha(v)beta3. Moreover, collagen, which constitutes 90% of its organic matrix, is minimally involved in binding of chicken osteoclasts to bone.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, HLTH SCI CTR, DENT BRANCH, DEPT BIOL CHEM, HOUSTON, TX 77225 USA; NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	Scripps Research Institute; University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	ROSS, FP (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DEPT PATHOL & LAB MED, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA.		Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Teitelbaum, Steven/0000-0002-4054-6679; Farach-Carson, Mary/0000-0002-4526-3088	NCI NIH HHS [CA50286, CA47526] Funding Source: Medline; NIAMS NIH HHS [AR39273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047526, R01CA050286, R37CA050286, U01CA047526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BARSHAVIT Z, 1983, J CLIN INVEST, V72, P516, DOI 10.1172/JCI110999; BEACHAM DA, 1990, EXP CELL RES, V189, P69, DOI 10.1016/0014-4827(90)90258-C; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BODARY SC, 1990, J BIOL CHEM, V265, P5938; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DEDHAR S, 1987, J CELL BIOL, V104, P585, DOI 10.1083/jcb.104.3.585; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MIZUNO M, 1991, BONE MINER, V13, P1, DOI 10.1016/0169-6009(91)90046-3; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROBEY PG, 1989, J CELL BIOL, V108, P719, DOI 10.1083/jcb.108.2.719; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SAUK JJ, 1990, EXP CELL RES, V188, P105, DOI 10.1016/0014-4827(90)90283-G; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; VAES G, 1988, CLIN ORTHOP RELAT R, P239; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; ZHANG R, 1990, J BIOL CHEM, V265, P15375	57	486	516	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9901	9907						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	8486670				2022-12-25	WOS:A1993LA68900106
J	BAJZAR, L; NESHEIM, M				BAJZAR, L; NESHEIM, M			THE EFFECT OF ACTIVATED PROTEIN-C ON FIBRINOLYSIS IN CELL-FREE PLASMA CAN BE ATTRIBUTED SPECIFICALLY TO ATTENUATION OF PROTHROMBIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CLOT LYSIS; PLASMINOGEN-ACTIVATOR; WHOLE-BLOOD; FACTOR-VA; INHIBITOR; MECHANISM; COFACTOR; THROMBIN	The effect of human activated protein C (APC) on tissue plasminogen activator (tPA)-induced fibrinolysis was studied in cell free plasma and in a system of purified components. Clots were produced by adding plasma or a solution of fibrinogen and plasminogen to the wells of a microtiter plate containing small separated aliquots of Ca2+, thrombin, and tPA, plus and minus APC. Initial clotting and subsequent fibrinolysis were monitored continuously by turbidity. The lysis time of dialyzed normal human plasma (NHP) was longer than that of dialyzed barium citrate-adsorbed plasma (BAP). APC had no effect on the lysis time of BAP but shortened the lysis time of NHP to that of BAP. Two fractions were produced from material eluted from the barium citrate pellet by precipitation of selective components with polyethylene glycol 8000 (PEG). One fraction comprised materials which precipitated at 5% PEG (5% PF) and the other materials which precipitated between 5 and 40% PEG (5-40% PF). Both fractions together, but neither alone, prolonged the lysis time of BAP, an effect which could be reversed by APC. Fractionation of the 5% PF showed that the component with the required activity has properties of the procoagulant surface and can be replaced with vesicles of phosphatidylcholine/phosphatidylserine (PCPS). In addition, the 5-40% PF can be replaced with either the combination of purified coagulation Factors II, IX, and X or Factor II plus the prothrombin activator Factor Xa. When Factor Xa was used as the activator in BAP plus PSPC vesicles, a dose-dependent saturable increase in lysis time was observed with a half-maximal increase occurring at 32 pM Factor Xa. This effect was eliminated by APC. In a system of purified components comprising PCPS vesicles, Factors V and 11, protein S, plasminogen and fibrinogen; the prothrombin activators Factor Xa and ecarin both induced a prolongation of the lysis time. APC prevented prolongation by Factor Xa but not by ecarin. The time courses of the generation of thrombin and plasmin during fibrinolysis of clots produced from systems of purified components in the presence and absence of APC, and with Factor Xa as the prothrombin activator, were determined by standardized activity assays using chromogenic substrates. In the absence of APC the lysis time was 145 min, and prothrombin was quantitatively converted to thrombin. In the presence of APC, however, the lysis time was reduced to 100 min with no evidence for the activation of prothrombin. The time course of the generation of plasmin during lysis was retarded in the absence of APC. The final concentrations of plasmin produced in both conditions were indistinguishable, however. These data indicate that activation of prothrombin generates an as yet unidentified antifibrinolytic component(s), and the profibrinolytic effect of APC can be rationalized by its ability to inhibit the activation of prothrombin.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada								BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BURDICK MD, 1987, THROMB RES, V45, P413, DOI 10.1016/0049-3848(87)90230-1; COLUCCI M, 1984, J CLIN INVEST, V74, P200, DOI 10.1172/JCI111402; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DANGELO A, 1987, BLOOD, V69, P231; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; DEFOUW NJ, 1987, THROMB HAEMOSTASIS, V57, P176; DEFOUW NJ, 1988, FIBRINOLYSIS, V2, P235; ELECTRICWALA A, 1990, Fibrinolysis, V4, P121; ESMON NL, 1982, J BIOL CHEM, V257, P859; FAY WP, 1989, BIOCHEMISTRY-US, V28, P5773, DOI 10.1021/bi00440a011; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; SAKATA Y, 1986, BLOOD, V68, P1218; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; TAYLOR FB, 1985, THROMB RES, V37, P155, DOI 10.1016/0049-3848(85)90042-8; TAYLOR FB, 1981, FED PROC, V40, P2092; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; VANHINSBERGH VWM, 1985, BLOOD, V65, P444; VLASUK G P, 1990, Fibrinolysis, V4, P8; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEINSTEIN RE, 1991, THROMB RES, V63, P123, DOI 10.1016/0049-3848(91)90275-2; ZOLTON R P, 1973, Thrombosis Research, V3, P23, DOI 10.1016/0049-3848(73)90123-0	31	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8608	8616						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473306				2022-12-25	WOS:A1993KX81100037
J	LOW, MG; HUANG, KS				LOW, MG; HUANG, KS			PHOSPHATIDIC-ACID, LYSOPHOSPHATIDIC ACID, AND LIPID-A ARE INHIBITORS OF GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-D - SPECIFIC-INHIBITION OF A PHOSPHOLIPASE BY PRODUCT ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINNESOTA RE595 LIPOPOLYSACCHARIDE; D GPI-PLD; PLASMA; PURIFICATION; PROTEINS; RECEPTOR	Previous work has suggested that the glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) purified from bovine serum is inhibited by phosphatidic acid (PA). In this study we report on the specificity and mechanism of this phenomenon using [H-3]myristate-labeled variant surface glycoprotein dispersed in Nonidet P-40 as substrate. Inhibition of GPI-PLD by PAs (IC50 approximately 1 muM) was relatively independent of the length or degree of unsaturation of the fatty acyl chains. It was also observed that lysophosphatidic acid and several natural and synthetic lipid A preparations were inhibitory in the same concentration range. The inhibitory potency of PA, lysophosphatidic acid, and lipid A was dependent on the detergent concentration in the assay but in all cases this was in a large (i.e. >100-fold) molar excess over the inhibitor. The inhibitory lipids did not affect substrate availability nor did they reduce hydrolysis of variant surface glycoprotein by a bacterial phosphatidylinositol-specific phospholipase C. Studies with a wide range of other lipids, detergents, and phosphate esters indicated that inhibition was specific for lipids containing a phosphomonoester group. The data suggest that inhibition is due to a direct interaction between PA (or lipid A) and the GPI-PLD rather than an indirect effect on the substrate particle.	HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, NUTLEY, NJ 07110 USA	Roche Holding	LOW, MG (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040083, R01GM035873, R55GM040083] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35873, GM-40083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCHAUER H, 1990, J BIOL CHEM, V265, P9159; BANGHAM AD, 1962, BIOCHIM BIOPHYS ACTA, V59, P103, DOI 10.1016/0006-3002(62)90701-1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; CAROFF M, 1991, J BIOL CHEM, V266, P18543; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GRABAREK J, 1990, J BIOL CHEM, V265, P8117; HELLER M, 1992, BIOCHIM BIOPHYS ACTA, V1109, P109, DOI 10.1016/0005-2736(92)90073-U; HERELD D, 1986, J BIOL CHEM, V261, P3813; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; HUANG KS, 1990, J BIOL CHEM, V265, P17738; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JOHNSON RS, 1990, J BIOL CHEM, V265, P8108; Low M.G., 1992, LIPID MODIFICATION P, P117; Low M. G., 1990, MOL CELL BIOL MEMBRA, P35; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; MALIK AS, 1986, BIOCHEM J, V240, P519, DOI 10.1042/bj2400519; METZ CN, 1991, CELL BIOL INT REP, V15, P875, DOI 10.1016/0309-1651(91)90039-L; METZ CN, 1992, AM J PATHOL, V140, P1275; METZ CN, 1991, J BIOL CHEM, V266, P17733; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; QIAN Z, 1991, FASEB J, V5, P315, DOI 10.1096/fasebj.5.3.2001791; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SESKO AM, 1991, FASEB J, V5, pA839; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; STUETZ P, 1991, INFECTIOUS DISEASE C, V5, P847; TSANG TC, 1992, FASEB J, V6, pA1922; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WAITE M, 1987, HDB LIPID RES, V5; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	37	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8480	8490						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473292				2022-12-25	WOS:A1993KX81100019
J	TANAKA, S; KAYTES, P; KURKINEN, M				TANAKA, S; KAYTES, P; KURKINEN, M			AN ENHANCER FOR TRANSCRIPTION OF COLLAGEN-IV GENES IS ACTIVATED BY F9 CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE ELEMENT; BASEMENT-MEMBRANE COLLAGEN; HEAD-TO-HEAD; RETINOIC ACID; ALPHA-2(IV) COLLAGEN; STRUCTURAL ORGANIZATION; BIDIRECTIONAL PROMOTER; TERATOCARCINOMA CELLS; CARCINOMA-CELLS; EXPRESSION	Expression of collagen IV genes is developmentally regulated and cell type-specific. To identify transcriptional control elements for the mouse alpha2(IV) collagen gene, several promoter constructs were transiently transfected into mouse PYS-2 (parietal yolk sac) cells. Within the 5.5-kb (kilobase) upstream and 8.5-kb downstream sequences from the transcription start site, we have identified several regulatory active regions. Here, we report characterization of the most proximal 0.3-kb enhancer found at 4.5-kb upstream of the alpha2(IV) collagen gene. This enhancer is transcriptionally active in cells that make collagen IV such as PYS-2 cells and differentiated F9 cells, but has little if any activity in cells that do not make collagen IV including NIH 3T3 cells and undifferentiated F9 embryonal carcinoma stem cells. This enhancer, linked to the herpes simplex virus TK gene promoter, confers a cell type-specific and differentiation-induced expression on the TK gene as well. Mutational and 5' and 3' deletion analysis demonstrate that this enhancer activity requires two identical response elements (GAACAAT) present in the 0.3-kb enhancer sequence. In gel shift assay, the GAACAAT element forms a complex that is specific for cells that make collagen IV.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, PISCATAWAY, NJ 08854 USA; UPJOHN CO, KALAMAZOO, MI 49001 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pfizer					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034090] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34090] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BLUMBERG B, 1990, EXTRACELLULAR MATRIX, P115; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1990, J MOL EVOL, V30, P479, DOI 10.1007/BF02101102; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; GUO XD, 1989, J BIOL CHEM, V264, P17574; Hogan B. L. M, 1983, CANCER SURV, V2, P115; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KURKINEN M, 1985, ANN NY ACAD SCI, V460, P267, DOI 10.1111/j.1749-6632.1985.tb51174.x; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; OGAWA K, 1988, J BIOL CHEM, V263, P8384; PETTITT J, 1991, J BIOL CHEM, V266, P16149; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POLLNER R, 1990, ANN NY ACAD SCI, V580, P44, DOI 10.1111/j.1749-6632.1990.tb17916.x; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SANDELL LJ, 1990, EXTRACELLULAR MATRIX; SAUS J, 1989, J BIOL CHEM, V264, P6318; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1987, FEBS LETT, V225, P188; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VENKITARAMAN AR, 1989, NUCLEIC ACIDS RES, V17, P3314, DOI 10.1093/nar/17.8.3314; VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092-8674(90)90176-F; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WANG SY, 1988, J CELL PHYSIOL, V136, P305, DOI 10.1002/jcp.1041360213; YANG-YEN H-F, 1990, New Biologist, V2, P351	50	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8862	8870						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	8473330				2022-12-25	WOS:A1993KX81100072
J	ROESSER, JR; LIITTSCHWAGER, K; LEFF, SE				ROESSER, JR; LIITTSCHWAGER, K; LEFF, SE			REGULATION OF TISSUE-SPECIFIC SPLICING OF THE CALCITONIN CALCITONIN GENE-RELATED PEPTIDE GENE BY RNA-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DROSOPHILA DOUBLESEX GENE; SEXUAL-DIFFERENTIATION; NUCLEAR RIBONUCLEOPROTEINS; MUSCLE TROPOMYOSIN; TRANSFORMER GENE; SINGLE GENE; CGRP GENE; EXPRESSION; INVITRO	Transcripts of the rat calcitonin/calcitonin gene-related peptide (CGRP) gene are alternatively spliced in a tissue-specific manner resulting in the production of calcitonin mRNA and peptide in thyroid C cells and CGRP mRNA and peptide in neurons. Transfection studies using calcitonin and chimaeric human beta-globin/calcitonin exon minigene constructs showed that the splice acceptor and exon specific to calcitonin mRNA are spliced much less efficiently in CGRP-producing cells (F9 teratocarcinomas) than in cells that preferentially make calcitonin (HeLa cells). In vitro splicing of chimaeric human beta-globin/calcitonin transcripts in HeLa nuclear extracts were inhibited by the addition of nuclear extract from CGRP-favoring cells or tissues such as rat brain. This inhibition was specific as splicing of human beta-globin first intron transcripts was not affected by comparable amounts of rat brain extract. Fractionation of rat brain nuclear extracts allowed the partial purification of two brain-specific polypeptides of apparent molecular mass of 43 and 41 kDa which preferentially bind RNA containing the calcitonin-specific splice acceptor. Since these polypeptides cofractionate with the calcitonin mRNA-specific splicing inhibition activity, we suggest that they may mediate the inhibition of splicing observed in vitro and underlie, in part, the inefficient calcitonin mRNA production observed in CGRP-favoring cells in vivo.	STANFORD UNIV,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001404] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40125, GM 07149-17] Funding Source: Medline; NINDS NIH HHS [NS 01404] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; ADEMA GJ, 1991, BIOCHEM BIOPH RES CO, V178, P985, DOI 10.1016/0006-291X(91)90989-K; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CHU G, 1981, GENE, V13, P197, DOI 10.1016/0378-1119(81)90008-1; COTE GJ, 1991, NUCLEIC ACIDS RES, V19, P3601, DOI 10.1093/nar/19.13.3601; COTE GJ, 1992, NUCLEIC ACIDS RES, V20, P2361, DOI 10.1093/nar/20.9.2361; COTE GJ, 1990, MOL ENDOCRINOL, V4, P1744, DOI 10.1210/mend-4-11-1744; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDBROOKE MR, 1985, EMBO J, V4, P715, DOI 10.1002/j.1460-2075.1985.tb03688.x; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LIBRI D, 1989, J BIOL CHEM, V264, P2935; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1988, GENE DEV, V2, P1262; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SABATE MI, 1985, J BIOL CHEM, V260, P2589; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SERRAFIN PR, 1988, GENE DEV, V2, P215; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; ZACHAR Z, 1987, EMBO J, V6, P4410; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; [No title captured]	63	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8366	8375						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	8463344				2022-12-25	WOS:A1993KW97900111
J	FLACHMANN, R; MICHALOWSKI, CB; LOFFELHARDT, W; BOHNERT, HJ				FLACHMANN, R; MICHALOWSKI, CB; LOFFELHARDT, W; BOHNERT, HJ			SECY, AN INTEGRAL SUBUNIT OF THE BACTERIAL PREPROTEIN TRANSLOCASE, IS ENCODED BY A PLASTID GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING PROTEINS; ESCHERICHIA-COLI; CYANOPHORA-PARADOXA; BACILLUS-SUBTILIS; ALKALINE-PHOSPHATASE; GREEN CHLOROPLASTS; CYANELLE GENOME; GENES INDICATE; EXPORT GENE; STR OPERON	Although the paradigm for the acquisition of photosynthetic organelles is the endocytosis of cyanobacteria-like progenitors by heterotrophic protists, details of this evolutionary process are unclear. The small organellar chromosomes are remnants of the larger bacterial genomes with most genes from the endosymbiont's DNA having been either relocated to the protist's nucleus or entirely lost. As a result of those gene transfers, differences exist between plastids from different algal phyla and higher plants. We report here on the retention of a secY gene in cyanelle (=plastid) DNA of the eukaryotic protist Cyanophora paradoxa. This cyanelle secY encodes a functional protein homologous to SecY of Escherichia coli, identified as a subunit of the preprotein translocase complex. Similarity of the cyanelle and E. coli SecY topology, predicted from sequence information, has been confirmed experimentally through SecY-PhoA fusion protein analysis in E. coli. Cyanelle SecY, expressed in an E. coli secY mutant, substituted for the defective prokaryotic SecY. A plastid-encoded gene for a membrane protein functioning in protein transport across plastid membranes is unprecedented in higher plants. From these results we infer that a functional homolog of the prokaryotic preprotein translocation machinery is retained in some plastids.	UNIV ARIZONA, DEPT BIOCHEM, TUCSON, AZ 85721 USA; UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA; UNIV VIENNA, INST ALLGEMEINE BOT, A-1090 VIENNA, AUSTRIA; UNIV VIENNA, LUDWIG BOLTZMAN FORSCHUNGSSTELLE BIOCHEM, A-1090 VIENNA, AUSTRIA	University of Arizona; University of Arizona; University of Arizona; University of Vienna; Ludwig Boltzmann Institute; University of Vienna			Bohnert, Hans J/A-7104-2009					AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ARNDT E, 1992, BIOCHIM BIOPHYS ACTA, V1130, P113, DOI 10.1016/0167-4781(92)90474-E; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AUER J, 1991, BIOCHIMIE, V73, P683, DOI 10.1016/0300-9084(91)90048-6; BERENGUER J, 1987, FEBS LETT, V224, P401, DOI 10.1016/0014-5793(87)80492-1; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BRYANT DA, 1990, FEBS LETT, V259, P273, DOI 10.1016/0014-5793(90)80026-F; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; JANSSEN I, 1989, CURR GENET, V15, P335, DOI 10.1007/BF00419913; JANSSEN I, 1987, PLANT MOL BIOL, V9, P479, DOI 10.1007/BF00015879; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KOIVULA T, 1991, FEBS LETT, V288, P114, DOI 10.1016/0014-5793(91)81015-Z; KRAUS M, 1990, PLANT MOL BIOL, V15, P561, DOI 10.1007/BF00017831; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MICHALOWSKI CB, 1990, MOL GEN GENET, V224, P222, DOI 10.1007/BF00271555; MICHALOWSKI CB, 1991, J BIOL CHEM, V266, P11866; MICHALOWSKI CB, 1991, PLANT PHYSIOL, V95, P329, DOI 10.1104/pp.95.1.329; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; NAKAMURA K, 1990, FEBS LETT, V273, P75, DOI 10.1016/0014-5793(90)81054-R; NEUMANNSPALLART C, 1990, FEBS LETT, V268, P55, DOI 10.1016/0014-5793(90)80971-K; OHAMA T, 1989, J MOL EVOL, V29, P381, DOI 10.1007/BF02602908; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLAIMAUER B, 1991, FEBS LETT, V284, P169, DOI 10.1016/0014-5793(91)80677-U; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SCARAMUZZI CD, 1992, FEBS LETT, V304, P119, DOI 10.1016/0014-5793(92)80601-C; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SUGIURA M, 1989, ANNU REV CELL BIOL, V5, P51, DOI 10.1146/annurev.cb.05.110189.000411; SUH JW, 1990, MOL MICROBIOL, V4, P305, DOI 10.1111/j.1365-2958.1990.tb00597.x; TURNER S, 1989, NATURE, V337, P380, DOI 10.1038/337380a0; VALENTIN K, 1990, PLANT MOL BIOL, V15, P575, DOI 10.1007/BF00017832; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WASMANN CC, 1987, CYANOBACTERIA, P303; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	50	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7514	7519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463282				2022-12-25	WOS:A1993KV14100099
J	HSU, MH; GRIFFIN, KJ; WANG, Y; KEMPER, B; JOHNSON, EF				HSU, MH; GRIFFIN, KJ; WANG, Y; KEMPER, B; JOHNSON, EF			A SINGLE AMINO-ACID SUBSTITUTION CONFERS PROGESTERONE 6-BETA-HYDROXYLASE ACTIVITY TO RABBIT CYTOCHROME-P450 2C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ENZYME; FORM; GENE; HYDROXYLATION; MUTATION; CLONING; REGION; DNA; 3B	A cDNA encoding a naturally occurring variant of cytochrome P450 (P450) 2C3 that catalyzes the 6beta- and 16alpha-hydroxylation of progesterone exhibits six differences of nucleotide sequence leading to five amino acid substitutions from that encoding 2C3, a progesterone 16alpha-hydroxylase that does not catalyze 6beta-hydroxylation. Analysis of chimeric and mutant enzymes indicates that a Ser/Thr difference at position 364 underlies the difference between the two enzymes in 6beta-hydroxylase activity as well as sensitivity to the inhibitor, 16alpha-methylprogesterone. In addition, an Ile/Met difference at position 178 influences the apparent K(m) for progesterone. The two mutations, S364T and I178M, together convert 2C3 to a form that exhibits kinetic properties which are similar to the 2C3v enzyme, and the reciprocal mutations in 2C3v convert it to an enzyme that resembles 2C3. Interestingly, position 364 of 2C3 maps to a substrate-contacting domain suggested by models for mammalian P450 enzymes based on the structure of P450cam. Ile178 is highly conserved among mammalian microsomal P450s with the exception of CYP4A and CYP19 enzymes which exhibit a Met at this alignment position.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM NX4, LA JOLLA, CA 92037 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA	Scripps Research Institute; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001, R01GM035897] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM35897, GM31001] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; BRUMMET SR, 1991, US BIOCH EDITORIAL C, V17, P22; CHAN G, 1990, BIOCHEMISTRY-US, V29, P3743, DOI 10.1021/bi00467a021; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DIETER HH, 1982, SCIENCE, V217, P741, DOI 10.1126/science.6808664; DIETER HH, 1982, J BIOL CHEM, V257, P9315; GOTOH O, 1992, J BIOL CHEM, V267, P83; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; JOHNSON EF, 1983, J BIOL CHEM, V258, P2785; JOHNSON EF, 1980, J BIOL CHEM, V255, P304; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; PETERSON JA, 1977, J BIOL CHEM, V252, P4431; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWAB GE, 1985, BIOCHEMISTRY-US, V24, P7222, DOI 10.1021/bi00346a030; TUSIELUNA MT, 1990, J BIOL CHEM, V265, P20916; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	28	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6939	6944						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463225				2022-12-25	WOS:A1993KV14100024
J	IKEDASAITO, M; DOU, Y; YONETANI, T; OLSON, JS; LI, TS; REGAN, R; GIBSON, QH				IKEDASAITO, M; DOU, Y; YONETANI, T; OLSON, JS; LI, TS; REGAN, R; GIBSON, QH			LIGAND DIFFUSION IN THE DISTAL HEME POCKET OF MYOGLOBIN - A PRIMARY DETERMINANT OF GEMINATE REBINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; BINDING; HEMOGLOBIN; RECOMBINATION; SIMULATION; PROTEINS; NO	There are at least two picosecond kinetic components in the rebinding of NO to native sperm whale myoglobin. Petrich et al. (Petrich, J. W., Lambry, J.-C., Kuczera, K., Karplus, M., Poyart, C., and Martin, J.-L. (1991) Biochemistry 30, 3975-3987) attribute the slowing of the reaction to a movement of the iron atom out of the plane of the heme following ligand dissociation. In contrast, Gibson et al. (Gibson, Q. H., Regan, R., Elber, R., Olson, J. S., and Carver, T. E. (1992) J. Biol. Chem. 267, 22022-22034) have explained multiphasic geminate reactions by diffusion of NO into the distal heme pocket as determined by its detailed structure. O2 and NO rebinding to iron and cobalt derivatives of native, V68F, and V68I sperm whale myoglobin has been examined. Each iron protein shows a biphasic time course of NO rebinding reactions with widely different rates and amplitudes. Although cobalt does not move out of the plane of the porphyrin on ligand removal, the reactions of the iron and cobalt derivatives of each protein were closely similar. The time course of O2 rebinding to cobalt was also similar to that of NO rebinding to iron. These results are consistent with a primary role for the structure of the distal pocket in determining diffusion of ligands away from the metal atom and as a result the time course of picosecond ligand rebinding.	CORNELL UNIV,DEPT BIOCHEM & MOLEC & CELL BIOL,ITHACA,NY 14853; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251	Cornell University; Case Western Reserve University; University of Pennsylvania; Rice University; Rice University			Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL014508, R01HL014508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649, R01GM039492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14508] Funding Source: Medline; NIGMS NIH HHS [GM 39492, GM-35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; ELBER R, 1993, IN PRESS ADV COMPUTA; FERMI G, 1982, J MOL BIOL, V155, P495, DOI 10.1016/0022-2836(82)90483-1; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; HOARD JL, 1973, P NATL ACAD SCI USA, V70, P3919, DOI 10.1073/pnas.70.12.3919; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961	16	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					6855	6857						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	8463211				2022-12-25	WOS:A1993KV14100009
